WO2019083007A1 - Pyridine compound and harmful-arthropod control agent containing same - Google Patents

Pyridine compound and harmful-arthropod control agent containing same

Info

Publication number
WO2019083007A1
WO2019083007A1 PCT/JP2018/039843 JP2018039843W WO2019083007A1 WO 2019083007 A1 WO2019083007 A1 WO 2019083007A1 JP 2018039843 W JP2018039843 W JP 2018039843W WO 2019083007 A1 WO2019083007 A1 WO 2019083007A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
nmr
cdcl
methyl
Prior art date
Application number
PCT/JP2018/039843
Other languages
French (fr)
Japanese (ja)
Inventor
康 片桐
拓和 高田
Original Assignee
住友化学株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 住友化学株式会社 filed Critical 住友化学株式会社
Priority to JP2019550314A priority Critical patent/JPWO2019083007A1/en
Publication of WO2019083007A1 publication Critical patent/WO2019083007A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4

Definitions

  • the present invention relates to pyridine compounds and harmful arthropod control agents containing the same.
  • Patent Document 1 describes that certain compounds have a pest control effect.
  • An object of the present invention is to provide a compound having excellent control efficacy against harmful arthropods.
  • R 1 and R 2 are the same or different, and C1-C15 chain hydrocarbon group ⁇ The C1-C15 chain hydrocarbon group may have one or more substituents selected from group A ⁇ , C3-C8 cycloalkyl group or C3-C8 cycloalkenyl group ⁇ The C3-C8 cycloalkyl group and the C3-C8 cycloalkenyl group may have one or more substituents selected from Group B ⁇
  • R 3 represents a (C 1 -C 3 alkoxy) C 1 -C 3 alkyl group, a benzyl group optionally having one or more substituents selected from group B, a formyl group
  • R 10 represents a C1-C4 chain hydrocarbon group or a cyclopropyl group ⁇ wherein the C1-C4 chain hydrocarbon
  • n 0 or 1 and m and p are the same or different and each represents 0, 1 or 2.
  • Group A C 1 -C 6 alkoxy, C 3 -C 6 alkenyloxy, C 3 -C 6 alkynyloxy, C 1 -C 6 alkylsulfanyl, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 2 -C 6 alkylcarbonyl
  • a C2-C6 alkylcarbonyloxy group ⁇ wherein the C1-C6 alkoxy group, the C3-C6 alkenyloxy group, the C3-C6 alkynyloxy group, the C1-C6 alkylsulfanyl group, the C1-C6 alkylsulfinyl group, the C1 -C6 alkylsulfonyl group, the C2-C6 alkylcarbonyl group and the C2-C6 alkylcarbonyl
  • Group B C1-C6 chain hydrocarbon group, C1-C6 alkoxy group, C3-C6 alkenyloxy group, C3-C6 alkynyloxy group, C1-C6 alkylsulfanyl group, C1-C6 alkylsulfinyl group, C1-C6 alkyl A sulfonyl group, a C2-C6 alkyl carbonyl group, a C2-C6 alkyl carbonyloxy group ⁇ the C1-C6 chain hydrocarbon group, the C1-C6 alkoxy group, the C3-C6 alkenyloxy group, the C3-C6 alkynyloxy group
  • the C1-C6 alkylsulfanyl group, the C1-C6 alkylsulfinyl group, the C1-C6 alkylsulfonyl group, the C2-C6 alkylcarbonyl group and the C2-C6 alkylcarbonyloxy group have one
  • Group C A group consisting of a C1-C3 alkyl group optionally having one or more halogen atoms, a halogen atom and a cyano group.
  • Group D a group consisting of cyclopropyl, halogen and cyano.
  • a compound represented by hereinafter, referred to as a compound X of the present invention.
  • Group B is a C1-C6 chain hydrocarbon group, a C1-C6 alkoxy group, a C3-C6 alkenyloxy group, a C3-C6 alkynyloxy group, a C1-C6 alkylsulfanyl group, a C1-C6 alkylsulfinyl group, C1-C6 alkylsulfonyl group, C2-C6 alkylcarbonyl group, C2-C6 alkylcarbonyloxy group ⁇ C1-C6 chain hydrocarbon group, said C1-C6 alkoxy group, said C3-C6 alkenyloxy group, said C3-C6 alkyloxy group
  • R 2 is a C1-C10 chain hydrocarbon group ⁇
  • the C1-C10 chain hydrocarbon group has one or more substituents selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom
  • R 1 is a C1-C10 chain hydrocarbon group ⁇ wherein the C1-C10 chain hydrocarbon group has one or more substituents selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom
  • the compound according to any one of [1] to [4], which may be [6] The compound according to any one of [1] to [5], wherein L 1 and L 2 are a single bond.
  • a harmful arthropod control composition comprising the compound according to any one of [1] to [6] and an inert carrier.
  • composition according to [7] which comprises one or more components selected from the group consisting of Group (a) and Group (b): Group (a): a group consisting of an insecticidal active ingredient, an acaricidal active ingredient and a nematode active ingredient; Group (b): bactericidal active ingredient.
  • a method for controlling noxious arthropods which comprises applying an effective amount of the compound according to any one of [1] to [6] to a harmful arthropod or a habitat of the harmful arthropod.
  • a method for controlling noxious arthropods which comprises applying an effective amount of the composition according to [7] or [8] to a harmful arthropod or a habitat of the harmful arthropod.
  • a seed or vegetative organ which retains an effective amount of the compound according to any one of [1] to [6] or an effective amount of the composition according to [7] or [8].
  • harmful arthropods can be controlled.
  • halogen atom is a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
  • substituent has 2 or more halogen atoms, it means that those halogen atoms may be the same or different.
  • substituent has two or more groups or atoms selected from a specific group (for example, a group consisting of a cyano group and a halogen atom), those groups or atoms may be the same or different. .
  • the expression “optionally having one or more substituents selected from group X” is a substituent selected from group X When two or more are present, those substituents may be the same or different.
  • CX-CY in the present specification means that the number of carbon atoms is X to Y.
  • C1-C6 means that the number of carbon atoms is 1 to 6.
  • the "chain hydrocarbon group” represents an alkyl group, an alkenyl group or an alkynyl group.
  • alkyl group for example, methyl group, ethyl group, propyl group, isopropyl group, 1,1-dimethylpropyl group, 1,2-dimethylpropyl group, butyl group, tert-butyl group, pentyl group, hexyl group, Examples include octyl, decyl and pentadecyl.
  • alkenyl group for example, vinyl group, 1-propenyl group, 2-propenyl group, 1-methyl-1-propenyl group, 1-methyl-2-propenyl group, 1,2-dimethyl-1-propenyl group
  • Examples include 3-butenyl group, 4-pentenyl group, 5-hexenyl group, 7-octenyl group, 1-decenyl group and 1-pentadecenyl group.
  • alkynyl group for example, ethynyl group, 1-propynyl group, 2-propynyl group, 1-methyl-2-propynyl group, 1,1-dimethyl-2-propynyl group, 2-butynyl group, 4-pentynyl group 5-hexynyl group, 7-octynyl group, 1-decynyl group and 1-pentadecynyl group.
  • alkanediyl group for example, methanediyl group, 1,1-ethanediyl group, 1,2-ethanediyl group, 1,1-propanediyl group, 2,2-propanediyl group, 1,2-propanediyl group and There may be mentioned 1,3-propanediyl group.
  • alkenediyl group include ethene-1,1-diyl group, ethene-1,2-diyl group, 1-propene-1,2-diyl group, 1-propene-1,3-diyl group and 2- Examples include propene-1,3-diyl group.
  • cycloalkyl group for example, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group and cyclooctyl group can be mentioned.
  • cycloalkenyl group for example, cyclopropenyl group, cyclobutenyl group, cyclopentenyl group, cyclohexenyl group and cyclooctenyl group can be mentioned.
  • the “benzyl group optionally having one or more substituents selected from group B” is, for example, benzyl group, 2-fluorobenzyl group, 4-methylbenzyl group, 4- (trifluoromethoxy) benzyl group, And 4-acetylbenzyl group.
  • each optical isomer and a mixture containing them in any ratio are also included in the compound of the present invention.
  • a compound of the present invention X includes two or more geometric isomers derived from a carbon-carbon double bond or a carbon-nitrogen double bond, and a mixture containing them in any ratio.
  • the compound of the present invention X is added with an acid such as hydrochloride, sulfate, nitrate, phosphate, acetate or benzoate by mixing with an acid such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid or benzoic acid May form salts.
  • an acid such as hydrochloride, sulfate, nitrate, phosphate, acetate or benzoate by mixing with an acid such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid or benzoic acid May form salts.
  • Embodiment 2 A compound according to Embodiment 1, wherein R 3 is a benzyl group, C (O) R 10 , C (O) OR 10 or a hydrogen atom.
  • a compound according to Aspect 4 wherein R 4 and R 5 are the same or different and are a C1-C2 alkyl group optionally having one or more halogen atoms.
  • Aspect 6 The compound according to Aspect 4, wherein R 4 and R 5 are a methyl group.
  • R 2 is a C1-C10 chain hydrocarbon group ⁇ the C1-C10 chain hydrocarbon group may have one or more substituents selected from group E ⁇ , C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group ⁇ The C3-C6 cycloalkyl group and the C3-C6 cycloalkenyl group may have one or more substituents selected from group F ⁇
  • Group F a group consisting of a C1-C4 alkyl group optionally having one or more halogen atoms and a halogen atom.
  • R 2 is a C1-C10 chain hydrocarbon group ⁇ The C1-C10 chain hydrocarbon group may have one or more substituents selected from Group E ⁇ , C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group ⁇ The C3-C6 cycloalkyl group and the C3-C6 cycloalkenyl group may have one or more substituents selected from group F ⁇ A compound that is [Aspect 9] In aspect 3, R 2 is a C 1 -C 10 chain hydrocarbon group ⁇ The C 1 -C 10 chain hydrocarbon group may have one or more substituents selected from group E ⁇ , C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group ⁇ The C3-C6 cycloalkyl
  • R 2 is a C1-C10 chain hydrocarbon group ⁇ wherein the C1-C10 chain hydrocarbon group is at least one selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted ⁇ , a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
  • R 2 is a C1-C10 chain hydrocarbon group ⁇ wherein the C1-C10 chain hydrocarbon group is at least one selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted ⁇ , a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
  • R 2 is a C1-C10 chain hydrocarbon group ⁇ wherein the C1-C10 chain hydrocarbon group is at least one selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted ⁇ , a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
  • R 2 is a C1-C10 chain hydrocarbon group ⁇ wherein the C1-C10 chain hydrocarbon group is at least one member selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted ⁇ , a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
  • R 2 is a C1-C10 chain hydrocarbon group ⁇ wherein the C1-C10 chain hydrocarbon group is at least one selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted ⁇ , a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
  • R 1 is a C1-C15 chain hydrocarbon group ⁇ the C1-C15 chain hydrocarbon group may have one or more substituents selected from group E ⁇ , C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group ⁇ The C3-C6 cycloalkyl group and the C3-C6 cycloalkenyl group may have one or more substituents selected from group F The compound which is ⁇ .
  • R 1 is a C1-C15 chain hydrocarbon group optionally having one or more substituents selected from group E.
  • Embodiment 23 A compound of the present invention wherein R 1 is a C1-C15 alkyl group or a C2-C15 alkenyl group.
  • R 1 is a C1-C15 chain hydrocarbon group ⁇ wherein the C1-C15 chain hydrocarbon group has one or more substituents selected from Group E.
  • Embodiment 25 The compound according to any of Embodiments 1 to 20, wherein R 1 is a C1-C15 chain hydrocarbon group optionally having one or more substituents selected from Group E.
  • Embodiment 26 A compound according to any of embodiments 1 to 20, wherein R 1 is a C1-C15 alkyl group or a C2-C15 alkenyl group.
  • Embodiment 27 A compound according to Embodiment 27, wherein R 3 is a benzyl group, C (O) R 10 , C (O) OR 10 or a hydrogen atom.
  • Embodiment 31 A compound according to Embodiment 30, wherein R 4 and R 5 are the same or different and are a C1-C2 alkyl group optionally having one or more halogen atoms.
  • R 2 is a C1-C10 chain hydrocarbon group ⁇ The C1-C10 chain hydrocarbon group may have one or more substituents selected from Group E ⁇ , C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group ⁇ The C3-C6 cycloalkyl group and the C3-C6 cycloalkenyl group may have one or more substituents selected from group F ⁇
  • Group F a group consisting of a C1-C4 alkyl group optionally having one or more halogen atoms and a halogen atom.
  • R 2 is a C1-C10 chain hydrocarbon group ⁇ the C1-C10 chain hydrocarbon group may have one or more substituents selected from Group E ⁇ , C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group ⁇ The C3-C6 cycloalkyl group and the C3-C6 cycloalkenyl group may have one or more substituents selected from group F ⁇
  • R 2 is a C1-C10 chain hydrocarbon group ⁇ wherein the C1-C10 chain hydrocarbon group is at least one selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted ⁇ , a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
  • Embodiment 41 In Embodiment 29, R 2 is a C1-C10 chain hydrocarbon group ⁇ wherein the C1-C10 chain hydrocarbon group is at least one selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted ⁇ , a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
  • R 2 is a C1-C10 chain hydrocarbon group ⁇ wherein the C1-C10 chain hydrocarbon group is one or more selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted ⁇ , a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
  • R 2 is a C1-C10 chain hydrocarbon group ⁇ wherein the C1-C10 chain hydrocarbon group is at least one selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted ⁇ , a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
  • R 2 is a C1-C10 chain hydrocarbon group ⁇ wherein the C1-C10 chain hydrocarbon group is at least one selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted ⁇ , a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
  • R 1 is a C 1 -C 15 chain hydrocarbon group ⁇ even if the C 1 -C 15 chain hydrocarbon group has one or more substituents selected from group E ⁇ , C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group ⁇ wherein the C3-C6 cycloalkyl group and the C3-C6 cycloalkenyl group have one or more substituents selected from group F Compound that is good.
  • R 1 is a C1-C15 chain hydrocarbon group optionally having one or more substituents selected from group E.
  • Embodiment 49 A compound of the present invention X, wherein R 1 is a C1-C15 alkyl group or a C2-C15 alkenyl group.
  • R 1 is a C1-C15 chain hydrocarbon group ⁇ wherein the C1-C15 chain hydrocarbon group has one or more substituents selected from Group E.
  • the compound represented by the formula (Ib) (hereinafter referred to as compound (Ib)) is a compound represented by the formula (Ia) (hereinafter referred to as compound (Ia)) and the compound represented by the formula (R-1)
  • the compound (R-1) can be produced by reacting in the presence of a base.
  • R 3a represents a (C 1 -C 3 alkoxy) C 1 -C 3 alkyl group, or a benzyl group which may have one or more substituents selected from group B, and X 1 represents a chlorine atom or a bromine atom , Iodine atom, C 1 -C 10 perfluoroalkanesulfonyloxy group or tosyloxy group, and the other symbols have the same meanings as described above.
  • the reaction is usually carried out in a solvent.
  • Examples of the solvent used for the reaction include hydrocarbons such as hexane, toluene and xylene (hereinafter referred to as hydrocarbons); diethyl ether, ethylene glycol dimethyl ether, methyl tert-butyl ether (hereinafter referred to as MTBE), and tetrahydrofuran
  • hydrocarbons such as hexane, toluene and xylene
  • MTBE methyl tert-butyl ether
  • halogenated hydrocarbons such as chloroform and chlorobenzene (hereinafter referred to as halogenated hydrocarbons)
  • dimethylformamide hereinafter referred to as DMF
  • N -Aprotic polar solvents such as methyl pyrrolidone and dimethyl sulfoxide (hereinafter referred to as DMSO) (hereinafter referred to as aprotic polar solvents)
  • esters such as ethyl acetate (
  • Examples of the base used for the reaction include alkali metal carbonates such as sodium carbonate and potassium carbonate (hereinafter referred to as alkali metal carbonates); organic bases such as triethylamine and pyridine (hereinafter referred to as organic bases) .
  • alkali metal carbonates such as sodium carbonate and potassium carbonate
  • organic bases such as triethylamine and pyridine
  • the compound (R-1) is used in a proportion of usually 1 mol to 10 mol and the base is usually used in a proportion of 1 mol to 10 mol based on 1 mol of the compound (Ia).
  • the reaction time is usually in the range of 5 minutes to 72 hours.
  • the reaction temperature is usually in the range of ⁇ 20 ° C. to 100 ° C.
  • compound (Ib) can be isolated by post-treatment operations such as adding water to the reaction mixture, extracting with an organic solvent, and drying and concentrating the organic layer.
  • the compound (R-1) is a commercially available compound or can be produced according to a known method.
  • the compound represented by the formula (Ic) is a compound of the compound (Ia) and the compound represented by the formula (R-2) (hereinafter referred to as the compound (R-2)) It can be produced by reacting in the presence of [Wherein, R 3b represents C (O) R 10 or C (O) OR 10 , and the other symbols have the same meanings as described above. ]
  • the reaction is usually carried out in a solvent.
  • the solvent used for the reaction include hydrocarbons, ethers, halogenated hydrocarbons, aprotic polar solvents, esters and mixtures thereof.
  • a base used for reaction an alkali metal carbonate and organic bases are mentioned, for example.
  • the compound (R-2) is usually used in a proportion of 1 mol to 10 mol and the base is usually used in a proportion of 1 mol to 10 mol with respect to 1 mol of the compound (Ia).
  • the reaction time is usually in the range of 5 minutes to 24 hours.
  • the reaction temperature is usually in the range of ⁇ 20 ° C. to 100 ° C.
  • compound (Ic) can be isolated by performing post-treatment operations such as adding water to the reaction mixture, extracting with an organic solvent, and drying and concentrating the organic layer.
  • the compound (R-2) is a commercially available compound or can be produced according to a known method.
  • the compound represented by the formula (Id) (hereinafter referred to as a compound (Id)) is a compound of the compound (Ia) and the compound represented by the formula (R-3) (hereinafter referred to as a compound (R-3)) It can be manufactured by [Wherein, the symbols have the same meanings as described above. ]
  • the reaction is carried out without solvent or in a solvent.
  • the solvent used for the reaction include hydrocarbons, ethers, halogenated hydrocarbons, aprotic polar solvents, esters and mixtures thereof. You may use a base for reaction as needed. As a base used for reaction, organic bases are mentioned, for example.
  • the compound (R-3) is usually used in a proportion of 1 mol to 100 mol, relative to 1 mol of the compound (Ia).
  • the base is usually used in a proportion of 1 mole to 10 moles relative to 1 mole of the compound (Ia).
  • the reaction time is usually in the range of 5 minutes to 72 hours.
  • the reaction temperature is usually in the range of ⁇ 20 ° C. to 180 ° C.
  • water is added to the reaction mixture, extraction is performed with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to isolate the compound (Id).
  • the compound (R-3) is a commercially available compound or can be produced according to a known method.
  • the compound represented by the formula (Ie) (hereinafter referred to as compound (Ie)) is a compound of the compound (Ia) and the compound represented by the formula (R-4) (hereinafter referred to as compound (R-4)) It can be manufactured by [Wherein, the symbols have the same meanings as described above. ]
  • the reaction is usually carried out in a solvent.
  • the solvent used for the reaction include hydrocarbons, ethers, halogenated hydrocarbons, aprotic polar solvents, esters and mixtures thereof. You may use a base for reaction as needed.
  • the base used in the reaction examples include alkali metal hydrogen carbonates such as sodium hydrogen carbonate and potassium hydrogen carbonate (hereinafter referred to as alkali metal hydrogen carbonates); and organic bases.
  • the compound (R-4) is usually used in a proportion of 1 mole to 10 moles relative to 1 mole of the compound (Ia).
  • the base is usually used in a proportion of 1 mole to 10 moles relative to 1 mole of the compound (Ia).
  • the reaction time is usually in the range of 5 minutes to 72 hours.
  • the reaction temperature is usually in the range of ⁇ 20 ° C. to 80 ° C.
  • compound (Ie) can be isolated by post-treatment operations such as adding water to the reaction mixture, extracting with an organic solvent, and drying and concentrating the organic layer.
  • the compound (R-4) is a commercially available compound.
  • a compound represented by the formula (Ig) (hereinafter referred to as a compound (Ig)) is produced by reacting a compound represented by the formula (If) (hereinafter referred to as a compound (If)) with an oxidizing agent.
  • a compound represented by the formula (If) hereinafter referred to as a compound (If)
  • an oxidizing agent e.g., a compound (Ig)
  • the reaction is usually carried out in a solvent.
  • solvents used for the reaction include halogenated hydrocarbons; nitriles such as acetonitrile (hereinafter referred to as nitriles); esters; alcohols such as methanol and ethanol (hereinafter referred to as alcohols); acetic acid; These mixtures are mentioned.
  • the oxidizing agent used for the reaction examples include sodium periodate, m-chloroperbenzoic acid (hereinafter referred to as mCPBA) and hydrogen peroxide.
  • mCPBA m-chloroperbenzoic acid
  • hydrogen peroxide sodium carbonate or a catalyst may be used as needed.
  • tungstic acid and sodium tungstate are mentioned, for example.
  • the oxidizing agent is usually used in a proportion of 1 mole to 10 moles relative to 1 mole of the compound (If).
  • sodium carbonate sodium carbonate is usually used in a ratio of 0.01 mol to 1 mol with respect to 1 mol of compound (If).
  • the catalyst When a catalyst is used, the catalyst is usually used in a proportion of 0.01 to 0.5 mol per 1 mol of compound (If).
  • the reaction time is usually in the range of 5 minutes to 24 hours.
  • the reaction temperature is usually in the range of ⁇ 20 ° C. to 80 ° C.
  • water is added to the reaction mixture, extraction is carried out with an organic solvent, and the organic layer is optionally treated with an aqueous solution of a reducing agent (eg sodium sulfite, sodium thiosulfate) and an aqueous solution of a base (eg sodium hydrogencarbonate)
  • a reducing agent eg sodium sulfite, sodium thiosulfate
  • a base eg sodium hydrogencarbonate
  • the compound (Ia) can be produced by reacting a compound represented by the formula (M-1) (hereinafter referred to as compound (M-1)), a palladium catalyst and a base.
  • M-1 a compound represented by the formula (M-1)
  • R 30 represents a 2-propenyl group or 2-butenyl group, and the other symbols have the same meanings as described above.
  • the reaction is usually carried out in a solvent.
  • the solvent used for the reaction include halogenated hydrocarbons, alcohols, aprotic polar solvents, esters, ethers, water and mixtures thereof.
  • a base used for reaction an alkali metal carbonate and organic bases are mentioned, for example.
  • a palladium catalyst used for reaction tetrakis triphenyl phosphine palladium (0) and dibenzylidene acetone palladium (0) are mentioned, for example.
  • the palladium catalyst is usually used in a proportion of 0.01 to 0.5 mol, and the base is usually used in a proportion of 1 mol to 10 mol, relative to 1 mol of the compound (M-1).
  • the reaction time is usually in the range of 5 minutes to 24 hours.
  • the reaction temperature is usually in the range of ⁇ 20 ° C. to 80 ° C.
  • water is added to the reaction mixture, and when compound (Ia) precipitates, the solid is filtered off; compound (Ia) is isolated by post-treatment operation such as extraction with an organic solvent can do.
  • the compound represented by the formula (M-3) (hereinafter referred to as the compound (M-3)) is a compound represented by the formula (M-2) (hereinafter referred to as the compound (M-2)) and the compound represented by the formula (R) It can be produced by reacting a compound represented by -5) (hereinafter referred to as compound (R-5)).
  • R 31 is a C1-C13 chain hydrocarbon group ⁇ the C1-C13 chain hydrocarbon group may have one or more substituents selected from Group A ⁇ , C 1 -C 6 alkoxy] Group, C2-C6 alkylcarbonyl group, C2-C6 alkylcarbonyloxy group ⁇ wherein the C1-C6 alkoxy group, the C2-C6 alkylcarbonyl group and the C2-C6 alkylcarbonyloxy group have one or more halogen atoms
  • C3-C8 cycloalkyl group, or C3-C8 cycloalkenyl group ⁇ wherein the C3-C8 cycloalkyl group and the C3-C8 cycloalkenyl group have one or more substituents selected from Group B.
  • the reaction is usually carried out in a solvent.
  • the solvent used for the reaction include ethers, hydrocarbons, halogenated hydrocarbons and mixtures thereof.
  • the compound (R-5) is usually used in a proportion of 1 mole to 10 moles relative to 1 mole of the compound (M-2).
  • the reaction time is usually in the range of 5 minutes to 24 hours.
  • the reaction temperature is usually in the range of ⁇ 20 ° C. to 80 ° C.
  • the compound (M-3) can be isolated by performing post-treatment operations such as adding water to the reaction mixture and filtering and drying the precipitated solid.
  • the compound (R-5) is a commercially available compound, or can be produced, for example, according to the method described in Organic Letters, 2014, 16, 6424-6427.
  • the compound (M-2) can be produced by reacting a compound represented by the formula (M-4) (hereinafter referred to as a compound (M-4)) with an oxidizing agent.
  • a compound represented by the formula (M-4) hereinafter referred to as a compound (M-4)
  • an oxidizing agent used for the reaction include manganese (IV) oxide, Dess-Martin reagent and 2-iodoxybenzoic acid.
  • the reaction is usually carried out in a solvent.
  • the solvent used for the reaction include halogenated hydrocarbons, nitriles, esters and mixtures thereof.
  • the oxidizing agent is usually used in a proportion of 1 mole to 50 moles relative to 1 mole of the compound (M-4).
  • the reaction time is usually in the range of 5 minutes to 24 hours.
  • the reaction temperature is usually in the range of ⁇ 20 ° C. to 80 ° C.
  • water is added to the reaction mixture, extraction is performed with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to isolate the compound (M-2).
  • the compound (M-4) can be produced by reacting a compound represented by the formula (M-5) (hereinafter referred to as a compound (M-5)) with a reducing agent.
  • a compound represented by the formula (M-5) hereinafter referred to as a compound (M-5)
  • a reducing agent used for the reaction include lithium aluminum hydride, lithium borohydride and diisobutylaluminum hydride.
  • the reaction is usually carried out in a solvent.
  • the solvent used for the reaction include hydrocarbons, ethers, halogenated hydrocarbons and mixtures thereof.
  • a reducing agent is usually used in a proportion of 2 mol to 10 mol per 1 mol of compound (M-5).
  • the reaction time is usually in the range of 5 minutes to 24 hours.
  • the reaction temperature is usually in the range of -80 ° C to 40 ° C.
  • water is added to the reaction mixture, extraction is performed with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to isolate the compound (M-4).
  • the compound (M-5) is a compound represented by the formula (M-6) (hereinafter referred to as compound (M-6)) and a compound represented by the formula (R-6) (hereinafter referred to as the compound (R-6) Can be produced by reacting with [Wherein, X 2 represents a chlorine atom, a bromine atom, an iodine atom, a mesyloxy group or a tosyloxy group, and the other symbols have the same meanings as described above. ] The reaction can be carried out according to production method 1.
  • the compound (R-6) is a commercially available compound or can be produced according to a known method.
  • the compound (M-6) is a compound represented by the formula (M-7) (hereinafter referred to as a compound (M-7)) and a compound represented by the formula (M-8) (hereinafter referred to as a compound (M-8) Can be produced by reacting with [Wherein, R 33 represents a methyl group or an ethyl group, and the other symbols have the same meanings as described above. ]
  • the reaction is carried out without solvent or in a solvent.
  • the solvent used for the reaction includes, for example, ethers, hydrocarbons, aprotic polar solvents and mixtures thereof.
  • the compound (M-8) is usually used in a ratio of 0.1 to 10 moles relative to 1 mole of the compound (M-7).
  • the reaction temperature is usually in the range of -20 ° C to 200 ° C.
  • the reaction time is usually in the range of 5 minutes to 72 hours.
  • solid is collected by filtration when compound (M-6) precipitates; water is added and extracted with an organic solvent when compound (M-6) does not precipitate; To isolate compound (M-6).
  • the compound (M-7) and the compound (M-8) are commercially available compounds, or can be produced according to known methods.
  • the compound represented by the formula (M-9) (hereinafter referred to as a compound (M-9)) is a compound (M-2) and the compound represented by the formula (R-7) (hereinafter referred to as a compound (R-7) Can be produced by reacting with [Wherein, the symbols have the same meanings as described above. ] The reaction can be carried out, for example, according to the method described in Journal of Organic Chemistry, 2008, 73, 5558-5565.
  • Compound (R-7) is a commercially available compound or can be produced according to the method described in, for example, Journal of Medicinal Chemistry, 2007, 50, 6367-6382.
  • the compound represented by the formula (M-11) (hereinafter referred to as a compound (M-11)) is a compound represented by the formula (M-10) (hereinafter referred to as a compound (M-10)), the formula (R-11) It can manufacture by making the compound shown by -8) (it is hereafter described as a compound (R-8)), and a base react.
  • L 3 represents an oxygen atom
  • Compound (R-8) is a commercially available compound or can be produced according to a known method. The reaction is usually carried out in a solvent.
  • Examples of the solvent used for the reaction include hydrocarbons, ethers, halogenated hydrocarbons, aprotic polar solvents, esters and mixtures thereof.
  • Examples of the base used for the reaction include sodium hydride, alkali metal carbonates and organic bases.
  • the compound (R-8) is usually used in a proportion of 1 mol to 10 mol and the base is usually used in a proportion of 1 mol to 10 mol with respect to 1 mol of the compound (M-10).
  • the reaction time is usually in the range of 5 minutes to 24 hours.
  • the reaction temperature is usually in the range of ⁇ 20 ° C. to 100 ° C.
  • compound (M-11) can be isolated by post-treatment operation such as adding water to the reaction mixture, extracting with an organic solvent, and drying and concentrating the organic layer.
  • Reference manufacturing method 8 Compound (M-10) can be produced by reacting compound (M-4) with a chlorinating agent.
  • the chlorinating agent used for the reaction includes, for example, thionyl chloride, phosphorus oxychloride and oxalyl chloride.
  • the reaction is usually carried out in a solvent.
  • the solvent used for the reaction include hydrocarbons, halogenated hydrocarbons, ethers, nitriles, esters and mixtures thereof.
  • a chlorinating agent is usually used in a ratio of 1 mol to 10 mol per 1 mol of compound (M-4).
  • the reaction time is usually in the range of 5 minutes to 24 hours.
  • the reaction temperature is usually in the range of ⁇ 20 ° C. to 100 ° C.
  • the reaction mixture can be added with water, extracted with an organic solvent, and subjected to post-treatment procedures such as drying and concentration of the organic layer to isolate the compound (M-10).
  • the compound represented by the formula (M-13) (hereinafter referred to as the compound (M-13)) is a compound represented by the compound (M-4) or the formula (R-9) (hereinafter referred to as the compound (R-9) Can be produced by reacting a base and a base. [Wherein, the symbols have the same meanings as described above. ] The reaction may be carried out according to Reference Production Method 7 using compound (M-4) instead of compound (M-10) and compound (R-9) instead of compound (R-8). it can.
  • Compound (R-9) is a commercially available compound or can be produced according to a known method.
  • the compound represented by the formula (M-15) (hereinafter referred to as the compound (M-15)) is a compound represented by the formula (M-14) (hereinafter referred to as the compound (M-14)) and the compound represented by the formula (R-14) It can be produced by reacting the compound represented by -10) (hereinafter referred to as compound (R-10)). [Wherein, the symbols have the same meanings as described above. ] The reaction can be carried out according to Reference Production Method 6.
  • Compound (R-10) is a commercially available compound, or can be produced according to the method described in, for example, Journal of Medicinal Chemistry, 2007, 50, 6367-6382.
  • Reference manufacturing method 11 Compound (M-14) can be produced by reacting a compound represented by formula (M-16) (hereinafter referred to as compound (M-16)) with an oxidizing agent. [Wherein, the symbols have the same meanings as described above. ] The reaction can be carried out according to Reference Production Method 2.
  • Reference manufacturing method 12 Compound (M-16) can be produced by reacting a compound represented by formula (M-17) (hereinafter referred to as compound (M-17)) with a base.
  • a compound represented by formula (M-17) hereinafter referred to as compound (M-17)
  • R 34 represents a methyl group or a trifluoromethyl group, and the other symbols have the same meanings as described above.
  • the reaction is usually carried out in a solvent.
  • a solvent used for reaction alcohol is mentioned, for example.
  • a base used for reaction an alkali metal carbonate is mentioned, for example.
  • a base is usually used in a proportion of 0.1 mol to 10 mol per 1 mol of a compound (M-17).
  • the reaction time is usually in the range of 5 minutes to 24 hours.
  • the reaction temperature is usually in the range of ⁇ 20 ° C. to 80 ° C.
  • the reaction mixture can be added with water, extracted with an organic solvent, and subjected to post-treatment procedures such as drying and concentration of the organic layer to isolate the compound (M-16).
  • the compound (M-17) is a compound represented by the formula (M-18) (hereinafter referred to as compound (M-18)) and a compound represented by the formula (R-11) (hereinafter referred to as the compound (R-11) Can be produced by reacting with [Wherein, the symbols have the same meanings as described above. ]
  • the reaction is carried out without solvent or in a solvent.
  • the solvent used for the reaction include hydrocarbons, ethers, halogenated hydrocarbons and mixtures thereof.
  • the compound (R-11) is usually used in a proportion of 1 mol to 100 mol, relative to 1 mol of the compound (M-18).
  • the reaction time is usually in the range of 5 minutes to 24 hours.
  • the reaction temperature is usually in the range of ⁇ 20 ° C. to 180 ° C.
  • the reaction mixture can be added with water, extracted with an organic solvent, and subjected to post-treatment procedures such as drying and concentration of the organic layer to isolate the compound (M-17).
  • the compound (R-11) is a commercially available compound.
  • Reference manufacturing method 14 Compound (M-18) can be produced by reacting a compound represented by formula (M-19) (hereinafter referred to as compound (M-19)) with an oxidizing agent. [Wherein, the symbols have the same meanings as described above. ] The reaction can be carried out according to production method 5.
  • the compound represented by the formula (M-21) (hereinafter referred to as a compound (M-21)) is a compound represented by the formula (M-20) (hereinafter referred to as a compound (M-20)), the formula (R-20) It can be produced by reacting a compound represented by -12) (hereinafter referred to as compound (R-12)) and a base. [Wherein, the symbols have the same meanings as described above. ] The reaction can be carried out according to Reference Production Method 7.
  • the compound (R-12) is a commercially available compound or can be produced according to a known method.
  • Reference manufacturing method 16 Compound (M-20) can be produced by reacting compound (M-16) with a chlorinating agent. [Wherein, the symbols have the same meanings as described above. ] The reaction can be carried out according to the method described in Reference Production Method 8.
  • the compound represented by the formula (M-23) (hereinafter referred to as the compound (M-23)) is a compound represented by the formula (M-22) (hereinafter referred to as the compound (M-22)), the compound represented by the formula (R-22) It can be produced by reacting a compound represented by -13) (hereinafter referred to as compound (R-13)), a metal catalyst and a base.
  • X 3 represents a bromine atom or an iodine atom
  • R 35 represents a C 1 -C 13 chain hydrocarbon group ⁇ the C 1 -C 13 chain hydrocarbon group has one or more substituents selected from group A
  • group A which may be, C2-C6 alkylcarbonyl group, C2-C6 alkylcarbonyloxy group ⁇ wherein the C2-C6 alkylcarbonyl group and the C2-C6 alkylcarbonyloxy group have one or more halogen atoms
  • Examples of the metal catalyst used for the reaction include copper (I) iodide, tetrakis (triphenylphosphine) palladium (0) and dichlorobis (triphenylphosphine) palladium (II).
  • Examples of the base used for the reaction include organic bases and alkali metal carbonates.
  • the reaction is usually carried out in a solvent.
  • the solvent used for the reaction includes, for example, ethers, hydrocarbons, aprotic polar solvents and mixtures thereof.
  • the compound (R-13) is usually at a ratio of 1 mol to 10 mol, the metal catalyst is usually at a ratio of 0.01 to 0.5 mol, and the base is usually at 1 mol to 1 mol of the compound (M-22). It is used in a proportion of 1 to 100 moles.
  • the reaction time is usually in the range of 5 minutes to 48 hours.
  • the reaction temperature is usually in the range of ⁇ 20 ° C. to 80 ° C.
  • the reaction mixture can be extracted with an organic solvent, and the organic layer can be subjected to post-treatment procedures such as drying and concentration to isolate the compound (M-23).
  • the compound (R-13) is a commercially available compound or can be produced according to a known method.
  • the compound (M-22) is a compound represented by the formula (M-24) (hereinafter referred to as a compound (M-24)), and a compound represented by the formula (R-14) (hereinafter the compound (R-14) It can be produced by reacting)) with an organometallic compound.
  • the reaction is usually carried out in a solvent.
  • a solvent used for reaction hydrocarbons, ethers, and these mixtures are mentioned, for example.
  • the organic metal compound used for the reaction include C1-C4 alkyllithium and C1-C4 alkylmagnesium chloride. Lithium chloride may be used for the reaction, if necessary.
  • the compound (R-14) is usually used at a ratio of 1 mole to 10 mol and the organic metal compound is usually used at a ratio of 1 mole to 10 mol with respect to 1 mol of the compound (M-24).
  • lithium chloride lithium chloride is usually used in a proportion of 1 mole to 10 moles relative to 1 mole of the compound (M-24).
  • the reaction time is usually in the range of 5 minutes to 48 hours.
  • the reaction temperature is usually in the range of -80 ° C to 100 ° C.
  • the reaction mixture can be added with water, extracted with an organic solvent, and subjected to post-treatment procedures such as drying and concentration of the organic layer to isolate the compound (M-22).
  • Compound (R-14) is a commercially available compound or can be produced according to a known method.
  • the compound (M-24) can be produced by reacting a compound represented by the formula (M-25) (hereinafter referred to as compound (M-25)) with a compound (R-6). [Wherein, the symbols have the same meanings as described above. ] The reaction can be carried out according to production method 1.
  • the compound (M-25) is a compound represented by the formula (M-26) (hereinafter referred to as compound (M-26)) and a compound represented by the formula (R-15) (hereinafter referred to as the compound (R-15) Can be produced by reacting with [Wherein, the symbols have the same meanings as described above. ]
  • the reaction is usually carried out in a solvent.
  • a solvent used for reaction alcohol, ether, and these mixtures are mentioned, for example.
  • the compound (R-15) is usually used in a proportion of 2 mol to 20 mol per 1 mol of the compound (M-26).
  • the reaction time is usually in the range of 5 minutes to 48 hours.
  • reaction temperature is usually in the range of -20 ° C to 140 ° C.
  • compound (M-25) can be isolated by performing post-treatment procedures such as filtration and drying of the precipitated solid.
  • Compound (M-26) and compound (R-15) are commercially available compounds, or can be produced according to known methods.
  • the compound represented by the formula (M-27) (hereinafter referred to as the compound (M-27)) is a compound (M-22), the compound represented by the formula (R-16) (hereinafter the compound (R-16) Can be produced by reacting a metal catalyst and a base).
  • M represents B (OR 36 ) 2 or 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl group
  • R 36 represents a hydrogen atom or a C1-C6 alkyl group
  • the reaction is usually carried out in a solvent.
  • the solvent used for the reaction includes, for example, ethers, hydrocarbons, aprotic polar solvents, water and mixtures thereof.
  • the metal catalyst used for the reaction include tetrakis (triphenylphosphine) palladium (0), 1,1′-bis (diphenylphosphino) ferrocenepalladium (II) dichloride, tris (dibenzylideneacetone) dipalladium (0) And palladium catalysts such as palladium (II) acetate, and bis (cyclooctadiene) nickel (0).
  • a base used for reaction an alkali metal carbonate and organic bases are mentioned, for example.
  • a ligand may be used for the reaction, if necessary.
  • Examples of the ligand used for the reaction include triphenylphosphine, xanthophos, 2,2′-bis (diphenylphosphino) -1,1′-binaphthyl, 1,1′-bis (diphenylphosphino) ferrocene, 2 Dicyclohexylphosphino-2 ′, 4 ′, 6′-triisopropylbiphenyl, 2-dicyclohexylphosphino-2 ′, 6′-dimethoxybiphenyl and 1,2-bis (diphenylphosphino) ethane.
  • the compound (R-16) is usually at a ratio of 1 mol to 10 mol
  • the metal catalyst is usually at a ratio of 0.01 to 0.5 mol
  • the base is usually at 1 mol to 1 mol of the compound (M-22). It is used in a proportion of 0.1 to 5 moles.
  • the ligand is generally used in a ratio of 0.01 to 1 mole relative to 1 mole of the compound (M-22).
  • the reaction time is usually in the range of 5 minutes to 48 hours.
  • the reaction temperature is usually in the range of -20 ° C to 200 ° C.
  • reaction mixture can be extracted with an organic solvent, and the organic layer can be subjected to post-treatment procedures such as drying and concentration to isolate the compound (M-27).
  • Compound (R-16) is a commercially available compound or can be produced according to a known method.
  • the compound of the present invention or the compound of the present invention X is a group (a), a group (b), a group (c), a group (d), a group (e), a group (f), a group (g), and a group (h) And one or more components (hereinafter referred to as "the components") selected from the group consisting of The said combined use or combined use means using the compound X of the present invention and this component simultaneously, separately or at time intervals.
  • the compound of the present invention X and the component may be contained in separate formulations or may be contained in one formulation.
  • composition A containing one or more components selected from the group consisting of groups (a) and (b), and the compound X of the present invention.
  • Group (a) includes acetylcholinesterase inhibitors (eg carbamate insecticides, organophosphorus insecticides), GABAergic chloride ion channel antagonists (eg phenylpyrazole insecticides), sodium channel modulators (eg pyrethroid insecticides) Nicotinic acetylcholine receptor antagonistic modulators (eg, neonicotinoid insecticides), nicotinic acetylcholine receptor allosteric modulators, glutamatergic chloride ion channel allosteric modulators (eg, macrolide insecticides), juvenile hormone mimic , Multi-site inhibitor, chordal organ TRPV channel modulator, mite growth inhibitor, mitochondrial ATP biosynthesis enzyme inhibitor, oxidative phosphorylation uncoupling agent, nicotinic acetylcholine receptor Channel blockers (eg, nereistoxin insecticides), chitin synthesis inhibitors, molting inhibitors, ecdysone receptor
  • Group (b) includes nucleic acid synthesis inhibitors (eg, phenylamide fungicides, acyl amino acid fungicides), cell division and cytoskeleton inhibitors (eg, MBC fungicides), respiratory inhibitors (eg, QoI fungicides) , QiI fungicides), amino acid synthesis and protein synthesis inhibitors (eg, anilinopyridine fungicides), signal transduction inhibitors, lipid synthesis and membrane synthesis inhibitors, sterol biosynthesis inhibitors (eg, triazole etc.
  • nucleic acid synthesis inhibitors eg, phenylamide fungicides, acyl amino acid fungicides
  • cell division and cytoskeleton inhibitors eg, MBC fungicides
  • respiratory inhibitors eg, QoI fungicides
  • QiI fungicides QiI fungicides
  • amino acid synthesis and protein synthesis inhibitors eg, anilinopyridine fungicides
  • DMI DMI
  • bactericidal agents cell wall synthesis inhibitors, melanin synthesis inhibitors, plant defense inducers, multi-acting point contact active disinfectants, microbial disinfectants, and other bactericidal active ingredients. These are described in the classification based on the mechanism of action of FRAC.
  • Group (c) is a group of plant growth regulators (including mycorrhizal fungi and rhizobia).
  • Group (d) is a group of safeners.
  • Group (e) is a group of synergists.
  • Group (f) is a group of repellent components consisting of a bird repellent component, an insect repellent component, and an animal repellent component.
  • Group (g) is a group of mollusc components.
  • Group (h) is a group of insect pheromone.
  • alanicarb (Salyx + SX) means a combination of alanicarb (Salyx) and SX.
  • the abbreviation SX means any one compound of the present invention X selected from the compound groups SX1 to SX540 described in the Examples.
  • all of the components described below are known components and can be obtained from commercially available preparations or can be produced by known methods. When the component is a microorganism, it can also be obtained from a bacteria depository.
  • the numbers in parentheses indicate CAS RN (registered trademark).
  • Combinations of the present component of the above group (a) with the compound of the present invention Abamectin + SX, acephate + SX, acequinocyl + SX, acetamiprid + SX, acririnathrin + SX, acynonapyr + SX, afidopyropene + SX, afoxolaneal (Afoxolaner) + SX, alaniccarb (alanycarb) + SX, aldicarb (aldicarb) + SX, allethrin + SX, alpha-cypermethrin (alpha-cypermethrin) + SX, alpha-endosulfan (alpha-endosulfan) + SX, phosphorylated Aluminum (phosphide) + SX, amitraz (Amitraz) + SX, azadirachtin + SX, azamethiphos (Azamethiphos) + SX, azin
  • pomonella granulosis virus V15 (Cydia pomonella GV V15) + SX
  • C. pomonella granulosa virus V22 (Cydia pomonella GV V22) + SX
  • Cryptofrebbia leukotreta granulosa virus (Cr yptophlebia leucotreta GV) + SX
  • Dendrolimus punctatus cytoploid virus Dendrolimus punctatus cypovirus
  • SX Helicoverpa armigera nuclear polyhedrosis virus BV-0003 strain (Helicoverpa armigera NPV BV-0003) + SX
  • Helicoverpa zea Body disease virus (Helicoverpa zea NPV) + SX
  • Lymantria dispar nuclear polyhedrosis virus (Lymantria dispar NPV) + SX
  • Mamastra brassicae nuclear polyhedrosis virus (Mamestra brassicae
  • Bacillus sphaericus 2362 Bacillus sphaericus 2362 + SX, Bacillus sphaericus ABTS 1743 (Bacillus sphaericus ABTS 1743) + SX, Bacillus sphaericus Serotype H 5a 5 b (Bacillus sphaericus Serotype H 5 a 5 b) + SX, Bacillus thuringiensis AQ 52 strain (Bacillus thuringiensis AQ 52) + SX, Bacillus thuringiensis BD # 32 strain (Bacillus thuringiensis BD # 32) + SX, Bacillus thuringiensis CR-371 strain (Bacillus thuringiensis CR-371) + SX, Bacillus thuringiensis subspecies ABTS-1857 (Bacillus thuringiensis subsp.
  • Aizawai ABTS-1857 + SX, Bacillus thuringiensis subspecies AM65-52 strain (Bacillus thuringiensis subsp. Aizawai AM65-52) + SX Bacillus thuringiensis subspecies GC-91 (Bacillus thuringiensis subsp. Aizawai GC-91) + SX, Bacillus thuringin S. aiwai subspecies Serotype H-7 (Bacillus thuringiensis subsp. Aizawai Serotype H-7) + SX, Bacillus thuringiensis cristae subsp. ABTS 351 strain (Bacillus thuringiensis subsp.
  • Bacillus thuringiensis isla elensis variant serotype H-14 Bacillus thuringiensis var. israelensis serotype H- 14
  • SX Bacillus thuringiensis-Japonensis variant buibui strain (Bacillus thuringiensis var. Japonensis buibui) + SX, Bacillus thuringiensis-San Diego variant M-7 strain (Bacillus thuringiensis var. San diego M-7) + SX, Bacillus thuringiensis 7216 variant (Bacillus thuringiensis var.
  • PRAA4-1T Chromobacterium subtsugae PRAA4-1T + SX, Dactylella ellipsospora + SX, Dactylaria thaumasia + SX, Hilstera minesitensis mins.
  • pasteuria nishizawae Pn1 strain (Pasteuria nishizawae Pn1) + SX, P. pipetrae SX, Pasteuria usgae + SX, Pasteuria thoynei + SX, Serratia entomophila + SX, Verticillium chlamydosporium + SX, Vertici Lilium ⁇ recan NCIM 1312 strain (Verticillium lecani NCIM 1312) + SX, acetoprole (acetoprole) + SX, Celastrus angulatus bark (bark of Celastrus angulatus) + SX, concanamycin A (concanamycin A) + SX, sun leaf dried leaves (dried leaves) of Dryopteris filix-mas) + SX, extract of Artemisia absinthium + SX, Cassia nigricans extract (ex tract of Cassia nigricans + SX, extract of clitoria ternatea + S
  • Bacillus amyloliquefaciens strain AT332 Bacillus amyloliquefaciens AT 332) + SX
  • Bacillus amyloliquefaciens strain B3 Bacillus amyloliquefaciens B3) + SX
  • Bacillus amyloliquefaciens D747 strain Bacillus amyloliquefaciens D747) + SX
  • Bacillus amyloliquefaciens DB 101 strain Bacillus amyloliquefaciens DB101
  • Bacillus amyloliquefaciens DB 102 strain Bacillus amyloliquefaciens DB 102) + SX
  • Bacillus amyloliquefaciens GB03 strain Bacillus amyloliquefaciens GB03 strain
  • subtilis strain QST 714 Bacillus subtilis QST 714) + SX, Bacillus subtilis var. Amyloliquefaciens FZB 24 strain (Bacillus subtilis var. Amyloliquefaciens FZB24) + SX, Bacillus subtilis Y 1336 (Bacillus subtilis Y 1336) + SX, Burkholderia cepacia + SX, Burkholderia cepacia-Wisconsin type J 82 (Burkholderia cepacia type Wisconsin J 82) + SX, Burkholderia cepacia ⁇ Wisconsin M54 strain (Burkholderia cepacia type Wisconsin M54) + SX, Candida oleophila O strain (Candida oleophila O) + SX, Candida saitoana (Candida saitoana) + SX, Ketomium cupreum (Chaetium cupreum) ) + SX, Clonostachys
  • Carotobola CGE 234 M 403 strain Erwi nia carotovora subsp. carotovora CGE 234 M 403 strain (Erwi nia carotovora subsp. carotovora CGE 234 M 403) + SX, Fusarium oxysporum Fo 47 strain (Fusarium oxysporum Fo 47) + SX, Gliocladium catenulatum J 1446 (Gliocladium catenulatum J 1446) + SX, Paenibacillus polymixer AC-1 strain (Paenibacillus AC) -1) + SX, Paenibacillus polymyxa BS-0105 strain (Paenibacillus polymyxa BS-0105) + SX, Pantoea agglomerans E 325 strain (Pantoea agglomerans E 325) + SX, Flebiopsis gigantea VRA 1992 strain (Phlebiopsis gig
  • the ratio of the compound of the present invention X to the component is not particularly limited, but the weight ratio (the compound of the present invention: this component) is from 1000: 1 to 1: 1000, 500: 1 to 1: 500, 100: 1 to 1: 100, 50: 1 to 1:50, 20: 1 to 1:20, 10: 1 to 1:10, 3: 1 to 1: 3, 1: 1 to 1: 500, 1: 1 to 1: 100, 1: 1 to 1:50, 1: 1 to 1:20, 1: 1 to 1:10 and the like.
  • the compound X of the present invention is effective against noxious arthropods such as noxious insects and noxious mites, noxious nematodes, and noxious molluscs.
  • noxious arthropods such as noxious insects and noxious mites, noxious nematodes, and noxious molluscs.
  • harmful arthropods, harmful nematodes and harmful molluscs include, for example, the following.
  • Hemiptera Hemetobiunka (Laodelphax striatellus), Tobiirounka (Nilaparvata lugens), Sejirounka (Sogatella furcifera), Corn locust (Peregrinus maidis), Red-winged deer (Javesella pellucida), Black-footed Michalica Planthopper family (Delphacidae); Green leafhopper (Nephotettix cincticeps), Yellow-tailed leafhopper (Nephotettix virescens), Black-tailed green leafhopper (Nephotettix nigropictus), Yellow-tailed leafhopper (Recilia dorsalis), Black-tailed leafminus moth , Corn leaf hopper (Dalbulus maidis), white leafhopper (Cofana spectra), etc., leafhopper family (Cicadelidae); Mahanarva posticata, Mahanarva fimbriolat
  • Pecan leaf phylloxera (Phylloxera notabilis), Southern pecan leaf phylloxera (Phylloxera russellae), and the like (Phylloxeridae); (Adelgidae); rice black bug (Scot inophara lurida), Malayan rice black bug (Scot inophara coarctata), green grass bug (Nezara antennata), rhizophorid bug (Eysarcoris aeneus), dryback beetle (Eysarcoris lewisi), Red-headed Bug (Eysarcoris ventralis), Gray-backed Bug (Eysarcoris annamita), Brown-backed Bug (Halyomorpha halys), Red-headed Bug (Nezara viridula), Brown stink bug (Euschistus heros), Red banded stink bug (Piez Sturgeon (Pentatomidae) such as melacanthus; Sturgeon (Cydnidae) such as Burrower
  • Helicidae (Coreidae); , Ameri Red-tailed bug family (Lygaeidae) such as Blissus leucopterus; Red-backed squirrel (Trigonotylus caelestialium); Stink bug family (Miridae); Trichoderma faecalis (Trialeurodes vaporariorum), B. tabaci (Bemisia tabaci), Scutellaria barbata (Dialeurodes citri), Scutellaria barbata L.
  • Ameri Red-tailed bug family (Lygaeidae) such as Blissus leucopterus; Red-backed squirrel (Trigonotylus caelestialium); Stink bug family (Miridae); Trichoderma faecalis (Trialeurodes vaporariorum), B. tabaci (Bemisia tabaci), Scutellaria barbata (Dialeurodes citri), Scutellaria barbata L.
  • Lepidoptera Chilo suppressalis, Darkheaded stem borer (Chilo polychrysus), White stem borer (Scirpophaga innotata), Itten's tree magnolia (Scirpophaga incertulas), Rupela albina, Kobnomiga (Cnaphatailicalis) Casino meiga (Marasmia exigua), cotton moth (Notarcha derogata), foxtail moth (Ostrinia furnacalis), European corn borer (Ostrinia nubilalis), black-tailed moth (Hellula undulis), monquil chronome moth (Herpetogramma lucitose, Pe) Caseworms (Nymphula depunctalis), Sugarcane borer (Diatraea saccharalis), and other parts of the family (Crambidae); Ringworm (Pyralidae); Spodoptera litura, Spodoptera exigua, Mythimna separata
  • Arctiidae Giant Sugarcane b Orster (Telchin licus) Kastoniagae (Castniidae); Himebokuto (Cossus insularis) et al. (Cossidae); Family (Limacodidae); Staphymopoda (Stathmopoda niessa) etc .; Stathmopodidae; Acherontia lachesis et al. Sphingidae (Sphingidae); And the like. Seschidae (Sesiidae), etc .; Hemperididae (Hesperiidae) such as the rice tortoise (Parnara guttata);
  • Thysanoptera Thysanoptera: Thripsidae (Frankliniella occidentalis), Thripsidae (Thrips palmi), Chalyssus thripsus (Scirtothrips dorsalis), Thrips tabaci (Thrips tabaci), Hydrangea thripsus (Frankliniella intronacea) , Thripidae such as Echinothrips americanus etc .; Thripsidae (Phlaeothripidae) such as Haekohrips aculeatus.
  • Diptera Anemoneid family (Anthomyiidae) such as fly (Delia platura), onion fly (Delia antiqua), sugar beet fly (Pegomya cunicularia) etc .; Rice leafminer fly (Agromyza oryzae), tomato leafminer fly (Liriomyza sativae), bean leafminer fly (Liriomyza trifolii), leafminer fly (Chromatomyia horticola), etc.
  • Anemoneid family such as fly (Delia platura), onion fly (Delia antiqua), sugar beet fly (Pegomya cunicularia) etc .
  • Rice leafminer fly Agromyza oryzae
  • tomato leafminer fly Liriomyza sativae
  • bean leafminer fly Liriomyza trifolii
  • leafminer fly Chromatomyia horticola
  • Leafworm family (Agromyzidae); Bactrocera cucurbitae), mandarin orange fruit fly (Bactrocera dorsalis), egg fruit fly (Bactrocera latiphrons), olive fruit fly (Bactrocera oleae), quince land fruit fly (Bactrocera tryoni), citechine fruit fly (Ceratitis capitaphy) Tephritidae (Tephritidae), such as pomonella), sweet potato weeds (Rhacochlaena japonica); ; Drosophilidae such as Drosophila melanogaster (Drosophila suzukii); Psyllididae (Phoridae) such as the giant flea fly (Megaselia spiracularis); dimorphism fly family (Sciaridae) such as Hessian fly (Mayetiola destructor), Bacteriidae (Cecidomyiidae) such as incocarid fly (Ors
  • Culex quinquefasciatus Culex pipiens molestus Forskal, Culexidae such as Culex quinquefasciatus; Culicidae; Prosimulium yezoensis; House fly (Musca domestica), house fly (Muscina stabulans), sea fly (Stomoxys calcitrans), house fly (Haematobia irritans) such as house fly (Muscidae); ); (Chironomus plumosus), Chironomus yoshimatsui (Chironomus yoshimatsui), Chironomidae such as Gray midges (Glyptotendipes tokunagai) (Chironomidae); fanniidae (Fannidae).
  • Coleoptera Coleoptera (Coleoptera): Western corn rootworm (Diabrotica virgifera virgifera), Southern corn rootworm (Diabrotica undecimpunctata howardi), Northen corn rootworm (Diabrotica barberi), Mexican corn rootworm (Diabrotica virgifera zeae), Banded Cuicabiotic (Diabrotica virgifera zeae) balteata), Cucurbit Beetle (Diabrotica speciosa), Bean Leaf Beetle (Cerotoma trifurcata), Cubial Leaf Beetle (Oulema melanopus), Ground Leaf Beetle (Aulacophora femoralis), Sweet potato leaf beetle (Phyllotreta striolata), Cabbagel flea beetle (Phyllotreta pusilla), Cabbage stem flea beetle (Psylliodes chrysocephala), Colorado potato beetle (Leptinotarsa
  • Carabidae (Anomala albopilosa), Anemone carp (Popillia japonica), Anchovy (Heptophylla picea), European Chafer (Rhizotrogus majalis), Black marsh (Tomarus gibbosus), Holotrichia sp. of the genus Phyllophaga (Phyllophaga spp.), Diloboderus abderus, etc. Diloboderus (Diloboderus spp.), etc.
  • Scarabaeidae Sudabaeidae
  • postfasciatus alfalfata weevil (Hypera postica), tree weevil (Sitophilus zeamais), rice weevil (Echinocnemus squameus), rice water weevil (Lissorhoptrus oryzophilus), weed beetles (Rhabs celus lineatocollis) venatus), Southern Corn Billbug (Sphenophorus callosus), Soybean stalk weevil (Sternechus subsignatus), Sugarcane weevil (Sphenophorus levis), Crustacean weevil (Scepticus griseus), Scuticularis semen (Scepticus uniformis) , Brazilian bean weevil (Zabrotes subfasciatus), Pinus spinach (Tomicus piniperda), Coffee Berry Borer (Hypothenemus hampei), Aracanthus sp., Such as Arac
  • Ladybird family such as Epilachna vigintopoctopusta such as Coccinidae, such as Tricholium castaneum, Tribolium fascium, etc .; Epilachna vigintopoctopusta, etc .; Bostrychidae); Pantopus spp. (Ptinidae); Pteris (Anoplophora malasiaca), Migdolus fryanus etc.
  • Cerambycidae Click beetles such as common woodpeckers (Melanotus legatus), insect beetles (Anchastus spp.), Genus Conodes (Conoderus spp.), Genus Cotennisa (Ctenicera spp.), Genus Limonius (Limonius spp.), And genus Aeolus (Aeolus spp.) Family (Elateridae); Staphylinidae (Staphylinidae), such as Paederus fuscipes, etc; A beetle family (Anobidae) such as a beetle (Stegobium paniceum).
  • Orthoptera (Orthoptera): Toocta grasshopper (Locusta migratoria), Toroca grasshopper (Dociostaurus maroccanus), Australia Tobibatata (Chortoicetes terminifera), Red-footed grasshopper (Nomadacris septemfasciata), Brown Locust (Locustana pardalis Aritraceilogues) Locust (Calliptamus italicus), Differential grasshopper (Melanoplus differentialis), Two striped grasshopper (Melanoplus bivittatus), Migratory grasshopper (Melanoplus cerichelimel at least 2 times), Red-Legged grasshopper (Mel ), Yellow-winged locust (Gastrimargus musicus), Spur-throated locust (Austracris guttulosa), Kobayinago (Oxya yezoensis), Hanekinainago (Oxya japonica), Trichophyton (
  • Hymenoptera (Hymenoptera): Japanese gossip (Athalia rosae), Japanese black-billed wasp (Athalia japonica), etc. (Tenthredinidae); Fireflies (Solenopsis invicta), Red-winged Ants (Solenopsis geminata), etc. Tolushinella (Solenopsis spp. leaf-cutting ant (Atta capiguara) et al. (Atta spp.), Anemone spp. (Acromyrmex spp.), Anemone spp.
  • Black-headed ants (Formica fusca japonica), Ammet's ants (Pristomyrmex punctutus), Ascidian (Pheidole noda), Ascidian (Pheidole megacephala), Ascidian (Camponotus japonicus), Red-billed ants (Camponotus obscuripes), etc.
  • Anemone family such as the genus Quasi (Pogonomyrmex), Anopheles (Wasmania auropunctata), an ant family (Formicidae) such as Anoplolepis gracilipes, etc .
  • Vespa analis Fabriciusi Vespa velutina, Polistes jokahamae (Vespidae) such as Vespidae;
  • Cockroach (Blattodea): German cockroach (Blattella germanica) and other German cockroaches (Blattellidae); (Blattidae); Yamato termites (Reticulitermes speratus), house termites (Coptotermes formosanus), American termites (Incisitermes minor), Dicta termites (Cryptotermes domesticus), Taiwan termites (Odontotermes formosanus), red-handed termites (Neotermes) Glyptotermes satsumensis), Chinese termite (Glyptotermes nakajimai), catan termite (Glyptotermes fuscus), giant termite (Hodotermopsis sjostedti), black-and-white termite (Coptotermes guangzhouensis) , Aphid termites (Reticulitermes amamianus), Mitatake termites (Reticulitermes miyatakei), Cameron termites (Reticulitermes
  • Flea order (Siphonaptera): cat flea (Ctenocephalidae felis), dog flea (Ctenocephalides canis), castor flea (Pulex irritans), pheasant flyfish (Xenopsylla cheopis), sunanose (Tunga penetrans), chick flea (Echidnophaga gallinacea) Fleas (Nosopsyllus fasciatus).
  • Lice (Anoplura): pig lice (Haematopinus suis), lice (Haematopinus eurysternus), sheep lice (Dalmalinia ovis), lice (Linognathus seypsus), lice (Pediculus humanis), lice (Pediculucus humanus corporis) Barbed lice (Phthirus pubis).
  • Psyllids (Mallophagida): Bovine lava (Dalmalinia bovis), sheep baldness (Dalmalinia ovis) etc. Bovicola sp. (Bovicola spp.); P. Of the genus Fericola (Felocpla spp), Peanut (Lipeurus caponis) and the like Peurus (Lipeurus spp.), Trimenopon sp. (Trimenopon spp), Menopon sp. (Menopon spp.) And the like.
  • Eriophyidae such as Schizoctella (Shevtchenkella sp.); Red-handed spider mite (Tenuipalpidae) such as (Brevipalpus phoenicis); Tannertidae (Tuckerellidae); Andersoni (Dermacentor and ersoni), Ixodes ovatus, Ixodes persulcatus, Ixodes ricinus, Black legged tick (Ixodes scapularis), American kill mite (Amblyomma americanum), amblyomumium platinum ), Ixodidae such as Boophilus microplus, Boophilus annulatus, Rhipicephalus sanguineus, etc .; Tyrophagus pu Acaridae (Acaridae), such as Trichophagus similis, etc .; Dermatophagoides such as Dermatophagoides farinae, Dermatophagoides pteronyssinus, etc.
  • Arachnida (Araneae): Anemone family (Eutichuridae) such as Chehiracanthium japonicum etc .; A hymenodontid family (Theridiidae) such as Latrodectus hasseltii.
  • Obiayasuda (Polydesmida): Nephetidae (Oxidus gracilis), Red-crested cod (Nedyopus tambanus), etc.
  • Isopoda Armadillidiidae, such as Armadillium vulgare.
  • Lipopoda Chopoda: The Scutigera such as Thereuonema hilgendorfi; Scoopendra subspinipes such as Scoopendradidae; Gastropoda (Gastropoda): Black-tailed slug (Limax marginatus), black-tailed slug (Limax flavus), etc. (Limacidae); Monopidae (Ampullariidae) of the family; Monopidae (Lymnaeidae), such as the black-and-white alga (Austropheplella)
  • Nematoda Aphelenchoides sp. (Aphelenchoides besseyi etc.) Aphelenchoididae (Aphelenchoididae); And the like (Pratylenchidae), etc .; Java spp.
  • Heteroderidae such as Glossodera (Globodera pallida); Hoprolases (Hoplolaimidae), such as Rotylenchulus reniformis; Strawberry nematode (Nothotylenchus acris), jichi Anguinidae (Anguinidae) such as Lexus gypsy (Ditylenchus dipsaci); Tylenculidae (Tylenchulidae) such as Tylenchulus seminetrans; Trichodoridae); Parasitaphelenchidae such as Bursaphelenchus xylophilus.
  • Hoprolases Hoplolaimidae
  • Rotylenchulus reniformis such as Rotylenchulus reniformis
  • Strawberry nematode Nothotylenchus acris
  • jichi Anguinidae Anguinidae
  • the target harmful insects, harmful mites and other harmful arthropods, harmful molluscs and harmful nematodes have reduced drug sensitivity to insecticides, acaricides, molluscicides and nematocides, or drug resistance They may be sexually developed harmful insects, harmful arthropods such as harmful mites, harmful molluscs and harmful nematodes.
  • the targeted insecticides, acaricides, insecticides other than nematocides and nematocides, acaricides The use of a composition comprising a molluscicide and a nematocide component is desirable.
  • the compounds X of the present invention can also be used to protect plants from plant diseases caused by insect-borne viruses or insect-borne bacteria.
  • Such insect-borne viruses include, for example, the following.
  • Rice hatching virus (Rice tungro spherical virus), rice tungro bacillus virus (Rice tungro bacilliform virus), rice grassy stunt virus (Rice grassy stunt virus), rice ragged stunt virus (Rice ragged stunt virus), rice streak dead virus ( Rice stripe virus), Rice black streaked dwarf virus, Rice southern black streaked dwarf virus, Rice gall dwarf virus, Rice hoja disease (Rice hoja) blanca virus), rice yellow leaf virus (Rice yellow stunt virus), rice yellow mottle virus, rice dwarf virus, wheat cereals northern virus (Northern cereal mosaic virus), barley yellow dwarf virus (Barley yellow dwarf virus) , Barley mild mosaic virus, Barley yellow dwarf PAV Iris (Barley yellow dwarf virus-PAV), wheat yellow dwarf RPS virus (Cereal yellow dwarf virus-RPS), wheat yellow leaf virus (Wheat yellow leaf virus), Oat sterile dwarf virus, Wheat streak mosaic virus, corn dwarf mosaic virus Maize dwarf mosaic virus, Maize stripe virus, Maize chlorotic mottle virus, Maize chlorotic dwarf virus,
  • insect-borne bacteria examples include the following.
  • Rice yellow dwarf phytoplasma (Candidatus Phytoplasma oryzae), Candidatus Phytoplasma asteris, Maize bushy stunt phytoplasma, citrus greening fungus Asian type (Candidatus Liberbacter asiaticus), citrus greening fungus African type (Candidatus Liberbacter aflicanus), Type (Candidatus Liberbacter americanus).
  • the noxious arthropod controlling composition of the present invention contains the present compound, the present compound X or the composition A and an inert carrier (hereinafter referred to as the present composition).
  • the composition of the present invention is generally prepared by mixing the compound of the present invention, the compound X of the present invention or the composition A with an inert carrier such as a solid carrier, a liquid carrier, a gaseous carrier, etc.
  • Add auxiliaries for formulation add emulsion, oil, powder, granules, wettable, water dispersible granule, flowable, dry flowable, microcapsule, aerosol, poison bait, resin formulation, shampoo, It is formulated into a paste-like preparation, a foam, a carbon dioxide preparation, a tablet and the like.
  • composition of the present invention contains usually 0.0001 to 95% by weight of the compound of the present invention, the compound of the present invention X or the composition A.
  • solid carriers used in formulation include clays (kaolin clay, diatomaceous earth, bentonite, fuvasami clay, acid clay etc.), dry silica, wet silica, talc, ceramic, and other inorganic minerals (sericite, quartz, Fine powders and particles such as sulfur, activated carbon, calcium carbonate etc., chemical fertilizers (ammonium sulfate, ammonium phosphate, ammonium nitrate, urea, sodium chloride etc.) and synthetic resins (polypropylene, polyacrylonitrile, polymethyl methacrylate, polyethylene terephthalate) And polyester resins, nylon resins such as nylon-6, nylon-11, and nylon-66, polyamide resins, polyvinyl chloride, polyvinylidene chloride, vinyl chloride-propylene copolymers, and the like.
  • clays kaolin clay, diatomaceous earth, bentonite, fuvasami clay, acid clay etc.
  • dry silica wet silica,
  • liquid carriers examples include water, alcohols (methanol, ethanol, isopropyl alcohol, butanol, hexanol, benzyl alcohol, ethylene glycol, propylene glycol, phenoxyethanol etc.), ketones (acetone, methyl ethyl ketone, cyclohexanone etc.), aromatic hydrocarbons (Toluene, xylene, ethylbenzene, dodecylbenzene, phenylxylylethane, methylnaphthalene etc.), aliphatic hydrocarbons (hexane, cyclohexane, kerosene, light oil etc.), esters (ethyl acetate, butyl acetate, isopropyl myristate, Ethyl oleate, diisopropyl adipate, diisobutyl adipate, propylene glycol monomethyl ether acetate, etc., nitriles (ace
  • Gaseous carriers include, for example, fluorocarbons, butane gas, LPG (liquefied petroleum gas), dimethyl ether and carbon dioxide gas.
  • surfactants examples include nonionic surfactants such as polyoxyethylene alkyl ether, polyoxyethylene alkyl aryl ether, polyethylene glycol fatty acid ester, and anions such as alkyl sulfonate, alkyl benzene sulfonate, and alkyl sulfate. Surfactants may be mentioned.
  • fixing agents As other pharmaceutical adjuvants, fixing agents, dispersing agents, coloring agents, stabilizers and the like, specifically, for example, casein, gelatin, saccharides (starch, gum arabic, cellulose derivatives, alginic acid etc.), lignin derivatives, bentonite, Synthetic water-soluble polymers (polyvinyl alcohol, polyvinyl pyrrolidone, polyacrylic acids, etc.), isopropyl acid phosphate, 2,6-di-tert-butyl-4-methylphenol, BHA (2-tert-butyl-4-methoxyphenol) And a mixture of 3-tert-butyl-4-methoxyphenol).
  • saccharides starch, gum arabic, cellulose derivatives, alginic acid etc.
  • lignin derivatives bentonite
  • Synthetic water-soluble polymers polyvinyl alcohol, polyvinyl pyrrolidone, polyacrylic acids, etc.
  • isopropyl acid phosphate 2,6
  • Examples of the base material of the resin preparation include vinyl chloride polymers, polyurethane and the like, and phthalate esters (dimethyl phthalate, dioctyl phthalate, etc.), adipates, etc. may be used as necessary for these bases. And a plasticizer such as stearic acid may be added.
  • the resin formulation is obtained by kneading the compound in the base using a common kneading apparatus, and then molding by injection molding, extrusion molding, press molding and the like, and if necessary, through further steps such as molding and cutting, It can be processed into resin preparations such as plate-like, film-like, tape-like, net-like and string-like.
  • resin preparations are processed, for example, as animal collars, animal ear tags, sheet preparations, drawstrings, horticultural posts.
  • substrates for poison bait include cereal flour, vegetable oil, sugar, crystalline cellulose and the like, and further, if necessary, antioxidants such as dibutyl hydroxytoluene and nordihydroguaiaretic acid, preservatives such as dehydroacetic acid and the like.
  • antioxidants such as dibutyl hydroxytoluene and nordihydroguaiaretic acid
  • preservatives such as dehydroacetic acid and the like
  • an inhibitor against misphagy by children and pets such as capsicum powder, a cheese flavor, and an insect-inducing flavor such as onion flavor peanut oil are added.
  • the method of controlling a harmful arthropod of the present invention comprises directly administering an effective amount of the compound of the present invention, the compound of the present invention or the composition of the present invention to the harmful arthropod and / or Application to soil, house, animals etc. It can also be applied to seeds.
  • Examples of the application method of the compound of the present invention, the compound X of the present invention or the composition of the present invention include stem and leaf treatment, soil treatment, root treatment, shower treatment, smoke treatment, water surface treatment and seed treatment.
  • plants include whole plants, stems and leaves, flowers, ears, fruits, trunks, branches, crowns, seeds, vegetative organs and seedlings.
  • the vegetative organ means the plant roots, stems, leaves, etc. that have the ability to grow when the site is separated from the main body and installed in the soil.
  • the vegetative reproductive organs for example, tuberous root, creeping root, bulb, corm or solid bulb, tuber, tuber, rhizome, stolon Rhizophores, cane cuttings, propagule and vine cutting.
  • a toothpick is also called a runner (runner), and a basket is also called a sprout and is divided into a broad bud and a bulbil (bulbil).
  • “Vine” means shoots such as sweet potato and yam (collectively referred to as leaves and stems, shoot).
  • bulbs corms, tubers, rhizomes, stem fragments, rhizomes or tuberous roots are collectively referred to as bulbs. Cultivation of potato starts by planting tubers in the soil, but the tubers used are generally called seed potatoes.
  • the compound X of the present invention or the composition of the present invention As a method of applying an effective amount of the compound of the present invention, the compound X of the present invention or the composition of the present invention to a plant or a soil for cultivating plants, for example, the compound of the present invention, the compound of the present invention X or the composition of the present invention
  • the method of applying the effective dose of this invention compound, this invention compound X, or this invention composition to the soil after planting is mentioned.
  • a method for controlling an arthropod pest by applying an effective amount of the compound of the present invention, the compound X of the present invention or the composition of the present invention to the soil before planting or after planting is, for example, Method of directly controlling harmful arthropods by applying an effective amount of the compound of the present invention, the compound of the present invention or the composition of the present invention to the rhizosphere of a crop to be protected from damage such as feeding by animals And the effective amount of the compound of the present invention, the compound of the present invention, or the composition of the present invention into the interior of the plant body to control a harmful arthropod feeding on a plant.
  • the application amount thereof is usually 1 to 10000 g in the amount of the compound of the present invention or compound X of the present invention per 10000 m 2 It is.
  • the amount of the compound of the present invention or the compound X of the present invention is usually 0.001 to 100 g based on 1 Kg of seeds or vegetative organs.
  • the application rate of composition A is usually 0.001 to 100 g per kg of seed or vegetative organ.
  • compound X of the present invention or composition A is formulated into an emulsion, a wettable powder, a flowable, etc., it is usually diluted with water so that the concentration of the active ingredient is 0.01 to 10000 ppm. And granules, dusts, etc. are usually applied as such.
  • formulations and their dilutions may be sprayed directly onto plants, such as harmful arthropods or crops to be protected from harmful arthropods, and harmful arthropods that inhabit the soil of cultivated land
  • the soil may be treated to control.
  • the resin preparation processed into a sheet or string can be treated by a method such as wrapping around a crop, spreading it in the vicinity of a crop, spreading it on stock soil, or the like.
  • the application amount thereof is the compound of the present invention per 1 m 2 of treated area or an amount of the present compound X, usually from 0.01 ⁇ 1000 mg, in an amount of compound of the invention or the invention compound X per processing space 1 m 3 if the process in the space, generally 0.01 ⁇ 500 mg It is.
  • compound X of the present invention or composition A is formulated into an emulsion, a wettable powder, a flowable, etc., it is usually diluted with water so that the concentration of the active ingredient is 0.1 to 10000 ppm. Apply oil, aerosol, smoke, poison bait etc. as it is.
  • the compound of the present invention X or the composition of the present invention is used for ectoparasite control of small animals such as cattle, horses, pigs, sheep, goats and chickens, domestic animals such as dogs, cats, rats and mice It can be used on animals in a manner known in the art.
  • small animals such as cattle, horses, pigs, sheep, goats and chickens
  • domestic animals such as dogs, cats, rats and mice
  • systemic suppression for example, it is administered by tablet, feed mixing, suppository, injection (intramuscular, subcutaneous, intravenous, intraperitoneal etc.) and is intended for non-systemic suppression.
  • the amount of the compound of the present invention or the compound of the present invention X when administered to an animal is usually in the range of 0.1 to 1000 mg per 1 kg of animal weight.
  • the compound of the present invention, the compound of the present invention X or the composition of the present invention can be used as a control agent for arthropod pests in agricultural land such as fields, paddy fields, lawns, orchards. Examples of plants include the following.
  • Agricultural products corn, rice, wheat, barley, rye, oats, sorghum, cotton, soybeans, peanuts, buckwheat, sugar beet, rapeseed, sunflower, sugar cane, tobacco etc.
  • Vegetables Solanaceous vegetables (eggplant, tomatoes, peppers, peppers, potatoes, etc.), Cucurbitaceae vegetables (eg, cucumbers, pumpkins, zucchini, watermelons, melons, etc.), Brassicaceae vegetables (radish, turnip, horseradish, kohlrabi, Chinese cabbage, cabbage) , Mustard, broccoli, cauliflower etc.), Asteraceae vegetables (eg burdock, shung chrysanthemum, artichoke, lettuce etc.), a liliaceous vegetables (scallion, onion, garlic, asparagus etc.), vegidaceae vegetables (carrots, parsley, celery, American buffalo) Etc.), vecoraceae vegetables (spinach, swiss char
  • Fruits Fruits; Fruits (apples, pears, Japanese pears, cullins, quince etc.), Core fruits (momo, plums, nectarines, jujubes, apricots, prunes etc.), citrus fruits (palms, oranges, lemons, limes, grapefruits) Etc), nuts (nuts, walnuts, hazelnuts, almonds, pistachios, cashews, macadamias etc), berries (blueberries, cranberries, blackberries, raspberries etc), grapes, oysters, olives, loquats, bananas, coffee, etc. Date palm, coconut palm, etc.
  • Trees other than fruit trees tea, mulberry, flowering trees, street trees (astera, birch, dogwood, eucalyptus, eucalyptus, ginkgo, lilac, maple, oak, poplar, persimmon, perennial, fusarium, plananas, persimmon, perianthus, birch, fir tree, tsuga, nezu, pine Spruce, yew etc. etc.
  • the above-mentioned plants also include plants which can be produced by natural mating, plants which can be generated by mutation, F1 hybrid plants and genetically modified crops.
  • genetically modified crops include HPPD (4-hydroxyphenylpyruvate dioxygenase enzyme) inhibitors such as isoxaflutole, ALS (acetolactate synthetase) inhibitors such as imazethapyr and thifensulfuron methyl, EPSP (5 -Plants with resistance to herbicides such as -enolpyruvyl shikimate-3-phosphate synthetase inhibitor, glutamine synthetase inhibitor, PPO (protoporphyrinogen oxidase) inhibitor, bromoxynil, or dicamba
  • HPPD 4-hydroxyphenylpyruvate dioxygenase enzyme
  • ALS acetolactate synthetase
  • EPSP -Plants with resistance to herbicides such as -enolpyruvyl
  • the above-mentioned plant is not particularly limited as long as it is a commonly grown variety.
  • Me represents a methyl group
  • Et represents an ethyl group
  • Pr represents a propyl group
  • iPr represents an isopropyl group
  • Bu represents a butyl group
  • Pen represents a pentyl group
  • Hex hexyl.
  • TBu represents a tert-butyl group
  • cPr represents a cyclopropyl group
  • cBu represents a cyclobutyl group
  • cPen represents a cyclopentyl group
  • cHex represents a cyclohexyl group
  • Ph represents a phenyl group.
  • CHMeCH 2 CH 3 represents a 1-methylpropyl group
  • (CH 2) 2 CHMe 2 represents a 3-methylbutyl group
  • C ⁇ CcHex represents a 2-cyclohexylethynyl group
  • cPr, cBu, cPen and cHex have a substituent, the substituent is indicated before the symbol together with the substitution position.
  • 3,3-Me 2 -cBu represents a 3,3-dimethylcyclobutyl group
  • CH 2 (4-OMe-cHex) represents a (4-methoxycyclohexyl) methyl group.
  • Reference Production Example 15 The compounds produced according to the method described in Reference Production Example 14 and the physical properties thereof are shown below.
  • Formula (A-9) In the compounds represented by the above, compounds wherein R 2x is described in [Table 2].
  • Reference Production Example 17 The compounds produced according to the method described in Reference Production Example 16 and the physical properties thereof are shown below. In the compounds represented by formula (A-9), compounds wherein R 2x is as described in [Table 3].
  • the present compound 1 1 H-NMR (CDCl 3 ) ⁇ : 6.60-6.48 (0.5 H, m), 6.28 (0.5 H, d), 6.14 (0.5 H, d), 5. 76-5. 65 (0.5 H, m) , 2.36-2.11 (7H, m), 2.01 (3H, s), 1.89-1.78 (1H, m), 1.51-1.14 (12H, m), 0.90-0.81 (3H, m).
  • Production Example 2 The compounds produced according to the method described in Production Example 1 and the physical properties thereof are shown below.
  • Formula (A-2) In the compounds shown by these, compounds in which R 1x and R 2x are any combination of those described in [Table 4].
  • the present compound 6 1 H-NMR (CDCl 3 ) ⁇ : 6.57-6.45 (1 H, m), 6.34-6.18 (1 H, m), 5.87-5. 75 (1 H, m), 2. 35 (1.5 H, s), 2.31 (1.5 H, s), 2. 27 (1.5 H, s), 2. 19 (1.5 H, s), 2.01 (1.5 H, s), 2.02 (1.5 H, s), 1. 84 (1.5 H, dd), 1.50 (1.5 H, s) 1.5 H, dd).
  • the present compound 8 1 H-NMR (DMSO-d 6 ) ⁇ : 2.17 (6H, s), 1.80 (6H, s).
  • the present compound 9 1 H-NMR (CDCl 3 ) ⁇ : 9.77 (0.5 H, s), 9. 50 (0.5 H, s), 7.
  • the present compound 10 1 H-NMR (CDCl 3 ) ⁇ : 8.45 (0.5 H, s), 8.34 (0.5 H, s), 6.63 to 6.72 (0.5 H, m), 6.51 (0.5 H, d), 6.32 (0.5H, d), 5.80-5.88 (0.5H, m), 2.91-3.02 (1H, m), 2.75-2.87 (1H, m), 2.36 (1.5H, s), 2.29 (1.5 H, s) , 2.27 (1.5 H, s), 2.21 (1.5 H, s), 2.02 (3 H, s).
  • the present compound 16 1 H-NMR (CDCl 3 ) ⁇ : 8.08 (1 H, s), 4.55 (2 H, s), 3.42-3. 31 (1 H, m), 2.79-2.67 (2 H, m), 2.
  • the present compound 20 1 H-NMR (CDCl 3 ) ⁇ : 2.46 (3H, s), 2.37 (3H, s), 2.13 (2H, t), 2.03 (3H, s), 1.49-1 to 38 (2H, m) ), 0.92 (3H, t).
  • Invention compound 98 1 H-NMR (CDCl 3 ) ⁇ : 8.38 (1 H, s), 6.78 (0.5 H, dt), 6.41 (0.5 H, d), 6.20 (0.5 H, d), 5.79 (0.5 H , dt), 2.58-2.39 (3H, m), 2.37 (1.5H, s), 2.32-2.24 (1H, m), 2.29 (1.5H, s), 2.28 (1.5H, s), 2.22 (1.5H) , s), 2.02 (3H, s).
  • the present compound 99 1 H-NMR (CDCl 3 ) ⁇ : 9.40 (0.5 H, s), 9.14 (0.5 H, s), 6.37-6.24 (1 H, m), 6.13-6.06 (0.5 H, m), 5.82-5.70 (0.5 H, m), 3.45 (0.5 H, m), 3.19 (0.5 H, m), 2. 32 (1.5 H, s), 2.30 (1.5 H, s), 2.20-2.08 (1 H, m) , 2.01 (1.5 H, s), 2.00 (1.5 H, s), 1.92-1. 83 (1 H, m), 1.51-1. 29 (2 H, m), 1.
  • Invention compound 121 1 H-NMR (CDCl 3 ) ⁇ : 5.17 (0.5 H, m), 4.95 (0.5 H, m), 3.38 (1 H, s), 3.25 (1 H, s), 2.27 (1.5 H, s), 2.25 (1.5 H, s), 2.21 (1.5 H, s), 2.21 (1.5 H, s), 2.18 (1 H, m), 2.02 (1.5 H, s), 2.02 (1.5 H, s), 1.94 (1 H, m), 0.59 (1.5 H, s), 1.51 (1.5 H, s), 0.99 (1.5 H, t), 0.87 (1.5 H, t).
  • the present compound 25 1 H-NMR (CDCl 3 ) ⁇ : 10.15 (1H, s), 5.88 (1H, s), 3.39 (6H, s), 2.45 (3H, s), 2.29 (3H, s), 2.00 (3H, s).
  • the present compound 26 1 H-NMR (CDCl 3 ) ⁇ : 2.46 (3H, s), 2.37 (3H, s), 2.13 (2H, t), 2.03 (3H, s), 1.49-1 to 37 (2H, m) ), 0.92 (3H, t).
  • the present compound 27 1 H-NMR (CDCl 3 ) ⁇ : 6.13 (0.5 H, d), 6.03 (0.5 H, d), 5.92-5. 74 (1 H, m), 2.50 (1.5 H, s), 2.48 1.5 H, s), 2. 47 (1.5 H, s), 2. 39 (1.5 H, s), 2. 28 (1.5 H, s), 2. 25 (1.5 H, s), 2.23-2.15 (1 H, m), 2.07 (1.5) H, s), 2.05 (1.5 H, s), 1.80-1.89 (1 H, m), 1.49-1 .16 (12 H, m), 0.93-0.83 (3 H, m).
  • Production Example 6 The compounds produced according to the method described in Production Example 5 and the physical properties thereof are shown below.
  • Formula (A-3) In the compound shown by these, compounds in which R 1x and R 2x are any combination described in [Table 5].
  • the present compound 28 1 H-NMR (CDCl 3 ) ⁇ : 6.13 (0.5 H, d), 6.04 (0.5 H, d), 5.88 (0.5 H, m), 5. 78 (0.5 H, m), 2.50 (1.5 H, s), 2.48 (1.5 H, s), 2. 47 (1.5 H, s), 2. 39 (1.5 H, s), 2. 28 (1.5 H, s), 2. 25 (1.5 H, s), 2. 20 (1 H, m) ), 2.07 (1.5 H, s), 2.05 (1.5 H, s), 1. 84 (1 H, m), 1. 45 (1 H, m), 1.33 (3 H, m), 1.22 (2 H, m), 0.91 (1.5 H) , t), 0.84 (1.5 H, t).
  • the compound of the present invention 29 1 H-NMR (CDCl 3 ) ⁇ : 6.13 (0.5 H, d), 6.04 (0.5 H, d), 5.87 (0.5 H, m), 5. 78 (0.5 H, m), 2.50 (1.5 H, s), 2.48 (1.5 H, s), 2.47 (1.5 H, s), 2. 39 (1.5 H, s), 2. 28 (1.5 H, s), 2. 25 (1.5 H, s), 2.21 (1 H, m) ), 2.07 (1.5 H, s), 2.05 (1.5 H, s), 1. 85 (1 H, m), 1.41 (2 H, m), 1. 27 (2 H, m), 0.93 (1.5 H, t), 0.83 (1.5) H, t).
  • the present compound 30 1 H-NMR (CDCl 3 ) ⁇ : 6.14 (0.5 H, d), 6.05 (0.5 H, d), 5.95-5.75 (1 H, m), 2.50 (1.5 H, s), 2.48 3H, s), 2. 39 (1.5 H, s), 2. 28 (1.5 H, s), 2. 25 (1.5 H, s), 2.23-2.13 (1 H, m), 2.08 (1.5 H, s), 2.05 (1.5 H) , s), 1.88-1.79 (1 H, m), 1.51-1. 43 (1 H, m), 1.41-1. 30 (1 H, m), 0.96 (1.5 H, t), 0.84 (1.5 H, t).
  • the present compound 31 1 H-NMR (CDCl 3 ) ⁇ : 6.13 (0.5 H, d), 6.02 (0.5 H, d), 5. 93 (0.5 H, m), 5. 77 (0.5 H, m), 2.50 (1.5 H, s), 2.48 (1.5 H, s), 2.47 (1.5 H, s), 2. 39 (1.5 H, s), 2. 29 (1.5 H, s), 2. 26 (1.5 H, s), 2.22 (1 H, m) ), 2.07 (1.5 H, s), 2.05 (1.5 H, s), 1. 86 (1 H, m), 1.09 (1.5 H, t), 0.93 (1.5 H, t).
  • the compound of the present invention 32 1 H-NMR (CDCl 3 ) ⁇ : 6.16 (0.5 H, d), 6.09 (0.5 H, d), 5.98-5.84 (1 H, m), 2.50 (1.5 H, s), 2.48 3H, s), 2. 39 (1.5 H, s), 2. 29 (1.5 H, s), 2. 26 (1.5 H, s), 2.08 (1.5 H, s), 2.05 (1.5 H, s), 1. 88 (1.5 H, s) dd), 1.51 (1.5 H, dd).
  • the present compound 33 1 H-NMR (CDCl 3 ) ⁇ : 6.53 (1 H, dd), 5.52 (1 H, dd), 5.48 (1 H, dd), 2.50 (3 H, s), 2.49 (3 H, s), 2.30 (3H, s), 2.06 (3H, s).
  • the present compound 34 1 H-NMR (CDCl 3 ) ⁇ : 2.47 (6H, s), 2.36 (3H, s), 2.04 (6H, s).
  • the present compound 35 1 H-NMR (CDCl 3 ) ⁇ : 6.76 (0.5 H, dd), 6.53 (0.5 H, t), 6.21 (0.5 H, d), 5.98 (0.5 H, d), 5.95 (0.5 H, d), 5.58 (0.5 H, d), 2. 48 (1.5 H, s), 2.51 (3 H, s), 2. 39 (1.5 H, s), 2. 29 (1.5 H, s), 2.22 (1.5 H, s) ), 2.08 (1.5 H, s), 2.06 (1.5 H, s), 1. 85 (1.5 H, s), 1.81 (3 H, s), 1. 74 (1.5 H, s).
  • the present compound 36 1 H-NMR (CDCl 3 ) ⁇ : 6.46-6.38 (1H, m), 5.91-5.80 (1H, m), 3.06-2.94 (1H, m), 2.75-2.63 (1H, m) , 2.52 (1.5 H, s), 2. 49 (1.5 H, s), 2. 47 (1.5 H, s), 2. 39 (1.5 H, s), 2. 28 (1.5 H, s), 2. 25 (1.5 H, s), 2.08 (1.5 H, s), 2.06 (1.5 H, s).
  • the present compound 37 1 H-NMR (CDCl 3 ) ⁇ : 6.08 (0.5 H, d), 5.90 (0.5 H, d), 5.82 (0.5 H, dd), 5.61 (0.5 H, dd), 2.50 (1.5 H, s), 2.48 (1.5 H, s), 2.46 (1.5 H, s), 2.40 (1.5 H, s), 2.28 (1.5 H, s), 2.26 (1.5 H, s), 2.18-2.09 (1 H) , m), 2.07 (1.5 H, s), 2.05 (1.5 H, s), 1.89-1.49 (5 H, m), 1.39-0.99 (5 H, m).
  • the present compound 38 1 H-NMR (CDCl 3 ) ⁇ : 6.71 (0.5 H, d), 6.17 (0.5 H, d), 5. 44 (0.5 H, d), 5.05 (0.5 H, d), 3.68 (1.5 H, s), 3.66 (1.5 H, s), 2. 49 (1.5 H, s), 2. 48 (3 H, s), 2. 45 (1.5 H, s), 2.31 (1.5 H, s), 2. 30 (1.5 H, s) ), 2.05 (3H, s).
  • the present compound 39 1 H-NMR (CDCl 3 ) ⁇ : 4.42 (2H, s), 3.92 (3H, s), 3.31 (3H, s), 2.57 (3H, s), 2.50 (3H, s), 2.10 (3H, s).
  • the present compound 40 1 H-NMR (CDCl 3 ) ⁇ : 8.16 (1H, s), 3.97 (3H, s), 2.60 (3H, s), 2.51 (3H, s), 2.35 (3H, s), 2.09 (3H, s).
  • the present compound 41 1 H-NMR (CDCl 3 ) ⁇ : 4.99 (2H, s), 2.60 (3H, s), 2.50 (3H, s), 2.35 (3H, s), 2.05 (3H, s), 1.83 (3H, s), 1.77 (3H, s).
  • Invention compound 42 1 H-NMR (CDCl 3 ) ⁇ : 5.34 (1H, s), 3.45 (6H, s), 2.61 (3H, s), 2.49 (3H, s), 2.34 (3H, s), 2.04 (3H, s).
  • Invention compound 43 1 H-NMR (CDCl 3 ) ⁇ : 2.54 (3H, s), 2.49 (3H, s), 2.44 (2H, t), 2.36 (3H, s), 2.07 (3H, s), 1.68-1.58 (2H, m), 1.06 (3H, t).
  • Invention compound 44 1 H-NMR (CDCl 3 ) ⁇ : 4.41 (2H, s), 3.31-3.22 (1H, m), 2.57 (3H, s), 2.48 (3H, s), 2.36 (3H, s) ), 2.04 (3H, s), 1.97-1.87 (2H, m), 1.81-1.67 (3H, m), 1.37-1.15 (5H, m).
  • the present compound 45 1 H-NMR (CDCl 3 ) ⁇ : 4.40 (2H, s), 3.34 (2H, dd), 2.57 (3H, s), 2.49 (3H, s), 2.35 (3H, s), 2.05 (3H, s), 1.57 (2H, m), 0.90 (3H, t).
  • Invention compound 46 1 H-NMR (CDCl 3 ) ⁇ : 3.50 to 3.43 (4H, m), 2.79 (2H, m), 2.53 (3H, s), 2.47 (3H, s), 2.36 (3H, s) ), 2.02 (3H, s), 1.19 (3H, t).
  • Invention compound 47 1 H-NMR (CDCl 3 ) ⁇ : 5.43 (1H, m), 5.16 (1H, m), 3.23 (2H, d), 2.48 (3H, s), 2.47 (3H, s), 2.34 (3H, s), 2.19 (2H, m), 2.03 (3H, s), 1.03 (3H, t).
  • the present compound 48 1 H-NMR (CDCl 3 ) ⁇ : 3.34 (2H, s), 2.58 (3H, s), 2.48 (3H, s), 2.39 (3H, s), 2.15-2.07 (2H, m) ), 2.04 (3H, s), 1.07 (3H, t).
  • Invention compound 49 1 H-NMR (CDCl 3 ) ⁇ : 5.53-5.39 (2H, m), 2.52 (3H, s), 2.49 (2H, m), 2.47 (3H, s), 2.36 (3H, s) ), 2.19 (2H, m), 2.03 (3H, s), 1.58 (3H, m).
  • the present compound 50 1 H-NMR (CDCl 3 ) ⁇ : 5.82 (1H, m), 5.09-4.99 (2H, m), 2.49 (3H, s), 2.49-2.42 (2H, m), 2.47 (3H) , s), 2.35 (3H, s), 2.12 (2H, t), 2.02 (3H, s), 1.55 (2H, m).
  • the present compound 51 1 H-NMR (CDCl 3 ) ⁇ : 2.74-2.62 (2H, m), 2.53 (3H, s), 2.47 (3H, s), 2.37 (3H, s), 2.32-2.23 (2H , m), 2.02 (3H, s), 1.77 (3H, t).
  • Invention compound 52 1 H-NMR (CDCl 3 ) ⁇ : 2.65-2.51 (2H, m), 2.51 (3H, s), 2.48 (3H, s), 2.38 (3H, s), 2.03 (3H, s) ), 2.26 (2H, dt), 2.01 (1H, t), 1.72-1.61 (2H, m).
  • the present compound 101 1 H-NMR (CDCl 3 ) ⁇ : 6.36 (0.5 H, d), 6.29 (0.5 H, d), 5.96-5.82 (1 H, m), 2.61-2.52 (2 H, m), 2.51 (1.5 H, s), 2. 49 (1.5 H, s), 2. 49 (1.5 H, s), 2. 40 (1.5 H, s), 2. 38-2. 32 (1 H, m), 2. 33 (1.5 H, s), 2. 27 ( 1.5 H, s), 2.26-2.18 (1 H, m), 2.08 (1.5 H, s), 2.05 (1.5 H, s).
  • the present compound 102 1 H-NMR (CDCl 3 ) ⁇ : 6.18 (0.5 H, d), 6.08 (0.5 H, d), 5.82-5. 73 (1 H, m), 3.23 (0.5 H, m), 3.15 ( 0.5 H, m), 2.50 (1.5 H, s), 2. 48 (1.5 H, s), 2. 26 (1.5 H, s), 2. 24 (1.5 H, s), 2.22-2.13 (1 H, m), 2.06 (1.5) H, s), 2.04 (1.5 H, s), 1. 88-1.80 (1 H, m), 1.53-1. 43 (1 H, m), 1.41-1. 30 (1 H, m), 1.21 (3 H, d), 1.
  • the present compound compound 123 1 H-NMR (CDCl 3 ) ⁇ : 5.24 (0.5 H, dd), 4.94 (0.5 H, dd), 3.29 (1 H, br s), 3.17 (1 H, s), 2.49 (1.5 H) , s), 2.49 (1.5 H, s), 2. 48 (1.5 H, s), 2. 48 (1.5 H, s), 2. 46 (1.5 H, s), 2. 45 (1.5 H, s), 2. 32 (1.5 H, s) ), 2.30 (1.5 H, s), 2.16 (1 H, m), 2.03 (1.5 H, s), 2.03 (1.5 H, s), 1. 98 (1 H, m), 1.02 (1.5 H, t), 0.89 ( 1.5 H, t).
  • the present compound 53 1 H-NMR (CDCl 3 ) ⁇ : 2.49 (3H, s), 2.48-2.38 (5H, m), 2.35 (3H, s), 2.02 (3H, s), 1.49-1 .20 (16H , m), 0.88 (3H, t).
  • Production Example 8 The compounds produced according to the method described in Production Example 7 and the physical properties thereof are shown below. In the compound represented by the formula (A-3), compounds wherein R 1x and R 2x are any combination of those described in [Table 6].
  • the present compound 54 1 H-NMR (CDCl 3 ) ⁇ : 2.49 (3H, s), 2.47 (3H, s), 2.46-2.40 (2H, m), 2.35 (3H, s), 2.02 (3H, s) ), 1.49-1.39 (2H, m), 1.39-1.22 (8H, m), 0.89 (3H, t).
  • the present compound 55 1 H-NMR (CDCl 3 ) ⁇ : 2.49 (3H, s), 2.46 (3H, s), 2.46-2.40 (2H, m), 2.35 (3H, s), 2.02 (3H, s) ), 1.48-1.27 (8H, m), 0.89 (3H, t).
  • the present compound 56 1 H-NMR (CDCl 3 ) ⁇ : 2.49 (3H, s), 2.47 (3H, s), 2.54-2.38 (2H, m), 2.35 (3H, s), 2.02 (3H, s) ), 1.40-1.51 (2H, m), 1.39-1 .28 (4H, m), 0.91 (3H, t).
  • the present compound 57 1 H-NMR (CDCl 3 ) ⁇ : 2.49 (3H, s), 2.47 (3H, s), 2.48-2.41 (2H, m), 2.36 (3H, s), 2.02 (3H, s) ), 1.47-1.33 (4H, m), 0.94 (3H, t).
  • the present compound 58 1 H-NMR (CDCl 3 ) ⁇ : 2.49 (3H, s), 2.47 (3H, s), 2.46-2.38 (2H, m), 2.36 (3H, s), 2.02 (3H, s) ), 1.54-1.43 (2H, m), 0.97 (3H, t).
  • Invention compound 59 1 H-NMR (CDCl 3 ) ⁇ : 2.50 (3H, s), 2.47 (3H, s), 2.54-2.44 (2H, m), 2.37 (3H, s), 2.03 (3H, s) ), 1.09 (3H, t).
  • the present compound 60 1 H-NMR (CDCl 3 ) ⁇ : 2.50 (3H, s), 2.47 (3H, s), 2.46-2.37 (2H, m), 2.36 (3H, s), 2.03 (3H, s) ), 1.63-1.51 (1 H, m), 1.50-1. 39 (2 H, m), 1.29-1.21 (2 H, m), 0.89 (6 H, d).
  • the present compound 61 1 H-NMR (CDCl 3 ) ⁇ : 2.61-2.51 (2H, m), 2.50 (3H, s), 2.48 (3H, s), 2.36 (3H, s), 2.21-2.06 (2H , m), 2.03 (3H, s), 1.79-1.68 (2H, m).
  • the present compound 62 1 H-NMR (CDCl 3 ) ⁇ : 2.54-2.39 (8H, m), 2.35 (3H, s), 2.02 (3H, s), 1.81-1.62 (5H, m), 1.36-1.19 (6H, m), 1.01-0.88 (2H, m).
  • Invention compound 104 1 H-NMR (CDCl 3 ) ⁇ : 2.60-2.46 (2H, m), 2.50 (3H, s), 2.47 (3H, s), 2.40-2.35 (2H, m), 2.38 (3H , s), 2.02 (3H, s), 1.77-1.59 (4H, m).
  • Invention compound 105 1 H-NMR (CDCl 3 ) ⁇ : 3.18 (1H, m), 2.52-2.37 (2H, m), 2.47 (3H, s), 2.35 (3H, s), 2.00 (3H, s) ), 1.50-1.28 (6H, m), 1.24 (6H, d), 0.91 (3H, t).
  • the present compound 106 1 H-NMR (CDCl 3 ) ⁇ : 3.18 (1H, m), 2.57-2.38 (2H, m), 2.47 (3H, s), 2.35 (3H, s), 2.00 (3H, s) ), 1.50-1.28 (8H, m), 1.24 (6H, d), 0.91 (3H, t).
  • the present compound 107 1 H-NMR (CDCl 3 ) ⁇ : 2.77 (2H, q), 2.56-2.38 (2H, m), 2.48 (3H, s), 2.35 (3H, s), 2.02 (3H, s) ), 1.52-1.32 (6H, m), 1.25 (3H, t), 0.91 (3H, t).
  • Invention compound 108 1 H-NMR (CDCl 3 ) ⁇ : 2.77 (2H, q), 2.58-2.38 (2H, m), 2.48 (3H, s), 2.35 (3H, s), 2.02 (3H, s) ), 1.51-1.26 (8 H, m), 1.25 (3 H, t), 0.90 (3 H, t).
  • Invention compound 109 1 H-NMR (CDCl 3 ) ⁇ : 2.49 (3H, s), 2.47 (3H, s), 2.42-2.26 (2H, m), 2.35 (3H, s), 2.02 (3H, s) ), 1.77-1.57 (5H, m), 1.53-1.39 (1H, m), 1.21-0.92 (5H, m).
  • Invention compound 110 1 H-NMR (CDCl 3 ) ⁇ : 3.19 (1H, m), 2.47 (3H, s), 2.46-2.22 (2H, m), 2.34 (3H, s), 2.02 (3H, s) ), 1.73-1.58 (5H, m), 1.48-1.33 (1H, m), 1.22 (6H, d), 1.20-0.88 (5H, m).
  • the present compound 124 1 H-NMR (CDCl 3 ) ⁇ : 2.49 (3H, s), 2.46 (3H, s), 2.43 (2H, brs), 2.35 (3H, s), 2.02 (3H, s), 1.62 (1 H, m), 1.31 (2 H, m), 0.95 (6 H, d).
  • the present compound 125 1 H-NMR (CDCl 3 ) ⁇ : 2.50 (3H, s), 2.47 (3H, s), 2.47 (1H, m), 2.34 (3H, s), 2.23 (1H, br s) , 2.02 (3H, s), 1.69 (1H, m), 1.46-1.14 (4H, m), 0.89 (3H, t), 0.82 (3H, d).
  • Production Example 10 The compounds produced according to the method described in Production Example 9 and the physical properties thereof are shown below.
  • Formula (A-4) In the compound shown by these, compounds in which R A and R B are any combination of those described in [Table 7].
  • Invention compound 64 1 H-NMR (CDCl 3 ) ⁇ : 3.92 (3H, s), 2.54-2.45 (8H, m), 2.07 (3H, s), 1.50-1.40 (2H, m), 1.39-1.28 (4H, m), 0.90 (3H, t).
  • Invention compound 65 1 H-NMR (CDCl 3 ) ⁇ : 4.42 (2H, s), 3.92 (3H, s), 3.31 (3H, s), 2.57 (3H, s), 2.50 (3H, s), 2.10 (3H, s).
  • the present compound 66 1 H-NMR (CDCl 3 ) ⁇ : 4.47 (2H, s), 3.92 (3H, s), 3.33-3.23 (1H, m), 2.49 (3H, s), 2.58 (3H, s) ), 2.10 (3H, s), 1.96-1.86 (2H, m), 1.78-1.69 (2H, m), 1.58-1.48 (1H, m), 1.36-1.14 (5H, m).
  • the present compound 67 1 H-NMR (CDCl 3 ) ⁇ : 3.93 (3H, s), 2.77-2.71 (8H, m), 2.09 (3H, s), 1.67-1.67 (2H, m), 1.42-1.31 (4H, m), 0.90 (3H, t).
  • Invention compound 115 1 H-NMR (CDCl 3 ) ⁇ : 3.92 (3H, s), 3.20 (1H, m), 2.47 (3H, s), 2.39 (2H, d), 2.06 (3H, s), 1.76-1.56 (5H, m), 1.48-1.33 (1H, m), 1.23 (6H, d), 1.21-1.08 (3H, m), 1.07-0.93 (2H, m).
  • Invention compound 116 1 H-NMR (CDCl 3 ) ⁇ : 3.92 (3H, s), 3.18 (1H, m), 2.52-2.47 (2H, m), 2.47 (3H, s), 2.06 (3H, s) ), 1.49-1.26 (8H, m), 1.24 (6H, d), 0.89 (3H, t).
  • Invention compound 129 1 H-NMR (CDCl 3 ) ⁇ : 7.54-7.51 (2H, m), 7.46-7.37 (3H, m), 5.00 (2H, s), 4.63 (2H, s), 3.33 (1H , m), 2.49 (3H, s), 2.21 (3H, s), 1.30 (6H, d).
  • Invention compound 130 1 H-NMR (CDCl 3 ) ⁇ : 7.41-7.34 (5 H, m), 5.08 (1 H, m), 4. 78 (2 H, s), 3. 36 (2 H, m), 3.04 (1 H, m) ), 2.77 (2H, m), 2.49 (3H, s), 2.46-2.37 (4H, m), 2.21 (3H, s), 1.21 (6H, d).
  • Production Example 17 The compounds produced according to the method described in Production Example 16 and the physical properties thereof are shown below.
  • Formula (A-5) In the compounds shown by these, compounds in which R 3 , R A and R B are any combination of those described in [Table 8].
  • the present compound 72 1 H-NMR (CDCl 3 ) ⁇ : 3.95 (3H, s), 2.53 (6H, s), 2.17 (6H, s).
  • Invention compound 73 1 H-NMR (CDCl 3 ) ⁇ : 7.44-7.35 (5H, m), 4.78 (2H, s), 2.53 (6H, s), 2.21 (6H, s).
  • Invention compound 118 1 H-NMR (CDCl 3 ) ⁇ : 3.94 (3H, s), 3.49-3.20 (1H, m), 2.55-2.49 (2H, m), 2.48 (3H, s), 2.06 (3H) , s), 1.49-1.26 (8H, m), 1.24 (6H, d), 0.90 (3H, t).
  • Invention compound 119 1 H-NMR (CDCl 3 ) ⁇ : 3.46-3.20 (1H, m), 2.66-2.51 (2H, m), 2.16 (3H, s), 1.94 (3H, s), 1.48-1.19 (8H, m), 1.38 (6H, d), 0.88 (3H, t).
  • the present compound 74 1 H-NMR (CDCl 3 ) ⁇ : 7.49-7.30 (5H, m), 5.64 (1H, m), 4.83 (2H, s), 2.47 (3H, s), 2.42 (3H, s) ), 2.36-2.92 (7H, m), 1.78-1.55 (4H, m).
  • Production Example 20 The compounds produced according to the method described in Production Example 19 and the physical properties thereof are shown below.
  • the present compound 75 1 H-NMR (CDCl 3 ) ⁇ : 7.42-7.30 (5H, m), 5.70 (1H, m), 4.78 (2H, s), 2.63-2.56 (2H, m), 2.55-2.48 (2H, m), 2.46 (3H, s), 2.42 (3H, s), 2.15 (3H, s), 2.04-1.94 (2H, m).
  • the present compound 76 1 H-NMR (CDCl 3 ) ⁇ : 7.52-7.32 (5H, m), 4.86 (2H, s), 2.66 (3H, m), 2.51 (3H, s), 2.20 (3H, s) ).
  • Invention compound 77 1 H-NMR (CDCl 3 ) ⁇ : 7.50 to 7.27 (5H, m), 6.44 (1H, d), 5.85 (1H, dd), 4.80 (2H, s), 2.47 (3H, s) ), 2.36-2.24 (2H, m), 2.19 (3H, s), 2.16 (3H, s), 1.54-1.12 (22H, m), 0.88 (3H, t).
  • Production Example 24 The compounds produced according to the method described in Production Example 23 and the physical properties thereof are shown below.
  • Formula (A-6) In the compounds represented by the above, compounds in which R 1x is described in [Table 9].
  • Invention compound 78 1 H-NMR (CDCl 3 ) ⁇ : 7.50 to 7.28 (5H, m), 6.44 (1H, d), 5.88 (1H, dd), 4.79 (2H, s), 2.46 (3H, s) ), 2.25-2.36 (2H, m), 2.19 (3H, s), 2.15 (3H, s), 1.50-1. 14 (12H, m), 0.87 (3H, t).
  • Invention compound 79 1 H-NMR (CDCl 3 ) ⁇ : 7.49-7.31 (5H, m), 6.45 (1H, d), 5.85 (1H, td), 4.80 (2H, s), 2.48 (3H, s) ), 2.34-2.25 (2H, m), 2.20 (3H, s), 2.16 (3H, s), 1.59-1.38 (2H, m), 0.89 (3H, t).
  • the present compound 80 1 H-NMR (CDCl 3 ) ⁇ : 7.48-7.30 (5H, m), 6.46 (1H, d), 5.85-5. 76 (1H, m), 4.81 (2H, s), 2.50 (3H , s), 2.22 (3H, s), 2.17 (3H, s), 1.52 (3H, d).
  • Production Example 25 The compounds produced according to the method described in Production Example 7 and the physical properties thereof are shown below.
  • Formula (A-7) In the compound shown by these, compounds in which R A and R B are any combination of those described in [Table 10].
  • Invention compound 81 1 H-NMR (CDCl 3 ) ⁇ : 3.91 (1H, s), 2.98 (2H, t), 2.65 (3H, s), 2.25 (3H, s), 2.23 (3H, s), 1.71-1.60 (2H, m), 1.45-1.15 (24H, m), 0.87 (3H, t).
  • Invention compound 82 1 H-NMR (CDCl 3 ) ⁇ : 8.59 (1 H, s), 2.53 (2 H, t), 2. 29 (3 H, s), 2.03 (3 H, s), 2.02 (3 H, s), 1.60-1.50 (2H, m), 1.37-1.18 (14H, m), 0.88 (3H, t).
  • the present compound 83 1 H-NMR (CDCl 3 ) ⁇ : 8.26 (1H, s), 2.52 (2H, t), 2.28 (3H, s), 2.03 (3H, s), 2.02 (3H, s), 1.60-1.52 (2H, m), 1.37-1.26 (4H, m), 0.89 (3H, t).
  • Invention compound 84 1 H-NMR (CDCl 3 ) ⁇ : 2.54 (2H, t), 2.30 (3H, s), 2.06 (3H, s), 2.04 (3H, s), 1.69-1.57 (2H, m) ), 0.97 (3H, t).
  • the compound of the present invention 85 1 H-NMR (CDCl 3 ) ⁇ : 7.85 (1 H, s), 2.85-2.66 (1 H, m), 2.31 (3 H, s), 2.23 (3 H, s), 2.29-2.12 (2 H) , m), 1.98 (3H, s), 1.83-1.74 (2H, m), 1.72-1. 65 (1H, m), 1.53-1.44 (2H, m), 1.38-1.22 (3H, m).
  • Invention compound 86 1 H-NMR (CDCl 3 ) ⁇ : 8.58 (1 H, s), 3.16-3.04 (1 H, m), 2. 32 ( 3 H, s), 2.
  • the present compound 112 1 H-NMR (CDCl 3 ) ⁇ : 8.76 (1H, s), 2.60 (2H, q), 2.54-2.41 (2H, m), 2.28 (3H, s), 2.01 (3H, s) ), 1.52-1.18 (8H, m), 1.24 (3H, t), 0.86 (3H, t).
  • Invention compound 113 1 H-NMR (CDCl 3 ) ⁇ : 3.28 (1 H, m), 2.42 (2 H, d), 2.23 (3 H, s), 2.01 (3 H, s), 1. 74-1. 56 (7 H, m) ), 1.31-0.90 (4H, m), 1.23 (6H, d).
  • Invention compound 114 1 H-NMR (CDCl 3 ) ⁇ : 11.21 (1 H, s), 3.34 (1 H, m), 2.70-2.57 (2 H, m), 2.62 (3 H, s), 2.16 (3 H, s) ), 1.52-1.20 (8H, m), 1.46 (6H, d), 0.87 (3H, t).
  • Invention compound 126 1 H-NMR (CDCl 3 ) ⁇ : 2.49 (2H, m), 2.25 (3H, s), 2.24 (3H, s), 2.01 (3H, s), 1.63 (1H, m), 1.31 (2H, m), 0.94 (6H, d)
  • Invention compound 127 1 H-NMR (CDCl 3 ) ⁇ : 2.50 (1 H, dd), 2.27 (1 H, m), 2.26 (3 H, s), 2.25 (3 H, s), 2.01 (3 H, s), 1.83 (1H, m), 1.44-1.26 (3H, m), 1.14 (1H, m), 0.87 (3H, t), 0.83 (3H, d).
  • Invention compound 128 1 H-NMR (CDCl 3 ) ⁇ : 7.72 (1H, s), 2.52-2.44 (2H, m), 2.26 (3H, s), 2.24 (3H, s), 2.01 (3H, s) ), 1.49-1.16 (16H, m), 0.87 (3H, t).
  • the present compound 132 1 H-NMR (CDCl 3 ) ⁇ : 3.31-3.22 (1H, m), 2.49 (1H, d), 2.42 (1H, d), 2.26 (3H, s), 2.01 (3H, s) ), 1.73-1.60 (4H, m), 1.55-1.22 (6H, m), 1.24 (1.5H, d), 1.23 (1.5H, d), 1.01 (1.5H, m), 0.94 (1.5H, d) ), 0.85 (1.5 H, m), 0.83 (1.5 H, d).
  • Invention compound 133 1 H-NMR (CDCl 3 ) ⁇ : 3.30 (1H, m), 2.52 (1H, d), 2.43 (1H, d), 2.29 (3H, s), 2.02 (3H, s), 1.76-1.69 (2H, m), 1.67-1.61 (2H, m), 1.61-1.54 (3H, m), 1.43-1.35 (2H, m), 1.26-1.22 (6H, m), 1.04-0.90 (2H , m), 0.87 (3H, d), 0.82 (3H, d).
  • the present compound 137 1 H-NMR (CDCl 3 ) ⁇ : 2.48 (2H, m), 2.26 (3H, s), 2.24 (3H, s), 2.01 (3H, s), 1.45-0.36 (3H, m) ), 1.28-1.14 (2H, m), 0.94 (3H, d), 0.87 (3H, t).
  • Invention compound 140 1 H-NMR (CDCl 3 ) ⁇ : 8.19 (1H, s), 4.28 (1H, d), 4.25 (1H, d), 2.32 (3H, s), 2.12 (3H, s), 2.04 (3H, s), 1.34 (3H, t).
  • Invention compound 141 1 H-NMR (CDCl 3 ) ⁇ : 8.33 (1H, s), 4.56 (2H, q), 2.33 (3H, s), 2.14 (3H, s), 2.05 (3H, s).
  • Invention compound 142 1 H-NMR (CDCl 3 ) ⁇ : 8.44 (1 H, s), 8.23 (1 H, s), 4.43 (2 H, t), 2.64-2.47 (2 H, m), 2.33 (3 H, s) ), 2.13 (3H, s), 2.04 (3H, s).
  • Invention compound 143 1 H-NMR (CDCl 3 ) ⁇ : 8.44 (1H, s), 8.22 (1H, s), 4.27 (2H, t), 2.32 (3H, s), 2.31-2.16 (2H, m) ), 2.13 (3H, s), 2.04 (3H, s), 2.04-1.96 (2H, m).
  • Production Example 26 The compounds produced according to the method described in Production Example 5 and the physical properties thereof are shown below.
  • Formula (A-8) In the compound shown by these, compounds in which R A and R B are any combination described in [Table 11].
  • the present compound 88 1 H-NMR (CDCl 3 ) ⁇ : 2.76-2.70 (2H, m), 2.47 (3H, s), 2.36 (3H, s), 2.07 (3H, s), 2.04 (3H, s) ), 1.66-1.56 (2H, m), 1.43-1.20 (24H, m), 0.87 (3H, t).
  • Invention compound 89 1 H-NMR (CDCl 3 ) ⁇ : 2.76-2.70 (2H, m), 2.47 (3H, s), 2.36 (3H, s), 2.07 (3H, s), 2.04 (3H, s) ), 1.67-1.57 (2H, m), 1.43-1.12 (14H, m), 0.88 (3H, t).
  • the present compound 90 1 H-NMR (CDCl 3 ) ⁇ : 2.76-2.70 (2H, m), 2.47 (3H, s), 2.36 (3H, s), 2.07 (3H, s), 2.04 (3H, s) ), 1.67-1.58 (2H, m), 1.42-1.29 (4H, m), 0.89 (3H, t).
  • the present compound 91 1 H-NMR (CDCl 3 ) ⁇ : 2.75-2.69 (2H, m), 2.47 (3H, s), 2.36 (3H, s), 2.07 (3H, s), 2.04 (3H, s) ), 1.73-1.61 (2H, m), 0.99 (3H, t).
  • Invention compound 92 1 H-NMR (CDCl 3 ) ⁇ : 2.81-2.70 (1H, m), 2.56 (3H, s), 2.45 (3H, s), 2.37 (3H, s), 1.98 (3H, s) ), 1.93-1.15 (10H, m).
  • the present compound 93 1 H-NMR (CDCl 3 ) ⁇ : 3.25-3.15 (1H, m), 2.54 (3H, s), 2.46 (3H, s), 2.35 (3H, s), 1.99 (3H, s) ), 1.96-1.62 (8H, m).
  • the present compound 94 1 H-NMR (CDCl 3 ) ⁇ : 2.66 (3H, q), 2.54 (3H, s), 2.35 (3H, s), 2.07 (3H, s).
  • the present compound 134 1 H-NMR (CDCl 3 ) ⁇ : 3.18 (1H, m), 2.53-2.42 (2H, m), 2.49 (3H, s), 2.42-2.34 (2H, m), 2.35 (3H) , s), 2.32-22.23 (2H, m), 2.04-2.95 (2H, m), 2.01 (3H, s), 1.89 (1H, m), 1.54-1.42 (2H, m), 1.25 (6H, d) ).
  • Invention compound 135 1 H-NMR (CDCl 3 ) ⁇ : 3.24-3.13 (1H, m), 2.47 (1.5 H, s), 2.47 (1.5 H, s), 2.43-2.30 (2 H, m), 2.35 (1.5H, s), 2.34 (1.5 H, s), 2.00 (1.5 H, s), 2.00 (1.5 H, s), 1.71-1.62 (3 H, m), 1.58-1.19 (5 H, m), 1.23 (3H, d), 1.22 (3H, d), 1.06-0.96 (1H, m), 0.95 (1.5 H, d), 0.88-0.78 (1 H, m), 0.85 (1.5 H, d).
  • Invention compound 136 1 H-NMR (CDCl 3 ) ⁇ : 3.23-3.13 (1 H, m), 2.50-2.43 (1 H, m), 2.47 (1.5 H, s), 2.47 (1.5 H, s), 2.35 (1.5H, s), 2.34 (1.5 H, s), 2.35-2.29 (1 H, m), 2.02 (1.5 H, s), 2.02 (1.5 H, s), 1.69 (3 H, d), 1.46-1.29 (4H, m), 1.23 (6H, d), 1.10-0.86 (4H, m), 0.89 (3H, d), 0.83 (3H, d).
  • Invention compound 138 1 H-NMR (CDCl 3 ) ⁇ : 2.49 (3H, s), 2.46 (3H, s), 2.48-2.33 (2H, m), 2.35 (3H, s), 2.02 (3H, s) ), 1.47-1.34 (3H, m), 1.30-1. 16 (2H, m), 0.95 (3H, d), 0.89 (3H, t).
  • Invention compound 144 1 H-NMR (CDCl 3 ) ⁇ : 8.32 (1H, s), 4.29 (2H, dd), 2.52 (3H, s), 2.38 (3H, s), 2.26 (3H, s), 2.09 (3H, s), 1.32 (3H, t).
  • Invention compound 145 1 H-NMR (CDCl 3 ) ⁇ : 8.39 (1H, s), 4.56 (2H, q), 2.52 (3H, s), 2.39 (3H, s), 2.27 (3H, s), 2.11 (3H, s).
  • the present compound 146 1 H-NMR (CDCl 3 ) ⁇ : 8.33 (1 H, s), 4.43 (2 H, t), 2.63-2.50 (2 H, m), 2.53 (3 H, s), 2. 39 (3 H, s) ), 2.26 (3H, s), 2.10 (3H, s).
  • the present compound 150 was obtained according to the method described in Reference Production Example 26.
  • the present compound 150 1 H-NMR (CDCl 3 ) ⁇ : 7.58-7.33 (5H, m), 4.79 (2H, s), 3.19 (1H, m), 2.65-2.56 (2H, m), 2.46 (3H , s), 2.19 (3H, s), 1.55-1.15 (8H, m), 1.25 (6H, d), 0.87 (3H, t).
  • the present compound 152 was obtained according to the method described in Reference Production Example 4.
  • the present compound 152 1 H-NMR (CDCl 3 ) ⁇ : 7.51-7.30 (5 H, m), 7.00 (1 H, dd), 6.46 (1 H, dd), 5.42 (1 H, dd), 4.79 (2 H, s ), 3.20 (1H, m), 2.67-2.54 (2H, m), 2.28 (3H, s), 1.59-1.18 (8H, m), 1.28 (6H, d), 0.87 (3H, t).
  • the present compound 154 was obtained according to the method described in Production Example 5.
  • the present compound 154 1 H-NMR (CDCl 3 ) ⁇ : 3.18 (1H, m), 2.76 (2H, q), 2.55-2.38 (2H, m), 2.34 (3H, s), 2.02 (3H, s) ), 1.52-1.18 (8H, m), 1.26 (3H, t), 1.25 (6H, d), 0.89 (3H, t).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is any of the substituents described in [Table A12] to [Table A35]
  • Compounds that are groups hereinafter referred to as compound group SX1).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX2).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX3).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX4.
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX5).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX6.
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX7).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX8.
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX9).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX10).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX11).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX16).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX17).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any substituent as described in following it is hereafter described as compound group SX18).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX19).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX20).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX21).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX22).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX25
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX26).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX27
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX28).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • SX35 The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX35).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX36).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is any of the substituents described in [Table A12] to [Table A35]
  • Compounds that are groups (hereinafter referred to as compound group SX37).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX38).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX39).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX40).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX43
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX44).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX45
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX46).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35] ]
  • SX53 The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX53).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX54).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX55.
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX56).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX57).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX58).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described hereinafter referred to as compound group SX61).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX62).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX63
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described hereinafter referred to as compound group SX64).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any substituent as described in following is hereafter described as compound group SX71).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX72).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is any of the substituents described in [Table A12] to [Table A35]
  • Compounds that are groups (hereinafter referred to as compound group SX73).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX74).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX75
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described hereinafter referred to as compound group SX76).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX79).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX80).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX81).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX82).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX84).
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX89).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX90).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX91).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX92).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX93).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX94).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX97).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX98).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX99).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX100).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX107).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX108).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is any of the substituents described in [Table A12] to [Table A35]
  • Compounds that are groups (hereinafter referred to as compound group SX109).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX110).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX111).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX112).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX115).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX116).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX117).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX118).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX125).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • the compound which is any substituent as described in following it is hereafter described as compound group SX126).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX127).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX128).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX129).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX130).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX133.
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX134).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX135).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX136).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX143).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX144).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is any of the substituents described in [Table A12] to [Table A35]
  • Compounds that are groups (hereinafter referred to as compound group SX145).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX146).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX147).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX148).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX151).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX152).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX153).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX154).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX161).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX162).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX163
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX164).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX165).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX166).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX169).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX170).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX171.
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX172).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX173).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX179).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX180).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is any of the substituents described in [Table A12] to [Table A35]
  • Compounds that are groups (hereinafter referred to as compound group SX181).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX182).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX183).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX184).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX187).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX188).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX189).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX190).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX193
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX194).
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX197).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • the compound which is any substituent as described in following it is hereafter described as compound group SX198).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX199).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX200).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX201).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX202).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX205.
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX206).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX207).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX208).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX209).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX213).
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX215).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX216).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is any of the substituents described in [Table A12] to [Table A35]
  • Compounds that are groups (hereinafter referred to as compound group SX217).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX218).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX219).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX220).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX223).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX224).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX225.
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX226).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX228).
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX229).
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any substituent as described in following is hereafter described as compound group SX233.
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX234).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX235.
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX236).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX237).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX238).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX239).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX241.
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX242).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX243.
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX244).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX245).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX247).
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX249).
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX251).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • the compound which is any substituent as described in following it is hereafter described as compound group SX252).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is any of the substituents described in [Table A12] to [Table A35]
  • Compounds that are groups hereinafter referred to as compound group SX253
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX254).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX255).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX256).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX257).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX259).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX260).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX261.
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX262).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX263.
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX264).
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX269).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35] ]
  • SX270 The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX270).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described hereinafter referred to as compound group SX271.
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX272).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX273
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX274.
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX277).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX278).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX279.
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX280).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX281).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX283.
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX285).
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • the compound which is a substituent in any one of-(It is hereafter described as the compound group SX287).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX288).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is any of the substituents described in [Table A12] to [Table A35]
  • Compounds that are groups (hereinafter referred to as compound group SX289).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX290).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX291.
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX292).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX293
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX295.
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX296).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX297).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX298).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX299).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35] ]
  • SX305 The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX305).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX306).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX307).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX308).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX309).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX310).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX311).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX313).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX314).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX315).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX316).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX317).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX319).
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX321).
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX323).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX324).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is any of the substituents described in [Table A12] to [Table A35]
  • Compounds that are groups (hereinafter referred to as compound group SX325).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX326).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX327).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX328).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX329).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX331).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX332).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX333.
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX334).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX335).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX336).
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX341).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX343
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX344).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX345).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX346).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX347).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX 349).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX350).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX351.
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX352).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX353
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX355
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX357).
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX359).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • SX360 The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX360).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is any of the substituents described in [Table A12] to [Table A35]
  • Compounds that are groups (hereinafter referred to as compound group SX361).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX362).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX363
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX364).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX367).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX368).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX369).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX370).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX 374).
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35] ]
  • the compound which is a substituent in any one of-(It is described as compound group SX377 hereafter.).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX378).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX379).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX380).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX381.
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX382).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX383
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX385.
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX386).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX387).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX388).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX391).
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX393
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX395).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX396).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is any of the substituents described in [Table A12] to [Table A35]
  • Compounds that are groups hereinafter referred to as compound group SX397).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX398).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX399).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX400).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX403
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX404).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX405).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX406.
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX409).
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is a methyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R B is an ethyl group
  • R A is [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is a methyl group
  • R A is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX413).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R B is an ethyl group
  • R A is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX414).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX415).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX416).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX417).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX418).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX419).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX421.
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX422).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described below hereinafter referred to as compound group SX423
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds that are any of the substituents described below hereinafter referred to as compound group SX424).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX425).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX427).
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • Compounds which are any of the substituents described in hereinafter referred to as compound group SX429).
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is a methyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • the compound which is a substituent in any one of-(It is hereafter described as compound group SX431).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A is an ethyl group
  • R B is a group represented by [Table A12] to [Table A35] ]
  • the compound which is any one of the substituents as described in the following hereinafter referred to as compound group SX432).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX433).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX434.
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX435).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds that are combinations hereinafter referred to as compound group SX436).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds that are combinations hereinafter referred to as compound group SX437).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX440).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • a combination of compounds hereinafter referred to as compound group SX441).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX442).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX443.
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX444).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX445).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX446).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX447).
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX450).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds that are combinations hereinafter referred to as compound group SX451.
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX452).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • a compound (hereinafter referred to as a compound group SX453) which is a combination of
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX454).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX455).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX456).
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX459).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX460).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX461).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX462).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX463).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX464).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are a combination of hereinafter referred to as compound group SX465).
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX468).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX469).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX470).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any one of [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX471).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX472).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX473
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX474).
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are a combination of hereinafter referred to as compound group SX475).
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • a compound (hereinafter referred to as a compound group SX476) which is a combination of In the compound represented by formula (L-5), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX477).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX478).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX479).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX480).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX481).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX482).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX483.
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX486).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX487).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX488).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are a combination of hereinafter referred to as compound group SX489).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX490).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX491).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX492).
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are a combination of hereinafter, referred to as compound group SX493
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX494).
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX495).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX496).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX497).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are a combination of hereinafter referred to as compound group SX 498).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX499).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX500).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX501).
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX504).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX505).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX506).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX507).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX508.
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX509).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX510).
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX513).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX514).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX515).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX516).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX517).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX518).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX519).
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX522).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX523).
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX524).
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX525).
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX526).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX527).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX528).
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX531).
  • R 4 is a methyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX532.
  • R 4 is a methyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX533.
  • R 4 is a methyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX534.
  • R 4 is an ethyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX535).
  • R 4 is an ethyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations hereinafter referred to as compound group SX536).
  • R 4 is an ethyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • Compounds which are combinations of hereinafter referred to as compound group SX537).
  • R 4 is a cyclopropyl group
  • R 5 is a methyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • R 4 is a cyclopropyl group
  • R 5 is an ethyl group
  • R A and R B are any of those described in [Table A36] to [Table A41]
  • R 4 is a cyclopropyl group
  • R 5 is a cyclopropyl group
  • R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX540).
  • the compound S of the present invention represents the compounds described in the compound groups SX1 to SX540.
  • Formulation example 1 10 parts of any one of the compound S of the present invention is mixed into a mixture of 35 parts of xylene and 35 parts of DMF, and 14 parts of polyoxyethylene styryl phenyl ether and 6 parts of calcium dodecylbenzene sulfonate are added thereto and mixed. Obtain a formulation.
  • Formulation example 2 4 parts of sodium lauryl sulfate, 2 parts of calcium lignin sulfonate, 20 parts of wet silica and 54 parts of diatomaceous earth are mixed, and further 20 parts of any one of the compound S of the present invention is added and mixed to obtain a preparation.
  • Formulation example 3 To 2 parts of any one compound of the present invention S, 1 part of wet silica, 2 parts of calcium lignin sulfonate, 30 parts of bentonite and 65 parts of kaolin clay are added and mixed. Then, an appropriate amount of water is added to the mixture, and the mixture is further stirred, granulated with a granulator and blow-dried to obtain a preparation.
  • Formulation example 4 1 part of any one of the compound S of the present invention is mixed with an appropriate amount of acetone, 5 parts of wet silica, 0.3 parts of isopropyl acid phosphate and 93.7 parts of kaolin clay are added thereto and thoroughly mixed. Is removed by evaporation to obtain a preparation.
  • Formulation example 5 A formulation is obtained by thoroughly mixing 35 parts of a mixture of polyoxyethylene alkyl ether sulfate ammonium salt and wet silica (weight ratio 1: 1), 20 parts of any one of the compound S of the present invention and 45 parts of water .
  • Formulation Example 6 0.1 part of any one compound of the present invention S is mixed with a mixture of 5 parts of xylene and 5 parts of trichloroethane, and this is mixed with 89.9 parts of kerosene to obtain a preparation.
  • Formulation example 7 10 mg of any one compound of the present invention S is mixed with 0.5 mL of acetone, and this solution is added dropwise to 5 g of solid feed powder for animals (solid feed powder for rearing and breeding CE-2, a product of CLEA Japan, Inc.), Mix evenly. The acetone is then evaporated to dryness to obtain a toxic bait.
  • Formulation Example 8 0.1 parts of any one compound of the present invention S and 49.9 parts of neothiozole (manufactured by Chuo Kasei Co., Ltd.) are put into an aerosol can, fitted with an aerosol valve, filled with 25 parts of dimethyl ether and 25 parts of LPG and shaken. To obtain an oil aerosol by mounting the actuator.
  • Formulation Example 9 0.6 part of any one compound of the present invention S, 0.01 part of 2,6-di-tert-butyl-4-methylphenol, 5 parts of xylene, 3.39 parts of kerosene and 1 part of Reodol (registered trademark) ) A mixture of MO-60 and 50 parts of distilled water is filled into an aerosol container, and a valve is attached, and then 40 parts of LPG is filled through the valve to obtain an aqueous aerosol.
  • Formulation Example 10 0.1 g of any one of the compounds S of the present invention is mixed with 2 mL of propylene glycol and impregnated into a 4.0 cm ⁇ 4.0 cm, 1.2 cm thick ceramic plate to obtain a heated smoking agent.
  • Formulation example 11 Kneading obtained by melt-kneading 5 parts of any one compound of the present invention S and 95 parts of ethylene-methyl methacrylate copolymer (ratio of methyl methacrylate to total weight of copolymer: 10% by weight) The product is extruded from an extrusion molding machine to obtain a rod-shaped molding having a length of 15 cm and a diameter of 3 mm.
  • Formulation example 12 Five parts of any one compound of the present invention S and 95 parts of a soft vinyl chloride resin are melt-kneaded, and the obtained kneaded product is extruded from an extrusion molding machine to obtain a rod-like molding having a length of 15 cm and a diameter of 3 mm.
  • Formulation example 13 100 mg of any one of the compounds S of the present invention, 68.75 mg of lactose, 237.5 mg of corn starch, 43.75 mg of microcrystalline cellulose, 18.75 mg of polyvinylpyrrolidone, 28.75 mg of sodium carboxymethyl starch, and magnesium stearate2. 5 mg is mixed and the resulting mixture is compressed to a suitable size to obtain tablets.
  • Formulation example 14 25 mg of any one of the compound S of the present invention, 60 mg of lactose, 25 mg of corn starch, 6 mg of carmellose calcium, and 5% hydroxypropyl methylcellulose, and mixing the obtained mixture into hard shell gelatin capsules or hydroxypropyl methylcellulose capsules And get capsules.
  • Formulation example 15 100 mg of any one compound of the present invention S, fumaric acid 500 mg, sodium chloride 2000 mg, methyl paraben 150 mg, propyl paraben 50 mg, granular sugar 25000 mg, sorbitol (70% solution) 13000 mg, Veegum K 100 mg, perfume 35 mg, and coloring Distilled water is added to a final volume of 100 mL and mixed to give a suspension for oral administration.
  • Formulation example 16 5% by weight of any one of the compound S of the present invention is mixed with 5% by weight of an emulsifier, 3% by weight of benzyl alcohol and 30% by weight of propylene glycol so that the pH of this solution becomes 6.0 to 6.5. After adding phosphate buffer to the mixture, water is added as the remainder to obtain a solution for oral administration.
  • Formulation example 17 5% by weight of aluminum distearate is added to 57% by weight of fractionated palm oil and 3% by weight of polysorbate 85 and dispersed by heating. It is cooled to room temperature and 25% by weight of saccharin is dispersed in the oily vehicle. To this, 10% by weight of any one compound of the present invention S is distributed to obtain a pasty preparation for oral administration.
  • Formulation example 18 5% by weight of any one of the compounds S of the present invention is mixed with 95% by weight of limestone powder to obtain granules for oral administration using a wet granulation method.
  • Formulation example 19 5 parts of any one compound of the present invention S is mixed with 80 parts of diethylene glycol monoethyl ether, and 15 parts of propylene carbonate is mixed therewith to obtain a spot-on solution.
  • Formulation example 20 Ten parts of any one compound of the present invention S is mixed with 70 parts of diethylene glycol monoethyl ether, and 20 parts of 2-octyldodecanol is mixed therewith to obtain a pour-on liquid agent.
  • Formulation example 21 60 parts of a 42% aqueous solution of triethanolamine lauryl sulfate and 20 parts of propylene glycol are added to 0.5 part of any one compound of the present invention S, and after sufficient stirring until a homogeneous solution is obtained, water 19.5 Add parts and stir well to obtain a shampoo solution of uniform solution.
  • Formulation example 22 0.15% by weight of any one compound of the present invention S, 95% by weight of animal feed, and 4.85% by weight of a mixture consisting of dibasic calcium phosphate, diatomaceous earth, Aerosil (registered trademark), and carbonate (or chalk) Stir well to obtain an animal feed premix.
  • Formulation example 23 7.2 g of any one of the compounds S of the present invention and 92.8 g of FOSCO.RTM. S-55 are mixed at 100.degree. C., poured into a suppository form, and solidified by cooling to obtain a suppository.
  • test examples the efficacy of the present compound X against harmful arthropods is shown by test examples.
  • the test was performed at 25 ° C.
  • Test method 1 A test compound is prepared according to the method described in Preparation Example 5, and water containing 0.03% by volume of Syndyne (registered trademark) is added thereto to prepare a diluted solution containing a predetermined concentration of the test compound. About 30 cotton aphids (all stages) are inoculated to cucumber (Cucumis sativus) seedlings (the second true leaf development stage) planted in a container. One day later, the seedlings are sprayed with the diluted solution at a rate of 10 mL / seedling. After 5 days, the number of surviving insects is examined, and the control value is determined by the following equation.
  • Control value (%) ⁇ 1- (Cb ⁇ Tai) / (Cai ⁇ Tb) ⁇ ⁇ 100
  • Cb Number of tested insects in untreated area
  • Cai Number of surviving insects in survey in untreated area
  • Tb Number of tested insects in treated zone
  • Tai Number of surviving insects in survey in treated area
  • untreated group means It means a zone that performs the same operation as the treatment zone except that the test compound is not used.
  • Test Example 1-1 As a result of conducting a test according to the test method 1 by setting a predetermined concentration to 500 ppm and using the following compound of the present invention as a test compound, each of the following compounds of the present invention showed a control value of 90% or more.
  • the compounds of the invention 1, 2, 3, 5, 6, 7, 8, 9, 12, 13, 14, 15, 17, 18, 21, 22, 24, 25, 27, 28, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 41, 43, 44, 45, 46, 48, 49, 50, 51, 52, 54, 55, 56, 57, 59, 60, 61, 62, 63, 65, 66, 67, 68, 70, 71, 72, 81, 83, 84, 85, 88, 89, 90, 91, 95, 96, 97, 98, 101, 102, 103, 104, 105, 106, 107, 108, 109, 112, 114, 116, 117, 120, 124, 126, 127, 131, 134, 135, 136, 138, 140, 142, 146, 147 and 154
  • Test Example 1-2 As a result of conducting a test according to the test method 1 by setting a predetermined concentration to 200 ppm and using the following compound of the present invention as a test compound, all of the compounds of the present invention described below showed a control value of 90% or more.
  • the present invention compounds 1, 5, 6, 8, 9, 22, 27, 30, 31, 32, 33, 34, 35, 41, 46, 53, 56, 57, 58, 59, 60, 61, 62, 63, 64, 71, 72, 89, 92, 93, 97, 105, 106, 107, 108, 112, 120, 122, 123, 124, 125, 135, 138 and 154
  • Test example 2 The test was conducted according to Test Method 2 using a compound of the present invention described below as a test compound at a predetermined concentration of 500 ppm. As a result, all of the compounds of the present invention described below showed a mortality of 80% or more.
  • the compounds of the present invention 1, 4, 6, 8, 9, 27, 30, 32, 34, 35, 36, 40, 43, 53, 56, 60, 63, 64, 68, 94 and 97
  • Test method 3 A test compound is prepared according to the method described in Preparation Example 5, and water containing 0.03% by volume of Syndyne (registered trademark) is added thereto to prepare a diluted solution containing a predetermined concentration of the test compound.
  • the diluted solution is sprayed at a rate of 20 mL / seedling to cabbage (Brassicae oleracea) seedlings (second to third leaf development stage) planted in a container. After that, the stems and leaves of this seedling are cut and placed in a container covered with filter paper. Release 5 2nd instar larvae to this. After 5 days, the number of living worms is counted, and the mortality rate is calculated from the following equation.
  • Mortality rate% (1-number of surviving insects / 5) x 100
  • Test Example 3 The compound of the present invention described below was used as a test compound and tested according to Test Method 3 with a predetermined concentration of 500 ppm. As a result, all of the compounds of the present invention showed a mortality of 80% or more.
  • the compounds of the present invention 28, 29, 37, 44, 45, 47, 49, 54, 55, 62, 70, 73, 81, 83, 84, 88, 90, 95, 98, 104, 106, 107, 108, 109, 110, 111, 112, 114, 116, 118, 120, 122, 124, 125, 126, 127, 134, 136, 137, 138, 140, 150, 153 and 154
  • Test Example 4 The compound of the present invention described below was used as a test compound and tested according to Test Method 4 at a predetermined concentration of 500 ppm. As a result, all of the compounds of the present invention showed a mortality of 80% or more.
  • Compounds of the present invention 1, 2, 3, 5, 6, 14, 19, 21, 22, 24, 25, 27, 28, 29, 30, 30, 40, 45, 46, 47, 49, 50, 51, 52, 53, 54, 55, 56, 57, 60, 61, 62, 64, 67, 71, 76, 81, 83, 88, 89, 90, 92, 96, 97, 98, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 114, 115, 116, 120, 122, 124, 125, 126, 127, 128, 132, 133, 134, 135, 136, 137, 138, 140, 141, 150, 151, 153 and 154
  • Test Example 5 The compound of the present invention described below was tested as a test compound at a predetermined concentration of 500 ppm, and as a result, each of the compounds of the present invention described below showed a mortality of 90% or more.
  • Compounds of the present invention 27, 28, 29, 37, 46, 48, 52, 53, 54, 55, 56, 60, 61, 62, 64, 67, 84, 89, 91, 92, 93, 102, 103, 105, 106, 107, 108, 109, 110, 115, 116, 122, 124, 125, 135, 136, 138 and 154
  • Test method 6 A test compound is prepared according to the method described in Preparation Example 5, and water containing 0.03% by volume of Syndyne (registered trademark) is added thereto to prepare a diluted solution containing a predetermined concentration of the test compound.
  • Syndyne registered trademark
  • the B. tabaci adults are released and allowed to lay eggs for about 24 hours.
  • the seedlings are stored for 8 days, and larvae are hatched from the delivered eggs.
  • the diluted solution is sprayed onto the seedlings at a rate of 10 mL / seedling. After 7 days, the number of surviving insects is investigated, and the control value is determined by the following equation.
  • Control value (%) ⁇ 1- (Cb ⁇ Tai) / (Cai ⁇ Tb) ⁇ ⁇ 100
  • Cb The number of insects immediately before the treatment in the untreated zone
  • Cai The number of living insects in the survey of the untreated region
  • Tb The number of insects just before the treatment in the treated zone
  • Tai The number of living insects in the survey of the treated region Means a zone which performs the same operation as the treatment zone except that the test compound is not used.
  • Test Example 6 As a result of conducting a test according to the test method 6 by setting a predetermined concentration to 500 ppm and using the following compound of the present invention as a test compound, all of the following compounds of the present invention showed 90% or more of control value.
  • Compounds of the present invention 27, 30, 32, 36, 53, 56, 57, 60, 62, 63, 64, 72, 89, 90, 91, 92, 103, 106, 107, 108, 122, 124, 138, 142 and 154
  • Test Example 7 The compound of the present invention described below exhibited a mortality of 90% or more as a result of conducting a test according to test method 7 using a compound of the present invention described below as a test compound, with a predetermined concentration of 500 ppm.
  • Test method 8 A test compound is prepared according to the method described in Preparation Example 5, and water containing 0.03% by volume of Syndyne (registered trademark) is added thereto to prepare a diluted solution containing a predetermined concentration of the test compound. About 40 adult spider mite mites are released on kidney bean (Phaseolus vulgaris) seedlings (first true leaf development stage) planted in a container. One day later, the seedlings are sprayed with the diluted solution at a rate of 10 mL / seedling. After 7 days, the number of surviving insects is examined, and the control value is calculated by the following equation.
  • Control value (%) ⁇ 1- (Cb ⁇ Tai) / (Cai ⁇ Tb) ⁇ ⁇ 100
  • Cb Number of tested insects in untreated area
  • Cai Number of surviving insects in survey in untreated area
  • Tb Number of tested insects in treated zone
  • Tai Number of surviving insects in survey in treated area
  • untreated group means It means a zone that performs the same operation as the treatment zone except that the test compound is not used.
  • Test Example 8 As a result of conducting a test according to the test method 8 by setting a predetermined concentration to 500 ppm and using the following compound of the present invention as a test compound, the following compound of the present invention showed a control value of 90% or more.
  • Invention compounds 56, 105, 106, 108, 109, 115, 116, 122, 135, 136 and 154
  • Test Example 9 The compound of the present invention described below was used as a test compound and tested according to test method 9 with a predetermined concentration of 3.5 ppm, and all of the compounds of the present invention showed a mortality of 91% or more.
  • Compounds of the present invention 28, 29, 38, 47, 48, 54, 55, 64, 81, 103, 105, 106, 108, 110, 114, 116, 131, 134, 136, 140 and 146
  • Test Example 10 The compound of the present invention described below was used as a test compound and tested according to Test Method 10 with a predetermined concentration of 500 ppm. As a result, all of the compounds of the present invention showed a mortality of 80% or more.
  • the present compounds 27, 28, 29, 30, 31, 32, 33, 34, 36, 40, 43, 47, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 63, 64, 67, 68, 89, 90, 94, 102, 103, 105, 106, 107, 108, 116, 123, 124, 125, 134, 138 and 154
  • Test Example 11 As a result of conducting a test according to the test method 11 by setting a predetermined concentration to 500 ppm and using the following compound of the present invention as a test compound, all of the following compounds of the present invention showed 100% mortality.
  • the compounds of the present invention 29, 31, 33, 34, 47, 49, 50, 54, 55, 56, 57, 58, 59, 60, 63, 67, 68, 91, 94, 96, 125 and 134
  • Test Example 12-1 The test was conducted according to test method 12 using the following compound of the present invention as a test compound, with the predetermined time being set to 1 hour.
  • the present invention compounds 27, 28, 29, 30, 31, 33, 34, 37, 38, 43, 47, 49, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 67, 89, 90, 91, 93, 102, 103, 105, 106, 107, 108, 109, 116, 122, 123, 124, 125, 138, 144, 145, 146, 147 and 154
  • Test Example 12-2 As a result of conducting a test according to test method 12 by setting a predetermined time to 1 day and using the following compound of the present invention as a test compound, all of the following compounds of the present invention showed a mortality of 80% or more.
  • the present invention compounds 27, 28, 29, 30, 31, 33, 34, 37, 38, 43, 46, 47, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 67, 70, 89, 90, 91, 93, 102, 103, 105, 106, 107, 108, 109, 110, 115, 116, 118, 122, 123, 124, 125, 135, 138, 144, 145, 146, 146, 147 and 154
  • the compound of the present invention X exhibits an excellent control effect on harmful arthropods.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention provides a compound having an exceptional control effect on harmful arthropods. A compound represented by formula (I) [in the formula, R1 and R2 are the same or different and represent a C1-C15 chain hydrocarbon group, etc., R3 represents a (C1-C3 alkoxy)C1-C3 alkyl group, etc., R4 represents a C1-C2 alkyl group, etc., R5 represents a C1-C4 chain hydrocarbon group, etc., L1 represents a single bond, etc., L2 represents a single bond, etc., and n represents 0 or 1] has an exceptional control effect on harmful arthropods.

Description

ピリジン化合物及びそれを含有する有害節足動物防除剤Pyridine compound and harmful arthropod controlling agent containing the same
　本出願は２０１７年１０月２７日に出願された日本国特許出願第２０１７－２０７９２８に対する優先権及びその利益を主張するものであり、その全内容は参照することにより本出願に組み込まれる。
　本発明はピリジン化合物及びそれを含有する有害節足動物防除剤に関する。 This application claims priority to and the benefit of Japanese Patent Application No. 2017-207928 filed Oct. 27, 2017, the entire contents of which are incorporated herein by reference.
The present invention relates to pyridine compounds and harmful arthropod control agents containing the same.
　これまでに有害節足動物の防除を目的として、様々な化合物が検討されている。例えば、特許文献１には、ある種の化合物が有害生物防除効果を有することが記載されている。 So far, various compounds have been studied for the purpose of controlling harmful arthropods. For example, Patent Document 1 describes that certain compounds have a pest control effect.
国際公開第２０１６／０３９０４８号International Publication No. 2016/039048
　本発明は、有害節足動物に対して優れた防除効力を有する化合物を提供することを課題とする。 An object of the present invention is to provide a compound having excellent control efficacy against harmful arthropods.
　本発明は以下のとおりである。
［１］　式（Ｉ）
Figure JPOXMLDOC01-appb-C000002
 〔式中、
　Ｒ1及びＲ2は、同一又は相異なり、Ｃ１－Ｃ１５鎖式炭化水素基｛該Ｃ１－Ｃ１５鎖式炭化水素基は、群Ａより選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ８シクロアルキル基又はＣ３－Ｃ８シクロアルケニル基｛該Ｃ３－Ｃ８シクロアルキル基及び該Ｃ３－Ｃ８シクロアルケニル基は、群Ｂより選ばれる１以上の置換基を有していてもよい｝を表し、
　Ｒ3は、（Ｃ１－Ｃ３アルコキシ）Ｃ１－Ｃ３アルキル基、群Ｂより選ばれる１以上の置換基を有していてもよいベンジル基、ホルミル基、Ｃ（Ｏ）Ｒ10、Ｃ（Ｏ）ＯＲ10又は水素原子を表し、
　Ｒ10は、Ｃ１－Ｃ４鎖式炭化水素基又はシクロプロピル基｛該Ｃ１－Ｃ４鎖式炭化水素基及び該シクロプロピル基は、シアノ基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝を表し、
　Ｒ4は、１以上のハロゲン原子を有していてもよいＣ１－Ｃ２アルキル基又は群Ｃより選ばれる１以上の置換基を有していてもよいシクロプロピル基を表し、
　Ｒ5は、１以上のハロゲン原子を有していてもよいＣ１－Ｃ４鎖式炭化水素基又は群Ｃより選ばれる１以上の置換基を有していてもよいシクロプロピル基を表し、
　Ｌ1は、単結合、－Ｌ1A－Ｏ－＃、－Ｌ1A－ＮＲ6－＃、－Ｌ1A－Ｓ（Ｏ）m－＃、－Ｌ1A－Ｏ－Ｎ＝ＣＲ7－＃、－Ｌ1B－ＣＲ7＝Ｎ－Ｏ－＃、又は－Ｌ1B－ＣＲ7＝Ｎ－ＮＲ6－＃を表し、
　＃は、Ｒ1との結合位置を表し、
　Ｌ2は、単結合、－Ｌ2A－Ｏ－＊、－Ｌ2A－ＮＲ8－＊、－Ｌ2A－Ｓ（Ｏ）p－＊、－Ｌ2A－Ｏ－Ｎ＝ＣＲ9－＊、－Ｌ2B－ＣＲ9＝Ｎ－Ｏ－＊、又は－Ｌ2B－ＣＲ9＝Ｎ－ＮＲ8－＊を表し、
　＊は、Ｒ2との結合位置を表し、
　Ｒ6、Ｒ7、Ｒ8及びＲ9は、同一又は相異なり、１以上のハロゲン原子を有していてもよいＣ１－Ｃ３アルキル基又は水素原子を表し、
　Ｌ1A及びＬ2Aは、同一又は相異なり、Ｃ１－Ｃ３アルカンジイル基、Ｃ２－Ｃ３アルケンジイル基、エチンジイル基又はプロピンジイル基｛該Ｃ１－Ｃ３アルカンジイル基、該Ｃ２－Ｃ３アルケンジイル基及び該プロピンジイル基は、群Ｄより選ばれる１以上の置換基を有していてもよい｝を表し、
　Ｌ1B及びＬ2Bは、同一又は相異なり、単結合、Ｃ１－Ｃ３アルカンジイル基、Ｃ２－Ｃ３アルケンジイル基、エチンジイル基又はプロピンジイル基｛該Ｃ１－Ｃ３アルカンジイル基、該Ｃ２－Ｃ３アルケンジイル基及び該プロピンジイル基は、群Ｄより選ばれる１以上の置換基を有していてもよい｝を表し、
　ｎは、０又は１を表し、
　ｍ及びｐは、同一又は相異なり、０、１又は２を表す。
　群Ａ：Ｃ１－Ｃ６アルコキシ基、Ｃ３－Ｃ６アルケニルオキシ基、Ｃ３－Ｃ６アルキニルオキシ基、Ｃ１－Ｃ６アルキルスルファニル基、Ｃ１－Ｃ６アルキルスルフィニル基、Ｃ１－Ｃ６アルキルスルホニル基、Ｃ２－Ｃ６アルキルカルボニル基、Ｃ２－Ｃ６アルキルカルボニルオキシ基｛該Ｃ１－Ｃ６アルコキシ基、該Ｃ３－Ｃ６アルケニルオキシ基、該Ｃ３－Ｃ６アルキニルオキシ基、該Ｃ１－Ｃ６アルキルスルファニル基、該Ｃ１－Ｃ６アルキルスルフィニル基、該Ｃ１－Ｃ６アルキルスルホニル基、該Ｃ２－Ｃ６アルキルカルボニル基及び該Ｃ２－Ｃ６アルキルカルボニルオキシ基は、１以上のハロゲン原子を有していてもよい｝、Ｃ３－Ｃ８シクロアルキル基、Ｃ３－Ｃ８シクロアルケニル基、Ｃ３－Ｃ８シクロアルキルオキシ基、Ｃ３－Ｃ８シクロアルケニルオキシ基｛該Ｃ３－Ｃ８シクロアルキル基、該Ｃ３－Ｃ８シクロアルケニル基、該Ｃ３－Ｃ８シクロアルキルオキシ基及び該Ｃ３－Ｃ８シクロアルケニルオキシ基は、群Ｂより選ばれる１以上の置換基を有していてもよい｝、ハロゲン原子、シアノ基、ニトロ基、アミノ基、Ｃ（Ｏ）ＯＲ11及びＣ（Ｏ）ＮＲ12Ｒ13からなる群。
　Ｒ11、Ｒ12及びＲ13は、同一又は相異なり、Ｃ１－Ｃ３アルキル基又は水素原子を表す。
　群Ｂ：Ｃ１－Ｃ６鎖式炭化水素基、Ｃ１－Ｃ６アルコキシ基、Ｃ３－Ｃ６アルケニルオキシ基、Ｃ３－Ｃ６アルキニルオキシ基、Ｃ１－Ｃ６アルキルスルファニル基、Ｃ１－Ｃ６アルキルスルフィニル基、Ｃ１－Ｃ６アルキルスルホニル基、Ｃ２－Ｃ６アルキルカルボニル基、Ｃ２－Ｃ６アルキルカルボニルオキシ基｛該Ｃ１－Ｃ６鎖式炭化水素基、該Ｃ１－Ｃ６アルコキシ基、該Ｃ３－Ｃ６アルケニルオキシ基、該Ｃ３－Ｃ６アルキニルオキシ基、該Ｃ１－Ｃ６アルキルスルファニル基、該Ｃ１－Ｃ６アルキルスルフィニル基、該Ｃ１－Ｃ６アルキルスルホニル基、該Ｃ２－Ｃ６アルキルカルボニル基及び該Ｃ２－Ｃ６アルキルカルボニルオキシ基は、１以上のハロゲン原子を有していてもよい｝、ハロゲン原子、ニトロ基、ヒドロキシ基、アミノ基、オキソ基、Ｃ（Ｏ）ＯＲ11及びＣ（Ｏ）ＮＲ12Ｒ13からなる群。
　群Ｃ：１以上のハロゲン原子を有していてもよいＣ１－Ｃ３アルキル基、ハロゲン原子及びシアノ基からなる群。
　群Ｄ：シクロプロピル基、ハロゲン原子及びシアノ基からなる群。〕
で示される化合物（以下、本発明化合物Ｘと記す）。
［２］　群Ｂが、Ｃ１－Ｃ６鎖式炭化水素基、Ｃ１－Ｃ６アルコキシ基、Ｃ３－Ｃ６アルケニルオキシ基、Ｃ３－Ｃ６アルキニルオキシ基、Ｃ１－Ｃ６アルキルスルファニル基、Ｃ１－Ｃ６アルキルスルフィニル基、Ｃ１－Ｃ６アルキルスルホニル基、Ｃ２－Ｃ６アルキルカルボニル基、Ｃ２－Ｃ６アルキルカルボニルオキシ基｛該Ｃ１－Ｃ６鎖式炭化水素基、該Ｃ１－Ｃ６アルコキシ基、該Ｃ３－Ｃ６アルケニルオキシ基、該Ｃ３－Ｃ６アルキニルオキシ基、該Ｃ１－Ｃ６アルキルスルファニル基、該Ｃ１－Ｃ６アルキルスルフィニル基、該Ｃ１－Ｃ６アルキルスルホニル基、該Ｃ２－Ｃ６アルキルカルボニル基及び該Ｃ２－Ｃ６アルキルカルボニルオキシ基は、１以上のハロゲン原子を有していてもよい｝、ハロゲン原子、ニトロ基、ヒドロキシ基、アミノ基、Ｃ（Ｏ）ＯＲ11及びＣ（Ｏ）ＮＲ12Ｒ13からなる群である、［１］に記載の化合物（以下、本発明化合物と記す）。
［３］　Ｒ3が、ベンジル基、Ｃ（Ｏ）ＣＨ3、Ｃ（Ｏ）ＯＣＨ3、Ｃ（Ｏ）ＯＣＨ2ＣＨ＝ＣＨ2又は水素原子であり、
　Ｌ1が、単結合、－ＣＨ2－Ｏ－＃、－ＣＨ2－Ｏ－Ｎ＝ＣＲ7－＃、又は－ＣＲ7＝Ｎ－Ｏ－＃であり、
　Ｌ2が、単結合、－ＣＨ2－Ｏ－＊、－ＣＨ2－Ｏ－Ｎ＝Ｃ（ＣＨ3）－＊、又は－ＣＨ＝Ｎ－Ｏ－＊である、［１］又は［２］に記載の化合物。
［４］　Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、Ｃ３－Ｃ６シクロアルキル基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基である、［１］～［３］のいずれかに記載の化合物。
［５］　Ｒ1が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、Ｃ３－Ｃ６シクロアルキル基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝である、［１］～［４］のいずれかに記載の化合物。
［６］　Ｌ1及びＬ2が、単結合である、［１］～［５］のいずれかに記載の化合物。
［７］　［１］～［６］のいずれかに記載の化合物と、不活性担体とを含有する有害節足動物防除組成物。
［８］　群（ａ）及び群（ｂ）からなる群より選ばれる１以上の成分を含有する［７］に記載の組成物：
　群（ａ）：殺虫活性成分、殺ダニ活性成分及び殺線虫活性成分からなる群；
　群（ｂ）：殺菌活性成分。
［９］　［１］～［６］のいずれかに記載の化合物の有効量を有害節足動物又は有害節足動物の生息場所に施用する有害節足動物の防除方法。
［１０］　［７］又は［８］に記載の組成物の有効量を有害節足動物又は有害節足動物の生息場所に施用する有害節足動物の防除方法。
［１１］　［１］～［６］のいずれかに記載の化合物の有効量又は［７］もしくは［８］に記載の組成物の有効量を保持している種子又は栄養生殖器官。 The present invention is as follows.
[1] Formula (I)
Figure JPOXMLDOC01-appb-C000002
 [In the formula,
R 1 and R 2 are the same or different, and C1-C15 chain hydrocarbon group {The C1-C15 chain hydrocarbon group may have one or more substituents selected from group A} , C3-C8 cycloalkyl group or C3-C8 cycloalkenyl group {The C3-C8 cycloalkyl group and the C3-C8 cycloalkenyl group may have one or more substituents selected from Group B} Represents
R 3 represents a (C 1 -C 3 alkoxy) C 1 -C 3 alkyl group, a benzyl group optionally having one or more substituents selected from group B, a formyl group, C (O) R 10 , C (O) Represents OR 10 or a hydrogen atom,
R 10 represents a C1-C4 chain hydrocarbon group or a cyclopropyl group {wherein the C1-C4 chain hydrocarbon group and the cyclopropyl group are one or more substituents selected from the group consisting of a cyano group and a halogen atom Represents that it may have,
R 4 represents a C 1 -C 2 alkyl group which may have one or more halogen atoms or a cyclopropyl group which may have one or more substituents selected from group C,
R 5 represents a C1-C4 chain hydrocarbon group which may have one or more halogen atoms or a cyclopropyl group which may have one or more substituents selected from Group C,
L 1 represents a single bond, -L 1A -O - #, - L 1A -NR 6 - #, - L 1A -S (O) m - #, - L 1A -O-N = CR 7 - #, - L 1B -CR 7 = N-O- # or -L 1B -CR 7 = N-NR 6- #,
# Represents the bonding position with R 1 ,
L 2 represents a single bond, -L 2A -O - *, - L 2A -NR 8 - *, - L 2A -S (O) p - *, - L 2A -O-N = CR 9 - *, - L 2B -CR 9 = N-O- *, or -L 2B -CR 9 = N-NR 8 - * represents,
* Represents a bonding position with R 2 ,
R 6 , R 7 , R 8 and R 9 are the same or different and each represents a C1-C3 alkyl group optionally having one or more halogen atoms, or a hydrogen atom,
L 1A and L 2A are the same or different, and C 1 -C 3 alkanediyl group, C 2 -C 3 alkene diyl group, ethyne diyl group or propyne diyl group {C1-C 3 alkanediyl group, said C 2 -C 3 alkene diyl group and said propyne diyl group , And may optionally have one or more substituents selected from group D,
L 1B and L 2B are the same or different, and a single bond, a C 1 -C 3 alkanediyl group, a C 2 -C 3 alkene diyl group, an ethyne diyl group or a propyne diyl group {the C 1 -C 3 alkanediyl group, the C 2 -C 3 alkene diyl group and the The propyne diyl group may have one or more substituents selected from group D}.
n represents 0 or 1 and
m and p are the same or different and each represents 0, 1 or 2.
Group A: C 1 -C 6 alkoxy, C 3 -C 6 alkenyloxy, C 3 -C 6 alkynyloxy, C 1 -C 6 alkylsulfanyl, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 2 -C 6 alkylcarbonyl A C2-C6 alkylcarbonyloxy group {wherein the C1-C6 alkoxy group, the C3-C6 alkenyloxy group, the C3-C6 alkynyloxy group, the C1-C6 alkylsulfanyl group, the C1-C6 alkylsulfinyl group, the C1 -C6 alkylsulfonyl group, the C2-C6 alkylcarbonyl group and the C2-C6 alkylcarbonyloxy group may have one or more halogen atoms}, a C3-C8 cycloalkyl group, a C3-C8 cycloalkenyl Group, C3-C8 cycloalkyloxy group C3-C8 cycloalkenyloxy group {wherein the C3-C8 cycloalkyl group, the C3-C8 cycloalkenyl group, the C3-C8 cycloalkyloxy group and the C3-C8 cycloalkenyloxy group are one or more selected from group B A group consisting of a halogen atom, a cyano group, a nitro group, an amino group, C (O) OR 11 and C (O) NR 12 R 13 ;
R 11 , R 12 and R 13 are the same or different and each represents a C1-C3 alkyl group or a hydrogen atom.
Group B: C1-C6 chain hydrocarbon group, C1-C6 alkoxy group, C3-C6 alkenyloxy group, C3-C6 alkynyloxy group, C1-C6 alkylsulfanyl group, C1-C6 alkylsulfinyl group, C1-C6 alkyl A sulfonyl group, a C2-C6 alkyl carbonyl group, a C2-C6 alkyl carbonyloxy group {the C1-C6 chain hydrocarbon group, the C1-C6 alkoxy group, the C3-C6 alkenyloxy group, the C3-C6 alkynyloxy group The C1-C6 alkylsulfanyl group, the C1-C6 alkylsulfinyl group, the C1-C6 alkylsulfonyl group, the C2-C6 alkylcarbonyl group and the C2-C6 alkylcarbonyloxy group have one or more halogen atoms; May be}, a halogen atom, a nitro group, a hydroxy group Amino group, oxo group, C (O) group consisting of OR 11 and C (O) NR 12 R 13 .
Group C: A group consisting of a C1-C3 alkyl group optionally having one or more halogen atoms, a halogen atom and a cyano group.
Group D: a group consisting of cyclopropyl, halogen and cyano. ]
And a compound represented by (hereinafter, referred to as a compound X of the present invention).
[2] Group B is a C1-C6 chain hydrocarbon group, a C1-C6 alkoxy group, a C3-C6 alkenyloxy group, a C3-C6 alkynyloxy group, a C1-C6 alkylsulfanyl group, a C1-C6 alkylsulfinyl group, C1-C6 alkylsulfonyl group, C2-C6 alkylcarbonyl group, C2-C6 alkylcarbonyloxy group {C1-C6 chain hydrocarbon group, said C1-C6 alkoxy group, said C3-C6 alkenyloxy group, said C3-C6 alkyloxy group The C6 alkynyloxy group, the C1 to C6 alkyl sulfanyl group, the C1 to C6 alkyl sulfinyl group, the C1 to C6 alkyl sulfonyl group, the C2 to C6 alkyl carbonyl group, and the C2 to C6 alkyl carbonyloxy group are at least one of May have a halogen atom}, a halogen atom, a nitro group, a hydride The compound according to [1], which is a group consisting of an oxo group, an amino group, C (O) OR 11 and C (O) NR 12 R 13 (hereinafter referred to as the present compound).
[3] R 3 is a benzyl group, C (O) CH 3 , C (O) OCH 3 , C (O) OCH 2 CH = CH 2 or a hydrogen atom,
L 1 is a single bond, -CH 2 -O - #, - CH 2 -O-N = CR 7 - #, or a -CR 7 = N-O- #,
[1] or [2], wherein L 2 is a single bond, -CH 2 -O- *, -CH 2 -O-N = C (CH 3 )-*, or -CH = N-O- * The compound as described in.
[4] R 2 is a C1-C10 chain hydrocarbon group {The C1-C10 chain hydrocarbon group has one or more substituents selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound according to any one of [1] to [3], which may be}, a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
[5] R 1 is a C1-C10 chain hydrocarbon group {wherein the C1-C10 chain hydrocarbon group has one or more substituents selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound according to any one of [1] to [4], which may be
[6] The compound according to any one of [1] to [5], wherein L 1 and L 2 are a single bond.
[7] A harmful arthropod control composition comprising the compound according to any one of [1] to [6] and an inert carrier.
[8] The composition according to [7], which comprises one or more components selected from the group consisting of Group (a) and Group (b):
Group (a): a group consisting of an insecticidal active ingredient, an acaricidal active ingredient and a nematode active ingredient;
Group (b): bactericidal active ingredient.
[9] A method for controlling noxious arthropods, which comprises applying an effective amount of the compound according to any one of [1] to [6] to a harmful arthropod or a habitat of the harmful arthropod.
[10] A method for controlling noxious arthropods, which comprises applying an effective amount of the composition according to [7] or [8] to a harmful arthropod or a habitat of the harmful arthropod.
[11] A seed or vegetative organ which retains an effective amount of the compound according to any one of [1] to [6] or an effective amount of the composition according to [7] or [8].
　本発明により、有害節足動物を防除することができる。 According to the present invention, harmful arthropods can be controlled.
　本発明における置換基について説明する。
　「ハロゲン原子」とは、フッ素原子、塩素原子、臭素原子、又はヨウ素原子である。
　置換基が２以上のハロゲン原子を有している場合、それらのハロゲン原子は各々同一でも異なっていてもよいことを表す。
　置換基が特定の群（例えばシアノ基及びハロゲン原子からなる群）より選ばれる２以上の基又は原子を有している場合、それらの基又は原子は各々同一であっても異なっていてもよい。
　本明細書における「群Ｘより選ばれる１以上の置換基を有していてもよい」（ＸはＡ～Ｆのいずれか１つを意味する）との表記は、群Ｘより選ばれる置換基が２つ以上存在する場合、それらの置換基は各々同一でも異なっていてもよい。
　本明細書における「ＣＸ－ＣＹ」との表記は、炭素原子数がＸ乃至Ｙであることを意味する。例えば「Ｃ１－Ｃ６」との表記は、炭素原子数が１乃至６であることを意味する。
　「鎖式炭化水素基」とは、アルキル基、アルケニル基又はアルキニル基を表す。
　「アルキル基」としては、例えばメチル基、エチル基、プロピル基、イソプロピル基、１，１－ジメチルプロピル基、１，２－ジメチルプロピル基、ブチル基、ｔｅｒｔ－ブチル基、ペンチル基、ヘキシル基、オクチル基、デシル基及びペンタデシル基が挙げられる。
　「アルケニル基」としては、例えばビニル基、１－プロペニル基、２－プロペニル基、１－メチル－１－プロペニル基、１－メチル－２－プロペニル基、１，２－ジメチル－１－プロペニル基、３－ブテニル基、４－ペンテニル基、５－ヘキセニル基、７－オクテニル基、１－デセニル基及び１－ペンタデセニル基が挙げられる。
　「アルキニル基」としては、例えばエチニル基、１－プロピニル基、２－プロピニル基、１－メチル－２－プロピニル基、１，１－ジメチル－２－プロピニル基、２－ブチニル基、４－ペンチニル基、５－ヘキシニル基、７－オクチニル基、１－デシニル基及び１－ペンタデシニル基が挙げられる。
　「アルカンジイル基」としては、例えばメタンジイル基、１，１－エタンジイル基、１，２－エタンジイル基、１，１－プロパンジイル基、２，２－プロパンジイル基、１，２－プロパンジイル基及び１，３－プロパンジイル基が挙げられる。
　「アルケンジイル基」としては、例えばエテン－１，１－ジイル基、エテン－１，２－ジイル基、１－プロペン－１，２－ジイル基、１－プロペン－１，３－ジイル基及び２－プロペン－１，３－ジイル基が挙げられる。 The substituents in the present invention will be described.
The "halogen atom" is a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
When a substituent has 2 or more halogen atoms, it means that those halogen atoms may be the same or different.
When the substituent has two or more groups or atoms selected from a specific group (for example, a group consisting of a cyano group and a halogen atom), those groups or atoms may be the same or different. .
In the present specification, the expression “optionally having one or more substituents selected from group X” (X means any one of A to F) is a substituent selected from group X When two or more are present, those substituents may be the same or different.
The notation "CX-CY" in the present specification means that the number of carbon atoms is X to Y. For example, the notation "C1-C6" means that the number of carbon atoms is 1 to 6.
The "chain hydrocarbon group" represents an alkyl group, an alkenyl group or an alkynyl group.
As the "alkyl group", for example, methyl group, ethyl group, propyl group, isopropyl group, 1,1-dimethylpropyl group, 1,2-dimethylpropyl group, butyl group, tert-butyl group, pentyl group, hexyl group, Examples include octyl, decyl and pentadecyl.
As the “alkenyl group”, for example, vinyl group, 1-propenyl group, 2-propenyl group, 1-methyl-1-propenyl group, 1-methyl-2-propenyl group, 1,2-dimethyl-1-propenyl group, Examples include 3-butenyl group, 4-pentenyl group, 5-hexenyl group, 7-octenyl group, 1-decenyl group and 1-pentadecenyl group.
As the "alkynyl group", for example, ethynyl group, 1-propynyl group, 2-propynyl group, 1-methyl-2-propynyl group, 1,1-dimethyl-2-propynyl group, 2-butynyl group, 4-pentynyl group 5-hexynyl group, 7-octynyl group, 1-decynyl group and 1-pentadecynyl group.
As the “alkanediyl group”, for example, methanediyl group, 1,1-ethanediyl group, 1,2-ethanediyl group, 1,1-propanediyl group, 2,2-propanediyl group, 1,2-propanediyl group and There may be mentioned 1,3-propanediyl group.
Examples of the “alkenediyl group” include ethene-1,1-diyl group, ethene-1,2-diyl group, 1-propene-1,2-diyl group, 1-propene-1,3-diyl group and 2- Examples include propene-1,3-diyl group.
　「シクロアルキル基」としては、例えばシクロプロピル基、シクロブチル基、シクロペンチル基、シクロヘキシル基及びシクロオクチル基が挙げられる。
　「シクロアルケニル基」としては、例えばシクロプロペニル基、シクロブテニル基、シクロペンテニル基、シクロヘキセニル基及びシクロオクテニル基が挙げられる。 As the “cycloalkyl group”, for example, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group and cyclooctyl group can be mentioned.
As the "cycloalkenyl group", for example, cyclopropenyl group, cyclobutenyl group, cyclopentenyl group, cyclohexenyl group and cyclooctenyl group can be mentioned.
　「群Ｂより選ばれる１以上の置換基を有していてもよいベンジル基」とは、例えばベンジル基、２－フルオロベンジル基、４－メチルベンジル基、４－（トリフルオロメトキシ）ベンジル基、及び４－アセチルベンジル基が挙げられる。 The “benzyl group optionally having one or more substituents selected from group B” is, for example, benzyl group, 2-fluorobenzyl group, 4-methylbenzyl group, 4- (trifluoromethoxy) benzyl group, And 4-acetylbenzyl group.
　本発明化合物Ｘが１個又は複数個の不斉中心を有する場合、各々の光学異性体及びそれらを任意の割合で含む混合物も本発明化合物に含まれる。また、炭素－炭素二重結合、又は炭素－窒素二重結合に由来する２種以上の幾何異性体、及びそれらを任意の割合で含む混合物も本発明化合物Ｘに含まれる。 When the compound of the present invention X has one or more asymmetric centers, each optical isomer and a mixture containing them in any ratio are also included in the compound of the present invention. In addition, a compound of the present invention X includes two or more geometric isomers derived from a carbon-carbon double bond or a carbon-nitrogen double bond, and a mixture containing them in any ratio.
　本発明化合物Ｘは、塩酸、硫酸、硝酸、リン酸、酢酸又は安息香酸等の酸と混合することにより、塩酸塩、硫酸塩、硝酸塩、リン酸塩、酢酸塩又は安息香酸塩等の酸付加塩を形成することがある。 The compound of the present invention X is added with an acid such as hydrochloride, sulfate, nitrate, phosphate, acetate or benzoate by mixing with an acid such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid or benzoic acid May form salts.
　本発明化合物の態様としては、以下の化合物が挙げられる。 The following compounds may be mentioned as embodiments of the compound of the present invention.
〔態様１〕本発明化合物において、Ｌ1が、単結合、－Ｌ1A－Ｏ－＃、－Ｌ1A－Ｏ－Ｎ＝ＣＲ7－＃、又は－Ｌ1B－ＣＲ7＝Ｎ－Ｏ－＃であり、
　Ｌ2が、単結合、－Ｌ2A－Ｏ－＊、－Ｌ2A－Ｏ－Ｎ＝ＣＲ9－＊、又は－Ｌ2B－ＣＲ9＝Ｎ－Ｏ－＊であり、
　Ｒ3が、群Ｂより選ばれる１以上の置換基を有していてもよいベンジル基、Ｃ（Ｏ）Ｒ10、Ｃ（Ｏ）ＯＲ10又は水素原子である化合物。
〔態様２〕態様１において、Ｒ3が、ベンジル基、Ｃ（Ｏ）Ｒ10、Ｃ（Ｏ）ＯＲ10又は水素原子である化合物。
〔態様３〕態様１において、Ｒ3が、ベンジル基、Ｃ（Ｏ）ＣＨ3、Ｃ（Ｏ）ＯＣＨ3、Ｃ（Ｏ）ＯＣＨ2ＣＨ＝ＣＨ2又は水素原子である化合物。
〔態様４〕本発明化合物において、Ｌ1が、単結合、－ＣＨ2－Ｏ－＃、－ＣＨ2－Ｏ－Ｎ＝ＣＲ7－＃、又は－ＣＲ7＝Ｎ－Ｏ－＃であり、
　Ｌ2が、単結合、－ＣＨ2－Ｏ－＊、－ＣＨ2－Ｏ－Ｎ＝Ｃ（ＣＨ3）－＊、又は－ＣＨ＝Ｎ－Ｏ－＊であり、
　Ｒ3が、ベンジル基、Ｃ（Ｏ）ＣＨ3、Ｃ（Ｏ）ＯＣＨ3、Ｃ（Ｏ）ＯＣＨ2ＣＨ＝ＣＨ2又は水素原子である化合物。
〔態様５〕態様４において、Ｒ4及びＲ5が同一又は相異なり、１以上のハロゲン原子を有していてもよいＣ１－Ｃ２アルキル基である化合物。
〔態様６〕態様４において、Ｒ4及びＲ5がメチル基である化合物。
〔態様７〕態様１において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、群Ｅより選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基｛該Ｃ３－Ｃ６シクロアルキル基及び該Ｃ３－Ｃ６シクロアルケニル基は、群Ｆより選ばれる１以上の置換基を有していてもよい｝である化合物。
　群Ｅ：Ｃ３－Ｃ６シクロアルキル基｛該Ｃ３－Ｃ６シクロアルキル基は、群Ｆより選ばれる１以上の置換基を有していてもよい｝及びハロゲン原子からなる群。
　群Ｆ：１以上のハロゲン原子を有していてもよいＣ１－Ｃ４アルキル基及びハロゲン原子からなる群。
〔態様８〕態様２において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、群Ｅより選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基｛該Ｃ３－Ｃ６シクロアルキル基及び該Ｃ３－Ｃ６シクロアルケニル基は、群Ｆより選ばれる１以上の置換基を有していてもよい｝である化合物。
〔態様９〕態様３において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、群Ｅより選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基｛該Ｃ３－Ｃ６シクロアルキル基及び該Ｃ３－Ｃ６シクロアルケニル基は、群Ｆより選ばれる１以上の置換基を有していてもよい｝である化合物。
〔態様１０〕態様４において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、群Ｅより選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基｛該Ｃ３－Ｃ６シクロアルキル基及び該Ｃ３－Ｃ６シクロアルケニル基は、群Ｆより選ばれる１以上の置換基を有していてもよい｝である化合物。
〔態様１１〕態様５において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、群Ｅより選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基｛該Ｃ３－Ｃ６シクロアルキル基及び該Ｃ３－Ｃ６シクロアルケニル基は、群Ｆより選ばれる１以上の置換基を有していてもよい｝である化合物。
〔態様１２〕態様６において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、群Ｅより選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基｛該Ｃ３－Ｃ６シクロアルキル基及び該Ｃ３－Ｃ６シクロアルケニル基は、群Ｆより選ばれる１以上の置換基を有していてもよい｝である化合物。
〔態様１３〕態様１において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、Ｃ３－Ｃ６シクロアルキル基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基である化合物。
〔態様１４〕態様２において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、Ｃ３－Ｃ６シクロアルキル基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基である化合物。
〔態様１５〕態様３において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、Ｃ３－Ｃ６シクロアルキル基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基である化合物。
〔態様１６〕態様４において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、Ｃ３－Ｃ６シクロアルキル基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基である化合物。
〔態様１７〕態様５において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、Ｃ３－Ｃ６シクロアルキル基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基である化合物。
〔態様１８〕態様６において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、Ｃ３－Ｃ６シクロアルキル基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基である化合物。
〔態様１９〕本発明化合物において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、Ｃ３－Ｃ６シクロアルキル基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基であり、
　Ｒ3が、ベンジル基、Ｃ（Ｏ）ＣＨ3、Ｃ（Ｏ）ＯＣＨ3、Ｃ（Ｏ）ＯＣＨ2ＣＨ＝ＣＨ2又は水素原子であり、
　Ｒ4及びＲ5がメチル基であり、
　Ｌ1が単結合であり、
　Ｌ2が－ＣＨ2－Ｏ－＊、－ＣＨ2－Ｏ－Ｎ＝Ｃ（ＣＨ3）－＊、又は－ＣＨ＝Ｎ－Ｏ－＊である化合物。
〔態様２０〕本発明化合物において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、Ｃ３－Ｃ６シクロアルキル基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基であり、
　Ｒ3が、ベンジル基、Ｃ（Ｏ）ＣＨ3、Ｃ（Ｏ）ＯＣＨ3、Ｃ（Ｏ）ＯＣＨ2ＣＨ＝ＣＨ2又は水素原子であり、
　Ｒ4及びＲ5がメチル基であり、
　Ｌ1及びＬ2が単結合である化合物。
〔態様２１〕本発明化合物において、Ｒ1が、Ｃ１－Ｃ１５鎖式炭化水素基｛該Ｃ１－Ｃ１５鎖式炭化水素基は、群Ｅより選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基｛該Ｃ３－Ｃ６シクロアルキル基及び該Ｃ３－Ｃ６シクロアルケニル基は、群Ｆより選ばれる１以上の置換基を有していてもよい｝である化合物。
〔態様２２〕本発明化合物において、Ｒ1が、群Ｅより選ばれる１以上の置換基を有していてもよいＣ１－Ｃ１５鎖式炭化水素基である化合物。
〔態様２３〕本発明化合物において、Ｒ1が、Ｃ１－Ｃ１５アルキル基又はＣ２－Ｃ１５アルケニル基である化合物。
〔態様２４〕態様１～態様２０のいずれかにおいて、Ｒ1が、Ｃ１－Ｃ１５鎖式炭化水素基｛該Ｃ１－Ｃ１５鎖式炭化水素基は、群Ｅより選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基｛該Ｃ３－Ｃ６シクロアルキル基及び該Ｃ３－Ｃ６シクロアルケニル基は、群Ｆより選ばれる１以上の置換基を有していてもよい｝である化合物。
〔態様２５〕態様１～態様２０のいずれかにおいて、Ｒ1が、群Ｅより選ばれる１以上の置換基を有していてもよいＣ１－Ｃ１５鎖式炭化水素基である化合物。
〔態様２６〕態様１～態様２０のいずれかにおいて、Ｒ1が、Ｃ１－Ｃ１５アルキル基又はＣ２－Ｃ１５アルケニル基である化合物。 In [Mode 1] The present invention compounds, L 1 is a single bond, -L 1A -O - #, - L 1A -O-N = CR 7 - #, or -L 1B -CR 7 = N-O- # And
L 2 is a single bond, -L 2A -O - *, - L 2A -O-N = CR 9 - *, or -L 2B -CR 9 = N-O- * a and,
Compounds wherein R 3 is a benzyl group optionally having one or more substituents selected from group B, C (O) R 10 , C (O) OR 10 or a hydrogen atom.
Embodiment 2 A compound according to Embodiment 1, wherein R 3 is a benzyl group, C (O) R 10 , C (O) OR 10 or a hydrogen atom.
Embodiment 3 A compound according to Embodiment 1, wherein R 3 is a benzyl group, C (O) CH 3 , C (O) OCH 3 , C (O) OCH 2 CH = CH 2 or a hydrogen atom.
In [Mode 4] The compound of the present invention, L 1 is a single bond, -CH 2 -O - #, - CH 2 -O-N = CR 7 - #, or a -CR 7 = N-O- #,
L 2 is a single bond, -CH 2 -O- *, -CH 2 -O-N = C (CH 3 )-*, or -CH = N-O- *,
Compounds wherein R 3 is benzyl group, C (O) CH 3 , C (O) OCH 3 , C (O) OCH 2 CH = CH 2 or a hydrogen atom.
[Aspect 5] A compound according to Aspect 4, wherein R 4 and R 5 are the same or different and are a C1-C2 alkyl group optionally having one or more halogen atoms.
[Aspect 6] The compound according to Aspect 4, wherein R 4 and R 5 are a methyl group.
[Aspect 7] In aspect 1, R 2 is a C1-C10 chain hydrocarbon group {the C1-C10 chain hydrocarbon group may have one or more substituents selected from group E} , C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group {The C3-C6 cycloalkyl group and the C3-C6 cycloalkenyl group may have one or more substituents selected from group F} A compound that is
Group E: a group comprising a C3-C6 cycloalkyl group (wherein the C3-C6 cycloalkyl group may have one or more substituents selected from group F) and a halogen atom.
Group F: a group consisting of a C1-C4 alkyl group optionally having one or more halogen atoms and a halogen atom.
[Aspect 8] In Aspect 2, R 2 is a C1-C10 chain hydrocarbon group {The C1-C10 chain hydrocarbon group may have one or more substituents selected from Group E} , C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group {The C3-C6 cycloalkyl group and the C3-C6 cycloalkenyl group may have one or more substituents selected from group F} A compound that is
[Aspect 9] In aspect 3, R 2 is a C 1 -C 10 chain hydrocarbon group {The C 1 -C 10 chain hydrocarbon group may have one or more substituents selected from group E} , C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group {The C3-C6 cycloalkyl group and the C3-C6 cycloalkenyl group may have one or more substituents selected from group F} A compound that is
[Aspect 10] In Aspect 4, R 2 is a C1-C10 chain hydrocarbon group {the C1-C10 chain hydrocarbon group may have one or more substituents selected from Group E} , C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group {The C3-C6 cycloalkyl group and the C3-C6 cycloalkenyl group may have one or more substituents selected from group F} A compound that is
[Aspect 11] In Aspect 5, R 2 is a C 1 -C 10 chain hydrocarbon group {the C 1 -C 10 chain hydrocarbon group may have one or more substituents selected from Group E} , C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group {The C3-C6 cycloalkyl group and the C3-C6 cycloalkenyl group may have one or more substituents selected from group F} A compound that is
[Aspect 12] In Aspect 6, R 2 is a C 1 -C 10 chain hydrocarbon group {The C 1 -C 10 chain hydrocarbon group may have one or more substituents selected from Group E} , C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group {The C3-C6 cycloalkyl group and the C3-C6 cycloalkenyl group may have one or more substituents selected from group F} A compound that is
[Aspect 13] In aspect 1, R 2 is a C1-C10 chain hydrocarbon group {wherein the C1-C10 chain hydrocarbon group is at least one selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted}, a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
[Aspect 14] In aspect 2, R 2 is a C1-C10 chain hydrocarbon group {wherein the C1-C10 chain hydrocarbon group is at least one selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted}, a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
[Mode 15] In mode 3, R 2 is a C1-C10 chain hydrocarbon group {wherein the C1-C10 chain hydrocarbon group is at least one selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted}, a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
[Aspect 16] In Aspect 4, R 2 is a C1-C10 chain hydrocarbon group {wherein the C1-C10 chain hydrocarbon group is at least one selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted}, a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
[Aspect 17] In Aspect 5, R 2 is a C1-C10 chain hydrocarbon group {wherein the C1-C10 chain hydrocarbon group is at least one member selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted}, a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
[Aspect 18] In aspect 6, R 2 is a C1-C10 chain hydrocarbon group {wherein the C1-C10 chain hydrocarbon group is at least one selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted}, a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
[Aspect 19] In the compound of the present invention, R 2 is a C1-C10 chain hydrocarbon group {wherein the C1-C10 chain hydrocarbon group is at least one selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom Of the following: a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group,
R 3 is a benzyl group, C (O) CH 3 , C (O) OCH 3 , C (O) OCH 2 CH = CH 2 or a hydrogen atom,
R 4 and R 5 are methyl groups,
L 1 is a single bond,
Compounds wherein L 2 is —CH 2 —O— *, —CH 2 —O—N = C (CH 3 )-*, or —CH = N—O— *.
[Aspect 20] In the compound of the present invention, R 2 is a C1-C10 chain hydrocarbon group {wherein the C1-C10 chain hydrocarbon group is at least one selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom Of the following: a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group,
R 3 is a benzyl group, C (O) CH 3 , C (O) OCH 3 , C (O) OCH 2 CH = CH 2 or a hydrogen atom,
R 4 and R 5 are methyl groups,
The compound whose L 1 and L 2 are single bonds.
[Aspect 21] In the compound of the present invention, R 1 is a C1-C15 chain hydrocarbon group {the C1-C15 chain hydrocarbon group may have one or more substituents selected from group E }, C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group {The C3-C6 cycloalkyl group and the C3-C6 cycloalkenyl group may have one or more substituents selected from group F The compound which is}.
[Aspect 22] The compound of the present invention, wherein R 1 is a C1-C15 chain hydrocarbon group optionally having one or more substituents selected from group E.
Embodiment 23: A compound of the present invention wherein R 1 is a C1-C15 alkyl group or a C2-C15 alkenyl group.
[Aspect 24] In any of Aspects 1 to 20, R 1 is a C1-C15 chain hydrocarbon group {wherein the C1-C15 chain hydrocarbon group has one or more substituents selected from Group E. C3 to C6 cycloalkyl group or C3 to C6 cycloalkenyl group {wherein the C3 to C6 cycloalkyl group and the C3 to C6 cycloalkenyl group have one or more substituents selected from Group F Compounds which may be
Embodiment 25 The compound according to any of Embodiments 1 to 20, wherein R 1 is a C1-C15 chain hydrocarbon group optionally having one or more substituents selected from Group E.
Embodiment 26 A compound according to any of embodiments 1 to 20, wherein R 1 is a C1-C15 alkyl group or a C2-C15 alkenyl group.
　本発明化合物Ｘの態様としては、以下の化合物が挙げられる。 The following compounds may be mentioned as embodiments of the compound X of the present invention.
〔態様２７〕本発明化合物Ｘにおいて、Ｌ1が、単結合、－Ｌ1A－Ｏ－＃、－Ｌ1A－Ｏ－Ｎ＝ＣＲ7－＃、又は－Ｌ1B－ＣＲ7＝Ｎ－Ｏ－＃であり、
　Ｌ2が、単結合、－Ｌ2A－Ｏ－＊、－Ｌ2A－Ｏ－Ｎ＝ＣＲ9－＊、又は－Ｌ2B－ＣＲ9＝Ｎ－Ｏ－＊であり、
　Ｒ3が、群Ｂより選ばれる１以上の置換基を有していてもよいベンジル基、Ｃ（Ｏ）Ｒ10、Ｃ（Ｏ）ＯＲ10又は水素原子である化合物。
〔態様２８〕態様２７において、Ｒ3が、ベンジル基、Ｃ（Ｏ）Ｒ10、Ｃ（Ｏ）ＯＲ10又は水素原子である化合物。
〔態様２９〕態様２７において、Ｒ3が、ベンジル基、Ｃ（Ｏ）ＣＨ3、Ｃ（Ｏ）ＯＣＨ3、Ｃ（Ｏ）ＯＣＨ2ＣＨ＝ＣＨ2又は水素原子である化合物。
〔態様３０〕本発明化合物Ｘにおいて、Ｌ1が、単結合、－ＣＨ2－Ｏ－＃、－ＣＨ2－Ｏ－Ｎ＝ＣＲ7－＃、又は－ＣＲ7＝Ｎ－Ｏ－＃であり、
　Ｌ2が、単結合、－ＣＨ2－Ｏ－＊、－ＣＨ2－Ｏ－Ｎ＝Ｃ（ＣＨ3）－＊、又は－ＣＨ＝Ｎ－Ｏ－＊であり、
　Ｒ3が、ベンジル基、Ｃ（Ｏ）ＣＨ3、Ｃ（Ｏ）ＯＣＨ3、Ｃ（Ｏ）ＯＣＨ2ＣＨ＝ＣＨ2又は水素原子である化合物。
〔態様３１〕態様３０において、Ｒ4及びＲ5が同一又は相異なり、１以上のハロゲン原子を有していてもよいＣ１－Ｃ２アルキル基である化合物。
〔態様３２〕態様３０において、Ｒ4及びＲ5がメチル基である化合物。
〔態様３３〕態様２７において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、群Ｅより選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基｛該Ｃ３－Ｃ６シクロアルキル基及び該Ｃ３－Ｃ６シクロアルケニル基は、群Ｆより選ばれる１以上の置換基を有していてもよい｝である化合物。
　群Ｅ：Ｃ３－Ｃ６シクロアルキル基｛該Ｃ３－Ｃ６シクロアルキル基は、群Ｆより選ばれる１以上の置換基を有していてもよい｝及びハロゲン原子からなる群。
　群Ｆ：１以上のハロゲン原子を有していてもよいＣ１－Ｃ４アルキル基及びハロゲン原子からなる群。
〔態様３４〕態様２８において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、群Ｅより選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基｛該Ｃ３－Ｃ６シクロアルキル基及び該Ｃ３－Ｃ６シクロアルケニル基は、群Ｆより選ばれる１以上の置換基を有していてもよい｝である化合物。
〔態様３５〕態様２９において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、群Ｅより選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基｛該Ｃ３－Ｃ６シクロアルキル基及び該Ｃ３－Ｃ６シクロアルケニル基は、群Ｆより選ばれる１以上の置換基を有していてもよい｝である化合物。
〔態様３６〕態様３０において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、群Ｅより選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基｛該Ｃ３－Ｃ６シクロアルキル基及び該Ｃ３－Ｃ６シクロアルケニル基は、群Ｆより選ばれる１以上の置換基を有していてもよい｝である化合物。
〔態様３７〕態様３１において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、群Ｅより選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基｛該Ｃ３－Ｃ６シクロアルキル基及び該Ｃ３－Ｃ６シクロアルケニル基は、群Ｆより選ばれる１以上の置換基を有していてもよい｝である化合物。
〔態様３８〕態様３２において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、群Ｅより選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基｛該Ｃ３－Ｃ６シクロアルキル基及び該Ｃ３－Ｃ６シクロアルケニル基は、群Ｆより選ばれる１以上の置換基を有していてもよい｝である化合物。
〔態様３９〕態様２７において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、Ｃ３－Ｃ６シクロアルキル基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基である化合物。
〔態様４０〕態様２８において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、Ｃ３－Ｃ６シクロアルキル基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基である化合物。
〔態様４１〕態様２９において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、Ｃ３－Ｃ６シクロアルキル基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基である化合物。
〔態様４２〕態様３０において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、Ｃ３－Ｃ６シクロアルキル基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基である化合物。
〔態様４３〕態様３１において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、Ｃ３－Ｃ６シクロアルキル基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基である化合物。
〔態様４４〕態様３２において、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、Ｃ３－Ｃ６シクロアルキル基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基である化合物。
〔態様４５〕本発明化合物Ｘにおいて、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、Ｃ３－Ｃ６シクロアルキル基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基であり、
　Ｒ3が、ベンジル基、Ｃ（Ｏ）ＣＨ3、Ｃ（Ｏ）ＯＣＨ3、Ｃ（Ｏ）ＯＣＨ2ＣＨ＝ＣＨ2又は水素原子であり、
　Ｒ4及びＲ5がメチル基であり、
　Ｌ1が単結合であり、
　Ｌ2が－ＣＨ2－Ｏ－＊、－ＣＨ2－Ｏ－Ｎ＝Ｃ（ＣＨ3）－＊、又は－ＣＨ＝Ｎ－Ｏ－＊である化合物。
〔態様４６〕本発明化合物Ｘにおいて、Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、Ｃ３－Ｃ６シクロアルキル基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基であり、
　Ｒ3が、ベンジル基、Ｃ（Ｏ）ＣＨ3、Ｃ（Ｏ）ＯＣＨ3、Ｃ（Ｏ）ＯＣＨ2ＣＨ＝ＣＨ2又は水素原子であり、
　Ｒ4及びＲ5がメチル基であり、
　Ｌ1及びＬ2が単結合である化合物。
〔態様４７〕本発明化合物Ｘにおいて、Ｒ1が、Ｃ１－Ｃ１５鎖式炭化水素基｛該Ｃ１－Ｃ１５鎖式炭化水素基は、群Ｅより選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基｛該Ｃ３－Ｃ６シクロアルキル基及び該Ｃ３－Ｃ６シクロアルケニル基は、群Ｆより選ばれる１以上の置換基を有していてもよい｝である化合物。
〔態様４８〕本発明化合物Ｘにおいて、Ｒ1が、群Ｅより選ばれる１以上の置換基を有していてもよいＣ１－Ｃ１５鎖式炭化水素基である化合物。
〔態様４９〕本発明化合物Ｘにおいて、Ｒ1が、Ｃ１－Ｃ１５アルキル基又はＣ２－Ｃ１５アルケニル基である化合物。
〔態様５０〕態様２７～態様４６のいずれかにおいて、Ｒ1が、Ｃ１－Ｃ１５鎖式炭化水素基｛該Ｃ１－Ｃ１５鎖式炭化水素基は、群Ｅより選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基｛該Ｃ３－Ｃ６シクロアルキル基及び該Ｃ３－Ｃ６シクロアルケニル基は、群Ｆより選ばれる１以上の置換基を有していてもよい｝である化合物。
〔態様５１〕態様２７～態様４６のいずれかにおいて、Ｒ1が、群Ｅより選ばれる１以上の置換基を有していてもよいＣ１－Ｃ１５鎖式炭化水素基である化合物。
〔態様５２〕態様２７～態様４６のいずれかにおいて、Ｒ1が、Ｃ１－Ｃ１５アルキル基又はＣ２－Ｃ１５アルケニル基である化合物。 In [Mode 27] In the present invention compounds X, L 1 is a single bond, -L 1A -O - #, - L 1A -O-N = CR 7 - #, or -L 1B -CR 7 = N-O- # And
L 2 is a single bond, -L 2A -O - *, - L 2A -O-N = CR 9 - *, or -L 2B -CR 9 = N-O- * a and,
Compounds wherein R 3 is a benzyl group optionally having one or more substituents selected from group B, C (O) R 10 , C (O) OR 10 or a hydrogen atom.
Embodiment 28. A compound according to Embodiment 27, wherein R 3 is a benzyl group, C (O) R 10 , C (O) OR 10 or a hydrogen atom.
Embodiment 29: A compound according to Embodiment 27, wherein R 3 is a benzyl group, C (O) CH 3 , C (O) OCH 3 , C (O) OCH 2 CH = CH 2 or a hydrogen atom.
[Aspect 30] In the compound X of the present invention, L 1 is a single bond, —CH 2 —O— #, —CH 2 —O—N = CR 7 — #, or —CR 7 = N—O— #. ,
L 2 is a single bond, -CH 2 -O- *, -CH 2 -O-N = C (CH 3 )-*, or -CH = N-O- *,
Compounds wherein R 3 is benzyl group, C (O) CH 3 , C (O) OCH 3 , C (O) OCH 2 CH = CH 2 or a hydrogen atom.
Embodiment 31: A compound according to Embodiment 30, wherein R 4 and R 5 are the same or different and are a C1-C2 alkyl group optionally having one or more halogen atoms.
Aspect 32. A compound according to aspect 30, wherein R 4 and R 5 are methyl groups.
[Aspect 33] In Aspect 27, R 2 is a C1-C10 chain hydrocarbon group {The C1-C10 chain hydrocarbon group may have one or more substituents selected from Group E} , C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group {The C3-C6 cycloalkyl group and the C3-C6 cycloalkenyl group may have one or more substituents selected from group F} A compound that is
Group E: a group comprising a C3-C6 cycloalkyl group (wherein the C3-C6 cycloalkyl group may have one or more substituents selected from group F) and a halogen atom.
Group F: a group consisting of a C1-C4 alkyl group optionally having one or more halogen atoms and a halogen atom.
[Aspect 34] In Aspect 28, R 2 is a C1-C10 chain hydrocarbon group {the C1-C10 chain hydrocarbon group may have one or more substituents selected from Group E} , C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group {The C3-C6 cycloalkyl group and the C3-C6 cycloalkenyl group may have one or more substituents selected from group F} A compound that is
[Mode 35] In mode 29, R 2 is a C1-C10 chain hydrocarbon group {The C1-C10 chain hydrocarbon group may have one or more substituents selected from group E} , C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group {The C3-C6 cycloalkyl group and the C3-C6 cycloalkenyl group may have one or more substituents selected from group F} A compound that is
[Aspect 36] In Aspect 30, R 2 is a C1-C10 chain hydrocarbon group {The C1-C10 chain hydrocarbon group may have one or more substituents selected from Group E} , C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group {The C3-C6 cycloalkyl group and the C3-C6 cycloalkenyl group may have one or more substituents selected from group F} A compound that is
[Aspect 37] In Aspect 31, R 2 is a C1-C10 chain hydrocarbon group {The C1-C10 chain hydrocarbon group may have one or more substituents selected from Group E} , C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group {The C3-C6 cycloalkyl group and the C3-C6 cycloalkenyl group may have one or more substituents selected from group F} A compound that is
[Aspect 38] In Aspect 32, R 2 is a C1-C10 chain hydrocarbon group {The C1-C10 chain hydrocarbon group may have one or more substituents selected from Group E} , C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group {The C3-C6 cycloalkyl group and the C3-C6 cycloalkenyl group may have one or more substituents selected from group F} A compound that is
Embodiment 39 In Embodiment 27, R 2 is a C1-C10 chain hydrocarbon group {wherein the C1-C10 chain hydrocarbon group is at least one selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted}, a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
[Mode 40] In mode 28, R 2 is a C1-C10 chain hydrocarbon group {wherein the C1-C10 chain hydrocarbon group is at least one selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted}, a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
Embodiment 41: In Embodiment 29, R 2 is a C1-C10 chain hydrocarbon group {wherein the C1-C10 chain hydrocarbon group is at least one selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted}, a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
[Mode 42] In mode 30, R 2 is a C1-C10 chain hydrocarbon group {wherein the C1-C10 chain hydrocarbon group is one or more selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted}, a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
[Mode 43] In mode 31, R 2 is a C1-C10 chain hydrocarbon group {wherein the C1-C10 chain hydrocarbon group is at least one selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted}, a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
[Aspect 44] In Aspect 32, R 2 is a C1-C10 chain hydrocarbon group {wherein the C1-C10 chain hydrocarbon group is at least one selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound which is optionally substituted}, a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
[Aspect 45] In the compound X of the present invention, R 2 is a C1-C10 chain hydrocarbon group {the C1-C10 chain hydrocarbon group is selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom 1 And C 3 -C 6 cycloalkyl group or C 3 -C 6 cycloalkenyl group, which may have the above substituents},
R 3 is a benzyl group, C (O) CH 3 , C (O) OCH 3 , C (O) OCH 2 CH = CH 2 or a hydrogen atom,
R 4 and R 5 are methyl groups,
L 1 is a single bond,
Compounds wherein L 2 is —CH 2 —O— *, —CH 2 —O—N = C (CH 3 )-*, or —CH = N—O— *.
[Aspect 46] In the compound X of the present invention, R 2 is a C 1 -C 10 chain hydrocarbon group {the C 1 -C 10 chain hydrocarbon group is selected from the group consisting of a C 3 -C 6 cycloalkyl group and a halogen atom 1 And C 3 -C 6 cycloalkyl group or C 3 -C 6 cycloalkenyl group, which may have the above substituents},
R 3 is a benzyl group, C (O) CH 3 , C (O) OCH 3 , C (O) OCH 2 CH = CH 2 or a hydrogen atom,
R 4 and R 5 are methyl groups,
The compound whose L 1 and L 2 are single bonds.
[Aspect 47] In the compound X of the present invention, R 1 is a C 1 -C 15 chain hydrocarbon group {even if the C 1 -C 15 chain hydrocarbon group has one or more substituents selected from group E }, C3-C6 cycloalkyl group or C3-C6 cycloalkenyl group {wherein the C3-C6 cycloalkyl group and the C3-C6 cycloalkenyl group have one or more substituents selected from group F Compound that is good.
[Aspect 48] The compound of the present invention X, wherein R 1 is a C1-C15 chain hydrocarbon group optionally having one or more substituents selected from group E.
Embodiment 49 A compound of the present invention X, wherein R 1 is a C1-C15 alkyl group or a C2-C15 alkenyl group.
[Aspect 50] In any one of Aspects 27 to 46, R 1 is a C1-C15 chain hydrocarbon group {wherein the C1-C15 chain hydrocarbon group has one or more substituents selected from Group E. C3 to C6 cycloalkyl group or C3 to C6 cycloalkenyl group {wherein the C3 to C6 cycloalkyl group and the C3 to C6 cycloalkenyl group have one or more substituents selected from Group F Compounds which may be
Embodiment 51 A compound according to any of embodiments 27 to 46, wherein R 1 is a C1-C15 chain hydrocarbon group optionally having one or more substituents selected from group E.
Aspect 52. A compound according to any of aspects 27 to 46, wherein R 1 is a C1-C15 alkyl group or a C2-C15 alkenyl group.
　次に、本発明化合物Ｘの製造法について説明する。 Next, the process for producing the compound X of the present invention is described.
製造法１
　式（Ｉｂ）で示される化合物（以下、化合物（Ｉｂ）と記す）は、式（Ｉａ）で示される化合物（以下、化合物（Ｉａ）と記す）と式（Ｒ－１）で示される化合物（以下、化合物（Ｒ－１）と記す）とを塩基の存在下で反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000003
 ［式中、Ｒ3aは（Ｃ１－Ｃ３アルコキシ）Ｃ１－Ｃ３アルキル基、又は群Ｂより選ばれる１以上の置換基を有していてもよいベンジル基を表し、Ｘ1は塩素原子、臭素原子、ヨウ素原子、Ｃ１－Ｃ１０ペルフルオロアルカンスルホニルオキシ基又はトシルオキシ基を表し、その他の記号は前記と同じ意味を表す。］
　反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えば、ヘキサン、トルエン、キシレン等の炭化水素（以下、炭化水素類と記す）；ジエチルエーテル、エチレングリコールジメチルエーテル、メチルｔｅｒｔ－ブチルエーテル（以下、ＭＴＢＥと記す）、テトラヒドロフラン（以下、ＴＨＦと記す）等のエーテル（以下、エーテル類と記す）；クロロホルム、クロロベンゼン等のハロゲン化炭化水素（以下、ハロゲン化炭化水素類と記す）；ジメチルホルムアミド（以下、ＤＭＦと記す）、Ｎ－メチルピロリドン、ジメチルスルホキシド（以下、ＤＭＳＯと記す）等の非プロトン性極性溶媒（以下、非プロトン性極性溶媒と記す）；酢酸エチル等のエステル（以下、エステル類と記す）及びこれらの混合物が挙げられる。
　反応に用いられる塩基としては、例えば炭酸ナトリウム、炭酸カリウム等のアルカリ金属炭酸塩（以下、アルカリ金属炭酸塩類と記す）；トリエチルアミン、ピリジン等の有機塩基（以下、有機塩基類と記す）が挙げられる。
　反応には、化合物（Ｉａ）１モルに対して、化合物（Ｒ－１）が通常１モル～１０モルの割合、塩基が通常１モル～１０モルの割合で用いられる。
　反応時間は、通常５分間～７２時間の範囲である。反応温度は、通常－２０℃～１００℃の範囲である。
　反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより化合物（Ｉｂ）を単離することができる。
　化合物（Ｒ－１）は、市販の化合物であるか、公知の方法に準じて製造することができる。 Manufacturing method 1
The compound represented by the formula (Ib) (hereinafter referred to as compound (Ib)) is a compound represented by the formula (Ia) (hereinafter referred to as compound (Ia)) and the compound represented by the formula (R-1) Hereinafter, the compound (R-1) can be produced by reacting in the presence of a base.
Figure JPOXMLDOC01-appb-C000003
 [Wherein, R 3a represents a (C 1 -C 3 alkoxy) C 1 -C 3 alkyl group, or a benzyl group which may have one or more substituents selected from group B, and X 1 represents a chlorine atom or a bromine atom , Iodine atom, C 1 -C 10 perfluoroalkanesulfonyloxy group or tosyloxy group, and the other symbols have the same meanings as described above. ]
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include hydrocarbons such as hexane, toluene and xylene (hereinafter referred to as hydrocarbons); diethyl ether, ethylene glycol dimethyl ether, methyl tert-butyl ether (hereinafter referred to as MTBE), and tetrahydrofuran Hereinafter, ethers such as THF) (hereinafter referred to as ethers); halogenated hydrocarbons such as chloroform and chlorobenzene (hereinafter referred to as halogenated hydrocarbons); dimethylformamide (hereinafter referred to as DMF), N -Aprotic polar solvents such as methyl pyrrolidone and dimethyl sulfoxide (hereinafter referred to as DMSO) (hereinafter referred to as aprotic polar solvents); esters such as ethyl acetate (hereinafter referred to as esters) and mixtures thereof It can be mentioned.
Examples of the base used for the reaction include alkali metal carbonates such as sodium carbonate and potassium carbonate (hereinafter referred to as alkali metal carbonates); organic bases such as triethylamine and pyridine (hereinafter referred to as organic bases) .
In the reaction, the compound (R-1) is used in a proportion of usually 1 mol to 10 mol and the base is usually used in a proportion of 1 mol to 10 mol based on 1 mol of the compound (Ia).
The reaction time is usually in the range of 5 minutes to 72 hours. The reaction temperature is usually in the range of −20 ° C. to 100 ° C.
After completion of the reaction, compound (Ib) can be isolated by post-treatment operations such as adding water to the reaction mixture, extracting with an organic solvent, and drying and concentrating the organic layer.
The compound (R-1) is a commercially available compound or can be produced according to a known method.
製造法２
　式（Ｉｃ）で示される化合物（以下、化合物（Ｉｃ）と記す）は、化合物（Ｉａ）と式（Ｒ－２）で示される化合物（以下、化合物（Ｒ－２）と記す）とを塩基の存在下で反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000004
 ［式中、Ｒ3bはＣ（Ｏ）Ｒ10又はＣ（Ｏ）ＯＲ10を表し、その他の記号は前記と同じ意味を表す。］
　反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えば炭化水素類、エーテル類、ハロゲン化炭化水素類、非プロトン性極性溶媒、エステル類及びこれらの混合物が挙げられる。
　反応に用いられる塩基としては、例えばアルカリ金属炭酸塩類及び有機塩基類が挙げられる。
　反応には、化合物（Ｉａ）１モルに対して、化合物（Ｒ－２）が通常１モル～１０モルの割合で、塩基が通常１モル～１０モルの割合で用いられる。
　反応時間は、通常５分間～２４時間の範囲である。反応温度は、通常－２０℃～１００℃の範囲である。
　反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより化合物（Ｉｃ）を単離することができる。
　化合物（Ｒ－２）は市販の化合物であるか、公知の方法に準じて製造することができる。 Manufacturing method 2
The compound represented by the formula (Ic) (hereinafter referred to as the compound (Ic)) is a compound of the compound (Ia) and the compound represented by the formula (R-2) (hereinafter referred to as the compound (R-2)) It can be produced by reacting in the presence of
Figure JPOXMLDOC01-appb-C000004
 [Wherein, R 3b represents C (O) R 10 or C (O) OR 10 , and the other symbols have the same meanings as described above. ]
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include hydrocarbons, ethers, halogenated hydrocarbons, aprotic polar solvents, esters and mixtures thereof.
As a base used for reaction, an alkali metal carbonate and organic bases are mentioned, for example.
In the reaction, the compound (R-2) is usually used in a proportion of 1 mol to 10 mol and the base is usually used in a proportion of 1 mol to 10 mol with respect to 1 mol of the compound (Ia).
The reaction time is usually in the range of 5 minutes to 24 hours. The reaction temperature is usually in the range of −20 ° C. to 100 ° C.
After completion of the reaction, compound (Ic) can be isolated by performing post-treatment operations such as adding water to the reaction mixture, extracting with an organic solvent, and drying and concentrating the organic layer.
The compound (R-2) is a commercially available compound or can be produced according to a known method.
製造法３
　式（Ｉｄ）で示される化合物（以下、化合物（Ｉｄ）と記す）は、化合物（Ｉａ）と式（Ｒ－３）で示される化合物（以下、化合物（Ｒ－３）と記す）とを反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000005
 ［式中、記号は前記と同じ意味を表す。］
　反応は、無溶媒又は溶媒中で行われる。反応に用いられる溶媒としては、例えば炭化水素類、エーテル類、ハロゲン化炭化水素類、非プロトン性極性溶媒、エステル類及びこれらの混合物が挙げられる。
　反応には必要に応じて塩基を用いてもよい。反応に用いられる塩基としては、例えば有機塩基類が挙げられる。
　反応には、化合物（Ｉａ）１モルに対して、化合物（Ｒ－３）が通常１モル～１００モルの割合で用いられる。
　塩基が用いられる場合、化合物（Ｉａ）１モルに対して、塩基が通常１モル～１０モルの割合で用いられる。
　反応時間は、通常５分間～７２時間の範囲である。反応温度は、通常－２０℃～１８０℃の範囲である。
　反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより化合物（Ｉｄ）を単離することができる。
　化合物（Ｒ－３）は市販の化合物であるか、公知の方法に準じて製造することができる。 Manufacturing method 3
The compound represented by the formula (Id) (hereinafter referred to as a compound (Id)) is a compound of the compound (Ia) and the compound represented by the formula (R-3) (hereinafter referred to as a compound (R-3)) It can be manufactured by
Figure JPOXMLDOC01-appb-C000005
 [Wherein, the symbols have the same meanings as described above. ]
The reaction is carried out without solvent or in a solvent. Examples of the solvent used for the reaction include hydrocarbons, ethers, halogenated hydrocarbons, aprotic polar solvents, esters and mixtures thereof.
You may use a base for reaction as needed. As a base used for reaction, organic bases are mentioned, for example.
In the reaction, the compound (R-3) is usually used in a proportion of 1 mol to 100 mol, relative to 1 mol of the compound (Ia).
When a base is used, the base is usually used in a proportion of 1 mole to 10 moles relative to 1 mole of the compound (Ia).
The reaction time is usually in the range of 5 minutes to 72 hours. The reaction temperature is usually in the range of −20 ° C. to 180 ° C.
After completion of the reaction, water is added to the reaction mixture, extraction is performed with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to isolate the compound (Id).
The compound (R-3) is a commercially available compound or can be produced according to a known method.
製造法４
　式（Ｉｅ）で示される化合物（以下、化合物（Ｉｅ）と記す）は、化合物（Ｉａ）と式（Ｒ－４）で示される化合物（以下、化合物（Ｒ－４）と記す）とを反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000006
 ［式中、記号は前記と同じ意味を表す。］
　反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えば炭化水素類、エーテル類、ハロゲン化炭化水素類、非プロトン性極性溶媒、エステル類及びこれらの混合物が挙げられる。
　反応には必要に応じて塩基を用いてもよい。反応に用いられる塩基としては、例えば炭酸水素ナトリウム、炭酸水素カリウム等のアルカリ金属炭酸水素塩（以下、アルカリ金属炭酸水素塩類と記す）；及び有機塩基類が挙げられる。
　反応には、化合物（Ｉａ）１モルに対して、化合物（Ｒ－４）が通常１モル～１０モルの割合で用いられる。
　塩基が用いられる場合、化合物（Ｉａ）１モルに対して、塩基が通常１モル～１０モルの割合で用いられる。
　反応時間は、通常５分間～７２時間の範囲である。反応温度は、通常－２０℃～８０℃の範囲である。
　反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより化合物（Ｉｅ）を単離することができる。
　化合物（Ｒ－４）は市販の化合物である。 Manufacturing method 4
The compound represented by the formula (Ie) (hereinafter referred to as compound (Ie)) is a compound of the compound (Ia) and the compound represented by the formula (R-4) (hereinafter referred to as compound (R-4)) It can be manufactured by
Figure JPOXMLDOC01-appb-C000006
 [Wherein, the symbols have the same meanings as described above. ]
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include hydrocarbons, ethers, halogenated hydrocarbons, aprotic polar solvents, esters and mixtures thereof.
You may use a base for reaction as needed. Examples of the base used in the reaction include alkali metal hydrogen carbonates such as sodium hydrogen carbonate and potassium hydrogen carbonate (hereinafter referred to as alkali metal hydrogen carbonates); and organic bases.
In the reaction, the compound (R-4) is usually used in a proportion of 1 mole to 10 moles relative to 1 mole of the compound (Ia).
When a base is used, the base is usually used in a proportion of 1 mole to 10 moles relative to 1 mole of the compound (Ia).
The reaction time is usually in the range of 5 minutes to 72 hours. The reaction temperature is usually in the range of −20 ° C. to 80 ° C.
After completion of the reaction, compound (Ie) can be isolated by post-treatment operations such as adding water to the reaction mixture, extracting with an organic solvent, and drying and concentrating the organic layer.
The compound (R-4) is a commercially available compound.
製造法５
　式（Ｉｇ）で示される化合物（以下、化合物（Ｉｇ）と記す）は、式（Ｉｆ）で示される化合物（以下、化合物（Ｉｆ）と記す）と酸化剤とを反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000007
 ［式中、記号は前記と同じ意味を表す。］
　反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えばハロゲン化炭化水素類；アセトニトリル等のニトリル（以下、ニトリル類と記す）；エステル類；メタノール、エタノール等のアルコール（以下、アルコール類と記す）；酢酸；水及びこれらの混合物が挙げられる。
　反応に用いられる酸化剤としては、例えば過ヨウ素酸ナトリウム、ｍ－クロロ過安息香酸（以下、ｍＣＰＢＡと記す）及び過酸化水素が挙げられる。
　酸化剤として過酸化水素を用いる場合は、必要に応じて炭酸ナトリウム又は触媒を用いてもよい。
　反応に用いられる触媒としては、例えばタングステン酸及びタングステン酸ナトリウムが挙げられる。
　反応には、化合物（Ｉｆ）１モルに対して、酸化剤が通常１モル～１０モルの割合で用いられる。
　炭酸ナトリウムが用いられる場合、化合物（Ｉｆ）１モルに対して、炭酸ナトリウムが通常０．０１モル～１モルの割合で用いられる。触媒が用いられる場合、化合物（Ｉｆ）１モルに対して、触媒が通常０．０１～０．５モルの割合で用いられる。
　反応時間は、通常５分間～２４時間の範囲である。反応温度は、通常－２０℃～８０℃の範囲である。
　反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を必要に応じて還元剤（例えば亜硫酸ナトリウム、チオ硫酸ナトリウム）の水溶液、及び塩基（例えば炭酸水素ナトリウム）の水溶液で洗浄し、得られた有機層を乾燥、濃縮することにより、化合物（Ｉｇ）を単離することができる。 Manufacturing method 5
A compound represented by the formula (Ig) (hereinafter referred to as a compound (Ig)) is produced by reacting a compound represented by the formula (If) (hereinafter referred to as a compound (If)) with an oxidizing agent. Can.
Figure JPOXMLDOC01-appb-C000007
 [Wherein, the symbols have the same meanings as described above. ]
The reaction is usually carried out in a solvent. Examples of solvents used for the reaction include halogenated hydrocarbons; nitriles such as acetonitrile (hereinafter referred to as nitriles); esters; alcohols such as methanol and ethanol (hereinafter referred to as alcohols); acetic acid; These mixtures are mentioned.
Examples of the oxidizing agent used for the reaction include sodium periodate, m-chloroperbenzoic acid (hereinafter referred to as mCPBA) and hydrogen peroxide.
When hydrogen peroxide is used as the oxidizing agent, sodium carbonate or a catalyst may be used as needed.
As a catalyst used for reaction, tungstic acid and sodium tungstate are mentioned, for example.
In the reaction, the oxidizing agent is usually used in a proportion of 1 mole to 10 moles relative to 1 mole of the compound (If).
When sodium carbonate is used, sodium carbonate is usually used in a ratio of 0.01 mol to 1 mol with respect to 1 mol of compound (If). When a catalyst is used, the catalyst is usually used in a proportion of 0.01 to 0.5 mol per 1 mol of compound (If).
The reaction time is usually in the range of 5 minutes to 24 hours. The reaction temperature is usually in the range of −20 ° C. to 80 ° C.
After completion of the reaction, water is added to the reaction mixture, extraction is carried out with an organic solvent, and the organic layer is optionally treated with an aqueous solution of a reducing agent (eg sodium sulfite, sodium thiosulfate) and an aqueous solution of a base (eg sodium hydrogencarbonate) The compound (Ig) can be isolated by washing and drying and concentration of the obtained organic layer.
製造法６
　化合物（Ｉａ）は、式（Ｍ－１）で示される化合物（以下、化合物（Ｍ－１）と記す）、パラジウム触媒及び塩基を反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000008
 ［式中、Ｒ30は２－プロペニル基又は２－ブテニル基を表し、その他の記号は前記と同じ意味を表す。］
　反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えば、ハロゲン化炭化水素類、アルコール類、非プロトン性極性溶媒、エステル類、エーテル類、水及びこれらの混合物が挙げられる。
　反応に用いられる塩基としては、例えばアルカリ金属炭酸塩類及び有機塩基類が挙げられる。
　反応に用いられるパラジウム触媒としては、例えばテトラキストリフェニルホスフィンパラジウム（０）及びジベンジリデンアセトンパラジウム（０）が挙げられる。
　反応には、化合物（Ｍ－１）１モルに対して、パラジウム触媒が通常０．０１～０．５モルの割合、塩基が通常１モル～１０モルの割合で用いられる。
　反応時間は、通常５分間～２４時間の範囲である。反応温度は、通常－２０℃～８０℃の範囲である。
　反応終了後は、反応混合物に水を加え、化合物（Ｉａ）が析出する場合には固体をろ取する；有機溶媒で抽出する等の後処理操作を行うことにより、化合物（Ｉａ）を単離することができる。 Manufacturing method 6
The compound (Ia) can be produced by reacting a compound represented by the formula (M-1) (hereinafter referred to as compound (M-1)), a palladium catalyst and a base.
Figure JPOXMLDOC01-appb-C000008
 [Wherein, R 30 represents a 2-propenyl group or 2-butenyl group, and the other symbols have the same meanings as described above. ]
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include halogenated hydrocarbons, alcohols, aprotic polar solvents, esters, ethers, water and mixtures thereof.
As a base used for reaction, an alkali metal carbonate and organic bases are mentioned, for example.
As a palladium catalyst used for reaction, tetrakis triphenyl phosphine palladium (0) and dibenzylidene acetone palladium (0) are mentioned, for example.
In the reaction, the palladium catalyst is usually used in a proportion of 0.01 to 0.5 mol, and the base is usually used in a proportion of 1 mol to 10 mol, relative to 1 mol of the compound (M-1).
The reaction time is usually in the range of 5 minutes to 24 hours. The reaction temperature is usually in the range of −20 ° C. to 80 ° C.
After completion of the reaction, water is added to the reaction mixture, and when compound (Ia) precipitates, the solid is filtered off; compound (Ia) is isolated by post-treatment operation such as extraction with an organic solvent can do.
参考製造法１
　式（Ｍ－３）で示される化合物（以下、化合物（Ｍ－３）と記す）は、式（Ｍ－２）で示される化合物（以下、化合物（Ｍ－２）と記す）と式（Ｒ－５）で示される化合物（以下、化合物（Ｒ－５）と記す）とを反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000009
 ［式中、Ｒ31はＣ１－Ｃ１３鎖式炭化水素基｛該Ｃ１－Ｃ１３鎖式炭化水素基は、群Ａより選ばれる１以上の置換基を有していてもよい｝、Ｃ１－Ｃ６アルコキシ基、Ｃ２－Ｃ６アルキルカルボニル基、Ｃ２－Ｃ６アルキルカルボニルオキシ基｛該Ｃ１－Ｃ６アルコキシ基、該Ｃ２－Ｃ６アルキルカルボニル基及び該Ｃ２－Ｃ６アルキルカルボニルオキシ基は、１以上のハロゲン原子を有していてもよい｝、Ｃ３－Ｃ８シクロアルキル基、又はＣ３－Ｃ８シクロアルケニル基｛該Ｃ３－Ｃ８シクロアルキル基及び該Ｃ３－Ｃ８シクロアルケニル基は、群Ｂより選ばれる１以上の置換基を有していてもよい｝を表し、その他の記号は前記と同じ意味を表す。］
　反応は通常溶媒中で行われる。反応に用いられる溶媒としては、例えばエーテル類、炭化水素類、ハロゲン化炭化水素類及びこれらの混合物が挙げられる。
　反応には、化合物（Ｍ－２）１モルに対して、化合物（Ｒ－５）が通常１モル～１０モルの割合で用いられる。
　反応時間は、通常５分間～２４時間の範囲である。反応温度は、通常－２０℃～８０℃の範囲である。
　反応終了後は、反応混合物に水を加えて析出する固体をろ過、乾燥する等の後処理操作を行うことにより、化合物（Ｍ－３）を単離することができる。
　化合物（Ｒ－５）は、市販の化合物であるか、例えばOrganic Letters, 2014, 16, 6424-6427に記載の方法に準じて製造することができる。 Reference manufacturing method 1
The compound represented by the formula (M-3) (hereinafter referred to as the compound (M-3)) is a compound represented by the formula (M-2) (hereinafter referred to as the compound (M-2)) and the compound represented by the formula (R) It can be produced by reacting a compound represented by -5) (hereinafter referred to as compound (R-5)).
Figure JPOXMLDOC01-appb-C000009
 [Wherein, R 31 is a C1-C13 chain hydrocarbon group {the C1-C13 chain hydrocarbon group may have one or more substituents selected from Group A}, C 1 -C 6 alkoxy] Group, C2-C6 alkylcarbonyl group, C2-C6 alkylcarbonyloxy group {wherein the C1-C6 alkoxy group, the C2-C6 alkylcarbonyl group and the C2-C6 alkylcarbonyloxy group have one or more halogen atoms Optionally, C3-C8 cycloalkyl group, or C3-C8 cycloalkenyl group {wherein the C3-C8 cycloalkyl group and the C3-C8 cycloalkenyl group have one or more substituents selected from Group B. And the other symbols have the same meanings as described above. ]
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include ethers, hydrocarbons, halogenated hydrocarbons and mixtures thereof.
In the reaction, the compound (R-5) is usually used in a proportion of 1 mole to 10 moles relative to 1 mole of the compound (M-2).
The reaction time is usually in the range of 5 minutes to 24 hours. The reaction temperature is usually in the range of −20 ° C. to 80 ° C.
After completion of the reaction, the compound (M-3) can be isolated by performing post-treatment operations such as adding water to the reaction mixture and filtering and drying the precipitated solid.
The compound (R-5) is a commercially available compound, or can be produced, for example, according to the method described in Organic Letters, 2014, 16, 6424-6427.
参考製造法２
　化合物（Ｍ－２）は、式（Ｍ－４）で示される化合物（以下、化合物（Ｍ－４）と記す）と酸化剤とを反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000010
 ［式中、記号は前記と同じ意味を表す。］
　反応に用いられる酸化剤としては、例えば酸化マンガン（ＩＶ）、デス・マーチン試薬及び２－ヨードキシ安息香酸が挙げられる。
　反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えばハロゲン化炭化水素類、ニトリル類、エステル類及びこれらの混合物が挙げられる。
　反応には、化合物（Ｍ－４）１モルに対して、酸化剤が通常１モル～５０モルの割合で用いられる。
　反応時間は、通常５分間～２４時間の範囲である。反応温度は、通常－２０℃～８０℃の範囲である。
　反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより化合物（Ｍ－２）を単離することができる。 Reference manufacturing method 2
The compound (M-2) can be produced by reacting a compound represented by the formula (M-4) (hereinafter referred to as a compound (M-4)) with an oxidizing agent.
Figure JPOXMLDOC01-appb-C000010
 [Wherein, the symbols have the same meanings as described above. ]
Examples of the oxidizing agent used for the reaction include manganese (IV) oxide, Dess-Martin reagent and 2-iodoxybenzoic acid.
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include halogenated hydrocarbons, nitriles, esters and mixtures thereof.
In the reaction, the oxidizing agent is usually used in a proportion of 1 mole to 50 moles relative to 1 mole of the compound (M-4).
The reaction time is usually in the range of 5 minutes to 24 hours. The reaction temperature is usually in the range of −20 ° C. to 80 ° C.
After completion of the reaction, water is added to the reaction mixture, extraction is performed with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to isolate the compound (M-2).
参考製造法３
　化合物（Ｍ－４）は、式（Ｍ－５）で示される化合物（以下、化合物（Ｍ－５）と記す）と還元剤とを反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000011
 ［式中、Ｒ32はメチル基又はエチル基を表し、その他の記号は前記と同じ意味を表す。］
　反応に用いられる還元剤としては、例えば水素化アルミニウムリチウム、水素化ホウ素リチウム及び水素化ジイソブチルアルミニウムが挙げられる。
　反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えば炭化水素類、エーテル類、ハロゲン化炭化水素類及びこれらの混合物が挙げられる。
　反応には、化合物（Ｍ－５）１モルに対して、還元剤が通常２モル～１０モルの割合で用いられる。
　反応時間は、通常５分間～２４時間の範囲である。反応温度は、通常－８０℃～４０℃の範囲である。
　反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより化合物（Ｍ－４）を単離することができる。 Reference manufacturing method 3
The compound (M-4) can be produced by reacting a compound represented by the formula (M-5) (hereinafter referred to as a compound (M-5)) with a reducing agent.
Figure JPOXMLDOC01-appb-C000011
 [Wherein, R 32 represents a methyl group or an ethyl group, and the other symbols have the same meanings as described above. ]
Examples of the reducing agent used for the reaction include lithium aluminum hydride, lithium borohydride and diisobutylaluminum hydride.
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include hydrocarbons, ethers, halogenated hydrocarbons and mixtures thereof.
In the reaction, a reducing agent is usually used in a proportion of 2 mol to 10 mol per 1 mol of compound (M-5).
The reaction time is usually in the range of 5 minutes to 24 hours. The reaction temperature is usually in the range of -80 ° C to 40 ° C.
After completion of the reaction, water is added to the reaction mixture, extraction is performed with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to isolate the compound (M-4).
参考製造法４
　化合物（Ｍ－５）は、式（Ｍ－６）で示される化合物（以下、化合物（Ｍ－６）と記す）と式（Ｒ－６）で示される化合物（以下、化合物（Ｒ－６）と記す）とを反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000012
 ［式中、Ｘ2は塩素原子、臭素原子、ヨウ素原子、メシルオキシ基又はトシルオキシ基を表し、その他の記号は前記と同じ意味を表す。］
　反応は、製造法１に準じて実施することができる。
　化合物（Ｒ－６）は、市販の化合物であるか、公知の方法に準じて製造することができる。 Reference manufacturing method 4
The compound (M-5) is a compound represented by the formula (M-6) (hereinafter referred to as compound (M-6)) and a compound represented by the formula (R-6) (hereinafter referred to as the compound (R-6) Can be produced by reacting with
Figure JPOXMLDOC01-appb-C000012
 [Wherein, X 2 represents a chlorine atom, a bromine atom, an iodine atom, a mesyloxy group or a tosyloxy group, and the other symbols have the same meanings as described above. ]
The reaction can be carried out according to production method 1.
The compound (R-6) is a commercially available compound or can be produced according to a known method.
参考製造法５
　化合物（Ｍ－６）は、式（Ｍ－７）で示される化合物（以下、化合物（Ｍ－７）と記す）と式（Ｍ－８）で示される化合物（以下、化合物（Ｍ－８）と記す）とを反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000013
 ［式中、Ｒ33はメチル基又はエチル基を表し、その他の記号は前記と同じ意味を表す。］
　反応は無溶媒又は溶媒中で行われる。反応に用いられる溶媒としては、例えばエーテル類、炭化水素類、非プロトン性極性溶媒及びこれらの混合物が挙げられる。
　反応には、化合物（Ｍ－７）１モルに対して、化合物（Ｍ－８）が通常０．１～１０モルの割合で用いられる。
　反応温度は通常－２０℃から２００℃の範囲である。反応時間は通常５分～７２時間の範囲である。
　反応終了後は、化合物（Ｍ－６）が析出する場合には固体をろ取する；化合物（Ｍ－６）が析出しない場合には水を加えて有機溶媒で抽出する；等の後処理操作を行うことにより、化合物（Ｍ－６）を単離することができる。
　化合物（Ｍ－７）及び化合物（Ｍ－８）は、市販の化合物であるか、公知の方法に準じて製造することができる。 Reference manufacturing method 5
The compound (M-6) is a compound represented by the formula (M-7) (hereinafter referred to as a compound (M-7)) and a compound represented by the formula (M-8) (hereinafter referred to as a compound (M-8) Can be produced by reacting with
Figure JPOXMLDOC01-appb-C000013
 [Wherein, R 33 represents a methyl group or an ethyl group, and the other symbols have the same meanings as described above. ]
The reaction is carried out without solvent or in a solvent. The solvent used for the reaction includes, for example, ethers, hydrocarbons, aprotic polar solvents and mixtures thereof.
In the reaction, the compound (M-8) is usually used in a ratio of 0.1 to 10 moles relative to 1 mole of the compound (M-7).
The reaction temperature is usually in the range of -20 ° C to 200 ° C. The reaction time is usually in the range of 5 minutes to 72 hours.
After completion of the reaction, solid is collected by filtration when compound (M-6) precipitates; water is added and extracted with an organic solvent when compound (M-6) does not precipitate; To isolate compound (M-6).
The compound (M-7) and the compound (M-8) are commercially available compounds, or can be produced according to known methods.
参考製造法６
　式（Ｍ－９）で示される化合物（以下、化合物（Ｍ－９）と記す）は、化合物（Ｍ－２）と、式（Ｒ－７）で示される化合物（以下、化合物（Ｒ－７）と記す）とを反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000014
 ［式中、記号は前記と同じ意味を表す。］
　反応は、例えばJournal of Organic Chemistry, 2008, 73, 5558-5565に記載の方法に準じて実施することができる。
　化合物（Ｒ－７）は、市販の化合物であるか、例えばJournal of Medicinal Chemistry, 2007, 50, 6367-6382に記載の方法に準じて製造することができる。 Reference manufacturing method 6
The compound represented by the formula (M-9) (hereinafter referred to as a compound (M-9)) is a compound (M-2) and the compound represented by the formula (R-7) (hereinafter referred to as a compound (R-7) Can be produced by reacting with
Figure JPOXMLDOC01-appb-C000014
 [Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out, for example, according to the method described in Journal of Organic Chemistry, 2008, 73, 5558-5565.
Compound (R-7) is a commercially available compound or can be produced according to the method described in, for example, Journal of Medicinal Chemistry, 2007, 50, 6367-6382.
参考製造法７
　式（Ｍ－１１）で示される化合物（以下、化合物（Ｍ－１１）と記す）は、式（Ｍ－１０）で示される化合物（以下、化合物（Ｍ－１０）と記す）、式（Ｒ－８）で示される化合物（以下、化合物（Ｒ－８）と記す）、及び塩基を反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000015
 ［式中、Ｌ3は、酸素原子、－ＮＲ8－、－Ｓ（Ｏ）p－又は－Ｏ－Ｎ＝ＣＲ9－＊を表し、その他の記号は前記と同じ意味を表す。］
　化合物（Ｒ－８）は、市販の化合物であるか、公知の方法に準じて製造することができる。
　反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えば炭化水素類、エーテル類、ハロゲン化炭化水素類、非プロトン性極性溶媒、エステル類及びこれらの混合物が挙げられる。
　反応に用いられる塩基としては、例えば水素化ナトリウム、アルカリ金属炭酸塩類及び有機塩基類が挙げられる。
　反応には、化合物（Ｍ－１０）１モルに対して、化合物（Ｒ－８）が通常１モル～１０モルの割合で、塩基が通常１モル～１０モルの割合で用いられる。
　反応時間は、通常５分間～２４時間の範囲である。反応温度は、通常－２０℃～１００℃の範囲である。
　反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより化合物（Ｍ－１１）を単離することができる。 Reference manufacturing method 7
The compound represented by the formula (M-11) (hereinafter referred to as a compound (M-11)) is a compound represented by the formula (M-10) (hereinafter referred to as a compound (M-10)), the formula (R-11) It can manufacture by making the compound shown by -8) (it is hereafter described as a compound (R-8)), and a base react.
Figure JPOXMLDOC01-appb-C000015
 Wherein, L 3 represents an oxygen atom, -NR 8 -, - S ( O) p - or -O-N = CR 9 - * represents and the other symbols have the same meanings as described above. ]
Compound (R-8) is a commercially available compound or can be produced according to a known method.
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include hydrocarbons, ethers, halogenated hydrocarbons, aprotic polar solvents, esters and mixtures thereof.
Examples of the base used for the reaction include sodium hydride, alkali metal carbonates and organic bases.
In the reaction, the compound (R-8) is usually used in a proportion of 1 mol to 10 mol and the base is usually used in a proportion of 1 mol to 10 mol with respect to 1 mol of the compound (M-10).
The reaction time is usually in the range of 5 minutes to 24 hours. The reaction temperature is usually in the range of −20 ° C. to 100 ° C.
After completion of the reaction, compound (M-11) can be isolated by post-treatment operation such as adding water to the reaction mixture, extracting with an organic solvent, and drying and concentrating the organic layer.
参考製造法８
　化合物（Ｍ－１０）は、化合物（Ｍ－４）と塩素化剤とを反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000016
 ［式中、記号は前記と同じ意味を表す。］
　反応に用いられる塩素化剤としては、例えば塩化チオニル、オキシ塩化リン及び塩化オキサリルが挙げられる。
　反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えば炭化水素類、ハロゲン化炭化水素類、エーテル類、ニトリル類、エステル類及びこれらの混合物が挙げられる。
　反応には、化合物（Ｍ－４）１モルに対して、塩素化剤が通常１モル～１０モルの割合で用いられる。
　反応時間は、通常５分間～２４時間の範囲である。反応温度は、通常－２０℃～１００℃の範囲である。
　反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより化合物（Ｍ－１０）を単離することができる。 Reference manufacturing method 8
Compound (M-10) can be produced by reacting compound (M-4) with a chlorinating agent.
Figure JPOXMLDOC01-appb-C000016
 [Wherein, the symbols have the same meanings as described above. ]
The chlorinating agent used for the reaction includes, for example, thionyl chloride, phosphorus oxychloride and oxalyl chloride.
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include hydrocarbons, halogenated hydrocarbons, ethers, nitriles, esters and mixtures thereof.
In the reaction, a chlorinating agent is usually used in a ratio of 1 mol to 10 mol per 1 mol of compound (M-4).
The reaction time is usually in the range of 5 minutes to 24 hours. The reaction temperature is usually in the range of −20 ° C. to 100 ° C.
After completion of the reaction, the reaction mixture can be added with water, extracted with an organic solvent, and subjected to post-treatment procedures such as drying and concentration of the organic layer to isolate the compound (M-10).
参考製造法９
　式（Ｍ－１３）で示される化合物（以下、化合物（Ｍ－１３）と記す）は、化合物（Ｍ－４）、式（Ｒ－９）で示される化合物（以下、化合物（Ｒ－９）と記す）、及び塩基を反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000017
 ［式中、記号は前記と同じ意味を表す。］
　反応は、化合物（Ｍ－１０）に代えて化合物（Ｒ－９）を、化合物（Ｒ－８）に代えて化合物（Ｍ－４）を用いて、参考製造法７に準じて実施することができる。
　化合物（Ｒ－９）は、市販の化合物であるか、公知の方法に準じて製造することができる。 Reference manufacturing method 9
The compound represented by the formula (M-13) (hereinafter referred to as the compound (M-13)) is a compound represented by the compound (M-4) or the formula (R-9) (hereinafter referred to as the compound (R-9) Can be produced by reacting a base and a base.
Figure JPOXMLDOC01-appb-C000017
 [Wherein, the symbols have the same meanings as described above. ]
The reaction may be carried out according to Reference Production Method 7 using compound (M-4) instead of compound (M-10) and compound (R-9) instead of compound (R-8). it can.
Compound (R-9) is a commercially available compound or can be produced according to a known method.
参考製造法１０
　式（Ｍ－１５）で示される化合物（以下、化合物（Ｍ－１５）と記す）は、式（Ｍ－１４）で示される化合物（以下、化合物（Ｍ－１４）と記す）と式（Ｒ－１０）で示される化合物（以下、化合物（Ｒ－１０）と記す）とを反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000018
 ［式中、記号は前記と同じ意味を表す。］
　反応は、参考製造法６に準じて実施することができる。
　化合物（Ｒ－１０）は、市販の化合物であるか、例えばJournal of Medicinal Chemistry, 2007, 50, 6367-6382に記載の方法に準じて製造することができる。 Reference manufacturing method 10
The compound represented by the formula (M-15) (hereinafter referred to as the compound (M-15)) is a compound represented by the formula (M-14) (hereinafter referred to as the compound (M-14)) and the compound represented by the formula (R-14) It can be produced by reacting the compound represented by -10) (hereinafter referred to as compound (R-10)).
Figure JPOXMLDOC01-appb-C000018
 [Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to Reference Production Method 6.
Compound (R-10) is a commercially available compound, or can be produced according to the method described in, for example, Journal of Medicinal Chemistry, 2007, 50, 6367-6382.
参考製造法１１
　化合物（Ｍ－１４）は、式（Ｍ－１６）で示される化合物（以下、化合物（Ｍ－１６）と記す）と酸化剤とを反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000019
 ［式中、記号は前記と同じ意味を表す。］
　反応は、参考製造法２に準じて実施することができる。 Reference manufacturing method 11
Compound (M-14) can be produced by reacting a compound represented by formula (M-16) (hereinafter referred to as compound (M-16)) with an oxidizing agent.
Figure JPOXMLDOC01-appb-C000019
 [Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to Reference Production Method 2.
参考製造法１２
　化合物（Ｍ－１６）は、式（Ｍ－１７）で示される化合物（以下、化合物（Ｍ－１７）と記す）と、塩基とを反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000020
 ［式中、Ｒ34はメチル基又はトリフルオロメチル基を表し、その他の記号は前記と同じ意味を表す。］
　反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えばアルコール類が挙げられる。
　反応に用いられる塩基としては、例えばアルカリ金属炭酸塩類が挙げられる。
　反応には、化合物（Ｍ－１７）１モルに対して、塩基が通常０．１モル～１０モルの割合で用いられる。
　反応時間は、通常５分間～２４時間の範囲である。反応温度は、通常－２０℃～８０℃の範囲である。
　反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより化合物（Ｍ－１６）を単離することができる。 Reference manufacturing method 12
Compound (M-16) can be produced by reacting a compound represented by formula (M-17) (hereinafter referred to as compound (M-17)) with a base.
Figure JPOXMLDOC01-appb-C000020
 [Wherein, R 34 represents a methyl group or a trifluoromethyl group, and the other symbols have the same meanings as described above. ]
The reaction is usually carried out in a solvent. As a solvent used for reaction, alcohol is mentioned, for example.
As a base used for reaction, an alkali metal carbonate is mentioned, for example.
In the reaction, a base is usually used in a proportion of 0.1 mol to 10 mol per 1 mol of a compound (M-17).
The reaction time is usually in the range of 5 minutes to 24 hours. The reaction temperature is usually in the range of −20 ° C. to 80 ° C.
After completion of the reaction, the reaction mixture can be added with water, extracted with an organic solvent, and subjected to post-treatment procedures such as drying and concentration of the organic layer to isolate the compound (M-16).
参考製造法１３
　化合物（Ｍ－１７）は、式（Ｍ－１８）で示される化合物（以下、化合物（Ｍ－１８）と記す）と式（Ｒ－１１）で示される化合物（以下、化合物（Ｒ－１１）と記す）とを反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000021
 ［式中、記号は前記と同じ意味を表す。］
　反応は、無溶媒中又は溶媒中で行われる。反応に用いられる溶媒としては、例えば炭化水素類、エーテル類、ハロゲン化炭化水素類及びこれらの混合物が挙げられる。
　反応には、化合物（Ｍ－１８）１モルに対して、化合物（Ｒ－１１）が通常１モル～１００モルの割合で用いられる。
　反応時間は、通常５分間～２４時間の範囲である。反応温度は、通常－２０℃～１８０℃の範囲である。
　反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより化合物（Ｍ－１７）を単離することができる。
　化合物（Ｒ－１１）は、市販の化合物である。 Reference manufacturing method 13
The compound (M-17) is a compound represented by the formula (M-18) (hereinafter referred to as compound (M-18)) and a compound represented by the formula (R-11) (hereinafter referred to as the compound (R-11) Can be produced by reacting with
Figure JPOXMLDOC01-appb-C000021
 [Wherein, the symbols have the same meanings as described above. ]
The reaction is carried out without solvent or in a solvent. Examples of the solvent used for the reaction include hydrocarbons, ethers, halogenated hydrocarbons and mixtures thereof.
In the reaction, the compound (R-11) is usually used in a proportion of 1 mol to 100 mol, relative to 1 mol of the compound (M-18).
The reaction time is usually in the range of 5 minutes to 24 hours. The reaction temperature is usually in the range of −20 ° C. to 180 ° C.
After completion of the reaction, the reaction mixture can be added with water, extracted with an organic solvent, and subjected to post-treatment procedures such as drying and concentration of the organic layer to isolate the compound (M-17).
The compound (R-11) is a commercially available compound.
参考製造法１４
　化合物（Ｍ－１８）は、式（Ｍ－１９）で示される化合物（以下、化合物（Ｍ－１９）と記す）と酸化剤とを反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000022
 ［式中、記号は前記と同じ意味を表す。］
　反応は、製造法５に準じて実施することができる。 Reference manufacturing method 14
Compound (M-18) can be produced by reacting a compound represented by formula (M-19) (hereinafter referred to as compound (M-19)) with an oxidizing agent.
Figure JPOXMLDOC01-appb-C000022
 [Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to production method 5.
参考製造法１５
　式（Ｍ－２１）で示される化合物（以下、化合物（Ｍ－２１）と記す）は、式（Ｍ－２０）で示される化合物（以下、化合物（Ｍ－２０）と記す）、式（Ｒ－１２）で示される化合物（以下、化合物（Ｒ－１２）と記す）、及び塩基を反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000023
 ［式中、記号は前記と同じ意味を表す。］
　反応は、参考製造法７に準じて実施することができる。
　化合物（Ｒ－１２）は、市販の化合物であるか、公知の方法に準じて製造することができる。 Reference manufacturing method 15
The compound represented by the formula (M-21) (hereinafter referred to as a compound (M-21)) is a compound represented by the formula (M-20) (hereinafter referred to as a compound (M-20)), the formula (R-20) It can be produced by reacting a compound represented by -12) (hereinafter referred to as compound (R-12)) and a base.
Figure JPOXMLDOC01-appb-C000023
 [Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to Reference Production Method 7.
The compound (R-12) is a commercially available compound or can be produced according to a known method.
参考製造法１６
　化合物（Ｍ－２０）は、化合物（Ｍ－１６）と塩素化剤とを反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000024
 ［式中、記号は前記と同じ意味を表す。］
　反応は、参考製造法８に記載の方法に準じて実施することができる。 Reference manufacturing method 16
Compound (M-20) can be produced by reacting compound (M-16) with a chlorinating agent.
Figure JPOXMLDOC01-appb-C000024
 [Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Reference Production Method 8.
参考製造法１７
　式（Ｍ－２３）で示される化合物（以下、化合物（Ｍ－２３）と記す）は、式（Ｍ－２２）で示される化合物（以下、化合物（Ｍ－２２）と記す）、式（Ｒ－１３）で示される化合物（以下、化合物（Ｒ－１３）と記す）、金属触媒及び塩基を反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000025
 ［式中、Ｘ3は臭素原子又はヨウ素原子を表し、Ｒ35はＣ１－Ｃ１３鎖式炭化水素基｛該Ｃ１－Ｃ１３鎖式炭化水素基は、群Ａより選ばれる１以上の置換基を有していてもよい｝、Ｃ２－Ｃ６アルキルカルボニル基、Ｃ２－Ｃ６アルキルカルボニルオキシ基｛該Ｃ２－Ｃ６アルキルカルボニル基及び該Ｃ２－Ｃ６アルキルカルボニルオキシ基は、１以上のハロゲン原子を有していてもよい｝、Ｃ３－Ｃ８シクロアルキル基、Ｃ３－Ｃ８シクロアルケニル基｛該Ｃ３－Ｃ８シクロアルキル基及び該Ｃ３－Ｃ８シクロアルケニル基は、群Ｂより選ばれる１以上の置換基を有していてもよい｝を表し、その他の記号は前記と同じ意味を表す。］
　反応に用いられる金属触媒としては、例えばヨウ化銅（Ｉ）、テトラキス（トリフェニルホスフィン）パラジウム（０）及びジクロロビス(トリフェニルホスフィン)パラジウム（ＩＩ）が挙げられる。
　反応に用いられる塩基としては、例えば有機塩基類及びアルカリ金属炭酸塩類が挙げられる。
　反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えばエーテル類、炭化水素類、非プロトン性極性溶媒及びこれらの混合物が挙げられる。
　反応には、化合物（Ｍ－２２）１モルに対して、化合物（Ｒ－１３）が通常１モル～１０モルの割合、金属触媒が通常０．０１～０．５モルの割合、塩基が通常１～１００モルの割合で用いられる。
　反応時間は、通常５分間～４８時間の範囲である。反応温度は、通常－２０℃～８０℃の範囲である。
　反応終了後は、反応混合物を有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより化合物（Ｍ－２３）を単離することができる。
　化合物（Ｒ－１３）は、市販の化合物であるか、公知の方法に準じて製造することができる。 Reference manufacturing method 17
The compound represented by the formula (M-23) (hereinafter referred to as the compound (M-23)) is a compound represented by the formula (M-22) (hereinafter referred to as the compound (M-22)), the compound represented by the formula (R-22) It can be produced by reacting a compound represented by -13) (hereinafter referred to as compound (R-13)), a metal catalyst and a base.
Figure JPOXMLDOC01-appb-C000025
 [Wherein, X 3 represents a bromine atom or an iodine atom, and R 35 represents a C 1 -C 13 chain hydrocarbon group {the C 1 -C 13 chain hydrocarbon group has one or more substituents selected from group A Which may be, C2-C6 alkylcarbonyl group, C2-C6 alkylcarbonyloxy group {wherein the C2-C6 alkylcarbonyl group and the C2-C6 alkylcarbonyloxy group have one or more halogen atoms A C3-C8 cycloalkyl group, a C3-C8 cycloalkenyl group {wherein the C3-C8 cycloalkyl group and the C3-C8 cycloalkenyl group have one or more substituents selected from group B. And the other symbols have the same meanings as described above. ]
Examples of the metal catalyst used for the reaction include copper (I) iodide, tetrakis (triphenylphosphine) palladium (0) and dichlorobis (triphenylphosphine) palladium (II).
Examples of the base used for the reaction include organic bases and alkali metal carbonates.
The reaction is usually carried out in a solvent. The solvent used for the reaction includes, for example, ethers, hydrocarbons, aprotic polar solvents and mixtures thereof.
In the reaction, the compound (R-13) is usually at a ratio of 1 mol to 10 mol, the metal catalyst is usually at a ratio of 0.01 to 0.5 mol, and the base is usually at 1 mol to 1 mol of the compound (M-22). It is used in a proportion of 1 to 100 moles.
The reaction time is usually in the range of 5 minutes to 48 hours. The reaction temperature is usually in the range of −20 ° C. to 80 ° C.
After completion of the reaction, the reaction mixture can be extracted with an organic solvent, and the organic layer can be subjected to post-treatment procedures such as drying and concentration to isolate the compound (M-23).
The compound (R-13) is a commercially available compound or can be produced according to a known method.
参考製造法１８
　化合物（Ｍ－２２）は、式（Ｍ－２４）で示される化合物（以下、化合物（Ｍ－２４）と記す）と、式（Ｒ－１４）で示される化合物（以下、化合物（Ｒ－１４）と記す）と、有機金属化合物とを反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000026
 ［式中、記号は前記と同じ意味を表す。］
　反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えば炭化水素類、エーテル類及びこれらの混合物が挙げられる。
　反応に用いられる有機金属化合物としては、例えばＣ１－Ｃ４アルキルリチウム及びＣ１－Ｃ４アルキルマグネシウムクロリドが挙げられる。
　反応には、必要に応じて塩化リチウムを用いてもよい。
　反応には、化合物（Ｍ－２４）１モルに対して、化合物（Ｒ－１４）が通常１モル～１０モルの割合で、有機金属化合物が通常１モル～１０モルの割合で用いられる。
　塩化リチウムが用いられる場合、化合物（Ｍ－２４）１モルに対して、塩化リチウムが通常１モル～１０モルの割合で用いられる。
　反応時間は、通常５分間～４８時間の範囲である。反応温度は、通常－８０℃～１００℃の範囲である。
　反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより化合物（Ｍ－２２）を単離することができる。
　化合物（Ｒ－１４）は、市販の化合物であるか、公知の方法に準じて製造することができる。 Reference manufacturing method 18
The compound (M-22) is a compound represented by the formula (M-24) (hereinafter referred to as a compound (M-24)), and a compound represented by the formula (R-14) (hereinafter the compound (R-14) It can be produced by reacting)) with an organometallic compound.
Figure JPOXMLDOC01-appb-C000026
 [Wherein, the symbols have the same meanings as described above. ]
The reaction is usually carried out in a solvent. As a solvent used for reaction, hydrocarbons, ethers, and these mixtures are mentioned, for example.
Examples of the organic metal compound used for the reaction include C1-C4 alkyllithium and C1-C4 alkylmagnesium chloride.
Lithium chloride may be used for the reaction, if necessary.
In the reaction, the compound (R-14) is usually used at a ratio of 1 mole to 10 mol and the organic metal compound is usually used at a ratio of 1 mole to 10 mol with respect to 1 mol of the compound (M-24).
When lithium chloride is used, lithium chloride is usually used in a proportion of 1 mole to 10 moles relative to 1 mole of the compound (M-24).
The reaction time is usually in the range of 5 minutes to 48 hours. The reaction temperature is usually in the range of -80 ° C to 100 ° C.
After completion of the reaction, the reaction mixture can be added with water, extracted with an organic solvent, and subjected to post-treatment procedures such as drying and concentration of the organic layer to isolate the compound (M-22).
Compound (R-14) is a commercially available compound or can be produced according to a known method.
参考製造法１９
　化合物（Ｍ－２４）は、式（Ｍ－２５）で示される化合物（以下、化合物（Ｍ－２５）と記す）と化合物（Ｒ－６）とを反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000027
 ［式中、記号は前記と同じ意味を表す。］
　反応は、製造法１に準じて実施することができる。 Reference manufacturing method 19
The compound (M-24) can be produced by reacting a compound represented by the formula (M-25) (hereinafter referred to as compound (M-25)) with a compound (R-6).
Figure JPOXMLDOC01-appb-C000027
 [Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to production method 1.
参考製造法２０
　化合物（Ｍ－２５）は、式（Ｍ－２６）で示される化合物（以下、化合物（Ｍ－２６）と記す）と式（Ｒ－１５）で示される化合物（以下、化合物（Ｒ－１５）と記す）とを反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000028
 ［式中、記号は前記と同じ意味を表す。］
　反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えばアルコール類、エーテル類及びこれらの混合物が挙げられる。
　反応には、化合物（Ｍ－２６）１モルに対して、化合物（Ｒ－１５）が通常２モル～２０モルの割合で用いられる。
　反応時間は、通常５分間～４８時間の範囲である。反応温度は、通常－２０℃～１４０℃の範囲である。
　反応終了後は、析出した固体をろ過、乾燥する等の後処理操作を行うことにより化合物（Ｍ－２５）を単離することができる。
　化合物（Ｍ－２６）及び化合物（Ｒ－１５）は、市販の化合物であるか、公知の方法に準じて製造することができる。 Reference manufacturing method 20
The compound (M-25) is a compound represented by the formula (M-26) (hereinafter referred to as compound (M-26)) and a compound represented by the formula (R-15) (hereinafter referred to as the compound (R-15) Can be produced by reacting with
Figure JPOXMLDOC01-appb-C000028
 [Wherein, the symbols have the same meanings as described above. ]
The reaction is usually carried out in a solvent. As a solvent used for reaction, alcohol, ether, and these mixtures are mentioned, for example.
In the reaction, the compound (R-15) is usually used in a proportion of 2 mol to 20 mol per 1 mol of the compound (M-26).
The reaction time is usually in the range of 5 minutes to 48 hours. The reaction temperature is usually in the range of -20 ° C to 140 ° C.
After completion of the reaction, compound (M-25) can be isolated by performing post-treatment procedures such as filtration and drying of the precipitated solid.
Compound (M-26) and compound (R-15) are commercially available compounds, or can be produced according to known methods.
参考製造法２１
　式（Ｍ－２７）で示される化合物（以下、化合物（Ｍ－２７）と記す）は、化合物（Ｍ－２２）、式（Ｒ－１６）で示される化合物（以下、化合物（Ｒ－１６）と記す）、金属触媒及び塩基を反応させることにより製造することができる。
Figure JPOXMLDOC01-appb-C000029
 ［式中、ＭはＢ（ＯＲ36）2又は４，４，５，５－テトラメチル－１，３，２－ジオキサボロラン－２－イル基を表し、Ｒ36は水素原子又はＣ１－Ｃ６アルキル基を表し、その他の記号は前記と同じ意味を表す。］
　反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えばエーテル類、炭化水素類、非プロトン性極性溶媒、水及びこれらの混合物が挙げられる。
　反応に用いられる金属触媒としては、例えばテトラキス（トリフェニルホスフィン）パラジウム（０）、１，１’－ビス（ジフェニルホスフィノ）フェロセンパラジウム（ＩＩ）ジクロリド、トリス（ジベンジリデンアセトン）ジパラジウム（０）、酢酸パラジウム（ＩＩ）等のパラジウム触媒、及びビス（シクロオクタジエン）ニッケル（０）等が挙げられる。
　反応に用いられる塩基としては、例えばアルカリ金属炭酸塩類及び有機塩基類が挙げられる。
　反応には必要に応じて、配位子を用いてもよい。
　反応に用いられる配位子としては、例えばトリフェニルホスフィン、キサントホス、２，２’－ビス（ジフェニルホスフィノ）－１，１’－ビナフチル、１，１’－ビス（ジフェニルホスフィノ）フェロセン、２－ジシクロヘキシルホスフィノ－２’，４’，６’－トリイソプロピルビフェニル、２－ジシクロヘキシルホスフィノ－２’，６’－ジメトキシビフェニル及び１，２－ビス（ジフェニルホスフィノ）エタンが挙げられる。
　反応には、化合物（Ｍ－２２）１モルに対して、化合物（Ｒ－１６）が通常１モル～１０モルの割合、金属触媒が通常０．０１～０．５モルの割合、塩基が通常０．１～５モルの割合で用いられる。
　配位子が用いられる場合、化合物（Ｍ－２２）１モルに対して、配位子が通常０．０１～１モルの割合で用いられる。
　反応時間は、通常５分間～４８時間の範囲である。反応温度は、通常－２０℃～２００℃の範囲である。
　反応終了後は、反応混合物を有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより化合物（Ｍ－２７）を単離することができる。
　化合物（Ｒ－１６）は、市販の化合物であるか、公知の方法に準じて製造することができる。 Reference manufacturing method 21
The compound represented by the formula (M-27) (hereinafter referred to as the compound (M-27)) is a compound (M-22), the compound represented by the formula (R-16) (hereinafter the compound (R-16) Can be produced by reacting a metal catalyst and a base).
Figure JPOXMLDOC01-appb-C000029
 [Wherein, M represents B (OR 36 ) 2 or 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl group, and R 36 represents a hydrogen atom or a C1-C6 alkyl group And the other symbols have the same meanings as described above. ]
The reaction is usually carried out in a solvent. The solvent used for the reaction includes, for example, ethers, hydrocarbons, aprotic polar solvents, water and mixtures thereof.
Examples of the metal catalyst used for the reaction include tetrakis (triphenylphosphine) palladium (0), 1,1′-bis (diphenylphosphino) ferrocenepalladium (II) dichloride, tris (dibenzylideneacetone) dipalladium (0) And palladium catalysts such as palladium (II) acetate, and bis (cyclooctadiene) nickel (0).
As a base used for reaction, an alkali metal carbonate and organic bases are mentioned, for example.
A ligand may be used for the reaction, if necessary.
Examples of the ligand used for the reaction include triphenylphosphine, xanthophos, 2,2′-bis (diphenylphosphino) -1,1′-binaphthyl, 1,1′-bis (diphenylphosphino) ferrocene, 2 Dicyclohexylphosphino-2 ′, 4 ′, 6′-triisopropylbiphenyl, 2-dicyclohexylphosphino-2 ′, 6′-dimethoxybiphenyl and 1,2-bis (diphenylphosphino) ethane.
In the reaction, the compound (R-16) is usually at a ratio of 1 mol to 10 mol, the metal catalyst is usually at a ratio of 0.01 to 0.5 mol, and the base is usually at 1 mol to 1 mol of the compound (M-22). It is used in a proportion of 0.1 to 5 moles.
When a ligand is used, the ligand is generally used in a ratio of 0.01 to 1 mole relative to 1 mole of the compound (M-22).
The reaction time is usually in the range of 5 minutes to 48 hours. The reaction temperature is usually in the range of -20 ° C to 200 ° C.
After completion of the reaction, the reaction mixture can be extracted with an organic solvent, and the organic layer can be subjected to post-treatment procedures such as drying and concentration to isolate the compound (M-27).
Compound (R-16) is a commercially available compound or can be produced according to a known method.
　本発明化合物又は本発明化合物Ｘは、下記群（ａ）、群（ｂ）、群（ｃ）、群（ｄ）、群（ｅ）、群（ｆ）、群（ｇ）、及び群（ｈ）からなる群より選ばれる１以上の成分（以下、本成分と記す）と混用又は併用することができる。
　前記混用又は併用とは、本発明化合物Ｘと本成分とを、同時に、別々に又は時間間隔をおいて使用することを意味する。
　本発明化合物Ｘと本成分とを同時に使用する場合、本発明化合物Ｘ及び本成分が、それぞれ別個の製剤に含まれていてもよく、１つの製剤に含まれていてもよい。
　本発明の１つの側面は、群（ａ）及び群（ｂ）からなる群より選ばれる１以上の成分、並びに本発明化合物を含有する組成物である。
　本発明の１つの側面は、群（ａ）及び群（ｂ）からなる群より選ばれる１以上の成分、並びに本発明化合物Ｘを含有する組成物（以下、組成物Ａと記す）である。 The compound of the present invention or the compound of the present invention X is a group (a), a group (b), a group (c), a group (d), a group (e), a group (f), a group (g), and a group (h) And one or more components (hereinafter referred to as "the components") selected from the group consisting of
The said combined use or combined use means using the compound X of the present invention and this component simultaneously, separately or at time intervals.
When the compound of the present invention X and the component are simultaneously used, the compound of the present invention X and the component may be contained in separate formulations or may be contained in one formulation.
One aspect of the present invention is a composition comprising one or more components selected from the group consisting of Group (a) and Group (b), and a compound of the present invention.
One aspect of the present invention is a composition (hereinafter referred to as composition A) containing one or more components selected from the group consisting of groups (a) and (b), and the compound X of the present invention.
　群（ａ）は、アセチルコリンエステラーゼ阻害剤（例えばカーバメート系殺虫剤、有機リン系殺虫剤）、GABA作動性塩素イオンチャネルアンタゴニスト（例えばフェニルピラゾール系殺虫剤）、ナトリウムチャネルモジュレーター（例えば、ピレスロイド系殺虫剤）、ニコチン性アセチルコリン受容体拮抗モジュレーター（例えば、ネオニコチノイド系殺虫剤）、ニコチン性アセチルコリン受容体アロステリックモジュレーター、グルタミン酸作動性塩素イオンチャネルアロステリックモジュレーター（例えば、マクロライド系殺虫剤）、幼若ホルモンミミック、マルチサイト阻害剤、弦音器官TRPVチャネルモジュレーター、ダニ類生育阻害剤、ミトコンドリアATP生合成酵素阻害剤、酸化的リン酸化脱共役剤、ニコチン性アセチルコリン受容体チャネルブロッカー（例えば、ネライストキシン系殺虫剤）、キチン合成阻害剤、脱皮阻害剤、エクダイソン受容体アゴニスト、オクトパミン受容体アゴニスト、ミトコンドリア電子伝達系複合体I, II, III及びIVの阻害剤、電位依存性ナトリウムチャネルブロッカー、アセチルCoAカルボキシラーゼ阻害剤、リアノジン受容体モジュレーター（例えば、ジアミド系殺虫剤）、弦音器官モジュレーター、微生物殺虫剤の各々の活性成分、及びその他の殺虫活性成分、殺ダニ活性成分及び殺線虫活性成分からなる群である。これらは、IRACの作用機構に基づく分類に記載されている。 Group (a) includes acetylcholinesterase inhibitors (eg carbamate insecticides, organophosphorus insecticides), GABAergic chloride ion channel antagonists (eg phenylpyrazole insecticides), sodium channel modulators (eg pyrethroid insecticides) Nicotinic acetylcholine receptor antagonistic modulators (eg, neonicotinoid insecticides), nicotinic acetylcholine receptor allosteric modulators, glutamatergic chloride ion channel allosteric modulators (eg, macrolide insecticides), juvenile hormone mimic , Multi-site inhibitor, chordal organ TRPV channel modulator, mite growth inhibitor, mitochondrial ATP biosynthesis enzyme inhibitor, oxidative phosphorylation uncoupling agent, nicotinic acetylcholine receptor Channel blockers (eg, nereistoxin insecticides), chitin synthesis inhibitors, molting inhibitors, ecdysone receptor agonists, octopamine receptor agonists, inhibitors of mitochondrial electron transport complex I, II, III and IV, potentials Dependent sodium channel blocker, acetyl CoA carboxylase inhibitor, ryanodine receptor modulator (eg, diamide insecticide), chord tone organ modulator, each active ingredient of microbial insecticide, and other insecticidal active ingredients, acaricidal active ingredients and It is a group consisting of a nematode active ingredient. These are described in the classification based on IRAC's mechanism of action.
　群（ｂ）は、核酸合成阻害剤（例えば、フェニルアミド系殺菌剤、アシルアミノ酸系殺菌剤）、細胞分裂及び細胞骨格阻害剤（例えば、MBC殺菌剤）、呼吸阻害剤（例えば、QoI殺菌剤、QiI殺菌剤）、アミノ酸合成及びタンパク質合成阻害剤（例えば、アニリノピリジン系殺菌剤）、シグナル伝達阻害剤、脂質合成及び膜合成阻害剤、ステロール生合成阻害剤（例えば、トリアゾール系等のDMI殺菌剤）、細胞壁合成阻害剤、メラニン合成阻害剤、植物防御誘導剤、多作用点接触活性殺菌剤、微生物殺菌剤、及びその他の殺菌活性成分からなる群である。これらは、FRACの作用機構に基づく分類に記載されている。 Group (b) includes nucleic acid synthesis inhibitors (eg, phenylamide fungicides, acyl amino acid fungicides), cell division and cytoskeleton inhibitors (eg, MBC fungicides), respiratory inhibitors (eg, QoI fungicides) , QiI fungicides), amino acid synthesis and protein synthesis inhibitors (eg, anilinopyridine fungicides), signal transduction inhibitors, lipid synthesis and membrane synthesis inhibitors, sterol biosynthesis inhibitors (eg, triazole etc. DMI) And bactericidal agents), cell wall synthesis inhibitors, melanin synthesis inhibitors, plant defense inducers, multi-acting point contact active disinfectants, microbial disinfectants, and other bactericidal active ingredients. These are described in the classification based on the mechanism of action of FRAC.
　群（ｃ）は、植物成長調整成分（菌根菌及び根粒菌を含む）の群である。 Group (c) is a group of plant growth regulators (including mycorrhizal fungi and rhizobia).
　群（ｄ）は、薬害軽減成分の群である。 Group (d) is a group of safeners.
　群（ｅ）は、共力剤の群である。 Group (e) is a group of synergists.
　群（ｆ）は、鳥忌避成分、昆虫忌避成分、及び動物忌避成分からなる忌避成分の群である。 Group (f) is a group of repellent components consisting of a bird repellent component, an insect repellent component, and an animal repellent component.
　群（ｇ）は、殺軟体動物成分の群である。 Group (g) is a group of mollusc components.
　群（ｈ）は、昆虫フェロモンの群である。 Group (h) is a group of insect pheromone.
　以下に、本成分と本発明化合物Ｘの組み合わせの例を記載する。例えば、アラニカルブ（alanycarb）+SXはアラニカルブ（alanycarb）とSXとの組合せを意味する。
　なお、SXの略号は、実施例に記載の化合物群SX1～SX540から選ばれるいずれか１つの本発明化合物Ｘを意味する。また、以下に記載する本成分はいずれも公知の成分であり、市販の製剤から得るか、公知の方法により製造することができる。本成分が微生物の場合は、菌寄託機関から入手することもできる。なお、括弧内の数字はCAS RN（登録商標）を表す。 Below, the example of the combination of this component and this invention compound X is described. For example, alanicarb (Salyx + SX) means a combination of alanicarb (Salyx) and SX.
The abbreviation SX means any one compound of the present invention X selected from the compound groups SX1 to SX540 described in the Examples. In addition, all of the components described below are known components and can be obtained from commercially available preparations or can be produced by known methods. When the component is a microorganism, it can also be obtained from a bacteria depository. The numbers in parentheses indicate CAS RN (registered trademark).
　上記群（ａ）の本成分と本発明化合物Ｘとの組み合わせ：
　アバメクチン（abamectin）+SX、アセフェート（acephate）+SX、アセキノシル（acequinocyl）+SX、アセタミプリド（acetamiprid）+SX、アクリナトリン（acrinathrin）+SX、アシノナピル（acynonapyr）+SX、アフィドピロペン（afidopyropen）+SX、アフォキソラネル（afoxolaner）+SX、アラニカルブ（alanycarb）+SX、アルジカルブ（aldicarb）+SX、アレスリン（allethrin）+SX、アルファシペルメトリン（alpha-cypermethrin）+SX、アルファエンドスルファン（alpha-endosulfan）+SX、リン化アルミニウム（aluminium phosphide）+SX、アミトラズ（amitraz）+SX、アザジラクチン（azadirachtin）+SX、アザメチホス（azamethiphos）+SX、アジンホスエチル（azinphos-ethyl）+SX、アジンホスメチル（azinphos-methyl）+SX、アゾシクロチン（azocyclotin）+SX、ベンダイオカルブ（bendiocarb）+SX、ベンフルトリン（benfluthrin）+SX、ベンフラカルブ（benfuracarb）+SX、ベンスルタップ（bensultap）+SX、ベンゾキシメート（benzoximate）+SX、ベンズピリモキサン（benzpyrimoxan）+SX、ベータシフルトリン（beta-cyfluthrin）+SX、べータシペルメトリン（beta-cypermethrin）+SX、ビフェナゼート（bifenazate）+SX、ビフェントリン（bifenthrin）+SX、ビオアレスリン（bioallethrin）+SX、ビオレスメトリン（bioresmethrin）+SX、ビストリフルロン（bistrifluron）+SX、ホウ砂（borax）+SX、ホウ酸（boric acid）+SX、ブロフラニリド（broflanilide）+SX、ブロモプロピレート（bromopropylate）+SX、ブプロフェジン（buprofezin）+SX、ブトカルボキシム（butocarboxim）+SX、ブトキシカルボキシム（butoxycarboxim）+SX、カズサホス（cadusafos）+SX、シアン化カルシウム（calcium cyanide）+SX、リン化カルシウム（calcium phosphide）+SX、カルバリル（carbaryl）+SX、カルボフラン（carbofuran）+SX、カルボスルファン（carbosulfan）+SX、カルタップ塩酸塩（cartap hydrochloride）+SX、カルタップ（cartap）+SX、キノメチオナート（chinomethionat）+SX、クロラントラニリプロール（chlorantraniliprole）+SX、クロルデン（chlordane）+SX、クロレトキシホス（chlorethoxyfos）+SX、クロルフェナピル（chlorfenapyr）+SX、クロルフェンビンホス（chlorfenvinphos）+SX、クロルフルアズロン（chlorfluazuron）+SX、クロルメホス（chlormephos）+SX、クロルピクリン（chloropicrin）+SX、クロルピリホス（chlorpyrifos）+SX、クロルピリホスメチル（chlorpyrifos-methyl）+SX、クロマフェノジド（chromafenozide）+SX、クロフェンテジン（clofentezine）+SX、クロチアニジン（clothianidin）+SX、クマホス（coumaphos）+SX、クリオライト（cryolite）+SX、シアノホス（cyanophos）+SX、シアントラニリプロール（cyantraniliprole）+SX、シクラニリプロール（cycloniliprole）+SX、シクロプロトリン（cycloprothrin）+SX、シクロキサプリド（cycloxaprid）+SX、シエノピラフェン（cyenopyrafen）+SX、シフルメトフェン（cyflumetofen）+SX、シフルトリン（cyfluthrin）+SX、シハロジアミド（cyhalodiamide）+SX、シハロトリン（cyhalothrin）+SX、シヘキサチン（cyhexatin）+SX、シペルメトリン（cypermethrin）+SX、シフェノトリン（cyphenothrin）+SX、シロマジン（cyromazine）+SX、ダゾメット（dazomet）+SX、デルタメトリン（deltamethrin）+SX、デメトン－S－メチル（demeton-S-methyl）+SX、ジアフェンチウロン（diafenthiuron）+SX、ダイアジノン（diazinon）+SX、ジクロルボス（dichlorvos）+SX、ジクロロメゾチアズ（dicloromezotiaz）+SX、ジコホル（dicofol）+SX、ジクロトホス（dicrotophos）+SX、ジフロビダジン（diflovidazin）+SX、ジフルベンズロン（diflubenzuron）+SX、ジメフルトリン（dimefluthrin）+SX、ジメトエート（dimethoate）+SX、ジメチルビンホス（dimethylvinphos）+SX、ジノテフラン（dinotefuran）+SX、八ホウ酸二ナトリウム（disodium octaborate）+SX、ジスルホトン（disulfoton）+SX、DNOC（2-methyl-4,6-dinitrophenol）+SX、ドラメクチン（doramectin）+SX、エマメクチン安息香酸塩（emamectin-benzoate）+SX、エンペントリン（empenthrin）+SX、エンドスルファン（endosulfan）+SX、EPN（O-ethyl O-(4-nitrophenyl) phenylphosphonothioate）+SX、イプシロンメトフルトリン（epsilon-metofluthrin）+SX、イプシロンモンフルオロトリン（epsilon-momfluorothrin）+SX、エスフェンバレレート（esfenvalerate）+SX、エチオフェンカルブ（ethiofencarb）+SX、エチオン（ethion）+SX、エチプロール（ethiprole）+SX、エトプロホス（ethoprophos）+SX、エトフェンプロックス（etofenprox）+SX、エトキサゾール（etoxazole）+SX、ファンフル（famphur）+SX、フェナミホス（fenamiphos）+SX、フェナザキン（fenazaquin）+SX、酸化フェンブタスズ（fenbutatin oxide）+SX、フェニトロチオン（fenitrothion）+SX、フェノブカルブ（fenobucarb）+SX、フェノキシカルブ（fenoxycarb）+SX、フェンプロパトリン（fenpropathrin）+SX、フェンピロキシメート（fenpyroximate）+SX、フェンチオン（fenthion）+SX、フェンバレレート（fenvalerate）+SX、フィプロニル（fipronil）+SX、フロメトキン（flometoquin）+SX、フロニカミド（flonicamid）+SX、フルアクリピリム（fluacrypyrim）+SX、フルアザインドリジン（fluazaindolizine）+SX、フルアズロン（fluazuron）+SX、フルベンジアミド（flubendiamide）+SX、フルシクロクスロン（flucycloxuron）+SX、フルシトリネート（flucythrinate）+SX、フルエンスルホン（fluensulfone）+SX、フルフェンプロックス（flufenoprox）+SX、フルフェノクスロン（flufenoxuron）+SX、フルフィプロール（flufiprole）+SX、フルメトリン（flumethrin）+SX、フルオピラム（fluopyram）+SX、フルピラジフロン（flupyradifurone）+SX、フルピリミン（flupyrimin）+SX、フルララネル（fluralaner）+SX、フルバリネート（fluvalinate）+SX、フルキサメタミド（fluxametamide）+SX、ホルメタネート（formetanate）+SX、ホスチアゼート（fosthiazate）+SX、フラメトリン（furamethrin）+SX、フラチオカルブ（furathiocarb）+SX、ガンマシハロトリン（gamma-cyhalothrin）+SX、ハルフェンプロックス（halfenprox）+SX、ハロフェノジド（halofenozide）+SX、ヘプタフルトリン（heptafluthrin）+SX、ヘプテノホス（heptenophos）+SX、ヘキサフルムロン（hexaflumuron）+SX、ヘキシチアゾクス（hexythiazox）+SX、ヒドラメチルノン（hydramethylnon）+SX、ヒドロプレン（hydroprene）+SX、イミシアホス（imicyafos）+SX、イミダクロプリド（imidacloprid）+SX、イミプロトリン（imiprothrin）+SX、インドキサカルブ（indoxacarb）+SX、イソフェンホス（isofenphos）+SX、イソプロカルブ（isoprocarb）+SX、イソプロピルＯ－（メトキシアミノチオホスホリル）サリチラート（isopropyl-O-(methoxyaminothiophosphoryl)salicylate）+SX、イソキサチオン（isoxathion）+SX、イベルメクチン（ivermectin）+SX、カデスリン（kadethrin）+SX、カッパテフルトリン（kappa-tefluthrin）+SX、カッパビフェントリン（kappa-bifenthrin）+SX、キノプレン（kinoprene）+SX、ラムダシハロトリン（lambda-cyhalothrin）+SX、レピメクチン（lepimectin）+SX、石灰硫黄合剤（lime sulfur）+SX、ルフェヌロン（lufenuron）+SX、マシン油（machine oil）+SX、マラチオン（malathion）+SX、メカルバム（mecarbam）+SX、メペルフルトリン（meperfluthrin）+SX、メタフルミゾン（metaflumizone）+SX、メタム（metam）+SX、メタミドホス（methamidophos）+SX、メチダチオン（methidathion）+SX、メチオカルブ（methiocarb）+SX、メソミル（methomyl）+SX、メトプレン（methoprene）+SX、メトキシクロル（methoxychlor）+SX、メトキシフェノジド（methoxyfenozide）+SX、臭化メチル（methyl bromide）+SX、メトフルトリン（metofluthrin）+SX、メトルカルブ（metolcarb）+SX、メトキサジアゾン（metoxadiazone）+SX、メビンホス（mevinphos）+SX、ミルベメクチン（milbemectin）+SX、ミルベマイシンオキシム（milbemycin oxime）+SX、モンフルオロトリン（momfluorothrin）+SX、モノクロトホス（monocrotophos）+SX、モキシデクチン（moxidectin）+SX、ナレッド（naled）+SX、ニコチン（nicotine）+SX、硫酸ニコチン（nicotine-sulfate）+SX、ニテンピラム（nitenpyram）+SX、ノバルロン（novaluron）+SX、ノビフルムロン（noviflumuron）+SX、オメトエート（omethoate）+SX、オキサミル（oxamyl）+SX、オキシジメトンメチル（oxydemeton-methyl）+SX、パラチオン（parathion）+SX、パラチオンメチル（parathion-methyl）+SX、ペルメトリン（permethrin）+SX、フェノトリン（phenothrin）+SX、フェントエート（phenthoate）+SX、ホレート（phorate）+SX、ホサロン（phosalone）+SX、ホスメット（phosmet）+SX、ホスファミドン（phosphamidon）+SX、ホスフィン（phosphine）+SX、ホキシム（phoxim）+SX、ピリミカーブ（pirimicarb）+SX、ピリミホスメチル（pirimiphos-methyl）+SX、シアン化カリウム（potassium cyanide）+SX、プラレトリン（prallethrin）+SX、プロフェノホス（profenofos）+SX、プロフルトリン（profluthrin）+SX、プロパルギット（propargite）+SX、プロペタムホス（propetamphos）+SX、プロポキスル（propoxur）+SX、プロチオホス（prothiofos）+SX、ピフルブミド（pyflubumide）+SX、ピメトロジン（pymetrozine）+SX、ピラクロホス（pyraclofos）+SX、ピレトリン（pyrethrins）+SX、ピリダベン（pyridaben）+SX、ピリダリル（pyridalyl）+SX、ピリダフェンチオン（pyridaphenthion）+SX、ピリフルキナゾン（pyrifluquinazone）+SX、ピリミジフェン（pyrimidifen）+SX、ピリミノストロビン（pyriminostrobin）+SX、ピリプロール（pyriprole）+SX、ピリプロキシフェン（pyriproxyfen）+SX、キナルホス（quinalphos）+SX、レスメトリン（resmethrin）+SX、ロテノン（rotenone）+SX、セラメクチン（selamectin）+SX、シグマシペルメトリン（sigma-cypermethrin）+SX、シラフルオフェン（silafluofen）+SX、ホウ酸ナトリウム（sodium borate）+SX、シアン化ナトリウム（sodium cyanide）+SX、メタホウ酸ナトリウム（sodium metaborate）+SX、スピネトラム（spinetoram）+SX、スピノサド（spinosad）+SX、スピロジクロフェン（spirodiclofen）+SX、スピロメシフェン（spiromesifen）+SX、スピロピジオン(spiropidion)+SX、スピロテトラマト（spirotetramat）+SX、スルフルラミド（sulfluramid）+SX、スルホテップ（sulfotep）+SX、スルホキサフロル（sulfoxaflor）+SX、硫黄（sulfur）+SX、フッ化スルフリル（sulfuryl fluoride）+SX、吐酒石（tartar emetic）+SX、タウフルバリネート（tau-fluvalinate）+SX、テブフェノジド（tebufenozide）+SX、テブフェンピラド（tebufenpyrad）+SX、テブピリムホス（tebupirimfos）+SX、テフルベンズロン（teflubenzuron）+SX、テフルトリン（tefluthrin）+SX、テメホス（temephos）+SX、テルブホス（terbufos）+SX、テトラクロルビンホス（tetrachlorvinphos）+SX、テトラジホン（tetradifon）+SX、テトラメトリン（tetramethrin）+SX、テトラメチルフルトリン（tetramethylfluthrin）+SX、テトラニリプロール（tetraniliprole）+SX、シータシペルメトリン（theta-cypermethrin）+SX、チアクロプリド（thiacloprid）+SX、チアメトキサム（thiamethoxam）+SX、チオシクラム（thiocyclam）+SX、チオジカルブ（thiodicarb）+SX、チオファノックス（thiofanox）+SX、チオメトン（thiometon）+SX、チオスルタップ二ナトリウム塩（thiosultap-disodium）+SX、チオスルタップ一ナトリウム塩（thiosultap-monosodium）+SX、チオキサザフェン（tioxazafen）+SX、トルフェンピラド（tolfenpyrad）+SX、トラロメトリン（tralomethrin）+SX、トランスフルトリン（transfluthrin）+SX、トリアザメート（triazamate）+SX、トリアゾホス（triazophos）+SX、トリクロルホン（trichlorfon）+SX、トリフルメゾピリム（triflumezopyrim）+SX、トリフルムロン（triflumuron）+SX、トリメタカルブ（trimethacarb）+SX、チクロピラゾフロル（tyclopyrazoflor）+
SX、バミドチオン（vamidothion）+SX、XMC（3,5-dimethylphenyl N-methylcarbamate）+SX、キシリルカルブ（xylylcarb）+SX、ゼータシペルメトリン（zeta-cypermethrin）+SX、リン化亜鉛（zinc phosphide）+SX、３－ブロモ－Ｎ－［２，４－ジクロロ－６－（メチルカルバモイル）フェニル］－１－（３，５－ジクロロピリジン－２－イル）－１Ｈ－ピラゾール－５－カルボキサミド（1104384-14-6）+SX、Ｎ－［３－クロロ－１－（ピリジン－３－イル）－１Ｈ－ピラゾール－４－イル］－Ｎ－エチル－３－（３，３，３－トリフルオロプロパンスルフィニル）プロパンアミド（1477923-37-7）+SX、２－［３－（エタンスルホニル）ピリジン－２－イル］－５－（トリフルオロメタンスルホニル）ベンゾオキサゾール（1616678-32-0）+SX、４－［５－（３，５－ジクロロフェニル）－５－（トリフルオロメチル）－４，５－ジヒドロ－１，２－オキサゾール－３－イル］－２－メチル－Ｎ－（１－オキソチエタン－３－イル）ベンズアミド（1241050-20-3）+SX、３－メトキシ－Ｎ－（５－｛５－（トリフルオロメチル）－５－［３－（トリフルオロメチル）フェニル］－４，５－ジヒドロ－１，２－オキサゾール－３－イル｝インダン－１－イル）プロパンアミド（1118626-57-5）+SX、Ｎ－［２－ブロモ－６－クロロ－４－（１，１，１，２，３，３，３－ヘプタフルオロプロパン－２－イル）フェニル］－３－｛エチル［（ピリジン－４－イル）カルボニル］アミノ｝－２－メトキシベンズアミド（1429513-53-0）+SX、Ｎ－［２－ブロモ－６－クロロ－４－（１，１，１，２，３，３，３－ヘプタフルオロプロパン－２－イル）フェニル］－３－［エチル（４－シアノベンゾイル）アミノ］－２－メトキシベンズアミド（1609007-65-9）+SX、Ｎ－［２－ブロモ－６－ジフルオロメトキシ－４－（１，１，１，２，３，３，３－ヘプタフルオロプロパン－２－イル）フェニル］－３－｛メチル［（ピリジン－４－イル）カルボニル］アミノ｝－２－メトキシベンズアミド（1630969-78-6）+SX、１－｛２－フルオロ－４－メチル－５－［（２，２，２－トリフルオロエチル）スルフィニル］フェニル｝－３－（トリフルオロメチル）－１Ｈ－１，２，４－トリアゾール－５－アミン（885026-50-6）+SX、BT作物のタンパク質Cry1Ab（BT crop protein Cry1Ab）+SX、BT作物のタンパク質Cry1Ac（BT crop protein Cry1Ac）+SX、BT作物のタンパク質Cry1Fa（BT crop protein Cry1Fa）+SX、BT作物のタンパク質Cry1A.105（BT crop protein Cry1A.105）+SX、BT作物のタンパク質Cry2Ab（BT crop protein Cry2Ab）+SX、BT作物のタンパク質Vip3A（BT crop protein Vip3A）+SX、BT作物のタンパク質Cry3A（BT crop protein Cry3A）+SX、BT作物のタンパク質Cry3Ab（BT crop protein Cry3Ab）+SX、BT作物のタンパク質Cry3Bb（BT crop protein Cry3Bb）+SX、BT作物のタンパク質Cry34Ab1/Cry35Ab1（BT crop protein Cry34Ab1/Cry35Ab1）+SX、アドクソフィエス・オラナ顆粒病ウイルスBV-0001株（Adoxophyes orana granulosis virus BV-0001）+SX、アンチカルシア・ゲマタリス核多角体病ウイルス（Anticarsia gemmatalis mNPV）+SX、オートグラファ・カリフォルニア核多角体病ウイルスFV#11（Autographa californica mNPV FV#11）+SX、シジア・ポモネラ顆粒病ウイルス V15（Cydia pomonella GV V15）+SX、シジア・ポモネラ顆粒病ウイルスV22（Cydia pomonella GV V22）+SX、クリプトフレビア・ロイコトレタ顆粒病ウイルス（Cryptophlebia leucotreta GV）+SX、デンドロリムス・プンクタタス細胞質多面体ウイルス（Dendrolimus punctatus cypovirus）+SX、ヘリコベルパ・アルミゲラ核多角体病ウイルスBV-0003株（Helicoverpa armigera NPV BV-0003）+SX、ヘリコベルパ・ゼア核多角体病ウイルス（Helicoverpa zea NPV）+SX、リュマントリア・ディスパル核多角体病ウイルス（Lymantria dispar NPV）+SX、マメストラ・ブラシカエ核多角体病ウイルス（Mamestra brassicae NPV）+SX、マメストラ・コンフィグラタ核多角体病ウイルス（Mamestra configurata NPV）+SX、ネオディプリオン・アビエンティス核多角体病ウイルス（Neodiprion abietis NPV）+SX、ネオディプリオン・レコンテイ核多角体病ウイルス（Neodiprion lecontei NPV）+SX、ネオディプリオン・セルティファー核多角体病ウイルス（Neodiprion sertifer NPV）+SX、ノゼマ・ロクスタエ（Nosema locustae）+SX、オルギイア・プソイドツガタ核多角体病ウイルス（Orgyia pseudotsugata NPV）+SX、ピエリス・ラパエ顆粒病ウイルス（Pieris rapae GV）+SX、プロジア・インテルプンクテラ顆粒病ウイルス（Plodia interpunctella GV）+SX、スポドプテラ・エクシグア核多角体病ウイルス（Spodoptera exigua mNPV）+SX、スポドプテラ・リットラリス核多角体病ウイルス（Spodoptera littoralis mNPV）+SX、スポドプテラ・リツラ核多角体病ウイルス（Spodoptera litura NPV）+SX、アルスロボトリス・ダクチロイデス（Arthrobotrys dactyloides）+SX、バチルス・フィルムスGB-126株（Bacillus firmus GB-126）+SX、バチルス・フィルムスI-1582株（Bacillus firmus I-1582）+SX、バチルス・メガテリウム（Bacillus megaterium）+SX、バチルス sp. AQ175株（Bacillus sp.AQ175）+SX、バチルス sp.AQ177株（Bacillus sp.AQ177）+SX、バチルス sp.AQ178株（Bacillus sp.AQ178）+SX、バチルス・スファエリクス2362（Bacillus sphaericus 2362）+SX、バチルス・スファエリクスABTS1743（Bacillus sphaericus ABTS1743）+SX、バチルス・スファエリクスSerotype H5a5b株（Bacillus sphaericus Serotype H5a5b）+SX、バチルス・チューリンゲンシスAQ52株（Bacillus thuringiensis AQ52）+SX、バチルス・チューリンゲンシスBD#32株（Bacillus thuringiensis BD#32）+SX、バチルス・チューリンゲンシスCR-371株（Bacillus thuringiensis CR-371）+SX、バチルス・チューリンゲンシス・アイザワイ亜種ABTS-1857（Bacillus thuringiensis subsp. Aizawai ABTS-1857）+SX、バチルス・チューリンゲンシス・アイザワイ亜種AM65-52株（Bacillus thuringiensis subsp. Aizawai AM65-52）+SX、バチルス・チューリンゲンシス・アイザワイ亜種GC-91（Bacillus thuringiensis subsp. Aizawai GC-91）+SX、バチルス・チューリンゲンシス・アイザワイ亜種Serotype H-7（Bacillus thuringiensis subsp. Aizawai Serotype H-7）+SX、バチルス・チューリンゲンシス・クリスターキ亜種ABTS351株（Bacillus thuringiensis subsp. Kurstaki ABTS351）+SX、バチルス・チューリンゲンシス・クリスターキ亜種BMP123株（Bacillus thuringiensis subsp. Kurstaki BMP123）+SX、バチルス・チューリンゲンシス・クリスターキ亜種EG234株（Bacillus thuringiensis subsp. Kurstaki EG234）+SX、バチルス・チューリンゲンシス・クリスターキ亜種EG7841株（Bacillus thuringiensis subsp. Kurstaki EG7841）+SX、バチルス・チューリンゲンシス・クリスターキ亜種EVB113-19株（Bacillus thuringiensis subsp. Kurstaki EVB113-19）+SX、バチルス・チューリンゲンシス・クリスターキ亜種F810株（Bacillus thuringiensis subsp. Kurstaki F810）+SX、バチルス・チューリンゲンシス・クリスターキ亜種HD-1株（Bacillus thuringiensis subsp. Kurstaki HD-1）+SX、バチルス・チューリンゲンシス・クリスターキ亜種PB54株（Bacillus thuringiensis subsp. Kurstaki PB54）+SX、バチルス・チューリンゲンシス・クリスターキ亜種SA-11株（Bacillus thuringiensis subsp. Kurstaki SA-11）+SX、バチルス・チューリンゲンシス・クリスターキ亜種SA-12株（Bacillus thuringiensis subsp. Kurstaki SA-12）+SX、バチルス・チューリンゲンシス・テネブリオシス亜種NB176株（Bacillus thuringiensis subsp. Tenebriosis NB176）+SX、バチルス・チューリンゲンシス・チューリンゲンシス亜種MPPL002株（Bacillus thuringiensis subsp. Thuringiensis MPPL002）+SX、バチルス・チューリンゲンシス・モリソニ亜種（Bacillus thuringiensis subsp.morrisoni）+SX、バチルス・チューリンゲンシス・コルメリ変種（Bacillus thuringiensis var. colmeri）+SX、バチルス・チューリンゲンシス・ダームスタディエンシス変種24-91株（Bacillus thuringiensis var. darmstadiensis 24-91）+SX、バチルス・チューリンゲンシス・デンドロリムス変種（Bacillus thuringiensis var. dendrolimus）+SX、バチルス・チューリンゲンシス・ガレリア変種（Bacillus thuringiensis var. galleriae）+SX、バチルス・チューリンゲンシス・イスラエレンシス変種BMP144株（Bacillus thuringiensis var. israelensis BMP144）+SX、バチルス・チューリンゲンシス・イスラエレンシス変種serotype H-14（Bacillus thuringiensis var. israelensis serotype H-14）+SX、バチルス・チューリンゲンシス・ジャポネンシス変種buibui株（Bacillus thuringiensis var. japonensis buibui）+SX、バチルス・チューリンゲンシス・サンディエゴ変種M-7株（Bacillus thuringiensis var. san diego M-7）+SX、バチルス・チューリンゲンシス・7216変種（Bacillus thuringiensis var.7216）+SX、バチルス・チューリンゲンシス・アエジプチ変種（Bacillus thuringiensis var.aegypti）+SX、バチルス・チューリンゲンシス・T36変種（Bacillus thuringiensis var.T36）+SX、ボーベリア・バシアーナANT-03株（Beauveria bassiana ANT-03）+SX、ボーベリア・バシアーナATCC74040株（Beauveria bassiana ATCC74040）+SX、ボーベリア・バシアーナGHA株（Beauveria bassiana GHA）+SX、ボーベリア・ブロンニアティ（Beauveria brongniartii）+SX、バークホルデリア・リノジェンシスA396株（Burkholderia rinojensis A396）+SX、クロモバクテリウム・サブツガエPRAA4-1T株（Chromobacterium subtsugae PRAA4-1T）+SX、ダクチレラ・エリプソスポラ（Dactyllela ellipsospora）+SX、デクチラリア・サウマシア（Dectylaria thaumasia）＋SX、ヒルステラ・ミネソテンシス（Hirsutella minnesotensis）+SX、ヒルステラ・ロッシリエンシス（Hirsutella rhossiliensis）+SX、ヒルステラ・トンプソニ（Hirsutella thompsonii）+SX、ラゲニジウム・ギガンテウム（Lagenidium giganteum）+SX、レカニシリウム・レカニ KV01株（Lecanicillium lecanii KV01）+SX、レカニシリウム・レカニDAOM198499株の分生子（Lecanicillium lecanii conidia of strain DAOM198499）+SX、レカニシリウム・レカニDAOM216596株の分生子（Lecanicillium lecanii conidia of strain DAOM216596）+SX、メタリジウム・アニソプリアエF52株（Metarhizium anisopliae F52）+SX、メタリジウム・アニソプリアエ・アクリダム変種（Metarhizium anisopliae var. acridum）+SX、メタリジウム・フラボビリデ（Metarhizium flavoviride）+SX、モナクロスポリウム・フィマトパガム（Monacrosporium phymatopagum）+SX、ペキロマイセス・フモソロセウスApopka97株（Paecilomyces fumosoroseus Apopka97）+SX、ペキロマイセス・リラシナス251株（Paecilomyces lilacinus 251）+SX、ペキロマイセス・テヌイペスT1株（Paecilomyces tenuipes T1）+SX、パエニバチルス・ポピリア（Paenibacillus popilliae）+SX、パスツーリア・ニシザワエPn1株（Pasteuria nishizawae Pn1）+SX、パスツーリア・ペネトランス（Pasteuria penetrans）+SX、パスツーリア・ウスガエ（Pasteuria usgae）+SX、パスツーリア・トイネイ（Pasteuria thoynei）+SX、セラチア・エントモフィラ（Serratia entomophila）+SX、バーティシリウム・クラミドスポリウム（Verticillium chlamydosporium）+SX、バーティシリウム・レカニNCIM1312株（Verticillium lecani NCIM1312）+SX、アセトプロール(acetoprole)+SX、Celastrus angulatus樹皮(bark of Celastrus angulatus)+SX、コンカナマイシンＡ(concanamycin A)+SX、セイヨウオシダ乾燥葉(dried leaves of Dryopteris filix-mas)+SX、ニガヨモギ抽出物(extract of Artemisia absinthium)+SX、Cassia nigricans抽出物(extract of Cassia nigricans)+SX、クリトリア・テルナテアの抽出物(extract of clitoria　ternatea)+SX、ヒレハリソウ抽出物(extract of Symphytum officinale)+SX、アリタソウ抽出物
(extracts or simulated blend of Chenopodium ambrosioides)+SX、タンジー抽出物(extract of Tanacetum vulgare)+SX、セイヨウイラクサ抽出物(extract of Urtica dioica)+SX、ヤドリギ抽出物(extract of Viscum album)+SX、GS-オメガ/カッパHXTX-Hv1aペプチド(GS-omega/kappa HXTX-Hv1a peptide)+SX、ホップベータ酸のカリウム塩(potassium salt of hop beta acid)+SX、イソシクロセラム(isocycloseram)+SX、レノレマイシン(lenoremycin)+SX、ロチラネル(lotilaner)+SX、ニーム油(neem oil)+SX、アメリカアリタソウ種子油(oil of the seeds of Chenopodium anthelminticum)+SX、アルギニン酸プロピレングリコール(propylene glycol alginate)+SX、リアノジン(ryanodine)+SX、サロラネル(sarolaner)+SX、アリタソウから抽出したテルペン成分(terpene constituents of the extract of chenopodium ambrosioides near ambrosioides)+SX、スリナムニガキ木材抽出成分(wood extract of Quassia amara)+SX、Metarhizium anisopliae var. anisopliae BIPESCO 5/F52 + SX、Lecanicillium muscarium Ve6 + SX、N-ethyl-5-methyl-1-(3-methylbutan-2-yl)-N-(pyridazin-4-yl)-1H-pyrazole-4-carboxamide (1403615-77-9) + SX。 Combinations of the present component of the above group (a) with the compound of the present invention
Abamectin + SX, acephate + SX, acequinocyl + SX, acetamiprid + SX, acririnathrin + SX, acynonapyr + SX, afidopyropene + SX, afoxolaneal (Afoxolaner) + SX, alaniccarb (alanycarb) + SX, aldicarb (aldicarb) + SX, allethrin + SX, alpha-cypermethrin (alpha-cypermethrin) + SX, alpha-endosulfan (alpha-endosulfan) + SX, phosphorylated Aluminum (phosphide) + SX, amitraz (Amitraz) + SX, azadirachtin + SX, azamethiphos (Azamethiphos) + SX, azinphos-ethyl (azinphos-ethyl) + SX, azinphos-methyl (azinphos-methyl) + SX, azocyclotin (azocyclotintin) ) + SX, bendiocarb (bendiocarb) + SX, benfluthrin (benfluthrin) + SX, ben Flacarb (benfuracarb) + SX, bensultap (Sensultap) + SX, benzoximate (benzoximate) + SX, benzpyrimoxan (benzpyrimoxan) + SX, beta cyfluthrin (beta-cyfluthrin) + SX, betacypermethrin (beta) -cypermethrin) + SX, bifenazate + SX, bifenthrin + SX, bioallethrin + SX, bioresmethrin + SX, bistrifluron + SX, borax (borax) + SX, boric acid + SX, broflanilide + SX, bromopropylate + SX, buprofezin + SX, butocarboxim + SX, butoxycarboxim + SX, cadusafos + SX, calcium cyanide + SX, calcium phosphide + SX, carbaryl + SX, Carbofuran (carbofuran) + SX, carbosulfan (carbosulfan) + SX, cartap hydrochloride (cartap hydrochloride) + SX, cartap (cartap) + SX, kinomethionate (Xinomethionat) + SX, chlorantraniliprole (X chlorantraniliprole) + SX , Chorordan + SX, chlorethoxyfos + SX, chlorfenapyr + SX, chlorfenvinphos + SX, chlorfluazuron + SX, chlormephos (chlormephos) + SX, chlorpicrin (Chloropicrin) + SX, chlorpyrifos (chlorpyrifos) + SX, chlorpyrifos-methyl (chlorpyrifos-methyl) + SX, chromafenozide + SX, clofenthezine + SX, clothianidin (clothianidin) + SX, coumaphos (coumaphos) + SX, cryolite (Cryolite) + SX, cyanophos (cyanophos) + SX, cyan toranili Prorol (cyantraniliprole) + SX, cyclaniliprole (cyclonyliprole) + SX, cycloprothrin (cycloprothrin) + SX, cycloxaprid (cycloxaprid) + SX, sienopyraphen (cycloeprafen) + SX, ciflumethofen (cyflumetofen) + SX, cyfluthrin (cyfluthrin (cyfluthrin (cyfluthrin (cyfluthrin (cyfluthrin)) ) + SX, cyhalodiamide + SX, cyhalothrin + SX, cyhexatin + SX, cypermethrin + SX, cyphenothrin + SX, cyromazine + SX, dazomet (d) dazomet) + SX, deltamethrin (deltamethrin) + SX, demeton-S-methyl (demeton-S-methyl) + SX, diafenthiuron (diafenthiuron) + SX, diazinon (diazinon) + SX, dichlorvos (dichlorvos) + SX , Dichloromezotiaz + SX, Dicofol + SX, Dicrotophos + SX, Diflovidazine (diflovi) dazin) + SX, diflubenzuron + SX, dimefluthrin + SX, dimethoate + SX, dimethylvinphos (dimethylvinphos) + SX, dinotefuran + SX, disodium octaborate octaborate ) + SX, disulfoton (disulfoton) + SX, DNOC (2-methyl-4, 6-dinitrophenol) + SX, doramectin + SX, emamectin benzoate + SX, empenthrin + SX, endosulfan (endosulfan) + SX, EPN (O-ethyl O- (4-nitrophenyl) phenylphosphonothioate) + SX, epsilon methofluthrin (epsilon-metofluthrin) + SX, epsilon monfluorothrin (epsilon-momfluorothrin) + SX, Esfenvalerate + SX, ethiophencarb + SX, ethion + SX, ethiprole + SX, ethoprophos + SX, Tofenprox (etofenprox) + SX, etoxazole (Stoxazole) + SX, fenfur (famphur) + SX, fenamiphos (fenamiphos) + SX, fenazaquin + SX, fenbutatin oxide + SX, fenitrothion (fennitrothion) ) + SX, fenobucarb (fenobucarb) + SX, fenoxycarb (Fenoxycarb) + SX, fenpropathrin (fenpropathrin) + SX, fenpyroximate (fenpyroximate) + SX, fenthion (fenthion) + SX, fenvalerate (Sexvalerate) + SX, Fipronil (fipronil) + SX, flometoquin + SX, flonicamid (flonicamide) + SX, fluacrypirim (Sac) + SX, fluaza indolizine (Fluazaindolizine) + SX, fluazuron (fluazuron) + SX, flubendiamide (flubendiamide) + SX, flucycloxuron + SX, flucythrinate + S X, fluensulfone + SX, flufenoprox + SX, flufenoxuron + SX, flufiprole + SX, flumethrin + SX, fluopyram + SX , Flupyradifurone + SX, flupyrimin + SX, fluralaner + SX, fluvalinate + SX, fluxamethamide + SX, formetanate + SX, fosthiazet + SX Framethrin + SX, furathiocarb + SX, gamma-cyhalothrin + SX, halfenprox + SX, halofenozide + SX, heptafluthrin + SX, heptenophos + sx, hexaflumuron + SX, hexythiazox (hex ythiazox) + SX, hydramethylnon (hydramethylnon) + SX, hydroprene (hydroprene) + SX, imicyafos (imicyafos) + SX, imidacloprid + SX, imiprothrin + SX, indoxacarb (indooxacarb) + SX , Isophenphos (isofenphos) + SX, isoprocarb (isoprocarb) + SX, isopropyl O- (methoxyaminothiophosphoryl) salicylate (isopropyl-O-(methoxyaminothiophosphoryl) salicylate) + SX, isoxathion + SX, ivermectin + SX, kadethrin + SX, kappa-tefluthrin + SX, kappa-bifenthrin + SX, kinoprene + SX, lambda-cyhalothrin + SX, repimectin (Lepimectin) + SX, lime sulfur combination (lime sulfur) + SX, lufenuron (lufenuron) + SX, machine oil (machine oil) + SX, malathion + SX, mecarbam (mecarbam) + SX, meperfluthrin (meperfluthrin) + SX, metaflumizone (metaflumizone) + SX, metam (metam) + SX, methamidophos (methamidophos) + SX, methidathion + SX , Methiocarb + SX, methomyl + SX, methoprene (methoprene) + SX, methoxychlor + SX, methoxyfenozide + SX, methyl bromide + SX, methofutrin (metofluthrin) + SX, metolcarb + SX, methoxadiazone (SX), mevinphos (mevinphos) + SX, milbemectin + SX, milbemycin oxime + SX, monfluorothrin + SX, monochrome Topos (monocrotophos) + SX, moxidectin (moxidectin) + SX, nared (naled) + SX, nicotine (nicotine) + SX, Nicotine-Sulphate + SX, Nitenpyram (Nitenpyram) + SX, Novaluron (Novaluron) + SX, Noviflumuron + SX, Omethoate + SX, Oxamyl (OXamyl) + SX, Oxydimethone Methyl (oxydemeton-methyl) + SX, parathion + SX, parathion methyl (parathion-methyl) + SX, permethrin + SX, phenothrin + SX, phenthoate + SX, phorate ) + SX, phosalone (Psalone) + SX, phosmet (phosmet) + SX, phosphamidon (phosphamidon) + SX, phosphine (phosphine) + SX, phoxim (phoxim) + SX, pirimicarb (pirimicarb) + SX, pirimiphos-methyl (pirimiphos- methyl) + SX, potassium cyanide (potassium cyanide) + SX, prallethrin + SX, profenofos + 10 SX, profluthrin + SX, Propargite + SX, propetamphos + SX, propoxur + SX, prothiophos (prothiofos) + SX, pyflubumide + SX, pymetrozine + SX, pyraclofos (Pyraclofos + SX, pyrethrin (Pyrethrins) + SX, pyridaben + SX, pyridalyl + SX, pyridaphenthion + SX, pyrifluquinazone + SX, pyrimidifen + SX, pyriminostrobin + SX , Pyriprole + SX, pyriproxyfen + SX, quinalphos (X), resmethrin + SX, rotenone + SX, selamectin + SX, sigma cypermethrin (sigma -cypermethrin) + SX, silafluofen + SX, sodium borate + sodium SX, Sodium cyanide (Sydium cyanide) + SX, sodium metaborate (sodium metaborate) + SX, spinetoram (spinetoram) + SX, spinosad (spinosad) + SX, spirodiclofen (spirodiclofen) + SX, spiromesifen (spiromesifen) + SX, spiropidion + SX, spirotetramat + SX, sulfluramid (sulfluramid) + SX, sulfotep (sulfotep) + SX, sulfoxaflor (sulfofaflor) + SX, sulfur (sulfur) + SX, sulfuryl fluoride sulfuryl fluoride) + SX, tartar emetic + SX, tau-fluvalinate (tau-fluvalinate) + SX, tebufenozide + SX, tebufenpyrad + SX, tebupilimfos (tebupirimfos) + SX, teflubenzone ( teflubenzuron) + SX, tefluthrin + SX, temephos (temephos) + SX, terbufos (terbufos) + SX, tetrachlorvinphos (tetrach) lorvinphos) + SX, tetradiphone (Stradifon) + SX, tetramethrin (tetramethrin) + SX, tetramethylfluthrin (tetramethylfluthrin) + SX, tetraniliprol (tetraniliprole) + SX, theta-cypermethrin (theta-cypermethrin) + SX, thiacloprid (Thiacloprid) + SX, thiamethoxam + SX, thiocyclam (Siocyclam) + SX, thiodicarb (thiodicarb) + SX, thiophanox (Siofanox) + SX, thiometon (thiometon) + SX, thiosultap disodium salt (thiosultap- disodium + SX, thiosultap monosodium salt (thiosultap-monosodium) + SX, tiozazafen (tioxazafen) + SX, tolfenpyrad + SX, tralomethrin + SX, transfluthrin (transfluthrin) + SX, triazamate ) + SX, triazophos + SX, tricholfon + SX, Furumezopirimu (triflumezopyrim) + SX, triflumuron (triflumuron) + SX, trimethacarb (trimethacarb) + SX, cyclamate pyrazolium Furoru (tyclopyrazoflor) +
SX, vamidothione + SX, XMC (3,5-dimethylphenyl N-methylcarbamate) + SX, xylylcarb (xylylcarb) + SX, zetacypermethrin (zeta-cypermethrin) + SX, zinc phosphide (zinc phosphide) + SX , 3-bromo-N- [2,4-dichloro-6- (methylcarbamoyl) phenyl] -1- (3,5-dichloropyridin-2-yl) -1H-pyrazole-5-carboxamide (1104384-14- 6) + SX, N- [3-chloro-1- (pyridin-3-yl) -1H-pyrazol-4-yl] -N-ethyl-3- (3,3,3-trifluoropropanesulfinyl) propane Amide (1477923-37-7) + SX, 2- [3- (ethanesulfonyl) pyridin-2-yl] -5- (trifluoromethanesulfonyl) benzoxazole (1616678-32-0) + SX, 4- [5 -(3,5-dichlorophenyl) -5- Trifluoromethyl) -4,5-dihydro-1,2-oxazol-3-yl] -2-methyl-N- (1-oxothietan-3-yl) benzamide (1241050-20-3) + SX, 3- Methoxy-N- (5- {5- (trifluoromethyl) -5- [3- (trifluoromethyl) phenyl] -4,5-dihydro-1,2-oxazol-3-yl} indan-1-yl ) Propanamide (1118626-57-5) + SX, N- [2-bromo-6-chloro-4- (1,1,1,2,3,3,3-heptafluoropropan-2-yl) phenyl ] -3- {ethyl [(pyridin-4-yl) carbonyl] amino} -2-methoxybenzamide (1429513-53-0) + SX, N- [2-bromo-6-chloro-4- (1,1) 1,2,3,3,3-heptafluoropropan-2-yl) phenyl]- 3- [ethyl (4-cyanobenzoyl) amino] -2-methoxybenzamide (1609007-65-9) + SX, N- [2-bromo-6-difluoromethoxy-4- (1,1,1,2,3, 3,3,3-heptafluoropropan-2-yl) phenyl] -3- {methyl [(pyridin-4-yl) carbonyl] amino} -2-methoxybenzamide (1630969-78-6) + SX, 1- {2-Fluoro-4-methyl-5-[(2,2,2-trifluoroethyl) sulfinyl] phenyl} -3- (trifluoromethyl) -1H-1,2,4-triazol-5-amine ( 885026-50-6) + SX, BT crop protein Cry 1 Ab (BT crop protein Cry 1 Ab) + SX, BT crop protein Cry 1 Ac (BT crop protein Cry 1 Ac) + SX, BT crop protein Cry 1 Fa (BT crop protein Cry 1 Fa) + SX , BT crop protein Cry1A.105 (BT crop protein Cry1A.105) + S X, BT crop protein Cry2Ab (BT crop protein Cry2Ab) + SX, BT crop protein Vip3A (BT crop protein Vip3A) + SX, BT crop protein Cry3A (BT crop protein Cry3A) + SX, BT crop protein Cry3Ab (BT crop protein) BT crop protein Cry3Ab) + SX, BT crop protein Cry3Bb (BT crop protein Cry3Bb) + SX, BT crop protein Cry34Ab1 / Cry35Ab1 (BT crop protein Cry34Ab1 / Cry35Ab1) + SX, adococcus olana granulosa virus BV-0001 strain (Adoxophyes orana granulosis virus BV-0001) + SX, Anticarsia gematalis nuclear polyhedrosis virus (Anticarsia gemmatalis mNPV) + SX, Autographa california nuclear polyhedrosis virus FV # 11 (Autographa californica mNPV FV # 11) + SX, C. pomonella granulosis virus V15 (Cydia pomonella GV V15) + SX, C. pomonella granulosa virus V22 (Cydia pomonella GV V22) + SX, Cryptofrebbia leukotreta granulosa virus (Cr yptophlebia leucotreta GV) + SX, Dendrolimus punctatus cytoploid virus (Dendrolimus punctatus cypovirus) + SX, Helicoverpa armigera nuclear polyhedrosis virus BV-0003 strain (Helicoverpa armigera NPV BV-0003) + SX, Helicoverpa zea Body disease virus (Helicoverpa zea NPV) + SX, Lymantria dispar nuclear polyhedrosis virus (Lymantria dispar NPV) + SX, Mamastra brassicae nuclear polyhedrosis virus (Mamestra brassicae NPV) + SX, Mamastra configurata nuclear polyhedra Disease virus (Mamestra configurata NPV) + SX, neodiprion abientis nucleopolyhedrosis virus (Neodiprion abietis NPV) + SX, neodiprion recontei nuclear polyhedrosis virus (Neodiprion lecontei NPV) + SX, neodiprion Sertifer nuclear polyhedrosis virus (Neodiprion sertifer NPV) + SX, Nozema Roxtae (No sema locusta) + SX, Orgiia pseudotsugata nuclear polyhedrosis virus (Orgyia pseudotsugata NPV) + SX, Pieris rapae granule disease virus (Pieris rapae GV) + SX, Ploia interpunctella GV virus (Plodia interpunctella GV) + SX, Spodoptera exigua nuclear polyhedrosis virus (Spodoptera exigua mNPV) + SX, Spodoptera littoralis nuclear polyhedrosis virus (Spodoptera littoralis mNPV) + SX, Spodoptera litura nuclear polyhedrosis virus (Spodoptera litura NPV) + SX, Arthrobotris dactyloides + SX, Bacillus films GB-126 strain (Bacillus firmus GB-126) + SX, Bacillus films I-1582 strain (Bacillus firmus I-1582) + SX, Bacillus · Megathelium (Bacillus megaterium) + SX, Bacillus sp. AQ175 strain (Bacillus sp. AQ 175) + SX, Bacillus sp. AQ 177 strain (Bacillus sp. AQ 177) + SX, Bacillus sp. AQ 178 (Bacillus sp. AQ 178) + SX, Bacillus sphaericus 2362 (Bacillus sphaericus 2362) + SX, Bacillus sphaericus ABTS 1743 (Bacillus sphaericus ABTS 1743) + SX, Bacillus sphaericus Serotype H 5a 5 b (Bacillus sphaericus Serotype H 5 a 5 b) + SX, Bacillus thuringiensis AQ 52 strain (Bacillus thuringiensis AQ 52) + SX, Bacillus thuringiensis BD # 32 strain (Bacillus thuringiensis BD # 32) + SX, Bacillus thuringiensis CR-371 strain (Bacillus thuringiensis CR-371) + SX, Bacillus thuringiensis subspecies ABTS-1857 (Bacillus thuringiensis subsp. Aizawai ABTS-1857) + SX, Bacillus thuringiensis subspecies AM65-52 strain (Bacillus thuringiensis subsp. Aizawai AM65-52) + SX Bacillus thuringiensis subspecies GC-91 (Bacillus thuringiensis subsp. Aizawai GC-91) + SX, Bacillus thuringin S. aiwai subspecies Serotype H-7 (Bacillus thuringiensis subsp. Aizawai Serotype H-7) + SX, Bacillus thuringiensis cristae subsp. ABTS 351 strain (Bacillus thuringiensis subsp. Kurstaki ABTS 351) + SX, Bacillus thuringiensis cristaki Subspecies BMP123 strain (Bacillus thuringiensis subsp. Kurstaki BMP123) + SX, Bacillus thuringiensis chrysantalis subspecies EG234 (Bacillus thuringiensis subsp. Kurstaki EG234) + SX, Bacillus thuringiensis cristerchi subspecies EG 7841 strain (Bacillus thuringiensis subsp. Kurstaki EG7841) + SX, Bacillus thuringiensis cristaea subsp. EVB 113-19 (Bacillus thuringiensis subsp. Kurstaki EVB 113-19) + SX, Bacillus thuringiensis cristae subsp. F 810 (Bacillus thuringiensis subsp. Kurstaki F 810) + SX, Bacillus thuringiensis cristae subsp. HD-1 strain (Bacillus) s thuringiensis subsp. Kurstaki HD-1) + SX, Bacillus thuringiensis cristaea subsp. PB54 (Bacillus thuringiensis subsp. Kurstaki PB 54) + SX, Bacillus thuringiensis cristae subsp. SA-11 (Bacillus thuringiensis subsp. Kurstaki SA-11) + SX, Bacillus thuringiensis cristaea subsp. SA-12 (Bacillus thuringiensis subsp. Kurstaki SA-12) + SX, Bacillus thuringiensis subsp. NB176 (Bacillus thuringiensis subsp. Tenebriosis NB176) ) SX, Bacillus thuringiensis thuringiensis subsp. Strain MPPL 002 (Bacillus thuringiensis subsp. Thuringiensis MPPL 002) + SX, Bacillus thuringiensis morisoni subsp. (Bacillus thuringiensis subsp. Morrisoni) + SX, Bacillus thuringiensis kolmeri Variant (Bacillus thuringiensis var. Colmeri) + SX, Bacillus thuringiensis Dermistasis variant 24-91 (Bacillus thuringiensis var. Darmstadiensis 24-91) + SX, Bacillus thuringiensis dendolimus variant (Bacillus thuringiensis var. Dendrolimus) + SX, Bacillus thuringiensis galleria variant (Bacillus thuringiensis var. galleria e) + SX, Bacillus thuringiensis isla elensis variant BMP 144 strain (Bacillus thuringiensis var. israelensis BMP 144) + SX, Bacillus thuringiensis isla elensis variant serotype H-14 (Bacillus thuringiensis var. israelensis serotype H- 14) + SX, Bacillus thuringiensis-Japonensis variant buibui strain (Bacillus thuringiensis var. Japonensis buibui) + SX, Bacillus thuringiensis-San Diego variant M-7 strain (Bacillus thuringiensis var. San diego M-7) + SX, Bacillus thuringiensis 7216 variant (Bacillus thuringiensis var. 7216) + SX Bacillus thuringiensis aezipti variant (Bacillus thuringiensis var. Aegypti) + SX, Bacillus thuringiensis T36 variant (Bacillus thuringiensis var. T36) + SX, Bovelia basiana ANT-03 strain (Beauveria bassiana ANT-03) + SX , Beauveria bassiana ATCC 74040 strain (Beauvelia bassiana ATCC 74040) + SX, Beauberia bassiana GHA strain (Beauveria bassiana GHA) + SX, Beauberia bronniartii + SX, Burkholderia lenensis A 396 strain (Burkholdrino R. j. SX, Chromobacterium subsp. PRAA4-1T (Chromobacterium subtsugae PRAA4-1T) + SX, Dactylella ellipsospora + SX, Dactylaria thaumasia + SX, Hilstera minesitensis mins. Hirsutella rhossilie, Hirsutella rhossilie nsis) + SX, Hirstera thompsonii (Hirsutella thompsonii) + SX, Lagenidium giganteum (Lagenidium giganteum) + SX, Lecanicillium lecani strain KV01 (Lecanicillium lecanii KV01) + SX, Lecanicillium lecani DAOM 1984 99 of strain DAOM 1984 99) + SX, conidia of Lecanicillium lecani strain DAOM 216596 (Lecanicillium lecanii conidia of strain DAOM 216596) + SX, Metalidium anisopriae F 52 strain (Metarhizium anisopliae F 52) + SX, metallidium anisopliosis ah rivium acridum) + SX, Metarhizium flavoviride (Metarhizium flavoviride) + SX, Monacrosporium phymatopagum (Monacrosporium phymatopagum) + SX, Paecilomyces fumosoroseus Apopka 97 (Paecilomyces fumosoroseus Apopka 97) + SX, inus 251) + SX, Paecilomyces tenuipes T1 strain (Paecilomyces tenuipes T1) + SX, Paenibacillus popilliae + SX, P. pasteuria nishizawae Pn1 strain (Pasteuria nishizawae Pn1) + SX, P. pipetrae SX, Pasteuria usgae + SX, Pasteuria thoynei + SX, Serratia entomophila + SX, Verticillium chlamydosporium + SX, Vertici Lilium ・ recan NCIM 1312 strain (Verticillium lecani NCIM 1312) + SX, acetoprole (acetoprole) + SX, Celastrus angulatus bark (bark of Celastrus angulatus) + SX, concanamycin A (concanamycin A) + SX, sun leaf dried leaves (dried leaves) of Dryopteris filix-mas) + SX, extract of Artemisia absinthium + SX, Cassia nigricans extract (ex tract of Cassia nigricans + SX, extract of clitoria ternatea + SX, extract of Symphytum officinale + SX, extract of common lice
(extracts or simulated blends of Chenopodium ambrosioides) + SX, extract of Tanacetum vulgare + SX, Stinging nettle extract (extract of Urtica dioica) + SX, mistletoe extract (extract of Viscum album) + SX, GS -Omega / Kappa HXTX-Hv1a peptide (GS-omega / kappa HXTX-Hv1a peptide) + SX, potassium salt of hop beta acid (potassium salt of hop beta acid) + SX, isocycloceram (isocycloseram) + SX, renolemycin ( lenoremycin + SX, lotilaner + SX, neem oil (neem oil) + SX, oil of the seeds of Chenopodium anthelminticum + SX, propylene glycol alginate + SX, Ryanodine (Ryanodine) + SX, sarolaner (Salolaner) + SX, terpene component (terpene constituents of the extract of chenopodium ambrosioides near ambrosioides) + SX, wood extract of Quasisia amara + SX, Metarh izium anisopliae var. anisopliae BIPESCO 5 / F 52 + SX, Lecanicillium muscarium Ve 6 + SX, N-ethyl-5-methyl-1- (3-methylbutan-2-yl) -N- (pyridazin-4-yl) -1H- pyrazole-4-carboxamide (1403615-77-9) + SX.
　上記群（ｂ）の本成分と本発明化合物Ｘとの組み合わせ：
　アシベンゾラルSメチル（acibenzolar-S-methyl）+SX、アルジモルフ（aldimorph）+SX、アメトクトラジン（ametoctradin）+SX、アミノピリフェン(aminopyrifen)+SX、アミスルブロム（amisulbrom）+SX、アニラジン（anilazine）+SX、アザコナゾール（azaconazole）+SX、アゾキシストロビン（azoxystrobin）+SX、塩基性塩化銅（copper oxychloride）+SX、塩基性硫酸銅（basic copper sulfate）+SX、ベナラキシル（benalaxyl）+SX、ベナラキシルM（benalaxyl-M）+SX、ベノダニル（benodanil）+SX、ベノミル（benomyl）+SX、ベンチアバリカルブ（benthiavalicarb）+SX、ベンチアバリカルブイソプロピル（benthivalicarb-isopropyl）+SX、ベンゾビンジフルピル（benzovindiflupyr）+SX、ビナパクリル（binapacryl）+SX、ビフェニル（biphenyl）+SX、ビテルタノール（bitertanol）+SX、ビキサフェン（bixafen）+SX、ブラストサイジンS（blasticidin-S）+SX、ボスカリド（boscalid）+SX、ブロムコナゾール（bromuconazole）+SX、ブピリメート（bupirimate）+SX、キャプタホール（captafol）+SX、キャプタン（captan）+SX、カルベンダジム（carbendazim）+SX、カルボキシン（carboxin）+SX、カルプロパミド（carpropamid）+SX、キノメチオナート（chinomethionat）+SX、クロロネブ（chloroneb）+SX、クロロタロニル（chlorothalonil）+SX、クロゾリネート（chlozolinate）+SX、コレトクロリンＢ（colletochlorin B）+SX、水酸化銅(II)（copper(II) hydroxide）+SX、クモキシストロビン（coumoxystrobin）+SX、シアゾファミド（cyazofamid）+SX、シフルフェナミド（cyflufenamid）+SX、シモキサニル（cymoxanil）+SX、シプロコナゾール（cyproconazole）+SX、シプロジニル（cyprodinil）+SX、ジクロベンチアゾクス（dichlobentiazox）+SX、ジクロフルアニド（dichlofluanid）+SX、ジクロシメット（diclocymet）+SX、ジクロメジン（diclomezine）+SX、ジクロラン（dicloran）+SX、ジエトフェンカルブ（diethofencarb）+SX、ジフェノコナゾール（difenoconazole）+SX、ジフルメトリム（diflumetorim）+SX、ジメタクロン（dimethachlone）+SX、ジメチリモール（dimethirimol）+SX、ジメトモルフ（dimethomorph）+SX、ジモキシストロビン（dimoxystrobin）+SX、ジニコナゾール（diniconazole）+SX、ジニコナゾールM（diniconazole－M）+SX、ジノカップ（dinocap）+SX、ジピメティトロン（dipymetitrone）+SX、ジチアノン（dithianon）+SX、ドデシルベンゼンスルホン酸ビスエチレンジアミン銅(II)錯塩（dodecylbenzenesulphonic acid bisethylenediamine　copper(II) salt）+SX、ドデモルフ（dodemorph）+SX、ドジン（dodine）+SX、エジフェンホス（edifenphos）+SX、エノキサストロビン（enoxastrobin）+SX、エポキシコナゾール（epoxiconazole）+SX、エタコナゾール（etaconazole）+SX、エタボキサム（ethaboxam）+SX、エチリモール（ethirimol）+SX、エトリジアゾール（etridiazole）+SX、ファモキサドン（famoxadone）+SX、フェンアミドン（fenamidone）+SX、フェナミンストロビン（fenaminstrobin）+SX、フェナリモル（fenarimol）+SX、フェンブコナゾール（fenbuconazole）+SX、フェンフラム（fenfuram）+SX、フェンヘキサミド（fenhexamid）+SX、フェノキサニル（fenoxanil）+SX、フェンピクロニル（fenpiclonil）+SX、フェンピコキサミド（fenpicoxamid）+SX、フェンプロピジン（fenpropidin）+SX、フェンプロピモルフ（fenpropimorph）+SX、フェンピラザミン（fenpyrazamine）+SX、酢酸トリフェニル錫（fentin acetate）+SX、塩化トリフェニル錫（fentin chloride）+SX、水酸化トリフェニル錫（fentin hydroxide）+SX、フェルバム（ferbam）+SX、フェリムゾン（ferimzone）+SX、フルアジナム（fluazinam）+SX、フルジオキソニル（fludioxonil）+SX、フルフェノキシストロビン（flufenoxystrobin）+SX、フルインダピル（fluindapyr）+SX、フルモルフ（flumorph）+SX、フルオピコリド（fluopicolide）+SX、フルオルイミド（fluoroimide）+SX、フルオキサストロビン（fluoxastrobin）+SX、フルキンコナゾール（fluquinconazole）+SX、フルシラゾール（flusilazole）+SX、フルスルファミド（flusulfamide）+SX、フルチアニル（flutianil）+SX、フルトラニル（flutolanil）+SX、フルトリアホール（flutriafol）+SX、フルキサピロキサド（fluxapyroxad）+SX、ホルペット（folpet）+SX、ホセチル（fosetyl）+SX、フベリダゾール（fuberidazole）+SX、フララキシル（furalaxyl）+SX、フラメトピル（furametpyr）+SX、グアザチン（guazatine）+SX、ヘキサコナゾール（hexaconazole）+SX、ヒメキサゾール（hymexazole）+SX、イマザリル（imazalil）+SX、イミベンコナゾール（imibenconazole）+SX、イミノクタジン（iminoctadine）+SX、ヨードカルブ（iodocarb）+SX、イプコナゾール（ipconazole）+SX、イプフェントリフルコナゾール（ipfentrifluconazole）+SX、イプロベンホス（iprobenfos）+SX、イプロジオン（iprodione）+SX、イプロバリカルブ（iprovalicarb）+SX、イソフェタミド（isofetamid）+SX、イソフルシプラム（isoflucypram）+SX、イソプロチオラン（isoprothiolane）+SX、イソピラザム（isopyrazam）+SX、イソチアニル（isotianil）+SX、カスガマイシン（kasugamycin）+SX、クレソキシムメチル（kresoxim-methyl）+SX、ラミナリン（laminarin）+SX、マンコゼブ（mancozeb）+SX、マンデストロビン（mandestrobin）+SX、マンジプロパミド（mandipropamid）+SX、マンネブ（maneb）+SX、メフェントリフルコナゾール（mefentrifluconazole）+SX、メパニピリム（mepanipyrim）+SX、メプロニル（mepronil）+SX、メプチルジノカップ（meptyldinocap）+SX、メタラキシル（metalaxyl）+SX、メタラキシルM（metalaxyl-M）+SX、メトコナゾール（metconazole）+SX、メタスルホカルブ（methasulfocarb）+SX、メチラム（metiram）+SX、メトミノストロビン（metominostrobin）+SX、メトラフェノン（metrafenone）+SX、ミクロブタニル（myclobutanil）+SX、ナフチフィン（naftifine）+SX、ヌアリモール（nuarimol）+SX、オクチリノン（octhilinone）+SX、オフラセ（ofurace）+SX、オリサストロビン（orysastrobin）+SX、オキサジキシル（oxadixyl）+SX、オキサチアピプロリン（oxathiapiprolin）+SX、オキソリニック酸（oxolinic acid）+SX、オキスポコナゾール（oxpoconazole）+SX、オキスポコナゾールフマル酸塩（oxpoconazole fumarate）+SX、オキシカルボキシン（oxycarboxin）+SX、オキシテトラサイクリン（oxytetracycline）+SX、ペフラゾエート（pefurazoate）+SX、ペンコナゾール（penconazole）+SX、ペンシクロン（pencycuron）+SX、ペンフルフェン（penflufen）+SX、ペンチオピラド（penthiopyrad）+SX、フェナマクリル（phenamacril）+SX、フサライド（phthalide）+SX、ピカルブトラゾクス（picarbutrazox）+SX、ピコキシストロビン（picoxystrobin）+SX、ピペラリン（piperalin）+SX、ポリオキシン（polyoxins）+SX、プロベナゾール（probenazole）+SX、プロクロラズ（prochloraz）+SX、プロシミドン（procymidone）+SX、プロパモカルブ（propamocarb）+SX、プロピコナゾール（propiconazole）+SX、プロピネブ（propineb）+SX、プロキナジド（proquinazid）+SX、プロチオカルブ（prothiocarb）+SX、プロチオコナゾール（prothioconazole）+SX、ピジフルメトフェン（pydiflumetofen）+SX、ピラクロストロビン（pyraclostrobin）+SX、ピラメトストロビン（pyrametostrobin）+SX、ピラオキシストロビン（pyraoxystrobin）+SX、ピラプロポイン（pyrapropoyne）+SX、ピラジフルミド（pyraziflumid）+SX、ピラゾホス（pyrazophos）+SX、ピリベンカルブ（pyribencarb）+SX、ピリブチカルブ（pyributicarb）+SX、ピリフェノックス（pyrifenox）+SX、ピリメタニル（pyrimethanil）+SX、ピリモルフ（pyrimorph）+SX、ピリオフェノン（pyriofenone）+SX、ピリソキサゾール（pyrisoxazole）+SX、ピロキロン（pyroquilon）+SX、キノフメリン（quinofumelin）+SX、キノキシフェン（quinoxyfen）+SX、キントゼン（quintozene）+SX、セダキサン（sedaxane）+SX、シルチオファム（silthiofam）+SX、シメコナゾール（simeconazole）+SX、スピロキサミン（spiroxamine）+SX、ストレプトマイシン（streptomycin）+SX、硫黄（sulfur）+SX、テブコナゾール（tebuconazole）+SX、テブフロキン（tebufloquin）+SX、テクロフタラム（teclofthalam）+SX、テクナゼン（tecnazene）+SX、テルビナフィン（terbinafine）+SX、テトラコナゾール（tetraconazole）+SX、チアベンダゾール（thiabendazole）+SX、チフルザミド（thifluzamide）+SX、チオファネート（thiophanate）+SX、チオファネートメチル（thiophanate-methyl）+SX、チウラム（thiram）+SX、チアジニル（tiadinil）+SX、トルクロホスメチル（tolclofos-methyl）+SX、トルフェンピラド（tolfenpyrad）+SX、トルプロカルブ（tolprocarb）+SX、トリルフルアニド（tolylfluanid）+SX、トリアジメホン（triadimefon）+SX、トリアジメノール（triadimenol）+SX、トリアゾキシド（triazoxide）+SX、トリクロピリカルブ（triclopyricarb）+SX、トリシクラゾール（tricyclazole）+SX、トリデモルフ（tridemorph）+SX、トリフロキシストロビン（trifloxystrobin）+SX、トリフルミゾール（triflumizole）+SX、トリホリン（triforine）+SX、トリチコナゾール（triticonazole）+SX、バリダマイシン（validamycin）+SX、バリフェナレート（valifenalate）+SX、ビンクロゾリン（vinclozolin）+SX、ジネブ（zineb）+SX、ジラム（ziram）+SX、ゾキサミド（zoxamide）+SX、３－（ジフルオロメチル）－Ｎ－メトキシ－１－メチル－Ｎ－［（１Ｒ）－１－メチル－２－（２，４，６－トリクロロフェニル）エチル］ピラゾール－４－カルボキサミド（1639015-48-7）+SX、３－（ジフルオロメチル）－Ｎ－メトキシ－１－メチル－Ｎ－［（１Ｓ）－１－メチル－２－（２，４，６－トリクロロフェニル）エチル］ピラゾール－４－カルボキサミド（1639015-49-8）+SX、３－（ジフルオロメチル）－１－メチル－Ｎ－（１，１，３－トリメチルインダン－４－イル）ピラゾール－４－カルボキサミド（141573-94-6）+SX、３－（ジフルオロメチル）－１－メチル－Ｎ－［（３Ｒ）－１，１，３－トリメチルインダン－４－イル］ピラゾール－４－カルボキサミド（1352994-67-2）+SX、３－（ジフルオロメチル）－Ｎ－［（３Ｒ）－７－フルオロ－１，１，３－トリメチルインダン－４－イル］－１－メチルピラゾール－４－カルボキサミド（1513466-73-3）+SX、３－クロロ－５－フェニル－６－メチル－４－（２，６－ジフルオロフェニル）ピリダジン（1358061-55-8）+SX、Ｎ’－［４－（｛３－［（４－クロロフェニル）メチル］－１，２，４－チアジアゾール－５－イル｝オキシ）－２，５－ジメチルフェニル］－Ｎ－エチル－Ｎ－メチルメタンイミドアミド（1202781-91-6）+SX、２－｛３－［２－（１－｛［３，５－ビス（ジフルオロメチル）－１H－ピラゾール－１－イル］アセチル｝ピペリジン－４－イル）－１，３－チアゾール－４－イル］－４，５－ジヒドロ－１，２－オキサゾール－５－イル｝－３－クロロフェニル＝メタンスルホナ－ト（1360819-11-9）+SX、４－（２－ブロモ－４－フルオロフェニル）－N－（２－クロロ－６－フルオロフェニル）－１，３－ジメチル－１Ｈ－ピラゾール－５－アミン（1362477-26-6）+SX、２,２－ジメチル－９－フルオロ－５－（キノリン－３－イル）－２,３－ジヒドロベンゾ［ｆ］［１，４］オキサゼピン（1207749-50-5）+SX、２－［６－（３－フルオロ－４－メトキシフェニル）－５－メチルピリジン－２－イル］キナゾリン（1257056-97-5）+SX、５－フルオロ－２－［（４－メチルフェニル）メトキシ］－４－ピリミジンアミン（1174376-25-0）+SX、５－フルオロ－４－イミノ－３－メチル－１－トシル－３，４－ジヒドロピリミジン－２（１Ｈ）－オン（1616664-98-2）+SX、Ｎ’－（２，５－ジメチル－４－フェノキシフェニル）－Ｎ－エチル－Ｎ－メチルメタンイミドアミド（1052688-31-9）+SX、Ｎ’－｛４－［（４，５－ジクロロチアゾール－２－イル）オキシ］－２，５－ジメチルフェニル｝－Ｎ－エチル
－Ｎ－メチルメタンイミドアミド（929908-57-6）+SX、（２Ｚ）－３－アミノ－２－シアノ－３－フェニルアクリル酸エチル（39491-78-6）+SX、Ｎ－［（２－クロロチアゾール－５－イル）メチル］－Ｎ－エチル－６－メトキシ－３－ニトロピリジン－２－アミン（1446247-98-8）+SX、１－［２－（｛［１－（４－クロロフェニル）－１Ｈ－ピラゾール－３－イル］オキシ｝メチル）－３－メチルフェニル］－４－メチル－５－オキソ－４，５－ジヒドロ－１Ｈ－テトラゾール（1472649-01-6）+SX、α－［３－（４－クロロ－２－フルオロフェニル）－５－（２，４－ジフルオロフェニル）－４－イソキサゾリル］－３－ピリジンメタノール（1229605-96-2）+SX、（αＳ）－［３－（４－クロロ－２－フルオロフェニル）－５－（２，４－ジフルオロフェニル）－４－イソキサゾリル］－３－ピリジンメタノール（1229606-46-5）+SX、（αＲ）－［３－（４－クロロ－２－フルオロフェニル）－５－（２，４－ジフルオロフェニル）－４－イソキサゾリル］－３－ピリジンメタノール（1229606-02-3）+SX、２－｛［３－（２－クロロフェニル）－２－（２，４－ジフルオロフェニル）オキシラン－２－イル］メチル｝－２，４－ジヒドロ－３Ｈ－１，２，４－トリアゾール－３－チオン（1342260-19-8）+SX、２－｛［（２Ｒ，３Ｓ）－３－（２－クロロフェニル）－２－（２，４－ジフルオロフェニル）オキシラン－２－イル］メチル｝－２，４－ジヒドロ－３Ｈ－１，２，４－トリアゾール－３－チオン（1638897-70-7）+SX、２－｛［（２Ｓ，３Ｒ）－３－（２－クロロフェニル）－２－（２，４－ジフルオロフェニル）オキシラン－２－イル］メチル｝－２，４－ジヒドロ－３Ｈ－１，２，４－トリアゾール－３－チオン（1638897-71-8）+SX、２－｛［（２Ｒ，３Ｒ）－３－（２－クロロフェニル）－２－（２，４－ジフルオロフェニル）オキシラン－２－イル］メチル｝－２，４－ジヒドロ－３Ｈ－１，２，４－トリアゾール－３－チオン（1638897-72-9）+SX、２－｛［（２Ｓ，３Ｓ）－３－（２－クロロフェニル）－２－（２，４－ジフルオロフェニル）オキシラン－２－イル］メチル｝－２，４－ジヒドロ－３Ｈ－１，２，４－トリアゾール－３－チオン（1638897-73-0）+SX、１－｛［３－（２－クロロフェニル）－２－（２，４－ジフルオロフェニル）オキシラン－２－イル］メチル｝－１Ｈ－１，２，４－トリアゾール－５－イル　チオシアナト（1342260-26-7）+SX、１－｛［（２Ｒ，３Ｓ）－３－（２－クロロフェニル）－２－（２，４－ジフルオロフェニル）オキシラン－２－イル］メチル｝－１Ｈ－１，２，４－トリアゾール－５－イル　チオシアナト（1638897-82-1）+SX、１－｛［（２Ｓ，３Ｒ）－３－（２－クロロフェニル）－２－（２，４－ジフルオロフェニル）オキシラン－２－イル］メチル｝－１Ｈ－１，２，４－トリアゾール－５－イル　チオシアナト（1638897-84-3）+SX、１－｛［（２Ｒ，３Ｒ）－３－（２－クロロフェニル）－２－（２，４－ジフルオロフェニル）オキシラン－２－イル］メチル｝－１Ｈ－１，２，４－トリアゾール－５－イル　チオシアナト（1638897-86-5）+SX、１－｛［（２Ｓ，３Ｓ）－３－（２－クロロフェニル）－２－（２，４－ジフルオロフェニル）オキシラン－２－イル］メチル｝－１Ｈ－１，２，４－トリアゾール－５－イル　チオシアナト（1638897-89-8）+SX、５－（４－クロロベンジル）－２－クロロメチル－２－メチル－１－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタノール（1394057-11-4）+SX、（１Ｒ，２Ｓ，５Ｓ）－５－（４－クロロベンジル）－２－クロロメチル－２－メチル－１－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタノール（1801930-06-2）+SX、（１Ｓ，２Ｒ，５Ｒ）－５－（４－クロロベンジル）－２－クロロメチル－２－メチル－１－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタノール（1801930-07-3）+SX、（１Ｒ，２Ｒ，５Ｒ）－５－（４－クロロベンジル）－２－クロロメチル－２－メチル－１－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタノール（1801919-53-8）+SX、（１Ｓ，２Ｓ，５Ｓ）－５－（４－クロロベンジル）－２－クロロメチル－２－メチル－１－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタノール（1801919-54-9）+SX、（１Ｒ，２Ｒ，５Ｓ）－５－（４－クロロベンジル）－２－クロロメチル－２－メチル－１－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタノール（1801919-55-0）+SX、（１Ｓ，２Ｓ，５Ｒ）－５－（４－クロロベンジル）－２－クロロメチル－２－メチル－１－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタノール（1801919-56-1）+SX、（１Ｒ，２Ｓ，５Ｒ）－５－（４－クロロベンジル）－２－クロロメチル－２－メチル－１－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタノール（1801919-57-2）+SX、（１Ｓ，２Ｒ，５Ｓ）－５－（４－クロロベンジル）－２－クロロメチル－２－メチル－１－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタノール（1801919-58-3）+SX、メチル＝３－［（４－クロロフェニル）メチル］－２－ヒドロキシ－１－メチル－２－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタンカルボキシラート（1791398-02-1）+SX、メチル＝（１Ｒ，２Ｓ，３Ｓ）－３－［（４－クロロフェニル）メチル］－２－ヒドロキシ－１－メチル－２－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタンカルボキシラート（2080743-90-2）+SX、メチル＝（１Ｓ，２Ｒ，３Ｒ）－３－［（４－クロロフェニル）メチル］－２－ヒドロキシ－１－メチル－２－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタンカルボキシラート（2080743-91-3）+SX、メチル＝（１Ｒ，２Ｒ，３Ｒ）－３－［（４－クロロフェニル）メチル］－２－ヒドロキシ－１－メチル－２－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタンカルボキシラート（2080743-92-4）+SX、メチル＝（１Ｓ，２Ｓ，３Ｓ）－３－［（４－クロロフェニル）メチル］－２－ヒドロキシ－１－メチル－２－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタンカルボキシラート（2080743-93-5）+SX、メチル＝（１Ｒ，２Ｒ，３Ｓ）－３－［（４－クロロフェニル）メチル］－２－ヒドロキシ－１－メチル－２－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタンカルボキシラート（2080743-94-6）+SX、メチル＝（１Ｓ，２Ｓ，３Ｒ）－３－［（４－クロロフェニル）メチル］－２－ヒドロキシ－１－メチル－２－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタンカルボキシラート（2080743-95-7）+SX、メチル＝（１Ｒ，２Ｓ，３Ｒ）－３－［（４－クロロフェニル）メチル］－２－ヒドロキシ－１－メチル－２－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタンカルボキシラート（2081061-22-3）+SX、メチル＝（１Ｓ，２Ｒ，３Ｓ）－３－［（４－クロロフェニル）メチル］－２－ヒドロキシ－１－メチル－２－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタンカルボキシラート（2081061-23-4）+SX、２－クロロメチル－５－（４－フルオロベンジル）－２－メチル－１－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタノール（1394057-13-6）+SX、（１Ｒ，２Ｓ，５Ｓ）－２－クロロメチル－５－（４－フルオロベンジル）－２－メチル－１－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタノール（1801930-08-4）+SX、（１Ｓ，２Ｒ，５Ｒ）－２－クロロメチル－５－（４－フルオロベンジル）－２－メチル－１－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタノール（1801930-09-5）+SX、（１Ｒ，２Ｒ，５Ｒ）－２－クロロメチル－５－（４－フルオロベンジル）－２－メチル－１－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタノール（1638898-08-4）+SX、（１Ｓ，２Ｓ，５Ｓ）－２－クロロメチル－５－（４－フルオロベンジル）－２－メチル－１－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタノール（1638898-10-8）+SX、（１Ｒ，２Ｒ，５Ｓ）－２－クロロメチル－５－（４－フルオロベンジル）－２－メチル－１－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタノール（1638898-13-1）+SX、（１Ｓ，２Ｓ，５Ｒ）－２－クロロメチル－５－（４－フルオロベンジル）－２－メチル－１－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタノール（1638898-16-4）+SX、（１Ｒ，２Ｓ，５Ｒ）－２－クロロメチル－５－（４－フルオロベンジル）－２－メチル－１－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタノール（1638898-20-0）+SX、（１Ｓ，２Ｒ，５Ｓ）－２－クロロメチル－５－（４－フルオロベンジル）－２－メチル－１－（１Ｈ－１，２，４－トリアゾール－１－イルメチル）シクロペンタノール（1638898-24-4）+SX、（Ｒ）－２－［２－クロロ－４－（４－クロロフェノキシ）フェニル］－１－（１，２，４－トリアゾール－１－イル）ペント－３－イン－２－オール（1801919-59-4）+SX、（Ｒ）－２－［４－（４－クロロフェノキシ）－２－（トリフルオロメチル）フェニル］－１－（１，２，４－トリアゾール－１－イル）プロパン－２－オール（1616236-94-2）+SX、（Ｒ）－１－［４－（４－クロロフェノキシ）－２－（トリフルオロメチル）フェニル］－１－シクロプロピル－２－（１，２，４－トリアゾール－１－イル）エタノール（1801919-60-7）+SX、（Ｒ）－２－［４－（４－クロロフェノキシ）－２－（トリフルオロメチル）フェニル］－３－メチル－１－（１，２，４－トリアゾール－１－イル）ブタン－２－オール（1801919-61-8）+SX、３－［５－（４－クロロフェニル）－２，３－ジメチル－１，２－オキサゾリジン－３－イル］ピリジン（847749-37-5）+SX、アグロバクテリウム・ラジオバクターK1026株（Agrobacterium radiobactor K1026）+SX、アグロバクテリウム・ラジオバクターK84株（Agrobacterium radiobactor K84）+SX、バチルス・アミロリケファシエンスAT332株（Bacillus amyloliquefaciens AT332）+SX、バチルス・アミロリケファシエンスB3株（Bacillus amyloliquefaciens B3）+SX、バチルス・アミロリケファシエンスD747株（Bacillus amyloliquefaciens D747）+SX、バチルス・アミロリケファシエンスDB101株（Bacillus amyloliquefaciens DB101）+SX、バチルス・アミロリケファシエンスDB102株（Bacillus amyloliquefaciens DB102）+SX、バチルス・アミロリケファシエンスGB03株（Bacillus amyloliquefaciens GB03）+SX、バチルス・アミロリケファシエンスFZB24株（Bacillus amyloliquefaciens FZB24）+SX、バチルス・アミロリケファシエンスFZB42株（Bacillus amyloliquefaciens FZB42）+SX、バチルス・アミロリケファシエンスIN937a株（Bacillus amyloliquefaciens IN937a）+SX、バチルス・アミロリケファシエンスMBI600株（Bacillus amyloliquefaciens MBI600）+SX、バチルス・アミロリケファシエンスQST713株（Bacillus amyloliquefaciens QST713）+SX、バチルス・アミロリケファシエンス分離株B246株（Bacillus amyloliquefaciens isolate B246）+SX、バチルス・リケニホルミスHB-2株（Bacillus licheniformis HB-2）+SX、バチルス・リケニホルミスSB3086株（Bacillus licheniformis SB3086）+SX、バチルス・プミルスAQ717株（Bacillus pumilus AQ717）+SX、バチルス・プミルスBUF-33株（Bacillus pumilus BUF-33）+SX、バチルス・プミルスGB34株（Bacillus pumilus GB34）+SX、バチルス・プミルスQST2808株（Bacillus pumilus QST2808）+SX、バチルス・シンプレクスCGF2856株（Bacillus simplex CGF2856）+SX、バチルス・スブチリスAQ153株（Bacillus subtilis AQ153）+SX、バチルス・スブチリスAQ743株（Bacillus subtilis AQ743）+SX、バチルス・スブチリスD747株（Bacillus subtilis D747）+SX、バチルス・スブ
チリスDB101株（Bacillus subtilis DB101）+SX、バチルス・スブチリスFZB24株（Bacillus subtilis FZB24）+SX、バチルス・スブチリスGB03株（Bacillus subtilis GB03）+SX、バチルス・スブチリスHAI0404株（Bacillus subtilis HAI0404）+SX、バチルス・スブチリスIAB/BS03株（Bacillus subtilis IAB/BS03）+SX、バチルス・スブチリスMBI600株（Bacillus subtilis MBI600）+SX、バチルス・スブチリスQST30002/AQ30002株（Bacillus subtilis QST30002/AQ30002）+SX、バチルス・スブチリスQST30004/AQ30004株（Bacillus subtilis QST30004/AQ30004）+SX、バチルス・スブチリスQST713株（Bacillus subtilis QST713）+SX、バチルス・スブチリスQST714株（Bacillus subtilis QST714）+SX、バチルス・スブチリス var.アミロリクエファシエンスFZB24株（Bacillus subtilis var. Amyloliquefaciens FZB24）+SX、バチルス・スブチリスY1336株（Bacillus subtilis Y1336）+SX、バークホルデリア・セパシア（Burkholderia cepacia）+SX、バークホルデリア・セパシア・ウィスコンシン型J82株（Burkholderia cepacia type Wisconsin J82）+SX、バークホルデリア・セパシア・ウィスコンシン型M54株（Burkholderia cepacia type Wisconsin M54）+SX、カンジダ・オレオフィラO株（Candida oleophila O）+SX、カンジダ・サイトアナ（Candida saitoana）+SX、ケトミウム・クプレウム（Chaetomium cupreum）+SX、クロノスタキス・ロゼア（Clonostachys rosea）+SX、コニオシリウム・ミニタンスCGMCC8325株（Coniothyrium minitans CGMCC8325）+SX、コニオシリウム・ミニタンスCON/M/91-8株（Coniothyrium minitans CON/M/91-8）+SX、クリプトコッカス・アルビダス（cryptococcus albidus）+SX、エルビニア・カロトボーラsubsp.カロトボーラCGE234M403株（Erwinia carotovora subsp.carotovora CGE234M403）+SX、フザリウム・オキシスポラムFo47株（Fusarium oxysporum Fo47）+SX、グリオクラディウム・カテヌラタムJ1446株（Gliocladium catenulatum J1446）+SX、パエニバチルス・ポリミキサAC-1株（Paenibacillus polymyxa AC-1）+SX、パエニバチルス・ポリミキサBS-0105株（Paenibacillus polymyxa BS-0105）+SX、パントエア・アグロメランスE325株（Pantoea agglomerans E325）+SX、フレビオプシス・ギガンテアVRA1992株（Phlebiopsis gigantea VRA1992）+SX、シュードモナス・オーレオファシエンスTX-1株（Pseudomonas aureofaciens TX-1）+SX、シュードモナス・クロロラフィス63-28株（Pseudomonas chlororaphis 63-28）+SX、シュードモナス・クロロラフィス MA342株（Pseudomonas chlororaphis MA342）+SX、シュードモナス・フルオレッセンス1629RS株（Pseudomonas fluorescens 1629RS）+SX、シュードモナス・フルオレッセンスA506株（Pseudomonas fluorescens A506）+SX、シュードモナス・フルオレッセンスCL145A株（Pseudomonas fluorescens CL145A）+SX、シュードモナス・フルオレッセンスG7090株（Pseudomonas fluorescens G7090）+SX、シュードモナス・シリンガエ742RS株（Pseudomonas syringae 742RS）+SX、シュードモナス・シリンガエMA-4株（Pseudomonas syringae MA-4）+SX、シュードザイマ・フロキュローサPF-A22UL株（Pseudozyma flocculosa PF-A22UL）+SX、シュードモナス ロデシアHAI-0804株（Pseudomonas rhodesiae HAI-0804）+SX、ピシウム・オリガンドラムDV74株（Pythium oligandrum DV74）+SX、ストレプトマイセス・グリセオビリジスK61株（Streptomyces griseoviridis K61）+SX、ストレプトマイセス・リジカスWYCD108US株（Streptomyces lydicus WYCD108US）+SX、ストレプトマイセス・リジカスWYEC108株（Streptomyces lydicus WYEC108）+SX、タラロマイセス・フラバスSAY-Y-94-01株（Talaromyces flavus SAY-Y-94-01）+SX、タラロマイセス・フラバスV117b株（Talaromyces flavus V117b）+SX、トリコデルマ・アスペレルムICC012株（Trichoderma asperellum ICC012）+SX、トリコデルマ・アスペレルムSKT-1株（Trichoderma asperellum SKT-1)+SX、トリコデルマ・アスペレルムT34株（Trichoderma asperellum T34）+SX、トリコデルマ・アトロビリデCNCM 1-1237株（Trichoderma atroviride CNCM 1-1237）+SX、トリコデルマ・アトロビリデLC52株（Trichoderma atroviride LC52）+SX、トリコデルマ・アトロビリデSC1株（Trichoderma atroviride SC1）+SX、トリコデルマ・アトロビリデSKT-1株（Trichoderma atroviride SKT-1）+SX、トリコデルマ・ガムシーICC080株（Trichoderma gamsii ICC080）+SX、トリコデルマ・ハルジアナム21株（Trichoderma harzianum 21）+SX、トリコデルマ・ハルジアナムDB104株（Trichoderma harzianum DB104）+SX、トリコデルマ・ハルジアナムDSM14944株（Trichoderma harzianum DSM 14944）+SX、トリコデルマ・ハルジアナムESALQ-1303株（Trichoderma harzianum ESALQ-1303）+SX、トリコデルマ・ハルジアナムESALQ-1306株（Trichoderma harzianum ESALQ-1306）+SX、トリコデルマ・ハルジアナムIIHR-Th-2株（Trichoderma harzianum IIHR-Th-2）+SX、トリコデルマ・ハルジアナムkd株（Trichoderma harzianum kd）+SX、トリコデルマ・ハルジアナムMO1株（Trichoderma harzianum MO1）+SX、トリコデルマ・ハルジアナムSF株（Trichoderma harzianum SF）+SX、トリコデルマ・ハルジアナムT22株（Trichoderma harzianum T22）+SX、トリコデルマ・ハルジアナムT39株（Trichoderma harzianum T39）+SX、トリコデルマ・ハルジアナムTH35株（Trichoderma harzianum TH35）+SX、トリコデルマ・ポリスポラムIMI206039株（Trichoderma polysporum IMI206039）+SX、トリコデルマ・ストロマチカム（trichoderma stromaticum）+SX、トリコデルマ・ビレンスG-41株（Trichoderma virens G-41)+SX、トリコデルマ・ビレンスGL-21株（Trichoderma virens GL-21）+SX、トリコデルマ・ビリデ（Trichoderma viride）+SX、バリオボラックス・パラドクスCGF4526株（Variovorax paradoxus CGF4526）+SX、ハーピンタンパク（Harpin protein）+SX、ボルドー液(Bordeaux mixture)+SX、ブロモタロニル(bromothalonil)+SX、キチン(chitin)+SX、酢酸銅(II)(copper(II) acetate)+SX、硫酸銅(II)(copper(II) sulfate)+SX、亜リン酸水素二カリウム(dipotassium hydrogenphosphite)+SX、ティーツリー抽出物(extract from Melaleuca alternifolia)+SX、オオイタドリ抽出物(extract from Reynoutria sachalinensis)+SX、ハウチワマメ苗木の子葉からの抽出物(extract from the cotyledons of lupine plantlets("BLAD"))+SX、ニンニク抽出成分(extract of Allium sativum)+SX、スギナ抽出成分(extract of Equisetum arvense)+SX、キンレンカ抽出成分(extract of Tropaeolum majus)+SX、フロリルピコキサミド(florylpicoxamid)+SX、フルオピモミド(fluopimomide)+SX、ホセチルアルミニウム(fosetyl-aluminium)+SX、イミノクタジン酢酸塩(iminoctadine triacetate)+SX、イプフルフェノキン(ipflufenoquin)+SX、オークの葉及び樹皮(leaves and bark of Quercus)+SX、マシン油(mineral oils)+SX、oxine-copper + SX、亜リン酸(phosphorous acid)+SX、炭酸水素カリウム(potassium hydrogencarbonate)+SX、亜リン酸二水素カリウム(potassium dihydrogenphosphite)+SX、プロパミジン(propamidine)+SX、キラヤ科植物抽出成分(Quillaja extract)+SX、キンコナゾール(quinconazole)+SX、キヌアのサポニン(Saponins of Chenopodium quinoa)+SX、炭酸水素ナトリウム(sodium hydrogencarbonate)+SX、チモール(thymol)+SX、マスタードパウダー(yellow mustard powder)+SX、zinc thiazole + SX、Bacillus amyloliquefaciens F727 + SX、Bacillus subtilis BU1814 + SX、Pseudomonas sp. CAB-02 + SX、methyl ({2-methyl-5-[1-(4-methoxy-2-methylphenyl)-1H-pyrazol-3-yl]phenyl}methyl)carbamate (1605879-98-8) + SX、2-(difluoromethyl)-N-[1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]pyridine-3-carboxamide (1616239-21-4) + SX、2-(difluoromethyl)-N-[3-ethyl-1,1-dimethyl-2,3-dihydro-1H-inden-4-yl]pyridine-3-carboxamide (1847460-02-9) + SX、2-(difluoromethyl)-N-[3-propyl-1,1-dimethyl-2,3-dihydro-1H-inden-4-yl]pyridine-3-carboxamide (1847460-05-2) + SX、(2E,3Z)-5-{[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy}-2-(methoxyimino)-N,3-dimethylpent-3-enamide (1445331-27-0) + SX、Bacillus amyloliquefaciens subsp. plantarum D747 + SX、Pythium oligandrum M1 + SX、Trichoderma asperellum T25 + SX、Trichoderma asperellum TV1 + SX、Trichoderma atroviride IMI 206040 + SX、Trichoderma atroviride T11 + SX、Trichoderma harzianum ITEM908 + SX、Trichoderma harzianum T78 + SX、Pseudomonas chlororaphis strain AFS009 + SX。 Combination of the present component of the above group (b) with the compound of the present invention X:
Acibenzolar S methyl (acibenzolar-S-methyl) + SX, aldimorph + SX, ametoctradin + SX, aminopyrifen + SX, amisulblom + SX, anilazine + SX, Azaconazole (azaconazole) + SX, azoxystrobin (Saxoxystrobin) + SX, basic copper chloride (copper oxychloride) + SX, basic copper sulfate (basic copper sulfate) + SX, benalaxyl (benalaxyl) + SX, benalaxyl M ( benalaxyl-M) + SX, benodanil (senodanil) + SX, benomyl (benomyl) + SX, benthiavalicarb + SX, benibavaliab isopropyl (benthivalicarb-isopropyl) + SX, benzobin diflupyr (benzovidiflupyrr) ) + SX, binapacryl (SB) + SX, biphenyl (SB) + SX, Bitteranol + SX, Bixafen + SX, Blasticidin S (blasticidi) nS) + SX, boscalid + SX, bromuconazole + SX, bupirimate + SX, captafol + SX, captan + SX, carbendazim + SX, carboxin + SX, carpropamide (carpropamid) + SX, chinomethionate (chinomethionat) + SX, chloroneb (chloroneb) + SX, chlorothalonil + SX, clozolinate (Slo) + SX, choretochlorin B (colletochlorin B ) + SX, copper (II) hydroxide (copper (II) hydroxide) + SX, coumoxystrobin + SX, cyazofamid (cyazofamid) + SX, cyflufenamide (cyflufenamid) + SX, shimoxanil (cymoxanil) + SX Cyproconazole (cyproconazole) + SX, cyprodinil + SX, dichlobentiazox + SX, dichlofluanid + SX, dich Diclocymet + SX, diclomezine + SX, dichloran (Dicloran) + SX, dietofencarb (dithofencarb) + SX, difenoconazole + SX, diflumetorim + SX, dimethaclone (Sic) (Dimethirimol) + SX, dimethomorph + SX, dimoxystrobin + SX, diniconazole + SX, diniconazole M (diniconazole-M) + SX, dinopup (dinocap) + SX, dipymetitrone (dipymetitrone) ) + SX, dithianone (dithianon) + SX, dodecylbenzenesulfonic acid bis (ethylenediamine) copper (II) complex salt (dodecylbenzenesulfonic acid bisethylenediamine copper (II) salt) + SX, dodemorph (dodemorph) + SX, dodine (dodine) + SX, edifenphos (Edifenphos) + SX, enoxastrobin (enoxastrobin) + SX, epoxyconazole epoxiconazole) + SX, Etaconazole (Setaconazole) + SX, Ethaboxam (Ethaboxam) + SX, Ethyrimol (Ethirimol) + SX, Etridiazole + SX, Famoxadone (Famoxadone) + SX, Fenamidone (Senamide) + SX, Fenaminst Robin (fenaminstrobin) + SX, fenarimol (fenarimol) + SX, fenbuconazole (fenbuconazole) + SX, fenfuram (fenfuram) + SX, fenhexamid (fenhexamid) + SX, phenoxanyl (fenoxalin) + SX, fenpiclonil (fenpiclonil) + SX, fenpicoxamide + SX, fenpropidin + SX, fenpropimorph + SX, fenpyrazamine + SX, triphenyltin acetate + SX, chloride Triphenyltin (fentin chloride) + SX, triphenyltin hydroxide (fentin hydroxide) + SX, felbam (ferbam) + SX, Rimzone (ferimzone) + SX, fluazinam (SX), fludioxonil + SX, flufenoxystrobin + SX, fluindapyr + SX, flumorph + SX, fluopicolide + SX, fluoroimide + SX, fluoxastrobin + SX, fluquinconazole + SX, flusilazole + SX, flusulfamide + SX, flutianil + SX, flutolanil (Flutolanil) + SX, flutriafol + SX, fluxapyroxad (fluxapyroxad) + SX, folpet + SX, fosetyl + SX, fuberidazole + SX, furalaxyl + SX, furametpyr (Furametpyr) + SX, Guazatine (guazatine) + SX, hexaconazole (hexaconazole) + SX, Hymexazole + SX, Imazalil + SX, Imibenconazole + IX, Iminoctadine + SX, Iodocarb + SX, Ipconazole + SX, Ipfentrifluconazole (ipfentrifluconazole) ) + SX, Iprobenfos + SX, Iprodione (Iprodione) + SX, Iprovalicarb + SX, isofetamide + SX, isoflucypram + SX, isoprothiolane + SX, isopiroza ( isopyrazam) + SX, isotianil (isotianil) + SX, kasugamycin (Kasugamycin) + SX, kresoxim-methyl (kresoxim-methyl) + SX, laminarin + SX, mancozeb (mancozeb) + SX, mandestrobin + SX Mandipropamide + SX, Maneb + SX, Mefentrifl Nazole (mefentrifluconazole) + SX, mepanipyrim (Span), mepronil (mepronil) + SX, mepeptyldinocap + SX, metalaxyl (metalaxyl) + SX, metalaxyl M (metalaxyl-M) + SX, metconazole metconazole) + SX, metasulfocarb (methasulfocarb) + SX, methylam (metiram) + SX, metominostrobin + SX, metrafenone + SX, microbutanil (myclobutanil) + SX, naftifine + SX , Nuarimol (nuarimol) + SX, occhilinone (octhillinone) + SX, ofurace (ofurace) + SX, orysastrobin (orysastrobin) + SX, oxadixyl (Oxadixyl) + SX, oxathiapiprolin (oxathiapiprolin) + SX, oxolinic acid (oxolicic acid) + SX, oxpoconazole (oxpoconazole) + SX, oxpoconazole fumarate (oxpoconazole fumarate) + SX, oki Carboxin (oxycarboxin) + SX, oxytetracycline (SX), pefurazoate (Pefurozoate) + SX, penconazole (Penconazole) + SX, pencicuron (pencycuron) + SX, penflufen (Penflufen) + SX, penthiopyrad (penthiopyrad) + SX , Phenamacril + SX, phthalide + sX, picarbutrazox + sX, picoxystrobin + SX, piperaline (piperalin) + SX, polyoxins + polyoxins + SX, probenazole (Probenazole) + SX, Prochloraz (Prochloraz) + SX, Procymidone (Procymidone) + SX, Propamocarb (propamocarb) + SX, Propiconazole (Proconazole) + SX, Propineb (Propineb) + SX, Proquinazid + SX, Prothiocarb (prothiocarb) + SX, prothioconazole (prothioconazole) + SX, pidiflumethofen (py diflumetofen) + SX, pyraclostrobin + SX, pyrametostrobin + SX, pyraoxystrobin + SX, pyrapropoyne + SX, pyradiflumide + SX, pyrazophos (pyrazophos (pyrazophos (pyrazophos)) ) + SX, pyribencarb + SX, pyributicarb + SX, pyrifennox + SX, pyrimethanil + SX, pyrimorph + pyrene + SX, pyriophenone + SX, pyrisoxazole ( Pyrisoxazole) + SX, Pyroquilon + SX, Quinofumelin + SX, Quinoxyfen (quinoxyfen) + SX, Quintozene + SX, Sedaxane + SX, Silthiofam (Silthiofam) + SX, Simeconazole (Simeconazole) ) + SX, spiroxamine + SX, streptomycin + SX, sulfur sulfur) + SX, tebuconazole (tebuconazole) + SX, tebufloquin (tebufloquin) + SX, teclofthalam + SX, tecnazene + SX, terbinafine + SX, tetraconazole (tetraconazole) + SX, thiabendazole (Thiabendazole) + SX, thifluzamide + SX, thiophanate + SX, thiophanate methyl (thiophanate-methyl) + SX, thiuram (thiram) + SX, tiazinyl (tiadinil) + SX, tolclofos methyl (tolclofos-methyl) + SX, tolfenpyrad (stolfirad) + SX, tolprocarb (tolprocarb) + SX, tolyl fluanid (tolylfluanid) + SX, triadimefon (sX) + SX, triadimenol (triadimenol) + SX, triazoxide (triazole) + SX, triclomeリ カ ル リ カ ル ((triclopyricarb) + SX, tricyclazole (tricyclazole) + SX, tridemorph (tridemorph) + S X, trifloxystrobin + SX, triflumizole + SX, triforine + SX, triticonazole + SX, validamycin + SX, varifenalate + SX, vinclozolin + SX, zineb (Zineb) + SX, ziram (Ziram) + SX, zoxamide + SX, 3- (difluoromethyl) -N-methoxy-1-methyl-N- [( 1R) -1-Methyl-2- (2,4,6-trichlorophenyl) ethyl] pyrazole-4-carboxamide (1639015-48-7) + SX, 3- (difluoromethyl) -N-methoxy-1-methyl -N-[(1S) -1-Methyl-2- (2,4,6-trichlorophenyl) ethyl] pyrazole-4-carboxamide (1639015-49-8) + SX, 3- (difluoromethyl) -1- Methyl-N- 1,1,3-trimethylindan-4-yl) pyrazole-4-carboxamide (141573-94-6) + SX, 3- (difluoromethyl) -1-methyl-N-[(3R) -1,1,4, 3-trimethylindan-4-yl] pyrazole-4-carboxamide (1352994-67-2) + SX, 3- (difluoromethyl) -N-[(3R) -7-fluoro-1,1,3-trimethylindan -4-yl] -1-methylpyrazole-4-carboxamide (1513466-73-3) + SX, 3-chloro-5-phenyl-6-methyl-4- (2,6-difluorophenyl) pyridazine (1358061-) 55-8) + SX, N '-[4-({3-[(4-chlorophenyl) methyl] -1,2,4-thiadiazol-5-yl} oxy) -2,5-dimethylphenyl] -N -Ethyl-N-methylmethaneimidamide (1202781-91-6) + S X, 2- {3- [2- (1-{[3,5-bis (difluoromethyl) -1H-pyrazol-1-yl] acetyl} piperidin-4-yl) -1,3-thiazole-4- [Yl] -4,5-dihydro-1,2-oxazol-5-yl} -3-chlorophenyl = methanesulfonate (1360819-11-9) + SX, 4- (2-bromo-4-fluorophenyl)- N- (2-chloro-6-fluorophenyl) -1,3-dimethyl-1H-pyrazol-5-amine (1362477-7-26) + SX, 2,2-dimethyl-9-fluoro-5- (quinoline) -3-yl) -2,3-dihydrobenzo [f] [1,4] oxazepine (1207749-50-5) + SX, 2- [6- (3-fluoro-4-methoxyphenyl) -5-methyl Pyridin-2-yl] quinazoline (1257056-97-5) + SX, 5-fluoro-2-[(4-methi) Phenyl) methoxy] -4-pyrimidinamine (1174376-25-0) + SX, 5-fluoro-4-imino-3-methyl-1-tosyl-3,4-dihydropyrimidin-2 (1H) -one (1616664) -98-2) + SX, N '-(2,5-dimethyl-4-phenoxyphenyl) -N-ethyl-N-methylmethaneimidamide (1052688-31-9) + SX, N'-{4- [(4,5-Dichlorothiazol-2-yl) oxy] -2,5-dimethylphenyl} -N-ethyl-N-methylmethaneimidamide (929908-57-6) + SX, (2Z) -3- Ethyl amino-2-cyano-3-phenylacrylate (39491-78-6) + SX, N-[(2-chlorothiazol-5-yl) methyl] -N-ethyl-6-methoxy-3-nitropyridine -2-amine (1446247-98-8) + SX, 1- [2-({[1- (4-chlorophenyl) -1] -Pyrazol-3-yl] oxy} methyl) -3-methylphenyl] -4-methyl-5-oxo-4,5-dihydro-1H-tetrazole (1472649-01-6) + SX, α- [3- (4-Chloro-2-fluorophenyl) -5- (2,4-difluorophenyl) -4-isoxazolyl] -3-pyridinemethanol (1229605-96-2) + SX, (αS)-[3- (4 -Chloro-2-fluorophenyl) -5- (2,4-difluorophenyl) -4-isoxazolyl] -3-pyridinemethanol (1229606-46-5) + SX, (αR)-[3- (4-chloro) -2-Fluorophenyl) -5- (2,4-difluorophenyl) -4-isoxazolyl] -3-pyridinemethanol (1229606-02-3) + SX, 2-{[3- (2-chlorophenyl) -2 -(2,4-difluorophenyl) oxirane- -Yl] methyl} -2,4-dihydro-3H-1,2,4-triazole-3-thione (1342260-19-8) + SX, 2-{[(2R, 3S) -3- (2-) Chlorophenyl) -2- (2,4-difluorophenyl) oxirane-2-yl] methyl} -2,4-dihydro-3H-1,2,4-triazole-3-thione (1638897-70-7) + SX , 2-{[(2S, 3R) -3- (2-chlorophenyl) -2- (2,4-difluorophenyl) oxiran-2-yl] methyl} -2,4-dihydro-3H-1,2, 4-triazole-3-thione (1638897-71-8) + SX, 2-{[(2R, 3R) -3- (2-chlorophenyl) -2- (2,4-difluorophenyl) oxirane-2-yl [Methyl] -2,4-dihydro-3H-1,2,4-triazole-3-thione (163889) 7-72-9) + SX, 2-{[(2S, 3S) -3- (2-chlorophenyl) -2- (2,4-difluorophenyl) oxiran-2-yl] methyl} -2,4- Dihydro-3H-1,2,4-triazole-3-thione (1638897-73-0) + SX, 1-{[3- (2-chlorophenyl) -2- (2,4-difluorophenyl) oxirane-2 -Yl] methyl} -1H-1,2,4-triazol-5-yl thiocyanate (1342260-26-7) + SX, 1-{[(2R, 3S) -3- (2-chlorophenyl) -2-] (2,4-Difluorophenyl) oxiran-2-yl] methyl} -1H-1,2,4-triazol-5-yl thiocyanato (1638897-82-1) + SX, 1-{[(2S, 3R) -3- (2-chlorophenyl) -2- (2,4-difluorophenyl) oxirane-2-i [Methyl] -1H-1,2,4-triazol-5-yl thiocyanate (1638897-84-3) + SX, 1-{[(2R, 3R) -3- (2-chlorophenyl) -2- (2) , 4-Difluorophenyl) oxiran-2-yl] methyl} -1H-1,2,4-triazol-5-yl thiocyanato (1638897-86-5) + SX, 1-{[(2S, 3S) -3 -(2-chlorophenyl) -2- (2,4-difluorophenyl) oxiran-2-yl] methyl} -1H-1,2,4-triazol-5-yl thiocyanate (1638897-89-8) + SX, 5- (4-chlorobenzyl) -2-chloromethyl-2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentanol (1394057-11-4) + SX, (1R , 2S, 5S) -5- (4-Chlorobenzyl) -2-chloromethyl -2-Methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentanol (1801930-06-2) + SX, (1S, 2R, 5R) -5- (4-chlorobenzyl) ) -2-Chloromethyl-2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentanol (1801930-07-3) + SX, (1R, 2R, 5R) -5 -(4-Chlorobenzyl) -2-chloromethyl-2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentanol (1801919-53-8) + SX, (1S, (1S, 2S, 5S) -5- (4-Chlorobenzyl) -2-chloromethyl-2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentanol (1801919-54-9) + SX, (1R, 2R, 5S) -5- (4-chlorobenzyl) -2-chloro Ethyl 2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentanol (1801919-55-0) + SX, (1S, 2S, 5R) -5- (4-chloro) Benzyl) -2-chloromethyl-2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentanol (1801919-56-1) + SX, (1R, 2S, 5R)- 5- (4-Chlorobenzyl) -2-chloromethyl-2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentanol (1801919-57-2) + SX, (1S 2,2R, 5S) -5- (4-Chlorobenzyl) -2-chloromethyl-2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentanol (1801919-58-3) ) + SX, methyl = 3-[(4-chlorophenyl) methyl] -2- hydride Xyl-1-methyl-2- (1H-1,2,4-triazol-1-ylmethyl) cyclopentanecarboxylate (1791398-02-1) + SX, methyl = (1R, 2S, 3S) -3- [ (4-chlorophenyl) methyl] -2-hydroxy-1-methyl-2- (1H-1,2,4-triazol-1-ylmethyl) cyclopentanecarboxylate (208074-90-2) + SX, methyl = ( 1S, 2R, 3R) -3-[(4-chlorophenyl) methyl] -2-hydroxy-1-methyl-2- (1H-1,2,4-triazol-1-ylmethyl) cyclopentanecarboxylate (2080743- 91-3) + SX, methyl = (1R, 2R, 3R) -3-[(4-chlorophenyl) methyl] -2-hydroxy-1-methyl-2- (1H-1,2,4-triazole-1 -Ilmethyl) cyclo Pentane carboxylate (2080743-92-4) + SX, methyl = (1S, 2S, 3S) -3-[(4-chlorophenyl) methyl] -2-hydroxy-1-methyl-2- (1H-1,2 , 4-Triazol-1-ylmethyl) cyclopentanecarboxylate (2080743-93-5) + SX, methyl = (1R, 2R, 3S) -3-[(4-chlorophenyl) methyl] -2-hydroxy-1- Methyl-2- (1H-1,2,4-triazol-1-ylmethyl) cyclopentanecarboxylate (2080743-94-6) + SX, methyl = (1S, 2S, 3R) -3-[(4-chlorophenyl) ) Methyl] -2-hydroxy-1-methyl-2- (1H-1,2,4-triazol-1-ylmethyl) cyclopentanecarboxylate (2080743-95-7) + SX, methyl = (1R, 2S, 3R) -3-[( -Chlorophenyl) methyl] -2-hydroxy-1-methyl-2- (1H-1,2,4-triazol-1-ylmethyl) cyclopentanecarboxylate (2081061-22-3) + SX, methyl = (1S, 2R, 3S) -3-[(4-chlorophenyl) methyl] -2-hydroxy-1-methyl-2- (1H-1,2,4-triazol-1-ylmethyl) cyclopentanecarboxylate (2081061-23 4) + SX, 2-chloromethyl-5- (4-fluorobenzyl) -2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentanol (1394057-13-6) + SX, (1R, 2S, 5S) -2-chloromethyl-5- (4-fluorobenzyl) -2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentanol 1801930-08-4 + SX, (1S, 2R, 5R) -2-chloromethyl-5- (4-fluorobenzyl) -2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentanol 1801930-09-5) + SX, (1R, 2R, 5R) -2-chloromethyl-5- (4-fluorobenzyl) -2-methyl-1- (1H-1,2,4-triazole-1-l) (Ilmethyl) cyclopentanol (1638898-08-4) + SX, (1S, 2S, 5S) -2-chloromethyl-5- (4-fluorobenzyl) -2-methyl-1- (1H-1,2,5 4-Triazol-1-ylmethyl) cyclopentanol (1638898-10-8) + SX, (1R, 2R, 5S) -2-chloromethyl-5- (4-fluorobenzyl) -2-methyl-1- ( 1H-1,2,4-triazol-1-ylmethyl) cyclopentano (1638898-13-1) + SX, (1S, 2S, 5R) -2-chloromethyl-5- (4-fluorobenzyl) -2-methyl-1- (1H-1,2,4-triazole) 1-ylmethyl) cyclopentanol (1638898-16-4) + SX, (1R, 2S, 5R) -2-chloromethyl-5- (4-fluorobenzyl) -2-methyl-1- (1H-1, 2,4-Triazol-1-ylmethyl) cyclopentanol (1638898-20-0) + SX, (1S, 2R, 5S) -2-chloromethyl-5- (4-fluorobenzyl) -2-methyl-1 -(1H-1,2,4-triazol-1-ylmethyl) cyclopentanol (1638898-24-4) + SX, (R) -2- [2-chloro-4- (4-chlorophenoxy) phenyl] -1- (1,2,4-triazol-1-yl) pent-3-yn-2-ol (1 801919-59-4) + SX, (R) -2- [4- (4-chlorophenoxy) -2- (trifluoromethyl) phenyl] -1- (1,2,4-triazol-1-yl) Propan-2-ol (1616236-94-2) + SX, (R) -1- [4- (4-chlorophenoxy) -2- (trifluoromethyl) phenyl] -1-cyclopropyl-2- (1) , 2,4-triazol-1-yl) ethanol (1801919-60-7) + SX, (R) -2- [4- (4-chlorophenoxy) -2- (trifluoromethyl) phenyl] -3- Methyl-1- (1,2,4-triazol-1-yl) butan-2-ol (1801919-61-8) + SX, 3- [5- (4-chlorophenyl) -2,3-dimethyl-1 , 2-Oxazolidin-3-yl] pyridine (847749-37-5) + SX, Agrobacterium radiobacter K1026 (Agro) B. bacteria radiobactor K1026) + SX, Agrobacterium radiobacter K 84 strain (Agrobacterium radiobactor K 84) + SX, Bacillus amyloliquefaciens strain AT332 (Bacillus amyloliquefaciens AT 332) + SX, Bacillus amyloliquefaciens strain B3 (Bacillus amyloliquefaciens B3) + SX, Bacillus amyloliquefaciens D747 strain (Bacillus amyloliquefaciens D747) + SX, Bacillus amyloliquefaciens DB 101 strain (Bacillus amyloliquefaciens DB101) + SX, Bacillus amyloliquefaciens DB 102 strain (Bacillus amyloliquefaciens DB 102) + SX, Bacillus amyloliquefaciens GB03 strain (Bacillus amyloliquefaciens GB03) + SX, Bacillus amyloliquefaciens strain FZB24 (Bacillus amyloliquefaciens FZB24) + SX, Bacillus amyloliquefaciens strain FZB42 (Bacillus amyloliquefaciens FZB42) + SX , Bacillus amyloliquefaciens strain IN937a (Bacillus amyloli quefaciens IN 937a) + SX, Bacillus amyloliquefaciens MBI 600 (Bacillus amyloliquefaciens MBI 600) + SX, Bacillus amyloliquefaciens QST 713 (Bacillus amyloliquefaciens QST 713) + SX, Bacillus amyloliquefaciens isolate B 246 (Bacillus amyloliquefaciens isolate B246) + SX, Bacillus licheniformis HB-2 strain (Bacillus licheniformis HB-2) + SX, Bacillus licheniformis strain SB3086 (Bacillus licheniformis SB3086) + SX, Bacillus pumilus AQ 717 strain (Bacillus pumilus AQ717) + SX, Bacillus pumilus BUF-33 strain (Bacillus pumilus BUF-33) + SX, Bacillus pumilus GB 34 strain (Bacillus pumilus GB34) + SX, Bacillus pumilus QST 2808 strain (Bacillus pumilus QST 2808) + SX, Bacillus simplex CGF 2856 strain (Bacillus simplex CGF 2856) + SX, Bacillus subtilis AQ 153 strain (Bacillus subtilis AQ 153) + SX, Bacillus subtilis A Q 743 strain (Bacillus subti) lis AQ743) + SX, Bacillus subtilis D747 strain (Bacillus subtilis D747) + SX, Bacillus subtilis DB 101 strain (Bacillus subtilis DB 101) + SX, Bacillus subtilis FZB24 strain (Bacillus subtilis FZB24) + SX, Bacillus subtilis strain GB03 (Bacillus subtilis GB03) + SX, Bacillus subtilis HAI 0404 strain (Bacillus subtilis HAI 0404) + SX, Bacillus subtilis IAB / BS03 strain (Bacillus subtilis IAB / BS03) + SX, Bacillus subtilis MBI 600 strain (Bacillus subtilis MBI 600) + SX , Bacillus subtilis QST 30002 / AQ 30002 (Bacillus subtilis QST 30002 / AQ 30002) + SX, Bacillus subtilis QST 30004 / AQ 30004 (Bacillus subtilis QST 30004 / AQ 30004) + SX, Bacillus subtilis QST 713 (Bacillus subtilis QST 713) + SX, Bacillus · S. subtilis strain QST 714 (Bacillus subtilis QST 714) + SX, Bacillus subtilis var. Amyloliquefaciens FZB 24 strain (Bacillus subtilis var. Amyloliquefaciens FZB24) + SX, Bacillus subtilis Y 1336 (Bacillus subtilis Y 1336) + SX, Burkholderia cepacia + SX, Burkholderia cepacia-Wisconsin type J 82 (Burkholderia cepacia type Wisconsin J 82) + SX, Burkholderia cepacia · Wisconsin M54 strain (Burkholderia cepacia type Wisconsin M54) + SX, Candida oleophila O strain (Candida oleophila O) + SX, Candida saitoana (Candida saitoana) + SX, Ketomium cupreum (Chaetium cupreum) ) + SX, Clonostachys rosea + SX, Coniosrium minitans CGMCC 83 25 (Coniothyrium minitans CGMCC 8325) + SX, Coniosidium minitans CON / M / 91-8 (Coniothyrium minitans CON / M / 91-8) + SX, cryptococcus albidus (cryptococcus albidus) + SX, Erwinia carotobola subsp. Carotobola CGE 234 M 403 strain (Erwi nia carotovora subsp. carotovora CGE 234 M 403) + SX, Fusarium oxysporum Fo 47 strain (Fusarium oxysporum Fo 47) + SX, Gliocladium catenulatum J 1446 (Gliocladium catenulatum J 1446) + SX, Paenibacillus polymixer AC-1 strain (Paenibacillus AC) -1) + SX, Paenibacillus polymyxa BS-0105 strain (Paenibacillus polymyxa BS-0105) + SX, Pantoea agglomerans E 325 strain (Pantoea agglomerans E 325) + SX, Flebiopsis gigantea VRA 1992 strain (Phlebiopsis gigantea VRA 1992) + SX, Pseudomonas Aureofaciens strain TX-1 (Pseudomonas aureofaciens TX-1) + SX, Pseudomonas chlorolaphys 63-28 (Pseudomonas chlororaphis 63-28) + SX, Pseudomonas chlorolaphis MA 342 (Pseudomonas chlororaphis MA 342) + SX Pseudomonas fluorescens 1629 RS (Pseudomonas fluorescens 1629 RS) + SX, Pseudomonas flu Recessin A506 strain (Pseudomonas fluorescens A506) + SX, Pseudomonas fluorescens CL 145A strain (Pseudomonas fluorescens CL 145A) + SX, Pseudomonas fluorescens G7090 strain (Pseudomonas fluorescens G7090) + SX, Pseudomonas fluorescein strains (Ph. SX, Pseudomonas syringae strain MA-4 (Pseudomonas syringae MA-4) + SX, Pseudozyma flocculosa PF-A22UL strain (Pseudozyma flocculosa PF-A22UL) + SX, Pseudomonas rhodesia HAI-0804 strain (Pseudomonas rhodesiae HAI-0804) + SX, Pythium o ligand Rum DV 74 (Pythium oligondrum DV 74) + SX, Streptomyces griseoviridis K 61 (Streptomyces griseoviridis K 61) + SX, Streptomyces lydicus WYCD 108 US (Streptomyces lydicus WYCD 108 US) + SX, Streptomyces Lilycus WYEC 108 strain (Streptomyces lydicus WYEC 108) + SX, Talalomyce · Flavas SAY-Y-94-01 (Talaromyces flavus SAY-Y-94-01) + SX, Talaromyces flavas V 117b (Talaromyces flavus V 117 b) + SX, Trichoderma asperum ICC 012 (Trichoderma asperellum ICC 012) + SX, Trichoderma asperomem SKT-1 (Trichoderma asperellum SKT-1) + SX, Trichoderma asperomeum T34 (Trichoderma asperellum T34) + SX, Trichoderma atroviride CNCM 1-1237 (Trichoderma atroviride CNCM 1-1237) + SX, Trichoderma・ Atroviride LC52 strain (Trichoderma atroviride LC52) + SX, Trichoderma atroviride SC1 strain (Trichoderma atroviride SC1) + SX, Trichoderma atroviride SKT-1 strain (Trichoderma atroviride SKT-1) + SX, Trichoderma atroviride SIC-1 ICC 080) + SX, Trichoderma harzianum 21 strain (Trichoderma harzianum 21) + SX, Trichoderma harzianum DB 104 strain (Trichoderma harzianum DB 104) + SX, Trichoderma harzianum DSM 14944 (Trichoderma harzianum DSM 14944) + SX, Trichoderma harzianum ESALQ-1303 (Trichoderma harzianum ESALQ-1303) + SX, Trichoderma harzianum ESALQ-1306 strain (Trichoderma harzianum ESXQ 1306) Trichoderma harzianum II HR-Th-2 (Trichoderma harzianum II HR-Th-2) + SX, Trichoderma harzianum kd (Trichoderma harzianum kd) + SX, Trichoderma harzianum MO1 strain (Trichoderma harzianum MO1) + SX, Trichoderma Harsianum SF strain (Trichoderma harzianum SF) + SX, Trichoderma harzianum T22 strain (Trichoderma harzianum T22) + SX, Trichoderma harzianum T39 strain (Trichoderma harzianum T39) + SX, Trichoderma harzianum TH 35 strain (Trichoderma harzianum 35 mg) Trichoderma polysporum IMI206039 (Trichoderma polysporum IMI206039) + SX, Trichoderma str Machikamu (trichoderma stromatumum) + SX, Trichoderma virence G-41 strain (Trichoderma virens G-41) + SX, Trichoderma virence GL-21 strain (Trichoderma virens GL-21) + SX, Trichoderma viride (Trichoderma viride) + SX, Variovorax paradox CGF 4526 strain (Variovorax paradoxus CGF 4526) + SX, Harpin protein (Harpin protein) + SX, Bordeaux solution (Bordeaux mixture) + SX, bromothalonil (bromothalonil) + SX, chitin (chitin) + SX, acetate Copper (II) (copper (II) acetate) + SX, Copper (II) (copper (II) sulfate) + SX, Dipotassium hydrogen phosphite (dipotassium hydrogenphosphate) + SX, Tea tree extract (extract from Melaleuca alternifolia) + SX, extract from Reynoutria sachalinensis + SX, extract from cotyledon of cochlear seedlings ("BLAD") + SX, garlic extract (extract of Allium sativum) ) + SX, horsetail extract (extract of E) quisetum arvense + SX, extract of Tropaeolum majus + SX, florylpicoxamide + SX, fluopimomide + SX, fosetyl-aluminium + SX, iminoctadine acetate (Iminectadine acetate) iminoctadine triacetate + SX, ipflufenoquin + SX, oak leaves and bark of Quercus + SX, machine oils (mineral oils) + SX, oxine-copper + SX, phosphorous acid ( phosphoric acid + SX, potassium hydrogencarbonate + SX, potassium dihydrogenphosphate (potassium dihydrogenphosphate) + SX, propamidine + SX, Quillaja plant extract (Quillaja extract) + SX, quinconazole (quinconazole) + SX, Saponins of Chenopodium quinoa + SX, sodium hydrogencarbonate (soda hydrogencarbonate) + SX, thymol (thymol) + SX, mustard powder (yellow mustard powder) + SX, zinc thiazole + SX, Bacillus amyloliquefaci Ens F727 + SX, Bacillus subtilis BU 1814 + SX, Pseudomonas sp. CAB-02 + SX, methyl ({2-methyl-5- [1- (4-methoxy-2-methylphenyl) -1H-pyrazol-3-yl] phenyl} methyl) carbamate (1605879-98-8) + SX, 2- (difluoromethyl) -N- [1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl] pyridine-3- carboxamide (16162392-1-4) + SX, 2- (difluoromethyl) -N- [3-ethyl-1,1-dimethyl-2,3-dihydro-1H-inden-4-yl] pyridine-3-carboxamide ( 1847460-02-9) + SX, 2- (difluoromethyl) -N- [3-propyl-1,1-dimethyl-2,3-dihydro-1H-inden-4-yl] pyridine-3-carboxamide (1847460- 05-2) + SX, (2E, 3Z) -5-{[1- (4-chlorophenyl) -1H-pyrazol-3-yl] oxy} -2- (methoxyimino) -N, 3-dimethylpent-3- Enabide (1445331-27-0) + SX, Bacillus amyloliquefaciens subsp. plantarum D747 + SX, Pythium oligodrum M1 + SX, Trichoderma asperellum T25 + SX, Trichoderma TVer + SX, Trichoderma atroviride + +, +, +, + Trichoderma harzianum ITEM 908 + SX, Trichoderma harzianum T78 + SX, Pseudomonas chlororaphis strain AFS 009 + SX.
　上記群（ｃ）の本成分と本発明化合物Ｘとの組み合わせ：
　１－メチルシクロプロペン（1-methylcyclopropene）+SX、2,3,5－トリヨード安息香酸（2,3,5-triiodobenzoic acid）+SX、IAA（(1H-indol-3-yl)acetic acid）+SX、IBA（4-(1H-indol-3-yl)butyric acid）+SX、MCPA（2-(4-chloro-2-methylphenoxy)acetic acid）+SX、MCPB（4-(4-chloro-2-methylphenoxy)butyric acid）+SX、4-CPA（4-chlorophenoxyacetic acid）+SX、５－アミノレブリン酸塩酸塩（5-aminolevulinic acid hydrochloride）+SX、６－ベンジルアミノプリン（6-benzylaminopurine）+SX、アブシシン酸（abscisic acid）+SX、AVG（aminoethoxyvinylglycine）+SX、アンシミドール（ancymidol）+SX、ブトルアリン（butralin）+SX、炭酸カルシウム（calcium carbonate）+SX、塩化カルシウム（calcium chloride）+SX、ギ酸カルシウム（calcium formate）+SX、過酸化カルシウム（calcium peroxide）+SX、石灰硫黄（calcium polysulfide）+SX、硫酸カルシウム（calcium sulfate）+SX、クロルメコートクロリド（chlormequat-chloride）+SX、クロロプロファム（chlorpropham）+SX、塩化コリン（choline chloride）+SX、クロプロップ（cloprop）+SX、シアナミド（cyanamide）+SX、シクラニリド（cyclanilide）+SX、ダミノジッド（daminozide）+SX、デカン－１－オール（decan-1-ol）+SX、ジクロプロップ（dichlorprop）+SX、ジケグラック（dikegulac）+SX、ジメチピン（dimethipin）+SX、ジクワット（diquat）+SX、エテホン（ethephon）+SX、エチクロゼート（ethychlozate）+SX、フルメトラリン（flumetralin）+SX、フルルプリミドール（flurprimidol）+SX、ホルクロルフェヌロン（forchlorfenuron）+SX、ジベレリンＡ（Gibberellin A）+SX、ジベレリンＡ３（Gibberellin A3）+SX、イナベンフィド（inabenfide）+SX、カイネチン（Kinetin）+SX、マレイン酸ヒドラジド（maleic hydrazide）+SX、メフルイジド（mefluidide）+SX、メピコートクロリド（mepiquat-chloride）+SX、酸化型グルタチオン（oxidized glutathione）+SX、パクロブトラゾール（pacrobutrazol）+SX、ペンディメタリン（pendimethalin）+SX、プロヘキサジオンカルシウム（prohexandione-calcium）+SX、プロヒドロジャスモン（prohydrojasmon）+SX、ピラフルフェンエチル（pyraflufen-ethyl）+SX、シントフェン（sintofen）+SX、１－ナフタレン酢酸ナトリウム（sodium 1-naphthaleneacetate）+SX、シアン酸ナトリウム（sodium cyanate）+SX、ストレプトマイシン（streptmycin）+SX、チジアズロン（thidiazuron）+SX、トリアペンテノール（triapenthenol）+SX、トリブホス（Tribufos）+SX、トリネキサパックエチル（trinexapac-ethyl）+SX、ウニコナゾールP（uniconazole-P）+SX、２－（ナフタレン－１－イル）アセトアミド（2-(naphthalen-1-yl)acetamide）+SX、［４－オキソ－４－（２－フェニルエチル）アミノ］酪酸+SX、５－（トリフルオロメチル）ベンゾ［b］チオフェン－２－カルボン酸メチル+SX、３－［（６－クロロ－４－フェニルキナゾリン－２－イル）アミノ］－１－プロパノール+SX、グロマス・イントララディセス（Glomus intraradices）+SX、グロマス・モッセ（Glomus mosseae）+SX、グロマス・アグリゲイツム（Glomus aggregatum）+SX、グロマス・エツニカツム（Glomus etunicatum）+SX、ブラディリゾビウム・エルカニ（Bradyrhizobium elkani）+SX、ブラディリゾビウム・ジャポニカム（Bradyrhizobium japonicum）+SX、ブラディリゾビウム・ルピニ（Bradyrhizobium lupini）+SX、リゾビウム・レグミノサルム bv. トリホリ（Rhizobium leguminosarum bv. trifolii）+SX、リゾビウム・レグミノサルム bv. ファゼオリ（Rhizobium leguminosarum bv. phaseoli）+SX、リゾビウム・レグミノサルム bv.ビシアエ（Rhizobium leguminosarum bv. viciae）+SX、シノリゾビウム・メリロチ（Sinorhizobium meliloti）+SX、リゾビウム・フレディ（Rhizobium fredii）+SX、リゾビウム・ロチ（Rhizobium loti）+SX、リゾビウム・トリホリ（Rhizobium trifolii）+SX、リゾビウム・トロピシ（Rhizobium tropici）+SX、ホルモノネチン(formononetin)+SX、1,3-diphenylurea + SX、lipochitooligosaccharide SP104 +SX、Azorhizobium caulinodans + SX、Azospirillum amazonense + SX、Azospirillum brasilense XOH + SX、Azospirillum brasilense Ab-V5 + SX、Azospirillum brasilense Ab-V6 + SX、Azospirillum caulinodans + SX、Azospirillum halopraeferens + SX、Azospirillum irakense + SX、Azospirillum lipoferum + SX、Bradyrhizobium elkanii SEMIA 587 + SX、Bradyrhizobium elkanii SEMIA 5019 + SX、Bradyrhizobium japonicum TA-11 + SX、Bradyrhizobium japonicum USDA 110 + SX、Bradyrhizobium liaoningense + SX、Claroideoglomus claroideum + SX、Delftia acidovorans RAY209 + SX、Gigaspora margarita + SX、Gigaspora rosea + SX、Glomus deserticola + SX、Glomus monosporum + SX、Mesorhizobium ciceri + SX、Mesorhizobium huakii + SX、Rhizophagus clarus + SX、Rhizobium etli + SX、Rhizobium galegae + SX、Rhizophagus irregularis DAOM 197198 + SX、Paraglomus brasillianum + SX、Zucchini Yellow Mosaik Virus weak strain + SX。 Combination of the present component of the above group (c) with the compound of the present invention X:
1-methylcyclopropene (1-methylcyclopropene) + SX, 2,3,5-triiodobenzoic acid (2,3,5-triiodobenzoic acid) + SX, IAA ((1H-indol-3-yl) acetic acid) + SX, IBA (4- (1H-indol-3-yl) butyric acid) + SX, MCPA (2- (4-chloro-2-methylphenoxy) acetic acid) + SX, MCPB (4- (4-chloro-2) -Methylphenoxy) butyric acid) + SX, 4-CPA (4-chlorophenoxyacetic acid) + SX, 5-aminolevulinic acid hydrochloride (S-amino acid) + SX, 6-benzylaminopurine (6-benzylaminopurine) + SX, Abscisic acid (abscisic acid) + SX, AVG (aminoethoxyvinylglycine) + SX, ancimidol (ancymidol) + SX, butoralin (butralin) + SX, calcium carbonate (calcium carbonate) + SX, calcium chloride (calcium chloride) + SX, Calcium formate + SX, calcium peroxide + SX, calcium polysulfide + SX, calcium sulfate + SX, chlormeco Tochloride (chlormequat-chloride) + SX, chlorpropham (SX), choline chloride + SX, cloprop + SX, cyanamide (cyanamide) + SX, cyclanilide (SX), daminozide (Daminozide) + SX, decan-1-ol (decan-1-ol) + SX, dicloprop (dichlorprop) + SX, dikegulac (dikegulac) + SX, dimethypin (dimethipin) + SX, diquat + SX, Ethephon + SX, ethychlozate + SX, flumetralin + SX, flurprimidol + SX, forchlorfenuron + SX, gibberellin A (Gibberellin A) + SX, gibberellin A3 (Gibberellin A3) + SX, inabenfide (inabenfide) + SX, kinetin (Kinetin) + SX, maleic acid hydrazide (maleic hydrazide) + SX, mefluidide + SX, mepico Tochloride (mepiquat-chloride) + SX, oxidized glutathione (oxidized glutathione) + SX, paclobutrazol (pacrobutrazol) + SX, pendimethalin (pendimethalin) + SX, prohexadione calcium (prohexandione-calcium) + SX, Prohydrojasmon + SX, pyraflufen-ethyl + SX, sintofen + SX, sodium 1-naphthaleneacetate + SX, sodium cyanate + SX, streptomycin + SX, thidiazuron + SX, triapenthenol + SX, tribufos (Tribufos) + SX, trinexapac-ethyl + SX, uniconazole P (uniconazole-P) ) + SX, 2- (naphthalen-1-yl) acetamide (2- (naphthalen-1-yl) acetamide) + SX, [4-oxo-4- (2-phenyl ether) (Tyl) amino] butyric acid + SX, methyl 5- (trifluoromethyl) benzo [b] thiophene-2-carboxylate + SX, 3-[(6-chloro-4-phenylquinazolin-2-yl) amino] -1 -Propanol + SX, Glomus intraradices + SX, Glomas mossee + SX, Glomas aggregatum (Glomus aggregatum) + SX, Glomas etunicatum + SX, Brady Rhizobi Umm · el crab (Bradyrhizobium elkani) + SX, Brady rhizobium japonicum (Bradyrhizobium japonicum) + SX, Brady rhizobium lupini (Bradyrhizobium lupini) + SX, Rhizobium legminosarum bv. + SX, Rhizobium leguminosalum bv. Phazeo (Rhizobium leguminosarum bv. Phaseoli) + SX, Rhizobium leguminosalum bv. Bischie (Rhizobium leguminosarum bv. viciae) + SX, Sinorhizobium meliloti (Sinorhizobium meliloti) + SX, Rhizobium fredii (Rhizobium fredii) + SX, Rhizobium loti (Rhizobium loti) + SX, Rhizobium trifolium + SX, Rhizobium tropici + SX, Hormononetin (formononetin) + SX, 1,3-diphenylurea + SX, lipochitooligosaccharide SP104 + SX, Azorhizobium caulinodans + SX, Azospirillum amazonense + SX, Azospirillum brasilexexil + SX brasilense Ab-V5 + SX, Azospirillum brasilense Ab-V6 + SX, Azospirillum caulinodans + SX, Azospirillum halopraeferens + SX, Azospirillum irakense + SX, Azospirillum lipoferumium + + ii ii japonicum TA-11 + SX, Bradyrhizobium japonicum USDA 110 + SX, Bradyrhizobium lionaingense + SX, Claroideoglomus claroideum + SX, Delftia acido vorans RAY209 + SX, Gigaspora margarita + SX, Gigaspora rosea + SX, Glomus deserticola + SX, Glomus monosporum + SX, Mesorhizobium ciceri + SX, Mesorhizobium huakii + SX, Rhizophagus clarus + Silrium Rhizophagus irregularis DAOM 197198 + SX, Paraglomus brasillianum + SX, Zucchini Yellow Mosaik Virus weak strain + SX.
　上記群（ｄ）の本成分と本発明化合物Ｘとの組み合わせ：
　アリドクロール（allidochlor）+SX、ベノキサコール（benoxacor）+SX、クロキントセット（cloquintocet）+SX、クロキントセットメキシル（cloquintocet-mexyl）+SX、シオメトリニル（cyometrinil）+SX、シプロスルファミド（cyprosulfamide）+SX、ジクロルミド（dichlormid）+SX、ジシクロノン（dicyclonone）+SX、ジメピペラート（dimepiperate）+SX、ジスルホトン（disulfoton）+SX、ダイムロン（dymron）+SX、フェンクロラゾール（fenchlorazole）+SX、フェンクロラゾールエチル（fenchlorazole-ethyl）+SX、フェンクロリム（fenclorim）+SX、フルラゾール（flurazole）+SX、フリラゾール（furilazole）+SX、フルキソフェニム（fluxofenim）+SX、ヘキシム（Hexim）+SX、イソキサジフェン（isoxadifen）+SX、イソキサジフェンエチル（isoxadifen-ethyl）+SX、メコプロップ（mecoprop）+SX、メフェンピル（mefenpyr）+SX、メフェンピルエチル（mefenpyr-ethyl）+SX、メフェンピルジエチル（mefenpyr-diethyl）+SX、メフェナート（mephenate）+SX、メトカミフェン（metcamifen）+SX、オキサベトリニル（oxabetrinil）+SX、１，８－ナフタル酸無水物（1,8-naphthalic anhydride）+SX、１，８－オクタメチレンジアミン（1,8-octamethylene diamine）+SX、AD-67（4-(dichloroacetyl)-1-oxa-4-azaspiro [4.5] decane）+SX、CL-304415 (4-carboxy-3,4-dihydro-2H-1-benzopyran-4-acetic acid)+SX、CSB（1-bromo-4-[(chloromethyl)sulfonyl]benzene）+SX、DKA-24（2,2-dichloro-N-[2-oxo-2-(2-propenylamino)ethyl]-N-(2-propenyl)acetamide）+SX、MG191（2-(dichloromethyl)-2-methyl-1,3-dioxolane）+SX、MG-838（2-propenyl 1-oxa-4-azaspiro[4.5]decane-4-carbodithioate）+SX、PPG-1292（2,2-dichloro-N-(1,3-dioxan-2-ylmethyl)-N-(2-propenyl)acetamide）+SX、R-28725（3-(dichloroacetyl)-2,2-dimethyl-1,3-oxazolidine）+SX、R-29148（3-(dichloroacetyl)-2,2,5-trimethyl-1,3-oxazolidine）+SX、TI-35（1-(dichloroacetyl)azepane）+SX。 Combination of the present component of the above group (d) with the compound of the present invention X:
Aridochlor (allidochlor) + SX, benoxacor (benoxacor) + SX, cloquintoset (cloquintocet) + SX, cloquintocet mexyl (cloquintocet-mexyl) + SX, ciometrinil (cyometrinil) + SX, cyprosulfamide (cyprosulfamide) + SX, dichlormid (Diclormid) + SX, dicyclonone (Dicyclonone) + SX, dimepiperate (dimepiperate) + SX, disulfoton (disulfoton) + SX, dimron (dymron) + SX, fenchlorazole (Sintra) + SX, fenchlorazole Ethyl (fenchlorazole-ethyl) + SX, fenclorim (fenclorim) + SX, flurazole (flurazole) + SX, furilazole (furilazole) + SX, fluxophenim (fluxofenim) + SX, hexim (Hexim) + SX, isoxadifen (isoxadifen) + SX , Isoxadiphen-ethyl (isoxadifen-ethyl) + SX, mecoprop (mecoprop) + SX, mefenpyr (mefenpyr) + SX, mef Empirethyl (mefenpyr-ethyl) + SX, Mefenpyr-diethyl (Sef), Mephenate (mephenate) + SX, Metocamifen + SX, Oxabetrinil + SX, 1, 8 Naphthalic anhydride (1,8-naphthalic anhydride) + SX, 1,8-octamethylenediamine + SX, AD-67 (4- (dichloroacetyl) -1-oxa-4-azaspiro [4.5] decane ) + SX, CL-304415 (4-carboxy-3,4-dihydro-2H-1-benzopyran-4-acetic acid) + SX, CSB (1-bromo-4-[(chloromethyl) sulfonyl] benzene) + SX DKA-24 (2,2-dichloro-N- [2-oxo-2- (2-propenylamino) ethyl] -N- (2-propenyl) acetamide) + SX, MG 191 (2- (dichloromethyl) -2-) methyl-1,3-dioxolane) + SX, MG-838 (2-propenyl 1-oxa-4-azaspiro [4.5] decane-4-carbodithioate) + SX, PPG-1292 (2,2-dichloro-N- ( 1,3-dioxan-2-ylmethyl) -N- (2-propenyl) acetamide) + SX, R-28725 (3- (dichloroacetyl) -2,2-dimethyl-1,3-oxazolidine) + SX, R- 29148 (3- (dichloroacetyl) -2,2,5-trimethyl-1,3-oxazo lidine) + SX, TI-35 (1- (dichloroacetyl) azepane) + SX.
　上記群（ｅ）の本成分と本発明化合物Ｘとの組み合わせ：
　１－ドデシル-１Ｈ－イミダゾール（1-dodecyl-1H-imidazole）+SX、Ｎ－（２－エチルへキシル）－８，９，１０－トリノルボルン－５－エン－２，３－ジカルボキシイミド（N-(2-ethylhexyl)-8,9,10-trinorborn-5-ene-2,3-dicarboximide）+SX、ブカルポレート（bucarpolate）+SX、Ｎ,Ｎ－ジブチル－４－クロロベンゼンスルホンアミド（N,N-dibutyl-4-chlorobenzenesulfonamide）+SX、ジエトレート（dietholate）+SX、ジエチルマレエート（diethylmaleate）+SX、ピペロニルブトキシド（piperonyl butoxide）+SX、ピペロニルシクロネン（piperonyl cyclonene）+SX、ピプロタル（piprotal）+SX、プロピルイソム（propyl isome）+SX、サフロキサン（safroxan）+SX、セサメックス（sesamex）+SX、セサモリン（sesamolin）+SX、スルホキシド（sulfoxide）+SX、ベルブチン（Verbutin）+SX、DMC（1,1-bis(4-chlorophenyl)ethanol）+SX、FDMC（1,1-bis(4-chlorophenyl)-2,2,2-trifluoroethanol）+SX、ETN（1,2-epoxy-1,2,3,4-tetrahydronaphthalene）+SX、ETP（1,1,1-trichloro-2,3-expoxypropane）+SX、PSCP（phenylsaligenin cyclic phosphate）+SX、TBPT（S,S,S-tributyl phosphorotrithioate）+SX、TPP（triphenyl phosphate）+SX。 Combinations of the present component of the above group (e) with the compound of the present invention X:
1-dodecyl-1H-imidazole (1-dodecyl-1H-imidazole) + SX, N- (2-ethylhexyl) -8,9,10-trinolborn-5-ene-2,3-dicarboximide (N -(2-ethylhexyl) -8,9,10-trinorborn-5-ene-2,3-dicarboximide + SX, bucarpolate + SX, N, N-dibutyl-4-chlorobenzenesulfonamide (N, N -dibutyl-4-chlorobenzenesulfonate) + SX, dietholate + SX, diethylmaleate (diethylmaleate) + SX, piperonyl butoxide + SX, piperonyl cycloclone + SX, piprotal + SX, propyl isome + SX, safroxan + SX, sesamex + SX, sesamolin + SX, sulfoxide (sulfoxide) + SX, verbutin + SX, DMC (1,1 1-bis (4-chlorophenyl) ethanol) + SX, FDMC (1,1-bis (4-c) chlorophenyl) -2,2,2-trifluoroethanol) + SX, ETN (1,2-epoxy-1,2,3,4-tetrahydronaphthalene) + SX, ETP (1,1,1-trichloro-2,3-expoxypropane) ) + SX, PSCP (phenylsaligenin cyclic phosphate) + SX, TBPT (S, S, S, S-tributy phosphorothioate) + SX, TPP (triphenyl phosphate) + SX.
　上記群（ｆ）の本成分と本発明化合物Ｘとの組み合わせ：
　アントラキノン（anthraquinone）+SX、クロラロース（chloralose）+SX、アクレップ（acrep）+SX、ブトピロノキシル（butopyronoxyl）+SX、カンファー（camphor）+SX、ｄ－カンファー（d-camphor）+SX、カルボキシド（carboxide）+SX、フタル酸ジブチル（dibutyl phthalate）+SX、ディート（deet）+SX、ジメチルカーバート（dimethyl carbate）+SX、フタル酸ジメチル（dimethyl phthalate）+SX、こはく酸ジブチル（dibutyl succinate）+SX、アジピン酸ジブチル（dibutyl adipate）+SX、エトヘキサジオール（ethohexadiol）+SX、ヘキサミド（hexamide）+SX、イカリジン（icaridin）+SX、メトキン－ブチル（methoquin-butyl）+SX、メチルネオデカナミド（methylneodecanamide）+SX、２－（オクチルチオ）エタノール（2-(octylthio)ethanol）+SX、ブトキシポリプロピレングリコール（butoxypolypropylene glycol)+SX、オキサメート（oxamate）+SX、quwenzhi+SX、quyingding+SX、zengxiaon+SX、レベミド（rebemide）+SX、ナフテン酸銅（copper naphthenate）+SX、ナフテン酸亜鉛（zinc naphthenate）+SX。 Combination of the present component of the above group (f) with the compound of the present invention X:
Anthraquinone (anthraquinone) + SX, chloralose + SX, acrep (acrep) + SX, butopyronoxyl (butopyronoxyl) + SX, camphor (camphor) + SX, d-camphor (d-camphor) + SX, carboxide (carboxide) ) + SX, dibutyl phthalate + SX, deet + SX, dimethyl carbamate + SX, dimethyl phthalate + SX, dibutyl succinate + SX , Dibutyl adipate + SX, ethohexadiol + SX, hexamidide + SX, icaridin (icaridin) + SX, methoquin-butyl (methoquin-butyl) + SX, methyl neodecanamide (Methylneodecanamide) + SX, 2- (Octylthio) ethanol + SX, butoxypolypropylene glycol + SX, oxamate (oxamat) e) + SX, quwenzhi + SX, quyingding + SX, zengxiaon + SX, rebemide + SX, copper naphthenate + SX, zinc naphthenate + zinc SX.
　上記群（ｇ）の本成分と本発明化合物Ｘとの組み合わせ：
　ビス（トリブチルチン）オキシド（bis(tributyltin) oxide）+SX、アリシン（allicin）+SX、ブロモアセトアミド（bromoacetamide）+SX、クロエトカルブ（cloethocarb）+SX、硫酸銅（copper sulfate）+SX、フェンチン（fentin）+SX、リン酸鉄（III）（ferric phosphate）+SX、メタアルデヒド（metaldehyde）+SX、ニクロスアミド（niclosamide）+SX、ペンタクロロフェノール（pentachlorophenol）+SX、ナトリウムペンタクロロフェノキシド（sodium pentachlorophenoxide）+SX、タジムカルブ（tazimcarb）+SX、トラロピリル（tralopyril）+SX、トリフェンモルフ（trifenmorph）+SX。 Combinations of this component of the above group (g) with the compound of the present invention X:
Bis (tributyltin) oxide (bis (tributyltin) oxide) + SX, allicin (allicin) + SX, bromoacetamide (bromoacetamide) + SX, cloetocarb (s) + SX, copper sulfate (copper sulfate) + SX, phentin (fentin) ) + SX, ferric phosphate (ferric phosphate) + SX, metadehyde (metaldehyde) + SX, niclosamide (Niclosamide) + SX, pentachlorophenol + SX, sodium pentachlorophenoxide (sodium) SX, tazimcarb + SX, tralopyril + SX, trifenmorph + SX.
　上記群（ｈ）の本成分と本発明化合物Ｘとの組み合わせ：
　(E)-2-hexenal+SX、(E)-2-octadecenal+SX、(E)-4-tridecen-1-yl acetate+SX、(E)-5-decen-1-yl acetate+SX、(E)-5-decen-1-ol+SX、(E)-3,3-dimethylcyclohexylideneacetaldehyde+SX、(E)-7-dodecen-1-yl acetate+SX、(E)-8-dodecen-1-yl acetate+SX、(E)-9-dodecen-1-yl acetate+SX、(E)-10-hexadecenal+SX、(E)-11-hexadecen-1-yl acetate+SX、(E)-11-tetradecen-1-yl acetate+SX、(E)-11-tetradecen-1-ol+SX、(E)-4-tridecen-1-yl acetate+SX、(E)-6-methylhept-2-en-4-ol+SX、(Z)-2-(3,3-dimethylcyclohexylidene)ethanol+SX、(Z)-4-decen-1-yl acetate+SX、(Z)-4-tridecen-1-yl acetate+SX、(Z)-5-decen-1-yl acetate+SX、(Z)-5-decen-1-ol+SX、(Z)-7-tetradecenal+SX、(Z)-7-dodecen-1-yl acetate+SX、(Z)-8-dodecen-1-yl acetate+SX、(Z)-9-dodecen-1-yl acetate+SX、(Z)-8-dodecen-1-ol+SX、(Z)-9-hexadecenal+SX、(Z)-10-hexadecen-1-yl acetate+SX、(Z)-11-hexadecen-1-ol+SX、(Z)-11-hexadecenal+SX、(Z)-11-hexadecen-1-yl acetate+SX、(Z)-11-octadecenal+SX、(Z)-13-octadecenal+SX、(Z)-hexadec-13-en-11-yn-1-yl acetate+SX、(Z)-13-octadecenal+SX、(Z)-icos-13-en-10-one+SX、(Z)-7-tetradecenal+SX、(Z)-tetradec-9-en-1-ol+SX、(Z)-9-tetradecen-1-yl acetate+SX、(Z)-11-tetradecen-1-yl acetate+SX、(Z)-13-icosen-10-one+SX、(Z,E)-7,11-hexadecadien-1-yl acetate+SX、(Z,E)-9,12-tetradecadien-1-yl acetate+SX、(E,Z)-4,10-tetradecadien-1-yl acetate+SX、(E,E)-8,10-dodecadien-1-ol+SX、(E,E)-10,12-hexadecadienal+SX、(E,E)-9,11-tetradecadien-1-yl acetate+SX、(E,Z)-2,13-octadecadien-1-ol+SX、(E,Z)-3,13-octadecadien-1-ol+SX、(E,Z)-2,13-octadecadien-1-yl acetate+SX、(E,Z)-3,13-octadecadien-1-yl acetate+SX、(E,Z)-7,9-dodecadien-1-yl acetate+SX、(E,E)-7,9-dodecadien-1-yl acetate+SX、(Z,E)-9,12-tetradecadien-1-yl acetate+SX、(Z,E)-9,11-tetradecadien-1-yl acetate+SX、(Z,E)-7,11-hexadecadien-1-yl acetate+SX、(Z,Z)-3,13-octadecadien-1-ol+SX、(Z,Z)-4,7-decadien-1-yl acetate+SX、(Z,Z)-3,13-octadecadien-1-yl acetate+SX、(Z,Z)-7,11-hexadecadien-1-yl acetate+SX、(Z,Z,E)-7,11,13-hexadecatrienal+SX、(5R)-5-[(1Z)-1-decen-1-yl]dihydro-2(3H)-furanone+SX、(2R,5R)-ethyl-1,6-dioxaspiro[4,4]nonane+SX、(2R,5S)-ethyl-1,6-dioxaspiro[4,4]nonane+SX、(4R,8R)-4,8-dimethyldecanal+SX、(4R,8S)-4,8-dimethyldecanal+SX、2,4-dimethyl-5-ethyl-6,8-dioxabicyclo[3,2,1]octane+SX、(-)-4-methyl-3-heptanol+SX、1,7-dioxaspiro[5,5]undecane+SX、3-carene+SX、3-methylcyclohex-2-en-1-one+SX、14-methyloctadec-1-ene+SX、4-methylnonan-5-ol+SX、4-methylnonan-5-one+SX、4-(3-oxobutyl)phenyl acetate+SX、dodecyl acetate+SX、dodeca-8,10-dien-1-yl acetate+SX、ethyl (2E,4Z)-decadienoate+SX、ethyl 4-methyloctanoate+SX、methyl 2,6,10-trimethyldodecanoate+SX、tetradecan-1-ol+SX、tetradec-11-en-1-ol+SX、tetradec-11-en-1-yl acetate+SX、tridec-4-en-1-yl acetate+SX、(3S,6R)-3-methyl-6-isopropenyl-9-decen-1-yl acetate+SX、(3S,6S)-3-methyl-6-isopropenyl-9-decen-1-yl acetate+SX、アルファ－マルチストリアチン（alpha-multistriatin）+SX、アルファ－ピネン（alpha-pinene）+SX、エンド－ブレビコミン（endo-brevicomin）+SX、エキソ－ブレビコミン（exo-brevicomin）+SX、カンフェン（camphene）+SX、コドレルア（codlelure）+SX、コドレモン（codlemone）+SX、キュウルア（cuelure）+SX、ディスパールア（disparlure）+SX、ドミニカルア（dominicalure）+SX、オイゲノール（eugenol）+SX、ファルネソール（farnesol）+SX、フェロルア（ferrolure）+SX、フロンタリン（frontalin）+SX、ゴシップルア（gossyplure）+SX、グランドルア（grandlure）+SX、グランドルアI（grandlure I）+SX、グランドルアII（grandlure II）+SX、グランドルアIII（grandlure III）+SX、グランドルアIV（grandlure IV）+SX、ヘキサルア（hexalure）+SX、イプスジエノール（ipsdienol）+SX、イプセノール（ipsenol）+SX、ジャポニルア（japonilure）+SX、リネアチン（lineatin）+SX、リトルア（litlue）+SX、ループルア（looplure）+SX、メドルア（medlure）+SX、メガトモ酸（megatomoic acid）+SX、メチルオイゲノール（methyl eugenol）+SX、ムスカルア（muscalure）+SX、ネロリドール（nerolidol）+SX、オルフラルア（orfralure）+SX、オリクタルア（oryctalure）+SX、オストラモン（ostramone）+SX、リンコルア（rhyncolure)+SX、シグルア(siglure)+SX、ソルジジン（sordidin）+SX、スルカトール（sulcatol）+SX、トリメドルア（trimedlure）+SX、トリメドルアＡ（trimedlure A）+SX、トリメドルアＢ1（trimedlure B1）+SX、トリメドルアＢ2（trimedlure B2）+SX、トリメドルアＣ（trimedlure C）+SX、トランク－コール（trunc-call）+SX、（E）－バーベノール（(E)-verbenol）+SX、（Z）－バーベノール（(Z)-verbenol）+SX、トランス－バーベノール（trans-verbenol）+SX、S－バーベノン（(S)-verbenone）+SX。 Combinations of the present component of the above group (h) with the compound of the present invention X:
(E) -2-hexenal + SX, (E) -2-octadecenal + SX, (E) -4-tridecen-1-yl acetate + SX, (E) -5-decen-1-yl acetate + SX, (E) -5-decen-1-ol + SX, (E) -3,3-dimethylcyclohexylideneacetaldehyde + SX, (E) -7-dodecen-1-yl acetate + SX, (E) -8-dodecen-1 -yl acetate + SX, (E) -9-dodecen-1-yl acetate + SX, (E) -10-hexadecenal + SX, (E) -11-hexadecen-1-yl acetate + SX, (E)- 11-tetradecen-1-yl acetate + SX, (E) -11-tetradecen-1-ol + SX, (E) -4-tridecen-1-yl acetate + SX, (E) -6-methylhept-2-ene en-4-ol + SX, (Z) -2- (3,3-dimethylcyclohexylidene) ethanol + SX, (Z) -4-decen-1-yl acetate + SX, (Z) -4-tridecen-1- yl acetate + SX, (Z) -5-decen-1-yl acetate + SX, (Z) -5-decen-1-ol + SX, (Z) -7-tetradecenal + SX, (Z) -7- dodecen-1-yl acetate + SX, (Z) -8-dodecen-1-yl acetate + SX, (Z) -9-dodecen-1-yl acetate + SX, (Z) -8-dodecen-1-ol + SX, (Z) -9-hexadecenal + SX, (Z) -10-hexadecen-1-yl acetate + SX, (Z) -11-hexadecen-1-ol + SX, (Z) -11-hexadecenal + SX, (Z) -11-hexadecen-1-yl acetate + SX, (Z) -11-octadecenal + SX, (Z) -13-octadecenal + SX, (Z) -hexadec-13-en-11-yn -1-yl acetate + SX (Z) -13-octadecenal + SX, (Z) -icos-13-en-10-one + SX, (Z) -7-tetradecenal + SX, (Z) -tetradec-9-en-1-ol + SX, (Z) -9-tetradecen-1-yl acetate + SX, (Z) -11-tetradecen-1-yl acetate + SX, (Z) -13-icosen-10-one + SX, (Z, E ) -7,11-hexadecadien-1-yl acetate + SX, (Z, E) -9,12-tetradecadien-1-yl acetate + SX, (E, Z) -4,10-tetradecadien-1-yl acetate + SX, (E, E) -8,10-dodecadien-1-ol + SX, (E, E) -10,12-hexadecadienal + SX, (E, E) -9,11-tetradecadien-1-yl acetate + SX, (E, Z) -2, 13-octadecadien-1-ol + SX, (E, Z) -3, 13-octadecadien-1-ol + SX, (E, Z) -2, 13- octadecadien-1-yl acetate + SX, (E, Z) -3,13-octadecadien-1-yl acetate + SX, (E, Z) -7,9-dodecadien-1-yl acetate + SX, (E, (E, Z) E) -7,9-dodecadien-1-yl acetate + SX, (Z, E) -9,12-tetradecadadien-1-yl acetate + SX, (Z, E) -9,11-tetracadadien-1-yl acetate + SX, (Z, E) -7, 11-hexadecadien-1-yl acetate + SX, (Z, Z) -3, 13-octadecadien-1-ol + SX, (Z, Z) -4, 7 -decadien-1-yl acetate + SX, (Z, Z) -3,13-octadecadien-1-yl acetate + SX, (Z, Z) -7,11-hexadecadien-1-yl acetate + SX, (Z , Z, E) -7, 11, 13-hexadecatrienal + SX, (5R) -5-[(1Z) -1 -decen-1-yl] dihydro-2 (3H) -furanone + SX, (2R, 5R) -ethyl-1,6-dioxaspiro [4,4] nonane + SX, (2R, 5S) -ethyl-1, 6-dioxaspiro [4,4] nonane + SX, (4R, 8R) -4,8-dimethyldecanal + SX, (4R, 8S) -4,8-dimethyldecanal + SX, 2,4-dimethyl-5-ethyl- 6,8-dioxabicyclo [3,2,1] octane + SX, (−)-4-methyl-3-heptanol + SX, 1,7-dioxaspiro [5,5] undecane + SX, 3-carene + SX, 3-methylcyclohex-2-en-1-one + SX, 14-methyloctadec-1-ene + SX, 4-methylnonan-5-ol + SX, 4-methylnonan-5-one + SX, 4- (3-oxobutyl ) phenyl acetate + SX, dodecyl acetate + SX, dodeca-8,10-dien-1-yl acetate + SX, ethyl (2E, 4Z) -decadienoate + SX, ethyl 4-methyloctanoate + SX, methyl 2,6,10 -trimethyldodecanoate + SX, tetradecan-1-ol + SX, tetradec-11-en-1-ol + SX, tetradec-11-en-1-yl acetate + SX, tridec-4-en-1-yl acetate + SX , (3S, 6R) -3-methyl-6-isopropenyl-9-decen-1-yl acetate + SX, (3S, 6S) -3-methyl-6-isopropenyl-9-decen-1-yl acetate + SX , Alpha-multistriatin (alpha-multistriatin) + SX, alpha-pinene (alpha-pinene) + SX, end-brevikomi N (endo-brevicomin) + SX, exo-brevicomin (exo-brevicomin) + SX, camphene (camphene) + SX, codrelure (coddleure) + SX, codlemon (codlemone) + SX, cueure (cuelure) + SX, disparage (Disparlure) + SX, dominicalure + SX, eugenol (eugenol) + SX, farnesol (farnesol) + SX, ferrolure (ferrolure) + SX, frontalin (frontalin) + SX, gossy plure (gossyplure) + SX, grand lure (Grandlure) + SX, grandlure I (grandlure I) + SX, grandlure II (grandlure II) + SX, grandlure III (grandlure III) + SX, grandlure IV (grandlure IV) + SX, hexalure + SX, Ips Dienol (ipsdienol) + SX, Ipsenol (ipsenol) + SX, japonilure (japonilure) + SX, lineatein + SX, Little A (litlue) + SX, Loop Lure (loop Lure) + SX, Medlure (medlure) + SX, megatomoic acid + SX, methyl eugenol + SX, muscalure + SX, nerolidol + SX, orfralure + SX, oryctalure + SX, Ostramon (Ostramone) + SX, Linkorua (Rhyncolure) + SX, Siglure (Siglure) + SX, Sordizine (Sordidin) + SX, Sulcatol (Sulcatol) + SX, Trimedlure (Trimedlure) + SX, Trimedlure A (trimedlure A) + SX , Trimedlure B1 (trimedlure B1) + SX, Trimedlure B 2 (trimedlure B 2) + SX, Trimedlure C (trimedlure C) + SX, Trunk-call (trunc-call) + SX, (E) -verbeno ((E) -verbanol ) + SX, (Z)-Verbenol ((Z) -verbanol) + SX, trans-verbeno (trans-verbanol) + SX, S-verbenone ((S) -verbenone) + SX.
　本発明化合物Ｘと本成分との比は、特に限定されるものではないが、重量比（本発明化合物：本成分）で１０００：１～１：１０００、５００：１～１：５００、１００：１～１：１００、５０：１～１：５０、２０：１～１：２０、１０：１～１：１０、３：１～１：３、１：１～１：５００、１：１～１：１００、１：１～１：５０、１：１～１：２０、１：１～１：１０等が挙げられる。 The ratio of the compound of the present invention X to the component is not particularly limited, but the weight ratio (the compound of the present invention: this component) is from 1000: 1 to 1: 1000, 500: 1 to 1: 500, 100: 1 to 1: 100, 50: 1 to 1:50, 20: 1 to 1:20, 10: 1 to 1:10, 3: 1 to 1: 3, 1: 1 to 1: 500, 1: 1 to 1: 100, 1: 1 to 1:50, 1: 1 to 1:20, 1: 1 to 1:10 and the like.
　本発明化合物Ｘは、有害昆虫や有害ダニ類等の有害節足動物、有害線虫、及び有害軟体動物に対して効力を有する。有害節足動物、有害線虫、及び有害軟体動物としては、例えば以下のものが挙げられる。 The compound X of the present invention is effective against noxious arthropods such as noxious insects and noxious mites, noxious nematodes, and noxious molluscs. Examples of harmful arthropods, harmful nematodes and harmful molluscs include, for example, the following.
　半翅目（Hemiptera）：ヒメトビウンカ（Laodelphax striatellus）、トビイロウンカ（Nilaparvata lugens）、セジロウンカ（Sogatella furcifera）、トウモロコシウンカ（Peregrinus maidis）、キタウンカ（Javesella pellucida）、クロフツノウンカ（Perkinsiella saccharicida）、Tagosodes orizicolus等のウンカ科（Delphacidae）；ツマグロヨコバイ（Nephotettix cincticeps）、タイワンツマグロヨコバイ（Nephotettix virescens）、クロスジツマグロヨコバイ（Nephotettix nigropictus）、イナズマヨコバイ（Recilia dorsalis）、チャノミドリヒメヨコバイ（Empoasca onukii）、ジャガイモヒメヨコバイ（Empoasca fabae）、コーンリーフホッパー（Dalbulus maidis）、シロオオヨコバイ（Cofana spectra）等のヨコバイ科（Cicadellidae）；Mahanarva posticata、Mahanarva fimbriolata等のコガシラアワフキムシ科（Cercopidae）；マメクロアブラムシ（Aphis fabae）、ダイズアブラムシ（Aphis glycines）、ワタアブラムシ（Aphis gossypii）、ヨーロッパリンゴアブラムシ（Aphis pomi）、ユキヤナギアブラムシ（Aphis spiraecola）、モモアカアブラムシ（Myzus persicae）、ムギワラギクオマルアブラムシ（Brachycaudus helichrysi）、ダイコンアブラムシ（Brevicoryne brassicae）、Rosy apple aphid（Dysaphis plantaginea）、ニセダイコンアブラムシ（Lipaphis erysimi）、チューリップヒゲナガアブラムシ（Macrosiphum euphorbiae）、ジャガイモヒゲナガアブラムシ（Aulacorthum solani）、レタスヒゲナガアブラムシ（Nasonovia ribisnigri）、ムギクビレアブラムシ（Rhopalosiphum padi）、トウモロコシアブラムシ（Rhopalosiphum maidis）、ミカンクロアブラムシ（Toxoptera citricida）、モモコフキアブラムシ（Hyalopterus pruni）、ヒエノアブラムシ（Melanaphis sacchari）、オカボノクロアブラムシ（Tetraneura nigriabdominalis）、カンシャワタアブラムシ（Ceratovacuna lanigera）、リンゴワタムシ（Eriosoma lanigerum）等のアブラムシ科（Aphididae）；ブドウネアブラムシ（Daktulosphaira vitifoliae）、Pecan phylloxera（Phylloxera devastatrix）、Pecan leaf phylloxera（Phylloxera notabilis）、Southern pecan leaf phylloxera（Phylloxera russellae）等のネアブラムシ科（Phylloxeridae）；ツガカサアブラムシ（Adelges tsugae）、Adelges piceae、ヒメカサアブラムシ（Aphrastasia pectinatae）等のカサアブラムシ科（Adelgidae）；イネクロカメムシ（Scotinophara lurida）、Malayan rice black bug（Scotinophara coarctata）、アオクサカメムシ（Nezara antennata）、トゲシラホシカメムシ（Eysarcoris aeneus）、オオトゲシラホシカメムシ（Eysarcoris lewisi）、シラホシカメムシ（Eysarcoris ventralis）、ムラサキシラホシカメムシ（Eysarcoris annamita）、クサギカメムシ（Halyomorpha halys）、ミナミアオカメムシ（Nezara viridula）、Brown stink bug（Euschistus heros）、Red banded stink bug（Piezodorus guildinii）、Oebalus pugnax、Dichelops melacanthus等のカメムシ科（Pentatomidae）；Burrower brown bug（Scaptocoris castanea）等のツチカメムシ科（Cydnidae）；ホソヘリカメムシ（Riptortus pedestris）、クモヘリカメムシ（Leptocorisa chinensis）、ホソクモヘリカメムシ（Leptocorisa acuta）等のホソヘリカメムシ科（Alydidae）；ホソハリカメムシ（Cletus punctiger）、アシビロヘリカメムシ（Leptoglossus australis）等のヘリカメムシ科（Coreidae）；カンシャコバネナガカメムシ（Caverelius saccharivorus）、コバネヒョウタンナガカメムシ（Togo hemipterus）、アメリカコバネナガカメムシ（Blissus leucopterus）等のナガカメムシ科（Lygaeidae）；アカヒゲホソミドリカスミカメ（Trigonotylus caelestialium）、アカスジカスミカメ（Stenotus rubrovittatus）、フタトゲムギカスミカメ（Stenodema calcarata）、サビイロカスミカメ（Lygus lineolaris）等のカスミカメムシ科（Miridae）；オンシツコナジラミ（Trialeurodes vaporariorum）、タバココナジラミ（Bemisia tabaci）、ミカンコナジラミ（Dialeurodes citri）、ミカントゲコナジラミ（Aleurocanthus spiniferus）、チャトゲコナジラミ（Aleurocanthus camelliae）、ヒサカキワタフキコナジラミ（Pealius euryae）等のコナジラミ科（Aleyrodidae）；シュロマルカイガラムシ（Abgrallaspis cyanophylli）、アカマルカイガラムシ（Aonidiella aurantii）、ナシマルカイガラムシ（Diaspidiotus perniciosus）、クワシロカイガラムシ（Pseudaulacaspis pentagona）、ヤノネカイガラムシ（Unaspis yanonensis）、ニセヤノネカイガラムシ（Unaspis citri）等のマルカイガラムシ科（Diaspididae）；ルビーロウムシ（Ceroplastes rubens）等のカタカイガラムシ科（Coccidae）；イセリアカイガラムシ（Icerya purchasi）、キイロワタフキカイガラムシ（Icerya seychellarum）等のワタフキカイガラムシ科（Margarodidae）；ナスコナガイガラムシ（Phenacoccus solani）、クロテンコナカイガラムシ（Phenacoccus solenopsis）、フジコナカイガラムシ（Planococcus kraunhiae）、クワコナカイガラムシ（Pseudococcus comstocki）、ミカンコナカイガラムシ（Planococcus citri）、ガハニコナカイガラムシ（Pseudococcus calceolariae）、ナガオコナカイガラムシ（Pseudococcus longispinus）、タトルミーリーバグ（Brevennia rehi）等のコナカイガラムシ科（Pseudococcidae）；ミカンキジラミ（Diaphorina citri）、ミカントガリキジラミ（Trioza erytreae）、ナシキジラミ（Cacopsylla pyrisuga）、チュウゴクナシキジラミ（Cacopsylla chinensis）、ジャガイモトガリキジラミ（Bactericera cockerelli）、Pear psylla（Cacopsylla pyricola）等のキジラミ科（Psyllidae）；プラタナスグンバイ（Corythucha ciliata）、アワダチソウグンバイ（Corythucha marmorata）、ナシグンバイ（Stephanitis nashi）、ツツジグンバイ（Stephanitis pyrioides）等のグンバイムシ科（Tingidae）；トコジラミ（Cimex lectularius）等のトコジラミ科（Cimicidae）；Giant Cicada（Quesada gigas）等のセミ科（Cicadidae）；ブラジルサシガメ（Triatoma infestans）等のトリアトマ属（Triatoma spp.）。 Hemiptera (Hemiptera): Hemetobiunka (Laodelphax striatellus), Tobiirounka (Nilaparvata lugens), Sejirounka (Sogatella furcifera), Corn locust (Peregrinus maidis), Red-winged deer (Javesella pellucida), Black-footed Michalica Planthopper family (Delphacidae); Green leafhopper (Nephotettix cincticeps), Yellow-tailed leafhopper (Nephotettix virescens), Black-tailed green leafhopper (Nephotettix nigropictus), Yellow-tailed leafhopper (Recilia dorsalis), Black-tailed leafminus moth , Corn leaf hopper (Dalbulus maidis), white leafhopper (Cofana spectra), etc., leafhopper family (Cicadelidae); Mahanarva posticata, Mahanarva fimbriolata, etc., moss family (Cercopidae); Bean aphids (Aphis fabae), soybean aphids (Aphis glycines), cotton aphids (Aphis gossypii), European apple aphids (Aphis pomi), pokeweed aphids (Aphis spiraecola), green leaf aphids (Myzus persicae), moths Helichrysi), radish aphid (Brevicoryne brassicae), Rosy apple aphid (Dysaphis plantaginea), pseudonymous aphid (Lipaphis erysimi), tulip buffalo aphid (Macrosiphum euphorbiae), potato blight aphid Aphid beetle (Rhopalosiphum padi), corn aphid (Rhopalosiphum maidis), red-handed aphid (Toxoptera citricida), Pectinella aphid (Hyalopterus pruni), baboon The aphid family (Aphididae) such as the green buff beetle (Melanaphis sacchari), the black-winged aphid (Tetraneura nigriabdominalis), the black-winged aphid (Ceratovacuna lanigera), and the like. ), Pecan leaf phylloxera (Phylloxera notabilis), Southern pecan leaf phylloxera (Phylloxera russellae), and the like (Phylloxeridae); (Adelgidae); rice black bug (Scot inophara lurida), Malayan rice black bug (Scot inophara coarctata), green grass bug (Nezara antennata), rhizophorid bug (Eysarcoris aeneus), dryback beetle (Eysarcoris lewisi), Red-headed Bug (Eysarcoris ventralis), Gray-backed Bug (Eysarcoris annamita), Brown-backed Bug (Halyomorpha halys), Red-headed Bug (Nezara viridula), Brown stink bug (Euschistus heros), Red banded stink bug (Piez Sturgeon (Pentatomidae) such as melacanthus; Sturgeon (Cydnidae) such as Burrower brown bug (Scaptocoris castanea); Helicidae (Alydidae); Helicidae (Cletus punctiger), Helicidae (Leptoglossus australis), etc. Helicidae (Coreidae); , Ameri Red-tailed bug family (Lygaeidae) such as Blissus leucopterus; Red-backed squirrel (Trigonotylus caelestialium); Stink bug family (Miridae); Trichoderma faecalis (Trialeurodes vaporariorum), B. tabaci (Bemisia tabaci), Scutellaria barbata (Dialeurodes citri), Scutellaria barbata L. (Aleurocanthus spiniferus), Scutellaria plagiasus (Aleurocanthus camelliae) shields Whitefly family (Aleyrodidae); White-backed scale insect (Abgrallaspis cyanophylli), Red-backed scale insect (Aonidiella aurantii), Yellow-backed scale insect (Diaspidiotus perniciosus), Musk Red-tailed beetles (Diaspididae) such as P. (Pseudaulacaspis pentagona), Red-winged scale insects (Unaspis yanonensis), False-spotted scale insects (Unaspis citri) etc .; ), Irodridae (Icerya seychellarum), and the like (Margarodidae); mealybug such as comstocki), mealybug (Planococcus citri), mealybug (Pseudococcus calceolariae), mealybug (Pseudococcus longispinus), tuttle myri bug (Brevennia rehi) etc. (Pseudococcidae); Orange leaf lumber (Diaphorina citri), red leaf lice (Trioza erytreae), nashi lary tree (Cacopsylla pyrisuga), Chinese lice leafworm (Cacopsylla chinensis), potato leaf lice (Bacterica cocklellihichium icich (Psyllidae); Platypus guniensis (Corythucha ciliata), Amaryllidus gunbi (Corythucha marmorata), Nasygumbai (Stephanitis nashi), such as Gunzimbi (Stephanitis pyrioides), and the like (Tingidae); A semi-family (Cicadidae) such as Giant Cicada (Quesada gigas); Triatoma sp. (Triatoma spp.) Such as Brazilian Sasame Turtle (Triatoma infestans).
　鱗翅目（Lepidoptera）：ニカメイガ（Chilo suppressalis）、Darkheaded stem borer（Chilo polychrysus）、White stem borer（Scirpophaga innotata）、イッテンオオメイガ（Scirpophaga incertulas）、Rupela albina、コブノメイガ（Cnaphalocrocis medinalis）、Marasmia patnalis、イネハカジノメイガ（Marasmia exigua）、ワタノメイガ（Notarcha derogata）、アワノメイガ（Ostrinia furnacalis）、European corn borer（Ostrinia nubilalis）、ハイマダラノメイガ（Hellula undalis）、モンキクロノメイガ（Herpetogramma luctuosale）、シバツトガ（Pediasia teterrellus）、ライスケースワーム（Nymphula depunctalis）、Sugarcane borer（Diatraea saccharalis）等のツトガ科（Crambidae）；モロコシマダラメイガ（Elasmopalpus lignosellus）、ノシメマダラメイガ（Plodia interpunctella）、フタモンマダラノメイガ（Euzophera batangensis）等のメイガ科（Pyralidae）；ハスモンヨトウ（Spodoptera litura）、シロイチモジヨトウ（Spodoptera exigua）、アワヨトウ（Mythimna separata）、ヨトウガ（Mamestra brassicae）、イネヨトウ（Sesamia inferens）、シロナヨトウ（Spodoptera mauritia）、フタオビコヤガ（Naranga aenescens）、ツマジロクサヨトウ（Spodoptera frugiperda）、アフリカシロナヨトウ（Spodoptera exempta）、タマナヤガ（Agrotis ipsilon）、タマナギンウワバ（Autographa nigrisigna）、イネキンウワバ（Plusia festucae）、Soybean looper（Chrysodeixis includens）、トリコプルシア属（Trichoplusia spp.）、ニセアメリカタバコガ（Heliothis virescens）等のヘリオティス属（Heliothis spp.）、オオタバコガ（Helicoverpa armigera）、アメリカタバコガ（Helicoverpa zea）等のヘリコベルパ属（Helicoverpa spp.）、Velvetbean caterpillar（Anticarsia gemmatalis）、Cotton leafworm（Alabama argillacea）、Hop vine borer（Hydraecia immanis）等のヤガ科（Noctuidae）；モンシロチョウ（Pieris rapae）等のシロチョウ科（Pieridae）；ナシヒメシンクイ（Grapholita molesta）、スモモヒメシンクイ（Grapholita dimorpha）、マメシンクイガ（Leguminivora glycinivorella）、アズキサヤムシガ（Matsumuraeses azukivora）、リンゴコカクモンハマキ（Adoxophyes orana fasciata）、チャノコカクモンハマキ（Adoxophyes honmai）、チャハマキ（Homona magnanima）、ミダレカクモンハマキ（Archips fuscocupreanus）、コドリンガ（Cydia pomonella）、カンシャシンクイハマキ（Tetramoera schistaceana）、Bean Shoot Borer（Epinotia aporema）、Citrus fruit borer（Ecdytolopha aurantiana）等のハマキガ科（Tortricidae）；チャノホソガ（Caloptilia theivora）、キンモンホソガ（Phyllonorycter ringoniella）等のホソガ科（Gracillariidae）；モモシンクイガ（Carposina sasakii）等のシンクイガ科（Carposinidae）；Coffee Leaf miner（Leucoptera coffeella）、モモハモグリガ（Lyonetia clerkella）、ギンモンハモグリガ（Lyonetia prunifoliella）等のハモグリガ科（Lyonetiidae）；マイマイガ（Lymantria dispar）等のリマントリア属（Lymantria spp.）、チャドクガ（Euproctis pseudoconspersa）等のユープロクティス属（Euproctis spp.）等のドクガ科（Lymantriidae）；コナガ（Plutella xylostella）等のコナガ科（Plutellidae）；モモキバガ（Anarsia lineatella）、イモキバガ（Helcystogramma triannulella）、ワタアカミムシガ（Pectinophora gossypiella）、ジャガイモガ（Phthorimaea operculella）、Tuta absoluta等のキバガ科（Gelechiidae）；アメリカシロヒトリ（Hyphantria cunea）等のヒトリガ科（Arctiidae）；Giant Sugarcane borer（Telchin licus）等のカストニアガ科（Castniidae）；ヒメボクトウ（Cossus insularis）等のボクトウガ科（Cossidae）；ヨモギエダシャク（Ascotis selenaria）等のシャクガ科（Geometridae）；ヒロヘリアオイラガ（Parasa lepida）等のイラガ科（Limacodidae）；カキノヘタムシガ（Stathmopoda masinissa）等のニセマイコガ科（Stathmopodidae）；クロメンガタスズメ（Acherontia lachesis）等のスズメガ科（Sphingidae）；キクビスカシバ（Nokona feralis）、コスカシバ（Synanthedon hector）、ヒメコスカシバ（Synanthedon tenuis）等のスカシバガ科（Sesiidae）；イネツトムシ（Parnara guttata）等のセセリチョウ科（Hesperiidae）；イガ（Tinea translucens）、コイガ（Tineola bisselliella）等のヒロズコガ科（Tinedae）。 Lepidoptera: Chilo suppressalis, Darkheaded stem borer (Chilo polychrysus), White stem borer (Scirpophaga innotata), Itten's tree magnolia (Scirpophaga incertulas), Rupela albina, Kobnomiga (Cnaphatailicalis) Casino meiga (Marasmia exigua), cotton moth (Notarcha derogata), foxtail moth (Ostrinia furnacalis), European corn borer (Ostrinia nubilalis), black-tailed moth (Hellula undulis), monquil chronome moth (Herpetogramma lucitose, Pe) Caseworms (Nymphula depunctalis), Sugarcane borer (Diatraea saccharalis), and other parts of the family (Crambidae); Ringworm (Pyralidae); Spodoptera litura, Spodoptera exigua, Mythimna separata, Myodopa (Mamestra brassicae), Spurge (Sesamitimates) Roxayo spiny (Spodoptera frugiperda), African white spiny (Spodoptera exempta), spiny moth (Agrotis ipsilon), spiny edgy (Autographa nigrisigna), inykin iwaba (Plusia festucae), Soybean looper (Chrysodeixis includes, trichoc Heliothis sp. (Heliothis virescens), Heliothis spp., Helicoverpa armigera, Helicoverpa zea, etc. Helicoverpa spp., Velvetbean caterpillar (Anticarsia gemma) talis), Cotton leafworm (Alabama argillacea), Hop vine borer (Hydraecia immanis), etc .; Noctuidae; Pteris (Pieris rapae) dimorpha), legume mincing moth (Leguminivora glycinivorella), azuxamushi moth (Matsumuraeses azukivora), apple red pokemon mackerel (Adoxophyes orana fasciata), kanokokan monmai (Adoxophys honmai), chahamaki (Homona magnima trich.) (Cydia pomonella), Chinese chaff (Tetramoera schistaceana), Bean Shoot Borer (Epinotia aporema), Citrus fruit borer (Ecdytolopha aurantiana) such as Trichoideidae (Tortricidae); La) et al. (Gracillariidae); Carposina sasakii et al. (Carposinidae); Coffee Leaf miner (Leucoptera coffeella), Peach leafworm (Lyonetia clerkella), Gimone leafworm (Lyonetia prunifoliella) A member of the genus Lymantriidae (Lymantriidae) such as Lymantria sppar, such as Lymantria dispar, Euproctis pseudoconspersa, etc; (Plullidae); Psyllididae (Gelechiidae) such as peach moth (Anarsia lineatella), immature moth (Helcystogramma triannulella), cotton moth (Pectinophora gossy piella), potato moth (Phthorimaea operculella), Tuta absoluta etc. Arctiidae); Giant Sugarcane b Orster (Telchin licus) Kastoniagae (Castniidae); Himebokuto (Cossus insularis) et al. (Cossidae); Family (Limacodidae); Staphymopoda (Stathmopoda masinissa) etc .; Stathmopodidae; Acherontia lachesis et al. Sphingidae (Sphingidae); And the like. Seschidae (Sesiidae), etc .; Hemperididae (Hesperiidae) such as the rice tortoise (Parnara guttata);
　総翅目（Thysanoptera）：ミカンキイロアザミウマ（Frankliniella occidentalis）、ミナミキイロアザミウマ（Thrips palmi）、チャノキイロアザミウマ（Scirtothrips dorsalis）、ネギアザミウマ（Thrips tabaci）、ヒラズハナアザミウマ（Frankliniella intonsa）、イネアザミウマ（Stenchaetothrips biformis）、モトジロアザミウマ（Echinothrips americanus）等のアザミウマ科（Thripidae）；イネクダアザミウマ（Haplothrips aculeatus）等のクダアザミウマ科（Phlaeothripidae）。 Thysanoptera (Thysanoptera): Thripsidae (Frankliniella occidentalis), Thripsidae (Thrips palmi), Chalyssus thripsus (Scirtothrips dorsalis), Thrips tabaci (Thrips tabaci), Hydrangea thripsus (Frankliniella intronacea) , Thripidae such as Echinothrips americanus etc .; Thripsidae (Phlaeothripidae) such as Haekohrips aculeatus.
　双翅目（Diptera）：タネバエ（Delia platura）、タマネギバエ（Delia antiqua）、テンサイモグリハナバエ（Pegomya cunicularia）等のハナバエ科（Anthomyiidae）；シュガービートルートマゴット（Tetanops myopaeformis）等のハネフリバエ科（Ulidiidae）；イネハモグリバエ（Agromyza oryzae）、トマトハモグリバエ（Liriomyza sativae）、マメハモグリバエ（Liriomyza trifolii）、ナモグリバエ（Chromatomyia horticola）等のハモグリバエ科（Agromyzidae）；イネキモグリバエ（Chlorops oryzae）等のキモグリバエ科（Chloropidae）；ウリミバエ（Bactrocera cucurbitae）、ミカンコミバエ（Bactrocera dorsalis）、ナスミバエ（Bactrocera latifrons）、オリーブミバエ（Bactrocera oleae）、クインスランドミバエ（Bactrocera tryoni）、チチュウカイミバエ（Ceratitis capitata）、アップルマゴット（Rhagoletis pomonella）、オウトウハマダラミバエ（Rhacochlaena japonica）等のミバエ科（Tephritidae）；イネヒメハモグリバエ（Hydrellia griseola）、トウヨウイネクキミギワバエ（Hydrellia philippina）、イネクキミギワバエ（Hydrellia sasakii）等のミギワバエ科（Ephydridae）；オウトウショウジョウバエ（Drosophila suzukii）等のショウジョウバエ科（Drosophilidae）；オオキモンノミバエ（Megaselia spiracularis）等のノミバエ科（Phoridae）；オオチョウバエ（Clogmia albipunctata）等のチョウバエ科（Psychodidae）；チビクロバネキノコバエ(Bradysia difformis)等のクロバネキノコバエ科（Sciaridae）；ヘシアンバエ（Mayetiola destructor）、イネノシントメタマバエ（Orseolia oryzae）等のタマバエ科（Cecidomyiidae）；Diopsis macrophthalma等のシュモクバエ科（Diopsidae）；キリウジガガンボ（Tipula aino）、Common cranefly（Tipula oleracea）、European cranefly（Tipula paludosa）等のガガンボ科（Tipulidae）；アカイエカ（Culex pipiens pallens）、ネッタイシマカ（Aedes aegypti）、ヒトスジシマカ（Aedes albopicutus）、シナハマダラカ（Anopheles hyracanus sinesis）、コガタアカイエカ（Culex quinquefasciatus）、チカイエカ（Culex pipiens molestus Forskal）、ネッタイイエカ（Culex quinquefasciatus）等のカ科（Culicidae）；キアシオオブユ（Prosimulium yezoensis）、ツメ卜ゲブユ（Simulium ornatum）等のブユ科（Simulidae）；ウシアブ（Tabanus trigonus)等のアブ科（Tabanidae）；イエバエ（Musca domestica）、オオイエバエ（Muscina stabulans）、サシバエ（Stomoxys calcitrans）、ノサシバエ（Haematobia irritans）等のイエバエ科（Muscidae）；クロバエ科（Calliphoridae）；ニクバエ科（Sarcophagidae）；オオユスリカ（Chironomus plumosus）、セスジユスリカ（Chironomus yoshimatsui）、ハイイロユスリカ（Glyptotendipes tokunagai）等のユスリカ科(Chironomidae）；ヒメイエバエ科（Fannidae）。 Diptera (Diptera): Anemoneid family (Anthomyiidae) such as fly (Delia platura), onion fly (Delia antiqua), sugar beet fly (Pegomya cunicularia) etc .; Rice leafminer fly (Agromyza oryzae), tomato leafminer fly (Liriomyza sativae), bean leafminer fly (Liriomyza trifolii), leafminer fly (Chromatomyia horticola), etc. leafworm family (Agromyzidae); Bactrocera cucurbitae), mandarin orange fruit fly (Bactrocera dorsalis), egg fruit fly (Bactrocera latiphrons), olive fruit fly (Bactrocera oleae), quince land fruit fly (Bactrocera tryoni), citechine fruit fly (Ceratitis capitaphy) Tephritidae (Tephritidae), such as pomonella), sweet potato weeds (Rhacochlaena japonica); ; Drosophilidae such as Drosophila melanogaster (Drosophila suzukii); Psyllididae (Phoridae) such as the giant flea fly (Megaselia spiracularis); dimorphism fly family (Sciaridae) such as Hessian fly (Mayetiola destructor), Bacteriidae (Cecidomyiidae) such as incocarid fly (Orseolia oryzae); , Common cranefly (Tipula oleracea), European cranefly (Tipula paludosa), etc. (Tipulidae); Culex quinquefasciatus), Culex pipiens molestus Forskal, Culexidae such as Culex quinquefasciatus; Culicidae; Prosimulium yezoensis; House fly (Musca domestica), house fly (Muscina stabulans), sea fly (Stomoxys calcitrans), house fly (Haematobia irritans) such as house fly (Muscidae); ); (Chironomus plumosus), Chironomus yoshimatsui (Chironomus yoshimatsui), Chironomidae such as Gray midges (Glyptotendipes tokunagai) (Chironomidae); fanniidae (Fannidae).
　鞘翅目（Coleoptera）：ウエスタンコーンルートワーム（Diabrotica virgifera virgifera）、サザンコーンルートワーム（Diabrotica undecimpunctata howardi）、ノザンコーンルートワーム（Diabrotica barberi）、メキシカンコーンルートワーム（Diabrotica virgifera zeae）、バンデッドキューカンバービートル（Diabrotica balteata）、Cucurbit Beetle（Diabrotica speciosa）、ビーンリーフビートル（Cerotoma trifurcata）、クビアカクビホソハムシ（Oulema melanopus）、ウリハムシ（Aulacophora femoralis）、キスジノミハムシ（Phyllotreta striolata）、Cabbage flea beetle(Phyllotreta cruciferae)、Western black flea beetle（Phyllotreta pusilla）、Cabbage stem flea beetle(Psylliodes chrysocephala)、コロラドハムシ（Leptinotarsa decemlineata）、イネドロオイムシ（Oulema oryzae）、グレープ・コラスピス（Colaspis brunnea）、コーン・フレアビートル（Chaetocnema pulicaria）、サツマイモヒサゴトビハムシ（Chaetocnema confinis）、ポテト・フレアビートル（Epitrix cucumeris）、イネトゲハムシ（Dicladispa armigera）、southern corn leaf beetle（Myochrous denticollis）、ヨツモンカメノコハムシ（Laccoptera quadrimaculata）、タバコノミハムシ（Epitrix hirtipennis）等のハムシ科（Chrysomelidae）；Seedcorn beetle（Stenolophus lecontei）、Slender seedcorn beetle（Clivina impressifrons）等のオサムシ科（Carabidae）；ドウガネブイブイ（Anomala cuprea）、ヒメコガネ（Anomala rufocuprea）、アオドウガネ（Anomala albopilosa）、マメコガネ（Popillia japonica）、ナガチャコガネ（Heptophylla picea）、European Chafer（Rhizotrogus majalis）、クロマルコガネ（Tomarus gibbosus）、Holotrichia属（Holotrichia spp.）、ジューン・ビートル（Phyllophaga crinita）等のPhyllophaga属（Phyllophaga spp.）、Diloboderus abderus等のDiloboderus属（Diloboderus spp.）等のコガネムシ科（Scarabaeidae）；ワタミヒゲナガゾウムシ（Araecerus coffeae）、アリモドキゾウムシ（Cylas formicarius）、イモゾウムシ（Euscepes postfasciatus）、アルファルファタコゾウムシ（Ｈypera postica）、コクゾウムシ（Sitophilus zeamais）、イネゾウムシ（Echinocnemus squameus）、イネミズゾウムシ（Lissorhoptrus oryzophilus）、シロスジオサゾウムシ（Rhabdoscelus lineatocollis）、ワタミハナゾウムシ（Anthonomus grandis）、シバオサゾウムシ（Sphenophorus venatus）、Southern Corn Billbug（Sphenophorus callosus）、Soybean stalk weevil（Sternechus subsignatus）、Sugarcane weevil（Sphenophorus levis）、サビヒョウタンゾウムシ（Scepticus griseus）、トビイロヒョウタンゾウムシ（Scepticus uniformis）、ブラジルマメゾウムシ（Zabrotes subfasciatus）、マツノキクイムシ（Tomicus piniperda）、Coffee Berry Borer（Hypothenemus hampei）、Aracanthus mourei等のAracanthus属（Aracanthus spp.）、cotton root borer(Eutinobothrus brasiliensis)等のゾウムシ科（Curculionidae）；コクヌストモドキ（Tribolium castaneum）、ヒラタコクヌストモドキ（Tribolium confusum）等のゴミムシダマシ科（Tenebrionidae）；ニジュウヤホシテントウ（Epilachna vigintioctopunctata）等のテントウムシ科（Coccinellidae）；ヒラタキクイムシ（Lyctus brunneus）等のナガシンクイムシ科（Bostrychidae）；ヒョウホンムシ科（Ptinidae）；ゴマダラカミキリ（Anoplophora malasiaca）、Migdolus fryanus等のカミキリムシ科（Cerambycidae）；オキナワカンシャクシコメツキ（Melanotus okinawensis）、トビイロムナボソコメツキ（Agriotes fuscicollis）、クシコメツキ（Melanotus legatus）、アシブトコメツキ属（Anchastus spp.）、コノデルス属（Conoderus spp.）、クテニセラ属（Ctenicera spp.）、リモニウス属（Limonius spp.）、Aeolus属（Aeolus spp.）等のコメツキムシ科（Elateridae）；アオバアリガタハネカクシ（Paederus fuscipes）等のハネカクシ科（Staphylinidae）；ヒメマルカツオブシムシ（Anthrenus verbasci）、ハラジロカツオブシムシ（Dermestes maculates)等のカツオブシムシ科（Dermestidae）；タバコシバンムシ（Lasioderma serricorne）、ジンサンシバンムシ（Stegobium paniceum）等のシバンムシ科（Anobidae）。 Coleoptera (Coleoptera): Western corn rootworm (Diabrotica virgifera virgifera), Southern corn rootworm (Diabrotica undecimpunctata howardi), Northen corn rootworm (Diabrotica barberi), Mexican corn rootworm (Diabrotica virgifera zeae), Banded Cuicabiotic (Diabrotica virgifera zeae) balteata), Cucurbit Beetle (Diabrotica speciosa), Bean Leaf Beetle (Cerotoma trifurcata), Cubial Leaf Beetle (Oulema melanopus), Ground Leaf Beetle (Aulacophora femoralis), Sweet potato leaf beetle (Phyllotreta striolata), Cabbagel flea beetle (Phyllotreta pusilla), Cabbage stem flea beetle (Psylliodes chrysocephala), Colorado potato beetle (Leptinotarsa decemlineata), Ineo loim beetle (Oulema oryzae), grape colapice (Colaspis brunnea), Corn flare beetle (Chaetocnema pulicaria), sweet potato beetle (Chaetocnema confinis), potato flare beetle (Epitrix cucumeris), red leaf beetle (Dicladispa armigera), southern corn leaf beetle (Myochrous dentulis), Chrysomelidae (Chrysomelidae) such as tobacco flea beetle (Epitrix hirtipennis); Seedcorn beetle (Stenolophus lecontei), Slender seedcorn beetle (Clivina impressifrons) etc. Carabidae; (Anomala albopilosa), Anemone carp (Popillia japonica), Anchovy (Heptophylla picea), European Chafer (Rhizotrogus majalis), Black marsh (Tomarus gibbosus), Holotrichia sp. of the genus Phyllophaga (Phyllophaga spp.), Diloboderus abderus, etc. Diloboderus (Diloboderus spp.), etc. Scarabaeidae (Scarabaeidae); postfasciatus), alfalfata weevil (Hypera postica), tree weevil (Sitophilus zeamais), rice weevil (Echinocnemus squameus), rice water weevil (Lissorhoptrus oryzophilus), weed beetles (Rhabs celus lineatocollis) venatus), Southern Corn Billbug (Sphenophorus callosus), Soybean stalk weevil (Sternechus subsignatus), Sugarcane weevil (Sphenophorus levis), Crustacean weevil (Scepticus griseus), Scuticularis semen (Scepticus uniformis) , Brazilian bean weevil (Zabrotes subfasciatus), Pinus spinach (Tomicus piniperda), Coffee Berry Borer (Hypothenemus hampei), Aracanthus sp., Such as Aracanthus mourei et al. Ladybird family (Coccinellidae) such as Epilachna vigintopoctopusta such as Coccinidae, such as Tricholium castaneum, Tribolium condusum, etc .; Epilachna vigintopoctopusta, etc .; Bostrychidae); Pantopus spp. (Ptinidae); Pteris (Anoplophora malasiaca), Migdolus fryanus etc. Cerambycidae (Cerambycidae); Click beetles such as common woodpeckers (Melanotus legatus), insect beetles (Anchastus spp.), Genus Conodes (Conoderus spp.), Genus Cotennisa (Ctenicera spp.), Genus Limonius (Limonius spp.), And genus Aeolus (Aeolus spp.) Family (Elateridae); Staphylinidae (Staphylinidae), such as Paederus fuscipes, etc; A beetle family (Anobidae) such as a beetle (Stegobium paniceum).
　直翅目（Orthoptera）：トノサマバッタ（Locusta migratoria）、モロッコトビバッタ（Dociostaurus maroccanus）、オーストラリアトビバッタ（Chortoicetes terminifera）、アカトビバッタ（Nomadacris septemfasciata）、Brown Locust（Locustana pardalina）、Tree Locust（Anacridium melanorhodon）、Italian Locust（Calliptamus italicus）、Differential grasshopper（Melanoplus differentialis）、Two striped grasshopper（Melanoplus bivittatus）、Migratory grasshopper（Melanoplus sanguinipes）、Red-Legged grasshopper（Melanoplus femurrubrum）、Clearwinged grasshopper（Camnula pellucida）、サバクワタリバッタ（Schistocerca gregaria）、Yellow-winged locust（Gastrimargus musicus）、Spur-throated locust（Austracris guttulosa）、コバネイナゴ（Oxya yezoensis）、ハネナガイナゴ（Oxya japonica）、タイワンツチイナゴ（Patanga succincta）等のバッタ科（Acrididae）；ケラ（Gryllotalpa orientalis）等のケラ科（Gryllotalpidae）；ヨーロッパイエコオロギ（Acheta domestica）、エンマコオロギ（Teleogryllus emma）等のコオロギ科（Gryllidae）；Mormon cricket（Anabrus simplex）等のキリギリス科（Tettigoniidae）。 Orthoptera (Orthoptera): Toocta grasshopper (Locusta migratoria), Toroca grasshopper (Dociostaurus maroccanus), Australia Tobibatata (Chortoicetes terminifera), Red-footed grasshopper (Nomadacris septemfasciata), Brown Locust (Locustana pardalis Aritraceilogues) Locust (Calliptamus italicus), Differential grasshopper (Melanoplus differentialis), Two striped grasshopper (Melanoplus bivittatus), Migratory grasshopper (Melanoplus cerichelimel at least 2 times), Red-Legged grasshopper (Mel ), Yellow-winged locust (Gastrimargus musicus), Spur-throated locust (Austracris guttulosa), Kobayinago (Oxya yezoensis), Hanekinainago (Oxya japonica), Trichophyton (Patanga succincta), etc. e); Griglotalpidae such as Gryllotalpa orientalis; Acritaidae (Gryllidae) such as the European green cricket (Acheta domestica);
　膜翅目（Hymenoptera）：カブラハバチ（Athalia rosae）、ニホンカブラバチ（Athalia japonica）等のハバチ科（Tenthredinidae）；ヒアリ（Solenopsis invicta）、アカカミアリ（Solenopsis geminata）等のトフシアリ属（Solenopsis spp.）、Brown leaf-cutting ant（Atta capiguara）等のハキリアリ属（Atta spp.)、ヒメハキリアリ属（Acromyrmex spp.）、サシハリアリ(Paraponera clavata)、ルリアリ（Ochetellus glaber）、イエヒメアリ（Monomorium pharaonis）、アルゼンチンアリ（Linepithema humile）、クロヤマアリ(Formica fusca japonica)、アミメアリ(Pristomyrmex punctutus)、オオズアリ(Pheidole noda)、ツヤオオズアリ（Pheidole megacephala）、クロオオアリ（Camponotus japonicus）、ムネアカオオアリ（Camponotus obscuripes）等のオオアリ属、オキシデンタリスシュウカクアリ（Pogonomyrmex occidentalis）等のシュウカクアリ属（Pogonomyrmex）、コカミアリ（Wasmania auropunctata）等のコカミアリ属（Wasmania）、アシナガキアリ（Anoplolepis gracilipes）等のアリ科（Formicidae）；オオスズメバチ（Vespa mandarinia japonica）、ケブカスズメバチ（Vespa simillima）、コガタスズメバチ（Vespa analis Fabriciusi）、ツマアカスズメバチ（Vespa velutina）、セグロアシナガバチ（Polistes jokahamae）等のスズメバチ科（Vespidae）；モミノオオキバチ（Urocerus gigas）等のキバチ科（Siricidae）；アリガタバチ科（Bethylidae）。 Hymenoptera (Hymenoptera): Japanese gossip (Athalia rosae), Japanese black-billed wasp (Athalia japonica), etc. (Tenthredinidae); Fireflies (Solenopsis invicta), Red-winged Ants (Solenopsis geminata), etc. Tolushinella (Solenopsis spp. leaf-cutting ant (Atta capiguara) et al. (Atta spp.), Anemone spp. (Acromyrmex spp.), Anemone spp. ), Black-headed ants (Formica fusca japonica), Ammet's ants (Pristomyrmex punctutus), Ascidian (Pheidole noda), Ascidian (Pheidole megacephala), Ascidian (Camponotus japonicus), Red-billed ants (Camponotus obscuripes), etc. (Pogonomyrmex occidentalis) Anemone family (Wasmania) such as the genus Quasi (Pogonomyrmex), Anopheles (Wasmania auropunctata), an ant family (Formicidae) such as Anoplolepis gracilipes, etc .; Vespa analis Fabriciusi, Vespa velutina, Polistes jokahamae (Vespidae) such as Vespidae;
　ゴキブリ目（Blattodea）：チャバネゴキブリ（Blattella germanica）等のチャバネゴキブリ科（Blattellidae）；クロゴキブリ（Periplaneta fuliginosa）、ワモンゴキブリ（Periplaneta americana）、トビイロゴキブリ（Periplaneta brunnea）、トウヨウゴキブリ（Blatta orientalis）等のゴキブリ科（Blattidae）；ヤマトシロアリ（Reticulitermes speratus）、イエシロアリ（Coptotermes formosanus）、アメリカカンザイシロアリ（Incisitermes minor）、ダイコクシロアリ（Cryptotermes domesticus）、タイワンシロアリ（Odontotermes formosanus）、コウシュンシロアリ（Neotermes koshunensis）、サツマシロアリ（Glyptotermes satsumensis）、ナカジマシロアリ（Glyptotermes nakajimai）、カタンシロアリ（Glyptotermes fuscus）、オオシロアリ（Hodotermopsis sjostedti）、コウシュウイエシロアリ（Coptotermes guangzhouensis）、アマミシロアリ（Reticulitermes amamianus）、ミヤタケシロアリ（Reticulitermes miyatakei）、カンモンシロアリ（Reticulitermes kanmonensis）、タカサゴシロアリ（Nasutitermes takasagoensis）、ニトベシロアリ（Pericapritermes nitobei）、ムシャシロアリ（Sinocapritermes mushae）、Cornitermes cumulans等のシロアリ科（Termitidae）。 Cockroach (Blattodea): German cockroach (Blattella germanica) and other German cockroaches (Blattellidae); (Blattidae); Yamato termites (Reticulitermes speratus), house termites (Coptotermes formosanus), American termites (Incisitermes minor), Dicta termites (Cryptotermes domesticus), Taiwan termites (Odontotermes formosanus), red-handed termites (Neotermes) Glyptotermes satsumensis), Chinese termite (Glyptotermes nakajimai), catan termite (Glyptotermes fuscus), giant termite (Hodotermopsis sjostedti), black-and-white termite (Coptotermes guangzhouensis) , Aphid termites (Reticulitermes amamianus), Mitatake termites (Reticulitermes miyatakei), Cameron termites (Reticulitermes kanmonensis), Takasago termites (Nasutitermes takasagoensis), Nitobe termites (Pericapritermes nitobei), Musashi termitimates (Termitidae).
　ノミ目（Siphonaptera）：ネコノミ（Ctenocephalidae felis）、イヌノミ（Ctenocephalides canis）、ヒ卜ノミ（Pulex irritans）、ケオプスネズミノミ（Xenopsylla cheopis）、スナノミ（Tunga penetrans）、ニワトリノミ（Echidnophaga gallinacea）、ヨーロッパネズミノミ（Nosopsyllus fasciatus）。 Flea order (Siphonaptera): cat flea (Ctenocephalidae felis), dog flea (Ctenocephalides canis), castor flea (Pulex irritans), pheasant flyfish (Xenopsylla cheopis), sunanose (Tunga penetrans), chick flea (Echidnophaga gallinacea) Fleas (Nosopsyllus fasciatus).
　シラミ目（Anoplura）：ブタジラミ（Haematopinus suis）、ウシジラミ（Haematopinus eurysternus）、ヒツジシラミ(Dalmalinia ovis)、イヌジラミ（Linognathus seypsus）、ヒトジラミ（Pediculus humanis）、コロモジラミ（Pediculuc humanus corporis）、アタマジラミ（Pediculus humanus humanus）、ケジラミ（Phthirus pubis)。 Lice (Anoplura): pig lice (Haematopinus suis), lice (Haematopinus eurysternus), sheep lice (Dalmalinia ovis), lice (Linognathus seypsus), lice (Pediculus humanis), lice (Pediculucus humanus corporis) Barbed lice (Phthirus pubis).
　ハジラミ目（Mallophagida）：ウシハジラミ（Dalmalinia bovis）、ヒツジハジラミ（Dalmalinia ovis）等のボビコーラ属（Bovicola spp.）；イヌハジラミ（Trichodectes canis）等のケモノハジラミ属（Trichodectes spp.）、ネコハジラミ（Felicola subrostrata）等のフェリコラ属（Felocpla spp）、ニワトリナガハジラミ（Lipeurus caponis）等のペウルス属（Lipeurus spp.）、トリメノポン属（Trimenopon spp）、メノポン属（Menopon spp.）等のトリハジラミ科（Menoponidae）。 Psyllids (Mallophagida): Bovine lava (Dalmalinia bovis), sheep baldness (Dalmalinia ovis) etc. Bovicola sp. (Bovicola spp.); P. Of the genus Fericola (Felocpla spp), Peanut (Lipeurus caponis) and the like Peurus (Lipeurus spp.), Trimenopon sp. (Trimenopon spp), Menopon sp. (Menopon spp.) And the like.
　ダニ目（Acari）：ナミハダニ（Tetranychus urticae）、カンザワハダニ（Tetranychus kanzawai）、ミツユビナミハダニ（Tetranychus evansi）、ミカンハダニ（Panonychus citri）、リンゴハダニ（Panonychus ulmi）、オリゴニカス属（Oligonychus spp.）等のハダニ科（Tetranychidae）；ミカンサビダニ（Aculops pelekassi）、リュウキュウミカンサビダニ（Phyllocoptruta citri）、トマトサビダニ（Aculops lycopersici）、チャノサビダニ（Calacarus carinatus）、チャノナガサビダニ（Acaphylla theavagrans）、ニセナシサビダニ（Eriophyes chibaensis）、リンゴサビダニ（Aculus schlechtendali）、カキサビダニ（Aceria diospyri）、Aceria tosichella、シソサビダニ（Shevtchenkella sp.）等のフシダニ科（Eriophyidae）；チャノホコリダニ（Polyphagotarsonemus latus）等のホコリダニ科（Tarsonemidae）；ミナミヒメハダニ（Brevipalpus phoenicis）等のヒメハダニ科（Tenuipalpidae）；ケナガハダニ科（Tuckerellidae）；フタトゲチマダニ（Haemaphysalis longicornis）、キチマダニ（Haemaphysalis flava）、タイワンカクマダニ（Dermacentor taiwanensis）、アメリカイヌカクマダニ（Dermacentor variabilis）、デルマセントル・アンデルソニ（Dermacentor andersoni）、ヤマトマダニ（Ixodes ovatus）、シュルツマダニ（Ixodes persulcatus）、イクソデス・リシナス（Ixodes ricinus）、ブラックレッグドチック（Ixodes scapularis）、アメリカキララマダニ（Amblyomma americanum）、アンブリオンマ・マクラタム（Ambryomma maculatum）、オウシマダニ（Boophilus microplus）、ブーフィラス・アンヌラタス（Boophilus annulatus）、クリイロコイタマダニ（Rhipicephalus sanguineus）等のマダニ科（Ixodidae）；ケナガコナダニ（Tyrophagus putrescentiae）、ホウレンソウケナガコナダニ（Tyrophagus similis）等のコナダニ科（Acaridae）；コナヒョウヒダニ（Dermatophagoides farinae）、ヤケヒョウヒダニ（Dermatophagoides pteronyssinus）等のチリダニ科（Pyroglyphidae）；ホソツメダニ（Cheyletus eruditus）、クワガタツメダニ（Cheyletus malaccensis）、ミナミツメダニ（Cheyletus moorei）、イヌツメダニ（Cheyletiella yasguri）等のツメダニ科（Cheyletidae）；ミミヒゼンダニ（Otodectes cynotis）、ヒゼンダニ（Sarcoptes scabiei）等のヒゼンダニ科（Sarcoptidae）；イヌニキビダニ（Demodex canis）等のニキビダニ科（Demodicidae）；ズツキダニ科（Listrophoridae）；イエササラダニ科（Haplochthoniidae）；イエダニ（Ornithonyssus bacoti）、トリサシダニ（Ornithonyssus sylviarum）等のオオサシダニ科（Macronyssidae）；ワクモ（Dermanyssus gallinae）等のワクモ科（Dermanyssidae）；アカツツガムシ（Leptotrombidium akamushi）等のツツガムシ科（Trombiculidae）。 Acarids (Acari): Two-spotted spider mite (Tetranychus urticae), Kanzawa spider mite (Tetranychus kanzawai), Eurasian spider mite (Tetranychus evansi), red-eared spider mite (Panonychus citri), apple red spider mite (Panonychus ulmi), genus Oligonikius ; Scutellaris mite (Aculops pelekassi), Scutellaris mite (Phyllocoptruta citri), Tomato snail (Aculops lycopersici), Scutellaris mite (Calacarus carinatus), Scutellariae ica (Acaphylla theavagrans), Discolored snail Aculus schlechtendali), Aceria diospyri, Aceria tosichella, Shevtchenkella sp. Eriophyidae, such as Schizoctella (Shevtchenkella sp.); Red-handed spider mite (Tenuipalpidae) such as (Brevipalpus phoenicis); Tannertidae (Tuckerellidae); Andersoni (Dermacentor and ersoni), Ixodes ovatus, Ixodes persulcatus, Ixodes ricinus, Black legged tick (Ixodes scapularis), American kill mite (Amblyomma americanum), amblyomumium platinum ), Ixodidae such as Boophilus microplus, Boophilus annulatus, Rhipicephalus sanguineus, etc .; Tyrophagus pu Acaridae (Acaridae), such as Trichophagus similis, etc .; Dermatophagoides such as Dermatophagoides farinae, Dermatophagoides pteronyssinus, etc. (Pyroglyphidae); Blue-spotted mite (Chyletidae), such as the brown mite (Cheyletus moorei), and the dog's red-haired mite (Chyletiella yasguri); Demodicidae); Listrophoridae; House Lepidoptera (Haplochthoniidae); Ornithonyssus bacoti, Ornithonyssus sylviarum, etc .; Macronyssidae; Macrophyses (Dermanyssus gallinae) Red mite family (Dermanyssidae); red mites (Leptotrombidium akamushi) chiggers family, etc. (Trombiculidae).
　クモ目（Araneae）：カバキコマチグモ（Cheiracanthium japonicum）等のコマチグモ科（Eutichuridae）；セアカゴケグモ（Latrodectus hasseltii）等のヒメグモ科（Theridiidae）。
　オビヤスデ目（Polydesmida）：ヤケヤスデ（Oxidus gracilis）、アカヤスデ（Nedyopus tambanus）等のヤケヤスデ科（Paradoxosomatidae）。
　等脚目（Isopoda）：オカダンゴムシ（Armadillidium vulgare）等のオカダンゴムシ科（Armadillidiidae）。 Arachnida (Araneae): Anemone family (Eutichuridae) such as Chehiracanthium japonicum etc .; A hymenodontid family (Theridiidae) such as Latrodectus hasseltii.
Obiayasuda (Polydesmida): Nephetidae (Oxidus gracilis), Red-crested cod (Nedyopus tambanus), etc.
Isopoda: Armadillidiidae, such as Armadillium vulgare.
　唇脚綱（Chilopoda）：ゲジ（Thereuonema hilgendorfi）等のゲジ科（Scutigeridae）；トビズムカデ（Scolopendra subspinipes）等のオオムカデ科（Scolopendridae）；イッスンムカデ（Bothropolys rugosus）等のイッスンムカデ科（Ethopolidae）。
　腹足綱（Gastropoda）：チャコウラナメクジ（Limax marginatus）、キイロコウラナメクジ（Limax flavus）等のコウラナメクジ科（Limacidae）；ナメクジ（Meghimatium bilineatum）等のナメクジ科（Philomycidae）；スクミリンゴガイ（Pomacea canaliculata）等のリンゴガイ科（Ampullariidae）；ヒメモノアラガイ（Austropeplea ollula）等のモノアラガイ科（Lymnaeidae）。 Lipopoda (Chilopoda): The Scutigera such as Thereuonema hilgendorfi; Scoopendra subspinipes such as Scoopendradidae;
Gastropoda (Gastropoda): Black-tailed slug (Limax marginatus), black-tailed slug (Limax flavus), etc. (Limacidae); Monopidae (Ampullariidae) of the family; Monopidae (Lymnaeidae), such as the black-and-white alga (Austropheplella)
　線虫（Nematoda）：イネシンガレセンチュウ（Aphelenchoides besseyi）等のアフェレンコイデス科（Aphelenchoididae）；ミナミネグサレセンチュウ（Pratylenchus coffeae）、Pratylenchus brachyurus、ムギネグサレセンチュウ（Pratylenchus neglectus）、ラドフォルス・シミリス（Radopholus similis）等のプラティレンクス科（Pratylenchidae）；ジャワネコブセンチュウ（Meloidogyne javanica）、サツマイモネコブセンチュウ（Meloidogyne incognita）、キタネコブセンチュウ（Meloidogyne hapla）、ダイズシストセンチュウ（Heterodera glycines）、ジャガイモシストセンチュウ（Globodera rostochiensis）、ジャガイモシロシストセンチュウ（Globodera pallida）等のヘテロデラ科（Heteroderidae）；Rotylenchulus reniformis等のホプロライムス科（Hoplolaimidae）；イチゴメセンチュウ（Nothotylenchus acris）、ジチレンクス・ジプサシ（Ditylenchus dipsaci）等のアングイナ科（Anguinidae）；チレンクルス・セミペネトランス（Tylenchulus semipenetrans）等のティレンクルス科（Tylenchulidae）；ブドウオオハリセン（Xiphinema index）等のロンギドルス科（Longidoridae）；トリコドルス科（Trichodoridae）；マツノザイセンチュウ（Bursaphelenchus xylophilus）等のパラシタアフェレンクス科（Parasitaphelenchidae）。 Nematoda (Nematoda): Aphelenchoides sp. (Aphelenchoides besseyi etc.) Aphelenchoididae (Aphelenchoididae); And the like (Pratylenchidae), etc .; Java spp. Heteroderidae (Heteroderidae), such as Glossodera (Globodera pallida); Hoprolases (Hoplolaimidae), such as Rotylenchulus reniformis; Strawberry nematode (Nothotylenchus acris), jichi Anguinidae (Anguinidae) such as Lexus gypsy (Ditylenchus dipsaci); Tylenculidae (Tylenchulidae) such as Tylenchulus seminetrans; Trichodoridae); Parasitaphelenchidae such as Bursaphelenchus xylophilus.
　対象の有害昆虫、有害ダニ類等の有害節足動物、有害軟体動物及び有害線虫は、殺虫剤、殺ダニ剤、殺軟体動物剤及び殺線虫剤に薬剤感受性の低下した、又は薬剤抵抗性の発達した有害昆虫、有害ダニ類等の有害節足動物、有害軟体動物及び有害線虫であってもよい。ただし、薬剤感受性が大幅に低下した、又は薬剤抵抗性が大幅に発達した場合は、その対象となる殺虫剤、殺ダニ剤、殺軟体動物剤及び殺線虫剤以外の殺虫剤、殺ダニ剤、殺軟体動物剤及び殺線虫剤成分を含む組成物の使用が望ましい。 The target harmful insects, harmful mites and other harmful arthropods, harmful molluscs and harmful nematodes have reduced drug sensitivity to insecticides, acaricides, molluscicides and nematocides, or drug resistance They may be sexually developed harmful insects, harmful arthropods such as harmful mites, harmful molluscs and harmful nematodes. However, when the drug sensitivity is significantly reduced or drug resistance is significantly developed, the targeted insecticides, acaricides, insecticides other than nematocides and nematocides, acaricides The use of a composition comprising a molluscicide and a nematocide component is desirable.
　本発明化合物Ｘは、昆虫媒介性ウイルス又は昆虫媒介性細菌による植物病害から植物を保護するためにも用いることができる。 The compounds X of the present invention can also be used to protect plants from plant diseases caused by insect-borne viruses or insect-borne bacteria.
　かかる昆虫媒介性ウイルスとしては、例えば次のものが挙げられる。 Such insect-borne viruses include, for example, the following.
　イネ矮化ウイルス（Rice tungro spherical virus）、イネツングロ桿菌状ウイルス（Rice tungro bacilliform virus）、イネグラッシースタントウイルス（Rice grassy stunt virus）、イネラギッドスタントウイルス（Rice ragged stunt virus）、イネ縞葉枯ウイルス（Rice stripe virus）、黒条萎縮ウイルス（Rice black streaked dwarf virus）、イネ南方黒すじ萎縮ウイルス（Southern rice black-streaked dwarf virus）、稲こぶ萎縮ウイルス（Rice gall dwarf virus）、イネ白葉病（Rice hoja blanca virus）、イネ黄葉ウイルス（Rice yellow stunt virus）、Rice yellow mottle virus、イネ萎縮ウイルス（Rice dwarf virus）、ムギ北地モザイクウイルス（Northern cereal mosaic virus）、オオムギ黄萎ウイルス（Barley yellow dwarf virus）、オオムギ微斑ウイルス（Barley mild mosaic virus）、オオムギ黄萎PAVウイルス（Barley yellow dwarf virus-PAV）、ムギ類黄萎RPSウイルス（Cereal yellow dwarf virus-RPS）、コムギ黄葉ウイルス（Wheat yellow leaf virus）、Oat sterile dwarf virus、Wheat streak mosaic virus、トウモロコシ萎縮モザイクウイルス（Maize dwarf mosaic virus）、Maize stripe virus、Maize chlorotic mottle virus、Maize chlorotic dwarf virus、Maize rayado fino virus、サトウキビモザイクウイルス（Sugarcane mosaic virus）、Fiji disease virus、Sugarcane yellow leaf virus、ダイズ微斑モザイクウイルス（Soybean mild mosaic virus）、ソテツえそ萎縮ウイルス（Cycas necrotic stunt）、ダイズ矮化ウイルス（Soybean dwarf virus）、レンゲ萎縮ウイルス（Milk vetch dwarf virus）、ダイズモザイクウイルス（Soybean mosaic virus）、アルファルファモザイクウイルス（Alfalfa mosaic virus）、インゲンマメ黄斑モザイクウイルス（Bean yellow mosaic virus）、インゲンマメモザイクウイルス（Bean common mosaic virus）、インゲンマメ南部モザイクウイルス（Southern bean mosaic virus）、ラッカセイ矮化ウイルス（Peanut stunt virus）、ソラマメウイルトウイルス１（Broad bean wilt virus 1）、ソラマメウイルトウイルス２（Broad bean wilt virus 2）、ソラマメえそモザイクウイルス（Broad bean necrosis virus）、ソラマメ葉脈黄化ウイルス（Broad bean yellow vein virus）、クローバ葉脈黄化ウイルス（Clover yellow vein virus）、ラッカセイ斑紋ウイルス（Peanut mottle virus）、タバコ条斑ウイルス（Tobacco streak virus）、Bean pod mottle virus、Cowpea chlorotic mottle virus、Mung bean yellow mosaic virus、Soybean crinkle leaf virus、トマト退緑ウイルス（Tomato chlorosis virus）、トマト黄化えそウイルス（Tomato spotted wilt virus）、トマト黄化葉巻ウイルス（Tomato yellow leaf curl virus）、トマトアスパーミィウイルス（Tomato aspermy virus）、トマトインフェクシャスクロロシスウイルス（Tomato infectious chlorosis virus）、ジャガイモ葉巻ウイルス（Potato leafroll virus）、ジャガイモＹウイルス（Potato virus Y）、メロン黄化えそウイルス（Melon yellow spot virus）、メロンえそ斑点ウイルス（Melon necrotic spot virus）、スイカモザイクウイルス（Watermelon mosaic virus）、キュウリモザイクウイルス（Cucumber mosaic virus）、ズッキーニ黄斑モザイクウイルス（Zucchini yellow mosaic virus）、カブモザイクウイルス（Turnip mosaic virus）、カブ黄化モザイクウイルス（Turnip yellow mosaic virus）、カリフラワーモザイクウイルス（Cauliflower mosaic virus）、レタスモザイクウイルス（Lettuce mosaic virus）、セルリーモザイクウイルス（Celery mosaic virus）、ビートモザイクウイルス（Beet mosaic virus）、ウリ類退緑黄化ウイルス（Cucurbit chlorotic yellows virus）、トウガラシ退緑ウイルス（Capsicum chlorosis virus）、ビートシュードイエロースウイルス（Beet pseudo yellows virus）、リーキ黄色条斑ウイルス（Leak yellow stripe virus）、タマネギ萎縮ウイルス（Onion yellow dwarf virus）、サツマイモ斑紋モザイク病（Sweet potato feathery mottle virus）、サツマイモ縮葉モザイク病（Sweet potato shukuyo mosaic virus）、イチゴ斑紋ウイルス（Strawberry mottle virus）、イチゴマイルドイエローエッジウイルス（Strawberry mild yellow edge virus）、イチゴシュードマイルドイエローエッジウイルス（Strawberry pseudo mild yellow edge virus）、イチゴクリンクルウイルス（Strawberry crinkle virus）、イチゴべインバンディングウイルス（Strawberry vein banding virus）、ウメ輪紋ウイルス（plum pox virus）、キク茎えそウイルス（Chrysanthemum stem necrosis virus）、インパチェンスえそ斑点ウイルス（Impatiens necrotic spot virus）、アイリス黄斑ウイルス（Iris yellow spot virus）、ユリ微斑ウイルス（Lily mottle virus）、ユリ潜在ウイルス（Lilly symptomless virus）、チューリップモザイクウイルス等（Tulip mosaic virus）。 Rice hatching virus (Rice tungro spherical virus), rice tungro bacillus virus (Rice tungro bacilliform virus), rice grassy stunt virus (Rice grassy stunt virus), rice ragged stunt virus (Rice ragged stunt virus), rice streak dead virus ( Rice stripe virus), Rice black streaked dwarf virus, Rice southern black streaked dwarf virus, Rice gall dwarf virus, Rice hoja disease (Rice hoja) blanca virus), rice yellow leaf virus (Rice yellow stunt virus), rice yellow mottle virus, rice dwarf virus, wheat cereals northern virus (Northern cereal mosaic virus), barley yellow dwarf virus (Barley yellow dwarf virus) , Barley mild mosaic virus, Barley yellow dwarf PAV Iris (Barley yellow dwarf virus-PAV), wheat yellow dwarf RPS virus (Cereal yellow dwarf virus-RPS), wheat yellow leaf virus (Wheat yellow leaf virus), Oat sterile dwarf virus, Wheat streak mosaic virus, corn dwarf mosaic virus Maize dwarf mosaic virus, Maize stripe virus, Maize chlorotic mottle virus, Maize chlorotic dwarf virus, Maize rayado fino virus, Sugar cane mosaic virus (Sugarcane mosaic virus), Fiji disease virus, Sugarcane yellow leaf virus, soybean leaf mosaic virus mild mosaic virus, Cycas necrotic stunt, Soybean dwarf virus, Milk vetch dwarf virus, Soybean mosaic virus, Alfalfa mosaic virus (Alfalfa virus) mosaic virus), kidney bean yellow spot Iku virus (Bean yellow mosaic virus), bean common bean mosaic virus (Bean common mosaic virus), southern bean mosaic virus (Southern bean mosaic virus), peanut rooted virus (Peanut stunt virus), broad bean wilt virus 1 (Broad bean wilt virus) 1), Broad bean wilt virus 2 (Broad bean wilt virus 2), Broad bean necrosis virus (Broad bean necrosis virus), Broad bean yellow vein virus (Broad bean yellow vein virus), Clover yellow vein virus (Clover yellow vein) , Peanut mottle virus, Tobacco streak virus, Tobacco pod mottle virus, Cowpea chlorotic mottle virus, Mung bean yellow mosaic virus, Soybean crinkle leaf virus, Tomato dark green virus (Tomato chlorosis) virus), tomato yellowish eel Virus (Tomato spotted wilt virus), Tomato yellow leaf curl virus (Tomato yellow leaf curl virus), Tomato aspermy virus (Tomato aspermy virus), Tomato infectious chlorosis virus (Tomato infectious chlorosis virus), Potato leaf curl virus (Potato leafroll) virus, Potato virus Y (Potato virus Y), Melon yellow spot virus (Melon yellow spot virus), Melon necrotic spot virus (Melon necrotic spot virus), Watermelon mosaic virus (Watermelon mosaic virus), Cucumber mosaic virus Cucumber mosaic virus, Zucchini yellow mosaic virus, Turnip mosaic virus, Turnip yellow mosaic virus, Cauliflower mosaic virus, Lettuce mosaic virus Virus (Lettuce mosaic virus), celery mosaic virus (Celery mosaic virus), beet mosaic virus (Beet mosaic virus), Cucurbita chlorosis yellow virus (Cucurbit chlorotic yellows virus), red pepper mosaic virus (Capsicum chlorine virus), beet Pseudo yellows virus (Beet pseudo yellows virus), Leek yellow stripe virus, Leon yellow stripe virus, Onion yellow dwarf virus, Sweet potato feathery mottle virus, Sweet potato leaf disease (Sweet potato shukuyo mosaic virus), strawberry mottle virus (Strawberry mottle virus), strawberry mild yellow edge virus (Strawberry mild yellow edge virus), strawberry pseudomild yellow edge virus (Strawberry pseudo mild yellow edge virus), strawberry clin Virus (Strawberry crinkle virus), strawberry vein banding virus (Strawberry vein banding virus), plum ring virus (plum pox virus), chrysanthemum stem necrosis virus (Chrysanthemum stem necrosis virus), impatiens necrotic spot virus (Impatiens necrotic) spot virus), Iris yellow spot virus, Lily mottle virus, Lily symptomless virus, tulip mosaic virus etc. (Tulip mosaic virus).
　昆虫媒介性細菌としては、例えば次のものが挙げられる。 Examples of insect-borne bacteria include the following.
　イネ黄萎病ファイトプラズマ（Candidatus Phytoplasma oryzae）、Candidatus Phytoplasma asteris、Maize bushy stunt phytoplasma、カンキツグリーニング病菌アジア型（Candidatus Liberbacter asiaticus）、カンキツグリーニング病菌アフリカ型（Candidatus Liberbacter africanus）、カンキツグリーニング病菌アメリカ型（Candidatus Liberbacter americanus）。 Rice yellow dwarf phytoplasma (Candidatus Phytoplasma oryzae), Candidatus Phytoplasma asteris, Maize bushy stunt phytoplasma, citrus greening fungus Asian type (Candidatus Liberbacter asiaticus), citrus greening fungus African type (Candidatus Liberbacter aflicanus), Type (Candidatus Liberbacter americanus).
　本発明の有害節足動物防除組成物は、本発明化合物、本発明化合物Ｘ又は組成物Ａと不活性担体とを含有する（以下、本発明組成物と記す）。本発明組成物は、通常、本発明化合物、本発明化合物Ｘ又は組成物Ａと固体担体、液体担体、ガス状担体等の不活性担体とを混合し、必要に応じて界面活性剤、その他の製剤用補助剤を添加して、乳剤、油剤、粉剤、粒剤、水和剤、顆粒水和剤、フロアブル剤、ドライフロアブル剤、マイクロカプセル剤、エアゾール剤、毒餌剤、樹脂製剤、シャンプー剤、ペースト状製剤、泡沫剤、炭酸ガス製剤、錠剤等に製剤化されている。これらの製剤は蚊取り線香、電気蚊取りマット、液体蚊取り製剤、燻煙剤、燻蒸剤、シート製剤、スポットオン剤、経口処理剤に加工されて、使用されることもある。本発明組成物は、本発明化合物、本発明化合物Ｘ又は組成物Ａを通常０．０００１～９５重量％含有する。 The noxious arthropod controlling composition of the present invention contains the present compound, the present compound X or the composition A and an inert carrier (hereinafter referred to as the present composition). The composition of the present invention is generally prepared by mixing the compound of the present invention, the compound X of the present invention or the composition A with an inert carrier such as a solid carrier, a liquid carrier, a gaseous carrier, etc. Add auxiliaries for formulation, add emulsion, oil, powder, granules, wettable, water dispersible granule, flowable, dry flowable, microcapsule, aerosol, poison bait, resin formulation, shampoo, It is formulated into a paste-like preparation, a foam, a carbon dioxide preparation, a tablet and the like. These preparations may be used as processed into mosquito coil, electric mosquito mat, liquid mosquito formula, fuming agent, fumigant, sheet preparation, spot-on agent, oral treatment agent. The composition of the present invention contains usually 0.0001 to 95% by weight of the compound of the present invention, the compound of the present invention X or the composition A.
　製剤化の際に用いられる固体担体としては、例えば粘土類（カオリンクレー、珪藻土、ベントナイト、フバサミクレー、酸性白土等）、乾式シリカ、湿式シリカ、タルク、セラミック、その他の無機鉱物（セリサイト、石英、硫黄、活性炭、炭酸カルシウム等）、化学肥料（硫安、燐安、硝安、尿素、塩安等）等の微粉末及び粒状物等、並びに合成樹脂（ポリプロピレン、ポリアクリロニトリル、ポリメタクリル酸メチル、ポリエチレンテレフタレート等のポリエステル樹脂、ナイロン－６、ナイロン－１１、ナイロン－６６等のナイロン樹脂、ポリアミド樹脂、ポリ塩化ビニル、ポリ塩化ビニリデン、塩化ビニル－プロピレン共重合体等）が挙げられる。 Examples of solid carriers used in formulation include clays (kaolin clay, diatomaceous earth, bentonite, fuvasami clay, acid clay etc.), dry silica, wet silica, talc, ceramic, and other inorganic minerals (sericite, quartz, Fine powders and particles such as sulfur, activated carbon, calcium carbonate etc., chemical fertilizers (ammonium sulfate, ammonium phosphate, ammonium nitrate, urea, sodium chloride etc.) and synthetic resins (polypropylene, polyacrylonitrile, polymethyl methacrylate, polyethylene terephthalate) And polyester resins, nylon resins such as nylon-6, nylon-11, and nylon-66, polyamide resins, polyvinyl chloride, polyvinylidene chloride, vinyl chloride-propylene copolymers, and the like.
　液体担体としては、例えば水、アルコール類（メタノール、エタノール、イソプロピルアルコール、ブタノール、ヘキサノール、ベンジルアルコール、エチレングリコール、プロピレングリコール、フェノキシエタノール等）、ケトン類（アセトン、メチルエチルケトン、シクロヘキサノン等）、芳香族炭化水素類（トルエン、キシレン、エチルベンゼン、ドデシルベンゼン、フェニルキシリルエタン、メチルナフタレン等）、脂肪族炭化水素類（ヘキサン、シクロヘキサン、灯油、軽油等）、エステル類（酢酸エチル、酢酸ブチル、ミリスチン酸イソプロピル、オレイン酸エチル、アジピン酸ジイソプロピル、アジピン酸ジイソブチル、プロピレングリコールモノメチルエーテルアセテート等）、ニトリル類（アセトニトリル、イソブチロニトリル等）、エーテル類（ジイソプロピルエーテル、１，４－ジオキサン、１，２－ジメトキシエタン、ジエチレングリコールジメチルエーテル、ジエチレングリコールモノメチルエーテル、プロピレングリコールモノメチルエーテル、ジプロピレングリコールモノメチルエーテル、３－メトキシ－３－メチル－１－ブタノール等）、アミド類（ＤＭＦ、Ｎ，Ｎ－ジメチルアセトアミド等）、スルホキシド類（ジメチルスルホキシド等）、炭酸プロピレン及び植物油（大豆油、綿実油等）が挙げられる。 Examples of liquid carriers include water, alcohols (methanol, ethanol, isopropyl alcohol, butanol, hexanol, benzyl alcohol, ethylene glycol, propylene glycol, phenoxyethanol etc.), ketones (acetone, methyl ethyl ketone, cyclohexanone etc.), aromatic hydrocarbons (Toluene, xylene, ethylbenzene, dodecylbenzene, phenylxylylethane, methylnaphthalene etc.), aliphatic hydrocarbons (hexane, cyclohexane, kerosene, light oil etc.), esters (ethyl acetate, butyl acetate, isopropyl myristate, Ethyl oleate, diisopropyl adipate, diisobutyl adipate, propylene glycol monomethyl ether acetate, etc., nitriles (acetonitrile, isobutyric acid) Nitriles etc., Ethers (diisopropyl ether, 1,4-dioxane, 1,2-dimethoxyethane, diethylene glycol dimethyl ether, diethylene glycol monomethyl ether, propylene glycol monomethyl ether, dipropylene glycol monomethyl ether, 3-methoxy-3-methyl-1 -Butanol etc., amides (DMF, N, N-dimethyl acetamide etc.), sulfoxides (dimethyl sulfoxide etc.), propylene carbonate and vegetable oil (soybean oil, cottonseed oil etc.).
　ガス状担体としては、例えばフルオロカーボン、ブタンガス、ＬＰＧ（液化石油ガス）、ジメチルエーテル及び炭酸ガスが挙げられる。 Gaseous carriers include, for example, fluorocarbons, butane gas, LPG (liquefied petroleum gas), dimethyl ether and carbon dioxide gas.
　界面活性剤としては、例えばポリオキシエチレンアルキルエーテル、ポリオキシエチレンアルキルアリールエーテル、ポリエチレングリコール脂肪酸エステル等の非イオン界面活性剤、及びアルキルスルホン酸塩、アルキルベンゼンスルホン酸塩、アルキル硫酸塩等の陰イオン界面活性剤が挙げられる。 Examples of surfactants include nonionic surfactants such as polyoxyethylene alkyl ether, polyoxyethylene alkyl aryl ether, polyethylene glycol fatty acid ester, and anions such as alkyl sulfonate, alkyl benzene sulfonate, and alkyl sulfate. Surfactants may be mentioned.
　その他の製剤用補助剤としては、固着剤、分散剤、着色剤及び安定剤等、具体的には例えばカゼイン、ゼラチン、糖類（でんぷん、アラビアガム、セルロース誘導体、アルギン酸等）、リグニン誘導体、ベントナイト、合成水溶性高分子（ポリビニルアルコール、ポリビニルピロリドン、ポリアクリル酸類等）、酸性リン酸イソプロピル、２，６－ジ－ｔｅｒｔ－ブチル－４－メチルフェノール、ＢＨＡ（２－ｔｅｒｔ－ブチル－４－メトキシフェノールと３－ｔｅｒｔ－ブチル－４－メトキシフェノールとの混合物）が挙げられる。 As other pharmaceutical adjuvants, fixing agents, dispersing agents, coloring agents, stabilizers and the like, specifically, for example, casein, gelatin, saccharides (starch, gum arabic, cellulose derivatives, alginic acid etc.), lignin derivatives, bentonite, Synthetic water-soluble polymers (polyvinyl alcohol, polyvinyl pyrrolidone, polyacrylic acids, etc.), isopropyl acid phosphate, 2,6-di-tert-butyl-4-methylphenol, BHA (2-tert-butyl-4-methoxyphenol) And a mixture of 3-tert-butyl-4-methoxyphenol).
　樹脂製剤の基材としては、例えば塩化ビニル系重合体、ポリウレタン等を挙げることができ、これらの基材には必要によりフタル酸エステル類（フタル酸ジメチル、フタル酸ジオクチル等）、アジピン酸エステル類、ステアリン酸等の可塑剤が添加されていてもよい。樹脂製剤は該基材中に化合物を通常の混練装置を用いて混練した後、射出成型、押出成型、プレス成型等により成型することにより得られ、必要により更に成型、裁断等の工程を経て、板状、フィルム状、テープ状、網状、ひも状等の樹脂製剤に加工できる。これらの樹脂製剤は、例えば動物用首輪、動物用イヤータッグ、シート製剤、誘引ひも、園芸用支柱として加工される。
　毒餌の基材としては、例えば穀物粉、植物油、糖、結晶セルロース等が挙げられ、更に必要に応じて、ジブチルヒドロキシトルエン、ノルジヒドログアイアレチン酸等の酸化防止剤、デヒドロ酢酸等の保存料、トウガラシ末等の子供やペットによる誤食防止剤、チーズ香料、タマネギ香料ピーナッツオイル等の害虫誘引性香料等が添加される。 Examples of the base material of the resin preparation include vinyl chloride polymers, polyurethane and the like, and phthalate esters (dimethyl phthalate, dioctyl phthalate, etc.), adipates, etc. may be used as necessary for these bases. And a plasticizer such as stearic acid may be added. The resin formulation is obtained by kneading the compound in the base using a common kneading apparatus, and then molding by injection molding, extrusion molding, press molding and the like, and if necessary, through further steps such as molding and cutting, It can be processed into resin preparations such as plate-like, film-like, tape-like, net-like and string-like. These resin preparations are processed, for example, as animal collars, animal ear tags, sheet preparations, drawstrings, horticultural posts.
Examples of substrates for poison bait include cereal flour, vegetable oil, sugar, crystalline cellulose and the like, and further, if necessary, antioxidants such as dibutyl hydroxytoluene and nordihydroguaiaretic acid, preservatives such as dehydroacetic acid and the like Also, an inhibitor against misphagy by children and pets such as capsicum powder, a cheese flavor, and an insect-inducing flavor such as onion flavor peanut oil are added.
　本発明の有害節足動物の防除方法は、本発明化合物、本発明化合物Ｘ又は本発明組成物の有効量を有害節足動物に直接、及び／又は、有害節足動物の生息場所（植物、土壌、家屋内、動物等）に施用することにより行われる。また、種子に施用することもできる。本発明化合物、本発明化合物Ｘ又は本発明組成物の施用方法としては、例えば、茎葉処理、土壌処理、根部処理、シャワー処理、燻煙処理、水面処理及び種子処理が挙げられる。 The method of controlling a harmful arthropod of the present invention comprises directly administering an effective amount of the compound of the present invention, the compound of the present invention or the composition of the present invention to the harmful arthropod and / or Application to soil, house, animals etc. It can also be applied to seeds. Examples of the application method of the compound of the present invention, the compound X of the present invention or the composition of the present invention include stem and leaf treatment, soil treatment, root treatment, shower treatment, smoke treatment, water surface treatment and seed treatment.
　本発明において、植物としては、植物全体、茎葉、花、穂、果実、樹幹、枝、樹冠、種子、栄養生殖器官及び苗が挙げられる。 In the present invention, plants include whole plants, stems and leaves, flowers, ears, fruits, trunks, branches, crowns, seeds, vegetative organs and seedlings.
　栄養生殖器官とは、植物の根、茎、葉等のうち、その部位を本体から切り離して土壌に設置した場合に、成長する能力を持つものを意味する。栄養生殖器官としては、例えば、塊根（tuberous root）、横走根（creeping root）、鱗茎（bulb）、球茎（corm又はsolid bulb）、塊茎（tuber）、根茎（rhizome）、匍匐枝（stolon）、担根体（rhizophore）、茎断片（cane cuttings）、むかご（propagule）及びつる（vine cutting）が挙げられる。なお、匍匐枝は、ランナー（runner）と呼ばれることもあり、むかごは、珠芽とも呼ばれ、肉芽（broad bud）、鱗芽（bulbil）に分けられる。つるとは、サツマイモやヤマノイモ等の苗条（葉及び茎の総称、shoot）を意味する。鱗茎、球茎、塊茎、根茎、茎断片、担根体又は塊根を総称して、球根とも呼ばれている。イモの栽培は塊茎を土壌に植え付けることで始めるが、用いられる塊茎は一般に種芋と呼ばれる。 The vegetative organ means the plant roots, stems, leaves, etc. that have the ability to grow when the site is separated from the main body and installed in the soil. As the vegetative reproductive organs, for example, tuberous root, creeping root, bulb, corm or solid bulb, tuber, tuber, rhizome, stolon Rhizophores, cane cuttings, propagule and vine cutting. In addition, a toothpick is also called a runner (runner), and a basket is also called a sprout and is divided into a broad bud and a bulbil (bulbil). "Vine" means shoots such as sweet potato and yam (collectively referred to as leaves and stems, shoot). The bulbs, corms, tubers, rhizomes, stem fragments, rhizomes or tuberous roots are collectively referred to as bulbs. Cultivation of potato starts by planting tubers in the soil, but the tubers used are generally called seed potatoes.
　本発明化合物、本発明化合物Ｘ又は本発明組成物の有効量を、植物又は植物を栽培する土壌に施用する方法としては、例えば、植物へ本発明化合物、本発明化合物Ｘ又は本発明組成物の有効量を施用する方法、種子消毒や種子浸漬、種子コート等の種子又は栄養生殖器官へ本発明化合物、本発明化合物Ｘ又は本発明組成物の有効量を施用する方法、及び植物を植えつける前又は植えつけた後の土壌に本発明化合物、本発明化合物Ｘ又は本発明組成物の有効量を施用する方法が挙げられる。 As a method of applying an effective amount of the compound of the present invention, the compound X of the present invention or the composition of the present invention to a plant or a soil for cultivating plants, for example, the compound of the present invention, the compound of the present invention X or the composition of the present invention Method of applying an effective amount, method of applying an effective amount of a compound of the present invention, a compound X of the present invention or a composition of the present invention to seeds or vegetative reproductive organs such as seed disinfection or seed immersion, seed coat, and before planting plants Or the method of applying the effective dose of this invention compound, this invention compound X, or this invention composition to the soil after planting is mentioned.
　本発明化合物、本発明化合物Ｘ又は本発明組成物の有効量を、植物を植えつける前又は植えつけた後の土壌に施用することによる有害節足動物を防除する方法は、例えば、有害節足動物による摂食等の被害から保護しようとする作物の根圏に本発明化合物、本発明化合物Ｘ又は本発明組成物の有効量を施用して有害節足動物を直接防除する方法、及び根部等から植物体内部に本発明化合物、本発明化合物Ｘ又は本発明組成物の有効量を浸透移行させて、植物を摂食する有害節足動物を防除する方法が挙げられる。 A method for controlling an arthropod pest by applying an effective amount of the compound of the present invention, the compound X of the present invention or the composition of the present invention to the soil before planting or after planting is, for example, Method of directly controlling harmful arthropods by applying an effective amount of the compound of the present invention, the compound of the present invention or the composition of the present invention to the rhizosphere of a crop to be protected from damage such as feeding by animals And the effective amount of the compound of the present invention, the compound of the present invention, or the composition of the present invention into the interior of the plant body to control a harmful arthropod feeding on a plant.
　本発明化合物、本発明化合物Ｘ又は本発明組成物を農業分野の有害節足動物防除に用いる場合、その施用量は、１００００ｍ2あたりの本発明化合物又は本発明化合物Ｘの量で通常１～１００００ｇである。種子又は栄養生殖器官に施用する場合は、種子又は栄養生殖器官１Ｋｇに対して、本発明化合物又は本発明化合物Ｘの量が、通常０．００１～１００ｇである。組成物Ａの施用量は、種子又は栄養生殖器官１ｋｇあたり、通常０．００１～１００ｇである。本発明化合物、本発明化合物Ｘ又は組成物Ａが乳剤、水和剤、フロアブル剤等に製剤化されている場合は、通常、有効成分濃度が０．０１～１００００ｐｐｍとなるように水で希釈して施用し、粒剤、粉剤等は、通常、そのまま施用する。 When the compound of the present invention, the compound X of the present invention or the composition of the present invention is used for controlling arthropod pests in the agricultural field, the application amount thereof is usually 1 to 10000 g in the amount of the compound of the present invention or compound X of the present invention per 10000 m 2 It is. When applied to seeds or vegetative organs, the amount of the compound of the present invention or the compound X of the present invention is usually 0.001 to 100 g based on 1 Kg of seeds or vegetative organs. The application rate of composition A is usually 0.001 to 100 g per kg of seed or vegetative organ. When the compound of the present invention, compound X of the present invention or composition A is formulated into an emulsion, a wettable powder, a flowable, etc., it is usually diluted with water so that the concentration of the active ingredient is 0.01 to 10000 ppm. And granules, dusts, etc. are usually applied as such.
　これらの製剤や製剤の水希釈液は、有害節足動物又は有害節足動物から保護すべき作物等の植物に直接散布処理してもよく、また耕作地の土壌に生息する有害節足動物を防除するために、該土壌に処理してもよい。 These formulations and their dilutions may be sprayed directly onto plants, such as harmful arthropods or crops to be protected from harmful arthropods, and harmful arthropods that inhabit the soil of cultivated land The soil may be treated to control.
　また、シート状やひも状に加工した樹脂製剤を作物に巻き付ける、作物近傍に張り渡す、株元土壌に敷く等の方法により処理することもできる。 In addition, the resin preparation processed into a sheet or string can be treated by a method such as wrapping around a crop, spreading it in the vicinity of a crop, spreading it on stock soil, or the like.
　本発明化合物、本発明化合物Ｘ又は本発明組成物を家屋内に生息する有害節足動物の防除に用いる場合、その施用量は、面上に施用する場合は処理面積１ｍ2あたりの本発明化合物又は本発明化合物Ｘの量で、通常、０．０１～１０００ｍｇであり、空間に処理する場合は処理空間１ｍ3あたりの本発明化合物又は本発明化合物Ｘの量で、通常、０．０１～５００ｍｇである。本発明化合物、本発明化合物Ｘ又は組成物Ａが乳剤、水和剤、フロアブル剤等に製剤化されている場合は、通常有効成分濃度が０．１～１００００ｐｐｍとなるように水で希釈して施用し、油剤、エアゾール剤、燻煙剤、毒餌剤等はそのまま施用する。 When the compound of the present invention, the compound X of the present invention or the composition of the present invention is used for controlling harmful arthropods that live in a house, the application amount thereof is the compound of the present invention per 1 m 2 of treated area or an amount of the present compound X, usually from 0.01 ~ 1000 mg, in an amount of compound of the invention or the invention compound X per processing space 1 m 3 if the process in the space, generally 0.01 ~ 500 mg It is. When the compound of the present invention, compound X of the present invention or composition A is formulated into an emulsion, a wettable powder, a flowable, etc., it is usually diluted with water so that the concentration of the active ingredient is 0.1 to 10000 ppm. Apply oil, aerosol, smoke, poison bait etc. as it is.
　本発明化合物、本発明化合物Ｘ又は本発明組成物をウシ、ウマ、ブタ、ヒツジ、ヤギ、ニワトリ等の家畜、イヌ、ネコ、ラット、マウス等の小動物の外部寄生虫防除に用いる場合は、獣医学的に公知の方法で動物に使用することができる。具体的な使用方法としては、全身抑制を目的にする場合には、例えば錠剤、飼料混入、坐薬、注射（筋肉内、皮下、静脈内、腹腔内等）により投与され、非全身的抑制を目的とする場合には、例えば油剤若しくは水性液剤を噴霧する、ポアオン処理若しくはスポットオン処理を行う、シャンプー製剤で動物を洗う又は樹脂製剤を首輪や耳札にして動物に付ける等の方法により用いられる。動物に投与する場合の本発明化合物又は本発明化合物Ｘの量は、通常動物の体重１ｋｇに対して、０．１～１０００ｍｇの範囲である。 When the compound of the present invention, the compound of the present invention X or the composition of the present invention is used for ectoparasite control of small animals such as cattle, horses, pigs, sheep, goats and chickens, domestic animals such as dogs, cats, rats and mice It can be used on animals in a manner known in the art. As a specific method of use, for the purpose of systemic suppression, for example, it is administered by tablet, feed mixing, suppository, injection (intramuscular, subcutaneous, intravenous, intraperitoneal etc.) and is intended for non-systemic suppression. In this case, for example, oil or aqueous solution is sprayed, pour-on treatment or spot-on treatment is performed, the animal is washed with a shampoo preparation, or the resin preparation is used as a collar or ear tag and attached to the animal. The amount of the compound of the present invention or the compound of the present invention X when administered to an animal is usually in the range of 0.1 to 1000 mg per 1 kg of animal weight.
　また、本発明化合物、本発明化合物Ｘ又は本発明組成物は、畑、水田、芝生、果樹園等の農耕地における有害節足動物の防除剤として使用することができる。植物としては、例えば以下のものが挙げられる。 Furthermore, the compound of the present invention, the compound of the present invention X or the composition of the present invention can be used as a control agent for arthropod pests in agricultural land such as fields, paddy fields, lawns, orchards. Examples of plants include the following.
　農作物；トウモロコシ、イネ、コムギ、オオムギ、ライムギ、エンバク、ソルガム、ワタ、ダイズ、ピーナッツ、ソバ、テンサイ、ナタネ、ヒマワリ、サトウキビ、タバコ等、
　野菜；ナス科野菜（ナス、トマト、ピーマン、トウガラシ、ジャガイモ等）、ウリ科野菜（キュウリ、カボチャ、ズッキーニ、スイカ、メロン等）、アブラナ科野菜（ダイコン、カブ、セイヨウワサビ、コールラビ、ハクサイ、キャベツ、カラシナ、ブロッコリー、カリフラワー等）、キク科野菜（ゴボウ、シュンギク、アーティチョーク、レタス等）、ユリ科野菜（ネギ、タマネギ、ニンニク、アスパラガス等）、セリ科野菜（ニンジン、パセリ、セロリ、アメリカボウフウ等）、アカザ科野菜（ホウレンソウ、フダンソウ等）、シソ科野菜（シソ、ミント、バジル等）、イチゴ、サツマイモ、ヤマノイモ、サトイモ、インゲンマメ等、花卉、観葉植物等、
　果樹；仁果類（リンゴ、セイヨウナシ、ニホンナシ、カリン、マルメロ等）、核果類（モモ、スモモ、ネクタリン、ウメ、オウトウ、アンズ、プルーン等）、カンキツ類（ウンシュウミカン、オレンジ、レモン、ライム、グレープフルーツ等）、堅果類（クリ、クルミ、ハシバミ、アーモンド、ピスタチオ、カシューナッツ、マカダミアナッツ等）、液果類（ブルーベリー、クランベリー、ブラックベリー、ラズベリー等）、ブドウ、カキ、オリーブ、ビワ、バナナ、コーヒー、ナツメヤシ、ココヤシ等、
　果樹以外の樹；チャ、クワ、花木、街路樹（トネリコ、カバノキ、ハナミズキ、ユーカリ、イチョウ、ライラック、カエデ、カシ、ポプラ、ハナズオウ、フウ、プラタナス、ケヤキ、クロベ、モミノキ、ツガ、ネズ、マツ、トウヒ、イチイ等）等。 Agricultural products: corn, rice, wheat, barley, rye, oats, sorghum, cotton, soybeans, peanuts, buckwheat, sugar beet, rapeseed, sunflower, sugar cane, tobacco etc.
Vegetables; Solanaceous vegetables (eggplant, tomatoes, peppers, peppers, potatoes, etc.), Cucurbitaceae vegetables (eg, cucumbers, pumpkins, zucchini, watermelons, melons, etc.), Brassicaceae vegetables (radish, turnip, horseradish, kohlrabi, Chinese cabbage, cabbage) , Mustard, broccoli, cauliflower etc.), Asteraceae vegetables (eg burdock, shung chrysanthemum, artichoke, lettuce etc.), a liliaceous vegetables (scallion, onion, garlic, asparagus etc.), vegidaceae vegetables (carrots, parsley, celery, American buffalo) Etc.), vecoraceae vegetables (spinach, swiss chard etc.), sorghums vegetables (sesame, mint, basil etc.), strawberries, sweet potatoes, yams, taros, beans, etc., florets, houseplants etc.
Fruits; Fruits (apples, pears, Japanese pears, cullins, quince etc.), Core fruits (momo, plums, nectarines, jujubes, apricots, prunes etc.), citrus fruits (palms, oranges, lemons, limes, grapefruits) Etc), nuts (nuts, walnuts, hazelnuts, almonds, pistachios, cashews, macadamias etc), berries (blueberries, cranberries, blackberries, raspberries etc), grapes, oysters, olives, loquats, bananas, coffee, etc. Date palm, coconut palm, etc.
Trees other than fruit trees; tea, mulberry, flowering trees, street trees (astera, birch, dogwood, eucalyptus, eucalyptus, ginkgo, lilac, maple, oak, poplar, persimmon, perennial, fusarium, plananas, persimmon, perianthus, birch, fir tree, tsuga, nezu, pine Spruce, yew etc. etc.
　上記植物は、自然交配で作出しうる植物、突然変異により発生しうる植物、F1ハイブリッド植物、及び遺伝子組換え作物も含まれる。遺伝子組換え作物としては、例えばイソキサフルトール等のHPPD（４－ヒドロキシフェニルピルビン酸ジオキシゲナーゼ酵素）阻害剤、イマゼタピル、チフェンスルフロンメチル等のALS（アセト乳酸合成酵素）阻害剤、EPSP（５－エノールピルビルシキミ酸－３－リン酸合成酵素）阻害剤、グルタミン合成酵素阻害剤、PPO（プロトポルフィリノーゲン酸化酵素）阻害剤、ブロモキシニル、又はジカンバ等の除草剤に対する耐性が付与された植物；バチルス・チューリンゲンシス（Bacillus thuringiensis）などのバチルス属で知られている選択的毒素等を合成することが可能となった植物；有害昆虫由来の内在性遺伝子に部分的に一致する遺伝子断片等を合成し、標的有害昆虫体内でジーンサイレンシング（RNAi；RNA interference）を誘導することにより特異的な殺虫活性を付与することができる植物が挙げられる。 The above-mentioned plants also include plants which can be produced by natural mating, plants which can be generated by mutation, F1 hybrid plants and genetically modified crops. Examples of genetically modified crops include HPPD (4-hydroxyphenylpyruvate dioxygenase enzyme) inhibitors such as isoxaflutole, ALS (acetolactate synthetase) inhibitors such as imazethapyr and thifensulfuron methyl, EPSP (5 -Plants with resistance to herbicides such as -enolpyruvyl shikimate-3-phosphate synthetase inhibitor, glutamine synthetase inhibitor, PPO (protoporphyrinogen oxidase) inhibitor, bromoxynil, or dicamba A plant capable of synthesizing selective toxins and the like known in Bacillus genera such as Bacillus thuringiensis; gene fragments and the like partially corresponding to endogenous genes derived from harmful insects; Synthesized and specifically induced by inducing gene silencing (RNAi; RNA interference) in the target harmful insect body. Included are plants capable of conferring different insecticidal activities.
　上記植物は、一般的に栽培される品種であれば特に限定はない。 The above-mentioned plant is not particularly limited as long as it is a commonly grown variety.
　以下、本発明を製造例、製剤例及び試験例等によりさらに詳しく説明するが、本発明はこれらの例のみに限定されるものではない。 Hereinafter, the present invention will be described in more detail by production examples, formulation examples, test examples and the like, but the present invention is not limited to these examples.
　本明細書中、Meはメチル基を表し、Etはエチル基を表し、Prはプロピル基を表し、iPrはイソプロピル基を表し、Buはブチル基を表し、Penはペンチル基を表し、Hexはヘキシル基を表し、tBuはｔｅｒｔ－ブチル基を表し、cPrはシクロプロピル基を表し、cBuはシクロブチル基を表し、cPenはシクロペンチル基を表し、cHexはシクロヘキシル基を表し、Phはフェニル基を表す。例えば、CHMeCH2CH3は１－メチルプロピル基を表し、(CH2)2CHMe2は３－メチルブチル基を表し、CH2CH=CMe2は３－メチル－２－ブテニル基を表し、C≡CcHexは２－シクロヘキシルエチニル基を表し、CH2CH=NOCH2C≡CHは２－（プロパルギルオキシイミノ）エチル基を表す。また、cPr、cBu、cPen及びcHexが置換基を有する場合は、置換基を記号の前に置換位置とともに記す。例えば、3,3-Me2-cBuは３，３－ジメチルシクロブチル基を表し、CH2(4-OMe-cHex)は（４－メトキシシクロヘキシル）メチル基を表す。 In the present specification, Me represents a methyl group, Et represents an ethyl group, Pr represents a propyl group, iPr represents an isopropyl group, Bu represents a butyl group, Pen represents a pentyl group, and Hex represents hexyl. TBu represents a tert-butyl group, cPr represents a cyclopropyl group, cBu represents a cyclobutyl group, cPen represents a cyclopentyl group, cHex represents a cyclohexyl group, and Ph represents a phenyl group. For example, CHMeCH 2 CH 3 represents a 1-methylpropyl group, (CH 2) 2 CHMe 2 represents a 3-methylbutyl group, CH 2 CH = CMe 2 represents 3-methyl-2-butenyl group, C≡ CcHex represents a 2-cyclohexylethynyl group, and CH 2 CH = NOCH 2 C≡CH represents a 2- (propargyloxyimino) ethyl group. In addition, when cPr, cBu, cPen and cHex have a substituent, the substituent is indicated before the symbol together with the substitution position. For example, 3,3-Me 2 -cBu represents a 3,3-dimethylcyclobutyl group, and CH 2 (4-OMe-cHex) represents a (4-methoxycyclohexyl) methyl group.
参考製造例１
　２－イソプロピル－４－ヒドロキシ－５，６－ジメチルニコチン酸メチル２．６５ｇ、炭酸カリウム３．２８ｇ、アリルブロミド２．０５ｍＬ及びアセトニトリル５０ｍＬの混合物を還流下で２時間撹拌した。得られた混合物に水を加え、ＭＴＢＥで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体４１を３．１３ｇ得た。
Figure JPOXMLDOC01-appb-C000030
 　中間体４１：1H-NMR (CDCl3) δ: 6.07-5.93 (1H, m), 5.39 (1H, d), 5.25 (1H, d), 4.40 (2H, d), 3.90 (3H, s), 2.94 (1H, m), 2.49 (3H, s), 2.16 (3H, s), 1.25 (6H, d). Reference Production Example 1
A mixture of 2.65 g of methyl 2-isopropyl-4-hydroxy-5,6-dimethylnicotinate, 3.28 g of potassium carbonate, 2.05 mL of allyl bromide and 50 mL of acetonitrile was stirred under reflux for 2 hours. To the resulting mixture was added water and extracted with MTBE. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 3.13 g of an intermediate 41 represented by the following formula.
Figure JPOXMLDOC01-appb-C000030
 Intermediate 41: 1 H-NMR (CDCl 3 ) δ: 6.07-5.93 (1 H, m), 5. 39 ( 1 H, d), 5.25 (1 H, d), 4. 40 (2 H, d), 3. 90 (3 H, s) , 2.94 (1H, m), 2.49 (3H, s), 2.16 (3H, s), 1.25 (6H, d).
参考製造例２
　３．１３ｇの中間体４１及びトルエン３０ｍＬの混合物に、－７８℃でジイソブチルアルミニウムヒドリド（１．０Ｍトルエン溶液）２６．１ｍＬを加え、４時間撹拌した。得られた混合物に飽和酒石酸ナトリウムカリウム水溶液を加え、室温で１時間撹拌した。得られた混合物をＭＴＢＥで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下で濃縮し、下式に示される中間体４２を２．７９ｇ得た。
Figure JPOXMLDOC01-appb-C000031
 　中間体４２：1H-NMR (CDCl3) δ: 6.18-6.03 (1H, m), 5.43 (1H, d), 5.31 (1H, d), 4.73 (2H, d), 4.40 (2H, d), 3.34 (1H, m), 2.48 (3H, s), 2.17 (3H, s), 1.85 (1H, t), 1.27 (6H, d). Reference Production Example 2
To a mixture of 3.13 g of Intermediate 41 and 30 mL of toluene, 26.1 mL of diisobutylaluminum hydride (1.0 M solution in toluene) was added at -78.degree. C. and stirred for 4 hours. To the resulting mixture was added saturated aqueous sodium potassium tartrate solution, and the mixture was stirred at room temperature for 1 hour. The resulting mixture was extracted with MTBE. The obtained organic layer was dried over magnesium sulfate and concentrated under reduced pressure to obtain 2.79 g of Intermediate 42 represented by the following formula.
Figure JPOXMLDOC01-appb-C000031
 Intermediate 42: 1 H-NMR (CDCl 3 ) δ: 6.18-6.03 (1 H, m), 5.43 (1 H, d), 5.31 (1 H, d), 4.73 (2 H, d), 4. 40 (2 H, d) , 3.34 (1H, m), 2.48 (3H, s), 2.17 (3H, s), 1.85 (1H, t), 1.27 (6H, d).
参考製造例３
　６．４８ｇの中間体４２及びクロロホルム１００ｍＬの混合物に、二酸化マンガン２３．９ｇを加え、還流下で９時間撹拌した。得られた混合物をろ過し、ろ液を減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体４３を５．０９ｇ得た。
Figure JPOXMLDOC01-appb-C000032
 　中間体４３：1H-NMR (CDCl3) δ: 10.50 (1H, s), 6.13-6.00 (1H, m), 5.42 (1H, d), 5.32 (1H, d), 4.41 (2H, d), 3.87 (1H, m), 2.53 (3H, s), 2.20 (3H, s), 1.24 (6H, d). Reference Production Example 3
23.9 g of manganese dioxide was added to a mixture of 6.48 g of Intermediate 42 and 100 mL of chloroform, and the mixture was stirred under reflux for 9 hours. The resulting mixture was filtered and the filtrate was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 5.09 g of Intermediate 43 represented by the following formula.
Figure JPOXMLDOC01-appb-C000032
 Intermediate 43: 1 H-NMR (CDCl 3 ) δ: 10.50 (1 H, s), 6.13-6.00 (1 H, m), 5.42 (1 H, d), 5.32 (1 H, d), 4.41 (2 H, d) , 3.87 (1H, m), 2.53 (3H, s), 2.20 (3H, s), 1.24 (6H, d).
参考製造例４
　ノニルトリフェニルホスホニウムブロミド７．５４ｇ及びＴＨＦ２０ｍＬの混合物に、カリウムｔ－ブトキシド１．６９ｇを加え、室温で１０分間撹拌した。得られた混合物に４－（アリルオキシ）－２，５，６－トリメチルピリジン－３－カルボアルデヒド１．０３ｇを加え、室温で１時間撹拌した。得られた混合物に水を加え、酢酸エチルで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体１（Ｅ：Ｚ＝１：１）を１．５９ｇ得た。
Figure JPOXMLDOC01-appb-C000033
 　中間体１：1H-NMR (CDCl3) δ: 6.31 (0.5H, d), 6.24 (0.5H, d), 6.16-5.94 (1.5H, m), 5.78 (0.5H, td), 5.40-5.30 (1H, m), 5.27-5.16 (1H, m), 4.32-4.24 (2H, m), 2.49 (1.5H, s), 2.46 (1.5H, s), 2.44 (1.5H, s), 2.37 (1.5H, s), 2.23 (1H, q), 2.16 (1.5H, s), 2.15 (1.5H, s), 1.88 (1H, q), 1.14-1.51 (12H, m), 0.93-0.82 (3H, m). Reference Production Example 4
To a mixture of 7.54 g of nonyltriphenylphosphonium bromide and 20 mL of THF, 1.69 g of potassium t-butoxide was added, and stirred at room temperature for 10 minutes. To the resulting mixture was added 1.03 g of 4- (allyloxy) -2,5,6-trimethylpyridine-3-carbaldehyde, and the mixture was stirred at room temperature for 1 hour. To the resulting mixture was added water and extracted with ethyl acetate. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 1.59 g of Intermediate 1 (E: Z = 1: 1) represented by the following formula.
Figure JPOXMLDOC01-appb-C000033
 Intermediate 1: 1 H-NMR (CDCl 3 ) δ: 6.31 (0.5 H, d), 6.24 (0.5 H, d), 6.16-5.94 (1.5 H, m), 5.78 (0.5 H, td), 5.40- 5.30 (1H, m), 5.27-5.16 (1H, m), 4.32-4.24 (2H, m), 2.49 (1.5 H, s), 2.46 (1.5 H, s), 2.44 (1.5 H, s), 2.37 (1.5 H, s), 2.23 (1 H, q), 2. 16 (1.5 H, s), 2. 15 (1.5 H, s), 1. 88 (1 H, q), 1.14-1.51 (12 H, m), 0.93-0.82 ( 3H, m).
参考製造例５
　参考製造例４に記載の方法に準じて製造した化合物及びその物性値を以下に示す。
式（Ａ－１）
Figure JPOXMLDOC01-appb-C000034
 で示される化合物において、Ｒ1x及びＲ2xが［表１］に記載のいずれかの組み合わせである化合物。 Reference Production Example 5
The compounds produced according to the method described in Reference Production Example 4 and the physical properties thereof are shown below.
Formula (A-1)
Figure JPOXMLDOC01-appb-C000034
 In the compound shown by these, compounds in which R 1x and R 2x are any combination described in [Table 1].
Figure JPOXMLDOC01-appb-T000035
　中間体２：1H-NMR (CDCl3) δ: 6.31 (0.5H, d), 6.24 (0.5H, d), 6.14-5.94 (1.5H, m), 5.78 (0.5H, m), 5.40-5.38 (1H, m), 5.27-5.18 (1H, m), 4.29-4.25 (2H, m), 2.49 (1.5H, s), 2.46 (1.5H, s), 2.44 (1.5H, s), 2.37 (1.5H, s), 2.26-2.20 (1H, m), 2.16 (1.5H, s), 2.16 (1.5H, s), 1.92-1.85 (1H, m), 1.52-1.43 (1H, m), 1.38-1.30 (3H, m), 1.24-1.16 (2H, m), 0.90 (1.5H, t), 0.83 (1.5H, t).
　中間体３：1H-NMR (CDCl3) δ: 6.31 (0.5H, d), 6.24 (0.5H, d), 6.13-5.94 (1.5H, m), 5.78 (0.5H, m), 5.40-5.30 (1H, m), 5.26-5.19 (1H, m), 4.30-4.25 (2H, m), 2.48 (1.5H, s), 2.46 (1.5H, s), 2.44 (1.5H, s), 2.37 (1.5H, s), 2.27-2.20 (1H, m), 2.16 (1.5H, s), 2.16 (1.5H, s), 1.93-1.86 (1H, m), 1.50-1.20 (4H, m) 0.93 (1.5H, t), 0.82 (1.5H, t).
　中間体４：1H-NMR (CDCl3) δ: 6.32 (0.5H, d), 6.26 (0.5H, d), 6.14-5.94 (1.5H, m), 5.79 (0.5H, td), 5.40-5.30 (1H, m), 5.27-5.18 (1H, m), 4.32-4.25 (2H, m), 2.49 (1.5H, s), 2.46 (1.5H, s), 2.44 (1.5H, s), 2.37 (1.5H, s), 2.18-2.15 (1H, m), 2.17 (1.5H, s), 2.16 (1.5H, s), 1.91-1.84 (1H, m), 1.56-1.45 (1H, m), 1.43-1.31 (1H, m), 0.97 (1.5H, t), 0.84 (1.5H, t).
　中間体５：1H-NMR (CDCl3) δ: 6.31 (0.5H, d), 6.22 (0.5H, d), 6.14 (0.5H, m), 5.95-6.07 (1H, m), 5.76 (0.5H, m), 5.30-5.40 (1H, m), 5.19-5.26 (1H, m), 4.26-4.31 (2H, m), 2.49 (1.5H, s), 2.46 (1.5H, s), 2.44 (1.5H, s), 2.37 (1.5H, s), 2.29-2.21 (1H, m), 2.16 (1.5H, s), 2.16 (1.5H, s), 1.86-1.95 (1H, m), 1.10 (1.5H, t), 0.94 (1.5H, t).
　中間体６：1H-NMR (CDCl3) δ: 6.36-6.28 (1H, m), 6.16-5.84 (1.5H, m), 5.79 (0.5H, td), 5.30-5.40 (1H, m), 5.27-5.19 (1H, m), 4.29-4.25 (2H, m), 2.48 (1.5H, s), 2.47 (1.5H, s), 2.44 (1.5H, s), 2.37 (1.5H, s), 2.17 (1.5H, s), 2.16 (1.5H, s), 1.91 (1.5H, dd), 1.54 (1.5H, dd).
　中間体７：1H-NMR (CDCl3) δ: 6.72 (1H, dd), 6.03 (1H, m), 5.68 (1H, dd), 5.54 (1H, dd), 5.38 (1H, m), 5.25 (1H, m), 4.29 (2H, m), 2.51 (3H, s), 2.46 (3H, s), 2.17 (3H, s).
　中間体８：1H-NMR (CDCl3) δ: 7.10 (0.5H, dd), 6.54 (0.5H, t), 6.38 (0.5H, d), 6.19 (0.5H, d), 5.92-6.09 (1.5H, m), 5.66-5.58 (0.5H, m), 5.45-5.16 (2H, m), 4.35-4.23 (2H, m), 2.52 (1.5H, s), 2.48 (1.5H, s), 2.45 (1.5H, s), 2.36 (1.5H, s), 2.17 (3H, s), 1.85 (1.5H, s), 1.81 (3H, s), 1.74 (1.5H, s).
　中間体９：1H-NMR (CDCl3) δ: 6.64-6.54 (1H, m), 6.16-5.81 (2H, m), 5.40-5.20 (2H, m), 4.28-4.21 (2H, m), 3.08-2.96 (1H, m), 2.82-2.70 (1H, m), 2.50 (1.5H, s), 2.48 (1.5H, s), 2.46 (1.5H, s), 2.37 (1.5H, s), 2.18 (1.5H, s), 2.17 (1.5H, s).
　中間体１０：1H-NMR (CDCl3) δ: 6.27 (0.5H, d), 6.13-5.95 (2H, m), 5.59 (0.5H, dd), 5.40-5.30 (1H, m), 5.27-5.18 (1H, m), 4.34-4.25 (2H, m), 2.47 (3H, s), 2.44 (1.5H, s), 2.38 (1.5H, s), 2.16 (1.5H, s), 2.15 (1.5H, s), 1.99-1.55 (6H, m), 1.40-0.98 (5H, m).
　中間体４４：1H-NMR (CDCl3) δ: 6.51 (0.5H, d), 6.43 (0.5H, d), 6.23-5.77 (2H, m), 5.46-5.20 (2H, m), 4.31-4.22 (2H, m), 2.62-2.52 (1H, m), 2.51 (1.5H, s), 2.47 (1.5H, s), 2.45 (1.5H, s), 2.45-2.20 (3H, m), 2.38 (1.5H, s), 2.17 (1.5H, s), 2.16 (1.5H, s).
　中間体４５：1H-NMR (CDCl3) δ: 6.34 (0.5H, d), 6.29 (0.5H, d), 6.09-5.94 (1.5H, m), 5.84-5.73 (0.5H, m), 5.40-5.30 (1H, m), 5.26-5.18 (1H, m), 4.29-4.21 (2H, m), 3.31 (0.5H, m), 3.17 (0.5H, m), 2.48 (1.5H, s), 2.45 (1.5H, s), 2.25-2.18 (1H, m), 2.15 (1.5H, s), 2.14 (1.5H, s), 1.92-1.85 (1H, m), 1.56-1.46 (1H, m), 1.43-1.30 (1H, m), 1.22 (3H, d), 1.18 (3H, d), 0.97 (1.5H, t), 0.85 (1.5H, t).
　中間体４６：1H-NMR (CDCl3) δ: 6.33 (0.5H, d), 6.27 (0.5H, d), 6.08-5.93 (1.5H, m), 5.82-5.73 (0.5H, m), 5.40-5.29 (1H, m), 5.28-5.18 (1H, m), 4.29-4.20 (2H, m), 3.30 (0.5H, m), 3.16 (0.5H, m), 2.47 (1.5H, s), 2.45 (1.5H, s), 2.28-2.18 (1H, m), 2.15 (1.5H, s), 2.14 (1.5H, s), 1.94-1.86 (1H, m), 1.52-1.23 (4H, m), 1.21 (3H, d), 1.18 (3H, d), 0.93 (1.5H, t), 0.83 (1.5H, t).
　中間体４７：1H-NMR (CDCl3) δ: 6.33 (0.5H, d), 6.29 (0.5H, d), 6.15-5.94 (1.5H, m), 5.83-5.76 (0.5H, m), 5.40-5.29 (1H, m), 5.27-5.18 (1H, m), 4.30-4.24 (2H, m), 2.79 (1H, q), 2.69 (1H, q), 2.48 (1.5H, s), 2.45 (1.5H, s), 2.26-2.18 (1H, m), 2.17 (1.5H, s), 2.16 (1.5H, s), 1.92-1.83 (1H, m), 1.57-1.45 (1H, m), 1.42-1.31 (1H, m), 1.22 (1.5H, t), 1.17 (1.5H, t), 0.97 (1.5H, t), 0.85 (1.5H, t).
　中間体４８：1H-NMR (CDCl3) δ: 6.32 (0.5H, d), 6.27 (0.5H, d), 6.17-5.93 (1.5H, m), 5.82-5.74 (0.5H, m), 5.40-5.28 (1H, m), 5.26-5.18 (1H, m), 4.32-4.25 (2H, m), 2.79 (1H, q), 2.68 (1H, q), 2.47 (1.5H, s), 2.45 (1.5H, s), 2.29-2.19 (1H, m), 2.16 (1.5H, s), 2.16 (1.5H, s), 1.95-1.82 (1H, m), 1.52-1.22 (4H, m), 1.21 (1.5H, t), 1.16 (1.5H, t), 0.93 (1.5H, t), 0.83 (1.5H, t).
　中間体４９：1H-NMR (CDCl3) δ: 6.91－6.83 (1H, m), 6.09-5.97 (1H, m), 5.33 (1H, d), 5.22 (1H, d), 4.29 (2H, d), 2.54 (3H, s), 2.36 (3H, s), 2.29 (2H, t), 2.16 (3H, s), 1.92 (2H, t), 1.69-1.43 (6H, m).
　中間体５０：1H-NMR (CDCl3) δ: 7.81 (1H, d), 6.56 (1H, d), 6.04 (1H, m), 5.39 (1H, m), 5.28 (1H, m), 4.30-4.24 (4H, m), 2.58 (3H, s), 2.48 (3H, s), 2.18 (3H, s), 1.34 (3H, t).
Figure JPOXMLDOC01-appb-T000035
Intermediate 2: 1 H-NMR (CDCl 3 ) δ: 6.31 (0.5 H, d), 6.24 (0.5 H, d), 6.14-5.94 (1.5 H, m), 5. 78 (0.5 H, m), 5. 40- 5.38 (1H, m), 5.27-5.18 (1H, m), 4.29-4.25 (2H, m), 2.49 (1.5 H, s), 2.46 (1.5 H, s), 2.44 (1.5 H, s), 2.37 (1.5H, s), 2.26-2.20 (1 H, m), 2.16 (1.5 H, s), 2.16 (1.5 H, s), 1.92-1. 85 (1 H, m), 1.52-1. 43 (1 H, m), 1.38-1 .30 (3H, m), 1.24-1. 16 (2H, m), 0.90 (1.5 H, t), 0.83 (1.5 H, t).
Intermediate 3: 1 H-NMR (CDCl 3 ) δ: 6.31 (0.5 H, d), 6.24 (0.5 H, d), 6.13-5.94 (1.5 H, m), 5. 78 (0.5 H, m), 5. 40- 5.30 (1H, m), 5.26-5.19 (1H, m), 4.30-4.25 (2H, m), 2.48 (1.5 H, s), 2.46 (1.5 H, s), 2.44 (1.5 H, s), 2.37 (1.5 H, s), 2.27-2.20 (1 H, m), 2.16 (1.5 H, s), 2.16 (1.5 H, s), 1. 93-1. 86 (1 H, m), 1.50-1. 20 (4 H, m) 0.93 (1.5 H, t), 0.82 (1.5 H, t).
Intermediate 4: 1 H-NMR (CDCl 3 ) δ: 6.32 (0.5 H, d), 6.26 (0.5 H, d), 6.14-5.94 (1.5 H, m), 5.79 (0.5 H, td), 5.40 5.30 (1H, m), 5.27-5.18 (1H, m), 4.32-4.25 (2H, m), 2.49 (1.5 H, s), 2.46 (1.5 H, s), 2.44 (1.5 H, s), 2.37 (1.5 H, s), 2.18-2.15 (1 H, m), 2.17 (1.5 H, s), 2.16 (1.5 H, s), 1.91-1.84 (1 H, m), 1.56-1.45 (1 H, m), 1.43-1.31 (1 H, m), 0.97 (1.5 H, t), 0.84 (1.5 H, t).
Intermediate 5: 1 H-NMR (CDCl 3 ) δ: 6.31 (0.5 H, d), 6.22 (0.5 H, d), 6.14 (0.5 H, m), 5.95-6.07 (1 H, m), 5.76 (0.5 H, m), 5.30-5.40 (1H, m), 5.19-5.26 (1H, m), 4.26-4.31 (2H, m), 2.49 (1.5H, s), 2.46 (1.5H, s), 2.44 ( 1.5H, s), 2.37 (1.5H, s), 2.29-2.21 (1 H, m), 2.16 (1.5 H, s), 2.16 (1.5 H, s), 1.86-1.95 (1 H, m), 1.10 (1. 1.5 H, t), 0.94 (1.5 H, t).
Intermediate 6: 1 H-NMR (CDCl 3 ) δ: 6.36-6.28 (1H, m), 6.16-5.84 (1.5 H, m), 5.79 (0.5 H, td), 5.30-5.40 (1 H, m), 5.27-5.19 (1H, m), 4.29-4.25 (2H, m), 2.48 (1.5 H, s), 2.47 (1.5 H, s), 2.44 (1.5 H, s), 2.37 (1.5 H, s), 2.17 (1.5 H, s), 2.16 (1.5 H, s), 1. 91 (1.5 H, dd), 1.54 (1.5 H, dd).
Intermediate 7: 1 H-NMR (CDCl 3 ) δ: 6.72 (1 H, dd), 6.03 (1 H, m), 5.68 (1 H, dd), 5.54 (1 H, dd), 5.38 (1 H, m), 5.25 (1H, m), 4.29 (2H, m), 2.51 (3H, s), 2.46 (3H, s), 2.17 (3H, s).
Intermediate 8: 1 H-NMR (CDCl 3 ) δ: 7.10 (0.5 H, dd), 6.54 (0.5 H, t), 6.38 (0.5 H, d), 6.19 (0.5 H, d), 5.92-6.09 ( 1.5H, m), 5.66-5.58 (0.5H, m), 5.45-5.16 (2H, m), 4.35-4.23 (2H, m), 2.52 (1.5H, s), 2.48 (1.5 H, s), 2.45 (1.5 H, s), 2.36 (1.5 H, s), 2.17 (3 H, s), 1. 85 (1.5 H, s), 1.81 (3 H, s), 1. 74 (1.5 H, s).
Intermediate 9: 1 H-NMR (CDCl 3 ) δ: 6.64-6.54 (1 H, m), 6.16-5.81 (2 H, m), 5. 40-5. 20 (2 H, m), 4. 28-4. 21 (2 H, m), 3.08-2.96 (1H, m), 2.82-2.70 (1H, m), 2.50 (1.5 H, s), 2.48 (1.5 H, s), 2.46 (1.5 H, s), 2.37 (1.5 H, s), 2.18 (1.5 H, s), 2.17 (1.5 H, s).
Intermediate 10: 1 H-NMR (CDCl 3 ) δ: 6.27 (0.5 H, d), 6.13-5.95 (2 H, m), 5. 59 (0.5 H, dd), 5. 40-5. 30 (1 H, m), 5. 27- 5.18 (1H, m), 4.34-4.25 (2H, m), 2.47 (3H, s), 2.44 (1.5 H, s), 2.38 (1.5 H, s), 2.16 (1.5 H, s), 2.15 (1.5) H, s), 1.99-1.55 (6H, m), 1.40-0.98 (5H, m).
Intermediate 44: 1 H-NMR (CDCl 3 ) δ: 6.51 (0.5 H, d), 6.43 (0.5 H, d), 6.23-5.77 (2 H, m), 5.46-5.20 (2 H, m), 4.31- 4.22 (2H, m), 2.62-2.52 (1H, m), 2.51 (1.5 H, s), 2.47 (1.5 H, s), 2.45 (1.5 H, s), 2.45-2.20 (3 H, m), 2.38 (1.5 H, s), 2.17 (1.5 H, s), 2. 16 (1.5 H, s).
Intermediate 45: 1 H-NMR (CDCl 3 ) δ: 6.34 (0.5 H, d), 6.29 (0.5 H, d), 6.09-5.94 (1.5 H, m), 5. 84-5. 73 (0.5 H, m), 5.40-5.30 (1H, m), 5.26-5.18 (1H, m), 4.29-4.21 (2H, m), 3.31 (0.5 H, m), 3.17 (0.5 H, m), 2.48 (1.5 H, s) , 2.45 (1.5 H, s), 2.25-2.18 (1 H, m), 2.15 (1.5 H, s), 2.14 (1.5 H, s), 1.92-1. 85 (1 H, m), 1.56-1.46 (1 H, m) ), 1.43-1.30 (1 H, m), 1.22 (3 H, d), 1. 18 (3 H, d), 0.97 (1.5 H, t), 0.85 (1.5 H, t).
Intermediate 46: 1 H-NMR (CDCl 3 ) δ: 6.33 (0.5 H, d), 6.27 (0.5 H, d), 6.08-5.93 (1.5 H, m), 5.82-5. 73 (0.5 H, m), 5.40-5.29 (1H, m), 5.28-5.18 (1H, m), 4.29-4.20 (2H, m), 3.30 (0.5 H, m), 3.16 (0.5 H, m), 2.47 (1.5 H, s) , 2.45 (1.5 H, s), 2.28-2.18 (1 H, m), 2.15 (1.5 H, s), 2.14 (1.5 H, s), 1.94-1.86 (1 H, m), 1.52-1.23 (4 H, m) ), 1.21 (3H, d), 1.18 (3H, d), 0.93 (1.5 H, t), 0.83 (1.5 H, t).
Intermediate 47: 1 H-NMR (CDCl 3 ) δ: 6.33 (0.5 H, d), 6.29 (0.5 H, d), 6.15-5.94 (1.5 H, m), 5.83-5. 76 (0.5 H, m), 5.40-5.29 (1H, m), 5.27-5.18 (1H, m), 4.30-4.24 (2H, m), 2.79 (1H, q), 2.69 (1H, q), 2.48 (1.5 H, s), 2.45 (1.5H, s), 2.26-2.18 (1H, m), 2.17 (1.5 H, s), 2.16 (1.5 H, s), 1.92-1. 83 (1 H, m), 1.57-1. 45 (1 H, m), 1.42-1.31 (1 H, m), 1.22 (1.5 H, t), 1.17 (1.5 H, t), 0.97 (1.5 H, t), 0.85 (1.5 H, t).
Intermediate 48: 1 H-NMR (CDCl 3 ) δ: 6.32 (0.5 H, d), 6.27 (0.5 H, d), 6.17-5.93 (1.5 H, m), 5.82-5.74 (0.5 H, m), 5.40-5.28 (1H, m), 5.26-5.18 (1H, m), 4.32-4.25 (2H, m), 2.79 (1H, q), 2.68 (1H, q), 2.47 (1.5 H, s), 2.45 (1.5 H, s), 2.29-2 19. 19 (1 H, m), 2. 16 (1.5 H, s), 2. 16 (1.5 H, s), 1. 95-1. 82 (1 H, m), 1.52-1. 22 (4 H, m), 1.21 (1.5 H, t), 1.16 (1.5 H, t), 0.93 (1.5 H, t), 0.83 (1.5 H, t).
Intermediate 49: 1 H-NMR (CDCl 3 ) δ: 6.91-6.83 (1H, m), 6.09-5.97 (1H, m), 5.33 (1H, d), 5.22 (1H, d), 4.29 (2H, m) d), 2.54 (3H, s), 2.36 (3H, s), 2.29 (2H, t), 2.16 (3H, s), 1.92 (2H, t), 1.69-1.43 (6H, m).
Intermediate 50: 1 H-NMR (CDCl 3 ) δ: 7.81 (1 H, d), 6.56 (1 H, d), 6.04 (1 H, m), 5. 39 (1 H, m), 5. 28 (1 H, m), 4.30 -4.24 (4H, m), 2.58 (3H, s), 2.48 (3H, s), 2.18 (3H, s), 1.34 (3H, t).
参考製造例６
　水素化アルミニウムリチウム０．６１ｇ及びＴＨＦ２０ｍＬの混合物に、窒素雰囲気下０℃で４－（アリルオキシ）－３－（クロロメチル）－２，５，６－トリメチルピリジン１．８１ｇ及びＴＨＦ１０ｍＬの混合物を加え、室温で１時間撹拌した。得られた混合物に、氷冷下で水０．６ｍＬ、１５％水酸化ナトリウム水溶液０．６ｍＬ及び水１．８ｍＬを順次加え、室温で２時間撹拌した。得られた混合物をセライト（登録商標）でろ過し、ろ液を減圧下で乾燥した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体１１を１．４２ｇ得た。
Figure JPOXMLDOC01-appb-C000036
 　中間体１１：1H-NMR (CDCl3) δ: 6.15-6.03 (1H, m), 5.42 (1H, d), 5.28 (1H, d), 4.27 (2H, d), 2.44 (6H, s), 2.16 (6H, s). Reference Production Example 6
To a mixture of 0.61 g of lithium aluminum hydride and 20 mL of THF is added a mixture of 1.81 g of 4- (allyloxy) -3- (chloromethyl) -2,5,6-trimethylpyridine and 10 mL of THF at 0 ° C. under a nitrogen atmosphere, Stir at room temperature for 1 hour. To the resulting mixture, 0.6 mL of water, 0.6 mL of 15% aqueous sodium hydroxide solution and 1.8 mL of water were sequentially added under ice-cooling, and the mixture was stirred at room temperature for 2 hours. The resulting mixture was filtered through Celite®, and the filtrate was dried under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 1.42 g of Intermediate 11 represented by the following formula.
Figure JPOXMLDOC01-appb-C000036
 Intermediate 11: 1 H-NMR (CDCl 3 ) δ: 6.15-6.03 (1 H, m), 5.42 (1 H, d), 5. 28 ( 1 H, d), 4. 27 (2 H, d), 2. 44 (6 H, s) , 2.16 (6H, s).
参考製造例７
　４－（アリルオキシ）－３－（ヒドロキシメチル）－２，５，６－トリメチルピリジン１．６７ｇ及びＤＭＦ２０ｍＬの混合物に、窒素雰囲気下、６０％水素化ナトリウム（油性）０．３９ｇを加え、室温で１０分間撹拌した。得られた混合物に、ヨウ化メチル０．６０ｍＬを加え、室温で１時間撹拌した。得られた混合物に水を加え、ＭＴＢＥで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体１２を１．８３ｇ得た。
Figure JPOXMLDOC01-appb-C000037
 　中間体１２：1H-NMR (CDCl3) δ: 6.08 (1H, m), 5.44 (1H, m), 5.37 (1H, m), 4.45 (2H, s), 4.36 (2H, m), 3.40 (3H, s), 2.54 (3H, s), 2.46 (3H, s), 2.16 (3H, s). Reference Production Example 7
To a mixture of 1.67 g of 4- (allyloxy) -3- (hydroxymethyl) -2,5,6-trimethylpyridine and 20 mL of DMF was added 0.39 g of 60% sodium hydride (oil) under a nitrogen atmosphere, Stir for 10 minutes. To the resulting mixture, 0.60 mL of methyl iodide was added and stirred at room temperature for 1 hour. To the resulting mixture was added water and extracted with MTBE. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 1.83 g of Intermediate 12 represented by the following formula.
Figure JPOXMLDOC01-appb-C000037
 Intermediate 12: 1 H-NMR (CDCl 3 ) δ: 6.08 (1 H, m), 5. 44 (1 H, m), 5. 37 (1 H, m), 4. 45 (2 H, s), 4. 36 (2 H, m), 3. 40 (3H, s), 2.54 (3H, s), 2.46 (3H, s), 2.16 (3H, s).
参考製造例８
　参考製造例７に記載の方法に準じて製造した化合物及びその物性値を以下に示す。
Figure JPOXMLDOC01-appb-C000038
 　中間体１３：1H-NMR (CDCl3) δ: 6.09 (1H, m), 5.43 (1H, m), 5.28 (1H, m), 4.48 (2H, s), 4.37 (2H, d), 3.47 (2H, dd), 2.55 (3H, s), 2.45 (3H, s), 2.16 (3H, s), 1.67-1.58 (2H, m), 0.93 (3H, t). Reference Production Example 8
The compounds produced according to the method described in Reference Production Example 7 and the physical properties thereof are shown below.
Figure JPOXMLDOC01-appb-C000038
 Intermediate 13: 1 H-NMR (CDCl 3 ) δ: 6.09 (1 H, m), 5.43 (1 H, m), 5. 28 (1 H, m), 4. 48 (2 H, s), 4. 37 (2 H, d), 3. 47 (2H, dd), 2.55 (3H, s), 2.45 (3H, s), 2.16 (3H, s), 1.67-1.58 (2H, m), 0.93 (3H, t).
参考製造例９
　４－（アリルオキシ）－２，５，６－トリメチルピリジン－３－カルボアルデヒド０．８９ｇ、酢酸ナトリウム０．３９ｇ及びエタノール２０ｍＬの混合物に、Ｏ－メチルヒドロキシルアミン塩酸塩０．４０ｇを加え、室温で１時間撹拌した。得られた混合物に、飽和炭酸水素ナトリウム水溶液を加え、ＭＴＢＥで抽出した。得られた有機層を飽和食塩水で洗浄し、硫酸マグネシウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体１４を１．８３ｇ得た。
Figure JPOXMLDOC01-appb-C000039
 　中間体１４：1H-NMR (CDCl3) δ: 8.34 (1H, s), 6.06 (1H, m), 5.41 (1H, m), 5.31 (1H, m), 4.33 (2H, m), 3.99 (3H, s), 2.65 (3H, s), 2.48 (3H, s), 2.18 (3H, s). Reference Production Example 9
0.40 g of O-methylhydroxylamine hydrochloride is added to a mixture of 0.89 g of 4- (allyloxy) -2,5,6-trimethylpyridine-3-carbaldehyde, 0.39 g of sodium acetate and 20 mL of ethanol, Stir for 1 hour. To the resulting mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with MTBE. The obtained organic layer was washed with saturated brine, dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 1.83 g of Intermediate 14 represented by the following formula.
Figure JPOXMLDOC01-appb-C000039
 Intermediate 14: 1 H-NMR (CDCl 3 ) δ: 8.34 (1 H, s), 6.06 (1 H, m), 5.41 (1 H, m), 5.31 (1 H, m), 4.33 (2 H, m), 3.99 (3H, s), 2.65 (3H, s), 2.48 (3H, s), 2.18 (3H, s).
参考製造例１０
　アセトンオキシム０．９７ｇ及びＤＭＦ１０ｍＬの混合物に、窒素雰囲気下、６０％水素化ナトリウム（油性）０．５３ｇを加え、室温で１０分間撹拌した。得られた混合物に４－（アリルオキシ）－３－（クロロメチル）－２，５，６－トリメチルピリジン１．０３ｇ及びＤＭＦ１０ｍＬの混合物を加え、室温で３０分間撹拌した。得られた混合物に水を加え、ＭＴＢＥで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体１５を０．９３ｇ得た。
Figure JPOXMLDOC01-appb-C000040
 　中間体１５：1H-NMR (CDCl3) δ: 6.10 (1H, m), 5.41 (1H, m), 5.27 (1H, m), 5.11 (2H, m), 4.41 (2H, m), 2.56 (3H, s), 2.47 (3H, s), 2.17 (3H, s), 1.87 (3H, s), 1.80 (3H, s). Reference Production Example 10
Under a nitrogen atmosphere, 0.53 g of 60% sodium hydride (oil) was added to a mixture of 0.97 g of acetone oxime and 10 mL of DMF, and the mixture was stirred at room temperature for 10 minutes. A mixture of 1.03 g of 4- (allyloxy) -3- (chloromethyl) -2,5,6-trimethylpyridine and 10 mL of DMF was added to the obtained mixture, and the mixture was stirred at room temperature for 30 minutes. To the resulting mixture was added water and extracted with MTBE. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 0.93 g of Intermediate 15 represented by the following formula.
Figure JPOXMLDOC01-appb-C000040
 Intermediate 15: 1 H-NMR (CDCl 3 ) δ: 6.10 (1 H, m), 5.41 (1 H, m), 5. 27 (1 H, m), 5.11 (2 H, m), 4.41 (2 H, m), 2.56 (3H, s), 2.47 (3H, s), 2.17 (3H, s), 1.87 (3H, s), 1.80 (3H, s).
参考製造例１１
　参考製造例１０に記載の方法に準じて製造した化合物及びその物性値を以下に示す。
Figure JPOXMLDOC01-appb-C000041
 　中間体１６：1H-NMR (CDCl3) δ: 6.09 (1H, m), 5.44 (1H, m), 5.28 (1H, m), 4.50 (2H, s), 4.39 (2H, m), 3.37 (1H, m), 2.55 (3H, s), 2.44 (3H, s), 2.15 (3H, s), 2.03-1.10 (10H, m). Reference Production Example 11
The compounds produced according to the method described in Reference Production Example 10 and the physical properties thereof are shown below.
Figure JPOXMLDOC01-appb-C000041
 Intermediate 16: 1 H-NMR (CDCl 3 ) δ: 6.09 (1 H, m), 5. 44 (1 H, m), 5. 28 (1 H, m), 4.50 (2 H, s), 4. 39 (2 H, m), 3. 37 (1H, m), 2.55 (3H, s), 2.44 (3H, s), 2.15 (3H, s), 2.03-1.10 (10H, m).
参考製造例１２
　４－（アリルオキシ）－２，５，６－トリメチルピリジン－３－カルボアルデヒド０．５２ｇ及びクロロホルム１０ｍＬの混合物に、Ｎ，Ｎ－ジエチルアミノサルファートリフルオリド１．２２ｇを加え、室温で１時間撹拌した。得られた混合物に飽和炭酸水素ナトリウム水溶液を加え、クロロホルムで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体１７を０．４６ｇ得た。
Figure JPOXMLDOC01-appb-C000042
 　中間体１７：1H-NMR (CDCl3) δ: 7.01 (1H, t), 6.04 (1H, m), 5.43 (1H, m), 5.33 (1H, m), 4.34 (2H, m), 2.65 (3H, s), 2.50 (3H, s), 2.18 (3H, s). Reference Production Example 12
To a mixture of 0.52 g of 4- (allyloxy) -2,5,6-trimethylpyridine-3-carbaldehyde and 10 mL of chloroform was added 1.22 g of N, N-diethylaminosulfur trifluoride, and the mixture was stirred at room temperature for 1 hour. To the resulting mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with chloroform. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 0.46 g of Intermediate 17 represented by the following formula.
Figure JPOXMLDOC01-appb-C000042
 Intermediate 17: 1 H-NMR (CDCl 3 ) δ: 7.01 (1 H, t), 6.04 (1 H, m), 5.43 (1 H, m), 5.33 (1 H, m), 4.34 (2 H, m), 2.65 (3H, s), 2.50 (3H, s), 2.18 (3H, s).
参考製造例１３
　水素化アルミニウムリチウム０．０８ｇ及びＴＨＦ１４ｍＬの混合物に、窒素雰囲気下０℃で、４－（アリルオキシ）－２，５，６－トリメチルピリジン－３－アセトアルデヒド０．３１ｇをゆっくり加え、１５分間撹拌した。得られた混合物に飽和酒石酸ナトリウムカリウム水溶液を加え、室温で１時間撹拌した。得られた混合物を酢酸エチルで抽出し、得られた有機層を飽和食塩水で洗浄し、硫酸ナトリウムで乾燥し、減圧下で濃縮した。得られた残渣に窒素雰囲気下０℃で、ＤＭＦ７ｍＬを加えて溶解し、次に６０％水素化ナトリウム（油性）０．１７ｇを加え、１時間撹拌した。得られた混合物にヨウ化エチル１．２ｍＬを加え、室温で１時間撹拌した。得られた混合物に水を加え、酢酸エチルで抽出した。得られた有機層を硫酸ナトリウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体１８を０．２８ｇ得た。
Figure JPOXMLDOC01-appb-C000043
 　中間体１８：1H-NMR (CDCl3) δ: 6.09 (1H, m), 5.44 (1H, d), 5.29 (1H, d), 4.32 (2H, m), 3.53-3.46 (4H, m), 2.92 (2H, m), 2.51 (3H, s), 2.44 (3H, s), 2.16 (3H, s), 1.20 (3H, m). Reference Production Example 13
0.31 g of 4- (allyloxy) -2,5,6-trimethylpyridine-3-acetaldehyde was slowly added to a mixture of lithium aluminum hydride 0.08 g and THF 14 mL at 0 ° C. under a nitrogen atmosphere, and stirred for 15 minutes. To the resulting mixture was added saturated aqueous sodium potassium tartrate solution, and the mixture was stirred at room temperature for 1 hour. The obtained mixture was extracted with ethyl acetate, and the obtained organic layer was washed with saturated brine, dried over sodium sulfate and concentrated under reduced pressure. The obtained residue was dissolved by adding 7 mL of DMF at 0 ° C. under a nitrogen atmosphere, and then 0.17 g of 60% sodium hydride (oil) was added and stirred for 1 hour. To the resulting mixture was added 1.2 mL of ethyl iodide, and the mixture was stirred at room temperature for 1 hour. To the resulting mixture was added water and extracted with ethyl acetate. The resulting organic layer was dried over sodium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 0.28 g of Intermediate 18 represented by the following formula.
Figure JPOXMLDOC01-appb-C000043
 Intermediate 18: 1 H-NMR (CDCl 3 ) δ: 6.09 ( 1 H, m), 5. 44 (1 H, d), 5. 29 (1 H, d), 4.32 (2 H, m), 3.53-3. 46 (4 H, m) , 2.92 (2H, m), 2.51 (3H, s), 2.44 (3H, s), 2.16 (3H, s), 1.20 (3H, m).
参考製造例１４
　プロピルトリフェニルホスホニウムブロミド０．８０ｇ及びＴＨＦ５ｍＬの混合物に、カリウムｔ－ブトキシド０．２３ｇを加え、室温で３０分間撹拌した。得られた混合物に２－［４－（アリルオキシ）－２，５，６－トリメチル－３－ピリジル］アセトアルデヒド０．２３ｇを加え、室温で１時間撹拌した。得られた混合物に水を加え、酢酸エチルで抽出した。得られた有機層を硫酸ナトリウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体１９（Ｅ：Ｚ＝１：１）を０．２１ｇ得た。
Figure JPOXMLDOC01-appb-C000044
 　中間体１９：1H-NMR (CDCl3) δ: 6.07 (1H, m), 5.46-5.39 (2H, m), 5.30-5.20 (2H, m), 4.27 (2H, m), 3.37 (2H, d), 2.45 (3H, s), 2.44 (3H, s), 2.20 (2H, m), 2.16 (3H, s), 1.03 (3H, t). Reference Production Example 14
0.23 g of potassium t-butoxide was added to a mixture of 0.80 g of propyltriphenylphosphonium bromide and 5 mL of THF, and the mixture was stirred at room temperature for 30 minutes. To the resulting mixture was added 0.23 g of 2- [4- (allyloxy) -2,5,6-trimethyl-3-pyridyl] acetaldehyde, and the mixture was stirred at room temperature for 1 hour. To the resulting mixture was added water and extracted with ethyl acetate. The resulting organic layer was dried over sodium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 0.21 g of Intermediate 19 (E: Z = 1: 1) represented by the following formula.
Figure JPOXMLDOC01-appb-C000044
 Intermediate 19: 1 H-NMR (CDCl 3 ) δ: 6.07 (1 H, m), 5.4-6-5. 39 (2 H, m), 5. 30-5. 20 (2 H, m), 4. 27 (2 H, m), 3. 37 (2 H, 3 H) d), 2.45 (3H, s), 2.44 (3H, s), 2.20 (2H, m), 2.16 (3H, s), 1.03 (3H, t).
参考製造例１５
　参考製造例１４に記載の方法に準じて製造した化合物及びその物性値を以下に示す。
　式（Ａ－９）
Figure JPOXMLDOC01-appb-C000045
 で示される化合物において、Ｒ2xが［表２］に記載の化合物。 Reference Production Example 15
The compounds produced according to the method described in Reference Production Example 14 and the physical properties thereof are shown below.
Formula (A-9)
Figure JPOXMLDOC01-appb-C000045
 In the compounds represented by the above, compounds wherein R 2x is described in [Table 2].
Figure JPOXMLDOC01-appb-T000046
　中間体２０：1H-NMR (CDCl3) δ: 6.29 (0.5H, m), 6.09 (1H, m), 5.93 (0.5H, m), 5.49-5.38 (1H, m), 5.32-5.25 (1H, m), 4.77 (0.5H, m), 4.36-4.26 (2.5H, m), 3.64 (1.5H, s), 3.47 (1.5H, s), 3.41 (1H, m), 3.25 (1H, m), 2.47 (1.5H, s), 2.46 (1.5H, s), 2.45 (1.5H, s), 2.44 (1.5H, s), 2.16 (1.5H, s), 2.15 (1.5H, s).
　中間体２１：1H-NMR (CDCl3) δ: 6.08 (1H, m), 5.43-5.41 (3H, m), 5.28 (1H, m), 4.30 (2H, m), 2.61 (2H, m), 2.49 (3H, s), 2.44 (3H, s), 2.29-2.20 (2H, m), 2.16 (3H, s), 1.58 (3H, d).
　中間体２２：1H-NMR (CDCl3) δ: 6.31 (0.5H, m), 6.08 (1H, m), 5.89 (0.5H, m), 5.45 (1H, m), 5.29 (1H, m), 4.78 (0.5H, m), 4.42 (0.5H, m), 4.34-4.27 (2H, m), 3.56 (1.5H, s), 3.51 (1.5H, s), 2.67-2.58 (2H, m), 2.50 (1.5H, s), 2.47 (1.5H, s), 2.43 (3H, s), 2.32-2.21 (1H, m), 2.19-2.07 (4H, m).
　中間体２３：1H-NMR (CDCl3) δ: 6.08 (1H, m), 5.84 (1H, m), 5.44 (1H, m), 5.29 (1H, m), 5.04 (1H, m), 4.98 (1H, m), 4.28 (2H, m), 2.62-2.53 (2H, m), 2.47 (3H, s), 2.43 (3H, s), 2.18-2.09 (5H, m), 1.63-1.53 (2H, m).
　中間体５１：1H-NMR (CDCl3) δ: 6.07 (1H, m), 5.42 (1H, m), 5.27 (1H, m), 5.02 (1H, m), 4.27 (2H, d), 3.31 (2H, d), 2.44 (6H, s), 2.16 (3H, s), 1.75 (3H, s), 1.69 (3H, s).
　中間体５２：1H-NMR (CDCl3) δ: 6.12-5.99 (1H, m), 5.45-5.35 (1H, m), 5.29-5.21 (1.5H, m), 4.78 (0.5H, m), 4.28-4.24 (2H, m), 3.41 (1H, s), 3.27 (1H, s), 2.46 (1.5H, s), 2.44 (1.5H, s), 2.41 (1.5H, s), 2.38 (1.5H, s), 2.21-2.13 (4H, m), 1.98 (1H, m), 1.66 (1.5H, s), 1.44 (1.5H, s), 1.01 (1.5H, t), 0.86 (1.5H, t).
Figure JPOXMLDOC01-appb-T000046
Intermediate 20: 1 H-NMR (CDCl 3 ) δ: 6.29 (0.5 H, m), 6.09 (1 H, m), 5.93 (0.5 H, m), 5.49-5.38 (1 H, m), 5.32-5.25 ( 1H, m), 4.77 (0.5H, m), 4.36-4.26 (2.5H, m), 3.64 (1.5H, s), 3.47 (1.5H, s), 3.41 (1H, m), 3.25 (1H, s) m), 2.47 (1.5 H, s), 2. 46 (1.5 H, s), 2. 45 (1.5 H, s), 2. 44 (1.5 H, s), 2. 16 (1.5 H, s), 2. 15 (1.5 H, s) .
Intermediate 21: 1 H-NMR (CDCl 3 ) δ: 6.08 (1 H, m), 5.43-5. 41 (3 H, m), 5. 28 ( 1 H, m), 4. 30 (2 H, m), 2.61 (2 H, m) , 2.49 (3H, s), 2.44 (3H, s), 2.29-2.20 (2H, m), 2.16 (3H, s), 1.58 (3H, d).
Intermediate 22: 1 H-NMR (CDCl 3 ) δ: 6.31 (0.5 H, m), 6.08 (1 H, m), 5. 89 (0.5 H, m), 5. 45 (1 H, m), 5. 29 (1 H, m) , 4.78 (0.5H, m), 4.42 (0.5H, m), 4.34-4.27 (2H, m), 3.56 (1.5 H, s), 3.51 (1.5 H, s), 2.67-2.58 (2 H, m) , 2.50 (1.5 H, s), 2.47 (1.5 H, s), 2.43 (3 H, s), 2.22-2.21 (1 H, m), 2.19-2.07 (4 H, m).
Intermediate 23: 1 H-NMR (CDCl 3 ) δ: 6.08 (1 H, m), 5. 84 (1 H, m), 5. 44 (1 H, m), 5. 29 (1 H, m), 5.04 (1 H, m), 4.98 (1H, m), 4.28 (2H, m), 2.62-2.53 (2H, m), 2.47 (3H, s), 2.43 (3H, s), 2.18-2.09 (5H, m), 1.63-1.53 (2H , m).
Intermediate 51: 1 H-NMR (CDCl 3 ) δ: 6.07 (1 H, m), 5.42 (1 H, m), 5. 27 (1 H, m), 5.02 (1 H, m), 4. 27 (2 H, d), 3.31 (2H, d), 2.44 (6H, s), 2.16 (3H, s), 1.75 (3H, s), 1.69 (3H, s).
Intermediate 52: 1 H-NMR (CDCl 3 ) δ: 6.12-5.99 (1 H, m), 5.45-5. 35 (1 H, m), 5. 29-5. 21 (1.5 H, m), 4. 78 (0.5 H, m), 4.28-4.24 (2H, m), 3.41 (1H, s), 3.27 (1H, s), 2.46 (1.5 H, s), 2.44 (1.5 H, s), 2.41 (1.5 H, s), 2.38 (1.5) H, s), 2.21-2.13 (4 H, m), 1. 98 (1 H, m), 1. 66 (1.5 H, s), 1. 44 (1.5 H, s), 1.01 (1.5 H, t), 0.86 (1.5 H, t).
参考製造例１６
　２－［４－（アリルオキシ）－２，５，６－トリメチルピリジン－３－イル］アセトアルデヒド０．７９ｇ及びメタノール２０ｍＬの混合物に、（１－ジアゾ－２－オキソプロピル）ホスホン酸ジメチル（１０％アセトニトリル溶液）８．３１ｇ及び炭酸カリウム０．６０ｇを順次加え、室温で１８時間撹拌した。得られた混合物を減圧下で濃縮し、残渣に水を加え、ＭＴＢＥで抽出した。得られた有機層を水及び飽和食塩水で順次洗浄し、硫酸マグネシウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体２４を０．７０ｇ得た。
Figure JPOXMLDOC01-appb-C000047
 　中間体２４：1H-NMR (CDCl3) δ: 6.12 (1H, m), 5.46 (1H, m), 5.31 (1H, m), 4.40 (2H, m), 3.51 (2H, d), 2.56 (3H, s), 2.45 (3H, s), 2.17 (3H, s), 1.99 (1H, t). Reference Production Example 16
Dimethyl (1-diazo-2-oxopropyl) phosphonate (10% acetonitrile) in a mixture of 0.79 g of 2- [4- (allyloxy) -2,5,6-trimethylpyridin-3-yl] acetaldehyde and 20 mL of methanol Solution) 8.31 g and 0.60 g of potassium carbonate were sequentially added, and stirred at room temperature for 18 hours. The resulting mixture was concentrated under reduced pressure, water was added to the residue and extracted with MTBE. The obtained organic layer was washed successively with water and brine, dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 0.70 g of Intermediate 24 represented by the following formula.
Figure JPOXMLDOC01-appb-C000047
 Intermediate 24: 1 H-NMR (CDCl 3 ) δ: 6.12 (1H, m), 5.46 (1H, m), 5.31 (1H, m), 4.40 (2H, m), 3.51 (2H, d), 2.56 (3H, s), 2.45 (3H, s), 2.17 (3H, s), 1.99 (1H, t).
参考製造例１７
　参考製造例１６に記載の方法に準じて製造した化合物及びその物性値を以下に示す。
　式（Ａ－９）で示される化合物において、Ｒ2xが［表３］に記載の化合物。 Reference Production Example 17
The compounds produced according to the method described in Reference Production Example 16 and the physical properties thereof are shown below.
In the compounds represented by formula (A-9), compounds wherein R 2x is as described in [Table 3].
Figure JPOXMLDOC01-appb-T000048
　中間体２５：1H-NMR (CDCl3) δ: 6.09 (1H, m), 5.45 (1H, m), 5.30 (1H, m), 4.31 (2H, m), 2.89 (2H, t), 2.51 (3H, s), 2.44 (3H, s), 2.42-2.36 (2H, m), 2.16 (3H, s), 1.97 (1H, t).
　中間体２６：1H-NMR (CDCl3) δ: 6.10 (1H, m), 5.44 (1H, m), 5.28 (1H, m), 4.29 (2H, m), 2.73-2.66 (2H, m), 2.49 (3H, s), 2.44 (3H, s), 2.26 (2H, td), 2.16 (3H, s), 1.99 (1H, t), 1.77-1.67 (2H, m).
Figure JPOXMLDOC01-appb-T000048
Intermediate 25: 1 H-NMR (CDCl 3 ) δ: 6.09 (1H, m), 5.45 (1H, m), 5.30 (1H, m), 4.31 (2H, m), 2.89 (2H, t), 2.51 (3H, s), 2.44 (3H, s), 2.42-2.36 (2H, m), 2.16 (3H, s), 1.97 (1H, t).
Intermediate 26: 1 H-NMR (CDCl 3 ) δ: 6.10 (1H, m), 5.44 (1H, m), 5.28 (1H, m), 4.29 (2H, m), 2.73-2.66 (2H, m) , 2.49 (3H, s), 2.44 (3H, s), 2.26 (2H, td), 2.16 (3H, s), 1.99 (1H, t), 1.77-1.67 (2H, m).
参考製造例１８
　０．４１ｇの中間体２４及びＴＨＦ１０ｍＬの混合物に、リチウムジイソプロピルアミド（１．０８Ｍ　ＴＨＦ／ヘキサン溶液）１．８５ｍＬを加え、－７８℃で１０分間撹拌した。得られた混合物にヨウ化エチル０．３１ｍＬを加え、５０℃で２４時間撹拌した。得られた混合物に水を加え、ＭＴＢＥで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体２７を０．３５ｇ得た。
Figure JPOXMLDOC01-appb-C000049
 　中間体２７：1H-NMR (CDCl3) δ: 6.12 (1H, m), 5.45 (1H, m), 5.31 (1H, m), 4.41 (2H, m), 3.46 (2H, d), 2.56 (3H, s), 2.45 (3H, s), 2.19-2.08 (5H, m), 1.03 (3H, t). Reference Production Example 18
To a mixture of 0.41 g of Intermediate 24 and 10 mL of THF, 1.85 mL of lithium diisopropylamide (1.08 M THF / hexane solution) was added, and stirred at −78 ° C. for 10 minutes. To the resulting mixture was added 0.31 mL of ethyl iodide, and the mixture was stirred at 50 ° C. for 24 hours. To the resulting mixture was added water and extracted with MTBE. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 0.35 g of Intermediate 27 represented by the following formula.
Figure JPOXMLDOC01-appb-C000049
 Intermediate 27: 1 H-NMR (CDCl 3 ) δ: 6.12 (1H, m), 5.45 (1H, m), 5.31 (1H, m), 4.41 (2H, m), 3.46 (2H, d), 2.56 (3H, s), 2.45 (3H, s), 2.19-2.08 (5H, m), 1.03 (3H, t).
参考製造例１９
　参考製造例１８に記載の方法に準じて製造した化合物及びその物性値を以下に示す。
Figure JPOXMLDOC01-appb-C000050
 　中間体２８：1H-NMR (CDCl3) δ: 6.08 (1H, m), 5.45 (1H, m), 5.29 (1H, m), 4.41 (2H, m), 2.80 (2H, t), 2.51 (3H, s), 2.43 (3H, s), 2.36-2.28 (2H, m), 2.15 (3H, s), 1.77 (3H, t). Reference Production Example 19
The compounds produced according to the method described in Reference Production Example 18 and the physical properties thereof are shown below.
Figure JPOXMLDOC01-appb-C000050
 Intermediate 28: 1 H-NMR (CDCl 3 ) δ: 6.08 (1 H, m), 5. 45 (1 H, m), 5. 29 (1 H, m), 4.41 (2 H, m), 2. 80 (2 H, t), 2.51 (3H, s), 2.43 (3H, s), 2.36-2.28 (2H, m), 2.15 (3H, s), 1.77 (3H, t).
参考製造例２０
　２．８９ｇの中間体２０及びＴＨＦ３０ｍＬの混合物に、３Ｍ塩酸１０ｍＬを加え、室温で１９時間撹拌した。得られた混合物に飽和炭酸カリウム水溶液を加え、ＭＴＢＥで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体２９を２．４２ｇ得た。
Figure JPOXMLDOC01-appb-C000051
 　中間体２９：1H-NMR (CDCl3) δ: 9.82 (1H, s), 6.05 (1H, m), 5.43 (1H, m), 5.29 (1H, m), 4.30 (2H, m), 2.94-2.87 (2H, m), 2.69-2.62 (2H, m), 2.47 (3H, s), 2.44 (3H, s), 2.16 (3H, s). Reference Production Example 20
To a mixture of 2.89 g of Intermediate 20 and 30 mL of THF, 10 mL of 3 M hydrochloric acid was added and stirred at room temperature for 19 hours. To the resulting mixture was added saturated aqueous potassium carbonate solution, and the mixture was extracted with MTBE. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 2.42 g of Intermediate 29 represented by the following formula.
Figure JPOXMLDOC01-appb-C000051
 Intermediate 29: 1 H-NMR (CDCl 3 ) δ: 9.82 (1H, s), 6.05 (1H, m), 5.43 (1H, m), 5.29 (1H, m), 4.30 (2H, m), 2.94 -2.87 (2H, m), 2.69-2.62 (2H, m), 2.47 (3H, s), 2.44 (3H, s), 2.16 (3H, s).
参考製造例２１
　参考製造例２０に記載の方法に準じて製造した化合物及びその物性値を以下に示す。
Figure JPOXMLDOC01-appb-C000052
 　中間体３０：1H-NMR (CDCl3) δ: 9.76 (1H, s), 6.07 (1H, m), 5.43 (1H, m), 5.29 (1H, m), 4.28 (2H, m), 2.65-2.59 (2H, m), 2.52-2.45 (5H, m), 2.44 (3H, s), 2.16 (3H, s), 1.89-1.79 (2H, m). Reference Production Example 21
The compounds produced according to the method described in Reference Production Example 20 and the physical properties thereof are shown below.
Figure JPOXMLDOC01-appb-C000052
 Intermediate 30: 1 H-NMR (CDCl 3 ) δ: 9.76 (1H, s), 6.07 (1H, m), 5.43 (1H, m), 5.29 (1H, m), 4.28 (2H, m), 2.65 -2.59 (2H, m), 2.52-2.45 (5H, m), 2.44 (3H, s), 2.16 (3H, s), 1.89-1.79 (2H, m).
製造例１
　１．５９ｇの中間体１及びメタノール２０ｍＬの混合物に、窒素雰囲気下、炭酸カリウム１．３９ｇ及びテトラキス（トリフェニルホスフィン）パラジウム（０）０．０６ｇを順次加えた。得られた混合物を室温で１時間撹拌した。得られた混合物に水を加え、氷冷下で１０分間撹拌した。析出した固体をろ過し、得られた固体を水及びＭＴＢＥで順次洗浄し、減圧下で乾燥して、下式に示される本発明化合物１（Ｅ：Ｚ＝１：１）を１．２５ｇ得た。
Figure JPOXMLDOC01-appb-C000053
 　本発明化合物１：1H-NMR (CDCl3) δ: 6.60-6.48 (0.5H, m), 6.28 (0.5H, d), 6.14 (0.5H, d), 5.76-5.65 (0.5H, m), 2.36-2.11 (7H, m), 2.01 (3H, s), 1.89-1.78 (1H, m), 1.51-1.14 (12H, m), 0.90-0.81 (3H, m). Production Example 1
Under a nitrogen atmosphere, 1.39 g of potassium carbonate and 0.06 g of tetrakis (triphenylphosphine) palladium (0) were sequentially added to a mixture of 1.59 g of Intermediate 1 and 20 mL of methanol. The resulting mixture was stirred at room temperature for 1 hour. To the resulting mixture was added water, and stirred for 10 minutes under ice cooling. The precipitated solid is filtered, and the obtained solid is washed successively with water and MTBE, and dried under reduced pressure to obtain 1.25 g of the present compound 1 (E: Z = 1: 1) represented by the following formula The
Figure JPOXMLDOC01-appb-C000053
 The present compound 1: 1 H-NMR (CDCl 3 ) δ: 6.60-6.48 (0.5 H, m), 6.28 (0.5 H, d), 6.14 (0.5 H, d), 5. 76-5. 65 (0.5 H, m) , 2.36-2.11 (7H, m), 2.01 (3H, s), 1.89-1.78 (1H, m), 1.51-1.14 (12H, m), 0.90-0.81 (3H, m).
製造例２
　製造例１に記載の方法に準じて製造した化合物及びその物性値を以下に示す。
式（Ａ－２）
Figure JPOXMLDOC01-appb-C000054
 で示される化合物において、Ｒ1x及びＲ2xが［表４］に記載のいずれかの組み合わせである化合物。 Production Example 2
The compounds produced according to the method described in Production Example 1 and the physical properties thereof are shown below.
Formula (A-2)
Figure JPOXMLDOC01-appb-C000054
 In the compounds shown by these, compounds in which R 1x and R 2x are any combination of those described in [Table 4].
Figure JPOXMLDOC01-appb-T000055
　本発明化合物２：LC-MS: m/z = 234 ([M+H]+)；1H-NMR (CDCl3) δ: 6.56 (0.5H, m), 6.28 (0.5H, d), 6.14 (0.5H, d), 5.74 (0.5H, m), 2.35 (1.5H, s), 2.30 (1.5H, s), 2.26 (1.5H, s), 2.20 (1.5H, s), 2.17 (1H, m), 2.02 (1.5H, s), 2.01 (1.5H, s), 1.87 (1H, m), 1.42 (1H, m), 1.36-1.26 (3H, m), 1.26-2.19 (2H, m), 0.87 (1.5H, t), 0.83 (1.5H, t).
　本発明化合物３：LC-MS: m/z = 220 ([M+H]+)；1H-NMR (CDCl3) δ: 6.47 (0.5H, m), 6.29 (0.5H, d), 6.14 (0.5H, d), 5.69 (0.5H, m), 2.35 (1.5H, s), 2.30 (1.5H, s), 2.27 (1.5H, s), 2.20 (1.5H, s), 2.16 (1H, m), 2.02 (1.5H, s), 2.01 (1.5H, s), 1.84 (1H, m), 1.41-1.21 (4H, m), 0.88 (1.5H, t), 0.81 (1.5H, t).
　本発明化合物４：1H-NMR (CDCl3) δ: 9.68 (0.5H, s), 9.37 (0.5H, s), 6.57-6.47 (0.5H, m), 6.29 (0.5H, d), 6.15 (0.5H, d), 5.76-5.66 (0.5H, m), 2.35 (1.5H, s), 2.29 (1.5H, s), 2.27 (1.5H, s), 2.19 (1.5H, s), 2.18-2.09 (1H, m), 2.01 (3H, s), 1.88-1.77 (1H, m), 1.51-1.27 (2H, m), 0.92 (1.5H, d), 0.83 (1.5H, d).
　本発明化合物５：LC-MS: m/z = 192 ([M+H]+)；1H-NMR (CDCl3) δ: 6.32 (1H, m), 6.14 (0.5H, d), 5.61 (0.5H, m), 2.36 (1.5H, s), 2.32 (1.5H, s), 2.29 (1.5H, s), 2.19 (1.5H, s), 2.02 (1.5H, s), 2.01 (1.5H, s), 2.12 (1H, m), 1.83 (1H, m), 0.97 (1.5H, t), 0.85 (1.5H, t).
　本発明化合物６：1H-NMR (CDCl3) δ: 6.57-6.45 (1H, m), 6.34-6.18 (1H, m), 5.87-5.75 (1H, m), 2.35 (1.5H, s), 2.31 (1.5H, s), 2.27 (1.5H, s), 2.19 (1.5H, s), 2.01 (1.5H, s), 2.02 (1.5H, s), 1.84 (1.5H, dd), 1.50 (1.5H, dd).
　本発明化合物７：LC-MS: m/z = 164 ([M+H]+)；1H-NMR (CDCl3) δ: 6.66 (1H, dd), 6.09 (1H, dd), 5.44 (1H, dd), 2.37 (3H, s), 2.27 (3H, s), 2.02 (3H, s).
　本発明化合物８：1H-NMR (DMSO-d6) δ: 2.17 (6H, s), 1.80 (6H, s).
　本発明化合物９：1H-NMR (CDCl3) δ: 9.77 (0.5H, s), 9.50 (0.5H, s), 7.88 (0.5H, dd), 6.42 (0.5H, t), 6.32 (0.5H, d), 6.10 (0.5H, d), 5.93 (0.5H, d), 5.58 (0.5H, d), 2.37 (1.5H, s), 2.30 (1.5H, s), 2.26 (1.5H, s), 2.17 (1.5H, s), 2.02 (1.5H, s), 2.01 (1.5H, s), 1.80 (3H, s), 1.71 (3H, s).
　本発明化合物１０：1H-NMR (CDCl3) δ: 8.45 (0.5H, s), 8.34 (0.5H, s), 6.63-6.72 (0.5H, m), 6.51 (0.5H, d), 6.32 (0.5H, d), 5.80-5.88 (0.5H, m), 2.91-3.02 (1H, m), 2.75-2.87 (1H, m), 2.36 (1.5H, s), 2.29 (1.5H, s), 2.27 (1.5H, s), 2.21 (1.5H, s), 2.02 (3H, s).
　本発明化合物１１：LC-MS: m/z = 246 ([M+H]+)
　本発明化合物１２：LC-MS: m/z = 194 ([M+H]+)；1H-NMR (CDCl3) δ: 10.41 (1H, s), 7.90 (0.5H, d), 6.02 (0.5H, d), 5.67 (0.5H, d), 5.28 (0.5H, d), 3.63 (1.5H, s), 3.58 (1.5H, s), 2.34 (1.5H, s), 2.30 (1.5H, s), 2.28 (1.5H, s), 2.27 (1.5H, s), 2.02 (3H, s).
　本発明化合物１３：1H-NMR (CDCl3) δ: 4.48 (2H, s), 3.36 (3H, s), 2.36 (3H, s), 2.27 (3H, s), 2.00 (3H, s).
　本発明化合物１４：LC-MS: m/z = 195 ([M+H]+)；1H-NMR (CDCl3) δ: 10.90 (1H, s), 8.46 (1H, s), 3.99 (3H, s), 2.52 (3H, s), 2.44 (3H, s), 2.15 (3H, s).
　本発明化合物１５：LC-MS: m/z = 223 ([M+H]+)；1H-NMR (CDCl3) δ: 5.05 (2H, s), 2.43 (3H, s), 2.31 (3H, s), 2.05 (3H, s), 1.86 (3H, s), 1.80 (3H, s).
　本発明化合物１６：1H-NMR (CDCl3) δ: 8.08 (1H, s), 4.55 (2H, s), 3.42-3.31 (1H, m), 2.79-2.67 (2H, m), 2.36 (3H, s), 2.24 (3H, s), 2.03-1.91 (5H, m), 1.56-1.48 (1H, m), 1.36-1.11 (5H, m).
　本発明化合物１７：LC-MS: m/z = 210 ([M+H]+)；1H-NMR (CDCl3) δ: 4.61 (2H, s), 3.42 (2H, d), 2.37 (3H, s), 2.28 (3H, s), 2.01 (3H, s), 1.57 (2H, m), 0.89 (3H, t).
　本発明化合物１８：LC-MS: m/z = 210 ([M+H]+)；1H-NMR (CDCl3) δ: 3.57 (2H, m), 3.47 (2H, dd), 2.81 (2H, dd), 2.32 (3H, s), 2.26 (3H, s), 2.02 (3H, s), 1.16 (3H, t).
　本発明化合物１９：LC-MS: m/z = 206 ([M+H]+)；1H-NMR (CDCl3) δ: 5.36 (1H, m), 5.27 (1H, m), 3.31 (2H, d), 2.25 (3H, s), 2.25 (3H, s), 2.20 (2H, m), 2.01 (3H, s), 1.00 (3H, s).
　本発明化合物２０：1H-NMR (CDCl3) δ: 2.46 (3H, s), 2.37 (3H, s), 2.13 (2H, t), 2.03 (3H, s), 1.49-1.38 (2H, m), 0.92 (3H, t).
　本発明化合物２１：LC-MS: m/z = 206 ([M+H]+)；1H-NMR (CDCl3) δ: 5.46 (2H, m), 2.55 (2H, m), 2.28 (3H, s), 2.25 (3H, s), 2.25 (3H, s), 2.02 (3H, s), 1.62 (2H, m).
　本発明化合物２２：LC-MS: m/z = 206 ([M+H]+)；1H-NMR (CDCl3) δ: 5.84 (1H, m), 5.01 (1H, dd), 4.93 (1H, d), 2.51 (2H, dd), 2.27 (3H, s), 2.25 (3H, s), 2.11 (2H, dd), 2.01 (3H, s), 1.56 (2H, m).
　本発明化合物２３：LC-MS: m/z = 204 ([M+H]+)
　本発明化合物２４：LC-MS: m/z = 204 ([M+H]+)；1H-NMR (CDCl3) δ: 2.66-2.57 (2H, m), 2.30 (3H, s), 2.27-2.19 (2H, m), 2.25 (3H, s), 2.00 (3H, s), 1.95 (1H, t), 1.78-1.68 (2H, m).
　本発明化合物９８：1H-NMR (CDCl3) δ: 8.38 (1H, s), 6.78 (0.5H, dt), 6.41 (0.5H, d), 6.20 (0.5H, d), 5.79 (0.5H, dt), 2.58-2.39 (3H, m), 2.37 (1.5H, s), 2.32-2.24 (1H, m), 2.29 (1.5H, s), 2.28 (1.5H, s), 2.22 (1.5H, s), 2.02 (3H, s).
　本発明化合物９９：1H-NMR (CDCl3) δ: 9.40 (0.5H, s), 9.14 (0.5H, s), 6.37-6.24 (1H, m), 6.13-6.06 (0.5H, m), 5.82-5.70 (0.5H, m), 3.45 (0.5H, m), 3.19 (0.5H, m), 2.32 (1.5H, s), 2.30 (1.5H, s), 2.20-2.08 (1H, m), 2.01 (1.5H, s), 2.00 (1.5H, s), 1.92-1.83 (1H, m), 1.51-1.29 (2H, m), 1.26 (3H, d), 1.21 (3H, d), 0.91 (1.5H, t), 0.84 (1.5H, t).
　本発明化合物１００：1H-NMR (CDCl3) δ: 9.57 (0.5H, s), 9.31 (0.5H, s), 6.35-6.24 (1H, m), 6.13-6.07 (0.5H, m), 5.80-5.70 (0.5H, m), 3.45 (0.5H, m), 3.19 (0.5H, m), 2.33 (1.5H, s), 2.31 (1.5H, s), 2.22-2.10 (1H, m), 2.01 (1.5H, s), 2.00 (1.5H, s), 1.95-1.87 (1H, m), 1.46-1.13 (4H, m), 1.28 (3H, d), 1.23 (3H, d), 0.88 (1.5H, t), 0.83 (1.5H, t).
　本発明化合物１１７：1H-NMR (CDCl3) δ: 7.64 (1H, d), 7.52 (1H, d), 3.76 (3H, s), 2.47 (3H, s), 2.30 (3H, s), 2.02 (3H, s).
　本発明化合物１２０：1H-NMR (CDCl3) δ: 5.09 (1H, m), 3.24 (2H, d), 2.24 (6H, s), 2.02 (3H, s), 1.76 (3H, s), 1.65 (3H, s).
　本発明化合物１２１：1H-NMR (CDCl3) δ: 5.17 (0.5H, m), 4.95 (0.5H, m), 3.38 (1H, s), 3.25 (1H, s), 2.27 (1.5H, s), 2.25 (1.5H, s), 2.21 (1.5H, s), 2.21 (1.5H, s), 2.18 (1H, m), 2.02 (1.5H, s), 2.02 (1.5H, s), 1.94 (1H, m), 0.59 (1.5H, s), 1.51 (1.5H, s), 0.99 (1.5H, t), 0.87 (1.5H, t).
Figure JPOXMLDOC01-appb-T000055
The present compound 2: LC-MS: m / z = 234 ([M + H] + ); 1 H-NMR (CDCl 3 ) δ: 6.56 (0.5 H, m), 6.28 (0.5 H, d), 6.14 (0.5 H, d), 5. 74 (0.5 H, m), 2. 35 (1.5 H, s), 2. 30 (1.5 H, s), 2. 26 (1.5 H, s), 2. 20 (1.5 H, s), 2. 17 (1 H) , m), 2.02 (1.5 H, s), 2.01 (1.5 H, s), 1.87 (1 H, m), 1.42 (1 H, m), 1.36-1.26 (3 H, m), 1.26-2.19 (2 H, m) ), 0.87 (1.5 H, t), 0.83 (1.5 H, t).
The compound of the present invention 3: LC-MS: m / z = 220 ([M + H] + ); 1 H-NMR (CDCl 3 ) δ: 6.47 (0.5 H, m), 6.29 (0.5 H, d), 6.14 (0.5 H, d), 5. 69 (0.5 H, m), 2. 35 (1.5 H, s), 2. 30 (1.5 H, s), 2. 27 (1.5 H, s), 2. 20 (1.5 H, s), 2. 16 (1 H) , m), 2.02 (1.5 H, s), 2.01 (1.5 H, s), 1. 84 (1 H, m), 1.41-1. 21 (4 H, m), 0.88 (1.5 H, t), 0.81 (1.5 H, t) ).
The present compound 4: 1 H-NMR (CDCl 3 ) δ: 9.68 (0.5 H, s), 9. 37 (0.5 H, s), 6.57-6. 47 (0.5 H, m), 6.29 (0.5 H, d), 6.15 (0.5 H, d), 5. 76-5. 66 (0.5 H, m), 2. 35 (1.5 H, s), 2. 29 (1.5 H, s), 2. 27 (1.5 H, s), 2. 19 (1.5 H, s), 2. 18 -2.09 (1H, m), 2.01 (3H, s), 1.88-1.77 (1H, m), 1.51-1.27 (2H, m), 0.92 (1.5 H, d), 0.83 (1.5 H, d).
The present compound 5: LC-MS: m / z = 192 ([M + H] + ); 1 H-NMR (CDCl 3 ) δ: 6.32 (1 H, m), 6.14 (0.5 H, d), 5.61 (5.61 0.5H, m), 2.36 (1.5H, s), 2.32 (1.5H, s), 2.29 (1.5 H, s), 2.19 (1.5 H, s), 2.02 (1.5 H, s), 2.01 (1.5 H) , s), 2.12 (1 H, m), 1. 83 (1 H, m), 0.97 (1.5 H, t), 0.85 (1.5 H, t).
The present compound 6: 1 H-NMR (CDCl 3 ) δ: 6.57-6.45 (1 H, m), 6.34-6.18 (1 H, m), 5.87-5. 75 (1 H, m), 2. 35 (1.5 H, s), 2.31 (1.5 H, s), 2. 27 (1.5 H, s), 2. 19 (1.5 H, s), 2.01 (1.5 H, s), 2.02 (1.5 H, s), 1. 84 (1.5 H, dd), 1.50 (1.5 H, s) 1.5 H, dd).
The present compound 7: LC-MS: m / z = 164 ([M + H] + ); 1 H-NMR (CDCl 3 ) δ: 6.66 (1H, dd), 6.09 (1H, dd), 5.44 (1H , dd), 2.37 (3H, s), 2.27 (3H, s), 2.02 (3H, s).
The present compound 8: 1 H-NMR (DMSO-d 6 ) δ: 2.17 (6H, s), 1.80 (6H, s).
The present compound 9: 1 H-NMR (CDCl 3 ) δ: 9.77 (0.5 H, s), 9. 50 (0.5 H, s), 7. 88 (0.5 H, dd), 6.42 (0.5 H, t), 6.32 (0.5 H, d), 6.10 (0.5H, d), 5.93 (0.5H, d), 5.58 (0.5H, d), 2.37 (1.5H, s), 2.30 (1.5H, s), 2.26 (1.5H, s) s), 2.17 (1.5 H, s), 2.02 (1.5 H, s), 2.01 (1.5 H, s), 1.80 (3 H, s), 1.71 (3 H, s).
The present compound 10: 1 H-NMR (CDCl 3 ) δ: 8.45 (0.5 H, s), 8.34 (0.5 H, s), 6.63 to 6.72 (0.5 H, m), 6.51 (0.5 H, d), 6.32 (0.5H, d), 5.80-5.88 (0.5H, m), 2.91-3.02 (1H, m), 2.75-2.87 (1H, m), 2.36 (1.5H, s), 2.29 (1.5 H, s) , 2.27 (1.5 H, s), 2.21 (1.5 H, s), 2.02 (3 H, s).
The present compound 11: LC-MS: m / z = 246 ([M + H] + )
Invention compound 12: LC-MS: m / z = 194 ([M + H] + ); 1 H-NMR (CDCl 3 ) δ: 10.41 (1 H, s), 7.90 (0.5 H, d), 6.02 ( 0.5H, d), 5.67 (0.5H, d), 5.28 (0.5H, d), 3.63 (1.5H, s), 3.58 (1.5 H, s), 2.34 (1.5 H, s), 2.30 (1.5 H) , s), 2.28 (1.5 H, s), 2.27 (1.5 H, s), 2.02 (3 H, s).
Present compound 13: 1 H-NMR (CDCl 3 ) δ: 4.48 (2H, s), 3.36 (3H, s), 2.36 (3H, s), 2.27 (3H, s), 2.00 (3H, s).
The present compound 14: LC-MS: m / z = 195 ([M + H] + ); 1 H-NMR (CDCl 3 ) δ: 10.90 (1H, s), 8.46 (1H, s), 3.99 (3H , s), 2.52 (3H, s), 2.44 (3H, s), 2.15 (3H, s).
The present compound 15: LC-MS: m / z = 223 ([M + H] + ); 1 H-NMR (CDCl 3 ) δ: 5.05 (2H, s), 2.43 (3H, s), 2.31 (3H , s), 2.05 (3H, s), 1.86 (3H, s), 1.80 (3H, s).
The present compound 16: 1 H-NMR (CDCl 3 ) δ: 8.08 (1 H, s), 4.55 (2 H, s), 3.42-3. 31 (1 H, m), 2.79-2.67 (2 H, m), 2. 36 (3 H) , s), 2.24 (3H, s), 2.03-1.91 (5H, m), 1.56-1.48 (1H, m), 1.36-1.11 (5H, m).
The present compound 17: LC-MS: m / z = 210 ([M + H] + ); 1 H-NMR (CDCl 3 ) δ: 4.61 (2H, s), 3.42 (2H, d), 2.37 (3H) , s), 2.28 (3H, s), 2.01 (3H, s), 1.57 (2H, m), 0.89 (3H, t).
The present compound 18: LC-MS: m / z = 210 ([M + H] + ); 1 H-NMR (CDCl 3 ) δ: 3.57 (2H, m), 3.47 (2H, dd), 2.81 (2H , dd), 2.32 (3H, s), 2.26 (3H, s), 2.02 (3H, s), 1.16 (3H, t).
Invention compound 19: LC-MS: m / z = 206 ([M + H] + ); 1 H-NMR (CDCl 3 ) δ: 5.36 (1H, m), 5.27 (1H, m), 3.31 (2H) , d), 2.25 (3H, s), 2.25 (3H, s), 2.20 (2H, m), 2.01 (3H, s), 1.00 (3H, s).
The present compound 20: 1 H-NMR (CDCl 3 ) δ: 2.46 (3H, s), 2.37 (3H, s), 2.13 (2H, t), 2.03 (3H, s), 1.49-1 to 38 (2H, m) ), 0.92 (3H, t).
Invention compound 21: LC-MS: m / z = 206 ([M + H] + ); 1 H-NMR (CDCl 3 ) δ: 5.46 (2H, m), 2.55 (2H, m), 2.28 (3H , s), 2.25 (3H, s), 2.25 (3H, s), 2.02 (3H, s), 1.62 (2H, m).
Invention compound 22: LC-MS: m / z = 206 ([M + H] + ); 1 H-NMR (CDCl 3 ) δ: 5.84 (1H, m), 5.01 (1H, dd), 4.93 (1H , d), 2.51 (2H, dd), 2.27 (3H, s), 2.25 (3H, s), 2.11 (2H, dd), 2.01 (3H, s), 1.56 (2H, m).
Invention compound 23: LC-MS: m / z = 204 ([M + H] + )
Invention compound 24: LC-MS: m / z = 204 ([M + H] + ); 1 H-NMR (CDCl 3 ) δ: 2.66-2.57 (2H, m), 2.30 (3H, s), 2.27 -2.19 (2H, m), 2.25 (3H, s), 2.00 (3H, s), 1.95 (1H, t), 1.78-1.68 (2H, m).
Invention compound 98: 1 H-NMR (CDCl 3 ) δ: 8.38 (1 H, s), 6.78 (0.5 H, dt), 6.41 (0.5 H, d), 6.20 (0.5 H, d), 5.79 (0.5 H , dt), 2.58-2.39 (3H, m), 2.37 (1.5H, s), 2.32-2.24 (1H, m), 2.29 (1.5H, s), 2.28 (1.5H, s), 2.22 (1.5H) , s), 2.02 (3H, s).
The present compound 99: 1 H-NMR (CDCl 3 ) δ: 9.40 (0.5 H, s), 9.14 (0.5 H, s), 6.37-6.24 (1 H, m), 6.13-6.06 (0.5 H, m), 5.82-5.70 (0.5 H, m), 3.45 (0.5 H, m), 3.19 (0.5 H, m), 2. 32 (1.5 H, s), 2.30 (1.5 H, s), 2.20-2.08 (1 H, m) , 2.01 (1.5 H, s), 2.00 (1.5 H, s), 1.92-1. 83 (1 H, m), 1.51-1. 29 (2 H, m), 1. 26 (3 H, d), 1.21 (3 H, d), 0.91 (1.5 H, t), 0.84 (1.5 H, t).
The present compound 100: 1 H-NMR (CDCl 3 ) δ: 9.57 (0.5 H, s), 9.31 (0.5 H, s), 6.35-6.24 (1 H, m), 6.13-6.07 (0.5 H, m), 5.80-5.70 (0.5H, m), 3.45 (0.5H, m), 3.19 (0.5H, m), 2.33 (1.5 H, s), 2.31 (1.5 H, s), 2.22-2 .10 (1 H, m) , 2.01 (1.5 H, s), 2.00 (1.5 H, s), 1. 95-1.87 (1 H, m), 1. 46-1.13 (4 H, m), 1. 28 (3 H, d), 1.23 (3 H, d), 0.88 (1.5 H, t), 0.83 (1.5 H, t).
Invention compound 117: 1 H-NMR (CDCl 3 ) δ: 7.54 (1H, d), 7.52 (1H, d), 3.76 (3H, s), 2.47 (3H, s), 2.30 (3H, s), 2.02 (3H, s).
Invention compound 120: 1 H-NMR (CDCl 3 ) δ: 5.09 (1 H, m), 3.24 (2 H, d), 2. 24 (6 H, s), 2.02 (3 H, s), 1. 76 (3 H, s), 1.65 (3H, s).
Invention compound 121: 1 H-NMR (CDCl 3 ) δ: 5.17 (0.5 H, m), 4.95 (0.5 H, m), 3.38 (1 H, s), 3.25 (1 H, s), 2.27 (1.5 H, s), 2.25 (1.5 H, s), 2.21 (1.5 H, s), 2.21 (1.5 H, s), 2.18 (1 H, m), 2.02 (1.5 H, s), 2.02 (1.5 H, s), 1.94 (1 H, m), 0.59 (1.5 H, s), 1.51 (1.5 H, s), 0.99 (1.5 H, t), 0.87 (1.5 H, t).
製造例３
　０．３６ｇの中間体１７及びメタノール１０ｍＬの混合物に、窒素雰囲気下、炭酸カリウム０．４４ｇ及びテトラキス（トリフェニルホスフィン）パラジウム（０）０．０２ｇを順次加え、室温で１時間撹拌した。得られた混合物を減圧下濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（クロロホルム：メタノール＝９５：５）に付し、下式に示される本発明化合物２５を０．３１ｇ得た。
Figure JPOXMLDOC01-appb-C000056
 　本発明化合物２５：1H-NMR (CDCl3) δ: 10.15 (1H, s), 5.88 (1H, s), 3.39 (6H, s), 2.45 (3H, s), 2.29 (3H, s), 2.00 (3H, s). Production Example 3
Under a nitrogen atmosphere, 0.44 g of potassium carbonate and 0.02 g of tetrakis (triphenylphosphine) palladium (0) were sequentially added to a mixture of 0.36 g of Intermediate 17 and 10 mL of methanol, and the mixture was stirred at room temperature for 1 hour. The resulting mixture was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (chloroform: methanol = 95: 5) to obtain 0.31 g of the present compound 25 represented by the following formula.
Figure JPOXMLDOC01-appb-C000056
 The present compound 25: 1 H-NMR (CDCl 3 ) δ: 10.15 (1H, s), 5.88 (1H, s), 3.39 (6H, s), 2.45 (3H, s), 2.29 (3H, s), 2.00 (3H, s).
参考製造例２２
　４－ヒドロキシ－２，６－ジメチルピリジン１７．３ｇ及びメタノール３００ｍＬの混合物に、Ｎ－ヨードスクシンイミド７９．０ｇを加え、還流下で１１時間撹拌した。得られた混合物を室温に冷却し、析出した固体をろ過し、得られた固体をメタノールで洗浄し、減圧下で乾燥して、下式に示される中間体３１を４８．３ｇ得た。
Figure JPOXMLDOC01-appb-C000057
 　中間体３１：1H-NMR (DMSO-d6) δ: 2.47 (6H, s). Reference Production Example 22
79.0 g of N-iodosuccinimide was added to a mixture of 17.3 g of 4-hydroxy-2,6-dimethylpyridine and 300 mL of methanol, and the mixture was stirred under reflux for 11 hours. The resulting mixture was cooled to room temperature, and the precipitated solid was filtered, and the obtained solid was washed with methanol and dried under reduced pressure to obtain 48.3 g of Intermediate 31 represented by the following formula.
Figure JPOXMLDOC01-appb-C000057
 Intermediate 31: 1 H-NMR (DMSO-d 6 ) δ: 2.47 (6 H, s).
参考製造例２３
　１．３０ｇの中間体３１、ヨウ化メチル０．９８ｇ、炭酸セシウム１．６９ｇ及びアセトン１０ｍＬの混合物を、還流下で１時間撹拌した。得られた混合物に水を加え、ＭＴＢＥで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体３２を０．９５ｇ得た。
Figure JPOXMLDOC01-appb-C000058
 　中間体３２：1H-NMR (CDCl3) δ: 3.89 (3H, s), 2.73 (6H, s). Reference Production Example 23
A mixture of 1.30 g of intermediate 31, 0.98 g of methyl iodide, 1.69 g of cesium carbonate and 10 mL of acetone was stirred under reflux for 1 hour. To the resulting mixture was added water and extracted with MTBE. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 0.95 g of Intermediate 32 represented by the following formula.
Figure JPOXMLDOC01-appb-C000058
 Intermediate 32: 1 H-NMR (CDCl 3 ) δ: 3.89 (3H, s), 2.73 (6H, s).
参考製造例２４
　０．２５ｇの中間体３２及びＴＨＦ１０ｍＬの混合物に、窒素雰囲気下－７８℃でブチルリチウム（１．６４Ｍヘキサン溶液）０．４３ｍＬをゆっくり加え、１０分間撹拌した。得られた混合物にヨウ化メチル０．１２ｍＬを加え、さらに３０分間撹拌した。得られた混合物に水を加え、ＭＴＢＥで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体３３を０．１１ｇ得た。
Figure JPOXMLDOC01-appb-C000059
 　中間体３３：1H-NMR (CDCl3) δ: 3.78 (3H, s), 2.70 (3H, s), 2.45 (3H, s), 2.24 (3H, s). Reference Production Example 24
To a mixture of 0.25 g of Intermediate 32 and 10 mL of THF was slowly added 0.43 mL of butyllithium (1.64 M solution in hexane) at −78 ° C. under a nitrogen atmosphere, and stirred for 10 minutes. To the obtained mixture, 0.12 mL of methyl iodide was added, and the mixture was further stirred for 30 minutes. To the resulting mixture was added water and extracted with MTBE. The obtained organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 0.11 g of Intermediate 33 represented by the following formula.
Figure JPOXMLDOC01-appb-C000059
 Intermediate 33: 1 H-NMR (CDCl 3 ) δ: 3.78 (3H, s), 2.70 (3H, s), 2.45 (3H, s), 2.24 (3H, s).
参考製造例２５
　０．４７ｇの中間体３３及びトリエチルアミン１０ｍＬの混合物に、窒素雰囲気下で１－ペンチン０．３５ｇ、ヨウ化銅（Ｉ）０．０２ｇ及びビス（トリフェニルホスフィン）パラジウム（ＩＩ）クロリド０．０６ｇを順次加え、５０℃で３時間撹拌した。得られた混合物に水を加え、ＭＴＢＥで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体３４を０．３１ｇ得た。
Figure JPOXMLDOC01-appb-C000060
 　中間体３４：1H-NMR (CDCl3) δ: 3.95 (3H, s), 2.57 (3H, s), 2.48 (2H, t), 2.45 (3H, s), 2.13 (3H, s), 1.72-1.63 (2H, m), 1.08 (3H, t). Reference Production Example 25
In a mixture of 0.47 g of Intermediate 33 and 10 mL of triethylamine, under a nitrogen atmosphere, 0.35 g of 1-pentyne, 0.02 g of copper (I) iodide and 0.06 g of bis (triphenylphosphine) palladium (II) chloride It added sequentially and stirred at 50 degreeC for 3 hours. To the resulting mixture was added water and extracted with MTBE. The obtained organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 0.31 g of Intermediate 34 represented by the following formula.
Figure JPOXMLDOC01-appb-C000060
 Intermediate 34: 1 H-NMR (CDCl 3 ) δ: 3.95 (3H, s), 2.57 (3H, s), 2.48 (2H, t), 2.45 (3H, s), 2.13 (3H, s), 1.72 -1.63 (2H, m), 1.08 (3H, t).
製造例４
　０．３１ｇの中間体３４及びクロロホルム１０ｍＬの混合物に、三臭化ホウ素（２Ｍヘプタン溶液）１．４３ｍＬを加え、室温で３時間撹拌した。得られた混合物にメタノール及びトリエチルアミンを順次加え、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（クロロホルム：メタノール＝９０：１０）に付し、下式に示される本発明化合物２６を０．２１ｇ得た。
Figure JPOXMLDOC01-appb-C000061
 　本発明化合物２６：1H-NMR (CDCl3) δ: 2.46 (3H, s), 2.37 (3H, s), 2.13 (2H, t), 2.03 (3H, s), 1.49-1.37 (2H, m), 0.92 (3H, t). Production Example 4
To a mixture of 0.31 g of Intermediate 34 and 10 mL of chloroform, 1.43 mL of boron tribromide (2 M solution in heptane) was added and stirred at room temperature for 3 hours. Methanol and triethylamine were sequentially added to the obtained mixture, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (chloroform: methanol = 90: 10) to obtain 0.21 g of the present compound 26 represented by the following formula.
Figure JPOXMLDOC01-appb-C000061
 The present compound 26: 1 H-NMR (CDCl 3 ) δ: 2.46 (3H, s), 2.37 (3H, s), 2.13 (2H, t), 2.03 (3H, s), 1.49-1 to 37 (2H, m) ), 0.92 (3H, t).
製造例５
　１．０３ｇの本発明化合物１、クロロホルム２０ｍＬ及びトリエチルアミン０．７６ｇの混合物に、氷冷下でアセチルクロリド０．５３ｍＬを加え、室温で１時間撹拌した。得られた混合物に飽和炭酸水素ナトリウム水溶液を加え、クロロホルムで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝８０：２０）に付し、下式に示される本発明化合物２７を１．１２ｇ得た。
Figure JPOXMLDOC01-appb-C000062
 　本発明化合物２７：1H-NMR (CDCl3) δ: 6.13 (0.5H, d), 6.03 (0.5H, d), 5.92-5.74 (1H, m), 2.50 (1.5H, s), 2.48 (1.5H, s), 2.47 (1.5H, s), 2.39 (1.5H, s), 2.28 (1.5H, s), 2.25 (1.5H, s), 2.23-2.15 (1H, m), 2.07 (1.5H, s), 2.05 (1.5H, s), 1.80-1.89 (1H, m), 1.49-1.16 (12H, m), 0.93-0.83 (3H, m). Production Example 5
0.53 mL of acetyl chloride was added to a mixture of 1.03 g of the compound of the present invention 1, 20 mL of chloroform and 0.76 g of triethylamine under ice-cooling, and the mixture was stirred at room temperature for 1 hour. To the resulting mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with chloroform. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (hexane: ethyl acetate = 80: 20) to obtain 1.12 g of the present compound 27 represented by the following formula.
Figure JPOXMLDOC01-appb-C000062
 The present compound 27: 1 H-NMR (CDCl 3 ) δ: 6.13 (0.5 H, d), 6.03 (0.5 H, d), 5.92-5. 74 (1 H, m), 2.50 (1.5 H, s), 2.48 1.5 H, s), 2. 47 (1.5 H, s), 2. 39 (1.5 H, s), 2. 28 (1.5 H, s), 2. 25 (1.5 H, s), 2.23-2.15 (1 H, m), 2.07 (1.5) H, s), 2.05 (1.5 H, s), 1.80-1.89 (1 H, m), 1.49-1 .16 (12 H, m), 0.93-0.83 (3 H, m).
製造例６
　製造例５に記載の方法に準じて製造した化合物及びその物性値を以下に示す。
式（Ａ－３）
Figure JPOXMLDOC01-appb-C000063
 で示される化合物において、Ｒ1x及びＲ2xが［表５］に記載のいずれかの組み合わせである化合物。 Production Example 6
The compounds produced according to the method described in Production Example 5 and the physical properties thereof are shown below.
Formula (A-3)
Figure JPOXMLDOC01-appb-C000063
 In the compound shown by these, compounds in which R 1x and R 2x are any combination described in [Table 5].
Figure JPOXMLDOC01-appb-T000064
　本発明化合物２８：1H-NMR (CDCl3) δ: 6.13 (0.5H, d), 6.04 (0.5H, d), 5.88 (0.5H, m), 5.78 (0.5H, m), 2.50 (1.5H, s), 2.48 (1.5H, s), 2.47 (1.5H, s), 2.39 (1.5H, s), 2.28 (1.5H, s), 2.25 (1.5H, s), 2.20 (1H, m), 2.07 (1.5H, s), 2.05 (1.5H, s), 1.84 (1H, m), 1.45 (1H, m), 1.33 (3H, m), 1.22 (2H, m), 0.91 (1.5H, t), 0.84 (1.5H, t).
　本発明化合物２９：1H-NMR (CDCl3) δ: 6.13 (0.5H, d), 6.04 (0.5H, d), 5.87 (0.5H, m), 5.78 (0.5H, m), 2.50 (1.5H, s), 2.48 (1.5H, s), 2.47 (1.5H, s), 2.39 (1.5H, s), 2.28 (1.5H, s), 2.25 (1.5H, s), 2.21 (1H, m), 2.07 (1.5H, s), 2.05 (1.5H, s), 1.85 (1H, m), 1.41 (2H, m), 1.27 (2H, m), 0.93 (1.5H, t), 0.83 (1.5H, t).
　本発明化合物３０：1H-NMR (CDCl3) δ: 6.14 (0.5H, d), 6.05 (0.5H, d), 5.95-5.75 (1H, m), 2.50 (1.5H, s), 2.48 (3H, s), 2.39 (1.5H, s), 2.28 (1.5H, s), 2.25 (1.5H, s), 2.23-2.13 (1H, m), 2.08 (1.5H, s), 2.05 (1.5H, s), 1.88-1.79 (1H, m), 1.51-1.43 (1H, m), 1.41-1.30 (1H, m), 0.96 (1.5H, t), 0.84 (1.5H, t).
　本発明化合物３１：1H-NMR (CDCl3) δ: 6.13 (0.5H, d), 6.02 (0.5H, d), 5.93 (0.5H, m), 5.77 (0.5H, m), 2.50 (1.5H, s), 2.48 (1.5H, s), 2.47 (1.5H, s), 2.39 (1.5H, s), 2.29 (1.5H, s), 2.26 (1.5H, s), 2.22 (1H, m), 2.07 (1.5H, s), 2.05 (1.5H, s), 1.86 (1H, m), 1.09 (1.5H, t), 0.93 (1.5H, t).
　本発明化合物３２：1H-NMR (CDCl3) δ: 6.16 (0.5H, d), 6.09 (0.5H, d), 5.98-5.84 (1H, m), 2.50 (1.5H, s), 2.48 (3H, s), 2.39 (1.5H, s), 2.29 (1.5H, s), 2.26 (1.5H, s), 2.08 (1.5H, s), 2.05 (1.5H, s), 1.88 (1.5H, dd), 1.51 (1.5H, dd).
　本発明化合物３３：1H-NMR (CDCl3) δ: 6.53 (1H, dd), 5.52 (1H, dd), 5.48 (1H, dd), 2.50 (3H, s), 2.49 (3H, s), 2.30 (3H, s), 2.06 (3H, s).
　本発明化合物３４：1H-NMR (CDCl3) δ: 2.47 (6H, s), 2.36 (3H, s), 2.04 (6H, s).
　本発明化合物３５：1H-NMR (CDCl3) δ: 6.76 (0.5H, dd), 6.53 (0.5H, t), 6.21 (0.5H, d), 5.98 (0.5H, d), 5.95 (0.5H, d), 5.58 (0.5H, d), 2.48 (1.5H, s), 2.51 (3H, s), 2.39 (1.5H, s), 2.29 (1.5H, s), 2.22 (1.5H, s), 2.08 (1.5H, s), 2.06 (1.5H, s), 1.85 (1.5H, s), 1.81 (3H, s), 1.74 (1.5H, s).
　本発明化合物３６：1H-NMR (CDCl3) δ: 6.46-6.38 (1H, m), 5.91-5.80 (1H, m), 3.06-2.94 (1H, m), 2.75-2.63 (1H, m), 2.52 (1.5H, s), 2.49 (1.5H, s), 2.47 (1.5H, s), 2.39 (1.5H, s), 2.28 (1.5H, s), 2.25 (1.5H, s), 2.08 (1.5H, s), 2.06 (1.5H, s).
　本発明化合物３７：1H-NMR (CDCl3) δ: 6.08 (0.5H, d), 5.90 (0.5H, d), 5.82 (0.5H, dd), 5.61 (0.5H, dd), 2.50 (1.5H, s), 2.48 (1.5H, s), 2.46 (1.5H, s), 2.40 (1.5H, s), 2.28 (1.5H, s), 2.26 (1.5H, s), 2.18-2.09 (1H, m), 2.07 (1.5H, s), 2.05 (1.5H, s), 1.89-1.49 (5H, m), 1.39-0.99 (5H, m).
　本発明化合物３８：1H-NMR (CDCl3) δ: 6.71 (0.5H, d), 6.17 (0.5H, d), 5.44 (0.5H, d), 5.05 (0.5H, d), 3.68 (1.5H, s), 3.66 (1.5H, s), 2.49 (1.5H, s), 2.48 (3H, s), 2.45 (1.5H, s), 2.31 (1.5H, s), 2.30 (1.5H, s), 2.05 (3H, s).
　本発明化合物３９：1H-NMR (CDCl3) δ: 4.42 (2H, s), 3.92 (3H, s), 3.31 (3H, s), 2.57 (3H, s), 2.50 (3H, s), 2.10 (3H, s).
　本発明化合物４０：1H-NMR (CDCl3) δ: 8.16 (1H, s), 3.97 (3H, s), 2.60 (3H, s), 2.51 (3H, s), 2.35 (3H, s), 2.09 (3H, s).
　本発明化合物４１：1H-NMR (CDCl3) δ: 4.99 (2H, s), 2.60 (3H, s), 2.50 (3H, s), 2.35 (3H, s), 2.05 (3H, s), 1.83 (3H, s), 1.77 (3H, s).
　本発明化合物４２：1H-NMR (CDCl3) δ: 5.34 (1H, s), 3.45 (6H, s), 2.61 (3H, s), 2.49 (3H, s), 2.34 (3H, s), 2.04 (3H, s).
　本発明化合物４３：1H-NMR (CDCl3) δ: 2.54 (3H, s), 2.49 (3H, s), 2.44 (2H, t), 2.36 (3H, s), 2.07 (3H, s), 1.68-1.58 (2H, m), 1.06 (3H, t).
　本発明化合物４４：1H-NMR (CDCl3) δ: 4.41 (2H, s), 3.31-3.22 (1H, m), 2.57 (3H, s), 2.48 (3H, s), 2.36 (3H, s), 2.04 (3H, s), 1.97-1.87 (2H, m), 1.81-1.67 (3H, m), 1.37-1.15 (5H, m).
　本発明化合物４５：1H-NMR (CDCl3) δ: 4.40 (2H, s), 3.34 (2H, dd), 2.57 (3H, s), 2.49 (3H, s), 2.35 (3H, s), 2.05 (3H, s), 1.57 (2H, m), 0.90 (3H, t).
　本発明化合物４６：1H-NMR (CDCl3) δ: 3.50-3.43 (4H, m), 2.79 (2H, m), 2.53 (3H, s), 2.47 (3H, s), 2.36 (3H, s), 2.02 (3H, s), 1.19 (3H, t).
　本発明化合物４７：1H-NMR (CDCl3) δ: 5.43 (1H, m), 5.16 (1H, m), 3.23 (2H, d), 2.48 (3H, s), 2.47 (3H, s), 2.34 (3H, s), 2.19 (2H, m), 2.03 (3H, s), 1.03 (3H, t).
　本発明化合物４８：1H-NMR (CDCl3) δ: 3.34 (2H, s), 2.58 (3H, s), 2.48 (3H, s), 2.39 (3H, s), 2.15-2.07 (2H, m), 2.04 (3H, s), 1.07 (3H, t).
　本発明化合物４９：1H-NMR (CDCl3) δ: 5.53-5.39 (2H, m), 2.52 (3H, s), 2.49 (2H, m), 2.47 (3H, s), 2.36 (3H, s), 2.19 (2H, m), 2.03 (3H, s), 1.58 (3H, m).
　本発明化合物５０：1H-NMR (CDCl3) δ: 5.82 (1H, m), 5.09-4.99 (2H, m), 2.49 (3H, s), 2.49-2.42 (2H, m), 2.47 (3H, s), 2.35 (3H, s), 2.12 (2H, t), 2.02 (3H, s), 1.55 (2H, m).
　本発明化合物５１：1H-NMR (CDCl3) δ: 2.74-2.62 (2H, m), 2.53 (3H, s), 2.47 (3H, s), 2.37 (3H, s), 2.32-2.23 (2H, m), 2.02 (3H, s), 1.77 (3H, t).
　本発明化合物５２：1H-NMR (CDCl3) δ: 2.65-2.51 (2H, m), 2.51 (3H, s), 2.48 (3H, s), 2.38 (3H, s), 2.03 (3H, s), 2.26 (2H, dt), 2.01 (1H, t), 1.72-1.61 (2H, m).
　本発明化合物１０１： 1H-NMR (CDCl3) δ: 6.36 (0.5H, d), 6.29 (0.5H, d), 5.96-5.82 (1H, m), 2.61-2.52 (2H, m), 2.51 (1.5H, s), 2.49 (1.5H, s), 2.49 (1.5H, s), 2.40 (1.5H, s), 2.38-2.32 (1H, m), 2.33 (1.5H, s), 2.27 (1.5H, s), 2.26-2.18 (1H, m), 2.08 (1.5H, s), 2.05 (1.5H, s).
　本発明化合物１０２：1H-NMR (CDCl3) δ: 6.18 (0.5H, d), 6.08 (0.5H, d), 5.82-5.73 (1H, m), 3.23 (0.5H, m), 3.15 (0.5H, m), 2.50 (1.5H, s), 2.48 (1.5H, s), 2.26 (1.5H, s), 2.24 (1.5H, s), 2.22-2.13 (1H, m), 2.06 (1.5H, s), 2.04 (1.5H, s), 1.88-1.80 (1H, m), 1.53-1.43 (1H, m), 1.41-1.30 (1H, m), 1.21 (3H, d), 1.18 (3H, d), 0.96 (1.5H, t), 0.86 (1.5H, t).
　本発明化合物１０３：1H-NMR (CDCl3) δ: 6.18 (0.5H, d), 6.07 (0.5H, d), 5.82-5.72 (1H, m), 3.23 (0.5H, m), 3.14 (0.5H, m), 2.50 (1.5H, s), 2.48 (1.5H, s), 2.26 (1.5H, s), 2.24 (1.5H, s), 2.24-2.15 (1H, m), 2.06 (1.5H, s), 2.04 (1.5H, s), 1.91-1.82 (1H, m), 1.49-1.23 (4H, m), 1.21 (3H, d), 1.18 (3H, d), 0.93 (1.5H, t), 0.84 (1.5H, t).
　本発明化合物１２２：1H-NMR (CDCl3) δ: 4.96 (1H, dd), 3.18 (2H, d), 2.47 (6H, s), 2.34 (3H, s), 2.03 (3H, s), 1.75 (3H, s), 1.69 (3H, s).
　本発明化合物１２３：1H-NMR (CDCl3) δ: 5.24 (0.5H, dd), 4.94 (0.5H, dd), 3.29 (1H, br s), 3.17 (1H, s), 2.49 (1.5H, s), 2.49 (1.5H, s), 2.48 (1.5H, s), 2.48 (1.5H, s), 2.46 (1.5H, s), 2.45 (1.5H, s), 2.32 (1.5H, s), 2.30 (1.5H, s), 2.16 (1H, m), 2.03 (1.5H, s), 2.03 (1.5H, s), 1.98 (1H, m), 1.02 (1.5H, t), 0.89 (1.5H, t).
Figure JPOXMLDOC01-appb-T000064
The present compound 28: 1 H-NMR (CDCl 3 ) δ: 6.13 (0.5 H, d), 6.04 (0.5 H, d), 5.88 (0.5 H, m), 5. 78 (0.5 H, m), 2.50 (1.5 H, s), 2.48 (1.5 H, s), 2. 47 (1.5 H, s), 2. 39 (1.5 H, s), 2. 28 (1.5 H, s), 2. 25 (1.5 H, s), 2. 20 (1 H, m) ), 2.07 (1.5 H, s), 2.05 (1.5 H, s), 1. 84 (1 H, m), 1. 45 (1 H, m), 1.33 (3 H, m), 1.22 (2 H, m), 0.91 (1.5 H) , t), 0.84 (1.5 H, t).
The compound of the present invention 29: 1 H-NMR (CDCl 3 ) δ: 6.13 (0.5 H, d), 6.04 (0.5 H, d), 5.87 (0.5 H, m), 5. 78 (0.5 H, m), 2.50 (1.5 H, s), 2.48 (1.5 H, s), 2.47 (1.5 H, s), 2. 39 (1.5 H, s), 2. 28 (1.5 H, s), 2. 25 (1.5 H, s), 2.21 (1 H, m) ), 2.07 (1.5 H, s), 2.05 (1.5 H, s), 1. 85 (1 H, m), 1.41 (2 H, m), 1. 27 (2 H, m), 0.93 (1.5 H, t), 0.83 (1.5) H, t).
The present compound 30: 1 H-NMR (CDCl 3 ) δ: 6.14 (0.5 H, d), 6.05 (0.5 H, d), 5.95-5.75 (1 H, m), 2.50 (1.5 H, s), 2.48 3H, s), 2. 39 (1.5 H, s), 2. 28 (1.5 H, s), 2. 25 (1.5 H, s), 2.23-2.13 (1 H, m), 2.08 (1.5 H, s), 2.05 (1.5 H) , s), 1.88-1.79 (1 H, m), 1.51-1. 43 (1 H, m), 1.41-1. 30 (1 H, m), 0.96 (1.5 H, t), 0.84 (1.5 H, t).
The present compound 31: 1 H-NMR (CDCl 3 ) δ: 6.13 (0.5 H, d), 6.02 (0.5 H, d), 5. 93 (0.5 H, m), 5. 77 (0.5 H, m), 2.50 (1.5 H, s), 2.48 (1.5 H, s), 2.47 (1.5 H, s), 2. 39 (1.5 H, s), 2. 29 (1.5 H, s), 2. 26 (1.5 H, s), 2.22 (1 H, m) ), 2.07 (1.5 H, s), 2.05 (1.5 H, s), 1. 86 (1 H, m), 1.09 (1.5 H, t), 0.93 (1.5 H, t).
The compound of the present invention 32: 1 H-NMR (CDCl 3 ) δ: 6.16 (0.5 H, d), 6.09 (0.5 H, d), 5.98-5.84 (1 H, m), 2.50 (1.5 H, s), 2.48 3H, s), 2. 39 (1.5 H, s), 2. 29 (1.5 H, s), 2. 26 (1.5 H, s), 2.08 (1.5 H, s), 2.05 (1.5 H, s), 1. 88 (1.5 H, s) dd), 1.51 (1.5 H, dd).
The present compound 33: 1 H-NMR (CDCl 3 ) δ: 6.53 (1 H, dd), 5.52 (1 H, dd), 5.48 (1 H, dd), 2.50 (3 H, s), 2.49 (3 H, s), 2.30 (3H, s), 2.06 (3H, s).
The present compound 34: 1 H-NMR (CDCl 3 ) δ: 2.47 (6H, s), 2.36 (3H, s), 2.04 (6H, s).
The present compound 35: 1 H-NMR (CDCl 3 ) δ: 6.76 (0.5 H, dd), 6.53 (0.5 H, t), 6.21 (0.5 H, d), 5.98 (0.5 H, d), 5.95 (0.5 H, d), 5.58 (0.5 H, d), 2. 48 (1.5 H, s), 2.51 (3 H, s), 2. 39 (1.5 H, s), 2. 29 (1.5 H, s), 2.22 (1.5 H, s) ), 2.08 (1.5 H, s), 2.06 (1.5 H, s), 1. 85 (1.5 H, s), 1.81 (3 H, s), 1. 74 (1.5 H, s).
The present compound 36: 1 H-NMR (CDCl 3 ) δ: 6.46-6.38 (1H, m), 5.91-5.80 (1H, m), 3.06-2.94 (1H, m), 2.75-2.63 (1H, m) , 2.52 (1.5 H, s), 2. 49 (1.5 H, s), 2. 47 (1.5 H, s), 2. 39 (1.5 H, s), 2. 28 (1.5 H, s), 2. 25 (1.5 H, s), 2.08 (1.5 H, s), 2.06 (1.5 H, s).
The present compound 37: 1 H-NMR (CDCl 3 ) δ: 6.08 (0.5 H, d), 5.90 (0.5 H, d), 5.82 (0.5 H, dd), 5.61 (0.5 H, dd), 2.50 (1.5 H, s), 2.48 (1.5 H, s), 2.46 (1.5 H, s), 2.40 (1.5 H, s), 2.28 (1.5 H, s), 2.26 (1.5 H, s), 2.18-2.09 (1 H) , m), 2.07 (1.5 H, s), 2.05 (1.5 H, s), 1.89-1.49 (5 H, m), 1.39-0.99 (5 H, m).
The present compound 38: 1 H-NMR (CDCl 3 ) δ: 6.71 (0.5 H, d), 6.17 (0.5 H, d), 5. 44 (0.5 H, d), 5.05 (0.5 H, d), 3.68 (1.5 H, s), 3.66 (1.5 H, s), 2. 49 (1.5 H, s), 2. 48 (3 H, s), 2. 45 (1.5 H, s), 2.31 (1.5 H, s), 2. 30 (1.5 H, s) ), 2.05 (3H, s).
The present compound 39: 1 H-NMR (CDCl 3 ) δ: 4.42 (2H, s), 3.92 (3H, s), 3.31 (3H, s), 2.57 (3H, s), 2.50 (3H, s), 2.10 (3H, s).
The present compound 40: 1 H-NMR (CDCl 3 ) δ: 8.16 (1H, s), 3.97 (3H, s), 2.60 (3H, s), 2.51 (3H, s), 2.35 (3H, s), 2.09 (3H, s).
The present compound 41: 1 H-NMR (CDCl 3 ) δ: 4.99 (2H, s), 2.60 (3H, s), 2.50 (3H, s), 2.35 (3H, s), 2.05 (3H, s), 1.83 (3H, s), 1.77 (3H, s).
Invention compound 42: 1 H-NMR (CDCl 3 ) δ: 5.34 (1H, s), 3.45 (6H, s), 2.61 (3H, s), 2.49 (3H, s), 2.34 (3H, s), 2.04 (3H, s).
Invention compound 43: 1 H-NMR (CDCl 3 ) δ: 2.54 (3H, s), 2.49 (3H, s), 2.44 (2H, t), 2.36 (3H, s), 2.07 (3H, s), 1.68-1.58 (2H, m), 1.06 (3H, t).
Invention compound 44: 1 H-NMR (CDCl 3 ) δ: 4.41 (2H, s), 3.31-3.22 (1H, m), 2.57 (3H, s), 2.48 (3H, s), 2.36 (3H, s) ), 2.04 (3H, s), 1.97-1.87 (2H, m), 1.81-1.67 (3H, m), 1.37-1.15 (5H, m).
The present compound 45: 1 H-NMR (CDCl 3 ) δ: 4.40 (2H, s), 3.34 (2H, dd), 2.57 (3H, s), 2.49 (3H, s), 2.35 (3H, s), 2.05 (3H, s), 1.57 (2H, m), 0.90 (3H, t).
Invention compound 46: 1 H-NMR (CDCl 3 ) δ: 3.50 to 3.43 (4H, m), 2.79 (2H, m), 2.53 (3H, s), 2.47 (3H, s), 2.36 (3H, s) ), 2.02 (3H, s), 1.19 (3H, t).
Invention compound 47: 1 H-NMR (CDCl 3 ) δ: 5.43 (1H, m), 5.16 (1H, m), 3.23 (2H, d), 2.48 (3H, s), 2.47 (3H, s), 2.34 (3H, s), 2.19 (2H, m), 2.03 (3H, s), 1.03 (3H, t).
The present compound 48: 1 H-NMR (CDCl 3 ) δ: 3.34 (2H, s), 2.58 (3H, s), 2.48 (3H, s), 2.39 (3H, s), 2.15-2.07 (2H, m) ), 2.04 (3H, s), 1.07 (3H, t).
Invention compound 49: 1 H-NMR (CDCl 3 ) δ: 5.53-5.39 (2H, m), 2.52 (3H, s), 2.49 (2H, m), 2.47 (3H, s), 2.36 (3H, s) ), 2.19 (2H, m), 2.03 (3H, s), 1.58 (3H, m).
The present compound 50: 1 H-NMR (CDCl 3 ) δ: 5.82 (1H, m), 5.09-4.99 (2H, m), 2.49 (3H, s), 2.49-2.42 (2H, m), 2.47 (3H) , s), 2.35 (3H, s), 2.12 (2H, t), 2.02 (3H, s), 1.55 (2H, m).
The present compound 51: 1 H-NMR (CDCl 3 ) δ: 2.74-2.62 (2H, m), 2.53 (3H, s), 2.47 (3H, s), 2.37 (3H, s), 2.32-2.23 (2H , m), 2.02 (3H, s), 1.77 (3H, t).
Invention compound 52: 1 H-NMR (CDCl 3 ) δ: 2.65-2.51 (2H, m), 2.51 (3H, s), 2.48 (3H, s), 2.38 (3H, s), 2.03 (3H, s) ), 2.26 (2H, dt), 2.01 (1H, t), 1.72-1.61 (2H, m).
The present compound 101: 1 H-NMR (CDCl 3 ) δ: 6.36 (0.5 H, d), 6.29 (0.5 H, d), 5.96-5.82 (1 H, m), 2.61-2.52 (2 H, m), 2.51 (1.5 H, s), 2. 49 (1.5 H, s), 2. 49 (1.5 H, s), 2. 40 (1.5 H, s), 2. 38-2. 32 (1 H, m), 2. 33 (1.5 H, s), 2. 27 ( 1.5 H, s), 2.26-2.18 (1 H, m), 2.08 (1.5 H, s), 2.05 (1.5 H, s).
The present compound 102: 1 H-NMR (CDCl 3 ) δ: 6.18 (0.5 H, d), 6.08 (0.5 H, d), 5.82-5. 73 (1 H, m), 3.23 (0.5 H, m), 3.15 ( 0.5 H, m), 2.50 (1.5 H, s), 2. 48 (1.5 H, s), 2. 26 (1.5 H, s), 2. 24 (1.5 H, s), 2.22-2.13 (1 H, m), 2.06 (1.5) H, s), 2.04 (1.5 H, s), 1. 88-1.80 (1 H, m), 1.53-1. 43 (1 H, m), 1.41-1. 30 (1 H, m), 1.21 (3 H, d), 1. 18 (3 H) , d), 0.96 (1.5 H, t), 0.86 (1.5 H, t).
The present compound 103: 1 H-NMR (CDCl 3 ) δ: 6.18 (0.5 H, d), 6.07 (0.5 H, d), 5.82-5.72 (1 H, m), 3.23 (0.5 H, m), 3.14 (3) 0.5 H, m), 2.50 (1.5 H, s), 2. 48 (1.5 H, s), 2. 26 (1.5 H, s), 2. 24 (1.5 H, s), 2.24-2.15 (1 H, m), 2.06 (1.5) H, s), 2.04 (1.5 H, s), 1. 91-1. 82 (1 H, m), 1. 49-1.23 (4 H, m), 1.21 (3 H, d), 1. 18 (3 H, d), 0.93 (1.5 H, t), 0.84 (1.5 H, t).
Invention compound 122: 1 H-NMR (CDCl 3 ) δ: 4.96 (1H, dd), 3.18 (2H, d), 2.47 (6H, s), 2.34 (3H, s), 2.03 (3H, s), 1.75 (3H, s), 1.69 (3H, s).
The present compound compound 123: 1 H-NMR (CDCl 3 ) δ: 5.24 (0.5 H, dd), 4.94 (0.5 H, dd), 3.29 (1 H, br s), 3.17 (1 H, s), 2.49 (1.5 H) , s), 2.49 (1.5 H, s), 2. 48 (1.5 H, s), 2. 48 (1.5 H, s), 2. 46 (1.5 H, s), 2. 45 (1.5 H, s), 2. 32 (1.5 H, s) ), 2.30 (1.5 H, s), 2.16 (1 H, m), 2.03 (1.5 H, s), 2.03 (1.5 H, s), 1. 98 (1 H, m), 1.02 (1.5 H, t), 0.89 ( 1.5 H, t).
製造例７
　０．５９ｇの本発明化合物２７、１０％パラジウム／炭素０．０７ｇ及び酢酸エチル２０ｍＬの混合物を水素雰囲気下室温で３時間撹拌した。反応容器内を窒素で置換した後、得られた混合物をセライト（登録商標）でろ過し、ろ液を減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝８０：２０）に付し、下式に示される本発明化合物５３を０．５９ｇ得た。
Figure JPOXMLDOC01-appb-C000065
 　本発明化合物５３：1H-NMR (CDCl3) δ: 2.49 (3H, s), 2.48-2.38 (5H, m), 2.35 (3H, s), 2.02 (3H, s), 1.49-1.20 (16H, m), 0.88 (3H, t). Production Example 7
A mixture of 0.59 g of the compound of the present invention 27, 10% palladium / 0.07 g of carbon and 20 mL of ethyl acetate was stirred at room temperature under a hydrogen atmosphere for 3 hours. After the inside of the reaction vessel was purged with nitrogen, the resulting mixture was filtered through Celite (registered trademark), and the filtrate was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (hexane: ethyl acetate = 80: 20) to obtain 0.59 g of the present compound 53 represented by the following formula.
Figure JPOXMLDOC01-appb-C000065
 The present compound 53: 1 H-NMR (CDCl 3 ) δ: 2.49 (3H, s), 2.48-2.38 (5H, m), 2.35 (3H, s), 2.02 (3H, s), 1.49-1 .20 (16H , m), 0.88 (3H, t).
製造例８
　製造例７に記載の方法に準じて製造した化合物及びその物性値を以下に示す。式（Ａ－３）で示される化合物において、Ｒ1x及びＲ2xが［表６］に記載のいずれかの組み合わせである化合物。 Production Example 8
The compounds produced according to the method described in Production Example 7 and the physical properties thereof are shown below. In the compound represented by the formula (A-3), compounds wherein R 1x and R 2x are any combination of those described in [Table 6].
Figure JPOXMLDOC01-appb-T000066
　本発明化合物５４：1H-NMR (CDCl3) δ: 2.49 (3H, s), 2.47 (3H, s), 2.46-2.40 (2H, m), 2.35 (3H, s), 2.02 (3H, s), 1.49-1.39 (2H, m), 1.39-1.22 (8H, m), 0.89 (3H, t).
　本発明化合物５５：1H-NMR (CDCl3) δ: 2.49 (3H, s), 2.46 (3H, s), 2.46-2.40 (2H, m), 2.35 (3H, s), 2.02 (3H, s), 1.48-1.27 (8H, m), 0.89 (3H, t).
　本発明化合物５６：1H-NMR (CDCl3) δ: 2.49 (3H, s), 2.47 (3H, s), 2.54-2.38 (2H, m), 2.35 (3H, s), 2.02 (3H, s), 1.40-1.51 (2H, m), 1.39-1.28 (4H, m), 0.91 (3H, t).
　本発明化合物５７：1H-NMR (CDCl3) δ: 2.49 (3H, s), 2.47 (3H, s), 2.48-2.41 (2H, m), 2.36 (3H, s), 2.02 (3H, s), 1.47-1.33 (4H, m), 0.94 (3H, t).
　本発明化合物５８：1H-NMR (CDCl3) δ: 2.49 (3H, s), 2.47 (3H, s), 2.46-2.38 (2H, m), 2.36 (3H, s), 2.02 (3H, s), 1.54-1.43 (2H, m), 0.97 (3H, t).
　本発明化合物５９：1H-NMR (CDCl3) δ: 2.50 (3H, s), 2.47 (3H, s), 2.54-2.44 (2H, m), 2.37 (3H, s), 2.03 (3H, s), 1.09 (3H, t).
　本発明化合物６０：1H-NMR (CDCl3) δ: 2.50 (3H, s), 2.47 (3H, s), 2.46-2.37 (2H, m), 2.36 (3H, s), 2.03 (3H, s), 1.63-1.51 (1H, m), 1.50-1.39 (2H, m), 1.29-1.21 (2H, m), 0.89 (6H, d).
　本発明化合物６１：1H-NMR (CDCl3) δ: 2.61-2.51 (2H, m), 2.50 (3H, s), 2.48 (3H, s), 2.36 (3H, s), 2.21-2.06 (2H, m), 2.03 (3H, s), 1.79-1.68 (2H, m).
　本発明化合物６２：1H-NMR (CDCl3) δ: 2.54-2.39 (8H, m), 2.35 (3H, s), 2.02 (3H, s), 1.81-1.62 (5H, m), 1.36-1.19 (6H, m), 1.01-0.88 (2H, m).
　本発明化合物１０４：1H-NMR (CDCl3) δ: 2.60-2.46 (2H, m), 2.50 (3H, s), 2.47 (3H, s), 2.40-2.35 (2H, m), 2.38 (3H, s), 2.02 (3H, s), 1.77-1.59 (4H, m).
　本発明化合物１０５：1H-NMR (CDCl3) δ: 3.18 (1H, m), 2.52-2.37 (2H, m), 2.47 (3H, s), 2.35 (3H, s), 2.00 (3H, s), 1.50-1.28 (6H, m), 1.24 (6H, d), 0.91 (3H, t).
　本発明化合物１０６：1H-NMR (CDCl3) δ: 3.18 (1H, m), 2.57-2.38 (2H, m), 2.47 (3H, s), 2.35 (3H, s), 2.00 (3H, s), 1.50-1.28 (8H, m), 1.24 (6H, d), 0.91 (3H, t).
　本発明化合物１０７：1H-NMR (CDCl3) δ: 2.77 (2H, q), 2.56-2.38 (2H, m), 2.48 (3H, s), 2.35 (3H, s), 2.02 (3H, s), 1.52-1.32 (6H, m), 1.25 (3H, t), 0.91 (3H, t).
　本発明化合物１０８：1H-NMR (CDCl3) δ: 2.77 (2H, q), 2.58-2.38 (2H, m), 2.48 (3H, s), 2.35 (3H, s), 2.02 (3H, s), 1.51-1.26 (8H, m), 1.25 (3H, t), 0.90 (3H, t).
　本発明化合物１０９：1H-NMR (CDCl3) δ: 2.49 (3H, s), 2.47 (3H, s), 2.42-2.26 (2H, m), 2.35 (3H, s), 2.02 (3H, s), 1.77-1.57 (5H, m), 1.53-1.39 (1H, m), 1.21-0.92 (5H, m).
　本発明化合物１１０：1H-NMR (CDCl3) δ: 3.19 (1H, m), 2.47 (3H, s), 2.46-2.22 (2H, m), 2.34 (3H, s), 2.02 (3H, s), 1.73-1.58 (5H, m), 1.48-1.33 (1H, m), 1.22 (6H, d), 1.20-0.88 (5H, m).
　本発明化合物１２４：1H-NMR (CDCl3) δ: 2.49 (3H, s), 2.46 (3H, s), 2.43 (2H, brs), 2.35 (3H, s), 2.02 (3H, s), 1.62 (1H, m), 1.31 (2H, m), 0.95 (6H, d).
　本発明化合物１２５：1H-NMR (CDCl3) δ: 2.50 (3H, s), 2.47 (3H, s), 2.47 (1H, m), 2.34 (3H, s), 2.23 (1H, br s), 2.02 (3H, s), 1.69 (1H, m), 1.46-1.14 (4H, m), 0.89 (3H, t), 0.82 (3H, d).
Figure JPOXMLDOC01-appb-T000066
The present compound 54: 1 H-NMR (CDCl 3 ) δ: 2.49 (3H, s), 2.47 (3H, s), 2.46-2.40 (2H, m), 2.35 (3H, s), 2.02 (3H, s) ), 1.49-1.39 (2H, m), 1.39-1.22 (8H, m), 0.89 (3H, t).
The present compound 55: 1 H-NMR (CDCl 3 ) δ: 2.49 (3H, s), 2.46 (3H, s), 2.46-2.40 (2H, m), 2.35 (3H, s), 2.02 (3H, s) ), 1.48-1.27 (8H, m), 0.89 (3H, t).
The present compound 56: 1 H-NMR (CDCl 3 ) δ: 2.49 (3H, s), 2.47 (3H, s), 2.54-2.38 (2H, m), 2.35 (3H, s), 2.02 (3H, s) ), 1.40-1.51 (2H, m), 1.39-1 .28 (4H, m), 0.91 (3H, t).
The present compound 57: 1 H-NMR (CDCl 3 ) δ: 2.49 (3H, s), 2.47 (3H, s), 2.48-2.41 (2H, m), 2.36 (3H, s), 2.02 (3H, s) ), 1.47-1.33 (4H, m), 0.94 (3H, t).
The present compound 58: 1 H-NMR (CDCl 3 ) δ: 2.49 (3H, s), 2.47 (3H, s), 2.46-2.38 (2H, m), 2.36 (3H, s), 2.02 (3H, s) ), 1.54-1.43 (2H, m), 0.97 (3H, t).
Invention compound 59: 1 H-NMR (CDCl 3 ) δ: 2.50 (3H, s), 2.47 (3H, s), 2.54-2.44 (2H, m), 2.37 (3H, s), 2.03 (3H, s) ), 1.09 (3H, t).
The present compound 60: 1 H-NMR (CDCl 3 ) δ: 2.50 (3H, s), 2.47 (3H, s), 2.46-2.37 (2H, m), 2.36 (3H, s), 2.03 (3H, s) ), 1.63-1.51 (1 H, m), 1.50-1. 39 (2 H, m), 1.29-1.21 (2 H, m), 0.89 (6 H, d).
The present compound 61: 1 H-NMR (CDCl 3 ) δ: 2.61-2.51 (2H, m), 2.50 (3H, s), 2.48 (3H, s), 2.36 (3H, s), 2.21-2.06 (2H , m), 2.03 (3H, s), 1.79-1.68 (2H, m).
The present compound 62: 1 H-NMR (CDCl 3 ) δ: 2.54-2.39 (8H, m), 2.35 (3H, s), 2.02 (3H, s), 1.81-1.62 (5H, m), 1.36-1.19 (6H, m), 1.01-0.88 (2H, m).
Invention compound 104: 1 H-NMR (CDCl 3 ) δ: 2.60-2.46 (2H, m), 2.50 (3H, s), 2.47 (3H, s), 2.40-2.35 (2H, m), 2.38 (3H , s), 2.02 (3H, s), 1.77-1.59 (4H, m).
Invention compound 105: 1 H-NMR (CDCl 3 ) δ: 3.18 (1H, m), 2.52-2.37 (2H, m), 2.47 (3H, s), 2.35 (3H, s), 2.00 (3H, s) ), 1.50-1.28 (6H, m), 1.24 (6H, d), 0.91 (3H, t).
The present compound 106: 1 H-NMR (CDCl 3 ) δ: 3.18 (1H, m), 2.57-2.38 (2H, m), 2.47 (3H, s), 2.35 (3H, s), 2.00 (3H, s) ), 1.50-1.28 (8H, m), 1.24 (6H, d), 0.91 (3H, t).
The present compound 107: 1 H-NMR (CDCl 3 ) δ: 2.77 (2H, q), 2.56-2.38 (2H, m), 2.48 (3H, s), 2.35 (3H, s), 2.02 (3H, s) ), 1.52-1.32 (6H, m), 1.25 (3H, t), 0.91 (3H, t).
Invention compound 108: 1 H-NMR (CDCl 3 ) δ: 2.77 (2H, q), 2.58-2.38 (2H, m), 2.48 (3H, s), 2.35 (3H, s), 2.02 (3H, s) ), 1.51-1.26 (8 H, m), 1.25 (3 H, t), 0.90 (3 H, t).
Invention compound 109: 1 H-NMR (CDCl 3 ) δ: 2.49 (3H, s), 2.47 (3H, s), 2.42-2.26 (2H, m), 2.35 (3H, s), 2.02 (3H, s) ), 1.77-1.57 (5H, m), 1.53-1.39 (1H, m), 1.21-0.92 (5H, m).
Invention compound 110: 1 H-NMR (CDCl 3 ) δ: 3.19 (1H, m), 2.47 (3H, s), 2.46-2.22 (2H, m), 2.34 (3H, s), 2.02 (3H, s) ), 1.73-1.58 (5H, m), 1.48-1.33 (1H, m), 1.22 (6H, d), 1.20-0.88 (5H, m).
The present compound 124: 1 H-NMR (CDCl 3 ) δ: 2.49 (3H, s), 2.46 (3H, s), 2.43 (2H, brs), 2.35 (3H, s), 2.02 (3H, s), 1.62 (1 H, m), 1.31 (2 H, m), 0.95 (6 H, d).
The present compound 125: 1 H-NMR (CDCl 3 ) δ: 2.50 (3H, s), 2.47 (3H, s), 2.47 (1H, m), 2.34 (3H, s), 2.23 (1H, br s) , 2.02 (3H, s), 1.69 (1H, m), 1.46-1.14 (4H, m), 0.89 (3H, t), 0.82 (3H, d).
製造例９
　０．７７ｇの本発明化合物８、クロロホルム１０ｍＬ及びトリエチルアミン１．４１ｍＬの混合物に、氷冷下でクロロ炭酸メチル０．７８ｍＬを加え、室温で１時間撹拌した。得られた混合物に飽和炭酸水素ナトリウム水溶液を加え、クロロホルムで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝８０：２０）に付し、下式に示される本発明化合物６３を０．８３ｇ得た。
Figure JPOXMLDOC01-appb-C000067
 　本発明化合物６３：1H-NMR (CDCl3) δ: 3.93 (3H, s), 2.47 (6H, s), 2.09 (6H, s). Production Example 9
To a mixture of 0.77 g of the compound of the present invention 8, 10 mL of chloroform and 1.41 mL of triethylamine was added 0.78 mL of methyl chlorocarbonate under ice-cooling, and the mixture was stirred at room temperature for 1 hour. To the resulting mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with chloroform. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (hexane: ethyl acetate = 80: 20) to obtain 0.83 g of the present compound 63 represented by the following formula.
Figure JPOXMLDOC01-appb-C000067
 The present compound 63: 1 H-NMR (CDCl 3 ) δ: 3.93 (3H, s), 2.47 (6H, s), 2.09 (6H, s).
製造例１０
　製造例９に記載の方法に準じて製造した化合物及びその物性値を以下に示す。
式（Ａ－４）
Figure JPOXMLDOC01-appb-C000068
 で示される化合物において、ＲA及びＲBが［表７］に記載のいずれかの組み合わせである化合物。 Production Example 10
The compounds produced according to the method described in Production Example 9 and the physical properties thereof are shown below.
Formula (A-4)
Figure JPOXMLDOC01-appb-C000068
 In the compound shown by these, compounds in which R A and R B are any combination of those described in [Table 7].
Figure JPOXMLDOC01-appb-T000069
　本発明化合物６４：1H-NMR (CDCl3) δ: 3.92 (3H, s), 2.54-2.45 (8H, m), 2.07 (3H, s), 1.50-1.40 (2H, m), 1.39-1.28 (4H, m), 0.90 (3H, t).
　本発明化合物６５：1H-NMR (CDCl3) δ: 4.42 (2H, s), 3.92 (3H, s), 3.31 (3H, s), 2.57 (3H, s), 2.50 (3H, s), 2.10 (3H, s).
　本発明化合物６６：1H-NMR (CDCl3) δ: 4.47 (2H, s), 3.92 (3H, s), 3.33-3.23 (1H, m), 2.49 (3H, s), 2.58 (3H, s), 2.10 (3H, s), 1.96-1.86 (2H, m), 1.78-1.69 (2H, m), 1.58-1.48 (1H, m), 1.36-1.14 (5H, m).
　本発明化合物６７：1H-NMR (CDCl3) δ: 3.93 (3H, s), 2.77-2.71 (8H, m), 2.09 (3H, s), 1.67-1.67 (2H, m), 1.42-1.31 (4H, m), 0.90 (3H, t).
　本発明化合物１１５：1H-NMR (CDCl3) δ: 3.92 (3H, s), 3.20 (1H, m), 2.47 (3H, s), 2.39 (2H, d), 2.06 (3H, s), 1.76-1.56 (5H, m), 1.48-1.33 (1H, m), 1.23 (6H, d), 1.21-1.08 (3H, m), 1.07-0.93 (2H, m).
　本発明化合物１１６：1H-NMR (CDCl3) δ: 3.92 (3H, s), 3.18 (1H, m), 2.52-2.47 (2H, m), 2.47 (3H, s), 2.06 (3H, s), 1.49-1.26 (8H, m), 1.24 (6H, d), 0.89 (3H, t).
Figure JPOXMLDOC01-appb-T000069
Invention compound 64: 1 H-NMR (CDCl 3 ) δ: 3.92 (3H, s), 2.54-2.45 (8H, m), 2.07 (3H, s), 1.50-1.40 (2H, m), 1.39-1.28 (4H, m), 0.90 (3H, t).
Invention compound 65: 1 H-NMR (CDCl 3 ) δ: 4.42 (2H, s), 3.92 (3H, s), 3.31 (3H, s), 2.57 (3H, s), 2.50 (3H, s), 2.10 (3H, s).
The present compound 66: 1 H-NMR (CDCl 3 ) δ: 4.47 (2H, s), 3.92 (3H, s), 3.33-3.23 (1H, m), 2.49 (3H, s), 2.58 (3H, s) ), 2.10 (3H, s), 1.96-1.86 (2H, m), 1.78-1.69 (2H, m), 1.58-1.48 (1H, m), 1.36-1.14 (5H, m).
The present compound 67: 1 H-NMR (CDCl 3 ) δ: 3.93 (3H, s), 2.77-2.71 (8H, m), 2.09 (3H, s), 1.67-1.67 (2H, m), 1.42-1.31 (4H, m), 0.90 (3H, t).
Invention compound 115: 1 H-NMR (CDCl 3 ) δ: 3.92 (3H, s), 3.20 (1H, m), 2.47 (3H, s), 2.39 (2H, d), 2.06 (3H, s), 1.76-1.56 (5H, m), 1.48-1.33 (1H, m), 1.23 (6H, d), 1.21-1.08 (3H, m), 1.07-0.93 (2H, m).
Invention compound 116: 1 H-NMR (CDCl 3 ) δ: 3.92 (3H, s), 3.18 (1H, m), 2.52-2.47 (2H, m), 2.47 (3H, s), 2.06 (3H, s) ), 1.49-1.26 (8H, m), 1.24 (6H, d), 0.89 (3H, t).
製造例１１
　クロロ炭酸メチルの代わりにクロロ炭酸アリルを用い、製造例９に記載の方法に準じて下式に示される本発明化合物６８を得た。
Figure JPOXMLDOC01-appb-C000070
 　本発明化合物６８：1H-NMR (CDCl3) δ: 6.06-5.94 (1H, m), 5.48-5.41 (1H, m), 5.38-5.33 (1H, m), 4.78-4.73 (2H, m), 2.47 (6H, s), 2.10 (6H, s). Production Example 11
The compound of the present invention 68 represented by the following formula was obtained according to the method described in Production Example 9 using allyl chlorocarbonate instead of methyl chlorocarbonate.
Figure JPOXMLDOC01-appb-C000070
 Invention compound 68: 1 H-NMR (CDCl 3 ) δ: 6.06-5.94 (1 H, m), 5. 48-5. 41 (1 H, m), 5. 38-5. 33 (1 H, m), 4. 78-4. 73 (2 H, m) , 2.47 (6H, s), 2.10 (6H, s).
参考製造例２６
　４－ヒドロキシ－２，５，６－トリメチルニコチン酸エチル３１．４ｇ、炭酸カリウム３１．１ｇ、ベンジルブロミド２６．７ｍＬ及びアセトニトリル３００ｍＬの混合物を還流下４時間撹拌した。得られた混合物に水を加え、ＭＴＢＥで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体３５を３５．３ｇ得た。
Figure JPOXMLDOC01-appb-C000071
 　中間体３５：1H-NMR (CDCl3) δ: 7.45-7.29 (5H, m), 4.95 (2H, s), 4.34 (2H, q), 2.50 (3h, s), 2.49 (3H, s), 2.16 (3H, s), 1.31 (3H, t). Reference Production Example 26
A mixture of 31.4 g of ethyl 4-hydroxy-2,5,6-trimethylnicotinate, 31.1 g of potassium carbonate, 26.7 mL of benzyl bromide and 300 mL of acetonitrile was stirred under reflux for 4 hours. To the resulting mixture was added water and extracted with MTBE. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 35.3 g of Intermediate 35 represented by the following formula.
Figure JPOXMLDOC01-appb-C000071
 Intermediate 35: 1 H-NMR (CDCl 3 ) δ: 7.45-7.29 (5H, m), 4.95 (2H, s), 4.34 (2H, q), 2.50 (3h, s), 2.49 (3H, s) , 2.16 (3H, s), 1.31 (3H, t).
参考製造例２７
　４－ヒドロキシ－２，５，６－トリメチルニコチン酸エチルの代わりに２－イソプロピル－４－ヒドロキシ－５，６－ジメチルニコチン酸メチルを用い、参考製造例２６に記載の方法に準じて、下式に示される中間体５３を得た。
Figure JPOXMLDOC01-appb-C000072
 　中間体５３：1H-NMR (CDCl3) δ: 7.43-7.31 (5H, m), 4.91 (2H, s), 3.83 (3H, s), 2.96 (1H, m), 2.50 (3H, s), 2.18 (3H, s), 1.27 (6H, d). Reference Production Example 27
Using methyl 2-isopropyl-4-hydroxy-5,6-dimethylnicotinate in place of ethyl 4-hydroxy-2,5,6-trimethylnicotinate and according to the method described in Reference Production Example 26, the following formula The intermediate 53 shown in was obtained.
Figure JPOXMLDOC01-appb-C000072
 Intermediate 53: 1 H-NMR (CDCl 3 ) δ: 7.43-7.31 (5H, m), 4.91 (2H, s), 3.83 (3H, s), 2.96 (1H, m), 2.50 (3H, s) , 2.18 (3H, s), 1.27 (6H, d).
参考製造例２８
　水素化アルミニウムリチウム８．９５ｇ及びＴＨＦ２００ｍＬの混合物に、氷冷下で３５．３ｇの中間体３５及びＴＨＦ１００ｍＬの混合物を３０分間かけて加え、室温で１時間撹拌した。得られた混合物に氷冷下で水９．０ｍＬ、１５％水酸化ナトリウム水溶液９．０ｍＬ及び水２６．９ｍＬを順次加え、室温で２時間撹拌した。得られた混合物をセライト（登録商標）でろ過し、ろ液を減圧下で乾燥した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体３６を３０．３ｇ得た。
Figure JPOXMLDOC01-appb-C000073
 　中間体３６：1H-NMR (CDCl3) δ: 7.47-7.35 (5H, m), 4.92 (2H, s), 4.65 (2H, s), 2.56 (3H, s), 2.48 (3H, s), 2.22 (3H, s). Reference Production Example 28
To a mixture of lithium aluminum hydride 8.95 g and THF 200 mL was added a mixture of 35.3 g of Intermediate 35 and THF 100 mL over 30 minutes under ice-cooling, and stirred at room temperature for 1 hour. To the resulting mixture were sequentially added 9.0 mL of water, 9.0 mL of a 15% aqueous sodium hydroxide solution and 26.9 mL of water under ice-cooling, and the mixture was stirred at room temperature for 2 hours. The resulting mixture was filtered through Celite®, and the filtrate was dried under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 30.3 g of Intermediate 36 represented by the following formula.
Figure JPOXMLDOC01-appb-C000073
 Intermediate 36: 1 H-NMR (CDCl 3 ) δ: 7.47-7.35 (5H, m), 4.92 (2H, s), 4.65 (2H, s), 2.56 (3H, s), 2.48 (3H, s) , 2.22 (3H, s).
参考製造例２９
　参考製造例２８に記載の方法に準じて製造した化合物及びその物性値を以下に示す。
Figure JPOXMLDOC01-appb-C000074
 　中間体５４：1H-NMR (CDCl3) δ: 7.48-7.33 (5H, m), 4.91 (2H, s), 4.68 (2H, d), 3.33 (1H, m), 2.50 (3H, s), 2.22 (3H, s), 1.60 (1H, t), 1.27 (6H, d). Reference Production Example 29
The compounds produced according to the method described in Reference Production Example 28 and the physical properties thereof are shown below.
Figure JPOXMLDOC01-appb-C000074
 Intermediate 54: 1 H-NMR (CDCl 3 ) δ: 7.48-7.33 (5H, m), 4.91 (2H, s), 4.68 (2H, d), 3.33 (1H, m), 2.50 (3H, s) , 2.22 (3H, s), 1.60 (1 H, t), 1.27 (6 H, d).
製造例１２
　３０．３ｇの中間体３６及びクロロホルム３００ｍＬの混合物に、氷冷下で塩化チオニル１２．８ｍＬを加え、室温で１時間撹拌した。得られた混合物に、飽和炭酸水素ナトリウム水溶液を加え、クロロホルムで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下で濃縮し、下式に示される本発明化合物６９を３２．５ｇ得た。
Figure JPOXMLDOC01-appb-C000075
 　本発明化合物６９：1H-NMR (CDCl3) δ: 7.53-7.36 (5H, m), 4.97 (2H, s), 4.68 (2H, s), 2.60 (3H, s), 2.49 (3H, s), 2.21 (3H, s). Production Example 12
To a mixture of 30.3 g of Intermediate 36 and 300 mL of chloroform was added 12.8 mL of thionyl chloride under ice-cooling and stirred at room temperature for 1 hour. To the resulting mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with chloroform. The obtained organic layer was dried over magnesium sulfate and concentrated under reduced pressure to obtain 32.5 g of the present compound 69 represented by the following formula.
Figure JPOXMLDOC01-appb-C000075
 The present compound 69: 1 H-NMR (CDCl 3 ) δ: 7.53-7.36 (5H, m), 4.97 (2H, s), 4.68 (2H, s), 2.60 (3H, s), 2.49 (3H, s) ), 2.21 (3H, s).
製造例１３
　３．４９ｇの中間体５４及びクロロホルム６１ｍＬの混合物に、氷冷下で四臭化炭素８．０９ｇ及びトリフェニルホスフィン６．４０ｇを加え、室温で３０分間撹拌した。得られた混合物を減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝８０：２０）に付し、下式に示される本発明化合物１２９を３．３０ｇ得た。
Figure JPOXMLDOC01-appb-C000076
 　本発明化合物１２９：1H-NMR (CDCl3) δ: 7.54-7.51 (2H, m), 7.46-7.37 (3H, m), 5.00 (2H, s), 4.63 (2H, s), 3.33 (1H, m), 2.49 (3H, s), 2.21 (3H, s), 1.30 (6H, d). Production Example 13
To a mixture of 3.49 g of Intermediate 54 and 61 mL of chloroform was added 8.09 g of carbon tetrabromide and 6.40 g of triphenylphosphine under ice-cooling, and the mixture was stirred at room temperature for 30 minutes. The resulting mixture was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (hexane: ethyl acetate = 80: 20) to obtain 3.30 g of the present compound 129 represented by the following formula.
Figure JPOXMLDOC01-appb-C000076
 Invention compound 129: 1 H-NMR (CDCl 3 ) δ: 7.54-7.51 (2H, m), 7.46-7.37 (3H, m), 5.00 (2H, s), 4.63 (2H, s), 3.33 (1H , m), 2.49 (3H, s), 2.21 (3H, s), 1.30 (6H, d).
参考製造例３０
　４．８６ｇの本発明化合物１２９、ジメトキシエタン５０ｍＬ及び水１０ｍＬの混合物に、１，４－ジオキサスピロ［４，５］デカ－７－エン－８－ボロン酸ピナコールエステル５．０４ｇ、炭酸カリウム２．９０ｇ及びテトラキストリフェニルホスフィンパラジウム（０）０．４０ｇを加え、１００℃で５時間撹拌した。得られた混合物に水を加え、酢酸エチルで抽出した。得られた有機層を硫酸ナトリウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体５５を５．３５ｇ得た。
Figure JPOXMLDOC01-appb-C000077
 　中間体５５：1H-NMR (CDCl3) δ: 7.46-7.32 (5H, m), 5.00 (1H, m), 4.75 (2H, s), 3.95 (4H, s), 3.31 (2H, s), 3.10 (1H, m), 2.48 (3H, s), 2.24-2.16 (4H, m), 2.19 (3H, s), 1.78-1.70 (2H, m), 1.20 (6H, dd). Reference Production Example 30
In a mixture of 4.86 g of the compound of the present invention 129, 50 mL of dimethoxyethane and 10 mL of water, 5.04 g of 1,4-dioxaspiro [4,5] deca-7-en-8-boronic acid pinacol ester, 2.90 g of potassium carbonate And 0.40 g of tetrakistriphenylphosphine palladium (0) were added and stirred at 100 ° C. for 5 hours. To the resulting mixture was added water and extracted with ethyl acetate. The resulting organic layer was dried over sodium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 5.35 g of Intermediate 55 represented by the following formula.
Figure JPOXMLDOC01-appb-C000077
 Intermediate 55: 1 H-NMR (CDCl 3 ) δ: 7.46-7.32 (5H, m), 5.00 (1H, m), 4.75 (2H, s), 3.95 (4H, s), 3.31 (2H, s) , 3.10 (1H, m), 2.48 (3H, s), 2.24-2.16 (4H, m), 2.19 (3H, s), 1.78-1.70 (2H, m), 1.20 (6H, dd).
製造例１４
　５．３５ｇの中間体５５及びＴＨＦ３３ｍＬの混合物に、１０％塩酸１１ｍＬを加え、５０℃で２時間撹拌した。得られた混合物に、飽和炭酸水素ナトリウム水溶液を加え、酢酸エチルで抽出した。得られた有機層を硫酸ナトリウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝８０：２０）に付し、下式に示される本発明化合物１３０を３．１１ｇ得た。
Figure JPOXMLDOC01-appb-C000078
 　本発明化合物１３０：1H-NMR (CDCl3) δ: 7.41-7.34 (5H, m), 5.08 (1H, m), 4.78 (2H, s), 3.36 (2H, m), 3.04 (1H, m), 2.77 (2H, m), 2.49 (3H, s), 2.46-2.37 (4H, m), 2.21 (3H, s), 1.21 (6H, d). Production Example 14
To a mixture of 5.35 g of Intermediate 55 and 33 mL of THF, 11 mL of 10% hydrochloric acid was added and stirred at 50 ° C. for 2 hours. To the resulting mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with ethyl acetate. The resulting organic layer was dried over sodium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (hexane: ethyl acetate = 80: 20) to obtain 3.11 g of the present compound 130 represented by the following formula.
Figure JPOXMLDOC01-appb-C000078
 Invention compound 130: 1 H-NMR (CDCl 3 ) δ: 7.41-7.34 (5 H, m), 5.08 (1 H, m), 4. 78 (2 H, s), 3. 36 (2 H, m), 3.04 (1 H, m) ), 2.77 (2H, m), 2.49 (3H, s), 2.46-2.37 (4H, m), 2.21 (3H, s), 1.21 (6H, d).
製造例１５
　４－（アリルオキシ）－３－（クロロメチル）－２，５，６－トリメチルピリジンの代わりに本発明化合物６９を用い、参考製造例６に記載の方法に準じて、下式に示される本発明化合物７０を２５．０ｇ得た。
Figure JPOXMLDOC01-appb-C000079
 　本発明化合物７０：1H-NMR (CDCl3) δ: 7.49-7.34 (5H, m), 4.78 (2H, s), 2.45 (6H, s), 2.17 (6H, s). Production Example 15
The compound of the present invention represented by the following formula according to the method described in Reference Production Example 6 using Compound 69 of the present invention instead of 4- (allyloxy) -3- (chloromethyl) -2,5,6-trimethylpyridine 25.0 g of compound 70 was obtained.
Figure JPOXMLDOC01-appb-C000079
 Invention compound 70: 1 H-NMR (CDCl 3 ) δ: 7.49-7.34 (5H, m), 4.78 (2H, s), 2.45 (6H, s), 2.17 (6H, s).
製造例１６
　０．２３ｇの本発明化合物３４及びクロロホルム１０ｍＬの混合物に、氷冷下で７０％ｍＣＰＢＡ（３０％水含有）０．３５ｇを加え、１．５時間撹拌した。得られた混合物に飽和炭酸水素ナトリウム水溶液及び飽和チオ硫酸ナトリウム水溶液を順次加え、クロロホルムで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（クロロホルム：メタノール＝９５：５）に付し、下式に示される本発明化合物７１を０．２０ｇ得た。
Figure JPOXMLDOC01-appb-C000080
 　本発明化合物７１：1H-NMR (CDCl3) δ: 2.53 (6H, s), 2.38 (3H, s), 2.11 (6H, s). Production Example 16
Under ice-cooling, 0.35 g of 70% mCPBA (containing 30% water) was added to a mixture of 0.23 g of the compound of the present invention 34 and 10 mL of chloroform, and the mixture was stirred for 1.5 hours. Saturated aqueous sodium hydrogen carbonate solution and saturated aqueous sodium thiosulfate solution were sequentially added to the obtained mixture, and the mixture was extracted with chloroform. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (chloroform: methanol = 95: 5) to obtain 0.20 g of the present compound 71 represented by the following formula.
Figure JPOXMLDOC01-appb-C000080
 The present compound 71: 1 H-NMR (CDCl 3 ) δ: 2.53 (6H, s), 2.38 (3H, s), 2.11 (6H, s).
製造例１７
　製造例１６に記載の方法に準じて製造した化合物及びその物性値を以下に示す。
式（Ａ－５）
Figure JPOXMLDOC01-appb-C000081
 で示される化合物において、Ｒ3、ＲA及びＲBが［表８］に記載のいずれかの組み合わせである化合物。 Production Example 17
The compounds produced according to the method described in Production Example 16 and the physical properties thereof are shown below.
Formula (A-5)
Figure JPOXMLDOC01-appb-C000081
 In the compounds shown by these, compounds in which R 3 , R A and R B are any combination of those described in [Table 8].
Figure JPOXMLDOC01-appb-T000082
　本発明化合物７２：1H-NMR (CDCl3) δ: 3.95 (3H, s), 2.53 (6H, s), 2.17 (6H, s).
　本発明化合物７３：1H-NMR (CDCl3) δ: 7.44-7.35 (5H, m), 4.78 (2H, s), 2.53 (6H, s), 2.21 (6H, s).
　本発明化合物１１８：1H-NMR (CDCl3) δ: 3.94 (3H, s), 3.49-3.20 (1H, m), 2.55-2.49 (2H, m), 2.48 (3H, s), 2.06 (3H, s), 1.49-1.26 (8H, m), 1.24 (6H, d), 0.90 (3H, t).
　本発明化合物１１９：1H-NMR (CDCl3) δ: 3.46-3.20 (1H, m), 2.66-2.51 (2H, m), 2.16 (3H, s), 1.94 (3H, s), 1.48-1.19 (8H, m), 1.38 (6H, d), 0.88 (3H, t).
Figure JPOXMLDOC01-appb-T000082
The present compound 72: 1 H-NMR (CDCl 3 ) δ: 3.95 (3H, s), 2.53 (6H, s), 2.17 (6H, s).
Invention compound 73: 1 H-NMR (CDCl 3 ) δ: 7.44-7.35 (5H, m), 4.78 (2H, s), 2.53 (6H, s), 2.21 (6H, s).
Invention compound 118: 1 H-NMR (CDCl 3 ) δ: 3.94 (3H, s), 3.49-3.20 (1H, m), 2.55-2.49 (2H, m), 2.48 (3H, s), 2.06 (3H) , s), 1.49-1.26 (8H, m), 1.24 (6H, d), 0.90 (3H, t).
Invention compound 119: 1 H-NMR (CDCl 3 ) δ: 3.46-3.20 (1H, m), 2.66-2.51 (2H, m), 2.16 (3H, s), 1.94 (3H, s), 1.48-1.19 (8H, m), 1.38 (6H, d), 0.88 (3H, t).
参考製造例３１
　１６．１ｇの本発明化合物７３及びクロロホルム５０ｍＬの混合物に、氷冷下でトリフルオロ酢酸無水物３４．６ｍＬを加え、室温で３０分間撹拌した。得られた混合物を減圧下で濃縮した。得られた残渣にメタノール５０ｍＬを加えて溶解し、炭酸カリウム１７．３ｇを加えた。得られた混合物を室温で１０分間撹拌し、減圧下で濃縮した。得られた残渣に水を加え、酢酸エチルで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体３７を１６．１ｇ得た。
Figure JPOXMLDOC01-appb-C000083
 　中間体３７：1H-NMR (CDCl3) δ: 7.46-7.35 (5H, m), 5.05 (1H, s), 4.81 (2H, s), 4.59 (2H, s), 2.49 (3H, s), 2.20 (3H, s), 2.06 (3H, s). Reference Production Example 31
To a mixture of 16.1 g of the compound of the present invention 73 and 50 mL of chloroform was added 34.6 mL of trifluoroacetic anhydride under ice-cooling, and the mixture was stirred at room temperature for 30 minutes. The resulting mixture was concentrated under reduced pressure. To the obtained residue was added 50 mL of methanol for dissolution, and 17.3 g of potassium carbonate was added. The resulting mixture was stirred at room temperature for 10 minutes and concentrated under reduced pressure. Water was added to the obtained residue, and extracted with ethyl acetate. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 16.1 g of Intermediate 37 represented by the following formula.
Figure JPOXMLDOC01-appb-C000083
 Intermediate 37: 1 H-NMR (CDCl 3 ) δ: 7.46-7.35 (5H, m), 5.05 (1H, s), 4.81 (2H, s), 4.59 (2H, s), 2.49 (3H, s) , 2.20 (3H, s), 2.06 (3H, s).
参考製造例３２
　１６．１ｇの中間体３７及びクロロホルム２００ｍＬの混合物に、酸化マンガン（ＩＶ）５４．４ｇを加え、還流下２時間撹拌した。得られた混合物をセライト（登録商標）でろ過し、ろ液を減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体３８を１０．８ｇ得た。
Figure JPOXMLDOC01-appb-C000084
 　中間体３８：1H-NMR (CDCl3) δ: 10.13 (1H, s), 7.47-7.35 (5H, m), 4.82 (2H, s), 2.57 (3H, s), 2.55 (3H, s), 2.26 (3H, s). Reference Production Example 32
54.4 g of manganese (IV) oxide was added to a mixture of 16.1 g of Intermediate 37 and 200 mL of chloroform, and the mixture was stirred under reflux for 2 hours. The resulting mixture was filtered through Celite®, and the filtrate was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 10.8 g of Intermediate 38 represented by the following formula.
Figure JPOXMLDOC01-appb-C000084
 Intermediate 38: 1 H-NMR (CDCl 3 ) δ: 10.13 (1H, s), 7.47-7.35 (5H, m), 4.82 (2H, s), 2.57 (3H, s), 2.55 (3H, s) , 2.26 (3H, s).
製造例１８
　０．５１ｇの中間体３８及びメタノール１０ｍＬの混合物に、トリエチルアミン０．３１ｍＬ及びＯ－エチルヒドロキシルアミン塩酸塩０．２２ｇを加え、室温で２０分間撹拌した。得られた混合物に水を加え、酢酸エチルで抽出した。得られた有機層を飽和炭酸水素ナトリウム水溶液で洗浄し、硫酸ナトリウムで乾燥し、減圧下で濃縮し、下式に示される本発明化合物１４８を０．６３ｇ得た。
Figure JPOXMLDOC01-appb-C000085
 　本発明化合物１４８：1H-NMR (CDCl3) δ: 8.34 (1H, s), 7.46-7.35 (5H, m), 4.80 (2H, s), 4.32 (1H, d), 4.28 (1H, d), 2.50 (3H, s), 2.38 (3H, s), 2.20 (3H, s), 1.34 (3H, t). Production Example 18
0.31 mL of triethylamine and 0.22 g of O-ethylhydroxylamine hydrochloride were added to a mixture of 0.51 g of Intermediate 38 and 10 mL of methanol, and stirred at room temperature for 20 minutes. To the resulting mixture was added water and extracted with ethyl acetate. The obtained organic layer was washed with saturated aqueous sodium hydrogen carbonate solution, dried over sodium sulfate and concentrated under reduced pressure to obtain 0.63 g of the present compound 148 represented by the following formula.
Figure JPOXMLDOC01-appb-C000085
 Invention compound 148: 1 H-NMR (CDCl 3 ) δ: 8.34 (1 H, s), 7.46-7.35 (5 H, m), 4. 80 (2 H, s), 4.32 (1 H, d), 4. 28 (1 H, d ), 2.50 (3H, s), 2.38 (3H, s), 2.20 (3H, s), 1.34 (3H, t).
参考製造例３３
　１０．０ｇの中間体３１及びアセトニトリル５０ｍＬの混合物に、炭酸カリウム５．５３ｇ及びベンジルブロミド４．７５ｍＬを加え、還流下８時間撹拌した。得られた混合物に水を加え、クロロホルムで抽出した。得られた有機層を、硫酸マグネシウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体３９を１１．０ｇ得た。
Figure JPOXMLDOC01-appb-C000086
 　中間体３９：1H-NMR (CDCl3) δ: 7.69-7.66 (2H, m), 7.47-7.37 (3H, m), 5.04 (2H, s), 2.76 (6H, s). Reference Production Example 33
5.53 g of potassium carbonate and 4.75 mL of benzyl bromide were added to a mixture of 10.0 g of Intermediate 31 and 50 mL of acetonitrile, and the mixture was stirred under reflux for 8 hours. To the resulting mixture was added water, and extracted with chloroform. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 11.0 g of Intermediate 39 represented by the following formula.
Figure JPOXMLDOC01-appb-C000086
 Intermediate 39: 1 H-NMR (CDCl 3 ) δ: 7.69-7.66 (2H, m), 7.47-7.37 (3H, m), 5.04 (2H, s), 2.76 (6H, s).
参考製造例３４
　２．３４ｇの中間体３９及びＴＨＦ３０ｍＬの混合物に、－２０℃でイソプロピルマグネシウムブロミド・リチウムクロリド錯体（１Ｍ　ＴＨＦ溶液）３．８７ｍＬを加え、１０分間撹拌した。得られた混合物にヨウ化メチル０．６３ｍＬを加え、室温で１時間撹拌した。得られた混合物に飽和炭酸水素ナトリウム水溶液を加え、ＭＴＢＥで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される中間体４０を１．４６ｇ得た。
Figure JPOXMLDOC01-appb-C000087
 　中間体４０：1H-NMR (CDCl3) δ: 7.59-7.53 (2H, m), 7.46-7.34 (3H, m), 4.89 (2H, s), 2.74 (3H, s), 2.46 (3H, s), 2.23 (3H, s). Reference Production Example 34
To a mixture of 2.34 g of Intermediate 39 and 30 mL of THF, 3.87 mL of isopropylmagnesium bromide lithium chloride complex (1 M THF solution) was added at -20.degree. C. and stirred for 10 minutes. To the resulting mixture was added 0.63 mL of methyl iodide, and the mixture was stirred at room temperature for 1 hour. To the resulting mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with MTBE. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 1.46 g of an intermediate 40 represented by the following formula.
Figure JPOXMLDOC01-appb-C000087
 Intermediate 40: 1 H-NMR (CDCl 3 ) δ: 7.59-7.53 (2H, m), 7.46-7.34 (3H, m), 4.89 (2H, s), 2.74 (3H, s), 2.46 (3H, s) s), 2.23 (3H, s).
製造例１９
　０．８６ｇの中間体４０、ＤＭＦ１０ｍＬ及び水２ｍＬの混合物に、窒素雰囲気下で１－シクロヘキセニルボロン酸０．６１ｇ、炭酸カリウム１．０１ｇ及びテトラキス（トリフェニルホスフィン）パラジウム（０）０．２８ｇを順次加え、９０℃で１時間撹拌した。得られた混合物に水を加え、ＭＴＢＥで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝８０：２０）に付し、下式に示される本発明化合物７４を０．６８ｇ得た。
Figure JPOXMLDOC01-appb-C000088
 　本発明化合物７４：1H-NMR (CDCl3) δ: 7.49-7.30 (5H, m), 5.64 (1H, m), 4.83 (2H, s), 2.47 (3H, s), 2.42 (3H, s), 2.36-2.92 (7H, m), 1.78-1.55 (4H, m). Production Example 19
Under a nitrogen atmosphere, 0.61 g of 1-cyclohexenylboronic acid, 1.01 g of potassium carbonate and 0.28 g of tetrakis (triphenylphosphine) palladium (0) in a mixture of 0.86 g of Intermediate 40, 10 mL of DMF and 2 mL of water The solution was sequentially added and stirred at 90 ° C. for 1 hour. To the resulting mixture was added water and extracted with MTBE. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (hexane: ethyl acetate = 80: 20) to obtain 0.68 g of the present compound 74 represented by the following formula.
Figure JPOXMLDOC01-appb-C000088
 The present compound 74: 1 H-NMR (CDCl 3 ) δ: 7.49-7.30 (5H, m), 5.64 (1H, m), 4.83 (2H, s), 2.47 (3H, s), 2.42 (3H, s) ), 2.36-2.92 (7H, m), 1.78-1.55 (4H, m).
製造例２０
　製造例１９に記載の方法に準じて製造した化合物及びその物性値を以下に示す。
Figure JPOXMLDOC01-appb-C000089
 　本発明化合物７５：1H-NMR (CDCl3) δ: 7.42-7.30 (5H, m), 5.70 (1H, m), 4.78 (2H, s), 2.63-2.56 (2H, m), 2.55-2.48 (2H, m), 2.46 (3H, s), 2.42 (3H, s), 2.15 (3H, s), 2.04-1.94 (2H, m). Production Example 20
The compounds produced according to the method described in Production Example 19 and the physical properties thereof are shown below.
Figure JPOXMLDOC01-appb-C000089
 The present compound 75: 1 H-NMR (CDCl 3 ) δ: 7.42-7.30 (5H, m), 5.70 (1H, m), 4.78 (2H, s), 2.63-2.56 (2H, m), 2.55-2.48 (2H, m), 2.46 (3H, s), 2.42 (3H, s), 2.15 (3H, s), 2.04-1.94 (2H, m).
製造例２１
　０．６６ｇの中間体４０及びＤＭＦ１０ｍＬの混合物に、（フルオロスルホニル）ジフルオロ酢酸メチル０．９０ｇ及びヨウ化銅（Ｉ）０．５３ｇを順次加え、１００℃で５時間撹拌した。得られた混合物に水を加え、ＭＴＢＥで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーに付し、下式に示される本発明化合物７６を０．４５ｇ得た。
Figure JPOXMLDOC01-appb-C000090
 　本発明化合物７６：1H-NMR (CDCl3) δ: 7.52-7.32 (5H, m), 4.86 (2H, s), 2.66 (3H, m), 2.51 (3H, s), 2.20 (3H, s). Production Example 21
To a mixture of 0.66 g of Intermediate 40 and 10 mL of DMF was sequentially added 0.90 g of methyl (fluorosulfonyl) difluoroacetate and 0.53 g of copper (I) iodide, and the mixture was stirred at 100 ° C. for 5 hours. To the resulting mixture was added water and extracted with MTBE. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 0.45 g of the present compound 76 represented by the following formula.
Figure JPOXMLDOC01-appb-C000090
 The present compound 76: 1 H-NMR (CDCl 3 ) δ: 7.52-7.32 (5H, m), 4.86 (2H, s), 2.66 (3H, m), 2.51 (3H, s), 2.20 (3H, s) ).
製造例２２
　参考製造例２５に記載の方法に準じて、本発明化合物１４９を得た。
Figure JPOXMLDOC01-appb-C000091
 　本発明化合物１４９：1H-NMR (CDCl3) δ: 7.47-7.43 (2H, m), 7.40-7.32 (3H, m), 5.20 (2H, s), 2.66 (1H, m), 2.60 (3H, s), 2.44 (3H, s), 2.06 (3H, s), 1.61-1.48 (2H, m), 1.25 (3H, d), 1.04 (3H, t). Production Example 22
The present compound 149 was obtained according to the method described in Reference Production Example 25.
Figure JPOXMLDOC01-appb-C000091
 Invention compound 149: 1 H-NMR (CDCl 3 ) δ: 7.47-7.43 (2H, m), 7.40-7.32 (3H, m), 5.20 (2H, s), 2.66 (1H, m), 2.60 (3H , s), 2.44 (3H, s), 2.06 (3H, s), 1.61-1.48 (2H, m), 1.25 (3H, d), 1.04 (3H, t).
製造例２３
　テトラデシルトリフェニルホスホニウムブロミド２．１６ｇ及びＴＨＦ１０ｍＬの混合物に、窒素雰囲気下室温でカリウムｔ－ブトキシド０．４５ｇを加え、１０分間撹拌した。得られた混合物に０．３４ｇの中間体３８を加え、室温で３０分間撹拌した。得られた混合物に水を加え、ヘキサンで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９０：１０）に付し、下式に示される本発明化合物７７（Ｅ：Ｚ＝１：４）を０．５７ｇ得た。
Figure JPOXMLDOC01-appb-C000092
 　本発明化合物７７：1H-NMR (CDCl3) δ: 7.50-7.27 (5H, m), 6.44 (1H, d), 5.85 (1H, dd), 4.80 (2H, s), 2.47 (3H, s), 2.36-2.24 (2H, m), 2.19 (3H, s), 2.16 (3H, s), 1.54-1.12 (22H, m), 0.88 (3H, t). Production Example 23
To a mixture of 2.16 g of tetradecyltriphenylphosphonium bromide and 10 mL of THF was added 0.45 g of potassium t-butoxide at room temperature under a nitrogen atmosphere, and stirred for 10 minutes. To the resulting mixture was added 0.34 g of Intermediate 38 and stirred at room temperature for 30 minutes. To the resulting mixture was added water and extracted with hexane. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (hexane: ethyl acetate = 90: 10) to obtain 0.57 g of the present compound 77 (E: Z = 1: 4) represented by the following formula.
Figure JPOXMLDOC01-appb-C000092
 Invention compound 77: 1 H-NMR (CDCl 3 ) δ: 7.50 to 7.27 (5H, m), 6.44 (1H, d), 5.85 (1H, dd), 4.80 (2H, s), 2.47 (3H, s) ), 2.36-2.24 (2H, m), 2.19 (3H, s), 2.16 (3H, s), 1.54-1.12 (22H, m), 0.88 (3H, t).
製造例２４
　製造例２３に記載の方法に準じて製造した化合物及びその物性値を以下に示す。
式（Ａ－６）
Figure JPOXMLDOC01-appb-C000093
 で示される化合物において、Ｒ1xが［表９］に記載の化合物。 Production Example 24
The compounds produced according to the method described in Production Example 23 and the physical properties thereof are shown below.
Formula (A-6)
Figure JPOXMLDOC01-appb-C000093
 In the compounds represented by the above, compounds in which R 1x is described in [Table 9].
Figure JPOXMLDOC01-appb-T000094
　本発明化合物７８：1H-NMR (CDCl3) δ: 7.50-7.28 (5H, m), 6.44 (1H, d), 5.88 (1H, dd), 4.79 (2H, s), 2.46 (3H, s), 2.25-2.36 (2H, m), 2.19 (3H, s), 2.15 (3H, s), 1.50-1.14 (12H, m), 0.87 (3H, t).
　本発明化合物７９：1H-NMR (CDCl3) δ: 7.49-7.31 (5H, m), 6.45 (1H, d), 5.85 (1H, td), 4.80 (2H, s), 2.48 (3H, s), 2.34-2.25 (2H, m), 2.20 (3H, s), 2.16 (3H, s), 1.59-1.38 (2H, m), 0.89 (3H, t).
　本発明化合物８０：1H-NMR (CDCl3) δ: 7.48-7.30 (5H, m), 6.46 (1H, d), 5.85-5.76 (1H, m), 4.81 (2H, s), 2.50 (3H, s), 2.22 (3H, s), 2.17 (3H, s), 1.52 (3H, d).
Figure JPOXMLDOC01-appb-T000094
Invention compound 78: 1 H-NMR (CDCl 3 ) δ: 7.50 to 7.28 (5H, m), 6.44 (1H, d), 5.88 (1H, dd), 4.79 (2H, s), 2.46 (3H, s) ), 2.25-2.36 (2H, m), 2.19 (3H, s), 2.15 (3H, s), 1.50-1. 14 (12H, m), 0.87 (3H, t).
Invention compound 79: 1 H-NMR (CDCl 3 ) δ: 7.49-7.31 (5H, m), 6.45 (1H, d), 5.85 (1H, td), 4.80 (2H, s), 2.48 (3H, s) ), 2.34-2.25 (2H, m), 2.20 (3H, s), 2.16 (3H, s), 1.59-1.38 (2H, m), 0.89 (3H, t).
The present compound 80: 1 H-NMR (CDCl 3 ) δ: 7.48-7.30 (5H, m), 6.46 (1H, d), 5.85-5. 76 (1H, m), 4.81 (2H, s), 2.50 (3H , s), 2.22 (3H, s), 2.17 (3H, s), 1.52 (3H, d).
製造例２５
　製造例７に記載の方法に準じて製造した化合物及びその物性値を以下に示す。
式（Ａ－７）
Figure JPOXMLDOC01-appb-C000095
 で示される化合物において、ＲA及びＲBが［表１０］に記載のいずれかの組み合わせである化合物。 Production Example 25
The compounds produced according to the method described in Production Example 7 and the physical properties thereof are shown below.
Formula (A-7)
Figure JPOXMLDOC01-appb-C000095
 In the compound shown by these, compounds in which R A and R B are any combination of those described in [Table 10].
Figure JPOXMLDOC01-appb-T000096
　本発明化合物８１：1H-NMR (CDCl3) δ: 3.91 (1H, s), 2.98 (2H, t), 2.65 (3H, s), 2.25 (3H, s), 2.23 (3H, s), 1.71-1.60 (2H, m), 1.45-1.15 (24H, m), 0.87 (3H, t).
　本発明化合物８２：1H-NMR (CDCl3) δ: 8.59 (1H, s), 2.53 (2H, t), 2.29 (3H, s), 2.03 (3H, s), 2.02 (3H, s), 1.60-1.50 (2H, m), 1.37-1.18 (14H, m), 0.88 (3H, t).
　本発明化合物８３：1H-NMR (CDCl3) δ: 8.26 (1H, s), 2.52 (2H, t), 2.28 (3H, s), 2.03 (3H, s), 2.02 (3H, s), 1.60-1.52 (2H, m), 1.37-1.26 (4H, m), 0.89 (3H, t).
　本発明化合物８４：1H-NMR (CDCl3) δ: 2.54 (2H, t), 2.30 (3H, s), 2.06 (3H, s), 2.04 (3H, s), 1.69-1.57 (2H, m), 0.97 (3H, t).
　本発明化合物８５：1H-NMR (CDCl3) δ: 7.85 (1H, s), 2.85-2.66 (1H, m), 2.31 (3H, s), 2.23 (3H, s), 2.29-2.12 (2H, m), 1.98 (3H, s), 1.83-1.74 (2H, m), 1.72-1.65 (1H, m), 1.53-1.44 (2H, m), 1.38-1.22 (3H, m).
　本発明化合物８６：1H-NMR (CDCl3) δ: 8.58 (1H, s), 3.16-3.04 (1H, m), 2.32 (3H, s), 2.25 (3H, s), 1.99 (3H, s), 2.13-1.82 (4H, m), 1.72-1.53 (4H, m).
　本発明化合物８７：1H-NMR (DMSO-d6) δ: 2.35 (3H, q), 2.21 (3H, s), 1.81 (3H, s).
　本発明化合物１１１：1H-NMR (CDCl3) δ: 2.83 (2H, q), 2.62-2.53 (2H, m), 2.50 (3H, s), 2.11 (3H, s), 1.57-1.40 (2H, m), 1.39-1.23 (4H, m), 1.28 (3H, t), 0.85 (3H, t).
　本発明化合物１１２：1H-NMR (CDCl3) δ: 8.76 (1H, s), 2.60 (2H, q), 2.54-2.41 (2H, m), 2.28 (3H, s), 2.01 (3H, s), 1.52-1.18 (8H, m), 1.24 (3H, t), 0.86 (3H, t).
　本発明化合物１１３：1H-NMR (CDCl3) δ: 3.28 (1H, m), 2.42 (2H, d), 2.23 (3H, s), 2.01 (3H, s), 1.74-1.56 (7H, m), 1.31-0.90 (4H, m), 1.23 (6H, d).
　本発明化合物１１４：1H-NMR (CDCl3) δ: 11.21 (1H, s), 3.34 (1H, m), 2.70-2.57 (2H, m), 2.62 (3H, s), 2.16 (3H, s), 1.52-1.20 (8H, m), 1.46 (6H, d), 0.87 (3H, t).
　本発明化合物１２６：1H-NMR (CDCl3) δ: 2.49 (2H, m), 2.25 (3H, s), 2.24 (3H, s), 2.01 (3H, s), 1.63 (1H, m), 1.31 (2H, m), 0.94 (6H, d)
　本発明化合物１２７：1H-NMR (CDCl3) δ: 2.50 (1H, dd), 2.27 (1H, m), 2.26 (3H, s), 2.25 (3H, s), 2.01 (3H, s), 1.83 (1H, m), 1.44-1.26 (3H, m), 1.14 (1H, m), 0.87 (3H, t), 0.83 (3H, d).
　本発明化合物１２８：1H-NMR (CDCl3) δ: 7.72 (1H, s), 2.52-2.44 (2H, m), 2.26 (3H, s), 2.24 (3H, s), 2.01 (3H, s), 1.49-1.16 (16H, m), 0.87 (3H, t).
　本発明化合物１３１：1H-NMR (CDCl3) δ: 3.25 (1H, m), 2.55 (2H, d), 2.40-2.26 (4H, m), 2.29 (3H, s), 2.19 (1H, m), 2.07-1.99 (2H, m), 2.02 (3H, s), 1.47 (2H, m), 1.27 (6H, d).
　本発明化合物１３２：1H-NMR (CDCl3) δ: 3.31-3.22 (1H, m), 2.49 (1H, d), 2.42 (1H, d), 2.26 (3H, s), 2.01 (3H, s), 1.73-1.60 (4H, m), 1.55-1.22 (6H, m), 1.24 (1.5H, d), 1.23 (1.5H, d), 1.01 (1.5H, m), 0.94 (1.5H, d), 0.85 (1.5H, m), 0.83 (1.5H, d).
　本発明化合物１３３：1H-NMR (CDCl3) δ: 3.30 (1H, m), 2.52 (1H, d), 2.43 (1H, d), 2.29 (3H, s), 2.02 (3H, s), 1.76-1.69 (2H, m), 1.67-1.61 (2H, m), 1.61-1.54 (3H, m), 1.43-1.35 (2H, m), 1.26-1.22 (6H, m), 1.04-0.90 (2H, m), 0.87 (3H, d), 0.82 (3H, d).
　本発明化合物１３７：1H-NMR (CDCl3) δ: 2.48 (2H, m), 2.26 (3H, s), 2.24 (3H, s), 2.01 (3H, s), 1.45-0.36 (3H, m), 1.28-1.14 (2H, m), 0.94 (3H, d), 0.87 (3H, t).
　本発明化合物１４０：1H-NMR (CDCl3) δ: 8.19 (1H, s), 4.28 (1H, d), 4.25 (1H, d), 2.32 (3H, s), 2.12 (3H, s), 2.04 (3H, s), 1.34 (3H, t).
　本発明化合物１４１：1H-NMR (CDCl3) δ: 8.33 (1H, s), 4.56 (2H, q), 2.33 (3H, s), 2.14 (3H, s), 2.05 (3H, s).
　本発明化合物１４２：1H-NMR (CDCl3) δ: 8.44 (1H, s), 8.23 (1H, s), 4.43 (2H, t), 2.64-2.47 (2H, m), 2.33 (3H, s), 2.13 (3H, s), 2.04 (3H, s).
　本発明化合物１４３：1H-NMR (CDCl3) δ: 8.44 (1H, s), 8.22 (1H, s), 4.27 (2H, t), 2.32 (3H, s), 2.31-2.16 (2H, m), 2.13 (3H, s), 2.04 (3H, s), 2.04-1.96 (2H, m).
Figure JPOXMLDOC01-appb-T000096
Invention compound 81: 1 H-NMR (CDCl 3 ) δ: 3.91 (1H, s), 2.98 (2H, t), 2.65 (3H, s), 2.25 (3H, s), 2.23 (3H, s), 1.71-1.60 (2H, m), 1.45-1.15 (24H, m), 0.87 (3H, t).
Invention compound 82: 1 H-NMR (CDCl 3 ) δ: 8.59 (1 H, s), 2.53 (2 H, t), 2. 29 (3 H, s), 2.03 (3 H, s), 2.02 (3 H, s), 1.60-1.50 (2H, m), 1.37-1.18 (14H, m), 0.88 (3H, t).
The present compound 83: 1 H-NMR (CDCl 3 ) δ: 8.26 (1H, s), 2.52 (2H, t), 2.28 (3H, s), 2.03 (3H, s), 2.02 (3H, s), 1.60-1.52 (2H, m), 1.37-1.26 (4H, m), 0.89 (3H, t).
Invention compound 84: 1 H-NMR (CDCl 3 ) δ: 2.54 (2H, t), 2.30 (3H, s), 2.06 (3H, s), 2.04 (3H, s), 1.69-1.57 (2H, m) ), 0.97 (3H, t).
The compound of the present invention 85: 1 H-NMR (CDCl 3 ) δ: 7.85 (1 H, s), 2.85-2.66 (1 H, m), 2.31 (3 H, s), 2.23 (3 H, s), 2.29-2.12 (2 H) , m), 1.98 (3H, s), 1.83-1.74 (2H, m), 1.72-1. 65 (1H, m), 1.53-1.44 (2H, m), 1.38-1.22 (3H, m).
Invention compound 86: 1 H-NMR (CDCl 3 ) δ: 8.58 (1 H, s), 3.16-3.04 (1 H, m), 2. 32 ( 3 H, s), 2. 25 (3 H, s), 1.99 (3 H, s) ), 2.13-1.82 (4H, m), 1.72-1.53 (4H, m).
Invention compound 87: 1 H-NMR (DMSO-d 6 ) δ: 2.35 (3H, q), 2.21 (3H, s), 1.81 (3H, s).
Invention compound 111: 1 H-NMR (CDCl 3 ) δ: 2.83 (2H, q), 2.62-2.53 (2H, m), 2.50 (3H, s), 2.11 (3H, s), 1.57-1.40 (2H , m), 1.39-1.23 (4H, m), 1.28 (3H, t), 0.85 (3H, t).
The present compound 112: 1 H-NMR (CDCl 3 ) δ: 8.76 (1H, s), 2.60 (2H, q), 2.54-2.41 (2H, m), 2.28 (3H, s), 2.01 (3H, s) ), 1.52-1.18 (8H, m), 1.24 (3H, t), 0.86 (3H, t).
Invention compound 113: 1 H-NMR (CDCl 3 ) δ: 3.28 (1 H, m), 2.42 (2 H, d), 2.23 (3 H, s), 2.01 (3 H, s), 1. 74-1. 56 (7 H, m) ), 1.31-0.90 (4H, m), 1.23 (6H, d).
Invention compound 114: 1 H-NMR (CDCl 3 ) δ: 11.21 (1 H, s), 3.34 (1 H, m), 2.70-2.57 (2 H, m), 2.62 (3 H, s), 2.16 (3 H, s) ), 1.52-1.20 (8H, m), 1.46 (6H, d), 0.87 (3H, t).
Invention compound 126: 1 H-NMR (CDCl 3 ) δ: 2.49 (2H, m), 2.25 (3H, s), 2.24 (3H, s), 2.01 (3H, s), 1.63 (1H, m), 1.31 (2H, m), 0.94 (6H, d)
Invention compound 127: 1 H-NMR (CDCl 3 ) δ: 2.50 (1 H, dd), 2.27 (1 H, m), 2.26 (3 H, s), 2.25 (3 H, s), 2.01 (3 H, s), 1.83 (1H, m), 1.44-1.26 (3H, m), 1.14 (1H, m), 0.87 (3H, t), 0.83 (3H, d).
Invention compound 128: 1 H-NMR (CDCl 3 ) δ: 7.72 (1H, s), 2.52-2.44 (2H, m), 2.26 (3H, s), 2.24 (3H, s), 2.01 (3H, s) ), 1.49-1.16 (16H, m), 0.87 (3H, t).
Invention compound 131: 1 H-NMR (CDCl 3 ) δ: 3.25 (1H, m), 2.55 (2H, d), 2.40-2.26 (4H, m), 2.29 (3H, s), 2.19 (1H, m) ), 2.07-1.99 (2H, m), 2.02 (3H, s), 1.47 (2H, m), 1.27 (6H, d).
The present compound 132: 1 H-NMR (CDCl 3 ) δ: 3.31-3.22 (1H, m), 2.49 (1H, d), 2.42 (1H, d), 2.26 (3H, s), 2.01 (3H, s) ), 1.73-1.60 (4H, m), 1.55-1.22 (6H, m), 1.24 (1.5H, d), 1.23 (1.5H, d), 1.01 (1.5H, m), 0.94 (1.5H, d) ), 0.85 (1.5 H, m), 0.83 (1.5 H, d).
Invention compound 133: 1 H-NMR (CDCl 3 ) δ: 3.30 (1H, m), 2.52 (1H, d), 2.43 (1H, d), 2.29 (3H, s), 2.02 (3H, s), 1.76-1.69 (2H, m), 1.67-1.61 (2H, m), 1.61-1.54 (3H, m), 1.43-1.35 (2H, m), 1.26-1.22 (6H, m), 1.04-0.90 (2H , m), 0.87 (3H, d), 0.82 (3H, d).
The present compound 137: 1 H-NMR (CDCl 3 ) δ: 2.48 (2H, m), 2.26 (3H, s), 2.24 (3H, s), 2.01 (3H, s), 1.45-0.36 (3H, m) ), 1.28-1.14 (2H, m), 0.94 (3H, d), 0.87 (3H, t).
Invention compound 140: 1 H-NMR (CDCl 3 ) δ: 8.19 (1H, s), 4.28 (1H, d), 4.25 (1H, d), 2.32 (3H, s), 2.12 (3H, s), 2.04 (3H, s), 1.34 (3H, t).
Invention compound 141: 1 H-NMR (CDCl 3 ) δ: 8.33 (1H, s), 4.56 (2H, q), 2.33 (3H, s), 2.14 (3H, s), 2.05 (3H, s).
Invention compound 142: 1 H-NMR (CDCl 3 ) δ: 8.44 (1 H, s), 8.23 (1 H, s), 4.43 (2 H, t), 2.64-2.47 (2 H, m), 2.33 (3 H, s) ), 2.13 (3H, s), 2.04 (3H, s).
Invention compound 143: 1 H-NMR (CDCl 3 ) δ: 8.44 (1H, s), 8.22 (1H, s), 4.27 (2H, t), 2.32 (3H, s), 2.31-2.16 (2H, m) ), 2.13 (3H, s), 2.04 (3H, s), 2.04-1.96 (2H, m).
製造例２６
　製造例５に記載の方法に準じて製造した化合物及びその物性値を以下に示す。
式（Ａ－８）
Figure JPOXMLDOC01-appb-C000097
 で示される化合物において、ＲA及びＲBが［表１１］に記載のいずれかの組み合わせである化合物。 Production Example 26
The compounds produced according to the method described in Production Example 5 and the physical properties thereof are shown below.
Formula (A-8)
Figure JPOXMLDOC01-appb-C000097
 In the compound shown by these, compounds in which R A and R B are any combination described in [Table 11].
Figure JPOXMLDOC01-appb-T000098
　本発明化合物８８：1H-NMR (CDCl3) δ: 2.76-2.70 (2H, m), 2.47 (3H, s), 2.36 (3H, s), 2.07 (3H, s), 2.04 (3H, s), 1.66-1.56 (2H, m), 1.43-1.20 (24H, m), 0.87 (3H, t).
　本発明化合物８９：1H-NMR (CDCl3) δ: 2.76-2.70 (2H, m), 2.47 (3H, s), 2.36 (3H, s), 2.07 (3H, s), 2.04 (3H, s), 1.67-1.57 (2H, m), 1.43-1.12 (14H, m), 0.88 (3H, t).
　本発明化合物９０：1H-NMR (CDCl3) δ: 2.76-2.70 (2H, m), 2.47 (3H, s), 2.36 (3H, s), 2.07 (3H, s), 2.04 (3H, s), 1.67-1.58 (2H, m), 1.42-1.29 (4H, m), 0.89 (3H, t).
　本発明化合物９１：1H-NMR (CDCl3) δ: 2.75-2.69 (2H, m), 2.47 (3H, s), 2.36 (3H, s), 2.07 (3H, s), 2.04 (3H, s), 1.73-1.61 (2H, m), 0.99 (3H, t).
　本発明化合物９２：1H-NMR (CDCl3) δ: 2.81-2.70 (1H, m), 2.56 (3H, s), 2.45 (3H, s), 2.37 (3H, s), 1.98 (3H, s), 1.93-1.15 (10H, m).
　本発明化合物９３：1H-NMR (CDCl3) δ: 3.25-3.15 (1H, m), 2.54 (3H, s), 2.46 (3H, s), 2.35 (3H, s), 1.99 (3H, s), 1.96-1.62 (8H, m).
　本発明化合物９４：1H-NMR (CDCl3) δ: 2.66 (3H, q), 2.54 (3H, s), 2.35 (3H, s), 2.07 (3H, s).
　本発明化合物１３４：1H-NMR (CDCl3) δ: 3.18 (1H, m), 2.53-2.42 (2H, m), 2.49 (3H, s), 2.42-2.34 (2H, m), 2.35 (3H, s), 2.32-2.23 (2H, m), 2.04-2.95 (2H, m), 2.01 (3H, s), 1.89 (1H, m), 1.54-1.42 (2H, m), 1.25 (6H, d).
　本発明化合物１３５：1H-NMR (CDCl3) δ: 3.24-3.13 (1H, m), 2.47 (1.5H, s), 2.47 (1.5H, s), 2.43-2.30 (2H, m), 2.35 (1.5H, s), 2.34 (1.5H, s), 2.00 (1.5H, s), 2.00 (1.5H, s), 1.71-1.62 (3H, m), 1.58-1.19 (5H, m), 1.23 (3H, d), 1.22 (3H, d), 1.06-0.96 (1H, m), 0.95 (1.5H, d), 0.88-0.78 (1H, m), 0.85 (1.5H, d).
　本発明化合物１３６：1H-NMR (CDCl3) δ: 3.23-3.13 (1H, m), 2.50-2.43 (1H, m), 2.47 (1.5H, s), 2.47 (1.5H, s), 2.35 (1.5H, s), 2.34 (1.5H, s), 2.35-2.29 (1H, m), 2.02 (1.5H, s), 2.02 (1.5H, s), 1.69 (3H, d), 1.46-1.29 (4H, m), 1.23 (6H, d), 1.10-0.86 (4H, m), 0.89 (3H, d), 0.83 (3H, d).
　本発明化合物１３８：1H-NMR (CDCl3) δ: 2.49 (3H, s), 2.46 (3H, s), 2.48-2.33 (2H, m), 2.35 (3H, s), 2.02 (3H, s), 1.47-1.34 (3H, m), 1.30-1.16 (2H, m), 0.95 (3H, d), 0.89 (3H, t).
　本発明化合物１４４：1H-NMR (CDCl3) δ: 8.32 (1H, s), 4.29 (2H, dd), 2.52 (3H, s), 2.38 (3H, s), 2.26 (3H, s), 2.09 (3H, s), 1.32 (3H, t).
　本発明化合物１４５：1H-NMR (CDCl3) δ: 8.39 (1H, s), 4.56 (2H, q), 2.52 (3H, s), 2.39 (3H, s), 2.27 (3H, s), 2.11 (3H, s).
　本発明化合物１４６：1H-NMR (CDCl3) δ: 8.33 (1H, s), 4.43 (2H, t), 2.63-2.50 (2H, m), 2.53 (3H, s), 2.39 (3H, s), 2.26 (3H, s), 2.10 (3H, s).
　本発明化合物１４７：1H-NMR (CDCl3) δ: 8.33 (1H, s), 4.27 (2H, t), 2.53 (3H, s), 2.39 (3H, s), 2.31-2.17 (2H, m), 2.26 (3H, s), 2.10 (3H, s), 2.03-1.93 (2H, m).
Figure JPOXMLDOC01-appb-T000098
The present compound 88: 1 H-NMR (CDCl 3 ) δ: 2.76-2.70 (2H, m), 2.47 (3H, s), 2.36 (3H, s), 2.07 (3H, s), 2.04 (3H, s) ), 1.66-1.56 (2H, m), 1.43-1.20 (24H, m), 0.87 (3H, t).
Invention compound 89: 1 H-NMR (CDCl 3 ) δ: 2.76-2.70 (2H, m), 2.47 (3H, s), 2.36 (3H, s), 2.07 (3H, s), 2.04 (3H, s) ), 1.67-1.57 (2H, m), 1.43-1.12 (14H, m), 0.88 (3H, t).
The present compound 90: 1 H-NMR (CDCl 3 ) δ: 2.76-2.70 (2H, m), 2.47 (3H, s), 2.36 (3H, s), 2.07 (3H, s), 2.04 (3H, s) ), 1.67-1.58 (2H, m), 1.42-1.29 (4H, m), 0.89 (3H, t).
The present compound 91: 1 H-NMR (CDCl 3 ) δ: 2.75-2.69 (2H, m), 2.47 (3H, s), 2.36 (3H, s), 2.07 (3H, s), 2.04 (3H, s) ), 1.73-1.61 (2H, m), 0.99 (3H, t).
Invention compound 92: 1 H-NMR (CDCl 3 ) δ: 2.81-2.70 (1H, m), 2.56 (3H, s), 2.45 (3H, s), 2.37 (3H, s), 1.98 (3H, s) ), 1.93-1.15 (10H, m).
The present compound 93: 1 H-NMR (CDCl 3 ) δ: 3.25-3.15 (1H, m), 2.54 (3H, s), 2.46 (3H, s), 2.35 (3H, s), 1.99 (3H, s) ), 1.96-1.62 (8H, m).
The present compound 94: 1 H-NMR (CDCl 3 ) δ: 2.66 (3H, q), 2.54 (3H, s), 2.35 (3H, s), 2.07 (3H, s).
The present compound 134: 1 H-NMR (CDCl 3 ) δ: 3.18 (1H, m), 2.53-2.42 (2H, m), 2.49 (3H, s), 2.42-2.34 (2H, m), 2.35 (3H) , s), 2.32-22.23 (2H, m), 2.04-2.95 (2H, m), 2.01 (3H, s), 1.89 (1H, m), 1.54-1.42 (2H, m), 1.25 (6H, d) ).
Invention compound 135: 1 H-NMR (CDCl 3 ) δ: 3.24-3.13 (1H, m), 2.47 (1.5 H, s), 2.47 (1.5 H, s), 2.43-2.30 (2 H, m), 2.35 (1.5H, s), 2.34 (1.5 H, s), 2.00 (1.5 H, s), 2.00 (1.5 H, s), 1.71-1.62 (3 H, m), 1.58-1.19 (5 H, m), 1.23 (3H, d), 1.22 (3H, d), 1.06-0.96 (1H, m), 0.95 (1.5 H, d), 0.88-0.78 (1 H, m), 0.85 (1.5 H, d).
Invention compound 136: 1 H-NMR (CDCl 3 ) δ: 3.23-3.13 (1 H, m), 2.50-2.43 (1 H, m), 2.47 (1.5 H, s), 2.47 (1.5 H, s), 2.35 (1.5H, s), 2.34 (1.5 H, s), 2.35-2.29 (1 H, m), 2.02 (1.5 H, s), 2.02 (1.5 H, s), 1.69 (3 H, d), 1.46-1.29 (4H, m), 1.23 (6H, d), 1.10-0.86 (4H, m), 0.89 (3H, d), 0.83 (3H, d).
Invention compound 138: 1 H-NMR (CDCl 3 ) δ: 2.49 (3H, s), 2.46 (3H, s), 2.48-2.33 (2H, m), 2.35 (3H, s), 2.02 (3H, s) ), 1.47-1.34 (3H, m), 1.30-1. 16 (2H, m), 0.95 (3H, d), 0.89 (3H, t).
Invention compound 144: 1 H-NMR (CDCl 3 ) δ: 8.32 (1H, s), 4.29 (2H, dd), 2.52 (3H, s), 2.38 (3H, s), 2.26 (3H, s), 2.09 (3H, s), 1.32 (3H, t).
Invention compound 145: 1 H-NMR (CDCl 3 ) δ: 8.39 (1H, s), 4.56 (2H, q), 2.52 (3H, s), 2.39 (3H, s), 2.27 (3H, s), 2.11 (3H, s).
The present compound 146: 1 H-NMR (CDCl 3 ) δ: 8.33 (1 H, s), 4.43 (2 H, t), 2.63-2.50 (2 H, m), 2.53 (3 H, s), 2. 39 (3 H, s) ), 2.26 (3H, s), 2.10 (3H, s).
The present compound 147: 1 H-NMR (CDCl 3 ) δ: 8.33 ( 1 H, s), 4. 27 (2 H, t), 2.53 (3 H, s), 2. 39 (3 H, s), 2.31-2.17 (2 H, m) ), 2.26 (3H, s), 2.10 (3H, s), 2.03-1.93 (2H, m).
製造例２７
　０．４３ｇの本発明化合物７２及びメタノール２０ｍＬの混合物に、炭酸カリウム０．０３ｇを加え、室温で３日間撹拌した。得られた混合物を減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（クロロホルム：メタノール＝８０：２０）に付し、下式に示される本発明化合物９５を０．２４ｇ得た。
Figure JPOXMLDOC01-appb-C000099
 　本発明化合物９５：1H-NMR (DMSO-d6) δ: 2.29 (6H, s), 2.03 (6H, s). Production Example 27
0.03 g of potassium carbonate was added to a mixture of 0.43 g of the compound of the present invention 72 and 20 mL of methanol, and the mixture was stirred at room temperature for 3 days. The resulting mixture was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (chloroform: methanol = 80: 20) to obtain 0.24 g of the present compound 95 represented by the following formula.
Figure JPOXMLDOC01-appb-C000099
 Invention compound 95: 1 H-NMR (DMSO-d 6 ) δ: 2.29 (6H, s), 2.03 (6H, s).
製造例２８
　０．３０ｇの本発明化合物８及びＤＭＦ１０ｍＬの混合物に、水素化ナトリウム０．１６ｇ及びヨウ化メチル０．２５ｍＬを順次加え、室温で１４時間撹拌した。得られた混合物に水を加え、ＭＴＢＥで抽出した。得られた有機層を硫酸マグネシウムで乾燥し、減圧下濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝８０：２０）に付し、下式に示される本発明化合物９６を０．１８ｇ得た。
Figure JPOXMLDOC01-appb-C000100
 　本発明化合物９６：1H-NMR (CDCl3) δ: 3.70 (3H, s), 2.43 (6H, s), 2.16 (6H, s). Production Example 28
To a mixture of 0.30 g of the compound of the present invention 8 and 10 mL of DMF, 0.16 g of sodium hydride and 0.25 mL of methyl iodide were sequentially added, and stirred at room temperature for 14 hours. To the resulting mixture was added water and extracted with MTBE. The obtained organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (hexane: ethyl acetate = 80: 20) to obtain 0.18 g of the present compound 96 represented by the following formula.
Figure JPOXMLDOC01-appb-C000100
 The present compound 96: 1 H-NMR (CDCl 3 ) δ: 3.70 (3H, s), 2.43 (6H, s), 2.16 (6H, s).
製造例２９
　製造例７に記載の方法に準じて、本発明化合物９７を得た。
Figure JPOXMLDOC01-appb-C000101
 　本発明化合物９７：1H-NMR (CDCl3) δ: 8.11 (1H, s), 2.52-2.45 (2H, m), 2.27 (3H, s), 2.25 (3H, s), 2.01 (3H, s), 1.51-1.24 (6H, m), 0.88 (3H, t). Production Example 29
The compound of the present invention 97 was obtained according to the method described in Production Example 7.
Figure JPOXMLDOC01-appb-C000101
 Invention compound 97: 1 H-NMR (CDCl 3 ) δ: 8.11 (1 H, s), 2.52-2.45 (2 H, m), 2.27 (3 H, s), 2. 25 (3 H, s), 2.01 (3 H, s) ), 1.51-1.24 (6H, m), 0.88 (3H, t).
製造例３０
　参考製造例２６に記載の方法に準じて、本発明化合物１５０を得た。
Figure JPOXMLDOC01-appb-C000102
 　本発明化合物１５０：1H-NMR (CDCl3) δ: 7.58-7.33 (5H, m), 4.79 (2H, s), 3.19 (1H, m), 2.65-2.56 (2H, m), 2.46 (3H, s), 2.19 (3H, s), 1.55-1.15 (8H, m), 1.25 (6H, d), 0.87 (3H, t). Production Example 30
The present compound 150 was obtained according to the method described in Reference Production Example 26.
Figure JPOXMLDOC01-appb-C000102
 The present compound 150: 1 H-NMR (CDCl 3 ) δ: 7.58-7.33 (5H, m), 4.79 (2H, s), 3.19 (1H, m), 2.65-2.56 (2H, m), 2.46 (3H , s), 2.19 (3H, s), 1.55-1.15 (8H, m), 1.25 (6H, d), 0.87 (3H, t).
製造例３１
　製造例１６に記載の方法に準じて、本発明化合物１５１を得た。
Figure JPOXMLDOC01-appb-C000103
 　本発明化合物１５１：1H-NMR (CDCl3) δ: 7.52-7.30 (5H, m), 4.69 (2H, s), 3.25 (1H, m), 2.55-2.48 (2H, m), 2.45 (3H, s), 2.26 (3H, s), 1.65-1.12 (8H, m), 1.15 (6H, d), 0.86 (3H, t). Production Example 31
The present compound 151 was obtained according to the method described in Production Example 16.
Figure JPOXMLDOC01-appb-C000103
 Invention compound 151: 1 H-NMR (CDCl 3 ) δ: 7.52-7.30 (5H, m), 4.69 (2H, s), 3.25 (1H, m), 2.55-2.48 (2H, m), 2.45 (3H , s), 2.26 (3H, s), 1.65-1.12 (8H, m), 1.15 (6H, d), 0.86 (3H, t).
参考製造例３５
　参考製造例３１に記載の方法に準じて、中間体５６を得た。
Figure JPOXMLDOC01-appb-C000104
 　中間体５６：1H-NMR (CDCl3) δ: 7.51-7.33 (5H, m), 5.36 (1H, s), 4.83 (2H, s), 4.62 (2H, s), 3.24 (1H, m), 2.68-2.56 (2H, m), 2.10 (3H, s), 1.54-1.20 (8H, m), 1.27 (6H, d), 0.87 (3H, t). Reference Production Example 35
Intermediate 56 was obtained according to the method described in Reference Production Example 31.
Figure JPOXMLDOC01-appb-C000104
 Intermediate 56: 1 H-NMR (CDCl 3 ) δ: 7.51-7.33 (5H, m), 5.36 (1H, s), 4.83 (2H, s), 4.62 (2H, s), 3.24 (1H, m) , 2.68-2.56 (2H, m), 2.10 (3H, s), 1.54-1.20 (8H, m), 1.27 (6H, d), 0.87 (3H, t).
参考製造例３６
　参考製造例３２に記載の方法に準じて、中間体５７を得た。
Figure JPOXMLDOC01-appb-C000105
 　中間体５７：1H-NMR (CDCl3) δ: 10.52 (1H, s), 7.55-7.34 (5H, m), 4.65 (2H, s), 3.25 (1H, m), 2.69-2.57 (2H, m), 2.19 (3H, s), 1.56-1.19 (8H, m), 1.29 (6H, d), 0.87 (3H, t). Reference Production Example 36
An intermediate 57 was obtained according to the method described in Reference Production Example 32.
Figure JPOXMLDOC01-appb-C000105
 Intermediate 57: 1 H-NMR (CDCl 3 ) δ: 10.52 (1H, s), 7.55-7.34 (5H, m), 4.65 (2H, s), 3.25 (1H, m), 2.69-2.57 (2H, 2H, s) m), 2.19 (3H, s), 1.56-1.19 (8H, m), 1.29 (6H, d), 0.87 (3H, t).
製造例３２
　参考製造例４に記載の方法に準じて、本発明化合物１５２を得た。
Figure JPOXMLDOC01-appb-C000106
 　本発明化合物１５２：1H-NMR (CDCl3) δ: 7.51-7.30 (5H, m), 7.00 (1H, dd), 6.46 (1H, dd), 5.42 (1H, dd), 4.79 (2H, s), 3.20 (1H, m), 2.67-2.54 (2H, m), 2.28 (3H, s), 1.59-1.18 (8H, m), 1.28 (6H, d), 0.87 (3H, t). Production Example 32
The present compound 152 was obtained according to the method described in Reference Production Example 4.
Figure JPOXMLDOC01-appb-C000106
 The present compound 152: 1 H-NMR (CDCl 3 ) δ: 7.51-7.30 (5 H, m), 7.00 (1 H, dd), 6.46 (1 H, dd), 5.42 (1 H, dd), 4.79 (2 H, s ), 3.20 (1H, m), 2.67-2.54 (2H, m), 2.28 (3H, s), 1.59-1.18 (8H, m), 1.28 (6H, d), 0.87 (3H, t).
製造例３３
　製造例７に記載の方法に準じて、本発明化合物１５３を得た。
Figure JPOXMLDOC01-appb-C000107
 　本発明化合物１５３：1H-NMR (CDCl3) δ: 10.26 (1H, s), 3.32 (1H, m), 2.92 (2H, q), 2.69-2.52 (2H, m), 2.14 (3H, s), 1.53-1.17 (8H, m), 1.41 (6H, d), 1.26 (3H, t), 0.86 (3H, t). Production Example 33
The present compound 153 was obtained according to the method described in Production Example 7.
Figure JPOXMLDOC01-appb-C000107
 Invention compound 153: 1 H-NMR (CDCl 3 ) δ: 10.26 (1 H, s), 3.32 (1 H, m), 2. 92 (2 H, q), 2. 69-2. 52 (2 H, m), 2. 14 (3 H, s) ), 1.53-1.17 (8H, m), 1.41 (6H, d), 1.26 (3H, t), 0.86 (3H, t).
製造例３４
　製造例５に記載の方法に準じて、本発明化合物１５４を得た。
Figure JPOXMLDOC01-appb-C000108
 　本発明化合物１５４：1H-NMR (CDCl3) δ: 3.18 (1H, m), 2.76 (2H, q), 2.55-2.38 (2H, m), 2.34 (3H, s), 2.02 (3H, s), 1.52-1.18 (8H, m), 1.26 (3H, t), 1.25 (6H, d), 0.89 (3H, t). Production Example 34
The present compound 154 was obtained according to the method described in Production Example 5.
Figure JPOXMLDOC01-appb-C000108
 The present compound 154: 1 H-NMR (CDCl 3 ) δ: 3.18 (1H, m), 2.76 (2H, q), 2.55-2.38 (2H, m), 2.34 (3H, s), 2.02 (3H, s) ), 1.52-1.18 (8H, m), 1.26 (3H, t), 1.25 (6H, d), 0.89 (3H, t).
　次に、実施例に記載された製造例及び本明細書に記載された製造法のいずれかに準じて製造される本発明化合物Ｘの例を以下に示す。 Next, examples of the compound of the present invention X produced according to any of the production examples described in the examples and the production methods described herein are shown below.
式（Ｌ－１）
Figure JPOXMLDOC01-appb-C000109
 で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX1と記す）。 Formula (L-1)
Figure JPOXMLDOC01-appb-C000109
 In the compound represented by the formula, R 4 is a methyl group, R 5 is a methyl group, R B is a methyl group, and R A is any of the substituents described in [Table A12] to [Table A35] Compounds that are groups (hereinafter referred to as compound group SX1).
Figure JPOXMLDOC01-appb-T000110
Figure JPOXMLDOC01-appb-T000110
Figure JPOXMLDOC01-appb-T000111
Figure JPOXMLDOC01-appb-T000111
Figure JPOXMLDOC01-appb-T000112
Figure JPOXMLDOC01-appb-T000112
Figure JPOXMLDOC01-appb-T000113
Figure JPOXMLDOC01-appb-T000113
Figure JPOXMLDOC01-appb-T000114
Figure JPOXMLDOC01-appb-T000114
Figure JPOXMLDOC01-appb-T000115
Figure JPOXMLDOC01-appb-T000115
Figure JPOXMLDOC01-appb-T000116
Figure JPOXMLDOC01-appb-T000116
Figure JPOXMLDOC01-appb-T000117
Figure JPOXMLDOC01-appb-T000117
Figure JPOXMLDOC01-appb-T000118
Figure JPOXMLDOC01-appb-T000118
Figure JPOXMLDOC01-appb-T000119
Figure JPOXMLDOC01-appb-T000119
Figure JPOXMLDOC01-appb-T000120
Figure JPOXMLDOC01-appb-T000120
Figure JPOXMLDOC01-appb-T000121
Figure JPOXMLDOC01-appb-T000121
　式（Ｌ－１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX2と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX3と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX4と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX5と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX6と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX7と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX8と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX9と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX10と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX11と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX12と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX13と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX14と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX15と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX16と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX17と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX18と記す）。 In the compounds represented by formula (L-1), R 4 is a methyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX2).
In the compounds represented by formula (L-1), R 4 is a methyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX3).
In the compounds represented by formula (L-1), R 4 is a methyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX4).
In the compound represented by the formula (L-1), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX5).
In the compound represented by the formula (L-1), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX6).
In the compounds represented by formula (L-1), R 4 is an ethyl group, R 5 is a methyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX7).
In the compounds represented by formula (L-1), R 4 is an ethyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX8).
In the compounds represented by formula (L-1), R 4 is an ethyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX9).
In the compounds represented by formula (L-1), R 4 is an ethyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX10).
In the compound represented by the formula (L-1), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX11).
In the compound represented by the formula (L-1), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX12).
In the compound represented by the formula (L-1), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX13).
In the compound represented by the formula (L-1), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX14).
In the compound represented by the formula (L-1), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX15).
In the compound represented by the formula (L-1), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX16).
In the compound represented by the formula (L-1), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX17).
In the compound represented by formula (L-1), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any substituent as described in following (it is hereafter described as compound group SX18).
　式（Ｌ－１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX19と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX20と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX21と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX22と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX23と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX24と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX25と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX26と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX27と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX28と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX29と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX30と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX31と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX32と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX33と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX34と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX35と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX36と記す）。 In the compounds represented by formula (L-1), R 4 is a methyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX19).
In the compounds represented by formula (L-1), R 4 is a methyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX20).
In the compounds represented by formula (L-1), R 4 is a methyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX21).
In the compounds represented by formula (L-1), R 4 is a methyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX22).
In the compound represented by the formula (L-1), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX23).
In the compound represented by the formula (L-1), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX24).
In the compounds represented by formula (L-1), R 4 is an ethyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX25).
In the compounds represented by formula (L-1), R 4 is an ethyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX26).
In the compounds represented by formula (L-1), R 4 is an ethyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX27).
In the compounds represented by formula (L-1), R 4 is an ethyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX28).
In the compound represented by the formula (L-1), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX29).
In the compound represented by the formula (L-1), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX30).
In the compound represented by the formula (L-1), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX31).
In the compound represented by the formula (L-1), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX32).
In the compound represented by the formula (L-1), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX33).
In the compound represented by the formula (L-1), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX34).
In the compound represented by the formula (L-1), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX35).
In the compound represented by the formula (L-1), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX36).
式（Ｌ－２）
Figure JPOXMLDOC01-appb-C000122
 で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX37と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX38と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX39と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX40と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX41と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX42と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX43と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX44と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX45と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX46と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX47と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX48と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX49と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX50と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX51と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX52と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX53と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX54と記す）。 Formula (L-2)
Figure JPOXMLDOC01-appb-C000122
 In the compound represented by the formula, R 4 is a methyl group, R 5 is a methyl group, R B is a methyl group, and R A is any of the substituents described in [Table A12] to [Table A35] Compounds that are groups (hereinafter referred to as compound group SX37).
In the compounds represented by formula (L-2), R 4 is a methyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX38).
In the compounds represented by formula (L-2), R 4 is a methyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX39).
In the compounds represented by formula (L-2), R 4 is a methyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX40).
In the compound represented by the formula (L-2), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX41).
In the compound represented by the formula (L-2), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX42).
In the compounds represented by formula (L-2), R 4 is an ethyl group, R 5 is a methyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX43).
In the compounds represented by formula (L-2), R 4 is an ethyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX44).
In the compounds represented by formula (L-2), R 4 is an ethyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX45).
In the compounds represented by formula (L-2), R 4 is an ethyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX46).
In the compound represented by the formula (L-2), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX47).
In the compound represented by the formula (L-2), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX48).
In the compound represented by the formula (L-2), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX49).
In the compound represented by the formula (L-2), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX50).
In the compound represented by the formula (L-2), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX51).
In the compound represented by the formula (L-2), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX52).
In the compounds represented by Formula (L-2), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX53).
In the compound represented by formula (L-2), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX54).
　式（Ｌ－２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX55と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX56と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX57と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX58と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX59と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX60と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX61と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX62と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX63と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX64と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX65と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX66と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX67と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX68と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX69と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX70と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX71と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX72と記す）。 In the compounds represented by formula (L-2), R 4 is a methyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX55).
In the compounds represented by formula (L-2), R 4 is a methyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX56).
In the compounds represented by formula (L-2), R 4 is a methyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX57).
In the compounds represented by formula (L-2), R 4 is a methyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX58).
In the compound represented by the formula (L-2), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX59).
In the compound represented by the formula (L-2), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX60).
In the compounds represented by formula (L-2), R 4 is an ethyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described (hereinafter referred to as compound group SX61).
In the compounds represented by formula (L-2), R 4 is an ethyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX62).
In the compounds represented by formula (L-2), R 4 is an ethyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX63).
In the compounds represented by formula (L-2), R 4 is an ethyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described (hereinafter referred to as compound group SX64).
In the compound represented by the formula (L-2), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX65).
In the compound represented by the formula (L-2), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX66).
In the compounds represented by formula (L-2), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX67).
In the compound represented by the formula (L-2), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX68).
In the compound represented by the formula (L-2), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX69).
In the compound represented by the formula (L-2), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX70).
In the compound represented by formula (L-2), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any substituent as described in following (it is hereafter described as compound group SX71).
In the compound represented by formula (L-2), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX72).
式（Ｌ－３）
Figure JPOXMLDOC01-appb-C000123
 で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX73と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX74と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX75と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX76と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX77と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX78と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX79と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX80と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX81と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX82と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX83と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX84と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX85と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX86と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX87と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX88と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX89と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX90と記す）。 Formula (L-3)
Figure JPOXMLDOC01-appb-C000123
 In the compound represented by the formula, R 4 is a methyl group, R 5 is a methyl group, R B is a methyl group, and R A is any of the substituents described in [Table A12] to [Table A35] Compounds that are groups (hereinafter referred to as compound group SX73).
In the compounds represented by formula (L-3), R 4 is a methyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX74).
In the compounds represented by formula (L-3), R 4 is a methyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX75).
In the compounds represented by formula (L-3), R 4 is a methyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described (hereinafter referred to as compound group SX76).
In the compound represented by the formula (L-3), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX77).
In the compound represented by the formula (L-3), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX78).
In the compounds represented by formula (L-3), R 4 is an ethyl group, R 5 is a methyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX79).
In the compounds represented by formula (L-3), R 4 is an ethyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX80).
In the compounds represented by formula (L-3), R 4 is an ethyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX81).
In the compounds represented by formula (L-3), R 4 is an ethyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX82).
In the compound represented by the formula (L-3), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX83).
In the compound represented by the formula (L-3), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX84).
In the compound represented by the formula (L-3), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX85).
In the compound represented by the formula (L-3), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX86).
In the compound represented by the formula (L-3), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX87).
In the compound represented by the formula (L-3), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX88).
In the compound represented by the formula (L-3), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX89).
In the compound represented by the formula (L-3), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX90).
　式（Ｌ－３）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX91と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX92と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX93と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX94と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX95と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX96と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX97と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX98と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX99と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX100と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX101と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX102と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX103と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX104と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX105と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX106と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX107と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX108と記す）。 In the compounds represented by formula (L-3), R 4 is a methyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX91).
In the compounds represented by formula (L-3), R 4 is a methyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX92).
In the compounds represented by formula (L-3), R 4 is a methyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX93).
In the compounds represented by formula (L-3), R 4 is a methyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX94).
In the compound represented by the formula (L-3), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX95).
In the compound represented by the formula (L-3), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX96).
In the compounds represented by formula (L-3), R 4 is an ethyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX97).
In the compounds represented by formula (L-3), R 4 is an ethyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX98).
In the compounds represented by formula (L-3), R 4 is an ethyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX99).
In the compounds represented by formula (L-3), R 4 is an ethyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX100).
In the compound represented by the formula (L-3), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX101).
In the compound represented by the formula (L-3), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX102).
In the compound represented by the formula (L-3), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX103).
In the compound represented by the formula (L-3), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX104).
In the compound represented by the formula (L-3), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX105).
In the compound represented by the formula (L-3), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX106).
In the compounds represented by formula (L-3), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX107).
In the compound represented by the formula (L-3), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX108).
式（Ｌ－４）
Figure JPOXMLDOC01-appb-C000124
 で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX109と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX110と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX111と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX112と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX113と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX114と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX115と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX116と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX117と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX118と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX119と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX120と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX121と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX122と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX123と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX124と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX125と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX126と記す）。 Formula (L-4)
Figure JPOXMLDOC01-appb-C000124
 In the compound represented by the formula, R 4 is a methyl group, R 5 is a methyl group, R B is a methyl group, and R A is any of the substituents described in [Table A12] to [Table A35] Compounds that are groups (hereinafter referred to as compound group SX109).
In the compounds represented by Formula (L-4), R 4 is a methyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX110).
In the compound represented by the formula (L-4), R 4 is a methyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX111).
In the compound represented by the formula (L-4), R 4 is a methyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX112).
In the compound represented by the formula (L-4), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX113).
In the compound represented by the formula (L-4), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX114).
In the compounds represented by formula (L-4), R 4 is an ethyl group, R 5 is a methyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX115).
In the compounds represented by formula (L-4), R 4 is an ethyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX116).
In the compounds represented by formula (L-4), R 4 is an ethyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX117).
In the compounds represented by formula (L-4), R 4 is an ethyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX118).
In the compound represented by the formula (L-4), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX119).
In the compound represented by the formula (L-4), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX120).
In the compound represented by the formula (L-4), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX121).
In the compound represented by the formula (L-4), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX122).
In the compound represented by the formula (L-4), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX123).
In the compound represented by the formula (L-4), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX124).
In the compound represented by the formula (L-4), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX125).
In the compound represented by the formula (L-4), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any substituent as described in following (it is hereafter described as compound group SX126).
　式（Ｌ－４）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX127と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX128と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX129と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX130と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX131と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX132と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX133と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX134と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX135と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX136と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX137と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX138と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX139と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX140と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX141と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX142と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX143と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX144と記す）。 In the compounds represented by formula (L-4), R 4 is a methyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX127).
In the compounds represented by Formula (L-4), R 4 is a methyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX128).
In the compounds represented by Formula (L-4), R 4 is a methyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX129).
In the compounds represented by Formula (L-4), R 4 is a methyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX130).
In the compound represented by the formula (L-4), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX131).
In the compound represented by the formula (L-4), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX132).
In the compounds represented by formula (L-4), R 4 is an ethyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX133).
In the compounds represented by formula (L-4), R 4 is an ethyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX134).
In the compounds represented by formula (L-4), R 4 is an ethyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX135).
In the compounds represented by formula (L-4), R 4 is an ethyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX136).
In the compound represented by the formula (L-4), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX137).
In the compound represented by the formula (L-4), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX138).
In the compound represented by the formula (L-4), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX139).
In the compound represented by the formula (L-4), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX140).
In the compound represented by the formula (L-4), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX141).
In the compound represented by the formula (L-4), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX142).
In the compound represented by the formula (L-4), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX143).
In the compound represented by the formula (L-4), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX144).
式（Ｌ－５）
Figure JPOXMLDOC01-appb-C000125
 で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX145と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX146と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX147と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX148と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX149と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX150と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX151と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX152と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX153と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX154と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX155と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX156と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX157と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX158と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX159と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX160と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX161と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX162と記す）。 Formula (L-5)
Figure JPOXMLDOC01-appb-C000125
 In the compound represented by the formula, R 4 is a methyl group, R 5 is a methyl group, R B is a methyl group, and R A is any of the substituents described in [Table A12] to [Table A35] Compounds that are groups (hereinafter referred to as compound group SX145).
In the compounds represented by formula (L-5), R 4 is a methyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX146).
In the compounds represented by formula (L-5), R 4 is a methyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX147).
In the compounds represented by formula (L-5), R 4 is a methyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX148).
In the compound represented by the formula (L-5), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX149).
In the compound represented by the formula (L-5), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX150).
In the compounds represented by formula (L-5), R 4 is an ethyl group, R 5 is a methyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX151).
In the compounds represented by formula (L-5), R 4 is an ethyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX152).
In the compound represented by the formula (L-5), R 4 is an ethyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX153).
In the compound represented by the formula (L-5), R 4 is an ethyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX154).
In the compound represented by the formula (L-5), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX155).
In the compound represented by the formula (L-5), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX156).
In the compound represented by the formula (L-5), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX157).
In the compound represented by the formula (L-5), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX158).
In the compound represented by the formula (L-5), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX159).
In the compound represented by the formula (L-5), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX160).
In the compound represented by the formula (L-5), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX161).
In the compound represented by the formula (L-5), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX162).
　式（Ｌ－５）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX163と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX164と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX165と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX166と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX167と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX168と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX169と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX170と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX171と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX172と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX173と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX174と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX175と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX176と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX177と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX178と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX179と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX180と記す）。 In the compounds represented by formula (L-5), R 4 is a methyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX163).
In the compounds represented by formula (L-5), R 4 is a methyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX164).
In the compounds represented by formula (L-5), R 4 is a methyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX165).
In the compounds represented by formula (L-5), R 4 is a methyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX166).
In the compound represented by the formula (L-5), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX167).
In the compound represented by the formula (L-5), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX168).
In the compounds represented by formula (L-5), R 4 is an ethyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX169).
In the compounds represented by formula (L-5), R 4 is an ethyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX170).
In the compounds represented by formula (L-5), R 4 is an ethyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX171).
In the compound represented by formula (L-5), R 4 is an ethyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX172).
In the compound represented by the formula (L-5), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX173).
In the compound represented by the formula (L-5), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX174).
In the compound represented by the formula (L-5), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX175).
In the compound represented by the formula (L-5), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX176).
In the compound represented by the formula (L-5), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX177).
In the compound represented by the formula (L-5), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX178).
In the compounds represented by formula (L-5), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX179).
In the compound represented by the formula (L-5), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX180).
式（Ｌ－６）
Figure JPOXMLDOC01-appb-C000126
 で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX181と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX182と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX183と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX184と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX185と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX186と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX187と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX188と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX189と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX190と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX191と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX192と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX193と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX194と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX195と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX196と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX197と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX198と記す）。 Formula (L-6)
Figure JPOXMLDOC01-appb-C000126
 In the compound represented by the formula, R 4 is a methyl group, R 5 is a methyl group, R B is a methyl group, and R A is any of the substituents described in [Table A12] to [Table A35] Compounds that are groups (hereinafter referred to as compound group SX181).
In the compounds represented by formula (L-6), R 4 is a methyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX182).
In the compounds represented by formula (L-6), R 4 is a methyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX183).
In the compound represented by the formula (L-6), R 4 is a methyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX184).
In the compound represented by the formula (L-6), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX185).
In the compound represented by the formula (L-6), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX186).
In the compound represented by formula (L-6), R 4 is an ethyl group, R 5 is a methyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX187).
In the compounds represented by formula (L-6), R 4 is an ethyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX188).
In the compounds represented by formula (L-6), R 4 is an ethyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX189).
In the compounds represented by formula (L-6), R 4 is an ethyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX190).
In the compound represented by the formula (L-6), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX191).
In the compound represented by the formula (L-6), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX192).
In the compound represented by the formula (L-6), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX193).
In the compound represented by the formula (L-6), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX194).
In the compound represented by the formula (L-6), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX195).
In the compound represented by the formula (L-6), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX196).
In the compound represented by the formula (L-6), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX197).
In the compound represented by the formula (L-6), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any substituent as described in following (it is hereafter described as compound group SX198).
　式（Ｌ－６）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX199と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX200と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX201と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX202と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX203と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX204と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX205と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX206と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX207と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX208と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX209と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX210と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX211と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX212と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX213と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX214と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX215と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX216と記す）。 In the compounds represented by formula (L-6), R 4 is a methyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX199).
In the compounds represented by formula (L-6), R 4 is a methyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX200).
In the compounds represented by formula (L-6), R 4 is a methyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX201).
In the compounds represented by formula (L-6), R 4 is a methyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX202).
In the compound represented by the formula (L-6), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX203).
In the compound represented by the formula (L-6), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX204).
In the compounds represented by formula (L-6), R 4 is an ethyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX205).
In the compound represented by the formula (L-6), R 4 is an ethyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX206).
In the compound represented by formula (L-6), R 4 is an ethyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX207).
In the compound represented by the formula (L-6), R 4 is an ethyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX208).
In the compound represented by the formula (L-6), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX209).
In the compound represented by the formula (L-6), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX210).
In the compound represented by the formula (L-6), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX211).
In the compound represented by the formula (L-6), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX212).
In the compound represented by the formula (L-6), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX213).
In the compound represented by the formula (L-6), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX214).
In the compound represented by the formula (L-6), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX215).
In the compound represented by the formula (L-6), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX216).
式（Ｌ－７）
Figure JPOXMLDOC01-appb-C000127
 で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX217と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX218と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX219と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX220と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX221と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX222と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX223と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX224と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX225と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX226と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX227と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX228と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX229と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX230と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX231と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX232と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX233と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX234と記す）。 Formula (L-7)
Figure JPOXMLDOC01-appb-C000127
 In the compound represented by the formula, R 4 is a methyl group, R 5 is a methyl group, R B is a methyl group, and R A is any of the substituents described in [Table A12] to [Table A35] Compounds that are groups (hereinafter referred to as compound group SX217).
In the compounds represented by formula (L-7), R 4 is a methyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX218).
In the compounds represented by formula (L-7), R 4 is a methyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX219).
In the compounds represented by formula (L-7), R 4 is a methyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX220).
In the compound represented by the formula (L-7), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX221).
In the compound represented by the formula (L-7), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX222).
In the compounds represented by formula (L-7), R 4 is an ethyl group, R 5 is a methyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX223).
In the compound represented by the formula (L-7), R 4 is an ethyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX224).
In the compounds represented by formula (L-7), R 4 is an ethyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX225).
In the compound represented by the formula (L-7), R 4 is an ethyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX226).
In the compound represented by the formula (L-7), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX227).
In the compound represented by the formula (L-7), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX228).
In the compound represented by the formula (L-7), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX229).
In the compound represented by the formula (L-7), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX230).
In the compound represented by the formula (L-7), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX231).
In the compound represented by the formula (L-7), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX232).
In the compounds represented by formula (L-7), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any substituent as described in following (it is hereafter described as compound group SX233).
In the compounds represented by formula (L-7), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX234).
　式（Ｌ－７）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX235と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX236と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX237と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX238と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX239と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX240と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX241と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX242と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX243と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX244と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX245と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX246と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX247と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX248と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX249と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX250と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX251と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX252と記す）。 In the compounds represented by formula (L-7), R 4 is a methyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX235).
In the compounds represented by formula (L-7), R 4 is a methyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX236).
In the compounds represented by formula (L-7), R 4 is a methyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX237).
In the compounds represented by formula (L-7), R 4 is a methyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX238).
In the compound represented by the formula (L-7), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX239).
In the compound represented by the formula (L-7), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX240).
In the compounds represented by formula (L-7), R 4 is an ethyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX241).
In the compounds represented by formula (L-7), R 4 is an ethyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX242).
In the compounds represented by formula (L-7), R 4 is an ethyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX243).
In the compound represented by the formula (L-7), R 4 is an ethyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX244).
In the compound represented by the formula (L-7), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX245).
In the compound represented by the formula (L-7), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX246).
In the compound represented by the formula (L-7), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX247).
In the compound represented by the formula (L-7), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX248).
In the compound represented by the formula (L-7), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX249).
In the compound represented by the formula (L-7), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX250).
In the compound represented by the formula (L-7), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX251).
In the compound represented by the formula (L-7), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any substituent as described in following (it is hereafter described as compound group SX252).
式（Ｌ－８）
Figure JPOXMLDOC01-appb-C000128
 で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX253と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX254と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX255と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX256と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX257と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX258と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX259と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX260と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX261と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX262と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX263と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX264と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX265と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX266と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX267と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX268と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX269と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX270と記す）。 Formula (L-8)
Figure JPOXMLDOC01-appb-C000128
 In the compound represented by the formula, R 4 is a methyl group, R 5 is a methyl group, R B is a methyl group, and R A is any of the substituents described in [Table A12] to [Table A35] Compounds that are groups (hereinafter referred to as compound group SX253).
In the compounds represented by formula (L-8), R 4 is a methyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX254).
In the compounds represented by formula (L-8), R 4 is a methyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX255).
In the compounds represented by formula (L-8), R 4 is a methyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX256).
In the compound represented by the formula (L-8), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX257).
In the compound represented by the formula (L-8), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX258).
In the compounds represented by formula (L-8), R 4 is an ethyl group, R 5 is a methyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX259).
In the compounds represented by formula (L-8), R 4 is an ethyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX260).
In the compound represented by the formula (L-8), R 4 is an ethyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX261).
In the compound represented by the formula (L-8), R 4 is an ethyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX262).
In the compound represented by the formula (L-8), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX263).
In the compound represented by the formula (L-8), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX264).
In the compound represented by the formula (L-8), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX265).
In the compound represented by the formula (L-8), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX266).
In the compound represented by the formula (L-8), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX267).
In the compound represented by the formula (L-8), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX268).
In the compound represented by the formula (L-8), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX269).
In the compound represented by formula (L-8), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX270).
　式（Ｌ－８）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX271と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX272と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX273と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX274と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX275と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX276と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX277と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX278と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX279と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX280と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX281と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX282と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX283と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX284と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX285と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX286と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX287と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX288と記す）。 In the compounds represented by formula (L-8), R 4 is a methyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described (hereinafter referred to as compound group SX271).
In the compounds represented by formula (L-8), R 4 is a methyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX272).
In the compounds represented by formula (L-8), R 4 is a methyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX273).
In the compounds represented by formula (L-8), R 4 is a methyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX274).
In the compound represented by the formula (L-8), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX275).
In the compound represented by the formula (L-8), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX276).
In the compounds represented by formula (L-8), R 4 is an ethyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX277).
In the compounds represented by formula (L-8), R 4 is an ethyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX278).
In the compounds represented by formula (L-8), R 4 is an ethyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX279).
In the compounds represented by formula (L-8), R 4 is an ethyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX280).
In the compound represented by the formula (L-8), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX281).
In the compound represented by the formula (L-8), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX282).
In the compound represented by the formula (L-8), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX283).
In the compound represented by the formula (L-8), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX284).
In the compound represented by the formula (L-8), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX285).
In the compound represented by the formula (L-8), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX286).
In the compound represented by formula (L-8), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is a substituent in any one of-(It is hereafter described as the compound group SX287).
In the compound represented by the formula (L-8), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX288).
式（Ｌ－９）
Figure JPOXMLDOC01-appb-C000129
 で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX289と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX290と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX291と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX292と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX293と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX294と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX295と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX296と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX297と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX298と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX299と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX300と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX301と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX302と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX303と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX304と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX305と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX306と記す）。 Formula (L-9)
Figure JPOXMLDOC01-appb-C000129
 In the compound represented by the formula, R 4 is a methyl group, R 5 is a methyl group, R B is a methyl group, and R A is any of the substituents described in [Table A12] to [Table A35] Compounds that are groups (hereinafter referred to as compound group SX289).
In the compounds represented by formula (L-9), R 4 is a methyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX290).
In the compounds represented by formula (L-9), R 4 is a methyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX291).
In the compound represented by the formula (L-9), R 4 is a methyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX292).
In the compound represented by the formula (L-9), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX293).
In the compound represented by the formula (L-9), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX294).
In the compound represented by formula (L-9), R 4 is an ethyl group, R 5 is a methyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX295).
In the compounds represented by formula (L-9), R 4 is an ethyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX296).
In the compounds represented by formula (L-9), R 4 is an ethyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX297).
In the compound represented by the formula (L-9), R 4 is an ethyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX298).
In the compound represented by the formula (L-9), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX299).
In the compound represented by the formula (L-9), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX300).
In the compound represented by the formula (L-9), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX301).
In the compound represented by the formula (L-9), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX302).
In the compound represented by the formula (L-9), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX303).
In the compound represented by the formula (L-9), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX304).
In the compound represented by the formula (L-9), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX305).
In the compound represented by the formula (L-9), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX306).
　式（Ｌ－９）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX307と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX308と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX309と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX310と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX311と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX312と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX313と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX314と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX315と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX316と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX317と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX318と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX319と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX320と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX321と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX322と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX323と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX324と記す）。 In the compounds represented by formula (L-9), R 4 is a methyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX307).
In the compounds represented by formula (L-9), R 4 is a methyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX308).
In the compounds represented by formula (L-9), R 4 is a methyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX309).
In the compounds represented by formula (L-9), R 4 is a methyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX310).
In the compound represented by the formula (L-9), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX311).
In the compound represented by the formula (L-9), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX312).
In the compounds represented by formula (L-9), R 4 is an ethyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX313).
In the compounds represented by formula (L-9), R 4 is an ethyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX314).
In the compounds represented by formula (L-9), R 4 is an ethyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX315).
In the compound represented by formula (L-9), R 4 is an ethyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX316).
In the compound represented by the formula (L-9), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX317).
In the compound represented by the formula (L-9), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX318).
In the compound represented by the formula (L-9), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX319).
In the compound represented by the formula (L-9), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX320).
In the compound represented by the formula (L-9), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX321).
In the compound represented by the formula (L-9), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX322).
In the compound represented by the formula (L-9), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX323).
In the compound represented by the formula (L-9), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX324).
式（Ｌ－１０）
Figure JPOXMLDOC01-appb-C000130
 で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX325と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX326と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX327と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX328と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX329と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX330と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX331と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX332と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX333と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX334と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX335と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX336と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX337と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX338と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX339と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX340と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX341と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX342と記す）。 Formula (L-10)
Figure JPOXMLDOC01-appb-C000130
 In the compound represented by the formula, R 4 is a methyl group, R 5 is a methyl group, R B is a methyl group, and R A is any of the substituents described in [Table A12] to [Table A35] Compounds that are groups (hereinafter referred to as compound group SX325).
In the compounds represented by formula (L-10), R 4 is a methyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX326).
In the compounds represented by formula (L-10), R 4 is a methyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX327).
In the compounds represented by formula (L-10), R 4 is a methyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX328).
In the compound represented by the formula (L-10), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX329).
In the compound represented by the formula (L-10), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX330).
In the compounds represented by formula (L-10), R 4 is an ethyl group, R 5 is a methyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX331).
In the compounds represented by formula (L-10), R 4 is an ethyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX332).
In the compound represented by formula (L-10), R 4 is an ethyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX333).
In the compounds represented by formula (L-10), R 4 is an ethyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX334).
In the compound represented by the formula (L-10), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX335).
In the compound represented by the formula (L-10), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX336).
In the compound represented by the formula (L-10), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX 337).
In the compound represented by the formula (L-10), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX338).
In the compound represented by the formula (L-10), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX339).
In the compound represented by the formula (L-10), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX340).
In the compounds represented by formula (L-10), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX341).
In the compound represented by the formula (L-10), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any substituent as described in (following, it is described as compound group SX342).
　式（Ｌ－１０）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX343と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX344と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX345と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX346と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX347と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX348と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX349と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX350と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX351と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX352と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX353と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX354と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX355と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX356と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX357と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX358と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX359と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX360と記す）。 In the compounds represented by formula (L-10), R 4 is a methyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX343).
In the compounds represented by formula (L-10), R 4 is a methyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX344).
In the compounds represented by formula (L-10), R 4 is a methyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX345).
In the compounds represented by formula (L-10), R 4 is a methyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX346).
In the compound represented by the formula (L-10), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX347).
In the compound represented by the formula (L-10), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX348).
In the compound represented by the formula (L-10), R 4 is an ethyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX 349).
In the compounds represented by formula (L-10), R 4 is an ethyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX350).
In the compounds represented by formula (L-10), R 4 is an ethyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX351).
In the compounds represented by formula (L-10), R 4 is an ethyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX352).
In the compound represented by the formula (L-10), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX353).
In the compound represented by the formula (L-10), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX354).
In the compound represented by the formula (L-10), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX355).
In the compound represented by the formula (L-10), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX356).
In the compound represented by the formula (L-10), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX357).
In the compound represented by the formula (L-10), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX358).
In the compound represented by the formula (L-10), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX359).
In the compound represented by the formula (L-10), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX360).
式（Ｌ－１１）
Figure JPOXMLDOC01-appb-C000131
 で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX361と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX362と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX363と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX364と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX365と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX366と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX367と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX368と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX369と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX370と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX371と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX372と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX373と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX374と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX375と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX376と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX377と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX378と記す）。 Formula (L-11)
Figure JPOXMLDOC01-appb-C000131
 In the compound represented by the formula, R 4 is a methyl group, R 5 is a methyl group, R B is a methyl group, and R A is any of the substituents described in [Table A12] to [Table A35] Compounds that are groups (hereinafter referred to as compound group SX361).
In the compounds represented by formula (L-11), R 4 is a methyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX362).
In the compound represented by formula (L-11), R 4 is a methyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX363).
In the compounds represented by formula (L-11), R 4 is a methyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX364).
In the compound represented by the formula (L-11), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX365).
In the compound represented by the formula (L-11), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX366).
In the compounds represented by formula (L-11), R 4 is an ethyl group, R 5 is a methyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX367).
In the compounds represented by formula (L-11), R 4 is an ethyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX368).
In the compounds represented by formula (L-11), R 4 is an ethyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX369).
In the compounds represented by formula (L-11), R 4 is an ethyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX370).
In the compound represented by the formula (L-11), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX371).
In the compound represented by the formula (L-11), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX372).
In the compound represented by the formula (L-11), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX 373).
In the compound represented by the formula (L-11), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX 374).
In the compound represented by the formula (L-11), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX375).
In the compound represented by the formula (L-11), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX376).
In the compounds represented by formula (L-11), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is a substituent in any one of-(It is described as compound group SX377 hereafter.).
In the compound represented by formula (L-11), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX378).
　式（Ｌ－１１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX379と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX380と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX381と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX382と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX383と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX384と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX385と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX386と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX387と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX388と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX389と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX390と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX391と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX392と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX393と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX394と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX395と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX396と記す）。 In the compounds represented by formula (L-11), R 4 is a methyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX379).
In the compounds represented by formula (L-11), R 4 is a methyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX380).
In the compounds represented by formula (L-11), R 4 is a methyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX381).
In the compounds represented by formula (L-11), R 4 is a methyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX382).
In the compound represented by the formula (L-11), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX383).
In the compound represented by the formula (L-11), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX384).
In the compounds represented by formula (L-11), R 4 is an ethyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX385).
In the compounds represented by formula (L-11), R 4 is an ethyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX386).
In the compounds represented by formula (L-11), R 4 is an ethyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX387).
In the compounds represented by formula (L-11), R 4 is an ethyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX388).
In the compound represented by the formula (L-11), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX 389).
In the compound represented by the formula (L-11), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX390).
In the compound represented by the formula (L-11), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX391).
In the compound represented by the formula (L-11), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX392).
In the compound represented by the formula (L-11), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX393).
In the compound represented by the formula (L-11), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX394).
In the compound represented by the formula (L-11), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX395).
In the compound represented by formula (L-11), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX396).
式（Ｌ－１２）
Figure JPOXMLDOC01-appb-C000132
 で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX397と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX398と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX399と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX400と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX401と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX402と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX403と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX404と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX405と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX406と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX407と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX408と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX409と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX410と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX411と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX412と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがメチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX413と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲBがエチル基であり、ＲAが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX414と記す）。 Formula (L-12)
Figure JPOXMLDOC01-appb-C000132
 In the compound represented by the formula, R 4 is a methyl group, R 5 is a methyl group, R B is a methyl group, and R A is any of the substituents described in [Table A12] to [Table A35] Compounds that are groups (hereinafter referred to as compound group SX397).
In the compounds represented by formula (L-12), R 4 is a methyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX398).
In the compounds represented by formula (L-12), R 4 is a methyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX399).
In the compounds represented by formula (L-12), R 4 is a methyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX400).
In the compound represented by the formula (L-12), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX401).
In the compound represented by the formula (L-12), R 4 is a methyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX402).
In the compounds represented by formula (L-12), R 4 is an ethyl group, R 5 is a methyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX403).
In the compounds represented by formula (L-12), R 4 is an ethyl group, R 5 is a methyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX404).
In the compounds represented by formula (L-12), R 4 is an ethyl group, R 5 is an ethyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX405).
In the compounds represented by formula (L-12), R 4 is an ethyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX406).
In the compound represented by the formula (L-12), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX407).
In the compound represented by the formula (L-12), R 4 is an ethyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX408).
In the compound represented by the formula (L-12), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX409).
In the compound represented by the formula (L-12), R 4 is a cyclopropyl group, R 5 is a methyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX410).
In the compound represented by the formula (L-12), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is a methyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX411).
In the compound represented by the formula (L-12), R 4 is a cyclopropyl group, R 5 is an ethyl group, R B is an ethyl group, and R A is [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX412).
In the compound represented by formula (L-12), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is a methyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX413).
In the compound represented by formula (L-12), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R B is an ethyl group, and R A is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX414).
　式（Ｌ－１２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX415と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX416と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX417と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX418と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX419と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX420と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX421と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX422と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX423と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX424と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX425と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX426と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX427と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX428と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX429と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX430と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがメチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX431と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲAがエチル基であり、ＲBが、［表Ａ１２］～［表Ａ３５］に記載のいずれかの置換基である化合物（以下、化合物群SX432と記す）。 In the compounds represented by formula (L-12), R 4 is a methyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX415).
In the compounds represented by formula (L-12), R 4 is a methyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX416).
In the compounds represented by formula (L-12), R 4 is a methyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX417).
In the compounds represented by formula (L-12), R 4 is a methyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX418).
In the compound represented by the formula (L-12), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX419).
In the compound represented by the formula (L-12), R 4 is a methyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX420).
In the compounds represented by formula (L-12), R 4 is an ethyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX421).
In the compounds represented by formula (L-12), R 4 is an ethyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX422).
In the compound represented by formula (L-12), R 4 is an ethyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described below (hereinafter referred to as compound group SX423).
In the compounds represented by formula (L-12), R 4 is an ethyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds that are any of the substituents described below (hereinafter referred to as compound group SX424).
In the compound represented by the formula (L-12), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX425).
In the compound represented by the formula (L-12), R 4 is an ethyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX426).
In the compound represented by the formula (L-12), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX427).
In the compound represented by the formula (L-12), R 4 is a cyclopropyl group, R 5 is a methyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX428).
In the compound represented by the formula (L-12), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX429).
In the compound represented by the formula (L-12), R 4 is a cyclopropyl group, R 5 is an ethyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] Compounds which are any of the substituents described in (hereinafter referred to as compound group SX430).
In the compound represented by the formula (L-12), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is a methyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is a substituent in any one of-(It is hereafter described as compound group SX431).
In the compound represented by formula (L-12), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, R A is an ethyl group, and R B is a group represented by [Table A12] to [Table A35] ] The compound which is any one of the substituents as described in the following (hereinafter referred to as compound group SX432).
　式（Ｌ－１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX433と記す）。 In the compound represented by the formula (L-1), R 4 is a methyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX433).
Figure JPOXMLDOC01-appb-T000133
Figure JPOXMLDOC01-appb-T000133
Figure JPOXMLDOC01-appb-T000134
Figure JPOXMLDOC01-appb-T000134
Figure JPOXMLDOC01-appb-T000135
Figure JPOXMLDOC01-appb-T000135
Figure JPOXMLDOC01-appb-T000136
Figure JPOXMLDOC01-appb-T000136
Figure JPOXMLDOC01-appb-T000137
Figure JPOXMLDOC01-appb-T000137
Figure JPOXMLDOC01-appb-T000138
Figure JPOXMLDOC01-appb-T000138
　式（Ｌ－１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX434と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX435と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX436と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX437と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX438と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX439と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX440と記す）。
　式（Ｌ－１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX441と記す）。 In the compound represented by the formula (L-1), R 4 is a methyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX434).
In the compound represented by the formula (L-1), R 4 is a methyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX435).
In the compound represented by the formula (L-1), R 4 is an ethyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds that are combinations (hereinafter referred to as compound group SX436).
In the compound represented by the formula (L-1), R 4 is an ethyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds that are combinations (hereinafter referred to as compound group SX437).
In the compound represented by the formula (L-1), R 4 is an ethyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX438).
In the compound represented by the formula (L-1), R 4 is a cyclopropyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX439).
In the compound represented by the formula (L-1), R 4 is a cyclopropyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX440).
In the compound represented by the formula (L-1), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX441).
　式（Ｌ－２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX442と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX443と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX444と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX445と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX446と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX447と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX448と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX449と記す）。
　式（Ｌ－２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX450と記す）。 In the compound represented by the formula (L-2), R 4 is a methyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX442).
In the compound represented by the formula (L-2), R 4 is a methyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX443).
In the compound represented by the formula (L-2), R 4 is a methyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX444).
In the compound represented by the formula (L-2), R 4 is an ethyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX445).
In the compound represented by the formula (L-2), R 4 is an ethyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX446).
In the compound represented by the formula (L-2), R 4 is an ethyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX447).
In the compound represented by the formula (L-2), R 4 is a cyclopropyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX448).
In the compound represented by the formula (L-2), R 4 is a cyclopropyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX449).
In the compound represented by formula (L-2), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX450).
　式（Ｌ－３）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX451と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX452と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX453と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX454と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX455と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX456と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX457と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX458と記す）。
　式（Ｌ－３）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX459と記す）。 In the compound represented by the formula (L-3), R 4 is a methyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds that are combinations (hereinafter referred to as compound group SX451).
In the compound represented by the formula (L-3), R 4 is a methyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX452).
In the compound represented by the formula (L-3), R 4 is a methyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] And a compound (hereinafter referred to as a compound group SX453) which is a combination of
In the compound represented by the formula (L-3), R 4 is an ethyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX454).
In the compound represented by the formula (L-3), R 4 is an ethyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX455).
In the compound represented by the formula (L-3), R 4 is an ethyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX456).
In the compound represented by the formula (L-3), R 4 is a cyclopropyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX457).
In the compound represented by the formula (L-3), R 4 is a cyclopropyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX458).
In the compound represented by the formula (L-3), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX459).
　式（Ｌ－４）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX460と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX461と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX462と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX463と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX464と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX465と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX466と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX467と記す）。
　式（Ｌ－４）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX468と記す）。 In the compound represented by the formula (L-4), R 4 is a methyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX460).
In the compound represented by the formula (L-4), R 4 is a methyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX461).
In the compound represented by the formula (L-4), R 4 is a methyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX462).
In the compound represented by the formula (L-4), R 4 is an ethyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX463).
In the compound represented by the formula (L-4), R 4 is an ethyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX464).
In the compound represented by the formula (L-4), R 4 is an ethyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are a combination of (hereinafter referred to as compound group SX465).
In the compound represented by the formula (L-4), R 4 is a cyclopropyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX466).
In the compound represented by the formula (L-4), R 4 is a cyclopropyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX467).
In the compound represented by the formula (L-4), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX468).
　式（Ｌ－５）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX469と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX470と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX471と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX472と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX473と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX474と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX475と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX476と記す）。
　式（Ｌ－５）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX477と記す）。 In the compound represented by formula (L-5), R 4 is a methyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX469).
In the compound represented by formula (L-5), R 4 is a methyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX470).
In the compound represented by the formula (L-5), R 4 is a methyl group, R 5 is a cyclopropyl group, and R A and R B are any one of [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX471).
In the compound represented by formula (L-5), R 4 is an ethyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX472).
In the compound represented by the formula (L-5), R 4 is an ethyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX473).
In the compound represented by the formula (L-5), R 4 is an ethyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX474).
In the compound represented by the formula (L-5), R 4 is a cyclopropyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are a combination of (hereinafter referred to as compound group SX475).
In the compound represented by the formula (L-5), R 4 is a cyclopropyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] And a compound (hereinafter referred to as a compound group SX476) which is a combination of
In the compound represented by formula (L-5), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX477).
　式（Ｌ－６）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX478と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX479と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX480と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX481と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX482と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX483と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX484と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX485と記す）。
　式（Ｌ－６）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX486と記す）。 In the compound represented by the formula (L-6), R 4 is a methyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX478).
In the compound represented by the formula (L-6), R 4 is a methyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX479).
In the compound represented by the formula (L-6), R 4 is a methyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX480).
In the compound represented by the formula (L-6), R 4 is an ethyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX481).
In the compound represented by the formula (L-6), R 4 is an ethyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX482).
In the compound represented by the formula (L-6), R 4 is an ethyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX483).
In the compound represented by the formula (L-6), R 4 is a cyclopropyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX484).
In the compound represented by the formula (L-6), R 4 is a cyclopropyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX485).
In the compound represented by formula (L-6), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX486).
　式（Ｌ－７）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX487と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX488と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX489と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX490と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX491と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX492と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX493と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX494と記す）。
　式（Ｌ－７）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX495と記す）。 In the compound represented by the formula (L-7), R 4 is a methyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX487).
In the compound represented by the formula (L-7), R 4 is a methyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX488).
In the compound represented by the formula (L-7), R 4 is a methyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are a combination of (hereinafter referred to as compound group SX489).
In the compound represented by the formula (L-7), R 4 is an ethyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX490).
In the compound represented by the formula (L-7), R 4 is an ethyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX491).
In the compound represented by the formula (L-7), R 4 is an ethyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX492).
In the compound represented by the formula (L-7), R 4 is a cyclopropyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are a combination of (hereinafter, referred to as compound group SX493).
In the compound represented by the formula (L-7), R 4 is a cyclopropyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX494).
In the compound represented by formula (L-7), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX495).
　式（Ｌ－８）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX496と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX497と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX498と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX499と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX500と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX501と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX502と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX503と記す）。
　式（Ｌ－８）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX504と記す）。 In the compound represented by the formula (L-8), R 4 is a methyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX496).
In the compound represented by the formula (L-8), R 4 is a methyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX497).
In the compound represented by the formula (L-8), R 4 is a methyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are a combination of (hereinafter referred to as compound group SX 498).
In the compound represented by the formula (L-8), R 4 is an ethyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX499).
In the compound represented by the formula (L-8), R 4 is an ethyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX500).
In the compound represented by the formula (L-8), R 4 is an ethyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX501).
In the compound represented by the formula (L-8), R 4 is a cyclopropyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX502).
In the compound represented by the formula (L-8), R 4 is a cyclopropyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX503).
In the compound represented by formula (L-8), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX504).
　式（Ｌ－９）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX505と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX506と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX507と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX508と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX509と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX510と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX511と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX512と記す）。
　式（Ｌ－９）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX513と記す）。 In the compound represented by the formula (L-9), R 4 is a methyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX505).
In the compound represented by the formula (L-9), R 4 is a methyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX506).
In the compound represented by the formula (L-9), R 4 is a methyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX507).
In the compound represented by the formula (L-9), R 4 is an ethyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX508).
In the compound represented by the formula (L-9), R 4 is an ethyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX509).
In the compound represented by the formula (L-9), R 4 is an ethyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX510).
In the compound represented by the formula (L-9), R 4 is a cyclopropyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX511).
In the compound represented by the formula (L-9), R 4 is a cyclopropyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX512).
In the compound represented by the formula (L-9), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX513).
　式（Ｌ－１０）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX514と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX515と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX516と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX517と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX518と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX519と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX520と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX521と記す）。
　式（Ｌ－１０）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX522と記す）。 In the compound represented by the formula (L-10), R 4 is a methyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX514).
In the compound represented by the formula (L-10), R 4 is a methyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX515).
In the compound represented by the formula (L-10), R 4 is a methyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX516).
In the compound represented by the formula (L-10), R 4 is an ethyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX517).
In the compound represented by the formula (L-10), R 4 is an ethyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX518).
In the compound represented by the formula (L-10), R 4 is an ethyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX519).
In the compound represented by the formula (L-10), R 4 is a cyclopropyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX520).
In the compound represented by the formula (L-10), R 4 is a cyclopropyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX521).
In the compound represented by the formula (L-10), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX522).
　式（Ｌ－１１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX523と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX524と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX525と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX526と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX527と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX528と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX529と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX530と記す）。
　式（Ｌ－１１）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX531と記す）。 In the compound represented by formula (L-11), R 4 is a methyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX523).
In the compound represented by the formula (L-11), R 4 is a methyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX524).
In the compound represented by formula (L-11), R 4 is a methyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX525).
In the compound represented by formula (L-11), R 4 is an ethyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX526).
In the compound represented by the formula (L-11), R 4 is an ethyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX527).
In the compound represented by formula (L-11), R 4 is an ethyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX528).
In the compound represented by formula (L-11), R 4 is a cyclopropyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX529).
In the compound represented by formula (L-11), R 4 is a cyclopropyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX530).
In the compound represented by formula (L-11), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX531).
　式（Ｌ－１２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX532と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX533と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がメチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX534と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX535と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX536と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がエチル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX537と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がメチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX538と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がエチル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX539と記す）。
　式（Ｌ－１２）で示される化合物において、Ｒ4がシクロプロピル基であり、Ｒ5がシクロプロピル基であり、ＲA及びＲBが、［表Ａ３６］～［表Ａ４１］に記載のいずれかの組み合わせである化合物（以下、化合物群SX540と記す）。 In the compound represented by the formula (L-12), R 4 is a methyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX532).
In the compound represented by the formula (L-12), R 4 is a methyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX533).
In the compound represented by the formula (L-12), R 4 is a methyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX534).
In the compound represented by the formula (L-12), R 4 is an ethyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX535).
In the compound represented by the formula (L-12), R 4 is an ethyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations (hereinafter referred to as compound group SX536).
In the compound represented by the formula (L-12), R 4 is an ethyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX537).
In the compound represented by the formula (L-12), R 4 is a cyclopropyl group, R 5 is a methyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX538).
In the compound represented by the formula (L-12), R 4 is a cyclopropyl group, R 5 is an ethyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Compounds which are combinations of (hereinafter referred to as compound group SX539).
In the compound represented by formula (L-12), R 4 is a cyclopropyl group, R 5 is a cyclopropyl group, and R A and R B are any of those described in [Table A36] to [Table A41] Or a combination of compounds (hereinafter referred to as compound group SX540).
　次に本発明化合物Ｘの製剤例を示す。なお、部は重量部を表す。また、本発明化合物Ｓは、化合物群SX1～SX540に記載の化合物を表す。 Next, formulation examples of the compound X of the present invention are shown. In addition, a part represents a weight part. Further, the compound S of the present invention represents the compounds described in the compound groups SX1 to SX540.
製剤例１
　本発明化合物Ｓのいずれか１種１０部を、キシレン３５部とＤＭＦ３５部との混合物に混合し、そこにポリオキシエチレンスチリルフェニルエーテル１４部及びドデシルベンゼンスルホン酸カルシウム６部を加え、混合して製剤を得る。 Formulation example 1
10 parts of any one of the compound S of the present invention is mixed into a mixture of 35 parts of xylene and 35 parts of DMF, and 14 parts of polyoxyethylene styryl phenyl ether and 6 parts of calcium dodecylbenzene sulfonate are added thereto and mixed. Obtain a formulation.
製剤例２
　ラウリル硫酸ナトリウム４部、リグニンスルホン酸カルシウム２部、湿式シリカ２０部及び珪藻土５４部を混合し、更に本発明化合物Ｓのいずれか１種２０部を加え、混合して製剤を得る。 Formulation example 2
4 parts of sodium lauryl sulfate, 2 parts of calcium lignin sulfonate, 20 parts of wet silica and 54 parts of diatomaceous earth are mixed, and further 20 parts of any one of the compound S of the present invention is added and mixed to obtain a preparation.
製剤例３
　本発明化合物Ｓのいずれか１種２部に、湿式シリカ１部、リグニンスルホン酸カルシウム２部、ベントナイト３０部及びカオリンクレー６５部を加え混合する。ついで、この混合物に適当量の水を加え、さらに撹拌し、造粒機で造粒し、通風乾燥して製剤を得る。 Formulation example 3
To 2 parts of any one compound of the present invention S, 1 part of wet silica, 2 parts of calcium lignin sulfonate, 30 parts of bentonite and 65 parts of kaolin clay are added and mixed. Then, an appropriate amount of water is added to the mixture, and the mixture is further stirred, granulated with a granulator and blow-dried to obtain a preparation.
製剤例４
　本発明化合物Ｓのいずれか１種１部を適当量のアセトンに混合し、これに湿式シリカ５部、酸性リン酸イソプロピル０．３部及びカオリンクレー９３．７部を加え、十分混合し、アセトンを蒸発除去して製剤を得る。 Formulation example 4
1 part of any one of the compound S of the present invention is mixed with an appropriate amount of acetone, 5 parts of wet silica, 0.3 parts of isopropyl acid phosphate and 93.7 parts of kaolin clay are added thereto and thoroughly mixed. Is removed by evaporation to obtain a preparation.
製剤例５
　ポリオキシエチレンアルキルエーテルサルフェートアンモニウム塩及び湿式シリカの混合物（重量比１：１）３５部と、本発明化合物Ｓのいずれか１種２０部と、水４５部とを十分に混合し、製剤を得る。 Formulation example 5
A formulation is obtained by thoroughly mixing 35 parts of a mixture of polyoxyethylene alkyl ether sulfate ammonium salt and wet silica (weight ratio 1: 1), 20 parts of any one of the compound S of the present invention and 45 parts of water .
製剤例６
　本発明化合物Ｓのいずれか１種０．１部をキシレン５部及びトリクロロエタン５部の混合物に混合し、これをケロシン８９．９部に混合して製剤を得る。 Formulation Example 6
0.1 part of any one compound of the present invention S is mixed with a mixture of 5 parts of xylene and 5 parts of trichloroethane, and this is mixed with 89.9 parts of kerosene to obtain a preparation.
製剤例７
　本発明化合物Ｓのいずれか１種１０ｍｇをアセトン０．５ｍＬに混合し、この溶液を、動物用固形飼料粉末（飼育繁殖用固形飼料粉末ＣＥ－２、日本クレア株式会社商品）５ｇに滴下し、均一に混合する。ついでアセトンを蒸発乾燥させて毒餌剤を得る。 Formulation example 7
10 mg of any one compound of the present invention S is mixed with 0.5 mL of acetone, and this solution is added dropwise to 5 g of solid feed powder for animals (solid feed powder for rearing and breeding CE-2, a product of CLEA Japan, Inc.), Mix evenly. The acetone is then evaporated to dryness to obtain a toxic bait.
製剤例８
　本発明化合物Ｓのいずれか１種０．１部、ネオチオゾール（中央化成株式会社製）４９．９部をエアゾール缶に入れ、エアゾールバルブを装着した後、ジメチルエーテル２５部、ＬＰＧ２５部を充填し振とうを加え、アクチュエータを装着することにより油剤エアゾールを得る。 Formulation Example 8
0.1 parts of any one compound of the present invention S and 49.9 parts of neothiozole (manufactured by Chuo Kasei Co., Ltd.) are put into an aerosol can, fitted with an aerosol valve, filled with 25 parts of dimethyl ether and 25 parts of LPG and shaken. To obtain an oil aerosol by mounting the actuator.
製剤例９
　本発明化合物Ｓのいずれか１種０．６部、２，６－ジ－ｔｅｒｔ－ブチル－４－メチルフェノール０．０１部、キシレン５部、ケロシン３．３９部及び１部のレオドール（登録商標）ＭＯ－６０を混合したものと、蒸留水５０部とをエアゾール容器に充填し、バルブを装着した後、該バルブを通じてＬＰＧ４０部を充填して水性エアゾールを得る。 Formulation Example 9
0.6 part of any one compound of the present invention S, 0.01 part of 2,6-di-tert-butyl-4-methylphenol, 5 parts of xylene, 3.39 parts of kerosene and 1 part of Reodol (registered trademark) ) A mixture of MO-60 and 50 parts of distilled water is filled into an aerosol container, and a valve is attached, and then 40 parts of LPG is filled through the valve to obtain an aqueous aerosol.
製剤例１０
　本発明化合物Ｓのいずれか１種０．１ｇを、プロピレングリコール２ｍＬに混合し、４．０ｃｍ×４．０ｃｍ、厚さ１．２ｃｍのセラミック板に含浸させて、加熱式くん煙剤を得る。 Formulation Example 10
0.1 g of any one of the compounds S of the present invention is mixed with 2 mL of propylene glycol and impregnated into a 4.0 cm × 4.0 cm, 1.2 cm thick ceramic plate to obtain a heated smoking agent.
製剤例１１
　本発明化合物Ｓのいずれか１種５部とエチレン－メタクリル酸メチル共重合体（共重合体の総重量に対するメタクリル酸メチルの割合：１０重量％）９５部とを溶融混練し、得られた混練物を押出し成型機から押出し、長さ１５ｃｍ、直径３ｍｍの棒状成型体を得る。 Formulation example 11
Kneading obtained by melt-kneading 5 parts of any one compound of the present invention S and 95 parts of ethylene-methyl methacrylate copolymer (ratio of methyl methacrylate to total weight of copolymer: 10% by weight) The product is extruded from an extrusion molding machine to obtain a rod-shaped molding having a length of 15 cm and a diameter of 3 mm.
製剤例１２
　本発明化合物Ｓのいずれか１種５部及び軟質塩化ビニル樹脂９５部を溶融混練し、得られた混練物を押出し成型機から押出し、長さ１５ｃｍ、直径３ｍｍの棒状成型体を得る。 Formulation example 12
Five parts of any one compound of the present invention S and 95 parts of a soft vinyl chloride resin are melt-kneaded, and the obtained kneaded product is extruded from an extrusion molding machine to obtain a rod-like molding having a length of 15 cm and a diameter of 3 mm.
製剤例１３
　本発明化合物Ｓのいずれか１種１００ｍｇ、ラクトース６８．７５ｍｇ、トウモロコシデンプン２３７．５ｍｇ、微結晶性セルロース４３．７５ｍｇ、ポリビニルピロリドン１８．７５ｍｇ、ナトリウムカルボキシメチルデンプン２８．７５ｍｇ、及びステアリン酸マグネシウム２．５ｍｇを混合し、得られた混合物を適切な大きさに圧縮して、錠剤を得る。 Formulation example 13
100 mg of any one of the compounds S of the present invention, 68.75 mg of lactose, 237.5 mg of corn starch, 43.75 mg of microcrystalline cellulose, 18.75 mg of polyvinylpyrrolidone, 28.75 mg of sodium carboxymethyl starch, and magnesium stearate2. 5 mg is mixed and the resulting mixture is compressed to a suitable size to obtain tablets.
製剤例１４
　本発明化合物Ｓのいずれか１種２５ｍｇ、ラクトース６０ｍｇ、トウモロコシデンプン２５ｍｇ、カルメロースカルシウム６ｍｇ、及び５％ヒドロキシプロピルメチルセルロース適量を混合し、得られた混合物をハードシェルゼラチンカプセル又はヒドロキシプロピルメチルセルロースカプセルに充填し、カプセル剤を得る。 Formulation example 14
25 mg of any one of the compound S of the present invention, 60 mg of lactose, 25 mg of corn starch, 6 mg of carmellose calcium, and 5% hydroxypropyl methylcellulose, and mixing the obtained mixture into hard shell gelatin capsules or hydroxypropyl methylcellulose capsules And get capsules.
製剤例１５
　本発明化合物Ｓのいずれか１種１００ｍｇ、フマル酸５００ｍｇ、塩化ナトリウム２０００ｍｇ、メチルパラベン１５０ｍｇ、プロピルパラベン５０ｍｇ、顆粒糖２５０００ｍｇ、ソルビトール（７０％溶液）１３０００ｍｇ、Ｖｅｅｇｕｍ（登録商標）Ｋ１００ｍｇ、香料３５ｍｇ、及び着色料５００ｍｇに、最終容量が１００ｍＬとなるよう蒸留水を加え、混合して、経口投与用サスペンジョンを得る。 Formulation example 15
100 mg of any one compound of the present invention S, fumaric acid 500 mg, sodium chloride 2000 mg, methyl paraben 150 mg, propyl paraben 50 mg, granular sugar 25000 mg, sorbitol (70% solution) 13000 mg, Veegum K 100 mg, perfume 35 mg, and coloring Distilled water is added to a final volume of 100 mL and mixed to give a suspension for oral administration.
製剤例１６
　本発明化合物Ｓのいずれか１種５重量％を、乳化剤　５重量％、ベンジルアルコール３重量％、及びプロピレングリコール３０重量％に混合し、この溶液のｐＨが６．０～６．５となるようにリン酸塩緩衝液を加えた後、残部として水を加えて、経口投与用液剤を得る。 Formulation example 16
5% by weight of any one of the compound S of the present invention is mixed with 5% by weight of an emulsifier, 3% by weight of benzyl alcohol and 30% by weight of propylene glycol so that the pH of this solution becomes 6.0 to 6.5. After adding phosphate buffer to the mixture, water is added as the remainder to obtain a solution for oral administration.
製剤例１７
　分留ヤシ油５７重量％及び３重量％のポリソルベート８５中にジステアリン酸アルミニウム５重量％を加え、加熱により分散させる。これを室温に冷却し、その油状ビヒクル中にサッカリン２５重量％を分散させる。これに本発明化合物Ｓのいずれか１種１０重量％を配分し、経口投与用ペースト状製剤を得る。 Formulation example 17
5% by weight of aluminum distearate is added to 57% by weight of fractionated palm oil and 3% by weight of polysorbate 85 and dispersed by heating. It is cooled to room temperature and 25% by weight of saccharin is dispersed in the oily vehicle. To this, 10% by weight of any one compound of the present invention S is distributed to obtain a pasty preparation for oral administration.
製剤例１８
　本発明化合物Ｓのいずれか１種５重量％を石灰石粉９５重量％と混合し、湿潤顆粒形成法を使用して経口投与用粒剤を得る。 Formulation example 18
5% by weight of any one of the compounds S of the present invention is mixed with 95% by weight of limestone powder to obtain granules for oral administration using a wet granulation method.
製剤例１９
　本発明化合物Ｓのいずれか１種５部をジエチレングリコールモノエチルエーテル８０部に混合し、これに炭酸プロピレン１５部を混合して、スポットオン液剤を得る。 Formulation example 19
5 parts of any one compound of the present invention S is mixed with 80 parts of diethylene glycol monoethyl ether, and 15 parts of propylene carbonate is mixed therewith to obtain a spot-on solution.
製剤例２０
　本発明化合物Ｓのいずれか１種１０部をジエチレングリコールモノエチルエーテル７０部に混合し、これに２－オクチルドデカノール２０部を混合して、ポアオン液剤を得る。 Formulation example 20
Ten parts of any one compound of the present invention S is mixed with 70 parts of diethylene glycol monoethyl ether, and 20 parts of 2-octyldodecanol is mixed therewith to obtain a pour-on liquid agent.
製剤例２１
　本発明化合物Ｓのいずれか１種０．５部に、ラウリル硫酸トリエタノールアミンの４２％水溶液６０部、及びプロピレングリコール２０部を添加し、均一溶液になるまで十分撹拌した後、水１９．５部を加えてさらに十分撹拌し、均一溶液のシャンプー剤を得る。 Formulation example 21
60 parts of a 42% aqueous solution of triethanolamine lauryl sulfate and 20 parts of propylene glycol are added to 0.5 part of any one compound of the present invention S, and after sufficient stirring until a homogeneous solution is obtained, water 19.5 Add parts and stir well to obtain a shampoo solution of uniform solution.
製剤例２２
　本発明化合物Ｓのいずれか１種０．１５重量％、動物飼料９５重量％、並びに、第２リン酸カルシウム、珪藻土、Aerosil（登録商標）、及びカーボネート（又はチョーク）からなる混合物４．８５重量％を十分撹拌し、動物用飼料プレミックスを得る。 Formulation example 22
0.15% by weight of any one compound of the present invention S, 95% by weight of animal feed, and 4.85% by weight of a mixture consisting of dibasic calcium phosphate, diatomaceous earth, Aerosil (registered trademark), and carbonate (or chalk) Stir well to obtain an animal feed premix.
製剤例２３
　本発明化合物Ｓのいずれか１種７．２ｇ、及び９２．８ｇのホスコ（登録商標）Ｓ－５５を１００℃で混合し、坐剤形に注いで、冷却固化して、坐剤を得る。 Formulation example 23
7.2 g of any one of the compounds S of the present invention and 92.8 g of FOSCO.RTM. S-55 are mixed at 100.degree. C., poured into a suppository form, and solidified by cooling to obtain a suppository.
　次に、本発明化合物Ｘの有害節足動物に対する効力を試験例により示す。下記試験例において、試験は２５℃で行った。 Next, the efficacy of the present compound X against harmful arthropods is shown by test examples. In the following test examples, the test was performed at 25 ° C.
試験法１
　供試化合物を製剤例５に記載の方法に準じて製剤とし、これにシンダイン（登録商標）を０．０３容量％含有する水を加え、供試化合物を所定濃度含有する希釈液を調製する。
　容器に植えたキュウリ（Cucumis sativus）苗（第２本葉展開期）にワタアブラムシ（全ステージ）約３０頭を接種する。１日後、この苗に該希釈液を１０ｍＬ／苗の割合で散布する。更に５日後、生存虫数を調査し、以下の式により防除価を求める。
　防除価（％）＝｛１－（Ｃｂ×Ｔａｉ）／（Ｃａｉ×Ｔｂ）｝×１００
なお、式中の文字は以下の意味を表す。
　　　Ｃｂ：無処理区の供試虫数
　　　Ｃａｉ：無処理区の調査時の生存虫数
　　　Ｔｂ：処理区の供試虫数
　　　Ｔａｉ：処理区の調査時の生存虫数
　ここで無処理区とは、供試化合物を使用しないこと以外は処理区と同じ操作をする区を意味する。 Test method 1
A test compound is prepared according to the method described in Preparation Example 5, and water containing 0.03% by volume of Syndyne (registered trademark) is added thereto to prepare a diluted solution containing a predetermined concentration of the test compound.
About 30 cotton aphids (all stages) are inoculated to cucumber (Cucumis sativus) seedlings (the second true leaf development stage) planted in a container. One day later, the seedlings are sprayed with the diluted solution at a rate of 10 mL / seedling. After 5 days, the number of surviving insects is examined, and the control value is determined by the following equation.
Control value (%) = {1- (Cb × Tai) / (Cai × Tb)} × 100
The letters in the formula have the following meanings.
Cb: Number of tested insects in untreated area Cai: Number of surviving insects in survey in untreated area Tb: Number of tested insects in treated zone Tai: Number of surviving insects in survey in treated area Here, untreated group means It means a zone that performs the same operation as the treatment zone except that the test compound is not used.
試験例１－１
　所定濃度を５００ｐｐｍとし、下記の本発明化合物を供試化合物として用いて試験法１に従って試験を行った結果、下記の本発明化合物はいずれも防除価９０％以上を示した。
本発明化合物：１、２、３、５、６、７、８、９、１２、１３、１４、１５、１７、１８、２１、２２、２４、２５、２７、２８、３０、３１、３２、３３、３４、３５、３６、３７、３８、３９、４１、４３、４４、４５、４６、４８、４９、５０、５１、５２、５４、５５、５６、５７、５９、６０、６１、６２、６３、６５、６６、６７、６８、７０、７１、７２、８１、８３、８４、８５、８７、８８、８９、９０、９１、９５、９６、９７、９８、１０１、１０２、１０３、１０４、１０５、１０６、１０７、１０８、１０９、１１２、１１４、１１６、１１７、１１８、１２０、１２３、１２４、１２６、１２７、１３１、１３４、１３５、１３６、１３８、１４０、１４２、１４６、１４７及び１５４ Test Example 1-1
As a result of conducting a test according to the test method 1 by setting a predetermined concentration to 500 ppm and using the following compound of the present invention as a test compound, each of the following compounds of the present invention showed a control value of 90% or more.
The compounds of the invention: 1, 2, 3, 5, 6, 7, 8, 9, 12, 13, 14, 15, 17, 18, 21, 22, 24, 25, 27, 28, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 41, 43, 44, 45, 46, 48, 49, 50, 51, 52, 54, 55, 56, 57, 59, 60, 61, 62, 63, 65, 66, 67, 68, 70, 71, 72, 81, 83, 84, 85, 88, 89, 90, 91, 95, 96, 97, 98, 101, 102, 103, 104, 105, 106, 107, 108, 109, 112, 114, 116, 117, 120, 124, 126, 127, 131, 134, 135, 136, 138, 140, 142, 146, 147 and 154
試験例１－２
　所定濃度を２００ｐｐｍとし、下記の本発明化合物を供試化合物として用いて試験法１に従って試験を行った結果、下記に記載の本発明化合物はいずれも防除価９０％以上を示した。
本発明化合物：１、５、６、８、９、２２、２７、３０、３１、３２、３３、３４、３５、４１、４６、５３、５６、５７、５８、５９、６０、６１、６２、６３、６４、７１、７２、８９、９２、９３、９７、１０５、１０６、１０７、１０８、１１２、１２０、１２２、１２３、１２４、１２５、１３５、１３８及び１５４ Test Example 1-2
As a result of conducting a test according to the test method 1 by setting a predetermined concentration to 200 ppm and using the following compound of the present invention as a test compound, all of the compounds of the present invention described below showed a control value of 90% or more.
The present invention compounds: 1, 5, 6, 8, 9, 22, 27, 30, 31, 32, 33, 34, 35, 41, 46, 53, 56, 57, 58, 59, 60, 61, 62, 63, 64, 71, 72, 89, 92, 93, 97, 105, 106, 107, 108, 112, 120, 122, 123, 124, 125, 135, 138 and 154
試験法２
　供試化合物を製剤例５に記載の方法に準じて製剤とし、これに水を加え、供試化合物を所定濃度含有する希釈液を調製する。
　容器に、７．７ｇの人工飼料（インセクタＬＦ、日本農産工業）を置き、これに該希釈液２ｍＬを灌注する。該人工飼料上にハスモンヨトウ４齢幼虫５頭を放す。５日後、生存虫数を数え次式より死虫率を求める。
　　　死虫率（％）＝（１－生存虫数／５）×１００ Test method 2
A test compound is formulated according to the method described in Formulation Example 5, water is added thereto, and a diluted solution containing the test compound at a predetermined concentration is prepared.
In a container, 7.7 g of artificial feed (Insector LF, Japan Agro-Industrial) is placed, and 2 mL of the diluted solution is irrigated therein. Release 5 4th instar larvae from the artificial feed. After 5 days, the number of living insects is counted and the mortality rate is determined from the following equation.
Mortality rate (%) = (1-number of surviving insects / 5) x 100
試験例２
　所定濃度を５００ｐｐｍとし、下記の本発明化合物を供試化合物として用いて試験法２に従って試験を行った結果、下記の本発明化合物はいずれも死虫率８０％以上を示した。
本発明化合物：１、４、６、８、９、２７、３０、３２、３４、３５、３６、４０、４３、５３、５６、６０、６３、６４、６８、９４及び９７ Test example 2
The test was conducted according to Test Method 2 using a compound of the present invention described below as a test compound at a predetermined concentration of 500 ppm. As a result, all of the compounds of the present invention described below showed a mortality of 80% or more.
The compounds of the present invention: 1, 4, 6, 8, 9, 27, 30, 32, 34, 35, 36, 40, 43, 53, 56, 60, 63, 64, 68, 94 and 97
試験法３
　供試化合物を製剤例５に記載の方法に準じて製剤とし、これにシンダイン（登録商標）を０．０３容量％含有する水を加え、供試化合物を所定濃度含有する希釈液を調製する。
　容器に植えたキャベツ（Brassicae oleracea）苗（第２～３本葉展開期）に該希釈液を２０ｍＬ／苗の割合で散布する。その後、この苗の茎葉部を切り取り、ろ紙を敷いた容器内に入れる。これにハスモンヨトウ２齢幼虫５頭を放す。５日後、生存虫数を数え、次式より死虫率を求める。
　　　死虫率％＝（１－生存虫数／５）×１００ Test method 3
A test compound is prepared according to the method described in Preparation Example 5, and water containing 0.03% by volume of Syndyne (registered trademark) is added thereto to prepare a diluted solution containing a predetermined concentration of the test compound.
The diluted solution is sprayed at a rate of 20 mL / seedling to cabbage (Brassicae oleracea) seedlings (second to third leaf development stage) planted in a container. After that, the stems and leaves of this seedling are cut and placed in a container covered with filter paper. Release 5 2nd instar larvae to this. After 5 days, the number of living worms is counted, and the mortality rate is calculated from the following equation.
Mortality rate% = (1-number of surviving insects / 5) x 100
試験例３
　所定濃度を５００ｐｐｍとし、下記の本発明化合物を供試化合物として用いて試験法３に従って試験を行った結果、下記の本発明化合物はいずれも死虫率８０％以上を示した。
本発明化合物：２８、２９、３７、４４、４５、４７、４９、５４、５５、６２、６７、７０、７３、８１、８３、８４、８８、９０、９５、９８、１０４、１０６、１０７、１０８、１０９、１１０、１１１、１１２、１１４、１１６、１１８、１２０、１２２、１２４、１２５、１２６、１２７、１３４、１３６、１３７、１３８、１４０、１５０、１５３及び１５４ Test Example 3
The compound of the present invention described below was used as a test compound and tested according to Test Method 3 with a predetermined concentration of 500 ppm. As a result, all of the compounds of the present invention showed a mortality of 80% or more.
The compounds of the present invention: 28, 29, 37, 44, 45, 47, 49, 54, 55, 62, 70, 73, 81, 83, 84, 88, 90, 95, 98, 104, 106, 107, 108, 109, 110, 111, 112, 114, 116, 118, 120, 122, 124, 125, 126, 127, 134, 136, 137, 138, 140, 150, 153 and 154
試験法４
　供試化合物を製剤例５に記載の方法に準じて製剤とし、これにシンダイン（登録商標）を０．０３容量％含有する水を加え、供試化合物を所定濃度含有する希釈液を調製する。
　容器に植えたキャベツ苗（第２～３本葉展開期）に該希釈液を２０ｍＬ／苗の割合で散布する。その後、この苗の茎葉部を切り取り、ろ紙を敷いた容器内に入れる。これにコナガ２齢幼虫５頭を放す。５日後、生存虫数を数え、次式より死虫率を求める。
　　　死虫率％＝（１－生存虫数／５）×１００ Test method 4
A test compound is prepared according to the method described in Preparation Example 5, and water containing 0.03% by volume of Syndyne (registered trademark) is added thereto to prepare a diluted solution containing a predetermined concentration of the test compound.
The diluted solution is sprayed at a rate of 20 mL / seedling to cabbage seedlings (second to third leaf development stage) planted in a container. After that, the stems and leaves of this seedling are cut and placed in a container covered with filter paper. Release five 2nd instar larvae to this. After 5 days, the number of living worms is counted, and the mortality rate is calculated from the following equation.
Mortality rate% = (1-number of surviving insects / 5) x 100
試験例４
　所定濃度を５００ｐｐｍとし、下記の本発明化合物を供試化合物として用いて試験法４に従って試験を行った結果、下記の本発明化合物はいずれも死虫率８０％以上を示した。
本発明化合物：１、２、３、５、６、１４、１９、２１、２２、２４、２５、２７、２８、２９、３０、３７、４０、４５、４６、４７、４９、５０、５１、５２、５３、５４、５５、５６、５７、６０、６１、６２、６４、６７、７１、７６、８１、８３、８８、８９、９０、９２、９６、９７、９８、１０１、１０２、１０３、１０４、１０５、１０６、１０７、１０８、１０９、１１０、１１１、１１２、１１４、１１５、１１６、１２０、１２２、１２３、１２４、１２５、１２６、１２７、１２８、１３２、１３３、１３４、１３５、１３６、１３７、１３８、１４０、１４１、１５０、１５１、１５３及び１５４ Test Example 4
The compound of the present invention described below was used as a test compound and tested according to Test Method 4 at a predetermined concentration of 500 ppm. As a result, all of the compounds of the present invention showed a mortality of 80% or more.
Compounds of the present invention: 1, 2, 3, 5, 6, 14, 19, 21, 22, 24, 25, 27, 28, 29, 30, 30, 40, 45, 46, 47, 49, 50, 51, 52, 53, 54, 55, 56, 57, 60, 61, 62, 64, 67, 71, 76, 81, 83, 88, 89, 90, 92, 96, 97, 98, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 114, 115, 116, 120, 122, 124, 125, 126, 127, 128, 132, 133, 134, 135, 136, 137, 138, 140, 141, 150, 151, 153 and 154
試験法５
　供試化合物を製剤例５に記載の方法に準じて製剤とし、これにシンダイン（登録商標）を０．０３容量％含有する水を加え、供試化合物を所定濃度含有する希釈液を調製する。
　容器に植えたイネ（Oryza sativa）苗（第２葉展開期）に該希釈液を１０ｍＬ／苗の割合で散布する。その後、トビイロウンカ３齢幼虫を２０頭放す。６日後、生存虫数を調査し、以下の式により死虫率を求める。
　　　死虫率（％）＝｛１－生存虫数／２０｝×１００ Test method 5
A test compound is prepared according to the method described in Preparation Example 5, and water containing 0.03% by volume of Syndyne (registered trademark) is added thereto to prepare a diluted solution containing a predetermined concentration of the test compound.
The diluted solution is sprayed at a rate of 10 mL / seedling to rice (Oryza sativa) seedlings (second leaf development stage) planted in a container. After that, release the 20 third instar larvae of the dead planthopper. Six days later, the number of surviving insects is examined, and the mortality rate is determined by the following equation.
Mortality rate (%) = {1-number of surviving insects / 20} x 100
試験例５
　所定濃度を５００ｐｐｍとし、下記の本発明化合物を供試化合物として用いて試験法５に従って試験を行った結果、下記の本発明化合物はいずれも死虫率９０％以上を示した。
本発明化合物：２７、２８、２９、３７、４６、４８、５２、５３、５４、５５、５６、６０、６１、６２、６４、６７、８４、８９、９１、９２、９３、１０２、１０３、１０５、１０６、１０７、１０８、１０９、１１０、１１５、１１６、１２２、１２４、１２５、１３５、１３６、１３８及び１５４ Test Example 5
The compound of the present invention described below was tested as a test compound at a predetermined concentration of 500 ppm, and as a result, each of the compounds of the present invention described below showed a mortality of 90% or more.
Compounds of the present invention: 27, 28, 29, 37, 46, 48, 52, 53, 54, 55, 56, 60, 61, 62, 64, 67, 84, 89, 91, 92, 93, 102, 103, 105, 106, 107, 108, 109, 110, 115, 116, 122, 124, 125, 135, 136, 138 and 154
試験法６
　供試化合物を製剤例５に記載の方法に準じて製剤とし、これにシンダイン（登録商標）を０．０３容量％含有する水を加え、供試化合物を所定濃度含有する希釈液を調製する。
　容器に植えたトマト（Lycopersicon esculentum）苗に、タバココナジラミ成虫を放して約２４時間産卵させる。この苗を８日間保管し、産下された卵から幼虫を孵化させる。この苗に、該希釈液を１０ｍＬ／苗の割合で散布する。７日後、生存虫数を調査し、次の式により防除価を求める。
　防除価（％）＝｛１－（Ｃｂ×Ｔａｉ）／（Ｃａｉ×Ｔｂ）｝×１００
なお、式中の文字は以下の意味を表す。
　　　Ｃｂ：無処理区の処理直前の虫数
　　　Ｃａｉ：無処理区の調査時の生存虫数
　　　Ｔｂ：処理区の処理直前の虫数
　　　Ｔａｉ：処理区の調査時の生存虫数
　ここで無処理区とは、供試化合物を使用しないこと以外は処理区と同じ操作をする区を意味する。 Test method 6
A test compound is prepared according to the method described in Preparation Example 5, and water containing 0.03% by volume of Syndyne (registered trademark) is added thereto to prepare a diluted solution containing a predetermined concentration of the test compound.
In the tomato (Lycopersicon esculentum) seedlings planted in a container, the B. tabaci adults are released and allowed to lay eggs for about 24 hours. The seedlings are stored for 8 days, and larvae are hatched from the delivered eggs. The diluted solution is sprayed onto the seedlings at a rate of 10 mL / seedling. After 7 days, the number of surviving insects is investigated, and the control value is determined by the following equation.
Control value (%) = {1- (Cb × Tai) / (Cai × Tb)} × 100
The letters in the formula have the following meanings.
Cb: The number of insects immediately before the treatment in the untreated zone Cai: The number of living insects in the survey of the untreated region Tb: The number of insects just before the treatment in the treated zone Tai: The number of living insects in the survey of the treated region Means a zone which performs the same operation as the treatment zone except that the test compound is not used.
試験例６
　所定濃度を５００ｐｐｍとし、下記の本発明化合物を供試化合物として用いて試験法６に従って試験を行った結果、下記の本発明化合物はいずれも防除価９０％以上を示した。
本発明化合物：２７、３０、３２、３６、５３、５６、５７、６０、６２、６３、６４、７２、８９、９０、９１、９２、１０３、１０６、１０７、１０８、１２２、１２４、１３８、１４２及び１５４ Test Example 6
As a result of conducting a test according to the test method 6 by setting a predetermined concentration to 500 ppm and using the following compound of the present invention as a test compound, all of the following compounds of the present invention showed 90% or more of control value.
Compounds of the present invention: 27, 30, 32, 36, 53, 56, 57, 60, 62, 63, 64, 72, 89, 90, 91, 92, 103, 106, 107, 108, 122, 124, 138, 142 and 154
試験法７
　供試化合物を製剤例５に記載の方法に準じて製剤とし、これにシンダイン（登録商標）を０．０３容量％含有する水を加え、供試化合物を所定濃度含有する希釈液を調製する。
　容器に植えたキュウリ苗（第２葉展開期）に該希釈液を１０ｍＬ／苗の割合で散布する。その後、第１本葉を切り取り容器内に収容し、これにミカンキイロアザミウマの幼虫を約２０頭放す。７日後、生存虫数を調査し、次の式により死虫率を求める。
　　　死虫率（％）＝｛１－生存虫数／２０｝×１００ Test method 7
A test compound is prepared according to the method described in Preparation Example 5, and water containing 0.03% by volume of Syndyne (registered trademark) is added thereto to prepare a diluted solution containing a predetermined concentration of the test compound.
The diluted solution is sprayed at a rate of 10 mL / seedling to cucumber seedlings (second leaf development stage) planted in a container. After that, the first true leaf is cut out and placed in a container, and about 20 larvae of C. thunans are released. After 7 days, the number of surviving insects is examined, and the mortality rate is determined by the following equation.
Mortality rate (%) = {1-number of surviving insects / 20} x 100
試験例７
　所定濃度を５００ｐｐｍとし、下記の本発明化合物を供試化合物として用いて試験法７に従って試験を行った結果、下記の本発明化合物は死虫率９０％以上を示した。
本発明化合物：６４ Test Example 7
The compound of the present invention described below exhibited a mortality of 90% or more as a result of conducting a test according to test method 7 using a compound of the present invention described below as a test compound, with a predetermined concentration of 500 ppm.
The compound of the present invention: 64
試験法８
　供試化合物を製剤例５に記載の方法に準じて製剤とし、これにシンダイン（登録商標）を０．０３容量％含有する水を加え、供試化合物を所定濃度含有する希釈液を調製する。
　容器に植えたインゲンマメ（Phaseolus vulgaris）苗（第１本葉展開期）に約４０頭のナミハダニ雌成虫を放つ。１日後、この苗に該希釈液を１０ｍＬ／苗の割合で散布する。更に７日後、生存虫数を調査し、次式により防除価を算出する。
　防除価（％）＝｛１－（Ｃｂ×Ｔａｉ）／（Ｃａｉ×Ｔｂ）｝×１００
なお、式中の文字は以下の意味を表す。
　　　Ｃｂ：無処理区の供試虫数
　　　Ｃａｉ：無処理区の調査時の生存虫数
　　　Ｔｂ：処理区の供試虫数
　　　Ｔａｉ：処理区の調査時の生存虫数
　ここで無処理区とは、供試化合物を使用しないこと以外は処理区と同じ操作をする区を意味する。 Test method 8
A test compound is prepared according to the method described in Preparation Example 5, and water containing 0.03% by volume of Syndyne (registered trademark) is added thereto to prepare a diluted solution containing a predetermined concentration of the test compound.
About 40 adult spider mite mites are released on kidney bean (Phaseolus vulgaris) seedlings (first true leaf development stage) planted in a container. One day later, the seedlings are sprayed with the diluted solution at a rate of 10 mL / seedling. After 7 days, the number of surviving insects is examined, and the control value is calculated by the following equation.
Control value (%) = {1- (Cb × Tai) / (Cai × Tb)} × 100
The letters in the formula have the following meanings.
Cb: Number of tested insects in untreated area Cai: Number of surviving insects in survey in untreated area Tb: Number of tested insects in treated zone Tai: Number of surviving insects in survey in treated area Here, untreated group means It means a zone that performs the same operation as the treatment zone except that the test compound is not used.
試験例８
　所定濃度を５００ｐｐｍとし、下記の本発明化合物を供試化合物として用いて試験法８に従って試験を行った結果、下記の本発明化合物は防除価９０％以上を示した。
本発明化合物：５６、１０５、１０６、１０８、１０９、１１５、１１６、１２２、１３５、１３６及び１５４ Test Example 8
As a result of conducting a test according to the test method 8 by setting a predetermined concentration to 500 ppm and using the following compound of the present invention as a test compound, the following compound of the present invention showed a control value of 90% or more.
Invention compounds: 56, 105, 106, 108, 109, 115, 116, 122, 135, 136 and 154
試験法９
　供試化合物を製剤例５に記載の方法に準じて製剤とし、これに水を加え、供試化合物を所定濃度含有する希釈液を調製する。
　該希釈液中にアカイエカ終齢幼虫３０頭を放ち、１日後にその生死を調査し死虫率を求める。死虫率は下式により計算する。
　　　死虫率（％）＝（死亡虫数／供試虫数）×１００ Test method 9
A test compound is formulated according to the method described in Formulation Example 5, water is added thereto, and a diluted solution containing the test compound at a predetermined concentration is prepared.
In the diluted solution, 30 final-instar larvae of Culex pipiens are released, and after one day, their life and death are examined to determine the mortality rate. The mortality rate is calculated by the following formula.
Mortality rate (%) = (number of dead insects / number of test insects) x 100
試験例９
　所定濃度を３．５ｐｐｍとし、下記の本発明化合物を供試化合物として用いて試験法９に従って試験を行った結果、下記の本発明化合物はいずれも死虫率９１％以上を示した。
本発明化合物：２８、２９、３８、４７、４８、５４、５５、６４、８１、１０３、１０５、１０６、１０８、１１０、１１４、１１６、１３１、１３４、１３６、１４０及び１４６ Test Example 9
The compound of the present invention described below was used as a test compound and tested according to test method 9 with a predetermined concentration of 3.5 ppm, and all of the compounds of the present invention showed a mortality of 91% or more.
Compounds of the present invention: 28, 29, 38, 47, 48, 54, 55, 64, 81, 103, 105, 106, 108, 110, 114, 116, 131, 134, 136, 140 and 146
試験法１０
　供試化合物を製剤例５に記載の方法に準じて製剤とし、これに水を加え、供試化合物を所定濃度含有する希釈液を調製する。
　直径５．５ｃｍのカップの内側底部に同大の濾紙を敷き、濾紙上に該希釈液０．７ｍＬを滴下し、餌として該カップにショ糖３０ｍｇを均一に入れる。該カップにイエバエ雌成虫１０頭を放ち、蓋をする。２４時間後にイエバエの生死を調査し死虫率を求める。死虫率は下式により計算する。
　　　死虫率（％）＝（死亡虫数／供試虫数）×１００ Test method 10
A test compound is formulated according to the method described in Formulation Example 5, water is added thereto, and a diluted solution containing the test compound at a predetermined concentration is prepared.
The same size filter paper is placed on the inner bottom of a 5.5 cm diameter cup, and 0.7 mL of the diluted solution is dropped on the filter paper, and 30 mg of sucrose is uniformly poured into the cup as a bait. Release 10 adult housefly female adults into the cup and cover. After 24 hours, investigate the life and death of the housefly and determine the mortality rate. The mortality rate is calculated by the following formula.
Mortality rate (%) = (number of dead insects / number of test insects) x 100
試験例１０
　所定濃度を５００ｐｐｍとし、下記の本発明化合物を供試化合物として用いて試験法１０に従って試験を行った結果、下記の本発明化合物はいずれも死虫率８０％以上を示した。
本発明化合物：２７、２８、２９、３０、３１、３２、３３、３４、３６、４０、４３、４７、４９、５０、５１、５２、５３、５４、５５、５６、５７、５８、５９、６０、６１、６３、６４、６７、６８、８９、９０、９４、１０２、１０３、１０５、１０６、１０７、１０８、１１６、１２３、１２４、１２５、１３４、１３８及び１５４ Test Example 10
The compound of the present invention described below was used as a test compound and tested according to Test Method 10 with a predetermined concentration of 500 ppm. As a result, all of the compounds of the present invention showed a mortality of 80% or more.
The present compounds: 27, 28, 29, 30, 31, 32, 33, 34, 36, 40, 43, 47, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 63, 64, 67, 68, 89, 90, 94, 102, 103, 105, 106, 107, 108, 116, 123, 124, 125, 134, 138 and 154
試験法１１
　供試化合物を製剤例５に記載の方法に準じて製剤とし、これに水を加え、供試化合物を所定濃度含有する希釈液を調製する。
　直径５．５ｃｍのカップの内側底部に同大の濾紙を敷き、濾紙上に該希釈液０．７ｍＬを滴下し、餌として該カップにショ糖３０ｍｇを均一に入れる。該カップにチャバネゴキブリ雄成虫２頭を放ち、蓋をする。６日後にチャバネゴキブリの生死を調査し死亡虫数を数え、次式により死虫率を求める。
　　　死虫率（％）＝（死亡虫数／供試虫数）×１００ Test method 11
A test compound is formulated according to the method described in Formulation Example 5, water is added thereto, and a diluted solution containing the test compound at a predetermined concentration is prepared.
The same size filter paper is placed on the inner bottom of a 5.5 cm diameter cup, and 0.7 mL of the diluted solution is dropped on the filter paper, and 30 mg of sucrose is uniformly poured into the cup as a bait. Put two male adult German cockroaches into the cup and cover. After 6 days, the life and death of the German cockroach are investigated, the number of dead insects is counted, and the mortality rate is determined by the following equation.
Mortality rate (%) = (number of dead insects / number of test insects) x 100
試験例１１
　所定濃度を５００ｐｐｍとし、下記の本発明化合物を供試化合物として用いて試験法１１に従って試験を行った結果、下記の本発明化合物はいずれも死虫率１００％を示した。
本発明化合物：２９、３１、３３、３４、４７、４９、５０、５４、５５、５６、５７、５８、５９、６０、６３、６７、６８、９１、９４、９６、１２５及び１３４ Test Example 11
As a result of conducting a test according to the test method 11 by setting a predetermined concentration to 500 ppm and using the following compound of the present invention as a test compound, all of the following compounds of the present invention showed 100% mortality.
The compounds of the present invention: 29, 31, 33, 34, 47, 49, 50, 54, 55, 56, 57, 58, 59, 60, 63, 67, 68, 91, 94, 96, 125 and 134
試験法１２
　供試化合物が２００ｐｐｍとなるように調製したアセトン溶液を内容量２０ｍＬの容器に注ぎ、供試化合物が１０ｍｇ／ｍ2となるように容器の内面に均一にコーティングし、その後乾燥させる。
　該容器にアカイエカ雌成虫５頭を入れ、蓋を閉める。所定時間経過後にノックダウン虫数と死亡虫数との合計（苦死虫数）を調査し、次式により苦死虫率を求める。
　　　苦死虫率（％）＝（苦死虫数／供試虫数）×１００ Test method 12
Pour prepared acetone solution as test compound is 200ppm in a container having an inner volume of 20 mL, test compound is uniformly coated on the inner surface of the container so that 10 mg / m 2, then dried.
Put 5 adult female house mosquitoes into the container and close the lid. After the lapse of a predetermined time, the total of the number of knocked-down insects and the number of dead insects (the number of dead insects) is examined, and the mortality rate is determined by the following equation.
Writhing rate (%) = (number of writhing insects / number of test insects) x 100
試験例１２－１
　所定時間を１時間とし、下記の本発明化合物を供試化合物として用いて試験法１２に従って試験を行った結果、下記の本発明化合物はいずれも苦死虫率８０％以上を示した。
本発明化合物：２７、２８、２９、３０、３１、３３、３４、３７、３８、４３、４７、４９、５０、５１、５２、５４、５５、５６、５７、５８、５９、６０、６１、６２、６４、６７、８９、９０、９１、９３、１０２、１０３、１０５、１０６、１０７、１０８、１０９、１１６、１２２、１２３、１２４、１２５、１３８、１４４、１４５、１４６、１４７及び１５４ Test Example 12-1
The test was conducted according to test method 12 using the following compound of the present invention as a test compound, with the predetermined time being set to 1 hour.
The present invention compounds: 27, 28, 29, 30, 31, 33, 34, 37, 38, 43, 47, 49, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 67, 89, 90, 91, 93, 102, 103, 105, 106, 107, 108, 109, 116, 122, 123, 124, 125, 138, 144, 145, 146, 147 and 154
試験例１２－２
　所定時間を１日とし、下記の本発明化合物を供試化合物として用いて試験法１２に従って試験を行った結果、下記の本発明化合物はいずれも苦死虫率８０％以上を示した。
本発明化合物：２７、２８、２９、３０、３１、３３、３４、３７、３８、４３、４６、４７、５４、５５、５６、５７、５８、５９、６０、６１、６２、６４、６７、７０、８９、９０、９１、９３、１０２、１０３、１０５、１０６、１０７、１０８、１０９、１１０、１１５、１１６、１１８、１２２、１２３、１２４、１２５、１３５、１３８、１４４、１４５、１４６、１４７及び１５４ Test Example 12-2
As a result of conducting a test according to test method 12 by setting a predetermined time to 1 day and using the following compound of the present invention as a test compound, all of the following compounds of the present invention showed a mortality of 80% or more.
The present invention compounds: 27, 28, 29, 30, 31, 33, 34, 37, 38, 43, 46, 47, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 67, 70, 89, 90, 91, 93, 102, 103, 105, 106, 107, 108, 109, 110, 115, 116, 118, 122, 123, 124, 125, 135, 138, 144, 145, 146, 146, 147 and 154
　本発明化合物Ｘは、有害節足動物に対して優れた防除効果を示す。 The compound of the present invention X exhibits an excellent control effect on harmful arthropods.

Claims (11)

  1. 　式（Ｉ）
    Figure JPOXMLDOC01-appb-C000001
     〔式中、
    　Ｒ1及びＲ2は、同一又は相異なり、Ｃ１－Ｃ１５鎖式炭化水素基｛該Ｃ１－Ｃ１５鎖式炭化水素基は、群Ａより選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ８シクロアルキル基又はＣ３－Ｃ８シクロアルケニル基｛該Ｃ３－Ｃ８シクロアルキル基及び該Ｃ３－Ｃ８シクロアルケニル基は、群Ｂより選ばれる１以上の置換基を有していてもよい｝を表し、
    　Ｒ3は、（Ｃ１－Ｃ３アルコキシ）Ｃ１－Ｃ３アルキル基、群Ｂより選ばれる１以上の置換基を有していてもよいベンジル基、ホルミル基、Ｃ（Ｏ）Ｒ10、Ｃ（Ｏ）ＯＲ10又は水素原子を表し、
    　Ｒ10は、Ｃ１－Ｃ４鎖式炭化水素基又はシクロプロピル基｛該Ｃ１－Ｃ４鎖式炭化水素基及び該シクロプロピル基は、シアノ基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝を表し、
    　Ｒ4は、１以上のハロゲン原子を有していてもよいＣ１－Ｃ２アルキル基又は群Ｃより選ばれる１以上の置換基を有していてもよいシクロプロピル基を表し、
    　Ｒ5は、１以上のハロゲン原子を有していてもよいＣ１－Ｃ４鎖式炭化水素基又は群Ｃより選ばれる１以上の置換基を有していてもよいシクロプロピル基を表し、
    　Ｌ1は、単結合、－Ｌ1A－Ｏ－＃、－Ｌ1A－ＮＲ6－＃、－Ｌ1A－Ｓ（Ｏ）m－＃、－Ｌ1A－Ｏ－Ｎ＝ＣＲ7－＃、－Ｌ1B－ＣＲ7＝Ｎ－Ｏ－＃、又は－Ｌ1B－ＣＲ7＝Ｎ－ＮＲ6－＃を表し、
    　＃は、Ｒ1との結合位置を表し、
    　Ｌ2は、単結合、－Ｌ2A－Ｏ－＊、－Ｌ2A－ＮＲ8－＊、－Ｌ2A－Ｓ（Ｏ）p－＊、－Ｌ2A－Ｏ－Ｎ＝ＣＲ9－＊、－Ｌ2B－ＣＲ9＝Ｎ－Ｏ－＊、又は－Ｌ2B－ＣＲ9＝Ｎ－ＮＲ8－＊を表し、
    　＊は、Ｒ2との結合位置を表し、
    　Ｒ6、Ｒ7、Ｒ8及びＲ9は、同一又は相異なり、１以上のハロゲン原子を有していてもよいＣ１－Ｃ３アルキル基又は水素原子を表し、
    　Ｌ1A及びＬ2Aは、同一又は相異なり、Ｃ１－Ｃ３アルカンジイル基、Ｃ２－Ｃ３アルケンジイル基、エチンジイル基又はプロピンジイル基｛該Ｃ１－Ｃ３アルカンジイル基、該Ｃ２－Ｃ３アルケンジイル基及び該プロピンジイル基は、群Ｄより選ばれる１以上の置換基を有していてもよい｝を表し、
    　Ｌ1B及びＬ2Bは、同一又は相異なり、単結合、Ｃ１－Ｃ３アルカンジイル基、Ｃ２－Ｃ３アルケンジイル基、エチンジイル基又はプロピンジイル基｛該Ｃ１－Ｃ３アルカンジイル基、該Ｃ２－Ｃ３アルケンジイル基及び該プロピンジイル基は、群Ｄより選ばれる１以上の置換基を有していてもよい｝を表し、
    　ｎは、０又は１を表し、
    　ｍ及びｐは、同一又は相異なり、０、１又は２を表す。
    　群Ａ：Ｃ１－Ｃ６アルコキシ基、Ｃ３－Ｃ６アルケニルオキシ基、Ｃ３－Ｃ６アルキニルオキシ基、Ｃ１－Ｃ６アルキルスルファニル基、Ｃ１－Ｃ６アルキルスルフィニル基、Ｃ１－Ｃ６アルキルスルホニル基、Ｃ２－Ｃ６アルキルカルボニル基、Ｃ２－Ｃ６アルキルカルボニルオキシ基｛該Ｃ１－Ｃ６アルコキシ基、該Ｃ３－Ｃ６アルケニルオキシ基、該Ｃ３－Ｃ６アルキニルオキシ基、該Ｃ１－Ｃ６アルキルスルファニル基、該Ｃ１－Ｃ６アルキルスルフィニル基、該Ｃ１－Ｃ６アルキルスルホニル基、該Ｃ２－Ｃ６アルキルカルボニル基及び該Ｃ２－Ｃ６アルキルカルボニルオキシ基は、１以上のハロゲン原子を有していてもよい｝、Ｃ３－Ｃ８シクロアルキル基、Ｃ３－Ｃ８シクロアルケニル基、Ｃ３－Ｃ８シクロアルキルオキシ基、Ｃ３－Ｃ８シクロアルケニルオキシ基｛該Ｃ３－Ｃ８シクロアルキル基、該Ｃ３－Ｃ８シクロアルケニル基、該Ｃ３－Ｃ８シクロアルキルオキシ基及び該Ｃ３－Ｃ８シクロアルケニルオキシ基は、群Ｂより選ばれる１以上の置換基を有していてもよい｝、ハロゲン原子、シアノ基、ニトロ基、アミノ基、Ｃ（Ｏ）ＯＲ11及びＣ（Ｏ）ＮＲ12Ｒ13からなる群。
    　Ｒ11、Ｒ12及びＲ13は、同一又は相異なり、Ｃ１－Ｃ３アルキル基又は水素原子を表す。
    　群Ｂ：Ｃ１－Ｃ６鎖式炭化水素基、Ｃ１－Ｃ６アルコキシ基、Ｃ３－Ｃ６アルケニルオキシ基、Ｃ３－Ｃ６アルキニルオキシ基、Ｃ１－Ｃ６アルキルスルファニル基、Ｃ１－Ｃ６アルキルスルフィニル基、Ｃ１－Ｃ６アルキルスルホニル基、Ｃ２－Ｃ６アルキルカルボニル基、Ｃ２－Ｃ６アルキルカルボニルオキシ基｛該Ｃ１－Ｃ６鎖式炭化水素基、該Ｃ１－Ｃ６アルコキシ基、該Ｃ３－Ｃ６アルケニルオキシ基、該Ｃ３－Ｃ６アルキニルオキシ基、該Ｃ１－Ｃ６アルキルスルファニル基、該Ｃ１－Ｃ６アルキルスルフィニル基、該Ｃ１－Ｃ６アルキルスルホニル基、該Ｃ２－Ｃ６アルキルカルボニル基及び該Ｃ２－Ｃ６アルキルカルボニルオキシ基は、１以上のハロゲン原子を有していてもよい｝、ハロゲン原子、ニトロ基、ヒドロキシ基、アミノ基、オキソ基、Ｃ（Ｏ）ＯＲ11及びＣ（Ｏ）ＮＲ12Ｒ13からなる群。
    　群Ｃ：１以上のハロゲン原子を有していてもよいＣ１－Ｃ３アルキル基、ハロゲン原子及びシアノ基からなる群。
    　群Ｄ：シクロプロピル基、ハロゲン原子及びシアノ基からなる群。〕
    で示される化合物。     Formula (I)
    Figure JPOXMLDOC01-appb-C000001
     [In the formula,
    R 1 and R 2 are the same or different, and C1-C15 chain hydrocarbon group {The C1-C15 chain hydrocarbon group may have one or more substituents selected from group A} , C3-C8 cycloalkyl group or C3-C8 cycloalkenyl group {The C3-C8 cycloalkyl group and the C3-C8 cycloalkenyl group may have one or more substituents selected from Group B} Represents
    R 3 represents a (C 1 -C 3 alkoxy) C 1 -C 3 alkyl group, a benzyl group optionally having one or more substituents selected from group B, a formyl group, C (O) R 10 , C (O) Represents OR 10 or a hydrogen atom,
    R 10 represents a C1-C4 chain hydrocarbon group or a cyclopropyl group {wherein the C1-C4 chain hydrocarbon group and the cyclopropyl group are one or more substituents selected from the group consisting of a cyano group and a halogen atom Represents that it may have,
    R 4 represents a C 1 -C 2 alkyl group which may have one or more halogen atoms or a cyclopropyl group which may have one or more substituents selected from group C,
    R 5 represents a C1-C4 chain hydrocarbon group which may have one or more halogen atoms or a cyclopropyl group which may have one or more substituents selected from Group C,
    L 1 represents a single bond, -L 1A -O - #, - L 1A -NR 6 - #, - L 1A -S (O) m - #, - L 1A -O-N = CR 7 - #, - L 1B -CR 7 = N-O- # or -L 1B -CR 7 = N-NR 6- #,
    # Represents the bonding position with R 1 ,
    L 2 represents a single bond, -L 2A -O - *, - L 2A -NR 8 - *, - L 2A -S (O) p - *, - L 2A -O-N = CR 9 - *, - L 2B -CR 9 = N-O- *, or -L 2B -CR 9 = N-NR 8 - * represents,
    * Represents a bonding position with R 2 ,
    R 6 , R 7 , R 8 and R 9 are the same or different and each represents a C1-C3 alkyl group optionally having one or more halogen atoms, or a hydrogen atom,
    L 1A and L 2A are the same or different, and C 1 -C 3 alkanediyl group, C 2 -C 3 alkene diyl group, ethyne diyl group or propyne diyl group {C1-C 3 alkanediyl group, said C 2 -C 3 alkene diyl group and said propyne diyl group , And may optionally have one or more substituents selected from group D,
    L 1B and L 2B are the same or different, and a single bond, a C 1 -C 3 alkanediyl group, a C 2 -C 3 alkene diyl group, an ethyne diyl group or a propyne diyl group {the C 1 -C 3 alkanediyl group, the C 2 -C 3 alkene diyl group and the The propyne diyl group may have one or more substituents selected from group D}.
    n represents 0 or 1 and
    m and p are the same or different and each represents 0, 1 or 2.
    Group A: C 1 -C 6 alkoxy, C 3 -C 6 alkenyloxy, C 3 -C 6 alkynyloxy, C 1 -C 6 alkylsulfanyl, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 2 -C 6 alkylcarbonyl A C2-C6 alkylcarbonyloxy group {wherein the C1-C6 alkoxy group, the C3-C6 alkenyloxy group, the C3-C6 alkynyloxy group, the C1-C6 alkylsulfanyl group, the C1-C6 alkylsulfinyl group, the C1 -C6 alkylsulfonyl group, the C2-C6 alkylcarbonyl group and the C2-C6 alkylcarbonyloxy group may have one or more halogen atoms}, a C3-C8 cycloalkyl group, a C3-C8 cycloalkenyl Group, C3-C8 cycloalkyloxy group C3-C8 cycloalkenyloxy group {wherein the C3-C8 cycloalkyl group, the C3-C8 cycloalkenyl group, the C3-C8 cycloalkyloxy group and the C3-C8 cycloalkenyloxy group are one or more selected from group B A group consisting of a halogen atom, a cyano group, a nitro group, an amino group, C (O) OR 11 and C (O) NR 12 R 13 ;
    R 11 , R 12 and R 13 are the same or different and each represents a C1-C3 alkyl group or a hydrogen atom.
    Group B: C1-C6 chain hydrocarbon group, C1-C6 alkoxy group, C3-C6 alkenyloxy group, C3-C6 alkynyloxy group, C1-C6 alkylsulfanyl group, C1-C6 alkylsulfinyl group, C1-C6 alkyl A sulfonyl group, a C2-C6 alkyl carbonyl group, a C2-C6 alkyl carbonyloxy group {the C1-C6 chain hydrocarbon group, the C1-C6 alkoxy group, the C3-C6 alkenyloxy group, the C3-C6 alkynyloxy group The C1-C6 alkylsulfanyl group, the C1-C6 alkylsulfinyl group, the C1-C6 alkylsulfonyl group, the C2-C6 alkylcarbonyl group and the C2-C6 alkylcarbonyloxy group have one or more halogen atoms; May be}, a halogen atom, a nitro group, a hydroxy group Amino group, oxo group, C (O) group consisting of OR 11 and C (O) NR 12 R 13 .
    Group C: A group consisting of a C1-C3 alkyl group optionally having one or more halogen atoms, a halogen atom and a cyano group.
    Group D: a group consisting of cyclopropyl, halogen and cyano. ]
    A compound represented by
  2. 　群Ｂが、Ｃ１－Ｃ６鎖式炭化水素基、Ｃ１－Ｃ６アルコキシ基、Ｃ３－Ｃ６アルケニルオキシ基、Ｃ３－Ｃ６アルキニルオキシ基、Ｃ１－Ｃ６アルキルスルファニル基、Ｃ１－Ｃ６アルキルスルフィニル基、Ｃ１－Ｃ６アルキルスルホニル基、Ｃ２－Ｃ６アルキルカルボニル基、Ｃ２－Ｃ６アルキルカルボニルオキシ基｛該Ｃ１－Ｃ６鎖式炭化水素基、該Ｃ１－Ｃ６アルコキシ基、該Ｃ３－Ｃ６アルケニルオキシ基、該Ｃ３－Ｃ６アルキニルオキシ基、該Ｃ１－Ｃ６アルキルスルファニル基、該Ｃ１－Ｃ６アルキルスルフィニル基、該Ｃ１－Ｃ６アルキルスルホニル基、該Ｃ２－Ｃ６アルキルカルボニル基及び該Ｃ２－Ｃ６アルキルカルボニルオキシ基は、１以上のハロゲン原子を有していてもよい｝、ハロゲン原子、ニトロ基、ヒドロキシ基、アミノ基、Ｃ（Ｏ）ＯＲ11及びＣ（Ｏ）ＮＲ12Ｒ13からなる群である、請求項１に記載の化合物。 Group B is a C1-C6 chain hydrocarbon group, a C1-C6 alkoxy group, a C3-C6 alkenyloxy group, a C3-C6 alkynyloxy group, a C1-C6 alkylsulfanyl group, a C1-C6 alkylsulfinyl group, a C1-C6 Alkylsulfonyl group, C2 to C6 alkyl carbonyl group, C2 to C6 alkyl carbonyloxy group {C1 to C6 chain hydrocarbon group, the C1 to C6 alkoxy group, the C3 to C6 alkenyloxy group, the C3 to C6 alkynyloxy group Group, the C1-C6 alkylsulfanyl group, the C1-C6 alkylsulfinyl group, the C1-C6 alkylsulfonyl group, the C2-C6 alkylcarbonyl group and the C2-C6 alkylcarbonyloxy group are one or more halogen atoms; Which may have}, halogen atom, nitro group, hydroxy , An amino group, a group consisting of C (O) OR 11 and C (O) NR 12 R 13 , The compound according to claim 1.
  3. 　Ｒ3が、ベンジル基、Ｃ（Ｏ）ＣＨ3、Ｃ（Ｏ）ＯＣＨ3、Ｃ（Ｏ）ＯＣＨ2ＣＨ＝ＣＨ2又は水素原子であり、
    　Ｌ1が、単結合、－ＣＨ2－Ｏ－＃、－ＣＨ2－Ｏ－Ｎ＝ＣＲ7－＃、又は－ＣＲ7＝Ｎ－Ｏ－＃であり、
    　Ｌ2が、単結合、－ＣＨ2－Ｏ－＊、－ＣＨ2－Ｏ－Ｎ＝Ｃ（ＣＨ3）－＊、又は－ＣＨ＝Ｎ－Ｏ－＊である、請求項１又は請求項２に記載の化合物。     R 3 is a benzyl group, C (O) CH 3 , C (O) OCH 3 , C (O) OCH 2 CH = CH 2 or a hydrogen atom,
    L 1 is a single bond, -CH 2 -O - #, - CH 2 -O-N = CR 7 - #, or a -CR 7 = N-O- #,
    The L 1 is a single bond, -CH 2 -O- *, -CH 2 -O-N = C (CH 3 )-*, or -CH = N-O- *. The compound as described in.
  4. 　Ｒ2が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、Ｃ３－Ｃ６シクロアルキル基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝、Ｃ３－Ｃ６シクロアルキル基又はＣ３－Ｃ６シクロアルケニル基である、請求項１～請求項３のいずれかに記載の化合物。 R 2 is a C1-C10 chain hydrocarbon group {wherein the C1-C10 chain hydrocarbon group has one or more substituents selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound according to any one of claims 1 to 3, which is preferably a C3-C6 cycloalkyl group or a C3-C6 cycloalkenyl group.
  5. 　Ｒ1が、Ｃ１－Ｃ１０鎖式炭化水素基｛該Ｃ１－Ｃ１０鎖式炭化水素基は、Ｃ３－Ｃ６シクロアルキル基及びハロゲン原子からなる群より選ばれる１以上の置換基を有していてもよい｝である、請求項１～請求項４のいずれかに記載の化合物。 R 1 is a C1-C10 chain hydrocarbon group {wherein the C1-C10 chain hydrocarbon group has one or more substituents selected from the group consisting of a C3-C6 cycloalkyl group and a halogen atom The compound according to any one of claims 1 to 4, which is good.
  6. 　Ｌ1及びＬ2が、単結合である、請求項１～請求項５のいずれかに記載の化合物。 The compound according to any one of claims 1 to 5, wherein L 1 and L 2 are a single bond.
  7. 　請求項１～請求項６のいずれかに記載の化合物と、不活性担体とを含有する有害節足動物防除組成物。 An arthropod pest control composition comprising the compound according to any one of claims 1 to 6 and an inert carrier.
  8. 　群（ａ）及び群（ｂ）からなる群より選ばれる１以上の成分を含有する請求項７に記載の組成物：
    　群（ａ）：殺虫活性成分、殺ダニ活性成分及び殺線虫活性成分からなる群；
    　群（ｂ）：殺菌活性成分。     The composition according to claim 7, comprising one or more components selected from the group consisting of group (a) and group (b):
    Group (a): a group consisting of an insecticidal active ingredient, an acaricidal active ingredient and a nematode active ingredient;
    Group (b): bactericidal active ingredient.
  9. 　請求項１～請求項６のいずれかに記載の化合物の有効量を有害節足動物又は有害節足動物の生息場所に施用する有害節足動物の防除方法。 A method for controlling noxious arthropods which comprises applying an effective amount of the compound according to any one of claims 1 to 6 to a harmful arthropod or a habitat of the harmful arthropod.
  10. 　請求項７又は請求項８に記載の組成物の有効量を有害節足動物又は有害節足動物の生息場所に施用する有害節足動物の防除方法。 A method for controlling noxious arthropods, which comprises applying an effective amount of the composition according to claim 7 or 8 to a harmful arthropod or a habitat of the harmful arthropod.
  11. 　請求項１～請求項６のいずれかに記載の化合物の有効量又は請求項７もしくは請求項８に記載の組成物の有効量を保持している種子又は栄養生殖器官。 A seed or vegetative organ which holds an effective amount of the compound according to any one of claims 1 to 6 or an effective amount of the composition according to claim 7 or 8.
PCT/JP2018/039843 2017-10-27 2018-10-26 Pyridine compound and harmful-arthropod control agent containing same WO2019083007A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019550314A JPWO2019083007A1 (en) 2017-10-27 2018-10-26 Pyridine compound and harmful arthropod control agent containing it

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017207928 2017-10-27
JP2017-207928 2017-10-27

Publications (1)

Publication Number Publication Date
WO2019083007A1 true WO2019083007A1 (en) 2019-05-02

Family

ID=66246478

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/039843 WO2019083007A1 (en) 2017-10-27 2018-10-26 Pyridine compound and harmful-arthropod control agent containing same

Country Status (2)

Country Link
JP (1) JPWO2019083007A1 (en)
WO (1) WO2019083007A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012036177A (en) * 2010-07-16 2012-02-23 Sumitomo Chemical Co Ltd Pyridine compound and pest-control usage therefor
WO2015119099A1 (en) * 2014-02-05 2015-08-13 日本曹達株式会社 Pyridine compound and application therefor
WO2015199065A1 (en) * 2014-06-24 2015-12-30 日本曹達株式会社 Pyridine compound and use of same
WO2016039048A1 (en) * 2014-09-10 2016-03-17 日本曹達株式会社 Pyridine compound and use thereof
WO2017155052A1 (en) * 2016-03-09 2017-09-14 日本曹達株式会社 Pyridine compound and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012036177A (en) * 2010-07-16 2012-02-23 Sumitomo Chemical Co Ltd Pyridine compound and pest-control usage therefor
WO2015119099A1 (en) * 2014-02-05 2015-08-13 日本曹達株式会社 Pyridine compound and application therefor
WO2015199065A1 (en) * 2014-06-24 2015-12-30 日本曹達株式会社 Pyridine compound and use of same
WO2016039048A1 (en) * 2014-09-10 2016-03-17 日本曹達株式会社 Pyridine compound and use thereof
WO2017155052A1 (en) * 2016-03-09 2017-09-14 日本曹達株式会社 Pyridine compound and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CAS 30 November 2012 (2012-11-30), retrieved from STN Database accession no. 1408279-57-1 *

Also Published As

Publication number Publication date
JPWO2019083007A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
JP7274424B2 (en) Heterocyclic compound and harmful arthropod control agent containing the same
JP7196097B2 (en) Heterocyclic compound and harmful arthropod control agent containing the same
JP7253498B2 (en) Heterocyclic compound and harmful arthropod control agent containing the same
WO2020158889A1 (en) Heterocyclic compound and harmful arthropod control composition containing same
WO2019065568A1 (en) Heterocyclic compound and harmful arthropod-controlling agent containing same
WO2020171077A1 (en) Heterocyclic compound and harmful arthropod-controlling composition containing same
WO2018174170A1 (en) Fused heterocyclic compound and composition containing same
JP7082978B2 (en) Heterocyclic compounds and harmful arthropod control agents containing them
JP2019019116A (en) Heterocyclic compound and harmful arthropod controlling agent containing the same
JP7301042B2 (en) Heterocyclic compound and harmful arthropod control composition containing the same
JP7219717B2 (en) Heterocyclic compound and harmful arthropod control agent containing the same
WO2019083008A1 (en) Pyridine compound and pest control composition containing same
JP7489564B1 (en) Crystal of 2-(5-cyclopropyl-3-(ethylsulfonyl)pyridin-2-yl)-5-((trifluoromethyl)sulfinyl)benzo[d]oxazole
JP7489565B1 (en) Crystal of 2-(5-cyclopropyl-3-(ethylsulfonyl)pyridin-2-yl)-5-((trifluoromethyl)sulfonyl)benzo[d]oxazole
JP7428693B2 (en) Ether compound and harmful arthropod control composition containing the same
WO2019083007A1 (en) Pyridine compound and harmful-arthropod control agent containing same
WO2019208598A1 (en) Pyrimidine compound and harmful arthropod-controlling composition containing same
WO2019208599A1 (en) Pyrimidine compound and harmful arthropod-controlling composition containing same
WO2024080330A1 (en) Sulfonamide compound and harmful-arthropod controlling composition containing same
JP2021006508A (en) Heterocyclic compound and harmful arthropod control agent containing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18870308

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019550314

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18870308

Country of ref document: EP

Kind code of ref document: A1